Member Name,Primary Domain,Start Date,End Date,Funding Type,Status,Peer Reviewed?,Industry Grant?,Role,Title,Principal Investigator,Co-Investigators,Total Amount
"Adams, Paul","Medicine","1986/01","1988/01","Grants","Funded","False","False","Co-Investigator","Iron metabolism and hemochromatosis.","Paul Adams","","$25,457,397.00"
"Adams, Paul","Medicine","1989","1992","Grants","Funded","False","False","Co-Investigator","Isolation of Hepatic Ferritin Receptor.","Paul Adams","","$2,351,390.00"
"Adams, Paul","Medicine","1988","1993","Grants","Funded","False","False","Co-Investigator","Iron metabolism and hemochromatosis.","Paul Adams","","$16,447,885.00"
"Adams, Paul","Medicine","1989/07","1990/07","Grants","Funded","False","False","Co-Investigator","Mucosal iron in the control of iron absorption in a rat intestinal transplant model.","","","$31,698,119.00"
"Adams, Paul","Medicine","1989/04","","Grants","Funded","False","False","Co-Investigator","","","","$39,533,585.00"
"Adams, Paul","Medicine","1990/07","","Grants","Funded","False","False","Co-Investigator","Monocyte ferritin in hemochromatosis.","Paul Adams","","$22,410,187.00"
"Adams, Paul","Medicine","1992/08","1994/08","Grants","Funded","False","False","Co-Investigator","Interferon therapy in the treatment of chronic viral hepatitis.","","Ghent CN","$14,357,382.00"
"Adams, Paul","Medicine","1992/09","1994/09","Grants","Funded","False","False","Co-Investigator","Localization of the hemochromatosis gene - phase 1.","","","$39,318,017.00"
"Adams, Paul","Medicine","1992/12","1993/07","Grants","Funded","False","False","Co-Investigator","Adrenergic response in cirrhosis.","Paul Adams","Bierbrier G, Feldman RD.","$27,859,413.00"
"Adams, Paul","Medicine","1993/10","1995/10","Grants","Funded","False","False","Co-Investigator","Iron Regulatory Factor in Hemochromatosis.","Paul Adams","Flanagan PR","$6,969,280.00"
"Adams, Paul","Medicine","1995/07","","Grants","Funded","False","False","Co-Investigator","Localization of the hemochromatosis gene.","","","$42,521,052.00"
"Adams, Paul","Medicine","1995/07","","Grants","Funded","False","False","Co-Investigator","International Scientific Exchange Award - ‘‘Localization of the hemochromatosis gene"".","","","$19,579,022.00"
"Adams, Paul","Medicine","1996/07","","Grants","Funded","False","False","Co-Investigator","Natural history and response to therapy in persons with iron overload.","Paul Adams","Edwards C, Barton J","$74,011,537.00"
"Adams, Paul","Medicine","1996/07","","Grants","Funded","False","False","Co-Investigator","Natural history and response to therapy in persons with iron overload.","Paul Adams","Edwards C, Barton J","$551,492.00"
"Adams, Paul","Medicine","1996/10","","Grants","Funded","False","False","Co-Investigator","Blood donor screening for hereditary hemochromatosis.","","","$39,479,918.00"
"Adams, Paul","Medicine","1997/09","","Grants","Funded","False","False","Co-Investigator","Prevalence of C282Y mutation in end-stage liver disease.","","","$30,385,660.00"
"Adams, Paul","Medicine","1998/03","","Grants","Funded","False","False","Co-Investigator","Genotyping for hemochromatosis.","","","$31,074,738.00"
"Adams, Paul","Medicine","1998/07","1998/09","Grants","Funded","False","False","Co-Investigator","Nramp2 in hemochromatosis.","Paul Adams","J Hajek","$18,006,589.00"
"Adams, Paul","Medicine","1999/03","","Grants","Funded","False","False","Co-Investigator","Psychosocial impact of genetic testing for hemochromatosis.","","","$68,023,725.00"
"Adams, Paul","Medicine","2000/02","","Grants","Funded","False","False","Principal Investigator","HEmochromatosis and IRon overload Screening study (HEIRS)-NIH-NHLBI-HC-99-04.","Paul Adams","Bethesda, MD","$46,526,872.00"
"Adams, Paul","Medicine","2000/09","","Grants","Funded","False","False","Co-Investigator","Iron transport genes and proteins in hemochromatosis.","Paul Adams","S Chakrabarti","$57,058,835.00"
"Adams, Paul","Medicine","2001/01","2004/01","Grants","Funded","False","False","Co-Investigator","Utility assessment in Hepatitis C infection.","Paul Marotta","Paul Adams, P Marotta, B Feagan.","$57,108,400.00"
"Adams, Paul","Medicine","2001/08","2003/01","Grants","Funded","False","False","Co-Investigator","Hemochromatosis patients as voluntary blood donors.","Paul Adams","","$35,040,882.00"
"Adams, Paul","Medicine","2001/10","","Grants","Funded","False","False","Co-Investigator","Ethical, Social and Legal Implications of Genetic testing for hemochromatosis.","","","$42,639,016.00"
"Adams, Paul","Medicine","2003/01","2005/01","Grants","Funded","False","False","Co-Investigator","Hepcidin and hemochromatosis.","Paul Adams","D Thorburn","$66,182,509.00"
"Adams, Paul","Medicine","2003/09","","Grants","Funded","False","False","Co-Investigator","Quantitation of liver iron concentration using MRI.","Paul Adams","B Rutt","$62,558,577.00"
"Adams, Paul","Medicine","2005/02","","Grants","Funded","False","False","Principal Investigator","HEmochromatosis and IRon overload Screening study (HEIRS)-NIH-NHLBI-HC-99-04.","Adams P.","","$34,955,769.00"
"Adams, Paul","Medicine","2006/02","","Grants","Funded","False","False","Co-Investigator","HEmochromatosis and IRon overload Screening study (HEIRS)-NIH-NHLBI-HC-99-04.","Paul Adams","","$18,809,669.00"
"Adams, Paul","Medicine","2006/01","2010/12","Grants","Funded","True","False","Co-Investigator","NIH – NHLBI/NIDDK (Bethesda, MD) – Iron Status: A Pathway Analysis in Multiple Ethnicities. (McLaren C, PI and the HEIRS Study Group, R01 HL083328-01A1).","Paul Adams","McLaren C","$66,688,179.00"
"Adams, Paul","Medicine","2007/01","2010/06","Grants","Funded","False","False","Co-Investigator","Perfusion and lipid imaging with a liver specific CT contrast agent to detect progression of cirrhosis to hepatocellular carcinoma.","Paul Adams","Lee T, Adams PC, Chakrabarti S.","$7,016,874.00"
"Borrie, Michael","Medicine","2006/12","2009/11","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 1, Randomized, Placebo - Controlled, Double Blind, Dose - Escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenity of a Single Intravenous Dose of PF-04360365 (RN1219) in Adults with Mild to Moderate Alzheimer Disease. Protocol ID: A9951001.","Borrie MJ","Wells JL","$27,269,893.00"
"Borrie, Michael","Medicine","2006/12","2011/01","Grants","Funded","True","False","Principal Site Investigator","Utilizing High Field Magnetic Resonance Spectroscopy as a Biomarker for Mild Cognitive Impairment","Borrie MJ","Wells JL","$23,120,245.00"
"Borrie, Michael","Medicine","2006/01","2010/12","Grants","Funded","True","False","Principal Site Investigator","Alzheimer Disease Neuroimaging Initiative (ADNI)","Borrie MJ","Wells JL","$14,104,465.00"
"Borrie, Michael","Medicine","2006/08","2010/05","Grants","Funded","True","False","Principal Site Investigator","A Multi - Centre, Blinded, Randomized, Controlled Trial Comparing Different Regimens of the Antibiotics Doxycycline and Rifampin for Treatment of Alzheimer Disease","Molloy W.","Borrie MB, Wells JL et al.","$48,330,731.00"
"Borrie, Michael","Medicine","2005/01","2008/12","Grants","Funded","False","True","Principal Site Investigator","Multi - Site Collaborative Study for Genotype - Phenotype Associations in Alzheimer Disease – Genetic Alzheimer Disease Associations Longitudinal (GenADA Long) and Borrie MJ, Bartha R, Smith M. Longitudinal Imaging Substudy of GenADA.","Borrie MJ","Wells J.L.","$60,133,352.00"
"Borrie, Michael","Medicine","2005/01","2008/12","Grants","Funded","True","False","Principal Investigator","4.0 Tesla 1H Magnetic Resonance Spectroscopy as a Marker of Alzheimer Disease Status and Progression","Borrie MJ","Wells JL","$39,226,069.00"
"Borrie, Michael","Medicine","2005/01","2008/12","Clinical Trials","Funded","False","True","Principal Site Investigator","Magnetic Resonance Imaging in Alzheimer Disease: Longitudinal Part of Genotype - Phenotype Associations in Alzheimer Disease","Borrie MJ","Bartha R., Smith M.","$70,675,968.00"
"Borrie, Michael","Medicine","2005","2006","Grants","Funded","True","False","Collaborator","Info Rehab: Better Information for Better MSK Health and Quality of Life for Older Persons Summary of Research Proposal","Stolee P.","Borrie M.J., Wells J.L., et al.","$65,277,034.00"
"Borrie, Michael","Medicine","2004/01","2008/02","Clinical Trials","Funded","False","True","Principal Site Investigator","EFC 2946 Alzheimer Study: A Randomized, Multi - Centre, Double - Blind, Placebo - Controlled, 18 Month Study of Efficacy of Xaliproden in Patients with Mild to Moderate Dementia of Alzheimer’s Type","Borrie MJ","Wells J.L.","$25,915,866.00"
"Borrie, Michael","Medicine","2004/09","2005/12","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized, Double - Blind, Parallel Group Study Examining the Efficacy and Safety of Memantine on Behavioural Symptoms in Patients with Moderate to Severe Dementia of the Alzheimer’s Type (Study No. 10158)","","Borrie M.J., Wells J.L.","$33,676,514.00"
"Borrie, Michael","Medicine","2006/01","2007/10","Clinical Trials","Funded","False","True","Principal Site Investigator","An Open - Label Extension Study Examining the Safety and Tolerability of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer’s Type Having Completed Study No. 10158 (Study No. 10252)","Borrie MJ","Wells JL","$34,989,581.00"
"Borrie, Michael","Medicine","2004/06","2007/05","Clinical Trials","Funded","False","True","Principal Site Investigator","A Double - Blind Phase II Safety and Efficacy Evaluation of ONO - 2506PO in Patients with Mild to Moderate Alzheimer Disease","Borrie MJ","Wells J.L.","$46,008,762.00"
"Borrie, Michael","Medicine","2004/01","2008/01","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase III Study of the Efficacy and Safety of Alzhemed in Patients with Mild to Moderate Alzheimer Disease","Borrie MJ","Wells J.L.","$63,962,211.00"
"Borrie, Michael","Medicine","2004/01","2006/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Phase III Multi - Centre, Randomized, Double - Blind, Placebo - Controlled Study of the Effect of Daily Treatment with MPC - 7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer’s Type with Optional Follow - On After Month 12","Borrie MJ","Wells J.L.","$65,557,809.00"
"Borrie, Michael","Medicine","2004","2005","Clinical Trials","Funded","False","True","Principal Site Investigator","Long - Term Extension of Phase II Study EFC5286 of SR57667B in Patients with Mild to Moderate Alzheimer Disease (LTS 5283)","","Borrie M.J., Wells J.L.","$46,556,310.00"
"Borrie, Michael","Medicine","2004/09","2007/09","Grants","Funded","True","False","Principal Investigator","Markers for the Progression of Mild Cognitive Impairment (MCI) to Alzheimer Disease","Borrie MJ","Smith M., Bartha R., Lee T.Y., Murtha S., Wells J., Stolee P., Rylett J.","$16,738,226.00"
"Borrie, Michael","Medicine","2004/01","2008/03","Grants","Funded","True","False","Co-Investigator","Canadian Alzheimer Disease Quality of Life Study (CADQOL)","Borrie MJ","Wells J.L.","$69,493,012.00"
"Borrie, Michael","Medicine","2003","2005","Clinical Trials","Funded","False","True","Principal Site Investigator","Phase II Multi - Centre, Randomized, Double - Blind, Placebo - Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer’s Type","","Borrie M.J., Wells J.L.","$2,712,864.00"
"Borrie, Michael","Medicine","2003","2005","Clinical Trials","Funded","False","True","Principal Site Investigator","Multi - Site Collaborative Study for Genotype - Phenotype Associations in Alzheimer Disease - Genetic Alzheimer Disease Associations (GenADA)","","Borrie M.J., Wells J.L.","$27,161,739.00"
"Borrie, Michael","Medicine","2003","2005","Clinical Trials","Funded","False","True","Principal Site Investigator","Phase II Multi - Centre, Randomized, Double - Blind, Placebo - Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer Type","","Borrie M.J., Wells J.L.","$20,289,153.00"
"Borrie, Michael","Medicine","2003/01","2005/01","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase II Double - Blind, Randomized, Dose - Ranging, Placebo - Controlled, Multi - Centre, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer Type","","Borrie M.J., Wells J.L.","$16,539,924.00"
"Borrie, Michael","Medicine","2003/03","2004/11","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase II, Multi - Centre, Multi - National, Randomized, Double - Blind, Placebo - Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Patients with Mild - to - Moderate Alzheimer Disease","","Borrie M.J., Wells J.L.","$9,804,336.00"
"Borrie, Michael","Medicine","2003/04","2012/12","Grants","Funded","True","False","Principal Investigator","Magnetic Resonance Spectroscopy as a Measurement of Response to Cholinergic Treatment in Alzheimer Disease - Pilot Study","Borrie MJ","Smith M., Bartha R., Rylett J., Stolee P.","$6,461,761.00"
"Borrie, Michael","Medicine","2001","2003","Clinical Trials","Funded","False","False","Principal Investigator","The Patterns and Prevalence of Depressive Symptoms in Mild Cognitive Impairment. An Add - On Randomized Clinical Trial with Galantamine (Investigator Initiated)","","Borrie M.J., Wells J.L., Smith M.","$42,590,642.00"
"Borrie, Michael","Medicine","2001","2004","Clinical Trials","Funded","False","True","Site Investigator","A Randomized, 26 Week Double - Blind, Placebo - Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in the Treatment of Dementia Secondary to Cerebrovascular Disease (Gal-Int-26)","","Borrie M.J.","$42,618,373.00"
"Borrie, Michael","Medicine","2001","2002","Clinical Trials","Funded","False","True","Principal Site Investigator","Randomized Double - Blind Placebo - Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Subjects with Mild Cognitive Impairment Clinically at Risk for Development of Clinically Probably Alzheimer Disease (Gal-Int-11)","","Borrie M.J.","$33,035,385.00"
"Borrie, Michael","Medicine","2000","2007","Clinical Trials","Funded","False","True","Principal Site Investigator","Canadian Outcomes Study in Dementia (COSID)","","Borrie M.J., Wells J.L.","$47,167,918.00"
"Clark, William","Medicine","2007/07","2009/06","Grants","Funded","False","True","Co-Investigator","Octapharma Pharmazeutika: A Blinded Non-Inferiority Study to Compare Uniplas with Cryosuprenatant Plasma in Thrombotic Thrombocytopenic Purpura","Gail Rock","William Clark","$32,757,081.00"
"Clark, William","Medicine","2007/07","2010/06","Grants","Funded","False","True","Co-Investigator","Rituximab: A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients with Relapsed/Refractory TTP-HUS","Ronan Foley","Clark WF, London Health Sciences Centre","$300,316.00"
"Clark, William","Medicine","2006/07","2010/06","Grants","Funded","True","False","Co-investigator","Data coordinating facility for clinical research in kidney diseases","Dr. Amit X. Garg","Clark WF, London Health Sciences Centre","$11,502,819.00"
"Clark, William","Medicine","2002/07","2010/12","Grants","Funded","True","False","Principal Investigator","A seven year prospective cohort study on the characterization and management of long-term Medical complications from E.coli 0157:H7 infection in Walkerton, Ontario","William Clark","Clark WF, Garg AX, Howard J, Matsell J, Moist L, Salvadori M, Suri R in collaboration with Collins S, Marshall J","$32,167,571.00"
"Clark, William","Medicine","2003/07","2005/06","Grants","Funded","True","False","Co-investigator","Long-term risk of abnormal glucose homeostasis after E.coli 0157:H7 gastroenteritis: The Walkerton Health Study","Dr. Rita Suri","","$67,749,516.00"
"Clark, William","Medicine","2003/07","2004/06","Grants","Funded","False","False","Principal Investigator","To characterize high volume proteinuria with normal Albumin/creatinine ratio noted in 32 patients detected in the Walkerton Health Study","William Clark","Clark WF, London Health Sciences Centre","$44,050,379.00"
"Clark, William","Medicine","2001/07","2003/06","Grants","Funded","True","False","Principal Investigator","Plasma exchange in myeloma and associated renal failure","William Clark","","$3,767,520.00"
"Clark, William","Medicine","2001/07","2003/06","Grants","Funded","True","False","Principal Investigator","Plasma exchange in myeloma and associated renal failure","William Clark","","$9,072,833.00"
"Clark, William","Medicine","2000/07","2003/06","Grants","Funded","True","False","Co-investigator","Comparison of solvent detergent vs cryosupernatant plasma in TTP","Dr. Gail Rock","","$11,271,034.00"
"Clark, William","Medicine","1998/07","2001/06","Grants","Funded","True","False","Principal Investigator","Plasma exchange in myeloma associated with renal failure","William Clark","","$47,044,874.00"
"Clark, William","Medicine","1998/07","2000/06","Grants","Funded","False","False","Co-investigator","Study of cryosupernatant plasma vs fresh frozen plasma as a replacement fluid in plasma exchange for TTP and HUS","Dr. Gail Rock","","$28,540,340.00"
"Clark, William","Medicine","1997/07","1999/06","Grants","Funded","True","False","Co-investigator","Evaluation in the role of antibodies in HUS","Dr. Gail Rock","","$21,197,144.00"
"Clark, William","Medicine","1996/07","1998/06","Grants","Funded","True","False","Principal Investigator","SDG lignans in experimental lupus nephritis","William Clark","","$50,335,685.00"
"Clark, William","Medicine","1995/07","1996/06","Grants","Funded","True","False","Principal Investigator","Flaxseed in lupus nephritis: a prospective randomized, crossover study","William Clark","","$51,015,225.00"
"Clark, William","Medicine","1995/07","1996/06","Grants","Funded","True","False","Principal Investigator","Flaxseed in diabetic nephropathy: a dosing study","Dr. W. F. Clark","","$44,522,283.00"
"Clark, William","Medicine","1995/07","1996/06","Grants","Funded","True","False","Principal Investigator","Flaxseed in diabetic nephropathy","Dr. Ann Hall","","$58,688,378.00"
"Clark, William","Medicine","1994/07","1995/06","Grants","Funded","True","False","Principal Investigator","Flaxseed in a rat model of chronic renal allograft rejection","Dr. Anwar Parbtani","","$29,071,862.00"
"Clark, William","Medicine","1993/07","1995/06","Grants","Funded","True","False","Co-investigator","Effects of HUS on cognitive, academic and behavioural functioning","Dr. Peter Rowe","","$65,388,247.00"
"Clark, William","Medicine","1993/07","1995/06","Grants","Funded","True","False","Principal Investigator","Flaxseed in lupus nephritis","William Clark","","$34,482,223.00"
"Clark, William","Medicine","1993/07","1994/06","Grants","Funded","False","False","Principal Investigator","Flaxseed in lupus nephritis","William Clark","","$47,514,013.00"
"Clark, William","Medicine","1991/07","1992/06","Grants","Funded","False","False","Principal Investigator","Dietary therapies in rat remnant nephron model Clinical Project BF20","William Clark","","$23,871,791.00"
"Clark, William","Medicine","1990/07","1993/06","Grants","Funded","True","False","Principal Investigator","Fish oil therapy in SLE","Dr. W. F. Clark","","$54,147,063.00"
"Clark, William","Medicine","1988/07","1999/06","Grants","Funded","True","False","Principal Investigator","Chronic progressive model of renal injury","William Clark","","$3,409,922.00"
"Clark, William","Medicine","1987/07","1988/06","Grants","Funded","False","False","Principal Investigator","Effects of single and multiple doses of Itazigrel on platelet aggregation in patients with carotid and peripheral atherosclerosis","","","$404,843.00"
"Clark, William","Medicine","1987/07","1988/06","Grants","Funded","True","False","Principal Investigator","Platelet release reaction – association with renal hyperfiltration and the evolution of glomerulosclerosis – a final common pathway","William Clark","","$74,147,648.00"
"Clark, William","Medicine","1987/07","1988/06","Grants","Funded","True","False","Principal Investigator","Acute effects of eicosapentaenoic acid in patients with SLE","William Clark","","$25,208,931.00"
"Clark, William","Medicine","1987/07","1988/06","Grants","Funded","True","False","Principal Investigator","Platelet release reaction – association with renal hyperfiltration and the evolution of glomerulosclerosis – final common pathway","William Clark","","$58,841,017.00"
"Clark, William","Medicine","1985/07","1986/06","Grants","Funded","False","False","Principal Investigator","Effects of thromboxane synthase inhibitor in the treatment of NZB/NZW F–1 lupus mice: comparison of different drug dosage","William Clark","","$28,084,913.00"
"Clark, William","Medicine","1985/07","1986/06","Grants","Funded","False","False","Principal Investigator","PGE-1 and thomboxane synthase inhibitor treatment in mice with lupus-like syndrome","William Clark","","$62,610,570.00"
"Clark, William","Medicine","1985/07","1986/06","Grants","Funded","True","False","Principal Investigator","Antiplatelet therapy in murine lupus","William Clark","","$12,056,660.00"
"Clark, William","Medicine","1985/07","1986/06","Grants","Funded","True","False","Principal Investigator","The role of platelets in experimental lupus nephritis in NZB/NZW F-1 mice","William Clark","","$72,125,054.00"
"Clark, William","Medicine","1984/07","1987/06","Grants","Funded","True","False","Principal Investigator","Platelet immune complex interaction in the immunopathogenesis of renal disease","William Clark","","$59,768,871.00"
"Clark, William","Medicine","1984/07","1987/06","Grants","Funded","True","False","Principal Investigator","Platelet associated IgG in SLE","William Clark","","$46,819,447.00"
"Clark, William","Medicine","1982/07","1984/06","Grants","Funded","True","False","Principal Investigator","Platelet immune complex interaction in the immunopathogenesis of renal disease","William Clark","","$67,228,820.00"
"Clark, William","Medicine","1980/07","1983/06","Grants","Funded","True","False","Principal Investigator","Plasmapheresis in SLE diffuse proliferative glomerulonephritis","William Clark","","$14,814,259.00"
"Clark, William","Medicine","1982/07","1983/06","Grants","Funded","True","False","Principal Investigator","Retrospective analysis of immune parameters and disease activity Platelet immune complex interaction","William Clark","","$33,311,663.00"
"Clark, William","Medicine","1980/07","1982/06","Grants","Funded","True","False","Principal Investigator","Interaction of immune complexes and platelets in plasma","William Clark","","$32,367,332.00"
"Clark, William","Medicine","1980/07","1981/06","Grants","Funded","True","False","Principal Investigator","Plasmapheresis in SLE diffuse proliferative glomeruonephritis","William Clark","","$30,200,578.00"
"Clark, William","Medicine","1979/07","1980/06","Grants","Funded","True","False","Principal Investigator","Plasmapheresis in SLE diffuse proliferative glomeruonephritis-a pilot study","William Clark","","$14,409,250.00"
"Clark, William","Medicine","1979/07","1980/06","Grants","Funded","True","False","Principal Investigator","Platelets in renal disease","William Clark","","$38,828,046.00"
"Clark, William","Medicine","1979/07","1980/06","Grants","Funded","True","False","Principal Investigator","Pathogenesis of scarring in immune complex nephritis with particular reference to the role of the platelet","William Clark","","$69,297,759.00"
"Clark, William","Medicine","1977/07","1979/06","Grants","Funded","True","False","Principal Investigator","Platelet and immune complex nephritis","William Clark","","$37,449,420.00"
"Brymer, Chris","Medicine","1993","1994","Grants","Funded","False","False","Principal Investigator","Nimodipine for Geriatric Urge Incontinence: A randomized, double-blind, placebo-controlled, crossover trial.","Brymer C, Naglie G, Radomski S, Lemieux MC","","$67,388,948.00"
"Brymer, Chris","Medicine","1996","","Grants","Funded","False","False","Principal Investigator","The Prevalence of Urinary Retention in Institutional and Community Settings.","Borrie MJ, Brymer CD","","$49,514,713.00"
"Brymer, Chris","Medicine","1996","","Grants","Funded","False","False","Principal Investigator","The SMILE (Substance Misuse in London's Elderly) Project - A Community Based Approach. 1996. St. Mary's Fund. $97,000.00. ($25,000.00 extension awarded May 1997).","Brymer C, Rusnell I","","$60,051,020.00"
"Brymer, Chris","Medicine","1997/05","","Grants","Funded","False","False","Principal Investigator","The SMILE (Substance Misuse in London's Elderly) Project - A Community Based Approach.","Brymer C, Rusnell I","","$62,449,268.00"
"Brymer, Chris","Medicine","1997/10","","Grants","Funded","False","False","Principal Investigator","Development and Validation of an Inappropriate Prescribing in the Elderly Tool (IPET).","Brymer C, Naugler C, Stolee P","","$32,753,831.00"
"Brymer, Chris","Medicine","1998/03","","Grants","Funded","False","False","Principal Investigator","Determining Predictors of Adherence to Recommendations of Geriatric Outreach Team Assessments.","Stolee P, Brymer C, Borrie M, Griffiths N.","","$535,716.00"
"Brymer, Chris","Medicine","1999/03","","Grants","Funded","False","False","Principal Investigator","Application of the Inappropriate Prescribing in the Elderly Tool (IPET) in a Long Term Care Setting.","Brymer C, Stolee P, Feightner J, Viana L, Gill S.","","$25,440,337.00"
"Brymer, Chris","Medicine","2000","","Grants","Funded","False","False","Principal Investigator","Prevalence and Predictors of Durable Functional Gains.","Brymer C, Crilly R, Dasgupta M, Wanger K, Beaton C","","$47,256,184.00"
"Dasgupta, Monidipa","Medicine","2004","2004/04","Grants","Funded","True","False","","Hepatic Cytochrome Polymorphism and Response to Galantamine","","","$34,880,196.00"
"Blake, Peter","Medicine","1993","1995","Grants","Funded","False","False","Principal Investigator","The acute effects of amino acids and of their route of administration on hormonal mediators of metabolism in dialysis patients","PG Blake","","$68,136,620.00"
"Blake, Peter","Medicine","1993","1995","Grants","Funded","False","False","Principal Investigator","Malnutrition in dialysis patients","PG Blake","","$35,228,751.00"
"Blake, Peter","Medicine","1993","1993","Grants","Funded","False","True","Principal Investigator","Modification of an amino acid solution for peritoneal dialysis to reduce risk of acidemia","Jones M","Martis L, Oreopoulos DG, PG Blake (20% co-investigator)","$12,670,592.00"
"Blake, Peter","Medicine","1996","1997","Grants","Funded","False","True","Principal Investigator","What is the optimal APD prescription?","PG Blake","DG Oreopoulos","$43,536,268.00"
"Blake, Peter","Medicine","1996","1998","Grants","Funded","False","True","Collaborator","Comparison of local tolerability of subcutaneous injections of Epoietin alpha with citrate buffer and with phosphate buffer","PG Blake and investigators at 3 other sites (25%)","","$54,722,668.00"
"Blake, Peter","Medicine","1995","1996","Grants","Funded","False","True","Principal Investigator","Verification of performance data on the Focus series of dialyzers","PG Blake","","$59,133,584.00"
"Blake, Peter","Medicine","1995","1997","Grants","Funded","False","True","Co-Investigator","Evaluation of a blood volume monitor in routine hemodialysis","RM Lindsay","PG Blake, Kortas C, Clark WF (25% co-investigator)","$66,165,033.00"
"Blake, Peter","Medicine","1997","1998","Grants","Funded","False","True","Principal Investigator","Validation of PD Adequest for predicted versus measured clearances of dialysate and urine in PD patients","PG Blake","multiple co-investigators","$35,580,392.00"
"Blake, Peter","Medicine","1998","2000","Grants","Funded","False","True","Principal Investigator","A study to evaluate the safety of a 7.5% Icodextrin peritoneal dialysis solution in patients treated with peritoneal dialysis (PD) in North America","PG Blake","multiple co-investigators","$61,865,890.00"
"Blake, Peter","Medicine","1998","2000","Grants","Funded","False","True","Principal Investigator","A study to evaluate the safety and efficacy of a 7.5% Icodextrin peritoneal dialysis solution in patients treated with continuous ambulatory peritoneal dialysis (PD) in North America","PG Blake","multiple co-investigators","$52,704,110.00"
"Blake, Peter","Medicine","1999","2000","Grants","Funded","False","True","Principal Investigator","Investigation of iron status in predialysis patients","PG Blake","","$35,280,637.00"
"Blake, Peter","Medicine","1999","2001","Grants","Funded","False","True","Principal Investigator","Establishment of pre-dialysis clinic database","PG Blake (principal investigator)","","$62,704,420.00"
"Blake, Peter","Medicine","2000","2001","Grants","Funded","False","True","Principal Investigator","A study evaluating the initiation and titration of fixed doses of Novel Erythropoiesis Stimulating Protein (NESP) therapy in subjects with chronic renal insufficiency (CRI)","PG Blake","multiple co-investigators","$29,309,419.00"
"Blake, Peter","Medicine","2000","2001","Grants","Funded","False","True","Co-Principal Investigator","The use of intravenous Ferrlecit in patients with chronic renal failure and iron deficiency.","PG Blake, one of four co-principal investigators","","$40,214,461.00"
"Blake, Peter","Medicine","2001","2001","Grants","Funded","False","True","Principal Investigator","Comparison of EPREX injections delivered by 3-bevelled vs.5-bevelled needle in hemodialysis patients","PG Blake","","$20,630,276.00"
"Blake, Peter","Medicine","2003","2008","Grants","Funded","False","False","Co-Investigator","Investigation of dendritic cells in peritoneal effluent","JA Madrenas","","$48,358,077.00"
"Haddara, Wael","Medicine","2003","present","Clinical Trials","Funded","True","False","Co-Investigator","Multiple Organ Transplant Program - “Thyroxine in Organ Donors”","WMR Haddara","Dr Michael Sharpe, Division of Critical Care Medicine, University of Western Ontario, London, ON.","$51,862,083.00"
"Boughner, Derek","Medicine","2007/07","2010/06","Grants","Funded","True","False","Principal Investigator","A tissue engineering approach to bioprosthetic heart valve design","Dr. D. Boughner","Dr. K. Rogers, Dr.J.Lacefield","$63,625,204.00"
"House, Andrew","Medicine","2007/07","2008/06","Grants","Funded","True","False","Co-Investigator","N-Acetylcysteine and the effect on tubular secretion of creatinine in patients with chronic kidney disease","Louise Moist","A. House","$52,142,808.00"
"House, Andrew","Medicine","2006/09","2011/08","Grants","Funded","True","False","Co-Investigator","ACE-inhibition for the preservation of renal function and patient survival in kidney transplantation","Norman Muirhead","A. House","$7,129,464.00"
"House, Andrew","Medicine","2006/09","2009/08","Grants","Funded","True","False","Co-Investigator","3-D ultrasound phenotypes of atherosclerosis","David Spence","A. House","$46,084,190.00"
"House, Andrew","Medicine","2006/09","2009/08","Grants","Funded","True","False","Co-Investigator","Effect of treatment of subclinical hypothyroidism on atherosclerosis","David Spence","A. House","$35,966,559.00"
"House, Andrew","Medicine","2005/03","2006/02","Grants","Funded","True","False","Principal Investigator","The effect of oral mesna on plasma total homocysteine concentrations in subjects with normal kidney function","A House","D Freeman","$28,038,193.00"
"House, Andrew","Medicine","2004/09","2005/08","Grants","Funded","True","False","Co-Investigator","Decreasing plasma homocysteine concentration in hemodialysis patients","David Freeman","A. House","$27,916,007.00"
"House, Andrew","Medicine","2003/09","2004/06","Grants","Funded","True","False","Principal Investigator","Do vitamins for homocysteine improve carotid atherosclerosis in patients with diabetic nephropathy?","A. House","","$300,093.00"
"House, Andrew","Medicine","2003/09","2010/06","Grants","Funded","True","False","Site Investigator","Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT)","Dr. Andrew Bostom","A. House","$18,690,249.00"
"House, Andrew","Medicine","2002/09","2003/06","Grants","Funded","True","False","Co-Investigator","Epstein-Barr virus (EBV) cytotoxic T cell frequencies using Class I MHC EBV tetramers","Anthony Jevnikar","A. House","$52,991,369.00"
"House, Andrew","Medicine","2001/09","2002/06","Grants","Funded","True","False","Principal Investigator","Risk factors for post-transplant lymphoproliferative disorder in adult renal allograft recipients","A. House","","$62,247,794.00"
"House, Andrew","Medicine","2001/07","2003/06","Grants","Funded","True","False","Principal Investigator","Do vitamins for homocysteine improve carotid atherosclerosis in patients with diabetic nephropathy","A. House","","$17,722,924.00"
"House, Andrew","Medicine","2001/09","2007/08","Grants","Funded","True","False","Co.Principal Investigator","Diabetic Intervention with Vitamins to Improve Nephropathy (DIVINe)","David Spence/Andrew House","","$33,965,282.00"
"House, Andrew","Medicine","2000/09","2002/06","Grants","Funded","True","False","Principal Investigator","Comparison of the effects of high and low flux hemodialysis","A. House","","$61,639,405.00"
"House, Andrew","Medicine","1999/09","2001/06","Grants","Funded","True","False","Principal Investigator","Relationship of homocysteine to carotid atherosclerosis in renal transplant recipients","A. House","","$47,023,862.00"
"House, Andrew","Medicine","1999/09","2002/06","Grants","Funded","True","False","Principal Investigator","Extra-corporeal photopheresis for the induction of immune tolerance in cardiac and renal allograft recipients: effect of UV-irradiation and donor-specific leukocyte transfusion","A. House","","$731,723.00"
"House, Andrew","Medicine","2007/09","2010/06","Grants","Funded","False","True","Co-Investigator","EVOLVE: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events","Norman Muirhead","A. House","$28,832,918.00"
"House, Andrew","Medicine","2003/07","2005/06","Grants","Funded","False","True","Sub Investigator","An active surveillance plan to prospectively monitor the incidence and developmental history of PRCA among patients receiving epoetin alfa therapy (EPO-IMU-401)","","A. House","$69,176,167.00"
"House, Andrew","Medicine","2006/07","2011/06","Grants","Funded","False","True","Principal Site Investigator","A prospective, randomized, open-label, pilot study to compare the effect on carotid atherosclerosis of tacrolimus-based regimen with conversion from a tacrolimus to a sirolimus-based regimen in de novo renal transplant recipients","A. House","","$56,650,752.00"
"House, Andrew","Medicine","2005/09","2010/06","Grants","Funded","False","True","Co-Investigator","Comparative Evaluation of Safety & Efficacy of Sirolimus vs Cyclosporine when compared in a Regimen Containing Basiliximab, Mycophenolate Mofetil & Corticosteroids in Renal Allograft Recipients","Norman Muirhead","A. House","$56,165,685.00"
"House, Andrew","Medicine","2006/09","2007/06","Grants","Funded","False","True","Co-Investigator","A Phase 2 B Randomized, Multicenter, Open-Label Concentration Controlled Safety Study of ISA247 and Tacrolimus in De Novo Renal Transplant Patients","Anthony Jevnikar","A. House","$9,073,573.00"
"House, Andrew","Medicine","2005/01","2011/06","Grants","Funded","False","True","Co-Investigator","A Facilitated Access Program to Provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation","Norman Muirhead","A. House","$29,287,527.00"
"House, Andrew","Medicine","2005/09","2008/06","Grants","Funded","False","True","Co-Investigator","Evaluate the Efficacy and Safety of FTY720 Combined with Reduced-dose or Full-dose Neoral & corticosteroids Vs Mycophenolate Mofetil Combined with Full-dose Neoral & Corticosteroids","Norman Muirhead","A. House","$16,688,390.00"
"House, Andrew","Medicine","2005/09","2008/06","Grants","Funded","False","True","Co-Investigator","TREAT: Trial to Reduce Cardiovascular Events with Aranesp Therapy","Norman Muirhead","A. House","$69,961,090.00"
"House, Andrew","Medicine","2005/07","2007/06","Grants","Funded","False","True","Site Investigator","A Randomized Trial of TPA versus Unfractionated Heparin Lok for the Primary Prevention of Hemodialysis Catheter Malfunction","Louise Moist","A. House","$410,194.00"
"House, Andrew","Medicine","2004/09","2007/06","Grants","Funded","False","True","Co-Investigator","Clinical Regional transplant programs study of immunosuppressive therapy related toxicities in renal transplant recipients managed at regional or satellite community nephrology clinics","Anthony Jevnikar","A. House","$15,000,741.00"
"House, Andrew","Medicine","2004/09","2007/06","Grants","Funded","False","True","Co-Investigator","Data Management Regional transplant programs study of immunosuppressive therapy related toxicities in renal transplant recipients managed at regional or satellite community nephrology clinics","Anthony Jevnikar","A. House","$15,610,003.00"
"House, Andrew","Medicine","2004/09","2007/06","Grants","Funded","False","True","Co-Investigator","Evaluation of the long-term safety and efficacy of a tacrolimus-based 5-day steroid rapid withdrawal immunoprophylactic regimen in de novo renal transplantation","Anthony Jevnikar","A. House","$46,342,835.00"
"House, Andrew","Medicine","2004/09","2006/06","Grants","Funded","False","True","Co-Investigator","group study to demonstrate correction of anemia using subcutaneous injections of RO0503821 in patients with chronic kidney disease who are not on dialysis","Norman Muirhead","A. House","$21,896,149.00"
"House, Andrew","Medicine","2004/09","2006/06","Grants","Funded","False","True","Co-Investigator","An open label, randomized, multicentre, parallel group study to demonstrate correction of anemia using intravenous injections of R00503821 in patients with chronic kidney disease who are on dialysis","Norman Muirhead","A. House","$66,180,695.00"
"House, Andrew","Medicine","2004/09","2006/06","Grants","Funded","False","True","Co-Investigator","An open label, randomized, multicentre, parallel group study to determine the efficacy and safety of R00503821 when administered to patients with chronic kidney disease who are on dialysis","Norman Muirhead","A. House","$45,095,037.00"
"House, Andrew","Medicine","2004/09","2006/06","Grants","Funded","False","True","Co-Investigator","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the effects of Aliskiren on Proteinuria when Added to Standardized Losartan Therapy and Optional Antihypertensive Therapy in Patients with Hypertension and Type 2 Diabetes Mellitus","Norman Muirhead","A. House","$71,144,274.00"
"House, Andrew","Medicine","2004/09","2006/06","Grants","Funded","False","True","Co-Investigator","Randomized study to evaluate the efficacy of FTY720 combined with reduced dose or full dose neural & corticosteroids vs mycophenolate mofetil combined with full dose Neoral & corticosteroids","Norman Muirhead","A. House","$36,356,385.00"
"House, Andrew","Medicine","2003/09","2007/06","Grants","Funded","False","True","Co-Investigator","A multicentre 1:1 randomized, double blind, two arm parallel group study to evaluate and compare the efficacy and safety of modified release tacrolimus FK506E (MR4) versus Tacrolimus FK506","Anthony Jevnikar","A. House","$69,455,640.00"
"House, Andrew","Medicine","2007/09","2008/06","Grants","Funded","False","True","Co-Investigator","A multicentre 1:1 randomized, double blind, two arm parallel group study to evaluate and compare the efficacy and safety of modified release tacrolimus FK506E (MR4) versus Tacrolimus FK506 - EXTENSION","Anthony Jevnikar","A. House","$21,855,142.00"
"House, Andrew","Medicine","2003/07","2006/06","Grants","Funded","False","True","Sub Investigator","AURORA: A double blind, randomized, multicentre, phase IIIb, parallel group study to compare the effects of rosuvastin (10mg oral) with placebo on assessment of survival and cardiovascular events in hemodialysis","Anthony Jevnikar","A. House","$34,148,393.00"
"House, Andrew","Medicine","2003/07","2005/06","Grants","Funded","False","True","Sub Investigator","A double blind randomised dose ranging multicentre phase IIIb study to evaluate efficacy and safety of high dose candesartan on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria","Anthony Jevnikar","A. House","$35,839,807.00"
"House, Andrew","Medicine","2003/07","2005/06","Grants","Funded","False","True","Sub Investigator","An active surveillance plan to conduct serologic testing for anti-erythropoietin antibodies and prospectively monitor the incidence and developmental history of PRCA among patients receiving epoetin alfa therapy (EPO-IMU-402)","","A. House","$73,686,872.00"
"House, Andrew","Medicine","2002/07","2003/06","Grants","Funded","True","False","Sub Investigator","3-dimensional ultrasound versus intima-media thickness to detect effects of treatment for atherosclerosis","","A. House","$52,466,815.00"
"House, Andrew","Medicine","2002/07","2007/06","Grants","Funded","False","True","Co-Investigator","A Prospective, Multi-centre Study for the Determination of the Incidence of Cardiovascular Events and the Prevalence of Risk Factors for Cardiovascular Disease in Renal Transplantation","Anthony Jevnikar","A. House","$73,627,908.00"
"House, Andrew","Medicine","2002/07","2007/06","Grants","Funded","False","True","Co-Investigator","Data Management A Prospective, Multi-centre Study for the Determination of he Incidence of Cardiovascular Events and the Prevalence of Risk Factors for Cardiovascular Disease in Renal Transplant Patients","Anthony Jevnikar","A. House","$5,542,036.00"
"House, Andrew","Medicine","2002/07","2006/06","Grants","Funded","False","True","Co-Investigator","Prograf as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure","Anthony Jevnikar","A. House","$48,271,284.00"
"House, Andrew","Medicine","2002/07","2006/06","Grants","Funded","False","True","Principal Investigator","Immunosuppression without calcineurin inhibition in renal transplantation: a pilot study of a novel non-nephrotoxic regimen","A. House","","$23,483,116.00"
"Boughner, Derek","Medicine","2000/09","2007/01","Grants","Funded","True","False","Collaborator","Ontario consortium for cardiac imaging","Dr. Graham Wright","D.R. Boughner, A. Fenster","$30,615,486.00"
"Boughner, Derek","Medicine","2004/04","2007/04","Grants","Funded","True","False","Co-Applicant","Support of multi-user confocal microscope and digital imaging facility multi-user equipment and maintenance grant","Dr. Kem A. Rogers","","$6,794,185.00"
"House, Andrew","Medicine","2002/07","2004/06","Grants","Funded","False","True","Sub Investigator","Impact of hemoglobin maintenance and other strategies to prevent left ventricular mass growth in early renal insufficiency","","A. House","$4,907,586.00"
"Boughner, Derek","Medicine","2003/10","2005/10","Grants","Funded","True","False","Principal Investigator","The tissue engineered heart valve bioprostheses: cellular and structural aspects","Dr. D.R. Boughner","K. Rogers","$32,833,261.00"
"House, Andrew","Medicine","2001/07","2007/06","Grants","Funded","False","True","Sub Investigator","Rapamune Outcomes Assessment Registry","","A. House","$7,531,152.00"
"House, Andrew","Medicine","2001/07","2004/06","Grants","Funded","False","True","Sub Investigator","Early correction of anemia and progression of chronic renal insufficiency (ECAP)","","A. House","$35,889,815.00"
"House, Andrew","Medicine","2001/07","2002/06","Grants","Funded","False","True","Sub Investigator","Standard versus reduced-dose Tacrolimus plus Sirolimus in renal allograft recipients (TARGET)","","A. House","$63,674,090.00"
"Boughner, Derek","Medicine","2003/04","2004/03","Grants","Funded","True","False","Co-Investigator","Development of a tri-leaflet mechanical artificial heart valve","Dr. W.K. Wan","WK Wan, G. Campbell, D.R.Boughner","$13,600,467.00"
"House, Andrew","Medicine","2000/07","2003/06","Grants","Funded","False","True","Sub Investigator","Controlled study of 2 dose levels of sirolimus in renal allograft recipients (RapIV extension)","","A. House","$63,955,842.00"
"House, Andrew","Medicine","2000/07","2002/06","Grants","Funded","False","True","Sub Investigator","Randomized study of RAD with early versus delayed initiation of Neoral in renal transplant recipients at risk of delayed graft function","","A. House","$8,605,987.00"
"House, Andrew","Medicine","2000/07","2003/06","Grants","Funded","False","True","Sub Investigator","Impact of normalization of hemoglobin compared to partial correction on left ventricular structure in early dialysis patients","","A. House","$44,273,810.00"
"House, Andrew","Medicine","1999/07","2002/06","Grants","Funded","False","True","Sub Investigator","Controlled study of 2 dose levels of sirolimus in renal allograft recipients (RapIV)","","A. House","$23,813,713.00"
"House, Andrew","Medicine","1999/07","2003/06","Grants","Funded","False","True","Sub Investigator","Tacrolimus versus cyclosporine in patients at risk for chronic allograft nephropathy","","A. House","$33,626,398.00"
"House, Andrew","Medicine","1999/07","2002/06","Grants","Funded","False","True","Sub Investigator","A three-year, randomized study of RAD001 tablet versus mycophenolate mofetil in renal transplant recipients","","A. House","$38,163,412.00"
"House, Andrew","Medicine","1998/07","2003/06","Grants","Funded","False","True","Sub Investigator","A multicentre randomized study of effects of fluvastatin on major adverse cardiac events & progression of chronic kidney transplant dysfunction","","A. House","$30,946,218.00"
"Boughner, Derek","Medicine","2007/07","2008/06","Grants","Funded","True","False","Principal Investigator","Aortic sclerosis in an animal model: progression, regression and evaluation","Dr. D. Boughner","Dr. K. Rogers, Dr. Brian Rutt, Dr J. Lacefield","$24,115,543.00"
"House, Andrew","Medicine","1997/07","2003/06","Grants","Funded","False","True","Sub Investigator","Impact of hemoglobin maintenance and other strategies to prevent progression of left ventricular mass in early renal insufficiency","","A. House","$49,045,138.00"
"Boughner, Derek","Medicine","2001/07","2002/06","Grants","Funded","True","False","Principal Investigator","The native and bioprosthetic aortic valve – structural and cellular components","Dr. D. Boughner","","$36,079,437.00"
"Boughner, Derek","Medicine","2000/07","2002/06","Grants","Funded","True","False","Co-Applicant","Med Tech/UWO Prototype development Fund Hydrogel polymer artificial heart valve","Dr. G. Campbell","","$48,641,480.00"
"Boughner, Derek","Medicine","2001/10","2003/09","Grants","Funded","True","False","Co-Applicant","Development of Interventional Cardiac MRI","Dr. M. Drangova","","$45,062,580.00"
"Boughner, Derek","Medicine","1998/10","2001/10","Grants","Funded","True","False","Co-Applicant","Quantitative phase-contrast MRI for diagnosis of valvular heart disease","Dr. M. Drangova","","$4,012,639.00"
"Boughner, Derek","Medicine","1998/10","2001/10","Grants","Funded","True","False","Co-Applicant","MRC Group in Vascular Imaging","Dr. Brian Rutt","","$31,629,170.00"
"Boughner, Derek","Medicine","1998/01","2001/01","Grants","Funded","True","False","Principal Applicant","Heart valve prostheses - vascularity, fixation techniques and material design","D. Boughner","WK Wan","$35,431,876.00"
"Boughner, Derek","Medicine","1996/01","1999/01","Grants","Funded","True","False","Principal Applicant","Three-dimensional echocardiogarphy","D Boughner","P. Pflugfelder","$40,245,092.00"
"Boughner, Derek","Medicine","1995/07","1998/06","Grants","Funded","True","False","Principal Investigator","Heart valve bioprostheses biomaterials","D. Boughner","","$20,986,730.00"
"Boughner, Derek","Medicine","1994/07","1996/06","Grants","Funded","True","False","Principal Applicant","Three-dimensional echocardiography","Derek Boughner","P Pflugfelder","$14,702,841.00"
"Boughner, Derek","Medicine","1993/07","1995/06","Grants","Funded","True","False","Co-Applicant","Accelerated artery disease","P. Canham","","$55,287,224.00"
"Boughner, Derek","Medicine","1992/07","1995/06","Grants","Funded","True","False","Principal Applicant","Mechanical properties of bioprosthetic materials: myocardial architecture and collagen aging, cardiac and pulmonary function after heart transplantation","D Boughner","","$4,678,883.00"
"Boughner, Derek","Medicine","1989/07","1992/06","Grants","Funded","True","False","Principal Investigator","HSFO Career Investigator Award","D.R. Boughner","","$60,035,317.00"
"Boughner, Derek","Medicine","1988/07","1992/06","Grants","Funded","True","False","Principal Investigator","HSFO Grant-in-Aid","D. Boughner","","$15,108,415.00"
"George, Charles","Medicine","1988","1989","Grants","Funded","True","False","Principal Investigator","Narcolepsy Syndrome: Towards Improved Diagnosis and Treatment by Application of DNA Methodology","","","$2,716,427.00"
"George, Charles","Medicine","1992","1992","Grants","Funded","True","False","Principal Investigator","Assessment of Sleepiness & Performance in Disorders of Excessive Daytime Sleepiness","CFP George","","$36,989,907.00"
"George, Charles","Medicine","1995","1996","Grants","Funded","False","True","Principal Investigator","A Double-Blind, Placebo-Controlled Cross-Over Trial of Modafinil in the Treatment of Excessive Daytime Sleepiness in Narcoleptics","","","$22,930,900.00"
"George, Charles","Medicine","2002","2003","Grants","Funded","True","False","Principal Investigator","Prevalence of Sleep Disordered Breathing In Professional Football Players","C. George","","$40,186,946.00"
"George, Charles","Medicine","1990","1991","Grants","Funded","False","True","Principal Investigator","Effects of Zolpidem on Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease","","","$42,319,996.00"
"George, Charles","Medicine","1997","1998","Grants","Funded","True","False","Collaborator","Difficulty Weaning from the Ventilator: A Pilot Study to assess the Role of Neuromuscular Respirator Function","Dr. C. Bolton, Professor of Neurology","","$8,881,513.00"
"George, Charles","Medicine","2002","2004","Grants","Funded","False","True","Principal Investigator","A Double Blind, Placebo controlled and active comparator referenced, fixed-dose, randomised , parallel group phase III study of gaboxadol in non-elderly patients with primary insomnia.","C. George","","$38,054,485.00"
"George, Charles","Medicine","1993","1996","Grants","Funded","True","False","Principal Investigator","Assessment of Driving Performance and its Relationship to Sleepiness and Degree of Severity in Disorders of Excessive Daytime Somnolence","","","$69,309,923.00"
"George, Charles","Medicine","1993","1996","Grants","Funded","True","False","Principal Investigator","Assessment of Driving Performance and its Relationship to Sleepiness and Degree of Severity in Disorders of Excessive Daytime Somnolence","","","$71,257,795.00"
"George, Charles","Medicine","1996","1999","Grants","Funded","True","False","Principal Investigator","Assessment of Performance and Sleepiness in Disorders of Excessive Daytime Sleepiness","","","$31,994,733.00"
"George, Charles","Medicine","1992","1993","Grants","Funded","True","False","Principal Investigator","Assessment of Driving Performance & Sleepiness in Disorders of Excessive Daytime Sleepiness.","","","$6,673,089.00"
"George, Charles","Medicine","1996","2000","Grants","Funded","True","False","Collaborator","Multi-site study of Functional Outcomes of CPAP Use","Dr. T. Weaver, University of Pennsylvania","","$72,136,318.00"
"George, Charles","Medicine","2004","2008","Grants","Funded","True","False","Major","Impact of CPAP on Functional Outcomes in Milder OSA (CAT-NAP): A Phase IV Randomized Double Blind Placebo Controlled, Multi-Centered Clinical Trial.","Dr. T. Weaver, University of Pennsylvania","KA Ferguson","$53,302,782.00"
"George, Charles","Medicine","2005","2005","Grants","Funded","True","False","Major","Knowledge-based assistive device for narcoleptic patients.","M Salama","","$45,478,635.00"
"George, Charles","Medicine","1988","1989","Grants","Funded","True","False","Principal Investigator","Sleep & Breathing in Congestive Heart Failure","Charles George","","$56,438,865.00"
"George, Charles","Medicine","1987","1988","Grants","Funded","True","False","Principal Investigator","Sleep & Breathing in Obstructive Sleep Apnea & Chronic Obstructive Lung Disease","Charles George","","$2,991,681.00"
"George, Charles","Medicine","1989","1991","Grants","Funded","True","False","Major","The Cost Effectiveness of a Routine Pulse Oximetry Monitoring Strategy","D. Leasa","P. Pflugfelder, D. Ahmad, H. Wexler","$10,740,092.00"
"George, Charles","Medicine","1988","1990","Grants","Funded","True","False","Major","Sleep & Breathing in COPD","C. F. P. George","","$47,204,022.00"
"George, Charles","Medicine","1989","1990","Grants","Funded","True","False","Major","Sleep & Breathing in CHF","C. F. P. George","Co-Investigator: J. M. O. Arnold","$64,774,877.00"
"George, Charles","Medicine","1991","1992","Grants","Funded","True","False","Major","Assessment of Sleepiness in Driving Performance in Patients with Excessive Daytime Sleepiness (Sleep Apnea).","C. F. P. George","Co-Investigator: J. M. O. Arnold","$12,661,043.00"
"George, Charles","Medicine","1992","1993","Grants","Funded","True","False","Principal Investigator","Assessment of Sleepiness and Performance in Disorders of Excessive Daytime Sleepiness","C. F. P. George","","$20,795,930.00"
"George, Charles","Medicine","1994","1994","Grants","Funded","True","False","Major","Upper Airway Imaging and Oral Appliances in the Treatment of Obstructive Sleep Apnea.","K. A. Ferguson","","$67,798,354.00"
"George, Charles","Medicine","1997","1999","Grants","Funded","True","False","Principal Investigator","Sleep apnea and Automobile Accidents","C. F. P. George","K. A. Ferguson","$41,174,444.00"
"George, Charles","Medicine","1999","2001","Grants","Funded","True","False","Principal Investigator","Sleep Apnea and Automobile Accidents","C. F. P. George","K. A. Ferguson","$13,466,235.00"
"George, Charles","Medicine","2003","2004","Grants","Funded","False","True","Principal Investigator","Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (sodium oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patien.","C. F. P. George","K. A. Ferguson","$7,270,090.00"
"George, Charles","Medicine","1991","1992","Grants","Funded","True","False","Major","A Prospective Pilot Study of Assisted Nocturnal Ventilation in Amyotrophic Lateral Sclerosis","Dr. D. Ahmad","K. A. Ferguson, C. F. P. George, M. Strong","$52,502,302.00"
"George, Charles","Medicine","1999","2001","Grants","Funded","False","True","Major","Evaluation of the Stardust™ respiratory disorder diagnostic Device","K. A. Ferguson","","$35,177,831.00"
"George, Charles","Medicine","1999","2001","Grants","Funded","False","True","Principal Investigator","Double-blind placebo controlled study of the efficacy and safety of 3 doses of SR46349B in patients with obstructive sleep apnea syndrome","C. F. P. George","K. A. Ferguson","$8,911,138.00"
"George, Charles","Medicine","2002","2003","Grants","Funded","False","True","Principal Investigator","Comparison of efficacy and safety of Zolpidem-MR 12.5 mg and placebo in patients with primary insomnia. A double blind, randomized, placebo controlled parallel group study.","C. F. P. George","","$43,714,896.00"
"George, Charles","Medicine","1989","1990","Grants","Funded","True","False","Principal Investigator","Sleep & Breathing in Congestive Heart Failure","C. F. P. George","","$55,962,258.00"
"George, Charles","Medicine","1987","1988","Grants","Funded","True","False","Principal Investigator","Sleep & Breathing in Chronic Obstructive Pulmonary Disease","C. F. P. George","","$76,768.00"
"George, Charles","Medicine","1992","1992","Grants","Funded","True","False","Principal Investigator","Assessment of Patient's Sleep Quality in the Geriatric Assessment Unit.","R. Crilly, M. Camacho","","$30,034,332.00"
"George, Charles","Medicine","1995","1995","Grants","Funded","False","True","Principal Investigator","Phase II, Single-Dose, Two-Centre, Randomized, Double-Blind, Placebo-Controlled, Crossover, Safety and Efficacy Study of 10 mg Zaleplon, 10 mg Zolpidem and Placebo in Adult Outpatients with Insomnia and Chronic Obstructive Pulmonary Disease.","C. George","","$51,786,452.00"
"Farquhar, Donald","Medicine","1990","1990","Grants","Funded","True","False","Principal Investigator","Respiratory health of Prince Edward Island swine workers.","Farquhar D (PI)","Guernsey J (Co-PI).","$37,093,877.00"
"Farquhar, Donald","Medicine","1991","1991","Grants","Funded","True","False","Principal Investigator","Use of exercise testing in disability evaluation in coal workers’ pneumoconiosis","Farquhar D","Lemoine JR (Co-PI)","$17,726,614.00"
"Farquhar, Donald","Medicine","1999","1999","Grants","Funded","True","False","Co-Investigator","A randomized controlled trial of an educational outreach program for primary care physicians. MRC/ACMC Research in Medical Education (RIME) Fund","Shortt S,","Farquhar DRE, Myers KA, Levesque L.","$1,068,809.00"
"Farquhar, Donald","Medicine","1999","1999","Grants","Funded","True","False","Principal Investigator","An inventory of key competencies required to manage hospitalized and ambulatory patients in internal medicine – the residents’ viewpoint.","Farquhar DRE (PI),","Myers KA (Co-PI).","$58,749,664.00"
"Farquhar, Donald","Medicine","2000","2000","Grants","Funded","True","False","Co-Principal Investigator","Using intensive home care support to manage post-emergency room care.","Farquhar","O’Connor M, (Co-PI).","$23,171,303.00"
"Garg, Amit","Medicine","2005/07","2008/06","Grants","Funded","True","False","Co-Investigator","Cohort Study of Inflammatory Bowel Disease after Acute Enteric Infection in Walkerton, Ontario.","Marshall, John","Collins SM, Garg AX, Franchimont D, Moayyedi P","$53,437,134.00"
"Garg, Amit","Medicine","2005/07","2007/06","Grants","Funded","True","False","Principal Investigator","Better Use of Bibliographic Databases for Kidney Diseases.","Garg, Amit","McKibbon A, Wilczynski NL, Rehman F, Haynes RB","$40,078,379.00"
"Garg, Amit","Medicine","2005","2006","Grants","Funded","True","False","Co-Principal Investigator","Long-term Risk of Chronic Arthritis after Campylobacter Infection: The Walkerton Health Study.","Pope, Janet (Nominated PI)","Garg AX, Mamdani M, Marshall JK, Salvadori M","$27,229,553.00"
"Garg, Amit","Medicine","2004/09","2006/08","Grants","Funded","True","False","Co-Investigator","Improving Prescribing of Medications and Patient Safety in Long-term Care","Papaioannou, Alexandra","Dolovitch L, Raina P, Ray J, Garg AX, Holbrook A, Levine M, Kaasalainen S, Emili A","$72,467,687.00"
"Garg, Amit","Medicine","2004/01","2006/12","Grants","Funded","True","False","Principal Investigator","Long-term Medical Implications of Becoming a Living Kidney Donor: A Historical (Retrospective) Matched Cohort Study","Garg, Amit","Boudville N, Muirhead N, Knoll G, Gill J, Awarji C","$70,875,126.00"
"Garg, Amit","Medicine","2004","2005","Grants","Funded","True","False","Principal Investigator","The Long-term Renal Prognosis of Becoming a Living Kidney Donor: A Systematic Review, Meta-Analysis and Meta-regression.","","Boudville N, Muirhead N, Rosas-Arellano P","$53,594,250.00"
"Garg, Amit","Medicine","2003/12","2007/12","Grants","Funded","True","False","Co-Investigator","Short Daily Hemodialysis Trial.","Levin, Nathan & Lindsay, Robert","Bay W, Finkelstein F, Garg AX, Geronemus R, Gipson D, Lacson E, Messana J, Miller B, Ornt D, Reynolds J, Rocco M, Saran R, Simon D, Suri R, Vassalotti J","$9,664,915.00"
"Garg, Amit","Medicine","2003/01","2005/12","Grants","Funded","True","False","Co-Investigator","Long-term risk of abnormal glucose homeostasis after E.coli O157:H7 gastroenteritis.","Suri, Rita","Clark W, Garg A, Mahon J","$39,921,597.00"
"Garg, Amit","Medicine","2003/07","2006/06","Grants","Funded","True","False","Co-Investigator","McMaster PLUS: A cluster randomized clinical trial of an intervention to accelerate use of evidence-based information from digital libraries in clinical practice.","Haynes, Brian","Garg AX, Hayward R, Lohfeld L, Walter S","$11,068,450.00"
"Garg, Amit","Medicine","2002","2004","Grants","Funded","True","False","Co-Principal Investigator","Long-term Renal Complications from E.coliO157:H7 in Walkerton, Ontario.","Matsell, D (Nominated PI)","Haynes RB, Salvadori M","$64,330,871.00"
"Garg, Amit","Medicine","1999","2001","Grants","Funded","True","False","Principal Investigator","The Effect of Structured Patient Education in Chronic Disease Care.","Garg, Amit","Haynes RB","$49,814,934.00"
"Garg, Amit","Medicine","1999","2000","Grants","Funded","True","False","Principal Investigator","Do Anatomy Computer Models Disadvantage Student Spatial Learning?","Garg, Amit","Norman G","$74,554,532.00"
"Garg, Amit","Medicine","1998","1999","Grants","Funded","True","False","Principal Investigator","Understanding Sex Differences in Anatomy Spatial Learning","Garg, Amit","Norman G, Spero L, Taylor I","$56,339,216.00"
"Diachun, Laura","Medicine","2007","2007/06","Grants","Funded","True","False","Collaborator","Hospitalized Older Persons Education (HOPE) Practice-Based Curriculum: Enhancing practice and patient safety in diverse acute care contexts.","","Norris M, Anderson L, Sivjee K, Mehta R, Ryan D, Diachun L.","$12,419,771.00"
"Diachun, Laura","Medicine","2006/01","2007/05","Grants","Funded","True","False","Co-Principal Investigator","Evaluating the Impact of a two-week Elder Care Clerkship on Knowledge and Attitudes Towards Elderly Patients.","","VanBussel L, Diachun L","$29,110,047.00"
"Diachun, Laura","Medicine","2005/05","2008/04","Grants","Funded","True","False","Co-Principal Investigator","Evaluating the Impact of a two-week Elder Care Clerkship on Knowledge and Attitudes Towards Elderly Patients.","","Diachun L, VanBussel L","$24,038,040.00"
"Hodsman, Anthony","Medicine","1981/04","1988/06","Grants","Funded","True","False","Principal Site Investigator","Role of aluminum as an inhibitor of bone mineralization","","","$69,537,347.00"
"Hodsman, Anthony","Medicine","1984/07","1988/06","Grants","Funded","True","False","","Use of calcidiol or dietary calcium supplements to treat steroid-induced osteoporosis","","","$61,432,539.00"
"Hodsman, Anthony","Medicine","1986/07","1987/06","Grants","Funded","True","False","","Cyclical therapy for osteoporosis using parenteral parathyroid hormone: a pilot study","","","$31,166,568.00"
"Hodsman, Anthony","Medicine","1988/11","1989/10","Grants","Funded","True","False","","Cyclical therapy for osteoporosis using parathyroid hormone and/or calcitonin","","","$30,043,462.00"
"Hodsman, Anthony","Medicine","1991/10","1994/09","Grants","Funded","True","False","","Cyclical treatment of osteoporosis with Parathyroid Hormone and Calcitonin: A randomized, clinical trial","","","$46,315,365.00"
"Hodsman, Anthony","Medicine","1982/12","1982/12","Clinical Trials","Funded","False","True","Principal Site Investigator","To study cyclical therapy for osteoporosis","","","$28,164,698.00"
"Hodsman, Anthony","Medicine","2000/10","2006/09","Grants","Funded","True","False","Co-Applicant","Novel mechanisms of parathyroid hormone action","Dr. Patricia Watson","","$21,915,244.00"
"Hodsman, Anthony","Medicine","1989/11","1992/11","Clinical Trials","Funded","False","True","Principal Site Investigator","Cyclical therapy for osteoporosis using parathyroid hormone","","","$36,732,444.00"
"Hodsman, Anthony","Medicine","1991/06","1991/06","Grants","Funded","False","False","Principal Investigator","To support studies evaluating PTH(1-34) in the treatment of osteoporosis","","","$62,840,551.00"
"Hodsman, Anthony","Medicine","1991/07","1994/06","Clinical Trials","Funded","False","True","","To support ongoing clinical studies, using synthetic PTH in osteoporosis patients","","","$27,046,234.00"
"Hodsman, Anthony","Medicine","1991/07","1991/07","Grants","Funded","False","False","","MRC Summer Research Scholarship for Raymond Marier.","","","$54,061,610.00"
"Hodsman, Anthony","Medicine","1994/03","1997/06","Clinical Trials","Funded","False","True","","To determine the safety and efficacy of intermittent cyclical therapy etidronate in the prevention of corticosteroid-induced osteoporosis","","","$31,933,805.00"
"Hodsman, Anthony","Medicine","1994/03","1997/06","Clinical Trials","Funded","False","True","","To determine the efficacy and safety of risedronate (ne58095) in the treatment of postmenopausal women with established osteoporosis","","","$7,618,216.00"
"Hodsman, Anthony","Medicine","1994/03","1997/06","Clinical Trials","Funded","False","True","","To study long term comparison of raloxifene HCL, placebo and premarin in the prevention of osteoporosis in postmenopausal hysterectomized women","","","$69,923,509.00"
"Hodsman, Anthony","Medicine","1995/02","1998/06","Clinical Trials","Funded","False","True","","To study the comparison of raloxifene HCL and placebo in the treatment of postmenopausal women with osteoporosis","","","$28,478,440.00"
"Hodsman, Anthony","Medicine","1994/06","1997/09","Clinical Trials","Funded","False","True","","To assess the safety and efficacy of 3 doses of ALX1-11 in the treatment of postmenopausal osteoporosis","","","$68,662,674.00"
"Hodsman, Anthony","Medicine","1995/11","1996/11","Clinical Trials","Funded","False","True","","For evaluation of parathyroid hormone and raloxifene to reverse osteopenia in an animal model","","","$13,723,934.00"
"Hodsman, Anthony","Medicine","1996/07","2001/07","Clinical Trials","Funded","False","True","","To study effects of LY333334 (parathyroid hormone) in the treatment of postmenopausal women with osteoporosis","","","$55,294,738.00"
"Hodsman, Anthony","Medicine","1997/05","1999/05","Clinical Trials","Funded","False","True","","To study the effects of LY333334 compared with alendronate in postmenopausal women with osteoporosis","","","$7,475,785.00"
"Hodsman, Anthony","Medicine","1997/05","1998/04","Clinical Trials","Funded","False","True","","For study to compare the actions of PTH(1-31) and PTH(1-34) in human subjects","","","$41,072,443.00"
"Hodsman, Anthony","Medicine","1998/01","2000/01","Clinical Trials","Funded","False","True","","To study the effects of LY333334 in the treatment of osteoporosis in men","","","$10,999,227.00"
"Hodsman, Anthony","Medicine","1999/08","2002/10","Clinical Trials","Funded","False","True","","To study the effect of daily versus weekly dosing regimens of risedronate in the treatment of osteoporosis in postmenopausal women","","","$11,614,205.00"
"Hodsman, Anthony","Medicine","1999/08","2000/07","Clinical Trials","Funded","False","True","Principal Site Investigator","Filmless peripheral bone densitometry using phalangeal DEXA","","","$5,101,768.00"
"Hodsman, Anthony","Medicine","2000/01","2000","Clinical Trials","Funded","False","True","Principal Site Investigator","Continuing Outcomes Relevant to Evista (CORE): comparison of raloxifene HCl and placebo in the prevention of invasive breast cancer in postmenopausal women with osteoporosis","","","$2,302,965.00"
"Hodsman, Anthony","Medicine","2000/05","2001/04","Clinical Trials","Funded","False","True","","To assess the quality of life, safety, and resource utilization in post-menopausal women treated with Miacalcin NS® vs Fosamax®.","","","$41,078,735.00"
"Hodsman, Anthony","Medicine","1999/06","2002/06","Clinical Trials","Funded","False","True","","For extended follow up of patients in LY333334 trials","","","$43,549,441.00"
"Hodsman, Anthony","Medicine","2000/08","2004/06","Clinical Trials","Funded","False","True","","To study the effect of recombinant human parathyroid hormone (ALX1-11) on fracture incidence in women with postmenopausal osteoporosis","","","$35,357,738.00"
"Hodsman, Anthony","Medicine","2001/08","2001/10","Clinical Trials","Funded","False","True","Principal Site Investigator","Fosamax preference study","","","$3,995,557.00"
"Hodsman, Anthony","Medicine","2002/01","2004/06","Clinical Trials","Funded","False","True","","Open label extension study (OLES) of safety & efficacy of rhPTH(1-84) in women with postmenopausal osteoporosis who participated in ALX1-11","","","$61,279,281.00"
"Hodsman, Anthony","Medicine","2002/01","2011/02","Clinical Trials","Funded","False","True","Principal Site Investigator","To study safety and efficacy with intravenous zolendronic acid for treatment of Paget’s disease using risedronate as a comparator","","","$46,562,636.00"
"Hodsman, Anthony","Medicine","2002/01","2005/06","Clinical Trials","Funded","False","True","","To study sequential use of teriparatide and raloxifene HCL in the treatment of postmenopausal women with osteoporosis (GHBQ)","","","$51,533,073.00"
"Hodsman, Anthony","Medicine","2002/01","2007","Clinical Trials","Funded","False","True","Principal Site Investigator","To study efficacy of intravenous zolendronic acid in preventing subsequent osteoporotic fractures after a hip fracture","","","$29,742,845.00"
"Hodsman, Anthony","Medicine","2002/09","2010/09","Clinical Trials","Funded","False","True","Principal Site Investigator","Fracture incidence reduction and safety of TSE-424 (bazedoxifene acetate) compared to placebo and raloxifene in osteoporotic postmenopausal women","","","$16,541,639.00"
"Hodsman, Anthony","Medicine","2004/07","2007","Clinical Trials","Funded","False","True","Principal Site Investigator","To compare 75 mg Risedronate Dosed on Two Days Monthly with 5 mg risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed over 24 Months","","","$73,108,919.00"
"Hodsman, Anthony","Medicine","2004/07","2007","Clinical Trials","Funded","False","True","Principal Site Investigator","An Open-label study to determine how prior therapy with Alendronate or Risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of Teriparatide","","","$20,324,497.00"
"Hodsman, Anthony","Medicine","2004/07","2005/07","Clinical Trials","Funded","False","True","Principal Site Investigator","Assessing the efficacy and Tolerability of Lanthanum Carbonate in the reduction of Serum Phosphate Levels in End Stage Renal Disease Patients Receiving Dialysis","","","$28,240,322.00"
"Hodsman, Anthony","Medicine","2004/12","2005/12","Clinical Trials","Funded","False","True","Principal Site Investigator","Assessing the efficacy and Tolerability of Lanthanum Carbonate in the Reduction of Serum Phosphate Levels in end Stage Renal Disease Patients Receiving Dialysis (Optional Extension Study)","","","$15,806,539.00"
"Hodsman, Anthony","Medicine","2005/05","2006/04","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCL in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism Not Receiving Dialysis","","","$56,175,887.00"
"Hodsman, Anthony","Medicine","2005/10","2006/01","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Finding Study to Investigate the Safety, Tolerability and Efficacy of Ostabolin-C™ in Post-Menopausal Female Subjects with Low Bone Mineral Density","","","$25,586,233.00"
"Hodsman, Anthony","Medicine","2005/12","2007","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Extension Study to Investigate the Safety, Tolerability and Efficacy of Ostabolin-C™ in Post-Menopausal Women with Low Bone Mineral Density (Optional Extension Study)","","","$13,246,591.00"
"Hodsman, Anthony","Medicine","2006/05","2011/08","Clinical Trials","Funded","False","True","Principal Site Investigator","The Effect of Teriparatide Compared with Risedronate on Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures","","","$8,981,278.00"
"Hodsman, Anthony","Medicine","2006/09","2008","Grants","Funded","False","True","Principal Site Investigator","A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density","","","$49,965,979.00"
"Hodsman, Anthony","Medicine","2006/09","2009","Grants","Funded","False","True","Principal Site Investigator","ADVANCE: A Randomized Study to Evaluate the Effects of Cinacalcet plus low dose Vitamin D on Vascular Calcification in Subjects with Chronic Kidney Disease (CKD) Receiving Hemodialysis","","","$56,582,916.00"
"Hodsman, Anthony","Medicine","1990","1990/03","Grants","Funded","False","False","","Cyclical Therapy for Osteoporosis using parathyroid hormone","","","$72,241,973.00"
"Hodsman, Anthony","Medicine","1989","1989/07","Grants","Funded","False","False","","Cyclical therapy for Osteoporosis using parathyroid hormone","","","$56,473,627.00"
"Hodsman, Anthony","Medicine","1989","1989/03","Grants","Funded","False","False","","Towards purchase of Hologics QDR 100 Bone Densitometer","","","$59,014,776.00"
"Hodsman, Anthony","Medicine","1990","1990/07","Grants","Funded","False","False","","Technician Salary support for Osteoporosis Program","","","$29,839,520.00"
"Hodsman, Anthony","Medicine","1990","1990/07","Grants","Funded","False","False","","Dialysis Re-use Program, Support for Bone Histomorphometry Lab","","","$45,840,850.00"
"Hodsman, Anthony","Medicine","1990","1990/07","Grants","Funded","False","False","","Dialysis Re-use Program, Personnal Base Salary Support as Director, Hemodialysis Unit","","","$55,271,044.00"
"Hodsman, Anthony","Medicine","1991","1991/05","Grants","Funded","False","False","Principal Investigator","Comparison of the biological actions of hPTH (1-34) and hPTH-related Peptide (1-34) and hPTH-related Peptide (1-34) in normal human subjects","","","$38,109,188.00"
"Hodsman, Anthony","Medicine","1991","1991/07","Grants","Funded","False","False","","Summer Student","","","$25,653,716.00"
"Hodsman, Anthony","Medicine","1992","1992/01","Grants","Funded","False","False","","Localisation of IGF-1 in rat bone; influence of oophorectomy and parathyroid hormone therapy","","","$17,425,418.00"
"Hodsman, Anthony","Medicine","1997","1997/01","Grants","Funded","False","False","","Effect of an osteoporosis education and risk assessment self-referral program on adoption of prevention strategies","","","$6,881,446.00"
"Hodsman, Anthony","Medicine","1997","1997/01","Grants","Funded","False","False","Principal Investigator","Comparison of the actions of PTH(1-31) and PTH(1-34) in human subjects (Procter & Gamble, Canada)","","","$16,062,315.00"
"Hodsman, Anthony","Medicine","1998","1998/06","Grants","Funded","False","False","Principal Investigator","A comparison of phalangeal bone mineral density using digital radiography and radiographic absorptiometry","","","$50,587,420.00"
"Hodsman, Anthony","Medicine","1999","1999/06","Grants","Funded","False","False","","Regulation of Osteoblast OPGL Expression by PTH(1-34) and PTH(1-31)NH2","","","$58,891,166.00"
"Hodsman, Anthony","Medicine","1999","1999/06","Grants","Funded","False","False","","Regulation of Osteoblast OPGL Expression by PTH(1-34) and PTH(1-31)NH2","","","$66,815,651.00"
"Hodsman, Anthony","Medicine","2000/07","2001/06","Grants","Funded","True","False","Principal Investigator","Comparison of phalangeal bone mineral density using 2-dimensional areal bone densitometry (2-D DEXA) with quantitative computed densitometry","Dr. Anthony Hodsman","Dr. David Holdsworth","$25,818,981.00"
"Marotta, Paul","Medicine","1999","2000","Grants","Funded","False","False","Principal Investigator","Utility and Health Related Quality of Life Assessment for Liver Disease Patients","","","$58,464,147.00"
"Lindsay, Robert","Medicine","2004","2010","Grants","Funded","True","False","Principal Site Investigator","Randomized controlled trial of overnight home nocturnal hemodialysis versus conventional hemodialysis","Michael Rocco","","$7,351,792.00"
"Lindsay, Robert","Medicine","2004/07","2010/06","Grants","Funded","True","False","Co-Principal Investigator","Randomized controlled trial of In-Centre Daily versus conventional hemodialysis","","","$59,077,105.00"
"Lindsay, Robert","Medicine","1998/04","2011/04","Clinical Trials","Funded","True","False","Principal Investigator","The London Daily/Nocturnal Hemodialysis Study","Dr. Robert Lindsay","","$65,941,048.00"
"Lindsay, Robert","Medicine","2003","2014/12","Grants","Funded","False","True","Principal Investigator","Quotidian Hemodialysis International Registry","Principal Investigator","Dr. Gihad Nesrallah, Dr. Rita Suri, Dr. Louise Moist","$27,690,707.00"
"Lindsay, Robert","Medicine","2006/03","2006/12","Grants","Funded","True","False","Principal Investigator","Sodium Balance in Hemodialysis Patients","","","$51,807,023.00"
"Lindsay, Robert","Medicine","1978/07","1982/06","Grants","","False","False","","Studies into the adaptation to home dialysis","","H Burton, R Lindsay","$55,339,344.00"
"Lindsay, Robert","Medicine","1980","1982","Grants","","False","False","","Studies into the adaptation to home dialysis","R. Lindsay","H. Burton","$57,243,207.00"
"Lindsay, Robert","Medicine","1982","1985","Grants","","False","False","","Studies into the adaptation to home dialysis","R. Lindsay","H. Burton","$44,404,481.00"
"Lindsay, Robert","Medicine","1982","1984","Grants","","False","False","","The dialyser induced pulmonary vascular response Blood foreign surface interactions","R. Lindsay","","$73,693,224.00"
"Lindsay, Robert","Medicine","1983","1985","Grants","","False","False","","Studies into the adaptation to home dialysis","A Linton","W Sibbald, R Lindsay","$49,563,735.00"
"Lindsay, Robert","Medicine","1983","1985","Grants","","False","False","","The evaluation (in-vivo) of new dialysers and dialytic methods","R Lindsay","","$59,255,900.00"
"Lindsay, Robert","Medicine","1985","1987","Grants","","False","False","","Hypertension research","H. Burton","R. Lindsay","$22,240,229.00"
"Lindsay, Robert","Medicine","1982","1986","Grants","","False","False","","Studies into the adaptation to home dialysis","R Lindsay","H Burton","$34,861,461.00"
"Lindsay, Robert","Medicine","1982","1985","Grants","","False","False","","The dialyser induced pulmonary vascular response Blood foreign surface interactions","R Lindsay","A Linton, W Sibbald","$4,796,250.00"
"Lindsay, Robert","Medicine","1987","1989","Grants","","False","False","","The evaluation (in-vivo) of new dialysers and dialytic methods","H Burton","R Lindsay","$17,186,683.00"
"Lindsay, Robert","Medicine","1987","1988","Grants","","False","False","","Clinical trials in dialysis","R Lindsay","","$17,435,754.00"
"Lindsay, Robert","Medicine","1987","1988","Grants","","False","False","","Studies into the adaptation to home dialysis","R Lindsay","","$44,991,648.00"
"Lindsay, Robert","Medicine","1986","1987","Grants","","False","False","","Blood foreign surface interactions; thrombosis and complement systems","","","$37,909,444.00"
"Lindsay, Robert","Medicine","1987","1989","Grants","","False","False","","Clinical trials in dialysis","R. Lindsay","","$36,653,568.00"
"Lindsay, Robert","Medicine","1987","1990","Grants","","False","False","","Clinical trials in dialysis","R Lindsay","","$33,593,882.00"
"Lindsay, Robert","Medicine","1988","1989","Grants","","False","False","","Nutritional status in renal failure and its treatment","","R Lindsay","$21,856,717.00"
"Lindsay, Robert","Medicine","1987","1989","Grants","","False","False","","The evaluation (in-vivo) of new dialysers and dialytic methods","H. Burton","R. Lindsay","$41,946,981.00"
"Lindsay, Robert","Medicine","1988","1991","Grants","","False","False","","Studies into the adaptation to home dialysis","R. Lindsay","","$32,494,348.00"
"Lindsay, Robert","Medicine","1988","1989","Grants","Funded","False","False","Principal Investigator","Hypertension research","R Lindsay","H. Burton","$13,043,627.00"
"Lindsay, Robert","Medicine","1991","1992","Grants","","False","False","","Nutritional status in renal failure and its treatment","R. Lindsay","","$48,712,138.00"
"Lindsay, Robert","Medicine","1991","1992","Grants","","False","False","","Nutritional status in renal failure and its treatment","R. Lindsay","","$57,803,870.00"
"Lindsay, Robert","Medicine","1991","1992","Grants","","False","False","","Studies into the adaptation to home dialysis","R. Lindsay","","$72,165,297.00"
"Lindsay, Robert","Medicine","1992","1994","Grants","","False","False","","The evaluation (in-vivo) of new dialysers and dialytic methods Nutritional status in renal failure and its treatment","R. Lindsay","","$70,306,367.00"
"Lindsay, Robert","Medicine","1992","1992","Grants","","False","False","","Hypertension research","R. Lindsay","","$3,144,781.00"
"Lindsay, Robert","Medicine","1993","1994","Grants","","False","False","","Clinical trials in dialysis Nutritional status in renal failure and its treatment","R. Lindsay","","$56,153,953.00"
"Lindsay, Robert","Medicine","1994","1995","Grants","Funded","True","False","Principal Investigator","Clinical trials in dialysis Nutritional status in renal failure and its treatmentls in dialysis","","R. Lindsay","$35,996,623.00"
"Lindsay, Robert","Medicine","1994","1995","Grants","","False","False","","Clinical trials in dialysis Nutritional status in renal failure and its treatment in dialysis","R. Lindsay","","$59,790,937.00"
"Lindsay, Robert","Medicine","1995","1996","Grants","","False","False","","5&7","R. Lindsay","Clinical trials in dialysis Nutritional status in renal failure and its treatment","$9,712,158.00"
"Lindsay, Robert","Medicine","1995","1996","Grants","","False","False","","Clinical trials in dialysis Nutritional status in renal failure and its treatment","R. Lindsay","","$69,019,037.00"
"Lindsay, Robert","Medicine","1995","1996","Grants","Funded","True","False","Principal Applicant","Studies into the adaptation to home dialysis","R. Lindsay","","$74,577,287.00"
"Lindsay, Robert","Medicine","1996","1997","Grants","Funded","False","True","Principal Investigator","Nutritional status in renal failure and its treatment","R. Lindsay","","$12,849,844.00"
"Lindsay, Robert","Medicine","1996","1997","Grants","","False","False","","Nutritional status in renal failure and its treatment","R. Lindsay","","$66,641,377.00"
"Lindsay, Robert","Medicine","1996","1997","Grants","Funded","False","False","Principal Applicant","Clinical trials in dialysis","","R. Lindsay","$17,546,526.00"
"Lindsay, Robert","Medicine","1996","1997","Grants","","False","False","","Biosensors in dialysis Blood access development/monitoring","R Lindsay","","$43,242,213.00"
"Lindsay, Robert","Medicine","1997","1997","Grants","Funded","False","False","Principal Investigator","Biosensors in dialysis","","R. Lindsay","$12,502,826.00"
"Lindsay, Robert","Medicine","1997","1998","Grants","Funded","False","True","Principal Investigator","Blood access development/monitoring","R. Lindsay","P. Blake","$31,176,709.00"
"Lindsay, Robert","Medicine","1998","1999","Grants","Funded","True","False","Principal Investigator","Blood access development/monitoring","R. Lindsay","L. Moist","$43,000,866.00"
"Lindsay, Robert","Medicine","1998","1999","Grants","","False","False","","Blood access development/monitoring","","","$27,379,143.00"
"Lindsay, Robert","Medicine","1999","2000","Grants","Funded","False","False","Principal Applicant","Satellite fallback","R. Lindsay","","$70,401,203.00"
"Lindsay, Robert","Medicine","1999","2002","Grants","","False","False","","Satellite fallback","R. Lindsay","","$54,231,490.00"
"Lindsay, Robert","Medicine","1999","2000","Grants","","False","False","","Blood access development/monitoring","S. Pandeya","R. Lindsay","$23,027,697.00"
"Lindsay, Robert","Medicine","2000","2000","Grants","Funded","False","False","Principal Applicant","Blood access development/monitoring","R. Lindsay","","$33,024,676.00"
"Lindsay, Robert","Medicine","2000","2001","Grants","","False","False","","Blood access development/monitoring","L. Moist","R. Lindsay","$32,858,632.00"
"Lindsay, Robert","Medicine","2000","2001","Grants","Funded","False","False","Principal Investigator","Blood access development/monitoring","","R. Lindsay","$16,019,656.00"
"Lindsay, Robert","Medicine","2000","2001","Grants","Funded","False","False","Principal Investigator","The evaluation (in-vivo) of new dialysers and dialytic methods Blood access development/monitoring","R. Lindsay","","$58,968,359.00"
"Lindsay, Robert","Medicine","2000","2001","Grants","Funded","False","True","Principal Investigator","Clinical trials in dialysis","R. Lindsay","","$53,178,236.00"
"Lindsay, Robert","Medicine","2001","2004","Grants","","False","False","","Satellite fallback","R. Lindsay","","$11,401,735.00"
"Lindsay, Robert","Medicine","2003","2004","Grants","","False","False","","The evaluation (in-vivo) of new dialysers and dialytic methods Blood access development/monitoring","R. Lindsay","","$41,921,502.00"
"Crilly, Richard","Medicine","1996/07","1998/06","Grants","Funded","True","False","Principal Investigator","Cherryhill/Westown Community Project.","","","$35,774,142.00"
"Crilly, Richard","Medicine","1997/07","1998/06","Grants","Funded","True","False","Principal Investigator","Funding for Survey of Physicians Practice in the Management of Osteoporosis in Institutionalized Elderly.","","","$74,151,734.00"
"Crilly, Richard","Medicine","1997/07","1998/06","Grants","Funded","True","True","Co-Investigator","Effect of an Osteoporosis Education and Risk Assessment Self-Referral Program on Adoption of Prevention Strategies.","","Dr. Hodsman.","$21,493,739.00"
"Crilly, Richard","Medicine","1998","2001","Grants","Funded","True","True","Co-Investigator","Caring for Canada’s Elderly. The Case for Supporting and Endowment for Geriatric Research at London’s Parkwood Hospital. A Program Research, Education and Service for Appropriate Prescribing and Use of Medications in the Elderly.","","Borrie MJ, Brymer CD, Hindman D, Stolee P.","$22,942,688.00"
"Crilly, Richard","Medicine","1997","1998","Grants","Funded","True","False","Co-Investigator","Clinical Clerk Learning Experience with Community Pharmacists, Medications and Elderly at home.","","Borrie MJ, Brymer CD, Crilly RG, Wells J, Kenzie D.","$1,576,227.00"
"Crilly, Richard","Medicine","1998/01","1998/12","Grants","Funded","False","False","Co-Principal Investigator","Building and Evaluating the Cherryhill Healthy Ageing Program.","Kloseck, M.","","$70,780,615.00"
"Crilly, Richard","Medicine","1999/07","2000/06","Grants","Funded","True","False","Principal Investigator","Prevention of Hip Fractures in the Institutionalized Elderly.","","","$31,096,342.00"
"Crilly, Richard","Medicine","2000/07","2001/06","Grants","Funded","True","True","Principal Investigator","Investigation in the Changes in Size of Vertebrae on Treatment and the Effect on the Areal Density Measurements on BMD.","","","$41,181,686.00"
"Crilly, Richard","Medicine","2003/01","2003/12","Grants","Funded","True","True","Principal Investigator","Study of Osteoporosis and Hip Fracture in Nursing Homes","Crilly, R.","Kloseck, M.","$15,494,334.00"
"Crilly, Richard","Medicine","2000/07","2002/06","Grants","Funded","True","False","Co-Principal Investigator","An Innovative Approach to Care of the Elderly in the community: A pilot project of the Parkwood Geriatric Day Hospital in partnership with the Cherryhill Health Promotion and Information Centre.","Kloseck, M. (Co-PI), Crilly, R. (Co-PI)","Griffiths,N., Vickers, M.","$10,888,050.00"
"Crilly, Richard","Medicine","2001/07","2002/06","Grants","Funded","True","False","Co-Principal Investigator","Publication of 6-Year Research Outcomes of Community Capacity in the Cherryhill Community.","Crilly, R. (Co-PI), Kloseck, M. (Co-PI)","","$10,630,806.00"
"Crilly, Richard","Medicine","2001/07","2004/06","Grants","Funded","True","False","Collaborator","Project to Prevent Falls in Veterans.","","","$17,818,482.00"
"Crilly, Richard","Medicine","2003/07","2004/06","Grants","Funded","True","False","Principal Investigator","Evaluation of a Care Plan for Hip Fracture Patients.","","","$38,116,170.00"
"Crilly, Richard","Medicine","2003/01","2003/12","Grants","Funded","True","True","Principal Investigator","Effect of Abnormal Gait Patterns on Bone Loss After Hip Fracture.","","","$34,966,594.00"
"Crilly, Richard","Medicine","2002/07","2003/06","Grants","Funded","True","False","Co-Principal Investigator","Synthesis Research on Community Capacity: Operationalizing & Measuring Community Capacity.","Kloseck, M., Crilly, R. (Co-PI)","Lubell, J.","$65,284,345.00"
"Crilly, Richard","Medicine","2005/07","2006/06","Grants","Funded","True","False","Principal Investigator","The Importance of Aerobic Fitness in Rehabilitation of the Elderly.","","Overend, T.","$28,334,398.00"
"Crilly, Richard","Medicine","2006/07","2007/06","Grants","Funded","True","False","Co-Investigator","Innovation to Prevent Disability: Optimizing a Mobility in Aging Research Network","Petrella, R.","Jutai, J., Kloseck, M., Crilly, R.G., Borrie, M., Chesworth, B., Connelly, D., Overend, T., Doherty, T., Wells, J., Jones, G., Speechley, M.","$22,395,882.00"
"Crilly, Richard","Medicine","2007/07","2008/06","Grants","Funded","True","False","Co-Investigator","How do Providers Manage Pain in Hip Fracture Patients after they are educated about the RNAO BPG?","David Ryan, PhD, Psychologist","","$25,179,653.00"
"Hramiak, Irene","Medicine","1987","1988","Grants","Funded","True","False","Principal Investigator","Insulin sensitivity in type 1 diabetes","IM Hramiak","","$1,771,719.00"
"Hramiak, Irene","Medicine","1988","1989","Grants","Funded","True","False","Principal Investigator","Studies on 1) the effects of galanin and cyclosporine-A on canine insulin release and canine tissue sensitivity to insulin’s action. 2) The efficacy of a specific competitive antagonist to the action of the gastrin-releasing polypeptide (GRP)","IM Hramiak","TJ McDonald","$17,516,093.00"
"Hramiak, Irene","Medicine","1989","1990","Clinical Trials","Funded","False","True","Principal Investigator","Use of pre-mixed insulin preparations in diabetic subjects.","IM Hramiak","M Jenner","$11,086,683.00"
"Hramiak, Irene","Medicine","1989","1990","Clinical Trials","Funded","False","True","Collaborator","MK-538 in the prevention of diabetic retinopathy","C Canny","J Dupre, IM Hramiak","$22,576,664.00"
"Hramiak, Irene","Medicine","1990","1995","Clinical Trials","Funded","False","True","Collaborator","Tolrestat in the prevention and treatment of diabetic retinopathy","C Canny","J Dupre, IM Hramiak","$68,992,253.00"
"Hramiak, Irene","Medicine","1993","1996/12","Clinical Trials","Funded","False","True","Collaborator","Studies and effects of gliclazide on glucose tolerance and insulin sensitivity in volunteers with impaired glucose tolerance","J Dupre","IM Hramiak, R Feldman, R McManus","$7,632,252.00"
"Hramiak, Irene","Medicine","1994/07","1996/05","Clinical Trials","Funded","False","True","Principal Investigator","A double-blind, parallel, multi centre comparison of two doses of acetyl-L-carnitine (ALCAR) with placebo in the prevention of progression and treatment of diabetic peripheral neuropathy after 52 weeks of treatment","IM Hramiak","","$51,555,275.00"
"Hramiak, Irene","Medicine","1995/02","1996/12","Clinical Trials","Funded","False","True","Principal Investigator","Insulin lispro in the treatment of patients with type II diabetes after oral agent failure","IM Hramiak","","$29,790,539.00"
"Hramiak, Irene","Medicine","1995/10","1996/12","Clinical Trials","Funded","False","True","Principal Investigator","Free mixtures of insulin lispro protamine suspension (NPL) and insulin lispro: comparison with free mixtures of humulin N and humulin R in a twice daily regimen in the treatment of diabetes","IM Hramiak","J Dupré","$61,457,417.00"
"Hramiak, Irene","Medicine","1996/07","1999/06","Clinical Trials","Funded","False","True","Principal Investigator","Free mixtures of insulin lispro protamine suspension (NPL) and insulin lispro – extension study","IM Hramiak","J Dupré","$27,978,490.00"
"Hramiak, Irene","Medicine","1996/12","1998/10","Clinical Trials","Funded","False","True","Principal Investigator","A double-blind, placebo-controlled, multicentre, phase III study to evaluate the effects of pramlintide (AC137) on glycemic control as determined by glycated hemoglobin in patients with Type 1 diabetes mellitus","IM Hramiak","J Dupré","$22,883,037.00"
"Hramiak, Irene","Medicine","1997/12","1998/10","Clinical Trials","Funded","False","True","Principal Investigator","A long-term, multicenter, open-label extension study to evaluate the tolerability and effects of pramlintide (AC137) in patients completing Amylin protocol #137-117","IM Hramiak","J Dupré","$19,609,016.00"
"Hramiak, Irene","Medicine","1997/02","1997/02","Clinical Trials","Funded","False","True","Principal Investigator","A six month multicenter, randomized, parallel, open label, efficacy and safety comparison of the human insulin analogue X14 and Regular, human insulin as meal related insulin in a multiple injection regimen in subjects with Type 1 diabetes","IM Hramiak","TJ McDonald","$74,408,030.00"
"Hramiak, Irene","Medicine","1997/11","1998/06","Clinical Trials","Funded","False","True","Principal Investigator","16-week multicentre, controlled, randomized, open-label clinical trial compared HOE 901 insulin and NPH human insulin in subjects with Type 1 diabetes treated with insulin lispro","IM Hramiak","JL Mahon","$17,768,160.00"
"Hramiak, Irene","Medicine","1997/05","1998/09","Clinical Trials","Funded","False","True","Principal Investigator","A double blind randomized study of troglitazone (C1-991) versus placebo in Type II diabetes patients with compromised glycemic control on a combination therapy of sulfonylureas and metformin","IM Hramiak","J Dupré","$52,505,276.00"
"Hramiak, Irene","Medicine","1996/05","2000","Clinical Trials","Funded","False","True","Collaborator","Studies on the effects of GLP-1 on glycemic responses to meals in IDDM","J Dupré","TJ McDonald, IM Hramiak, M Behme","$41,667,089.00"
"Hramiak, Irene","Medicine","1997/10","1999/02","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of rhNGF in the treatment of patients with signs of diabetic neuropathy","IM Hramiak","J Dupré","$2,750,353.00"
"Hramiak, Irene","Medicine","1999/01","1999/07","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of rhNGF in the treatment of patients with signs of diabetic neuropathy - Extension","IM Hramiak","J Dupré","$19,309,444.00"
"Hramiak, Irene","Medicine","1998/08","1999","Clinical Trials","Funded","False","True","Principal Investigator","A 12-week dose ranging study with GI262570X in combination with non-micronized glibenclamide (semi-daonil) in patients with Type I diabetes mellitus","IM Hramiak","J Dupré","$9,900,686.00"
"Hramiak, Irene","Medicine","1999/05","1999/11","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of inhaled insulin compared with subcutaneous human insulin therapy in subjects with Type I diabetes mellitus: a 6 month, outpatient, parallel, comparative trial.","IM Hramiak","J Dupré","$10,695,094.00"
"Hramiak, Irene","Medicine","1999/10","2000","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of inhaled insulin compared with subcutaneous human insulin therapy in subjects with Type I diabetes mellitus: a 6 month, outpatient, parallel, comparative trial – Extension","IM Hramiak","J Dupré","$26,655,907.00"
"Hramiak, Irene","Medicine","2002/05","2003/11","Clinical Trials","Funded","False","True","Principal Investigator","Long term safety of EXUBERA (inhaled insulin): extension of therapy in subjects with Type 1 or Type 2 diabetes mellitus completing phase III randomized treatment trials (trends in pulmonary function after discontinuation of EXUBERA (inhaled insulin) 217-111-5069 Ext Ext","IM Hramiak","TL Paul","$29,672,771.00"
"Hramiak, Irene","Medicine","1999/08","2001","Clinical Trials","Funded","False","True","Principal Investigator","A long-term, double-blind, placebo-controlled, parallel-group study of Zenarestat in diabetic patients at risk of foot ulcer","IM Hramiak","JL Mahon, J Dupre","$59,984,742.00"
"Hramiak, Irene","Medicine","2000/01","2002","Clinical Trials","Funded","False","True","Principal Investigator","Target glycemic control and the incidence of symptomatic nocturnal hypoglycaemia in insulin naïve subjects with Type 2 diabetes on oral hypoglycaemic agent(s) and treated with insulin glargine or NPH human insulin","IM Hramiak","JL Mahon, J Dupre","$30,792,109.00"
"Hramiak, Irene","Medicine","2000/05","2001","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy, dose-ranging, and safety for RWJ-241947 in Type 2 diabetic subjects, inadequately controlled on diet, metformin or sulfonylurea: a 12 week double-blind, randomized, placebo-controlled study","IM Hramiak","TJ McDonald, J Dupre","$3,088,486.00"
"Hramiak, Irene","Medicine","2000/03","2006/07","Clinical Trials","Funded","False","True","Principal Investigator","A diabetes outcome progression trial.","IM Hramiak","TJ McDonald, T Paul","$61,367,714.00"
"Hramiak, Irene","Medicine","2000/05","2001","Clinical Trials","Funded","False","True","Principal Investigator","A multi national, multi-centre, randomised, open labelled, two period cross-over trial, comparing insulin aspart in Innovo delivery device with insulin lispro in HumaPen ergo delivery device in subjects with Type 1 and Type 2 diabetes","IM Hramiak","J Dupre","$55,531,425.00"
"Hramiak, Irene","Medicine","2001/07","2007/07","Clinical Trials","Funded","False","True","Principal Investigator","Evaluation of diabetic retinopathy progression in subjects with Type 2 diabetes mellitus","IM Hramiak","TL Paul, J Gonder","$5,883,388.00"
"Hramiak, Irene","Medicine","2001/11","2002/10","Clinical Trials","Funded","False","True","Principal Investigator","12-week, multinational, multicenter, controlled, open, 1:1:1 randomized parallel clinical trial to assess noninferiority between pre- and post-meal administration of HMR 1964 and pre-meal regular human insulin in subjects with type 1 diabetes mellitus receiving insulin glargine as the basal insulin therapy","IM Hramiak","TL Paul","$28,222,181.00"
"Hramiak, Irene","Medicine","2002/03","2002/12","Clinical Trials","Funded","False","True","Principal Investigator","Safety of Humalog in the treatment of pregestational diabetes during pregnancy","IM Hramiak","TJ McDonald","$57,222,487.00"
"Hramiak, Irene","Medicine","2003/04","2011/09","Clinical Trials","Funded","False","True","Principal Investigator","A multi-center, international, randomised, 2x2 factorial design study to evaluate the effects of Lantus (insulin glargine) versus standard care, and of omega-3 fatty acids versus placebo, in reducing cardiovascular morbidity and mortality in high risk people with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or early Type 2 diabetes mellitus: The Origin Trial (Outcome Reduction with Initial Glargine INtervention)","IM Hramiak","T Paul","$3,346,306.00"
"Hramiak, Irene","Medicine","2002/05","2010/12","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of EXUBERA (inhaled insulin) compared with subcutaneous human insulin therapy in adult subjects with Type 1 diabetes mellitus: a two-year, outpatient, open-label, parallel-group comparative trial, 217-1022","IM Hramiak","T Paul","$32,809,424.00"
"Hramiak, Irene","Medicine","2002/06","2008/12","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of EXUBERA (inhaled insulin compared with subcutaneous human insulin therapy in adult subjects with Type 2 diabetes mellitus: a two-year, outpatient, open-label, parallel-group comparative trial, 217-1029","IM Hramiak","T Paul","$48,331,057.00"
"Hramiak, Irene","Medicine","2004/06","2008/04","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of inhaled insulin (EXUBERA) compared with subcutaneous human insulin in the therapy of adult subject with type 1 or type 2 diabetes mellitus and chronic asthma: a one-year, multicentre, randomized, outpatient, open-label, parallel-group comparative trial","IM Hramiak","T Paul","$26,545,840.00"
"Hramiak, Irene","Medicine","2004/08","2008/01","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of inhaled human insulin (EXUBERA) compared with subcutaneous human insulin in the therapy of adult subject with type 1 or type 2 diabetes and chronic obstructive pulmonary disease: a one-year, multicenter, randomized, outpatient, open-label, parallel-group comparative trial","IM Hramiak","T Paul","$11,746,600.00"
"Hramiak, Irene","Medicine","2005/05","2007/12","Clinical Trials","Funded","False","True","Principal Investigator","A one-year, open, randomized, parallel, three-arm study comparing Exubera* (insulin dry powder pulmonary inhaler) vs Avandia (Rosiglitazone maleate) as add-on therapy vs Exubera substitution of sulfonylurea in patients with type 2 diabetes, poorly controlled on combination sulfonylurea and metformin treatment","IM Hramiak","T Paul","$19,755,653.00"
"Hramiak, Irene","Medicine","2004/06","2006/06","Clinical Trials","Funded","False","True","Principal Investigator","Safety and Efficacy of Exenatide in Patients with Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin","IM Hramiak","T Paul","$53,035,689.00"
"Hramiak, Irene","Medicine","2005/03","2005/11","Clinical Trials","Funded","False","True","Principal Investigator","A randomized, double-blind, placebo-controlled, parallel group, 16-week MICARDIS® (160 mg) tablets, proof-of-concept study, evaluating insulin sensitivity in overweight or obese, non-diabetic, normotensives, using the oral glucose tolerance test, with a clamp sub-group.","IM Hramiak","T Paul","$426,010.00"
"Hramiak, Irene","Medicine","2005/05","2006/08","Clinical Trials","Funded","False","True","Principal Investigator","Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients with type 2 diabetes, who are treated with a stable dose of metformin","IM Hramiak","T Paul","$49,456,161.00"
"Hramiak, Irene","Medicine","2005/09","2010/12","Clinical Trials","Funded","False","True","Principal Investigator","A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of saxagliptin (BMS-477118) in combination with metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone.","IM Hramiak","CG McDonald, TL Paul","$26,126,244.00"
"Hramiak, Irene","Medicine","2006/03","2007/12","Clinical Trials","Funded","False","True","Principal Investigator","A multicenter, double-blind, randomized, placebo-controlled dose ranging-phase 2 study to investigate efficacy, safety, tolerability, and pharmacokinetics of RO4389620 in patients with type 2 diabetes mellitus treated with a stable dose of metformin","IM Hramiak","CG McDonald, TL Paul","$54,447,889.00"
"Hramiak, Irene","Medicine","2006/06","2007/12","Clinical Trials","Funded","False","True","Principal Investigator","A multicenter, double-blind, randomized, placebo-controlled dose ranging-phase 2 study to investigate efficacy, safety, tolerability, and pharmacokinetics of RO4389620 in patients with type 2 diabetes mellitus treated with a stable dose of metformin, extension","IM Hramiak","CG McDonald, TL Paul","$21,498,408.00"
"Hramiak, Irene","Medicine","2006/10","2007/04","Clinical Trials","Funded","False","True","Principal Investigator","Predictive Study (Predictable Results and Experience in Diabetes Through Intensification and Control to Target: an Investigational Variability Evaluation)","IM Hramiak","TL Paul","$399,490.00"
"Hramiak, Irene","Medicine","2006/05","2010/12","Clinical Trials","Funded","False","True","Principal Investigator","Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors (CRESCENDO)","IM Hramiak","CG McDonald, TL Paul","$57,697,615.00"
"Hramiak, Irene","Medicine","2006/05","2007/09","Clinical Trials","Funded","False","True","Principal Investigator","Liraglutide effect and action in diabetes (lead 4): effect on glycemic control of liraglutide in combination with Rosiglitazone plus metformin versus Rosiglitazone plus metformin in type 2 diabetes (a twenty-six week double-blind parallel trial to investigate safety and efficacy).","IM Hramiak","CG McDonald, TL Paul","$61,431,532.00"
"Hramiak, Irene","Medicine","2006/12","2008/10","Clinical Trials","Funded","False","True","Principal Investigator","Target glycemic control and the incidence of documented symptomatic hypoglycaemia in insulin naïve subjects with type 2 diabetes failing on oral hypoglycaemic agent(s) and treated with lantus (insulin glargine) or levemir (insulin detemir): multicentre, multinational, randomized, open-label, comparative, parallel-group study.","IM Hramiak","CG McDonald, TL Paul","$13,534,697.00"
"Hramiak, Irene","Medicine","2007/02","2008/06","Clinical Trials","Funded","False","True","Principal Investigator","A multicentre, randomized, double-blind study to evaluate the safety and efficacy of the addition of sitagliptin (MK-0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combination with metformin)","IM Hramiak","CG McDonald, TL Paul","$65,815,652.00"
"Hramiak, Irene","Medicine","2007/04","2010/12","Clinical Trials","Funded","False","True","Principal Investigator","A randomised, parallel-group, open-labelled, multinational trial comparing the efficacy and safety of insulin detemir (levemir) versus human insulin (NPH insulin), used in combination with insulin aspart as bolus insulin, in the treatment of pregnant women with type 1 diabetes","IM Hramiak","CG McDonald, TL Paul","$73,450,081.00"
"Hramiak, Irene","Medicine","2007/08","2009/03","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of 2 mg/day of M100907 on sleep maintenance insomnia with a sub-study of the effect of M100907 on stable Type 2 diabetes mellitus: a 12-week, multi-center, randomized, double-blind, placebo-controlled study","IM Hramiak","CG McDonald, TL Paul","$52,855,452.00"
"Hramiak, Irene","Medicine","2007/08","2008/06","Clinical Trials","Funded","False","True","Principal Investigator","The effect of treatment interruption on safety of Exenatide in patients with Type 2 diabetes","IM Hramiak","CG McDonald, TL Paul","$57,308,317.00"
"Hramiak, Irene","Medicine","1986","1994","Clinical Trials","Funded","True","False","Collaborator","Diabetes Control and Complications Trial (DCCT)","J Dupre","IM Hramiak, NW Rodger, MJ Jenner","$15,784,871.00"
"Hramiak, Irene","Medicine","1987","1989","Grants","Funded","True","False","Principal Investigator","Insulin sensitivity during clinical remission in Type 1 diabetes mellitus","IM Hramiak","","$48,485,755.00"
"Hramiak, Irene","Medicine","1990","1993","Grants","Funded","True","False","Principal Investigator","Preservation of insulin secretion and insulin sensitivity in IDDM after high dose IV insulin treatment or pancreas islet transplantation","IM Hramiak","","$55,309,573.00"
"Hramiak, Irene","Medicine","1993","1999","Grants","Funded","True","False","Principal Investigator","The HOPE (Heart Outcome Prevention) study","IM Hramiak","","$69,456,744.00"
"Hramiak, Irene","Medicine","1993/05","1995","Grants","Funded","True","False","Principal Investigator","Regulatory function of the intestine and the efficacy of insulin in normal and diabetic people","IM Hramiak","","$22,614,479.00"
"Hramiak, Irene","Medicine","1993/07","1996/06","Grants","Funded","True","False","Collaborator","Beta adrenal receptor regulation in man: alterations with hypertension, ageing and dietary salt restriction","R Feldman","IM Hramiak","$41,417,436.00"
"Hramiak, Irene","Medicine","1995/03","2016","Clinical Trials","Funded","True","False","Co-Investigator","Epidemiology of diabetes intervention and complications (EDIC)","J Dupre","IM Hramiak","$31,131,022.00"
"Hramiak, Irene","Medicine","1996/07","1998/06","Grants","Funded","True","False","Collaborator","Function of pancreas islet autotransplants","J Dupre","P Atkinson, IM Hramiak, M Behme, P Zucker","$56,671,652.00"
"Hramiak, Irene","Medicine","1993/01","1999","Grants","Funded","True","False","Principal Investigator","The Heart Outcomes Prevention Evaluation – the ongoing outcomes (HOPE-TOO) study","IM Hramiak","B Wolfe","$57,637,613.00"
"Hramiak, Irene","Medicine","2000/11","2011/12","Clinical Trials","Funded","True","False","Principal Investigator","Action to Control Cardiovascular Risk in Diabetes (ACCORD)","IM Hramiak","CG McDonald, TL Paul","$31,685,964.00"
"Hramiak, Irene","Medicine","2001/06","2007/07","Grants","Funded","True","False","Principal Investigator","The genetics of kidneys in diabetes (GoKinD) study","IM Hramiak","CG McDonald, TJ McDonald, TL Paul","$4,957,800.00"
"Hramiak, Irene","Medicine","2001/07","2004/06","Grants","Funded","True","False","Collaborator","A prospective cohort study of latent autoimmune diabetes in adulthood (LADA)","JL Mahon","S Harris, IM Hramiak, M Behme","$34,833,629.00"
"McDonald, Charlotte","Medicine","2002","2010","Clinical Trials","Funded","True","False","Site Investigator","Action to Control Cardiovascular Risk in Diabetes (ACCORD)","Dr. IM Hramiak","Dr. TL Paul, Dr. CG McDonald, Dr. TJ McDonald","$48,697,427.00"
"McDonald, Charlotte","Medicine","2006","2008","Grants","Funded","True","False","Principal Investigator","Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients with Diabetes","Dr. CG McDonald","Dr. JL Mahon, Dr. RA Hegele","$3,845,889.00"
"Mahon, Jeffrey","Medicine","1989","1989","Clinical Trials","Funded","True","False","Principal Investigator","Chronic ASA ingestion in the community in Middlesex county: surveys of physicians and the general population","Jeffrey Mahon","","$39,212,593.00"
"Mahon, Jeffrey","Medicine","1991","1991","Clinical Trials","Funded","True","False","Principal Investigator","The feasibility of a randomized trial of the efficacy of N of 1 trials","Jeffrey Mahon","","$14,268,595.00"
"Mahon, Jeffrey","Medicine","1992","1992","Clinical Trials","Funded","True","False","Principal Investigator","The pharmacokinetics of a sustained-release preparation of nicotinamide.","Jeffrey Mahon","","$23,260,662.00"
"McDonald, Charlotte","Medicine","2005/09","2010/12","Grants","Funded","False","True","Co-Investigator","A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of saxagliptin (BMS-477118) in combination with metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone","IM Hramiak","CG McDonald, TL Paul","$71,398,170.00"
"McDonald, Charlotte","Medicine","2006/03","2007/06","Grants","Funded","False","True","Co-Investigator","A multicenter, double-blind, randomized, placebo-controlled dose ranging-phase 2 study to investigate efficacy, safety, tolerability, and pharmacokinetics of RO4389620 in patients with type 2 diabetes mellitus treated with a stable dose of metformin","IM Hramiak","CG McDonald, TL Paul","$10,101,164.00"
"McDonald, Charlotte","Medicine","2006/05","2010/12","Clinical Trials","Funded","False","True","Co-Investigator","Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors (CRESCENDO)","IM Hramiak","CG McDonald, TL Paul","$20,745,628.00"
"McDonald, Charlotte","Medicine","2006/05","2007/09","Clinical Trials","Funded","False","True","Co-Investigator","Liraglutide effect and action in diabetes (lead 4): effect on glycemic control of liraglutide in combination with Rosiglitazone plus metformin versus Rosiglitazone plus metformin in type 2 diabetes (a twenty-six week double-blind parallel trial to investigate safety and efficacy","IM Hramiak","GC McDonald, TL Paul","$62,824,183.00"
"McDonald, Charlotte","Medicine","2006/05","2007/12","Grants","Funded","False","True","Co-Investigator","A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249","IM Hramiak","CG McDonald, TL Paul","$29,422,151.00"
"McDonald, Charlotte","Medicine","2006/06","2006/10","Grants","Funded","False","False","Co-Investigator","A multicenter, randomized, placebo-controlled, double-blind, parallel-group, fixed-dose study evaluating the effect of one dose of rimonabant (20 mg/day) on glycemic control in type 2 diabetic patients inadequately controlled with insulin (ARPEGGIO)","IM Hramiak","CG McDonald, TL Paul","$36,990,676.00"
"McDonald, Charlotte","Medicine","2006/12","2008/10","Grants","Funded","False","True","Co-Investigator","Target glycemic control and the incidence of documented symptomatic hypoglycemia in insulin naïve subjects with type 2 diabetes failing on oral hypoglycemic agent(s) and treated with LANTUS (insulin glargine) or LEVEMIR (insulin detemir): multicenter, multinational, randomized, open-label, comparative, parallel-group study","IM Hramiak","CG McDonald, TL Paul","$48,794,135.00"
"McDonald, Charlotte","Medicine","2007/02","2009/06","Grants","Funded","False","True","Co-Investigator","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or in Combination With Metformin)","IM Hramiak","CG McDonald, TL Paul","$40,752,434.00"
"McDonald, Charlotte","Medicine","2006/04","2006/10","Grants","Funded","False","False","Co-Investigator","Predictive Study (Predictable Results and Experience in Diabetes through Intensification and Control to Target: an Investigational Variability Evaluation","IM Hramiak","TL Paul, CG McDonald","$31,108,425.00"
"McDonald, Charlotte","Medicine","2007/04","2010/12","Grants","Funded","False","True","Co-Investigator","A randomized, parallel-group, open-labelled, multinational trial comparing the efficacy and safety of insulin detemir (levemir) versus human insulin (NPH insulin), used in combination with insulin aspart as bolus insulin, in the treatment of pregnant women with type 1 diabetes","IM Hramiak","CG McDonald, TL Paul","$7,957,403.00"
"McDonald, Charlotte","Medicine","2007/06","2008/06","Grants","Funded","False","True","Co-Investigator","The effect of the treatment interruption on safety of Exenatide in patients with Type 2 diabetes","IM Hramiak","CG McDonald, TL Paul","$70,299,448.00"
"Feldman, Ross","Medicine","2009/07","2013/06","Grants","Funded","True","False","Principal Investigator","Determinants of adenylyl cyclase mediated vascular responses","Ross D. Feldman","","$74,200,983.00"
"Feldman, Ross","Medicine","2007/07","2009/06","Grants","Funded","True","False","Principal Investigator","Acute vascular effects of aldosterone","Ross D. Feldman","","$17,397,515.00"
"Pickering, J. Geoffrey","Medicine","1992","1995","Grants","Funded","True","False","Principal Investigator","Control of smooth muscle cell function by genetic manipulation","J.G. Pickering","","$60,502,913.00"
"Pickering, J. Geoffrey","Medicine","1995","1997","Grants","Funded","True","False","Principal Investigator","Role of fibrillar collagens in the vascular response to injury","J.G. Pickering","","$42,746,773.00"
"Pickering, J. Geoffrey","Medicine","1997/10","2000/09","Grants","Funded","True","False","Principal Investigator","Collagen degradation and vascular smooth muscle cell motility","J.G. Pickering","","$71,270,089.00"
"Pickering, J. Geoffrey","Medicine","1999/04","2002","Grants","Funded","True","False","Co-Investigator","Multi-user LMS 510 confocal microscope and digital imaging facility","S. Ferguson","J.G. Pickering (1 of 9)","$5,555,099.00"
"Pickering, J. Geoffrey","Medicine","2002/04","2007/03","Grants","Funded","True","False","Co-Investigator","Vascular and Cerebrovascular Transdisciplinary Training Program","A. Fenster","J.G. Pickering (1 of 9)","$23,612,282.00"
"Pickering, J. Geoffrey","Medicine","2002/04","2007/03","Grants","Funded","True","False","Co-Investigator","Multi-user LMS 510 confocal microscope and digital imaging facility","S. Ferguson","J.G. Pickering (1 of 9)","$16,129,697.00"
"Pickering, J. Geoffrey","Medicine","1996","1998","Grants","Funded","True","False","Co-Investigator","Chemokines and chemokine receptors in vascular smooth muscle.","D. Kelvin","J.G. Pickering","$64,176,665.00"
"Pickering, J. Geoffrey","Medicine","1998/07","2001/06","Grants","Funded","True","False","Co-Investigator","Chemokines in Cardiac Transplant Rejection","D. Kelvin","J.G. Pickering","$11,301,807.00"
"Pickering, J. Geoffrey","Medicine","2005/07","2007/06","Grants","Funded","True","False","Co-Investigator","Optimized micro-CT of the mouse heart and coronary vasculature","M. Drangova","J.G. Pickering","$9,551,733.00"
"Pickering, J. Geoffrey","Medicine","2006/07","2011/06","Grants","Funded","True","False","Co-Principal Investigator","Vascular Cell Programs and Responses in Atherosclerosis","J.G.Pickering, M. Huff","","$67,906,957.00"
"Pickering, J. Geoffrey","Medicine","2001/07","2006/06","Grants","Funded","True","False","Co-Principal Investigator","Vascular Cell Responses in Atherosclerosis: A Genomic Approach","J.G. Pickering, M. Huff","","$52,502,558.00"
"Pickering, J. Geoffrey","Medicine","1997/07","2000/06","Grants","Funded","True","False","Principal Investigator","Integrins and smooth muscle cell migration","J.G. Pickering","B.M.C. Chan","$20,030,388.00"
"Pickering, J. Geoffrey","Medicine","2000/07","2005/06","Grants","Funded","True","False","Principal Investigator","Control of Smooth Muscle Cell Differentiation","J.G. Pickering","B.M.C. Chan","$18,450,919.00"
"Pickering, J. Geoffrey","Medicine","2005/07","2010/06","Grants","Funded","True","False","Principal Investigator","Regulation of Smooth Muscle Differentiation and Longevity","J.G. Pickering","","$51,716,934.00"
"Pickering, J. Geoffrey","Medicine","2000/10","2005/09","Grants","Funded","True","False","Principal Investigator","Collagen processing and vascular smooth muscle cell motility","J.G. Pickering","","$23,474,076.00"
"Pickering, J. Geoffrey","Medicine","2005/03","2006/02","Grants","Funded","True","False","Principal Investigator","Novel Methods to Inhibit Cellular Aging and Increase Cellular Fitness","J.G. Pickering","","$151,081.00"
"Pickering, J. Geoffrey","Medicine","2005/10","2010/09","Grants","Funded","True","False","Principal Investigator","Assembly of extracellular matrix by vascular smooth muscle cells","J.G. Pickering","","$4,297,276.00"
"Pickering, J. Geoffrey","Medicine","1995","1996","Grants","Funded","True","False","Principal Investigator","Angiotensin II and angiotensin II antagonism in human vascular smooth muscle cells","J.G. Pickering","","$7,607,023.00"
"Pickering, J. Geoffrey","Medicine","1997","1998","Grants","Funded","True","False","Principal Investigator","Determination of the cellular mechanisms by which angiotensin II stimulates collagen production in human vascular smooth muscle cells","","","$52,318,989.00"
"Pickering, J. Geoffrey","Medicine","2002","2002","Grants","Funded","True","False","Principal Investigator","Nitric oxide delivery and SMC function","","","$73,375,632.00"
"Pickering, J. Geoffrey","Medicine","2004","2004/10","Grants","Funded","True","False","Principal Investigator","Role of Collagen Degradation in Myocardial Infarct Repair","J.G. Pickering","","$43,908,241.00"
"Pickering, J. Geoffrey","Medicine","1993","1993","Grants","Funded","True","False","Principal Investigator","Control of vascular smooth muscle cell function by genetic manipulation","J.G. Pickering","","$74,862,113.00"
"Pickering, J. Geoffrey","Medicine","1993","1993","Grants","Funded","True","False","Principal Investigator","Matrix elaboration in atherosclerosis analysis of gene expression.","J.G. Pickering","","$23,282,082.00"
"Pickering, J. Geoffrey","Medicine","1993","1993","Grants","Funded","False","False","Equipment - Research","Fluorescence Microscope","","","$19,857,427.00"
"Pickering, J. Geoffrey","Medicine","1994","1994","Grants","Funded","True","False","Principal Investigator","Integrins in vascular remodeling","J.G. Pickering","","$31,493,655.00"
"Pickering, J. Geoffrey","Medicine","1995","1995","Grants","Funded","True","False","Principal Investigator","Vascular repair in transgenic mice","J.G. Pickering","","$46,174,285.00"
"Pickering, J. Geoffrey","Medicine","1996","1996","Grants","Funded","True","False","Principal Investigator","Interplay between FGF 2 and collagen in the control of vascular smooth muscle cell migration","J.G. Pickering","","$66,328,760.00"
"Pickering, J. Geoffrey","Medicine","1996","1997","Grants","Funded","True","False","Principal Investigator","Gene Therapy of Allograft Vascular Disease","J.G. Pickering","L.H. Chow","$66,624,118.00"
"Pickering, J. Geoffrey","Medicine","1997","1997","Grants","Funded","True","False","Principal Investigator","Regulation and Function of a Novel Collagen Binding Heat Shock Protein in Vascular Smooth Muscle Cells","J.G. Pickering","","$57,625,338.00"
"Pickering, J. Geoffrey","Medicine","1998","1999","Grants","Funded","True","False","Principal Investigator","Molecular Basis of Human Vascular Smooth Muscle Differentiation","J.G. Pickering","","$60,423,569.00"
"Pickering, J. Geoffrey","Medicine","1999","1999","Grants","Funded","True","False","Principal Investigator","Novel genes associated with Differentiation of Human Vascular Smooth Muscle Cells","J.G. Pickering","","$46,073,367.00"
"Pickering, J. Geoffrey","Medicine","1999","1999","Grants","Funded","True","False","Co-Principal Investigator","Functional and Molecular Characterization of TRP Channels in Different Smooth Muscle Phenotypes","J.G. Pickering","H. Preksaitis","$52,256,241.00"
"Pickering, J. Geoffrey","Medicine","1999","1999/04","Grants","Funded","True","False","Principal Investigator","Pre B Cell Colony Enhancing Factor and Transplant Arteriopathy","J.G. Pickering","","$1,436,138.00"
"Pickering, J. Geoffrey","Medicine","2003","2003/06","Grants","Funded","True","False","Principal Investigator","Secreted Frizzled Related Proteins and Vascular Smooth Muscle Cells","","","$45,798,719.00"
"Pickering, J. Geoffrey","Medicine","1997","1998","Grants","Funded","True","False","Principal Investigator","Personnel support for post-doctoral fellow, Dr. Shaohua Li","J.G. Pickering","","$57,851,412.00"
"Pickering, J. Geoffrey","Medicine","1997","1998","Grants","Funded","True","False","Principal Investigator","Personnel support for post-doctoral fellow, Dr. Laura Saward","J.G. Pickering","","$53,435,600.00"
"Pickering, J. Geoffrey","Medicine","1998","2000","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Edward F. Rocnik","J.G. Pickering","","$64,424,788.00"
"Pickering, J. Geoffrey","Medicine","1998","1998","Grants","Funded","True","False","Principal Investigator","Personnel support for summer student, Vladislav Miropolsky","J.G. Pickering","","$44,949,845.00"
"Pickering, J. Geoffrey","Medicine","1999","1999","Grants","Funded","True","False","Principal Investigator","Personnel support for summer student, Vladislav Miropolsky","J.G. Pickering","","$65,294,547.00"
"Pickering, J. Geoffrey","Medicine","1999","1999","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Daniel Whang","J.G. Pickering","","$74,565,215.00"
"Pickering, J. Geoffrey","Medicine","2002","2002","Grants","Funded","True","False","Principal Investigator","Personnel support for summer student, Wilfred Lee","J.G. Pickering","","$18,471,747.00"
"Pickering, J. Geoffrey","Medicine","2002","2002","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Eric van der Veer","J.G. Pickering","","$5,693,706.00"
"Pickering, J. Geoffrey","Medicine","2003","2003/05","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Alison Maly","J.G. Pickering","","$10,571,870.00"
"Pickering, J. Geoffrey","Medicine","2003","2003/09","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Eric van der Veer","J.G. Pickering","","$7,475,035.00"
"Pickering, J. Geoffrey","Medicine","2004","2004","Grants","Funded","True","False","Principal Investigator","Personnel support for summer student, Wilfred Lee","J.G. Pickering","","$14,641,952.00"
"Pickering, J. Geoffrey","Medicine","2007/06","2009/06","Grants","Funded","True","False","Principal Investigator","Personnel support for post-doctoral fellow, Nica Borradaile","J.G. Pickering","","$30,803,601.00"
"Pickering, J. Geoffrey","Medicine","2007/05","2007/09","Grants","Funded","True","False","Principal Investigator","Personnel support for summer student, Aliya Nurmohammed","J.G. Pickering","","$32,113,187.00"
"Pickering, J. Geoffrey","Medicine","2006/09","2008/03","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Eric van der Veer","J.G. Pickering","","$35,886,598.00"
"Pickering, J. Geoffrey","Medicine","2006/05","2007/05","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Theodore Small","J.G. Pickering","","$16,391,274.00"
"Pickering, J. Geoffrey","Medicine","2006/05","2007/05","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Matthew Frontini","J.G. Pickering","","$29,717,017.00"
"Pickering, J. Geoffrey","Medicine","2006/05","2006/09","Grants","Funded","True","False","Principal Investigator","Personnel support for summer student, Jennifer Strong","J.G. Pickering","","$36,372,496.00"
"Pickering, J. Geoffrey","Medicine","2005","2005","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Eric van der Veer","J.G. Pickering","","$21,275,492.00"
"Pickering, J. Geoffrey","Medicine","2005","2005","Grants","Funded","True","False","Principal Investigator","Personnel support for summer student, Wilfred Lee","J.G. Pickering","","$58,036,108.00"
"Pickering, J. Geoffrey","Medicine","2005","2005/05","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Matthew Frontini","J.G. Pickering","","$67,644,296.00"
"Pickering, J. Geoffrey","Medicine","2005","2005","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Cynthia Ho","Principal Investigator","","$66,159,396.00"
"Kostuk, William","Medicine","2007/06","2008/12","Grants","Funded","False","True","Principal Site Investigator","A randomized, double-blind parallel group, phase 3, efficacy and safety study of AZD6140 compared with clopidogrel for prevention of vascular events in patients with non ST or ST elevation in acute coronary syndromes (ACS).","William Kostuk","","$27,777,604.00"
"Kostuk, William","Medicine","2007","2009","Grants","Funded","False","True","Principal Site Investigator","ATLAS - A randomized, double-blind, placebo controlled multi-center, dose evaluation and confirmation study to evaluate the safety and efficacy of Rivaroxaban in combination with aspirin alone or aspirin and thienopyridine in subjects with acute coronary syndrome.","William Kostuk","","$13,135,210.00"
"Kostuk, William","Medicine","2006","2012/02","Grants","Funded","False","True","Principal Site Investigator","FREEDOM – Future revascularization evaluation in patients with diabetes mellitus","William Kostuk","","$38,693,413.00"
"Kostuk, William","Medicine","2006","2013","Grants","Funded","False","True","Principal Site Investigator","AIM-HIGH - Atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on Global Health Outcomes","William Kostuk","","$15,068,058.00"
"Kostuk, William","Medicine","2005","2007/06","Grants","Funded","False","True","Principal Site Investigator","VIRON - A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 when Added to Conventional Therapy in Patients with Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)","William Kostuk","","$65,002,399.00"
"Kostuk, William","Medicine","2005","2007","Grants","Funded","False","True","Principal Site Investigator","PERISCOPE - A Double-Blind, Randomized Comparator-Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCl versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Intravascular Ultrasound","William Kostuk","","$45,593,379.00"
"Kostuk, William","Medicine","2005","2007","Grants","Funded","False","True","Principal Site Investigator","TIMI-38 – A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention","William Kostuk","","$52,559,081.00"
"Kostuk, William","Medicine","2001","2010","Grants","Funded","False","True","Principal Site Investigator","OAT - Occluded Artery Trial Total Occlusion Study of Canada -","William Kostuk","","$63,699,345.00"
"Kostuk, William","Medicine","2000","2006","Grants","Funded","False","False","Principal Site Investigator","COURAGE (Clinical outcomes utilizing revascularization and aggressive drug evaluation.","G.B. John Mancini","","$55,078,216.00"
"Kostuk, William","Medicine","2005","2006","Grants","Funded","False","True","Principal Site Investigator","SHINE - A Randomized Dose Ranging Study of Hexadecasaccharide including Active Control, in Patients with Unstable Angina or Non-ST-segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention.","William Kostuk","","$9,656,576.00"
"Kostuk, William","Medicine","2004","2006","Grants","Funded","False","True","Principal Site Investigator","STEEPLE - Safety and efficacy of enoxaparin in PCI patients, an international randomized evaluation -","William Kostuk","","$24,426,230.00"
"Kostuk, William","Medicine","2000","2004","Grants","Funded","False","True","Principal Site Investigator","IMAGINE – Ischemia Management with Accupril Post Bypass Graft via Inhibition with CoNverting Enzyme","William Kostuk","","$15,200,245.00"
"Kostuk, William","Medicine","1999","2004","Grants","Funded","False","True","Principal Site Investigator","CHARM - Candesartan Cilexetil (candesartan) in heart failure assessment of reduction in mortality and morbidity","William Kostuk","","$21,453,219.00"
"Kostuk, William","Medicine","1999","2004","Grants","Funded","False","True","Principal Site Investigator","WATCH (Warfarin and antiplatelet therapy study in chronic heart failure)","William Kostuk","","$41,095,594.00"
"Kostuk, William","Medicine","2000","2002","Grants","Funded","False","True","Principal Site Investigator","EPHESUS – Clinical Protocol for a double-blind, randomized, placebo-controlled trail evaluation the safety and efficacy of Eplerenone in patients with heart failure following acute myocardial infarction.","William Kostuk","","$8,976,041.00"
"Kostuk, William","Medicine","2000","2002","Grants","Funded","False","True","Principal Site Investigator","PRINCESS: PRevention of re-INfarction by early treatment of CErivaStatin Study.Prospective, multicentre, double-blind, randomised, placebo-controlled, parallel-group comparison of cerivastatin 0.4 mg versus placebo in early acute treatment of post-myocardial infarction with long term follow-up treatment by cerivastatiin both groups.","William Kostuk","","$61,884,285.00"
"Kostuk, William","Medicine","2000","2001","Grants","Funded","False","True","Principal Site Investigator","CREDO – Clopidogrel for reduction of evens during observation.","William Kostuk","","$64,180,919.00"
"Kostuk, William","Medicine","1997","2002","Grants","Funded","False","True","Principal Site Investigator","PEACE -Prevention of events with angiotensin converging enzyme inhibition -","William Kostuk","","$66,889,330.00"
"Kostuk, William","Medicine","2000","2002","Grants","Funded","False","True","Principal Site Investigator","CURE – Clopidogrel in unstable angina to prevent recurrent ischemic events","William Kostuk","","$68,228,693.00"
"Kostuk, William","Medicine","2000","2002","Grants","Funded","False","False","Principal Site Investigator","HOPE-TWO","William Kostuk","","$62,553,631.00"
"Kostuk, William","Medicine","2000","2001","Grants","Funded","False","False","Principal Site Investigator","PARR-2 et and recovery following revascularization evaluation of outcome and cost-effectiveness using an FDG-PET guided approach to management of patients with coronary artery disease and severe LV dysfunction.","William Kostuk","","$34,657,179.00"
"Kostuk, William","Medicine","2000","2002","Grants","Funded","False","False","Co-Investigator","Can computed rotational angiography demonstrate coronary artery disease in donor hearts -","William Kostuk","","$71,404,289.00"
"Kostuk, William","Medicine","1998","2004","Grants","Funded","False","True","Principal Site Investigator","ACTION – A coronary disease trial investigating outcome with nifedipine GITS","William Kostuk","","$51,515,715.00"
"Kostuk, William","Medicine","2000","2002","Grants","Funded","False","True","Principal Site Investigator","ESPRIT – Enhance suppression of the platelet GPIIb/IIIa receptor with integrilin -","William Kostuk","","$67,981,254.00"
"Kostuk, William","Medicine","2000","2001","Grants","Funded","False","True","Principal Site Investigator","LIMIT – A phase II, randomized double-blind, placebo-controlled, multicentre, angiographic trial of the safety and efficacy of rhuMab CD 18 in the acute myocardial infarction.","William Kostuk","","$57,317,457.00"
"Kostuk, William","Medicine","1998","2001","Grants","Funded","False","True","Principal Site Investigator","Randomized, double-blind, placebo controlled, parallel trial to assess the effect of Valsartan on exercise capacity, quality of life and signs and symptoms in patients with stable, chronic congestive heart failure (NYHA Class II-IV).","William Kostuk","","$7,131,664.00"
"Kostuk, William","Medicine","2000","2001","Grants","Funded","False","True","Principal Site Investigator","PRESTO – Prevention of restenosis with tranilast and its outcomes: a placebo-controlled trial -","William Kostuk","","$39,540,720.00"
"Kostuk, William","Medicine","1995","1999","Grants","Funded","False","True","Principal Site Investigator","MACH-1 The effect of Ro 40-5967 (Mibefridil) on all causes of mortality in comparison with placebo in patients with chronic heart failure (NYHA Class II-IV) treated for approximately 2- 3 years.","William Kostuk","","$4,575,072.00"
"Kostuk, William","Medicine","1995","1999","Grants","Funded","False","False","Principal Site Investigator","HOPE - Heart outcomes prevention evaluation – Canadian Cardiovascular Collaboration -","William Kostuk","","$67,917,179.00"
"Kostuk, William","Medicine","1997","1999","Grants","Funded","False","True","Principal Site Investigator","EXCITE –Efficacy and safety of Xemilofiban hydrochloride administration to patients undergoing coronary angioplasty or stent placement.","William Kostuk","","$9,742,969.00"
"Kostuk, William","Medicine","1998","1999","Grants","Funded","False","True","Principal Site Investigator","Multicentre, randomized double-blind, placebo-controlled, parallel trial to assess the effect of Valsartan on exercise capacity, quality of life, and signs and symptoms in patients with stable, chronic congestive heart failure (NYHA Class II-IV)","William Kostuk","","$42,736,137.00"
"Kostuk, William","Medicine","1997","1998","Grants","Funded","False","True","Principal Site Investigator","Double-blind, placebo-controlled, multi-centre, randomized, parallel group dose ranging study of the antianginal and anti-ischemic effects of Tedisamil Dihydrochloride in patients with documented coronary artery disease -","William Kostuk","","$22,712,653.00"
"Kostuk, William","Medicine","1992","1997","Grants","Funded","False","True","Principal Site Investigator","GENSIA – A multicentre, multinational study to evaluate the clinical utility and safety of the GenESA System to diagnose coronary artery disease in patients with known or suspected coronary artery disease","William Kostuk","","$3,317,943.00"
"Mangel, Joy","Medicine","2006/01","2012/01","Grants","Funded","True","False","Collaborator","A multi-center phase I/II clinical trial of CAMPATH-1H combined with CHOP chemotherapy for newly diagnosed peripheral T cell lymphomas.","Dr. R. Buckstein","","$39,550,559.00"
"Kostuk, William","Medicine","1995","1997","Grants","Funded","False","False","Principal Site Investigator","CAPRI – The effect of RO40-5967 in comparison with placebo in patients with chronic heart failure (NYA CLASS II-IV) treated for approximately 3 years. -","William Kostuk","","$24,157,220.00"
"Kostuk, William","Medicine","1996","1997","Grants","Funded","False","False","Principal Site Investigator","OASIS II – A phase II randomized comparative trial of Hirudin versus heparin and warfarin versus standard therapy for acute myocardial ischemia without ST elevation. -","William Kostuk","","$20,459,194.00"
"Kostuk, William","Medicine","1996","1997","Grants","Funded","False","False","Principal Site Investigator","CORE","William Kostuk","","$57,224,319.00"
"Kostuk, William","Medicine","1995","1997","Grants","Funded","False","True","Principal Site Investigator","ATLAS – Assessment of treatment with Lisinopril and survival -","William Kostuk","","$29,064,094.00"
"Kostuk, William","Medicine","1995","1999","Grants","Funded","False","True","Principal Site Investigator","PRAISE-2 A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.","William Kostuk","","$8,711,303.00"
"Mangel, Joy","Medicine","2004","2004/09","Grants","Funded","False","False","Major","To attend Royal College of Physicians and Surgeons of Canada Workshop for New Program Directors in Ottawa Sept 29-30 2004.","","","$45,360,928.00"
"Kostuk, William","Medicine","1996","1998","Grants","Funded","False","True","Principal Site Investigator","EPILOG-STENT Coronary Intervention in patients with coronary artery disease -","William Kostuk","","$20,824,127.00"
"Kostuk, William","Medicine","1996","1997","Grants","Funded","False","True","Principal Site Investigator","A double-blind placebo controlled study to assess the effects of Ro47-0203 (Bosentan) on the clinical status of patients with advanced chronic heart failure and the pharmacokinetics of Ro 47-0203 (Bosentan)","William Kostuk","","$35,812,207.00"
"Kostuk, William","Medicine","1995","1996","Grants","Funded","False","True","Principal Site Investigator","ACHIEVE – Accupril (Quinipril HCI) congestive heart failure investigation and economic variable evaluation -","William Kostuk","","$68,154,479.00"
"Kostuk, William","Medicine","1995","1996","Grants","Funded","False","True","Principal Site Investigator","Tedisamil K.219.5034 -","William Kostuk","","$64,301,613.00"
"Kostuk, William","Medicine","1994","1995","Grants","Funded","False","True","Principal Site Investigator","Evaluation of therapeutic interventions in patients with heart failure","Wiliam Kostuk","","$44,346,346.00"
"Kostuk, William","Medicine","1994","1995","Grants","Funded","False","True","Principal Site Investigator","Evaluation of pharmacological testing to assess myocardial ischemia Gensia -","","","$46,219,888.00"
"Kostuk, William","Medicine","1994","1995","Grants","Funded","False","False","Principal Site Investigator","Reduction of coronary artery disease risk factors – Canadian Cardiovascular Collaboration -","William Kostuk","","$71,745,399.00"
"Mangel, Joy","Medicine","2001","2002","Grants","Funded","False","False","Principal Investigator","Neutropenic complications of CHOP-Rituximab combination therapy for the treatment of non-Hodgkin’s lymphoma in the elderly.","Dr. Joy Mangel","","$32,718,109.00"
"Kostuk, William","Medicine","1993","1995","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$39,908,512.00"
"Kostuk, William","Medicine","1993","1995","Grants","Funded","False","True","Principal Site Investigator","Assessment of therapeutic interventions in patients with heart failure – Boehringer Ingelheim","William Kostuk","","$1,070,244.00"
"Kostuk, William","Medicine","1993","1994","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$19,759,620.00"
"Lewis, James","Medicine","1992/07","1994/06","Grants","Funded","False","False","Co-Investigator","Surfactant metabolism in acute lung injury.","J Lewis","","$45,631,526.00"
"Mangel, Joy","Medicine","2002","2003","Grants","Funded","False","False","Collaborator","A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/ refractory aggressive non-Hodgkin’s lymphoma.","Dr. Joy Mangel","","$6,594,061.00"
"Kostuk, William","Medicine","1993","1995","Grants","Funded","False","True","Principal Site Investigator","Evaluation of cardiac function and coronary vasculature in cardiac transplant patients","William Kostuk","","$36,268,313.00"
"Lewis, James","Medicine","1992/07","1997/06","Grants","Funded","False","False","Co-Investigator","Surfactant metabolism in acute lung injury.","J Lewis","","$58,974,179.00"
"Kostuk, William","Medicine","2005/07","2006/06","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","","","$49,129,979.00"
"Lewis, James","Medicine","1992/07","1993/06","Grants","Funded","False","False","Co-Investigator","Distribution of exogenously administered surfactant in acute lung injury.","J Lewis","","$27,883,240.00"
"Kostuk, William","Medicine","1993","1994","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$14,722,221.00"
"Lewis, James","Medicine","1992/07","1993/06","Grants","Funded","False","False","Co-Investigator","Endogenous surfactant metabolism and treatment responses in sepsis-associated lung injury.","J Lewis","","$35,603,929.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Evaluation of therapeutic interventions in patients with heart failure","Dr. William Kostuk","","$49,147,138.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","Dr. William Kostuk","","$43,575,222.00"
"Lewis, James","Medicine","1992/10","1993/10","Grants","Funded","False","False","Co-Investigator","Production of human surfactant proteins for artificial surfactant.","J Lewis","","$51,121,021.00"
"Kostuk, William","Medicine","1992","1994","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","Dr. William Kostuk","","$20,168,457.00"
"Lewis, James","Medicine","1993/07","1994/06","Grants","Funded","False","False","Co-Investigator","Surfactant metabolism and treatment responses in sepsis-associated lung injury.","J Lewis","","$23,923,109.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Evaluation of therapeutic interventions in patients with heart failure","Dr. Peter Pflugfelder","","$63,940,572.00"
"Kostuk, William","Medicine","1991","1994","Grants","Funded","False","True","Principal Site Investigator","Reduction of coronary artery risk factors","Dr. William Kostuk","","$33,168,405.00"
"Lewis, James","Medicine","1993/01","1994/01","Grants","Funded","False","True","Co-Investigator","Evaluation of exogenous surfactant in pediatric ARDS.","J Lewis","","$74,031,982.00"
"Kostuk, William","Medicine","1991","1993","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","Dr. William Kostuk","","$67,828,075.00"
"Lewis, James","Medicine","1993/07","1994/06","Grants","Funded","False","False","Co-Investigator","Surfactant-associated proteins and the immune system.","J Lewis","","$10,463,428.00"
"Lewis, James","Medicine","1994/07","1997/05","Grants","Funded","False","False","Co-Investigator","Exogenous surfactant therapy for acute lung injury.","J Lewis","R Veldhuizen","$65,363,483.00"
"Kostuk, William","Medicine","1991","1992","Grants","Funded","False","False","Principal Site Investigator","Evaluations in therapeutic interventions in patients with heart failure","William Kostuk","","$36,809,097.00"
"Kostuk, William","Medicine","1991","1992","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$69,648,280.00"
"Kostuk, William","Medicine","1991","1992","Grants","Funded","False","True","Principal Site Investigator","Evaluation of therapeutic interventions in patients in heart failure","Dr. William Kostuk","","$24,420,171.00"
"Lewis, James","Medicine","1994/07","1995/06","Grants","Funded","False","False","Co-Investigator","Evaluation of exogenous surfactant preparations in acute lung injury.","J Lewis","","$41,013,210.00"
"Kostuk, William","Medicine","1991","1992","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$50,853,978.00"
"Kostuk, William","Medicine","1990","1991","Grants","Funded","False","False","Principal Site Investigator","Evaluation of inotropic agents in patients with heart failure","William Kostuk","","$35,681,460.00"
"Lewis, James","Medicine","1994/07","1995/06","Grants","Funded","False","False","Co-Investigator","The structure-function relationships of surfactant associated protein A (SP-A).","J Lewis","R Veldhuizen","$50,651,266.00"
"Lewis, James","Medicine","1994/07","1995/06","Grants","Funded","False","False","Co-Investigator","Characterization of alveolar surfactant metabolism in normal and injured lungs.","J Lewis","","$11,133,982.00"
"Lewis, James","Medicine","1994/07","1995/06","Grants","Funded","False","False","Co-Investigator","Salvage of donor lung grafts damaged by aspiration pneumonitis.","R Novick","J Lewis","$8,105,048.00"
"Kostuk, William","Medicine","1990","1991","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","Dr. William Kostuk","","$69,103,945.00"
"Lewis, James","Medicine","1994/07","1995/06","Grants","Funded","False","False","Co-Investigator","Surfactant-associated proteins and the immune system.","","J Lewis, R McFadden, L Fraher","$43,887,301.00"
"Lewis, James","Medicine","1994/07","1995/06","Grants","Funded","False","False","Co-Investigator","Surfactant metabolism in acute lung injury. (R. Veldhuizen)","J Lewis","R Veldhuizen","$27,532,250.00"
"Lewis, James","Medicine","1994/05","1994/08","Grants","Funded","False","False","Co-Investigator","Surfactant Metabolism. (J. Marcou)","J Lewis","J Marcou","$16,462,958.00"
"Lewis, James","Medicine","1994/10","1995/09","Grants","Funded","False","False","Co-Investigator","Interaction between inhaled nitric oxide therapy and surfactant administration in acute lung injury.","D McCormack","J Lewis.","$52,742,551.00"
"Lewis, James","Medicine","1994/04","1995/03","Grants","Funded","False","False","Principal Investigator","Characterization of alveolar surfactant metabolism in normal and injured lungs.","J Lewis","","$369,735.00"
"Lewis, James","Medicine","1994/01","1997/12","Grants","Funded","False","False","Principal Investigator","Surfactant metabolism in acute lung injury.","J Lewis","","$27,903,254.00"
"Lewis, James","Medicine","1994/01","1997/12","Grants","Funded","False","False","Co-Investigator","Surfactant metabolism in acute lung injury.","J Lewis","R Veldhuizen","$70,083,528.00"
"Lewis, James","Medicine","1994/10","1995/09","Grants","Funded","False","True","Principal Investigator","Evaluation of an ultrasonic nebulizer for surfactant delivery.","J Lewis","","$54,406,588.00"
"Lewis, James","Medicine","1995/09","1998/08","Grants","Funded","False","False","Co-Investigator","The effects of mechanical ventilation on alveolar surfactant metabolism in acute lung injury. (C. Kerr)","J Lewis","C Kerr","$70,804,501.00"
"Lewis, James","Medicine","1995/07","1997/06","Grants","Funded","False","False","Co-Investigator","Exogenous surfactant therapy in lung transplantation.","R Novick","J Lewis","$68,218,962.00"
"Lewis, James","Medicine","1995/07","1996/06","Grants","Funded","False","False","Co-Investigator","Characterization of alveolar surfactant metabolism in normal and injured lungs.","J Lewis","R Veldhuizen","$65,886,376.00"
"Lewis, James","Medicine","1995/06","1997/08","Grants","Funded","False","False","Co-Investigator","Factors influencing efficacy of exogenous surfactant administration in acute lung injury. (S. Manwell)","J Lewis","S Manwell","$49,754,053.00"
"Lewis, James","Medicine","1995/09","1996/08","Grants","Funded","False","False","Co-Investigator","The role of the surfactant system in sepsis-induced lung injury. (J. Malloy)","J Lewis","J Malloy","$69,533,692.00"
"Lewis, James","Medicine","1995/10","1996/09","Grants","Funded","False","False","Co-Investigator","The effect of early exogenous surfactant administration on sepsis-induced extra-pulmonary organ injury.","W Sibbald","J Lewis","$57,703,850.00"
"Lewis, James","Medicine","1995/04","1996/03","Grants","Funded","False","False","Principal Investigator","Early exogenous surfactant treatment in septic adult rats.","J Lewis","","$1,620,430.00"
"Lewis, James","Medicine","1995/12","1996/12","Grants","Funded","False","True","Principal Investigator","Evaluation of a novel exogenous surfactant preparation in a sheep model of lung injury.","J Lewis","","$7,354,815.00"
"Lewis, James","Medicine","1995/06","1996/06","Grants","Funded","False","True","Principal Investigator","Evaluation of KL4 surfactant in a large animal model of lung injury.","J Lewis","","$18,805,972.00"
"Lewis, James","Medicine","1995","1999","Grants","Funded","False","True","Principal Investigator","Evaluation of a catheter device for aerosolization of surfactant.","J Lewis","","$13,249,687.00"
"Lewis, James","Medicine","1996/05","1997/04","Grants","Funded","False","False","Co-Investigator","A captive bubble tensiometer for research on pulmonary surfactant.","F Possmayer","J Lewis","$11,232,142.00"
"Lewis, James","Medicine","1996/07","1997/06","Grants","Funded","False","False","Co-Investigator","Interaction between inhaled nitric oxide therapy and surfactant administration in acute lung injury.","D McCormack","J Lewis.","$33,198,838.00"
"Lewis, James","Medicine","1996/07","1997/06","Grants","Funded","False","False","Co-Investigator","The role of the surfactant system in sepsis-induced lung injury. (J. Malloy)","J Lewis","J Malloy","$52,624,501.00"
"Lewis, James","Medicine","1996/07","1997/06","Grants","Funded","False","False","Co-Investigator","Effects of mechanical ventilation on the pulmonary surfactant system - A human pilot study.","M Sharpe","J Lewis","$3,285,044.00"
"Lewis, James","Medicine","1996/07","1997/06","Grants","Funded","False","False","Principal Investigator","Evaluation of exogenous surfactant in sepsis-induced lung injury.","J Lewis","","$36,269,836.00"
"Lewis, James","Medicine","1996/07","1997/07","Grants","Funded","False","False","Co-Investigator","The role of surfactant in acute bacterial pneumonia. (J. Vanderzwan)","J Lewis","J Vanderzwan","$41,384,290.00"
"Lewis, James","Medicine","1996/07","1997/06","Grants","Funded","False","False","Co-Investigator","Aggregate conversion of exogenous surfactant in vivo.","J Lewis","R Veldhuizen","$74,727,019.00"
"Lewis, James","Medicine","1996/07","1997/06","Grants","Funded","False","False","Co-Investigator","The role of surfactant system in sepsis-induced lung injury.","J Lewis","R Veldhuizen","$69,772,023.00"
"Lewis, James","Medicine","1996/07","1997/06","Grants","Funded","False","False","Co-Investigator","Surfactant alterations in septic adult rats. (J. Vanderzwan)","J Lewis","J Vanderzwan","$58,952,155.00"
"Lewis, James","Medicine","1996/01","1997/01","Grants","Funded","False","False","Co-Investigator","The effects of mechanical ventilation in septic adult rats.","J Lewis","","$9,435,620.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","False","Principal Site Investigator","Grant","William Kostuk","","$47,205,162.00"
"Lewis, James","Medicine","1997/07","2002/06","Grants","Funded","False","False","Co-Investigator","The role of pulmonary surfactant in acute lung injury.","J Lewis","R Veldhuizen","$19,180,781.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$63,298,330.00"
"Lewis, James","Medicine","1997/09","2003/08","Grants","Funded","False","False","Co-Investigator","The role of pulmonary surfactant in acute lung injury. (J. Malloy)","J Lewis","J Malloy","$51,182,261.00"
"Lewis, James","Medicine","1997/07","2002/06","Grants","Funded","False","False","Principal Investigator","Evaluation of the role of the surfactant system in acute lung injury.","J Lewis","","$11,041,484.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$57,946,814.00"
"Lewis, James","Medicine","1997/09","1998/08","Grants","Funded","False","False","Co-Investigator","The role of surfactant in acute bacterial pneumonia. (J. Vanderzwan)","J Lewis","J Vanderzwan","$67,428,679.00"
"Lewis, James","Medicine","1997/07","1998/06","Grants","Funded","False","False","Co-Investigator","Effects of mechanical ventilation on the pulmonary surfactant system-A human pilot study.","M Sharpe","J Lewis","$2,675,950.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$8,367,716.00"
"Lewis, James","Medicine","1997/07","1998/06","Grants","Funded","False","False","Co-Investigator","The therapeutic effects of exogenous NO and surfactant in an animal model of acute bacterial pneumonia.","","S Mehta, J Lewis, D McCormack, R Veldhuizen","$63,690,259.00"
"Lewis, James","Medicine","1997/07","1998/06","Grants","Funded","False","False","Principal Investigator","Changes in pulmonary surfactant aggregates effect immune cell function.","J Lewis","","$31,022,882.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$65,161,623.00"
"Lewis, James","Medicine","1997/07","1998/06","Grants","Funded","False","False","Co-Investigator","Modulation of pulmonary inflammation by nitric oxide.","","J Lewis, S Mehta, D McCormack","$73,308,269.00"
"Lewis, James","Medicine","1997/07","1998/06","Grants","Funded","False","False","Co-Investigator","Mechanisms responsible for the efficacy of exogenous surfactant administration.","","J Lewis, R Veldhuizen, F Possmayer","$9,009,532.00"
"Lewis, James","Medicine","1997/09","1998/08","Grants","Funded","False","False","Co-Investigator","The role of the pulmonary surfactant system in acid aspiration induced lung injury. (P. Puligandla)","J Lewis","P Puligandla","$1,626,348.00"
"Kostuk, William","Medicine","1986","1986","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$72,383,637.00"
"Kostuk, William","Medicine","1986","1986","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kosutk","","$47,477,516.00"
"Lewis, James","Medicine","1997/04","1998/03","Grants","Funded","False","False","Co-Investigator","The effects of mechanical ventilation on the surfactant system in sepsis-induced lung injury.","J Lewis","","$5,410,306.00"
"Lewis, James","Medicine","1998/07","1999/06","Grants","Funded","False","False","Principal Investigator","The effects of high frequency oscillation (HFO) on the efficacy of exogenous surfactant.","J Lewis","","$56,100,229.00"
"Kostuk, William","Medicine","1986","1986","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$29,453,636.00"
"Lewis, James","Medicine","1998/06","2000/08","Grants","Funded","False","False","Co-Investigator","The effects of mechanical ventilation on exogenous surfactant. (W. Mak)","J Lewis","W Mak","$48,767,529.00"
"Kostuk, William","Medicine","1986","1986","Grants","Funded","False","False","Principal Investigator","Grant","William Kostuk","","$63,185,338.00"
"Lewis, James","Medicine","1998/01","1998/12","Grants","Funded","False","False","Co-Investigator","The contribution of pulmonary inflammation to systemic sepsis.","J Lewis","R Veldhuizen","$29,343,516.00"
"Lewis, James","Medicine","1998/07","1999/06","Grants","Funded","False","False","Co-Investigator","Nitric oxide-surfactant interactions in acute lung injury.","","S Mehta, D McCormack, J Lewis, R Veldhuizen","$14,821,952.00"
"Lewis, James","Medicine","1998/06","1999/05","Grants","Funded","False","False","Principal Investigator","The contribution of pulmonary inflammation to systemic sepsis.","J Lewis","","$15,410,859.00"
"Kostuk, William","Medicine","1985","1985","Grants","Funded","False","False","Principal Applicant","Grant","William Kostuk","","$52,859,992.00"
"Lewis, James","Medicine","1998/06","1999/06","Grants","Funded","False","True","Principal Investigator","The effects of high frequency oscillation (HFO) on the efficacy of Survanta.","J Lewis","","$38,052,829.00"
"Lewis, James","Medicine","1998","1999","Clinical Trials","Funded","False","True","Co-Investigator","12 weeks treatment with 200 or 800 ?g/d Ciclesonide versus placebo followed by a 40 week treatment with Ciclesonide in asthmatic patients: A double-blind, randomized, parallel group study with an open label extension.","J Lewis","","$36,234,169.00"
"Kostuk, William","Medicine","1985","1985","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$68,194,452.00"
"Lewis, James","Medicine","1998","1999","Clinical Trials","Funded","False","True","Principal Investigator","rSP-C surfactant for the treatment of acute respiratory distress syndrome (ARDS). A randomized, open-label, multicentre parallel group, controlled pilot study.","J Lewis","","$61,286,238.00"
"Lewis, James","Medicine","1998","1999","Clinical Trials","Funded","False","True","Principal Investigator","A six month, double-blind (within formulation), randomized, multiple dose trial to compare the safety and efficacy of 20 mcg and 40 mcg of ipratropium bromide, as delivered by the RespimatTM device, to 18 mcg ATROVENT? Inhalation Aerosol (x2 puffs) and respective placebos in adults, with obstructive pulmonary disease.","J Lewis","","$8,728,960.00"
"Kostuk, William","Medicine","1985","1985","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$42,766,651.00"
"Lewis, James","Medicine","1999/06","2002/12","Grants","Funded","False","False","Co-Investigator","Significance of surfactant aggregate alterations in vivo.","J Lewis","","$60,677,748.00"
"Lewis, James","Medicine","1999/07","2000/06","Grants","Funded","False","False","Co-Investigator","Development and utilization of the isolated perfused rat lung model.","R Veldhuizen","J Lewis","$67,854,803.00"
"Kostuk, William","Medicine","1985","1985","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$44,250,489.00"
"Lewis, James","Medicine","1999/07","2000/06","Grants","Funded","False","False","Principal Investigator","Pulmonary inflammation and surfactant alterations in the development of sepsis.","J Lewis","","$68,896,346.00"
"Lewis, James","Medicine","1999/07","2000/06","Grants","Funded","False","False","Principal Investigator","Significance of surfactant aggregate alterations in vivo.","J Lewis","","$26,856,980.00"
"Lewis, James","Medicine","1999/06","2000/05","Grants","Funded","False","False","Co-Investigator","The significance of surfactant aggregate alterations in vivo.","J Lewis","","$20,222,781.00"
"Kostuk, William","Medicine","1984","1984","Grants","Funded","False","False","Principal Applicant","Grant","William Kostuk","","$59,147,664.00"
"Lewis, James","Medicine","1999","2000","Grants","Funded","False","True","Principal Investigator","Evaluation of PEG with Exogenous surfactant.","J Lewis","","$23,528,946.00"
"Lewis, James","Medicine","1999","2000","Clinical Trials","Funded","False","True","Principal Investigator","12 weeks treatment with 500 µg roflumilast versus 10 mg montelukast in patients with asthma.","J Lewis","","$39,418,949.00"
"Kostuk, William","Medicine","1984","1984","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$69,105,521.00"
"Lewis, James","Medicine","1999","2000","Clinical Trials","Funded","False","True","Principal Investigator","rSP-C surfactant for the treatment of acute respiratory distress syndrome (ARDS). A randomized, multicentre parallel group, controlled study. - Phase III.","J Lewis","","$18,778,322.00"
"Lewis, James","Medicine","2000/07","2001/06","Grants","Funded","False","False","Co-Investigator","The evaluation of high frequency oscillation and exogenous surfactant in acute lung injury. (M. Sen)","J Lewis","M Sen","$59,424,409.00"
"Kostuk, William","Medicine","1984","1984","Grants","Funded","False","True","Co-Applicant","Grant","William Kostuk","","$14,414,882.00"
"Lewis, James","Medicine","2000/07","2001/06","Grants","Funded","False","False","Co-Investigator","The role of SP-A in sepsis-induced lung injury.","J Lewis","R Veldhuizen","$38,038,424.00"
"Lewis, James","Medicine","2000/07","2001/06","Grants","Funded","False","False","Co-Investigator","The effect of different modes of ventilation on the pulmonary surfactant system in a pediatric population with respiratory failure secondary to bronchiolitis. (P. Puligandla)","J Lewis","P Puligandla","$66,936,295.00"
"Lewis, James","Medicine","2001/07","2003/06","Grants","Funded","False","False","Co-Investigator","NSERC Post Doctoral Fellowship Award (J. Malloy)","J Lewis","J. Malloy","$73,467,272.00"
"Kostuk, William","Medicine","1984","1984","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$31,905,061.00"
"Lewis, James","Medicine","2001/07","2002/06","Grants","Funded","False","False","Co-Investigator","Screening protocols to determine prevalence and awareness of EIA among varsity football players. (J Rumball)","J Lewis","J. Rumball","$68,931,818.00"
"Kostuk, William","Medicine","1983","1983","Grants","Funded","False","False","Principal Applicant","Grant","William Kostuk","","$19,779,087.00"
"Lewis, James","Medicine","2001/07","2002/06","Grants","Funded","False","False","Co-Investigator","The role of the surfactant system in bacterial pneumonia. (A. Brackenbury)","J Lewis","A. Brackenbury","$65,746,378.00"
"Lewis, James","Medicine","2001/12","2005/05","Grants","Funded","False","False","Co-Investigator","Use of exogenous surfactant to mitigate acute lung injury; Regional lung function assessed with functional CT imaging.","B Simon","J Lewis","$13,267,001.00"
"Kostuk, William","Medicine","1983","1983","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$2,404,846.00"
"Lewis, James","Medicine","2001","2002","Clinical Trials","Funded","False","True","Principal Site Investigator","Spiriva Assessment of FEV1 (SAFE).","J Lewis","","$22,032,223.00"
"Lewis, James","Medicine","2001","2002","Grants","Funded","False","True","Principal Site Investigator","The effectiveness and safety of an individualized Symbicort Turbuhaler maintenance dosing regimen (Symbicort Asthma Control Plan_ versus Symbicort Turbuhaler given as regular twice daily therapy – SMART).","J Lewis","","$58,123,035.00"
"Lewis, James","Medicine","2002/06","2007/07","Grants","Funded","True","False","Principal Investigator","The role of the surfactant system In acute lung injury.","J Lewis","R Veldhuizen","$18,533,015.00"
"Kostuk, William","Medicine","1983","1983","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$74,801,167.00"
"Lewis, James","Medicine","2002/06","2003/07","Grants","Funded","False","False","Co-Investigator","The Effect of Different Modes of Ventilation on the Pulmonary Surfactant System in a Pediatric Population with Respiratory Failure Secondary to Bronchiolitis. (P. Puligandla)","J Lewis","P Puligandla","$53,488,814.00"
"Lewis, James","Medicine","2002/06","2003/07","Grants","Funded","False","False","Co-Investigator","The effects of oxidized surfactant both in vitro and in vivo.","R Veldhuizen","J. Lewis, F. Possmayer","$30,707,082.00"
"Kostuk, William","Medicine","1983","1983","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$23,713,671.00"
"Lewis, James","Medicine","2002/01","2003/09","Clinical Trials","Funded","False","True","Co-Investigator","Spiriva? Assessment of FEV1. (SAFE) The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long-term treatment in patients with COPD. A one-year parallel group, double-blind, randomised, placebo-controlled study.","","J. Lewis, R. McFadden","$59,424,482.00"
"Lewis, James","Medicine","2003/07","2004/06","Grants","Funded","False","False","Principal Investigator","The role of SP-A in modulating host defence.","J Lewis","","$71,742,751.00"
"Kostuk, William","Medicine","1982","1982","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$10,584,322.00"
"Lewis, James","Medicine","2003/07","2004/06","Grants","Funded","False","False","Co-Investigator","Evaluation of pulmonary surfactant in mechanically ventilated trauma patients.","J Lewis","K. Bosma, R. Kao","$43,654,643.00"
"Lewis, James","Medicine","2003/07","2004/06","Grants","Funded","False","False","Co-Investigator","Block Term Grant Training Award","J Lewis","P. Pace","$35,553,539.00"
"Lewis, James","Medicine","2003/07","2004/06","Grants","Funded","False","False","Co-Investigator","Evaluation of Pulmonary Surfactant in Mechanically Ventilated Trauma Patients.","J Lewis","R. Veldhuizen","$51,899,399.00"
"Kostuk, William","Medicine","1982","1982","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$10,087,035.00"
"Lewis, James","Medicine","2003/10","2008/09","Grants","Funded","True","False","Co-Principal Investigator","The role of oxidative damage to surfactant in acute lung injury.","R Veldhuizen","J. Lewis","$70,233,849.00"
"Lewis, James","Medicine","2003","2004","Clinical Trials","Funded","False","True","Principal Investigator","A study in Canadian COPD patients to evaluate the nature, treatment and impact of COPD exacerbations in patients who are likely to benefit from treatment with Symbicort (Budesonide/formoterol) Turbuhaler. An open-label, multicentre descriptive study.","J Lewis","","$32,282,251.00"
"Kostuk, William","Medicine","1979","1982","Grants","Funded","False","False","Principal Applicant","Grant","William Kostuk","","$28,122,832.00"
"Lewis, James","Medicine","2004/07","2005/06","Grants","Funded","False","False","Co-Investigator","Block Term Training Award (A. Maruscak)","J Lewis","A Maruscak","$9,066,691.00"
"Lewis, James","Medicine","2005/01","2005/12","Grants","Funded","False","False","Co-Investigator","The role of SP-A in modulating host defense. (E. Truscott)","J Lewis","E Truscott","$11,558,464.00"
"Lewis, James","Medicine","2004","2006","Grants","Funded","False","True","Co-Principal Investigator","Venticute (rSP-C Surfactant) in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygenation impairment (VALID Study) – A randomized, multinational, multicenter, parallel group, double blind, control group study.","J Lewis","","$68,114,918.00"
"Kostuk, William","Medicine","1979","1982","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$64,220,687.00"
"Lewis, James","Medicine","2005/05","2005/08","Grants","Funded","False","False","Principal Investigator","Prolonged Ventilation of Adult Rats; bridging the gap between clinical studies and animal models.","J Lewis","","$21,392,341.00"
"Lewis, James","Medicine","2006/01","2007/01","Grants","Funded","True","False","Principal Investigator","The role of surfactant protein-A in modulating host defense.","J Lewis","E Truscott","$42,443,214.00"
"Lewis, James","Medicine","2005/10","2010/06","Grants","Funded","True","False","Co-Principal Investigator","Multi organ dysfunction in the systemic inflammatory response syndrome.","","R. Potter, D McCormack, S Mehta, Q Feng, J Lewis, R Veldhuizen.","$58,675,448.00"
"Lewis, James","Medicine","2005/07","2006/06","Grants","Funded","True","False","Principal Investigator","Role of oxidation in surfactant dysfunction. (A. Maruscak)","J Lewis","","$24,936,633.00"
"Kostuk, William","Medicine","1979","1982","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$2,166,540.00"
"Lewis, James","Medicine","2005/07","2006/06","Grants","Funded","True","False","Principal Investigator","Exploring the relationship between asthma and menstrual cycle.","C Lebrun","J Lewis, J Rumball","$1,722,684.00"
"Lewis, James","Medicine","2005/07","2007/06","Grants","Funded","True","False","Principal Investigator","Lung-liver interactions in ARDS and Multiorgan Failure.","J Lewis","J Lewis","$63,077,238.00"
"Lewis, James","Medicine","2005/01","2006/01","Grants","Funded","True","False","Principal Investigator","Lung-liver interactions in sepsis.","J Lewis","R Veldhuizen","$19,900,760.00"
"Kostuk, William","Medicine","1979","1982","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$55,954,917.00"
"Lewis, James","Medicine","2005/07","2006/06","Grants","Funded","True","False","Principal Investigator","Exploring the relationship between asthma and menstrual cycle.","J Lewis","J Rumball","$9,906,017.00"
"Lewis, James","Medicine","2005/07","2006/06","Grants","Funded","False","True","Co-Principal Investigator","Exploring the relationship between asthma and menstrual cycle.","C Lebrun","J Rumball, J Lewis","$21,713,846.00"
"Kostuk, William","Medicine","1979","1982","Grants","Funded","False","False","Principal Applicant","Grant","William Kostuk","","$13,816,460.00"
"Lewis, James","Medicine","2007/09","2008/08","Grants","Funded","True","False","Principal Investigator","The role of surfactant in acute lung injury and progression to multi-organ failure.","J Lewis","M Walker","$13,172,870.00"
"Kostuk, William","Medicine","1977","1978","Grants","Funded","False","False","Principal Applicant","","","","$7,507,689.00"
"Kostuk, William","Medicine","1977","1978","Grants","Funded","False","False","Principal Applicant","","","","$71,925,682.00"
"Kostuk, William","Medicine","1977","1978","Grants","Funded","False","False","Principal Applicant","","","","$569,348.00"
"Kostuk, William","Medicine","1977","1978","Grants","Funded","False","False","Principal Applicant","","","","$49,083,831.00"
"Kostuk, William","Medicine","1976","1977","Grants","Funded","False","False","Principal Applicant","","","","$9,838,105.00"
"Kostuk, William","Medicine","1975","1976","Grants","Funded","False","False","Principal Applicant","","","","$31,035,857.00"
"Kostuk, William","Medicine","1974","1975","Grants","Funded","False","False","Principal Applicant","","","","$52,488,810.00"
"Kostuk, William","Medicine","1989","1989","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$4,738,819.00"
"Kostuk, William","Medicine","1989","1989","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$58,591,534.00"
"Kostuk, William","Medicine","1990","1991","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","Dr. William Kostuk","","$58,873,957.00"
"Kostuk, William","Medicine","1988","1988/06","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$66,103,235.00"
"Kostuk, William","Medicine","1988","1988","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$53,293,379.00"
"Kostuk, William","Medicine","1988","1988","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$21,180,234.00"
"Kostuk, William","Medicine","1988","1988","Grants","Funded","False","False","Principal Site Investigator","Grant","William Kostuk","","$38,949,663.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$50,113,611.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$29,068,788.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$25,283,973.00"
"Kostuk, William","Medicine","1987","1987","Grants","Funded","False","True","Principal Site Investigator","","","","$23,735,873.00"
"Goldszmidt, Mark","Medicine","2003","2006","Grants","Funded","False","False","Co-Director","Group for the Advocacy and Advancement of Medical/Dental Education Scholarship","","","$30,004,007.00"
"Goldszmidt, Mark","Medicine","2003","2004","Grants","Funded","True","False","Principal Investigator","Improving the Discharge Summary: Evaluating an Educational Intervention for PGY 1 Residents in Internal Medicine.","Goldszmidt, M.","Eva K.","$66,212,877.00"
"Goldszmidt, Mark","Medicine","2001","2003","Grants","Funded","True","False","Principal Investigator","Modelling a process of developing an instructional plan for an internal medicine consult service","Goldszmidt, M.","","$62,187,630.00"
"Goldszmidt, Mark","Medicine","1998","1999","Grants","Funded","True","False","Principal Investigator","Teaching internal-medicine residents critical appraisal through a classic literature based journal club","Goldszmidt, M.","","$20,269,071.00"
"Pope, Janet","Medicine","2007/04","2010/12","Grants","Funded","True","False","Co-PI","Tool development: improving the utility of administrative databases for post-marketing surveillance of serious adverse events and health service utilization in patients receiving biologic response modifying drugs for rheumatoid arthritis","Claire Bombardier","Sasha Bernatsy/Janet E. Hux/ Janet Pope et al","$68,174,681.00"
"Chin-Yee, Ian","Medicine","1993","1994","Grants","Funded","False","False","Co-investigator","Flaxseed in lupus nephritis.","W.F. Clark","A.Parbtani I.Chin-Yee","$7,799,010.00"
"Chin-Yee, Ian","Medicine","1993","1994","Grants","Funded","False","False","Co-investigator","Development of Assays for DNA Adduct Formation and Repair, Metallothionein Status, and in vitro Cytotoxicity to Predict Patient Response to Chemotherapy in Human Leukemia.","J.Koropatnick","I. Chin-Yee","$58,493,495.00"
"Chin-Yee, Ian","Medicine","1993","1995","Grants","Funded","False","False","Co-investigator","A Methotrexate Transport Function as a Determinant of Drug Resistance In Vivo.","W.Flintoff","I. Chin-Yee","$15,696,323.00"
"Chin-Yee, Ian","Medicine","1994","1996","Grants","Funded","False","False","Co-investigator","A Methotrexate Transport Function as a Determinant of In Vivo Drug Resistance.","W.Flintoff","I. Chin-Yee","$64,950,184.00"
"Chin-Yee, Ian","Medicine","1995","1997","Grants","Funded","False","False","Co-investigator","The Efficacy of Diaspirin Cross-Linked Hemoglobin Solution in Sepsis, WE26-003","I. Chin-Yee","W. Sibbald","$69,284,632.00"
"Chin-Yee, Ian","Medicine","1998","2000","Grants","Funded","False","False","Co-investigator","The Effects of Storage on RBC Oxygen Delivery and Interaction with the Microcirculation.","M. D’Almeida","I. Chin-Yee","$19,496,434.00"
"Chin-Yee, Ian","Medicine","1999","2001","Grants","Funded","False","False","Co-investigator","Albumin compared to crystalloid for intravascular volume therapy of sepsis","C. Martin","I. Chin-Yee, W. Sibbald, G. Doig","$33,097,310.00"
"Chin-Yee, Ian","Medicine","2002","2002","Grants","Funded","False","False","Principal Site Investigator","Age of Blood Evaluation Pilot Study","P. Hebert, I. Chin-Yee, M. Blajchman","","$21,547,455.00"
"Chin-Yee, Ian","Medicine","2002","2004","Grants","Funded","False","False","Principal Investigator","Does Prestorage Leukoreduction Reduce Red Cell Adhesion and Improve Tissue Oxygenation in Microvasculature","I. Chin-Yee","","$46,853,850.00"
"Chin-Yee, Ian","Medicine","2002","2004","Grants","Funded","False","False","Co-investigator","Stem Cell Transplantation and Regenerative Therapeutics START","M. Bhatia","I. Chin-Yee","$20,095,558.00"
"Chin-Yee, Ian","Medicine","2004","2005","Grants","Funded","False","False","Principal Investigator","Improving Detection and Speciation of Malaria in the Community.","I. Chin-Yee","M. Keeney","$26,550,875.00"
"Chin-Yee, Ian","Medicine","2004/01","2007/12","Grants","Funded","True","False","Principal Investigator","Anemia and Transfusion in Myocardial Infarction.","I. Chin-Yee","Q. Feng, A. Xenocostas","$56,520,862.00"
"Chin-Yee, Ian","Medicine","1991","1992","Grants","Funded","False","False","Principal Investigator","Immune Response to Mycobacterial Cell Wall Extract","I. Chin-Yee","","$1,862,090.00"
"Chin-Yee, Ian","Medicine","1993","1995","Grants","Funded","False","False","Principal Investigator","Phase III Study of Granulocyte-Colony Stimulating Factor (G-CSF) in the Treatment of Severe Community Acquired Pneumonia","I. Chin-Yee, M. Keeney, D. McCormack","","$26,332,327.00"
"Chin-Yee, Ian","Medicine","1993","1995","Grants","Funded","False","False","Principal Investigator","Multiple Drug Resistance in Non-Hodgkin’s Lymphoma: Circumvention with Idarubicin.","I. Chin-Yee, A. Smith, J. Koropatnick, M. Kovacs","","$5,284,037.00"
"Chin-Yee, Ian","Medicine","1995","1996","Grants","Funded","False","False","Co-investigator","The Efficacy of Diaspirin Cross-Linked Hemoglobin Solution in Sepsis.","W. Sibbald","I. Chin-Yee, C. Martin","$46,646,158.00"
"Chin-Yee, Ian","Medicine","1995","1996","Grants","Funded","False","False","Principal Investigator","Effect of G-CSF on Neutrophils, Tissue Injury and Organ Function in a Murine Model of Sepsis.","I. Chin-Yee, C. Martin, W. Sibbald","","$68,518,644.00"
"Chin-Yee, Ian","Medicine","2001","2001","Grants","Funded","False","False","Principal Investigator","NESP A Multicenter, Blinded, Placebo-Controlled, Randomized Study of Novel Erythropoiesis Stimulating Protein (NESP for the Treatment of Anemia in Subjects with Lymphoproliferative Malignancies Receiving Chemotherapy","I. Chin-Yee","","$26,320,654.00"
"Chin-Yee, Ian","Medicine","2001","2002","Grants","Funded","False","False","Principal Investigator","Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Diffuse Large B Cell non-Hodgkins Lymphoma that is Refractory or Relapsed After Second Lind Combination Chemotherapy","I. Chin-Yee","","$26,375,768.00"
"Chin-Yee, Ian","Medicine","2002","2002","Grants","Funded","False","False","Principal Investigator","Whole Blood Hematopoietic Stem Cell Transplantation Following Myelo-ablative Chemotherapy for Multiple Myeloma: A Feasibility Study.","I. Chin-Yee","","$21,010,458.00"
"Chin-Yee, Ian","Medicine","1990","1991","Grants","Funded","False","False","Principal Investigator","Detection of Multi-Drug Resistance","I. Chin-Yee","","$72,055,362.00"
"Chin-Yee, Ian","Medicine","1991","1992","Grants","Funded","False","False","Principal Investigator","Multi-Drug Resistance in Hematologic Malignancies","I. Chin-Yee","","$72,995,221.00"
"Chin-Yee, Ian","Medicine","1992","1993","Grants","Funded","False","False","Principal Investigator","Lymphocyte Phenotypic Analysis of Renal Cell Carcinoma Patients Treated with High Dose Ranitidine.","I. Chin-Yee, W. Mertens","","$66,237,388.00"
"Chin-Yee, Ian","Medicine","1994","1995","Grants","Funded","False","False","Principal Investigator","Red Cell Storage and Interleukin 1 and 6 Levels","I. Chin-Yee","","$48,345,916.00"
"Chin-Yee, Ian","Medicine","1994","1994","Grants","Funded","False","False","Principal Investigator","Stem Cell Enumeration by Flow Cytometry","A. Smith, I. Chin-Yee","","$68,042,682.00"
"Chin-Yee, Ian","Medicine","1997","1997","Grants","Funded","False","False","Principal Investigator","Determining the Role of Red Blood Cell 2,3-DPG and Membrane Deformability on Tissue Oxygenation Following Blood Transfusion","I. Chin-Yee","M. D’Almeida","$26,226,956.00"
"Chin-Yee, Ian","Medicine","1998","1998","Grants","Funded","False","False","Principal Investigator","Influence of Nitric Oxide of Erythrocyte Diphosphoglycerate in Sepsis Syndrome","I. Chin-Yee","M.D’Almeida","$18,494,210.00"
"Chin-Yee, Ian","Medicine","2002","2004","Grants","Funded","False","False","Principal Investigator","Lymphoid Reconstitution Following Whole Blood Derived Stem Cell Transplantation in Multiple Myeloma","I. Chin-Yee","","$61,422,992.00"
"Chin-Yee, Ian","Medicine","2005","2007","Grants","Funded","False","False","Co-Investigator","Circulating endothelial cells and endothelial progenitor cells in the peripheral blood of breast cancer patients: Assay development and determination of potential clinical relevance.","A. Allan","I. Chin-Yee","$27,606,625.00"
"Chin-Yee, Ian","Medicine","2005","2007","Grants","Funded","True","False","Co-Investigator","Is Erythropoietin Cardioprotective during Anemia?","A. Xenocostas","I. Chin-Yee","$16,749,834.00"
"Chin-Yee, Ian","Medicine","2001/03","2001/12","Grants","Research Project – no Funding Involved","False","False","Lab Project","Establishing a Normal Range for Stem Cells in Healthy Adults. Ethics Approval Granted #08199E.","","","$58,512,481.00"
"Goldszmidt, Mark","Medicine","2007/01","2008/01","Grants","Funded","True","False","Co-Investigator","How Clinicians Think: An Investigation of the Cognitive Psychology of Medical Thinking and Reasoning","Minda J.P.","Devantier S., Haddara W., Goldszmidt, M.","$21,905,088.00"
"Goldszmidt, Mark","Medicine","2006","2007","Grants","Funded","True","False","Collaborator","An exploration of residents’ experience and perceptions of in-training evaluations","Watling C.,","Kenyon C., Singh I, Kortas C.,Haddara W, Schultz V., Zibrowski E., Lingard L., Goldszmidt M.","$35,161,832.00"
"Goldszmidt, Mark","Medicine","1993/01","1993/01","Grants","Funded","True","False","Principal Investigator","Complementary health care services: a survey of general practitioners' views.","Goldszmidt, M.","Levitt C.","$24,180,022.00"
"Suskin, Neville","Medicine","2007/07","2013/06","Grants","Funded","True","False","Principal Investigator","Cardiac Rehabilitative Programming as Secondary Preventative for Survivors of Transient Ischemic Attacks and Mild Non-Disabling Strokes: CR TIA RCT","Suskin","","$73,333,080.00"
"Suskin, Neville","Medicine","2005/12","2007/06","Grants","Funded","True","False","Co-Investigator","Effectiveness of a web-based intervention to promote physical activity in patients with heart disease: A randomized trial","Robert Reid","","$44,750,469.00"
"Suskin, Neville","Medicine","2003/07","2007/06","Grants","Funded","True","False","Principal Investigator","Improving cardiac rehabilitation participation in women and men","Suskin","","$49,909,994.00"
"Suskin, Neville","Medicine","2004/07","2007/06","Grants","Funded","True","False","Principal Investigator","Evaluation of the impact of exercise training on insulin resistance in patients with heart failure","Suskin","","$21,750,884.00"
"Suskin, Neville","Medicine","2003/07","2007/06","Grants","Funded","True","False","Co-Investigator","An evidence-based health services evaluation of information and management continuity in heart patients","Sherry Grace","","$35,789,741.00"
"Suskin, Neville","Medicine","2005/01","2007/06","Grants","Funded","True","False","Principal Investigator","Cardiac rehabilitation as secondary prevention with survivors of transient ischemic attacks and mild non-disabling strokes: an RCT","Suskin","","$45,052,520.00"
"Suskin, Neville","Medicine","2005/01","2007/06","Grants","Funded","True","False","Principal Investigator","Cardiac Rehabilitative Programming as Secondary Prevention for Survivors of Transient Ischemic Attacks and Mild Non-disabling Strokes","Suskin","","$44,951,991.00"
"Suskin, Neville","Medicine","2004/10","2009/12","Grants","Funded","True","False","Principal Investigator","Ontario Cardiac Rehabilitation Registry","Suskin","","$41,641,136.00"
"Suskin, Neville","Medicine","2005/03","2006/03","Grants","Funded","True","False","Principal Investigator","Inpatient Cardiac Rehab Programming to Facilitate Long-Term Secondary Prevention of Cardiac Events and Decrease Wait Times for Cardiac Services Study","Suskin","","$8,933,429.00"
"Suskin, Neville","Medicine","2005/09","2008/08","Grants","Funded","True","False","Co-Investigator","Contribution of physician and patient factors to cardiac rehabilitation referral and participation: A prospective, multi-level study","Sherry Grace","","$42,132,814.00"
"Suskin, Neville","Medicine","2002/09","2007/08","Grants","Funded","True","False","Co-Investigator","HF-ACTION: The Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing","Dave Rendall","","$42,988,347.00"
"Suskin, Neville","Medicine","2001/09","2009/08","Grants","Funded","True","False","Principal Investigator","Bumetanide has a more favorable effect on insulin resistance compared with furosemide in patients with heart failure","Suskin","","$20,243,379.00"
"Suskin, Neville","Medicine","2001","2002","Grants","Funded","True","False","Principal Investigator","Improving cardiac rehabilitation participation in women and men – Pilot","Suskin","","$40,325,830.00"
"Suskin, Neville","Medicine","2002","2005","Grants","Funded","True","False","Principal Investigator","Evaluation of an introductory videotape intervention to improve cardiac rehabilitation participation, the CR$P-2 pilot study","Suskin","","$7,433,921.00"
"Suskin, Neville","Medicine","2000","2004","Grants","Funded","True","False","Co-Investigator","The effect of a liberal vs. restricted transfusion strategy in elderly patients following coronary bypass surgery","ML Myers","Suskin","$5,435,985.00"
"Suskin, Neville","Medicine","1999","2001","Grants","Funded","True","False","Principal Investigator","Evaluation of post myocardial infarction cardiac rehabilitation participation and user fees","Suskin","","$22,293,211.00"
"Suskin, Neville","Medicine","1998","2000","Grants","Funded","True","False","Co-Investigator","Biobehavioural Aspects of Coronary Artery Disease","David Spence","Suskin","$9,006,244.00"
"Suskin, Neville","Medicine","1998","1999","Grants","Funded","True","False","Co-Investigator","Homocysteine and Outcome after Bypass Surgery (Ontario CR Pilot) Study","Richard Novick","Suskin","$65,318,299.00"
"Suskin, Neville","Medicine","1997","1999","Grants","Funded","True","False","Co-Investigator","Exercise Training Decreases Insulin Resistance in CAD (ExCADIR)","Robert McKelvie","Suskin","$65,754,545.00"
"Pope, Janet","Medicine","2007/03","2010/12","Grants","Funded","True","False","Co-PI","A prospective controlled study of the real-world effectiveness of biologic response modifying drugs in adults with rheumatoid arthritis","Claire Bombardier","Sasha Bernatsy/ Janet Pope et al","$18,013,504.00"
"Pope, Janet","Medicine","2007/02","2009/02","Grants","Funded","False","True","Principal Investigator","A multicentre, randomized, double-blind comparison of 4 dose regimens of PLA-695, naproxen, and placebo administered daily for 6 weeks in subjects with active osteoarthritis of the knee","Janet Pope","","$40,738,217.00"
"Pope, Janet","Medicine","2006/08","2008/08","Grants","Funded","False","True","Principal Investigator","A randomized, double-blind, placebo-controlled, multicentre, phase II/III study to evaluate the efficacy and safety of rituximab in subjects with moderate to severe systemic lupus erythematosus","Janet Pope","Invoiced per patient enrolled.","$38,944,796.00"
"Pope, Janet","Medicine","2006/02","2008/02","Grants","Funded","False","True","Principal Investigator","A long-term assessment of safety and physical function with AMG 108 subcutaneous monthly treatment in subjects with RA","Janet Pope","","$31,778,536.00"
"Pope, Janet","Medicine","2006/04","2007/05","Grants","Funded","False","True","Site PI","A randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety and pharmacokinetics of subcutaneous AMG 108 in subjects with rheumatoid arthritis","Janet Pope","","$27,853,112.00"
"Pope, Janet","Medicine","2006/09","2007/09","Grants","Funded","True","False","Principal Investigator","The Development of Classification Criteria for Scleroderma","Janet Pope","Murray Baron/All members of the CSRG","$38,199,659.00"
"Mangel, Joy","Medicine","2004/07","2006/06","Grants","Funded","False","False","Local Principal Investigator LRCC","A multicentre, phase II study of Tositumomab and Iodine-131 Tositumomab in patients with indolent non-Hodgkin’s lymphoma who have failed Rituximab.","","","$21,395,316.00"
"Pope, Janet","Medicine","2006/09","2008/03","Grants","Funded","True","False","Principal Investigator","A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma","Janet Pope","Andrew Leask","$29,437,381.00"
"Pope, Janet","Medicine","2006/05","2009/08","Grants","Funded","True","False","Principal Investigator","Comprehensive Care in Rheumatoid Arthritis. An Outcomes Based Pilot Project in an Under Serviced Area (Southwestern Ontario)","Janet Pope","Susan Ruth/ Andrew Thompson/ Nicole le Riche","$37,317,065.00"
"Mangel, Joy","Medicine","2005/07","2006/06","Grants","Funded","False","False","Local Principal Investigator LRCC","A phase II study of G3139 (Bcl-2 Antisense) and Rituximab in patients with recurrent B-cell non-Hodgkin’s lymphomas.","","","$51,887,969.00"
"Pope, Janet","Medicine","2006","2006/06","Grants","Funded","False","True","Site PI","Phase III “in-life” study of a topical gel formulation of nitroglycerin, MQX-503, and matching placebo in Raynaud’s phenomenon","Janet Pope","","$60,560,693.00"
"Pope, Janet","Medicine","2006/04","2007/04","Grants","Funded","False","True","Site PI","Randomized, multicentre, double-blind, placebo-controlled efficacy and safety study of PEG-uricase 8mg in two does regimens in hyperuricemic subjects with symptomatic gout","Janet Pope","","$39,273,226.00"
"Mangel, Joy","Medicine","2005/07","2006/06","Grants","Funded","False","False","Local Principal Investigator LRCC","A phase III trial of intravenous temsirolimus (CCI-779) in previously treated mantle cell lymphoma.","","","$10,593,371.00"
"Pope, Janet","Medicine","2006/02","2007/02","Grants","Funded","False","True","Site PI","A Phase II multicentre, randomized, blinded study of 14 weeks duration comparing the effect of CRx-139 plus DMARD therapy to that of steroid plus DMARD therapy using ACR-20 in subjects with active rheumatoid arthritis partially responsive to the DMARD","Janet Pope","","$25,884,725.00"
"Pope, Janet","Medicine","2005/07","2013/07","Grants","Funded","True","False","Co-PI","A New Emerging Team: The Canadian Scleroderma Research Group","Janet Pope/Murray Baron/Anie Philip","","$35,291,651.00"
"Pope, Janet","Medicine","2005/07","2007/04","Grants","Funded","True","False","Co-PI","Long-term risk of chronic arthritis after campylobacter infection: The Walkerton Health Study","Janet Pope","","$55,119,476.00"
"Pope, Janet","Medicine","2005/06","2006/07","Grants","Funded","True","False","Co-PI","Pilot Study: Long-term risk of chronic reactive arthritis (ReA) after campylobacter infection: The Walkerton Health Study","Janet Pope","","$37,356,783.00"
"Mangel, Joy","Medicine","2006/07","2010","Grants","Funded","False","False","Principal Investigator","Screening for leptomeningeal disease by high sensitivity flow cytometry in high-risk patients with aggressive non-Hodgkin’s lymphoma.","Dr. Joy Mangel","","$44,555,623.00"
"Pope, Janet","Medicine","2005/06","2009/11","Grants","Funded","False","True","Site PI","A prospective, randomized, double-blind, active controlled, parallel group, multi-centre trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis","Janet Pope","","$42,999,428.00"
"Pope, Janet","Medicine","2005/04","2007/04","Grants","Funded","False","True","Site PI","A Phase III multicentre , open label , follow-on study to CDP870-027 to assess the efficacy and safety of lyophilized CDP870, an engineered human anti-TNF PEG conjugate, dosed subcutaneously at 400mg every two weeks as additional medication to methotrexate, in the treatment of signs and symptoms and preventing structural damage in patients with RA","Janet Pope","","$41,012,669.00"
"Pope, Janet","Medicine","2005/01","2007/01","Grants","Funded","False","True","Site PI","A Phase III multi-centre, double-blind, placebo-controlled, parallel group 52-week study to assess the efficacy and safety of 2 dose regimens of lyophilized CDP870 given subcutaneously as additional medication to methotrexate in the treatment of signs and symptoms and preventing structural damage in patients with active rheumatoid arthritis who have an incomplete response to methotrexate","Janet Pope","","$45,414,477.00"
"Pope, Janet","Medicine","2005/03","2007/03","Grants","Funded","False","True","Site PI","A randomized, double-blind, placebo-controlled, parallel- group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis and an inadequate response to previous anti-TNF therapy","Janet Pope","","$29,452,411.00"
"Pope, Janet","Medicine","2005/04","2006/04","Grants","Funded","False","True","Site PI","A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multi-centre study to evaluate the safety, tolerability and disease-modifying efficacy of daily oral AAE581 (10, 25 and 50mg tablets) in patients with knee osteoarthritis, Kellgren-Lawrence grade 3 by X-ray","Janet Pope","","$72,821,257.00"
"Mangel, Joy","Medicine","2006/07","present","Grants","","False","False","Local Principal Investigator LRCC","A phase 3 randomized double-blind study of Galiximab in combination with Rituximab compared with Rituximab in combination with placebo for the treatment of subjects with relapsed or refractory follicular non-Hodgkin’s lymphoma.","","","$12,696,563.00"
"Pope, Janet","Medicine","2003/05","2006/07","Grants","Funded","False","True","Site PI","A randomized,multi-factorial,double-blind,parallel-group , dose ranging study of the efficacy and safety of Rituximab in combination with methotrexate in patients with active rheumatoid arthritis","Janet Pope","","$29,898,298.00"
"Pope, Janet","Medicine","2004/03","2008/09","Grants","Funded","False","True","Site PI","An open label study of the efficacy and safety of retreatments with Rituximab in patients with active rheumatoid arthritis who have had an inadequate response to anti-TNF? therapies","Janet Pope","","$2,965,765.00"
"Pope, Janet","Medicine","2005/04","2010/04","Grants","Funded","False","True","Site PI","A multicentre open label continuation study with D2E7 (adalimumab) for patients with rheumatoid arthritis who have completed a preceding clinical trial with D2E7","Janet Pope","","$4,057,516.00"
"Pope, Janet","Medicine","2002/11","2005/04","Grants","Funded","True","False","Site PI","A multicentre open label study with D2E7 (adalimimub) for patients with RA","Janet Pope","","$54,868,425.00"
"Mangel, Joy","Medicine","2007/07","2010","Grants","Funded","False","False","Local Principal Investigator LHSC","A randomized double-blind placebo controlled trial of Rituximab plus routine care for non-splenectomized adults with acute immune thrombocytopenic purpura.","Dr. D. Arnold","","$74,745,225.00"
"Pope, Janet","Medicine","2005/10","2007/10","Grants","Funded","False","True","Site PI","A multi-national, multicentre, randomized, double-blind, placebo-controlled , multiple dose, parallel group study to assess the efficacy, safety and tolerability of three doses of edratide (TV-4710) administered subcutaneously to systemic lupus erythematosus (SLE) patients","Janet Pope","","$12,205,054.00"
"Pope, Janet","Medicine","","","Grants","Funded","True","False","Site PI","A double-blind, placebo-controlled, parallel, randomized study to evaluate the efficacy and safety of 3 oral dose levels of TMI-005 in subjects with active rheumatoid arthritis on a background of methotrexate","Janet Pope","","$61,662,755.00"
"Pope, Janet","Medicine","2005/02","2007/02","Grants","Funded","False","True","Site PI","A phase 2A randomized, double-blind, placebo-controlled, multicentre study to compare 3 dose levels of CP-690,550 versus placebo, administered orally twice daily for 6 weeks , in the treatment of the signs and symptoms of subjects with active rheumatoid arthritis","Janet Pope","","$69,437,508.00"
"Pope, Janet","Medicine","2005/04","2006/07","Grants","Funded","True","False","Principal Investigator","Does SLE flare prior to menstruation? A case control study of premenopausal women with SLE, fibromyalgia, RA and healthy controls","Janet Pope","","$60,862,499.00"
"Pope, Janet","Medicine","2004/07","2012","Grants","Funded","True","False","Co-PI","The 1000 Canadian Faces of Lupus","Janet Pope","","$12,292,908.00"
"Pope, Janet","Medicine","2005/04","2006/04","Grants","Funded","True","False","Co-PI","Development of a Canadian scleroderma research group","Janet Pope/Murray Baron","","$28,151,892.00"
"Pope, Janet","Medicine","2004/04","2005/04","Grants","Funded","True","False","Co-PI","Development of a Canadian scleroderma research group $99,974 Yes Development of a Canadian scleroderma research group $ $99,974","Murray Baron / Janet Pope","","$53,490,033.00"
"Pope, Janet","Medicine","2004/04","2006/04","Grants","Funded","False","True","Co-PI","Development of a Canadian scleroderma research group","Murray Baron / Janet Pope","","$73,750,395.00"
"Pope, Janet","Medicine","2003/06","2008/06","Grants","Funded","True","False","Collaborator","Genetic and environmental factors in systemic lupus erythematosus (GenES Study) Yes Development of a Canadian scleroderma research group $ $99,974","Paul Fortin","Janet Pope","$10,608,769.00"
"Pope, Janet","Medicine","2004/04","2009/04","Grants","Funded","True","False","Collaborator","The role of thrombophilic factors in systemic lupus erythematosus (ThromboFIL Study)","Paul Fortin","Janet Pope","$15,026,502.00"
"Pope, Janet","Medicine","2003/01","2003/07","Grants","Funded","True","False","Principal Investigator","Prospective Registry to examine improved outcomes in scleroderma and Prospective Systemic Lupus Erythematosus (SLE) registry to examine improved outcomes in SLE","Janet Pope","","$29,702,912.00"
"Pope, Janet","Medicine","2002/08","2003/04","Grants","Funded","True","False","Principal Investigator","Risk Factors of Osteoporosis and Scleroderma","Janet Pope","","$17,040,169.00"
"Pope, Janet","Medicine","2002/08","2003/04","Grants","Funded","True","False","Principal Investigator","Risk Factors of Osteoporosis and Scleroderma","Janet Pope","","$48,368,940.00"
"Pope, Janet","Medicine","2002/09","2003","Grants","Funded","True","False","Collaborator","Malignancy in systemic lupus erythematosus","Ann Clarke","Janet Pope","$66,255,695.00"
"Pope, Janet","Medicine","2003/05","2005/08","Grants","Funded","True","False","Site PI","Rituximab in rheumatoid arthritis","Alison Kennedy, Global Project Manager, Roche","Janet Pope","$2,455,213.00"
"Pope, Janet","Medicine","2003/02","2004/09","Grants","Funded","True","False","Site PI","Safety and Tolerability of IV BMS-188667 in active RA","Jean-Claude Becker","Janet Pope","$5,867,506.00"
"Pope, Janet","Medicine","2003/12","2004","Grants","Funded","False","False","Site PI","Open label trial of safety and efficacy of Adalimumab (D2E7) in patients with active RA","Caroline Kwiatkowska","Janet Pope","$6,074,666.00"
"Pope, Janet","Medicine","2003/08","2005/08","Grants","Funded","False","False","Site PI","Alefacept and MTX in psoriatic arthritis","Theresa Podrebarac","Janet Pope","$21,663,654.00"
"Pope, Janet","Medicine","2003/10","2004/10","Grants","Funded","False","False","Site PI","Digital ulcers in systemic sclerosis (RAPIDS-2)","Fabrice Kramer","Janet Pope","$43,857,001.00"
"Pope, Janet","Medicine","2003/07","2005/07","Grants","Funded","False","False","Principal Investigator","Open label study of bosentan in pulmonary arterial hypertension (TRUST) Study","Janet Pope","","$619,721.00"
"Pope, Janet","Medicine","2003/02","2003/07","Grants","Funded","False","False","Site PI","Viagra in Raynaud’s secondary to scleroderma","Sandra Dickin","Janet Pope","$37,122,624.00"
"Pope, Janet","Medicine","2001/06","2017/12","Grants","Funded","False","True","Principal Investigator","CRA-Merck/Abbott Clinical Summer Studentship","Janet Pope","","$63,111,246.00"
"Pope, Janet","Medicine","2001/06","2004/09","Grants","Funded","True","False","Site PI/Supervisor","Medical student clinical preceptorship in rheumatology (x3); and Medical student research preceptorship (x1)","Janet Pope","","$43,865,145.00"
"Pope, Janet","Medicine","2001/06","2002/09","Grants","Funded","True","False","Site PI/Supervisor","Summer Research Training Program: Mega-analysis of prognostic indicators of scleroderma","Janet Pope","","$54,592,604.00"
"Pope, Janet","Medicine","2002/06","2003/09","Grants","Funded","True","False","Site PI/Supervisor","Summer Research Training Program: Morbidity and mortality in scleroderma","Janet Pope","","$74,617,391.00"
"Pope, Janet","Medicine","2001/09","2002/09","Grants","Funded","True","False","Site PI","Double-blind, placebo controlled withdrawal study of glucosamine sulfate in knee osteoarthritis","Jolanda Cibere","Janet Pope","$11,614,713.00"
"Pope, Janet","Medicine","1998/06","2001/09","Grants","Funded","False","False","Principal Investigator","A pilot study of the efficacy and toxicity of estrogen in postmenopausal women with SLE","Janet Pope","","$19,871,846.00"
"Pope, Janet","Medicine","2003/01","2004/01","Grants","Funded","False","False","Site PI","COX 189 (200 mg and 400 mg od) in patients with RA using Naproxen 500 mg as comparator","Alberto Gimona","Janet Pope","$30,635,431.00"
"Pope, Janet","Medicine","2002/03","2003/02","Grants","Funded","False","False","Site PI","Open label study of daily sc injections of anakinra in RA","Lidia Pirc","Janet Pope","$41,710,503.00"
"Pope, Janet","Medicine","2002/06","2002/12","Grants","Funded","False","False","Co-Investigator and Site PI","Pulmonary hypertension associated with scleroderma in Canada: An epidemiological study (PHASE Study)","Marie-Claude Lefebvre","Janet Pope","$8,494,615.00"
"Pope, Janet","Medicine","2002/07","2004/07","Grants","Funded","False","False","Site PI","Multicentre RCT dose ranging study of efficacy, safety and tolerability of AMG 719 in RA patients taking MTX","Nancy Lam","Janet Pope","$64,610,192.00"
"Pope, Janet","Medicine","2002/02","2004/02","Grants","Funded","False","False","Site PI","Safety of COX 189 for GI ulcers compared to naproxen and ibuprofen in osteoarthritis","Sylvie Giroux","Janet Pope","$49,577,052.00"
"Pope, Janet","Medicine","2002/01","2004/01","Grants","Funded","False","False","Site PI","Safety, efficacy and pharmokinetic profile of TNF-alpha antisense oligo-NT in RA.","K. Lea Sewell","Janet Pope","$8,589,319.00"
"Pope, Janet","Medicine","2002/02","2003/02","Grants","Funded","False","False","Site PI","Biologics Observational Switchover Study (BOSS) of Remicade to Enbrel in RA","Paul Boulos Haraoui","Janet Pope","$1,201,914.00"
"Pope, Janet","Medicine","2001/05","2001/05","Grants","Funded","False","False","Site PI","Digital Ulcers in Scleroderma","Carol Black","Janet Pope","$60,197,459.00"
"Pope, Janet","Medicine","2000/03","2003/03","Grants","Funded","False","False","Site PI","Combination Treatment with anakinra and PEG sTNF-R1 in RA patients taking MTX","Nancy Lam","Janet Pope","$63,286,783.00"
"Pope, Janet","Medicine","2001/03","2002/03","Grants","Funded","False","False","Site PI","COX189 in hip primary osteoarthritis","Alberto Gimona","Janet Pope","$62,964,157.00"
"Pope, Janet","Medicine","2001/05","2002/05","Grants","Funded","False","False","Site PI","Efficacy and safety of BIIL 284 BS in adult patients with active RA","Frederico Diaz-González","Janet Pope","$64,752,009.00"
"Pope, Janet","Medicine","2001/06","2004/06","Grants","Funded","False","False","Site PI","RCT and health economic evaluation of D2E7 in RA","Janet Pope","","$47,736,078.00"
"Pope, Janet","Medicine","2000/05","2005/05","Grants","Funded","False","False","Site PI","Trocade. RCT of safety and efficacy of Ro 32-3555 with anti-rheumatoid therapy in preventing standard joint damage","Janet Pope","","$2,668,117.00"
"Pope, Janet","Medicine","1998/07","2001/07","Grants","Funded","True","False","Collaborator","RCT of Methotrexate vs. gold in RA (Metgo)","John Esdaile","Janet Pope","$10,401,623.00"
"Pope, Janet","Medicine","1998","2001","Grants","Funded","True","False","Co-Investigator","RCT of arthroscopy vs. standard care in OA of the knee","Sandy Kirkley","Janet Pope","$21,928,748.00"
"Pope, Janet","Medicine","1995/07","2000/06","Grants","Funded","True","False","Collaborator","SMILE: Study of Methotrexate in lupus erythematosus","Paul Fortin","Janet Pope","$74,982,918.00"
"Pope, Janet","Medicine","1999","2001","Grants","Funded","False","False","Site PI","A novel treatment in ANCA associated with vasculitis","Janet Pope","","$18,954,192.00"
"Pope, Janet","Medicine","1999","1999","Grants","Funded","False","False","Site PI","RCT and open label follow-up study of longterm safety of Valdecoxib in RA","Janet Pope","","$11,207,603.00"
"Pope, Janet","Medicine","1999","1999","Grants","Funded","False","False","Site PI","New NSAID in rheumatoid arthritis","Janet Pope","","$68,268,079.00"
"Pope, Janet","Medicine","1998/12","2000/06","Grants","Funded","False","False","Site PI","RCT of GI outcomes of a COX 2 NSAID in RA and OA over 1 year","Janet Pope","","$35,486,915.00"
"Pope, Janet","Medicine","1999/01","2000/01","Grants","Funded","False","False","Site PI","RCT of the safety of a COX2 NSAID in OA","Janet Pope","","$74,404,091.00"
"Pope, Janet","Medicine","1998/11","1999/06","Grants","Funded","False","False","Site PI","RCT of the safety of an NSAID in OA","Janet Pope","","$28,114,913.00"
"Pope, Janet","Medicine","1997/03","1999/10","Grants","Funded","False","False","Site PI","Cost effectiveness study of Synvisc compared to standard care in knee OA - 1 year follow up","Janet Pope","","$28,868,698.00"
"Pope, Janet","Medicine","1998","1998/06","Grants","Funded","True","False","Principal Investigator","Grant to cover outstanding expenses for the RCT of MTX vs placebo in scleroderma","Janet Pope","","$44,102,851.00"
"Pope, Janet","Medicine","1996/01","1998/12","Grants","Funded","True","False","Principal Investigator","Hypertension in active SLE without renal disease: An investigation of the vascular integrity of lupus patients","Janet Pope","","$23,576,307.00"
"Pope, Janet","Medicine","1996/03","1997/12","Grants","Funded","True","False","Principal Investigator","Pilot study of the efficacy and toxicity of estrogen in postmenopausal women with SLE","Janet Pope","","$42,133,134.00"
"Pope, Janet","Medicine","1994/12","1998","Grants","Funded","True","False","Principal Investigator","Cost effectiveness of N of 1 trials compared to standard care in OA","Janet Pope","","$71,521,355.00"
"Pope, Janet","Medicine","1993/01","1997","Grants","Funded","True","False","Principal Investigator","Multi-centre RCT of MTX vs placebo in early diffuse scleroderma","Janet Pope","","$17,969,797.00"
"Pope, Janet","Medicine","1995/01","1996","Grants","Funded","True","False","Principal Investigator","Prevalence study of pericardial effusions, pleural effusions, anticardiolipin antibodies (abs) and antimitochondrial abs in SSc","Janet Pope","","$52,751,278.00"
"Pope, Janet","Medicine","1994/02","1995","Grants","Funded","True","False","Principal Investigator","Increased Pigmentation in Scleroderma","Janet Pope","","$1,432,484.00"
"Pope, Janet","Medicine","1993","1994","Grants","Funded","True","False","Principal Investigator","Fertility in RA. A Case Control Study","Janet Pope","","$63,950,587.00"
"Pope, Janet","Medicine","1993","1993","Grants","Funded","True","False","Principal Investigator","Inter- and intra-observer variability study of outcome measurements in scleroderma","Janet Pope","","$13,287,014.00"
"Wisenberg, Gerald","Medicine","1981","1982","Grants","Funded","True","False","Principal Investigator","Radionuclide equilibrium angiography during the pharmacological stress of dopamine","Wisenberg G","","$34,197,143.00"
"Wisenberg, Gerald","Medicine","1982","1983","Grants","Funded","True","False","Principal Investigator","Radionuclide equilibrium angiography during the pharmacological stress of dopamine","Wisenberg G","","$47,418,571.00"
"Wisenberg, Gerald","Medicine","1984","1985","Grants","Funded","True","False","Principal Investigator","Assessment of the diagnostic capabilities of NMR for the detection of coronary artery disease","Wisenberg G","","$51,208,433.00"
"Wisenberg, Gerald","Medicine","1985","1986","Grants","Funded","True","False","Principal Investigator","Assessment of the diagnostic capabilities of NMR for the detection of coronary artery disease","Wisenberg G","","$49,046,291.00"
"Wisenberg, Gerald","Medicine","1985","1986","Grants","Funded","True","False","Principal Investigator","NMR assessment of cardiac transplant rejection","Wisenberg G","","$40,140,579.00"
"Wisenberg, Gerald","Medicine","1986","1987","Grants","Funded","True","False","Principal Investigator","Gadolinium -DTPA as a flow tracer for myocardial magnetic resonance imaging","Wisenberg G","","$70,928,310.00"
"Wisenberg, Gerald","Medicine","1986","1988","Grants","Funded","True","False","Principal Investigator","NMR assessment of myocardial infarction size following thrombolytic therapy","Wisenberg G","","$48,724,589.00"
"Wisenberg, Gerald","Medicine","1987","1988","Grants","Funded","True","False","Principal Investigator","Gadolinium-DTPA as a flow tracer for myocardial magnetic resonance imaging","Wisenberg G","","$34,733,074.00"
"Wisenberg, Gerald","Medicine","1988","1989","Grants","Funded","True","False","Principal Investigator","Serial NMR Imaging and spectroscopy of canine myocardial Infarction","Wisenberg G","","$10,372,876.00"
"Wisenberg, Gerald","Medicine","1989","1990","Grants","Funded","True","False","Principal Investigator","Serial NMR Imaging and spectroscopy of canine myocardial Infarction","Wisenberg G","","$8,835,744.00"
"Wisenberg, Gerald","Medicine","1990","1991","Grants","Funded","True","False","Principal Investigator","NMR Studies of myocardial metabolism, injury & metabolic Dysregulation","Wisenberg G","","$27,608,864.00"
"Wisenberg, Gerald","Medicine","1991","1992","Grants","Funded","True","False","Principal Investigator","NMR Studies of myocardial metabolism, injury & metabolic dysregulation","Wisenberg G","","$45,510,583.00"
"Wisenberg, Gerald","Medicine","1992","1993","Grants","Funded","True","False","Principal Investigator","NMR Spectroscopic Studies of Myocardial Metabolism","Wisenberg G","","$47,741,418.00"
"Wisenberg, Gerald","Medicine","1993","1994","Grants","Funded","True","False","Principal Investigator","NMR Spectroscopic Studies of Myocardial Metabolism","Wisenberg G","","$28,134,028.00"
"Wisenberg, Gerald","Medicine","1994","1995","Grants","Funded","True","False","Principal Investigator","NMR Imaging and Spectroscopy in myocardial infarction and Transplantation","Wisenberg G","","$38,584,277.00"
"Wisenberg, Gerald","Medicine","1995","1996","Grants","Funded","True","False","Principal Investigator","NMR Imaging and Spectroscopy in myocardial infarction and Transplantation","Wisenberg G","","$16,909,124.00"
"Wisenberg, Gerald","Medicine","1996","1997","Grants","Funded","True","False","Principal Investigator","NMR Imaging and Spectroscopy in Myocardial Infarction and Transplantation","Wisenberg G","","$26,419,725.00"
"Wisenberg, Gerald","Medicine","1998/07","2000/06","Grants","Funded","True","False","Principal Investigator","MR Imaging and Spectroscopy of Combination Therapy Directed Against Myocardial Reperfusion Injury","Wisenberg G","","$51,163,652.00"
"Wisenberg, Gerald","Medicine","2000/07","2001/06","Grants","Funded","True","False","Principal Investigator","MR imaging and spectroscopy of combination therapy against myocardial reperfusion injury","Wisenberg G","","$66,532,252.00"
"Wisenberg, Gerald","Medicine","2005/07","2007/06","Grants","Funded","True","False","Principal Investigator","Optimizing the administration of marrow-derived stem cells to repair left ventricular structure and function in a canine model of myocardial infarction","Wisenberg G","","$25,539,934.00"
"Wisenberg, Gerald","Medicine","1983/03","1984/03","Grants","Funded","True","False","Co-Investigator","NMR imaging: Clinical evaluation and future impact on health Care","Nicholson RL","Kertesz A, Wisenberg G, Prato FS","$56,655,573.00"
"Wisenberg, Gerald","Medicine","1987/07","1989/06","Grants","Funded","True","False","Co-Investigator","Magnetic resonance imaging of the lungs and heart","Prato FS","Drost DJ, Nicholson RL, Wisenberg G","$55,911,898.00"
"Wisenberg, Gerald","Medicine","1989/07","1992/06","Grants","Funded","True","False","Co-Investigator","Magnetic resonance imaging of the heart","Prato FS","Drost DJ, Wisenberg G","$24,263,143.00"
"Wisenberg, Gerald","Medicine","1992/07","1995/09","Grants","Funded","True","False","Co-Investigator","Magnetic resonance imaging of ischemic heart disease","Prato FS","Wisenberg G, Drost DJ","$46,867,430.00"
"Wisenberg, Gerald","Medicine","1995/07","1998/09","Grants","Funded","True","False","Co-Investigator","Magnetic resonance imaging of ischemic heart disease","Prato FS","","$11,853,038.00"
"Klein, George","Medicine","1993/07","1996/06","Grants","Funded","True","False","Principal Investigator","Electrophysiology Studies in WPW *Held with Raymond Yee, DOM/Cardiology","George J. Klein","","$18,293,935.00"
"Wisenberg, Gerald","Medicine","1995","1995","Grants","Funded","True","False","Co-Investigator","HOPE Study, investigating effects of vitamin E and/or ramipril in reducing major events in patients with established atherosclerotic disease","","Wisenberg G, Southern RS","$67,444,122.00"
"Moist, Louise","Medicine","2007/05","2009/12","Grants","Funded","True","False","Principal Investigator","N-Acetylcysteine and the effect on tubular secretion of creatinine in patients","Dr. Louise Moist","","$56,675,592.00"
"Wisenberg, Gerald","Medicine","1996","1997","Grants","Funded","True","False","Co-Investigator","HOPE Study","","Wisenberg G, Southern RS","$70,257,116.00"
"Moist, Louise","Medicine","2007/06","2009/11","Grants","Funded","True","False","Principal Investigator","Vascular access: Understanding Patients’ Values Preferences and Beliefs","Dr. Louise Moist","","$42,413,769.00"
"Klein, George","Medicine","1994/07","1998/06","Grants","Funded","True","False","Principal Investigator","Feasibility of Local OperativeAblative Procedures/Supraventricular Arrhythmia Distinguished Research Professorship (peer-reviewed)","George J. Klein","","$50,049,193.00"
"Wisenberg, Gerald","Medicine","1996","1999","Grants","Funded","True","False","Co-Investigator","Magnetic Resonance Imaging of Ischemic Heart Disease","Prato FS","Wisenberg G","$13,551,341.00"
"Moist, Louise","Medicine","2006/03","2009/12","Grants","Funded","True","False","Principal Investigator","Validation of Co-morbidities among patients with end stage renal disease in CORR","Dr. Louise Moist","","$17,468,147.00"
"Wisenberg, Gerald","Medicine","1999","2000","Grants","Funded","True","False","Co-Investigator","Magnetic Resonance Imaging of Ischemic Heart Disease","Prato FS","Wisenberg G","$25,814,928.00"
"Moist, Louise","Medicine","2005/09","2008/10","Grants","Funded","True","False","Principal Investigator","Risk of pregnancy related hypertension in a cohort of women exposed to contaminated water compared to a age matched regional cohort","Dr. Louise Moist","","$14,024,947.00"
"Wisenberg, Gerald","Medicine","2001","2004","Grants","Funded","True","False","Co-Investigator","Magnetic Resonance Imaging of Ischemic Heart Disease","Prato FS","Drost DJ, Wisenberg G.","$46,434,505.00"
"Wisenberg, Gerald","Medicine","2004","2009","Grants","Funded","True","False","Co-Investigator","Imaging in Ischemic Heart Disease: Making Diagnosis, Following Therapy","Prato FS","Wells RG, Wisenberg G","$59,375,945.00"
"Moist, Louise","Medicine","2005","2006","Grants","Funded","True","False","Supervisor","The Effect of N-Acetylcysteine on Serum Creatinine in Patients with Chronic Kidney Disease","Dr. Louise Moist","","$64,614,070.00"
"Moist, Louise","Medicine","2004/03","2009/12","Grants","Funded","True","True","Co-Investigator, Site Principal Investigator","A Randomized Trial of TPA versus Unfractionated Heparin Lok for the Primary Prevention of Hemodialysis Catheter Malfunction","Dr. Brenda Hemmelgarn","","$25,043,060.00"
"Wisenberg, Gerald","Medicine","1984","1984","Grants","Funded","False","False","Principal Investigator","Anti-arrhythmic effects on left ventricular function","Wisenberg G","","$23,932,228.00"
"Moist, Louise","Medicine","2004/06","2010/12","Grants","Funded","True","False","Co-Investigator","Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study.","Dr. Charmaine Lok","","$45,575,294.00"
"Wisenberg, Gerald","Medicine","1986","1986","Grants","Funded","False","False","Principal Investigator","Isosorbide-5-moninitrate in chronic stable angina","Wisenberg G","","$35,248,079.00"
"Moist, Louise","Medicine","2004","2005","Grants","Funded","True","False","Co-applicant","An applied data research facility for the understanding, prevention and treatment of kidney diseases","Dr. Amit Garg","","$2,907,467.00"
"Wisenberg, Gerald","Medicine","1988","1988","Grants","Funded","False","False","Principal Investigator","Effects of Bisoprolol in chronic stable angina","Wisenberg G","","$1,501,554.00"
"Moist, Louise","Medicine","2003","2005","Grants","Funded","True","False","Principal Investigator","Preservation of Renal Function in High Risk CABG Patients Exposed to Cardio Bypass and NAC","Dr. Louise Moist","","$30,138,854.00"
"Wisenberg, Gerald","Medicine","1989","1989","Grants","Funded","False","False","Principal Investigator","Use of esmolol in unstable angina & non-Q wave myocardial infarction","Wisenberg G","","$71,603,362.00"
"Moist, Louise","Medicine","2003","2005","Grants","Funded","True","False","Principal Investigator","Preservation of Renal Function in High Risk CABG Surgery Patients Exposed to Cardio-Pulmonary Bypass with N-acetylcysteine: A Pilot Study","Dr. Louise Moist","","$28,047,005.00"
"Wisenberg, Gerald","Medicine","1988","1988","Grants","Funded","False","False","Principal Investigator","HEART Study – Study of early initiation of ACE inhibition (Ramipril) in acute myocardial infarction","Wisenberg G","","$22,680,374.00"
"Moist, Louise","Medicine","2003/03","2010/12","Grants","Funded","True","False","Co-Investigator","Study for Heart and Renal Protection (SHARP)","Dr. Adeera Levin","","$38,961,493.00"
"Moist, Louise","Medicine","2003/06","2009/12","Grants","Funded","True","False","Co-Investigator","Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study.","Dr. Charmaine Lok","","$56,144,231.00"
"Moist, Louise","Medicine","2002/07","2009/12","Grants","Funded","True","False","Co-Investigator","A 7-year Prospective Cohort Study on the Characterization and Management of Long Term Medical Complications from E-coli Infection in Walkerton, Ontario (The WEL (Waterborne E-Coli Long term) Investigators","Dr. William Clark","","$13,659,071.00"
"Wisenberg, Gerald","Medicine","1994","1994","Grants","Funded","False","False","Principal Investigator","CORE Study – Effects of RheothRx, a synthetic surfactant in acute myocardial infarction","Wisenberg G","","$40,606,151.00"
"Moist, Louise","Medicine","2002","2012","Grants","Funded","True","True","Co-Investigator","Dialysis Outcomes and Practice Patterns Study (DOPPS)","Dr. Ronald Pisoni","","$37,519,866.00"
"Wisenberg, Gerald","Medicine","1994","1994","Grants","Funded","False","False","Principal Investigator","OASIS Study – Comparative study of effects of hirudin vs heparin in unstable angina and non-Q wave myocardial infarction","Wisenberg G","","$13,882,626.00"
"Moist, Louise","Medicine","2003","2004","Grants","Funded","True","False","Principal Investigator","Graft stenosis and access flow","Dr. Louise Moist","","$59,072,893.00"
"Moist, Louise","Medicine","2002","2004","Grants","Funded","True","False","Co-Investigator","Prevention of Radiographic Contrast Induced Reductions in Renal Functioning and Length of ICU Stay In At Risk Critically Ill Diabetic and Non-Diabetic Patients: A Stratified Parallel Design randomized Controlled Trial (NAC)","Dr. Louise Moist","","$36,028,899.00"
"Wisenberg, Gerald","Medicine","1996","1997","Grants","Funded","False","False","Principal Investigator","OASIS II Study","Wisenberg G","","$38,030,511.00"
"Moist, Louise","Medicine","2000","2006","Grants","Funded","True","False","Co-Investigator","Care prior to dialysis: Impact of elements on patient outcomes","Dr. Adeera Levin","","$70,675,051.00"
"Moist, Louise","Medicine","2000","2001","Grants","Funded","True","False","Principal Investigator","Measurement of Residual Renal Function Among Patients on Dialysis","Dr. Louise Moist","","$21,131,026.00"
"Wisenberg, Gerald","Medicine","1996","1997","Grants","Funded","False","False","Principal Investigator","GUSTO III Study","Wisenberg G","","$59,389,108.00"
"Moist, Louise","Medicine","2000","2002","Grants","Funded","True","False","Principal Investigator","Monitoring of Synthetic A-V Grafts (GRAFTS)","Dr. Louise Moist","","$22,296,894.00"
"Wisenberg, Gerald","Medicine","1996","1997","Grants","Funded","False","False","Principal Investigator","Tedisamil Study","Wisenberg G","","$58,986,905.00"
"Moist, Louise","Medicine","2000","2002","Grants","Funded","True","False","Principal Investigator","TPA in-line mal-function","Dr. Louise Moist","","$20,737,266.00"
"Wisenberg, Gerald","Medicine","1997","1998","Grants","Funded","False","False","Principal Investigator","Assent II Study","Wisenberg G","","$43,326,459.00"
"Moist, Louise","Medicine","2000","2001","Grants","Funded","True","False","Co-Principal Investigator","Heparin Antibodies and Risk of Graft Thrombosis","Dr. Louise Moist","","$43,849,706.00"
"Wisenberg, Gerald","Medicine","1997","1998","Grants","Funded","False","False","Principal Investigator","Symphony Study","Wisenberg G","","$71,517,819.00"
"Wisenberg, Gerald","Medicine","1997","1998","Grants","Funded","False","False","Principal Investigator","Tedisamil II Study","Wisenberg G","","$71,279,890.00"
"Moist, Louise","Medicine","1999","2002","Grants","Funded","True","False","Co-Investigator","Satellite Dialysis Fall back Study in Ontario","Dr. Robert Lindsay","","$3,607,131.00"
"Klein, George","Medicine","1996/07","1999/06","Grants","Funded","True","False","Principal Investigator","Ablation in Atrial Fibrillation","George J. Klein","","$710,824.00"
"Wisenberg, Gerald","Medicine","1999","1999","Grants","Funded","False","False","Principal Investigator","CORE Study","Wisenberg G","","$16,980,232.00"
"Wisenberg, Gerald","Medicine","1999","2002","Grants","Funded","False","False","Principal Investigator","VALIANT Trial","Wisenberg G","","$42,964,964.00"
"Moist, Louise","Medicine","2001","2003","Grants","Funded","True","False","Principal Investigator","Clinical Epidemiology of Acute Renal Failure in the ICU","Dr. Louise Moist","","$33,184,405.00"
"Wisenberg, Gerald","Medicine","1999","1999","Grants","Funded","False","False","Principal Investigator","GUSTO IV Trial","Wisenberg G","","$55,007,717.00"
"Wisenberg, Gerald","Medicine","1999","1999","Grants","Funded","False","False","Principal Investigator","WATCH","Wisenberg G","","$69,658,223.00"
"Wisenberg, Gerald","Medicine","2000","2001","Grants","Funded","False","False","Principal Investigator","CURE","Wisenberg G","","$10,378,220.00"
"Klein, George","Medicine","1999/07","2000/06","Grants","Funded","True","False","Principal Investigator","Ablation in Atrial Fibrillation * Held with Allan C. Skanes","George J. Klein","","$52,552,322.00"
"Wisenberg, Gerald","Medicine","1996","2000","Grants","Funded","False","False","Collaborator","Magnetic Resonance Imaging of Ischemic Heart Disease","Prato FS","Wisenberg G","$26,241,996.00"
"Wisenberg, Gerald","Medicine","2000","2004","Grants","Funded","False","False","Collaborator","GD-DTPA Contrast Enhanced MRI myocardial infarction","Prato FS","Wisenberg G","$65,117,867.00"
"Wisenberg, Gerald","Medicine","2001","2002","Grants","Funded","False","False","Principal Investigator","SPORTIF Trial","Wisenberg G","","$61,662,511.00"
"Kim, Richard","Medicine","2005/10","2008/10","Grants","Funded","True","False","Co-Investigator","Drug disposition in intestinal disease","George K Dresser","David G Bailey, Richard B Kim","$50,738,776.00"
"Kim, Richard","Medicine","2002/07","2006/06","Grants","Funded","True","False","Co-Principal Investigator","Determinants of Individual Responsiveness to Drugs","Grant R. Wilkinson","C. Michael Stein, Alastair J Wood","$46,143,089.00"
"Kim, Richard","Medicine","2003/07","2006/06","Grants","Funded","True","False","Principal Investigator","Human Hepatic Drug Transporters in Drug Disposition","Richard B. Kim","Rommel G. Tirona, Ute I Schwarz","$64,600,788.00"
"Kim, Richard","Medicine","2007/08","2009/02","Grants","Funded","False","True","Principal Investigator","In vitro assessment of drug uptake and efflux transporters to the disposition of a number of statin class of drugs","Richard B. Kim","","$10,876,622.00"
"Kim, Richard","Medicine","2006/07","2007/03","Grants","Funded","False","True","PI","Role of uptake transporters expressed in the kidney to the disposition of a Lilly compound","Richard B. Kim","Rommel G. Tirona","$45,476,524.00"
"Kim, Richard","Medicine","2004/04","2007/03","Grants","Funded","True","False","Co-Applicant","Dietary constituents and drug uptake transporters","David G Bailey","Richard B Kim, George K Dresser","$65,680,281.00"
"Kim, Richard","Medicine","2002/09","2006/06","Grants","Funded","True","False","Co-Applicant","Pharmacogenetics of Arrhythmia Therapy","Roden","Richard B Kim","$10,514,048.00"
"Kim, Richard","Medicine","2004/01","2005/12","Grants","Funded","True","False","Co-Applicant","Genetic Determinants of Antiretroviral Metabolism","Wilkinson","Richard B Kim","$57,436,239.00"
"Kim, Richard","Medicine","2003/10","2006/06","Grants","Funded","False","True","Principal Investigator","Drug Uptake and Efflux Transporters in Drug Disposition","Richard B Kim","","$16,181,667.00"
"Kim, Richard","Medicine","2004/09","2006/08","Grants","Funded","False","True","Principal Investigator","In Vitro Assessment of the Interactions of A-848837 with Hepatic Transporters","Richard B Kim","","$69,840,862.00"
"Kim, Richard","Medicine","2005/09","2006/03","Grants","Funded","False","True","Principal Investigator","P-gp and mectin transport","Richard B Kim","","$59,016,934.00"
"Kim, Richard","Medicine","2005/09","2006/03","Grants","Funded","False","True","Principal Investigator","OATP and antihistamine uptake","Richard B Kim","","$11,972,646.00"
"Kim, Richard","Medicine","2002/04","2004/09","Grants","Funded","False","True","Principal Investigator","Characterization of intestinal metabolism and transport of byk33043, its metabolite byk204895 and byk199022","Richard B Kim","","$18,900,666.00"
"Kim, Richard","Medicine","2004/01","2005/01","Grants","Funded","False","True","Principal Investigator","In Vitro Assessment of OATP-C Variants and Atrasentan Cellular Uptake","Richard B Kim","","$23,095,120.00"
"Kim, Richard","Medicine","2003/02","2005/02","Grants","Funded","False","True","Principal Investigator","Study Agreement: The proposed study is to assess the role of drug uptake transporters in the hepatic uptake of a compound developed by Merck.","Richard B Kim","","$33,878,796.00"
"Kim, Richard","Medicine","2004/06","2005/01","Grants","Funded","False","True","Principal Investigator","This is a grant for training a Boehringer-Ingelheim scientist in the area of drug uptake transporter expression systems.","Richard B Kim","","$36,761,388.00"
"Kim, Richard","Medicine","2003/12","2005/05","Grants","Funded","False","True","Principal Investigator","In vitro assessment of the role of polymorphisms in human OATP-C and the relevance of MRP2 to the cellular uptake and efflux of rosuvastatin","Richard B Kim","","$53,616,317.00"
"Kim, Richard","Medicine","2004/12","2005/11","Grants","Funded","False","True","Principal Investigator","Wyeth Education Agreement","Richard B Kim","","$590,258.00"
"McDonald, Charlotte","Medicine","2007/08","2009/03","Grants","Funded","False","True","Site Investigator","Efficacy and safety of 2 mg/day of M100907 on sleep maintenance insomnia with a sub-study of the effect of M100907 on stable Type 2 diabetes mellitus: a 12-week, multi-center, randomized, double-blind, placebo-controlled study","IM Hramiak","CG McDonald, TL Paul","$58,422,311.00"
"Mahon, Jeffrey","Medicine","1993","1996","Clinical Trials","Funded","True","False","Principal Investigator","The efficacy and cost-effectiveness of N of 1 trials","Jeffrey Mahon","","$38,560,427.00"
"Mahon, Jeffrey","Medicine","1993","1993","Clinical Trials","Funded","True","False","Principal Investigator","Screening for insulin dependent diabetes mellitus","Jeffrey Mahon","","$48,687,735.00"
"Mahon, Jeffrey","Medicine","1994","1996","Clinical Trials","Funded","True","False","Co-Investigator","A randomized controlled trial of active compression-decompression versus standard cardiopulmonary resuscitation for cardiac arres","Ian Stiell","","$12,907,687.00"
"Myers, Kathryn","Medicine","1994/07","1996","Grants","Funded","True","False","Co-Principal Investigator","Research In Postgraduate Education; A comparison of the on-call experience of internal medicine residents at two teaching hospitals.","Myers K","Palepu A.","$31,026,649.00"
"Myers, Kathryn","Medicine","1995/11","1999","Grants","Funded","True","False","Principal Investigator","Research in Postgraduate Education-Improving the accuracy of death certification by house officers.","Myers K","","$39,582,895.00"
"Myers, Kathryn","Medicine","1995/11","1997","Grants","Funded","True","False","Co-Investigator","Research in Postgraduate Education-Application for R4 positions in Internal Medicine and its subspecialties: A nation-wide survey of the current process and the interest in a centralize.","Raj S.","Simpson C, Link C, Myers K.","$20,163,047.00"
"Myers, Kathryn","Medicine","2016/01","2024/01","Grants","Funded","False","False","Co-Investigator","Award in Medical Education Research-Development of an educational program in effective consultation letter writing.","Keely E","Myers K, Dojeji S.","$23,924,091.00"
"Myers, Kathryn","Medicine","1998/01","2001","Grants","Funded","True","False","Co-Investigator","Research in Postgraduate Education-Improving consultation letter writing skills of residents: Using a rating scale to provide feedback.","Myers KA","Keely E, S. Dojeiji","$2,275,475.00"
"Myers, Kathryn","Medicine","1998/01","1999","Grants","Funded","True","False","Co-Principal Investigator","Research in Postgraduate Education; A needs assessment of Internal Medicine residents education in the Emergency Room.","Hoar S","McLellan C, Myers KA, Evans GA.","$22,368,257.00"
"Myers, Kathryn","Medicine","","","Grants","","False","False","","Competencies of the specialist physicians: The residents’perspective. award","Farquhar DRE.","Myers KA.","$20,529,125.00"
"Myers, Kathryn","Medicine","2016/01","2024/01","Grants","Funded","False","False","Co-Investigator","Improving the quality of vital statitics through education: Evaluating workshops for community physicians.","Myers KA","","$819,407.00"
"Myers, Kathryn","Medicine","2002/07","2007/01","Grants","Funded","True","False","Co-Investigator","Medical Education Research Grant-Development and evaluation of a practice audit tool for consultation letters.","Keely EJ","Myers KA, Campbell C, Dojeiji S.","$65,352,562.00"
"Myers, Kathryn","Medicine","2004","2008","Grants","Funded","True","False","Co-Investigator","The Structured Oral Examination: A comparison of reliability of rater pairs.","Touchie","Ainslie M, Murto S, Myers KA","$47,920,050.00"
"Myers, Kathryn","Medicine","2004/07","2005/07","Grants","Funded","True","False","Site Investigator","Ontario OatH Study. A prospective cohort study to determine the association of continuity of care with patient outcomes after discharge from hospital.","Van Walraven","et al.","$60,857,789.00"
"Thompson, Andrew","Medicine","2006/07","present","Grants","Funded","True","False","Principal Investigator","Canadian Arthritis Referral Study – Phase 3","","","$59,424,966.00"
"Thompson, Andrew","Medicine","2006/05","present","Grants","Funded","False","False","Primary Author","The Arthritis Society Guide to Arthritis Medications","","","$30,388,869.00"
"Thompson, Andrew","Medicine","2007/06","present","Grants","Funded","True","False","Principal Investigator","Pictorial versus Prose Based Medication Information Sheets","","","$46,779,329.00"
"Thompson, Andrew","Medicine","2005/07","","Grants","Funded","False","False","Principal Investigator","Canadian Arthritis Referral Study – Phase 1","","","$40,204,725.00"
"Kovacs, Michael","Medicine","1992","1994","Grants","Funded","False","False","Co-investigator","Does sepsis reduce the effectiveness of transfused red blood cells to support tissue O2 need?","Sibbald WJ","Ellis CG, Martin CM,.","$45,936,697.00"
"Kovacs, Michael","Medicine","1993","1994","Grants","Funded","False","False","Co-Applicant","A randomized trial on the use of minidose warfarin to maintain patency of central venous access in patients with thrombocytopenia. 1993 - 1994 ? Complete ? Grant Co-investigator PI, Victoria Campus ?","Cruickshank M","","$56,798,516.00"
"Kovacs, Michael","Medicine","1995","2002","Grants","Funded","False","False","Principal Site Investigator","MY-7: A comparative study of dexamethasone versus prednisone (both in combination with melphalan) as induction therapy in untreated symptomatic myeloma with an additional assessment of dexamethasone versus no additional treatment as maintenance therapy in non-progressing patients.","","","$27,076,149.00"
"Kovacs, Michael","Medicine","1996","1999","Grants","Funded","False","False","Principal Site Investigator","Recurrence of Clots in This Pregnancy (ROCIT).","","P. Brill-Edwards, McMaster University","$45,138,462.00"
"Kovacs, Michael","Medicine","1996","2000","Grants","Funded","False","False","Principal Site Investigator","A randomized trial on the efficacy of non-cross resistant, consolidation chemotherapy following sequential response-adapted induction treatment for adult acute myelogenous leukaemia","","","$17,462,665.00"
"Kovacs, Michael","Medicine","1996","1999","Grants","Funded","False","False","Co-Applicant","Short duration anticoagulation for acute secondary venous thromboembolism.","Kearon M","Gent MC, Ginsberg J, Willan AR, Hirsh J, Anderson DR, Wells P.","$17,094,677.00"
"Kovacs, Michael","Medicine","2006","2007","Grants","Funded","False","True","Principal Site Investigator","International, multicentre, randomised, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0mg) once a week and SR34006 (2.5mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity (Equinox)","","","$72,052,351.00"
"Wells, Jennie","Medicine","2006/12","2009/11","Clinical Trials","Funded","True","True","Co-Investigator","A Phase I, Randomized, Placebo-controlled, double-blind, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenity of a single Intravenous dose of PF-04360365 (RN1219) in Adults with Mild to Moderate Alzheimer Disease,","Borrie MJ","Borrie MJ, Wells JL et al.","$30,873,514.00"
"Wells, Jennie","Medicine","2006/12","2011/01","Grants","Funded","True","False","Co-Investigator","Utilizing High field Magnetic Resonance Spectroscopy as a biomarker for Mild Cognitive Impairment.","Borrie MJ","Wells JL et al.","$26,554,872.00"
"Wells, Jennie","Medicine","2006/08","2010/05","Grants","Funded","True","False","Co-Investigator","A Multi-Centre, Blinded Randomized, Controlled Trial Comparing Different Regimens of the Antibiotics Doxycycline and Rifampin for Treatment of Alzheimer Disease.","Molloy W","Borrie M, Wells J, et al.","$26,158,442.00"
"Wells, Jennie","Medicine","2004/01","2006/01","Clinical Trials","Funded","True","True","Site Investigator","Phase III Multi-centre, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer’s Type.","Borrie MJ (Site principle investigator)","Wells JL (site co-investigator), Borrie MJ","$12,284,912.00"
"Wells, Jennie","Medicine","2006","2007","Grants","Funded","True","False","Co-Investigator","Mandated Geriatric Rehabilitation Outcome Reporting in Ontario: Assessing and Enhancing Comprehensiveness.","Egan M (co-PI), Connelly D (co-PI)","Wells J, Mackenzie R","$55,926,889.00"
"Wells, Jennie","Medicine","2005","2007","Grants","Funded","True","False","Co-Investigator","Rehabilitating Patients with Dementia who have had a Hip Fracture","McGilton K","Wells J, Davis A, Rochon E, Calabrese S, Teare G, Naglie G, Biscardi M.","$48,820,344.00"
"Wells, Jennie","Medicine","2005/01","2006/01","Grants","Funded","True","False","Principal Site Investigator","InfoRehab: Better Information for Better MSK Health and Quality of Life for Older Persons.","Stolee P","Berg K, Borrie, MJ, Chesworth BM, Cook RJ, Egan My, Hirdes JP, Jaglal SB, Joiner IC, McKillop I, Wells JL, Zhu Mu.","$31,954,573.00"
"Wells, Jennie","Medicine","2004/01","2005/01","Clinical Trials","Funded","True","True","Site Investigator","Efficacy of 15 mg and 50 mg of S18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 2-months oral administration period – an international multicentre, 3 parallel groups, randomized, double blind, placebo-controlled phase II study.","Wells J","","$13,926,873.00"
"Wells, Jennie","Medicine","2006/01","2007/10","Clinical Trials","Funded","True","True","Co-Investigator","An Open-label Extension Study Examining the Safety and Tolerability of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer’s type, having completed study No.19158 (Study No.10252).","Borrie M.","Wells JL, Borrie MJ","$9,464,912.00"
"Wells, Jennie","Medicine","2004/01","2008/02","Clinical Trials","Funded","True","True","Co-Investigator","EFC 2946 Alzheimer Study: A randomized, multi-centre, double-blind, placebo-controlled, 18-month study of efficacy of Xaliproden in patients with Mild to Moderate Dementia of Alzheimer’s type.","Borrie M.","Wells JL, Borrie MJ","$28,608,007.00"
"Wells, Jennie","Medicine","2005/07","2008/06","Clinical Trials","Funded","True","True","Co-Investigator","Longitudinal Imaging Substudy of GenADA","Borrie MJ","Bartha R, Smith M, Wells JL, Borrie MJ","$71,965,592.00"
"Wells, Jennie","Medicine","2004/09","2007/09","Grants","Funded","True","False","Co-Investigator","Markers for the Progression from Mild Cognitive Impairment to Alzheimer disease.","Borrie MJ","Borrie MJ, Smith M, Bartha R, Lee T, Murtha S, Wells JL, Stolee P, Rylet J.","$18,664,768.00"
"Wells, Jennie","Medicine","2004/01","2008/01","Clinical Trials","Funded","True","True","Co-Investigator","A phase III study of the efficacy and safety of Alzhemed in patients with mild to moderate Alzheimer disease","Borrie MJ","Wells JL, Borrie MJ","$17,055,794.00"
"Wells, Jennie","Medicine","2004/06","2007/05","Clinical Trials","Funded","True","True","Co-Investigator","A double-blind phase II safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer disease.","Borrie MJ","Wells JL","$1,158,576.00"
"Wells, Jennie","Medicine","2004/01","2005/01","Clinical Trials","Funded","True","True","Co-Investigator","Long-term extension of phase II study EFC5286 of SR57667B in patients with mild to moderate Alzheimer disease (LTS5283).","Borrie MJ","Wells JL (site co-investigator).","$65,513,297.00"
"Wells, Jennie","Medicine","2005/07","2008/06","Clinical Trials","Funded","True","True","Co-Investigator","Neuroimaging component of Genotype-Phenotype associations in Alzheimer disease, 1.5 T substudy of GenADA Long","Borrie MJ","Wells JL, Borrie MJ","$67,360,965.00"
"Wells, Jennie","Medicine","2004/01","2006/01","Grants","Funded","True","False","Co-Investigator","Alzheimer Disease Neuroimaging Initiative (ADNI-024)","Borrie MJ","Borrie MJ, Wells JL","$70,400,042.00"
"Wells, Jennie","Medicine","2005/01","2008/12","Grants","Funded","True","False","Co-Investigator","4.0 Tesla 1H Magnetic Resonance Spectroscopy as a marker of Alzheimer Disease status and progression.","Borrie MJ","Wells JL","$53,931,003.00"
"Wells, Jennie","Medicine","2004/01","2008/01","Clinical Trials","Funded","True","True","Co-Investigator","NeuroImaging component of genotype-phenotype associations in Alzheimer Disease – 4.0T substudy of GenADA","Borrie MJ","Wells JL, Borrie MJ","$74,476,151.00"
"Wells, Jennie","Medicine","2004/09","2005/12","Clinical Trials","Funded","True","True","Co-Investigator","A Randomized, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine on Behavioural symptoms in Patients with Moderate to Severe Dementia of the Alzheimer's Type. (Study No. 10158)","Borrie MJ","Borrie MJ, Wells JL","$19,144,413.00"
"Wells, Jennie","Medicine","2003/01","2005/01","Clinical Trials","Funded","True","True","Co-Investigator","Phase II Multi-centre, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer’s Type.","Borrie MJ (Site principle investigator)","Wells JL (co-investigator)","$33,963,192.00"
"Wells, Jennie","Medicine","2003/08","2005/08","Clinical Trials","Funded","True","True","Co-Investigator","An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment.","Borrie MJ","Borrie MJ , Wells JL","$26,197,523.00"
"Wells, Jennie","Medicine","2003/01","2005/01","Clinical Trials","Funded","True","True","Co-Investigator","A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multi center, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer's Type.","Borrie MJ","Borrie MJ , Wells JL","$8,248,190.00"
"Wells, Jennie","Medicine","2003/05","2005/01","Clinical Trials","Funded","True","True","Co-Investigator","Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimer's disease (GenADA).","Borrie MJ","Borrie MJ , Wells JL","$14,697,058.00"
"Wells, Jennie","Medicine","2003/03","2004/11","Clinical Trials","Funded","True","True","Co-Investigator","A Phase II, Multicenter, Multinational, Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of SR57667B in Patients with Mild-to-Moderate Alzheimer's Disease.","Borrie MJ","Borrie MJ, Wells JL","$58,364,755.00"
"Wells, Jennie","Medicine","2002/09","2005/09","Grants","Funded","True","False","Co-Investigator","The Canadian Alzheimer's Disease Quality of Life Study (CADQOL)","Borrie MJ","Borrie MJ, Wells JL","$16,994,075.00"
"Wells, Jennie","Medicine","2003/05","2004/04","Clinical Trials","Funded","True","True","Co-Investigator","An 80-Week, Randomized, Multi-Center, Parallel-group, Double-blind Study of the Efficacy and Safety of Atorvastatin 80 mg Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer’s Disease.","Borrie MJ","Borrie MJ, Wells JL","$43,730,813.00"
"Wells, Jennie","Medicine","2005/01","2008/12","Clinical Trials","Funded","True","True","Co-Investigator","Multi-site Collaborative Study for Genotype-Phenotype Associations in Alzhiemer Disease Longitudinal Follow-up (Genetic Alzheimer Disease Associations Longitudinal (GenADA Long).","Borrie MJ","Wells JL, Borrie MJ","$49,276,243.00"
"Wells, Jennie","Medicine","2002/01","2003/01","Clinical Trials","Funded","True","True","Co-Investigator","Extend Program. Participant in recruiting for this observational, nonrandomized trial assessing the success of switching patients to Exelon.","Borrie MJ","Wells JL, Borrie MJ","$66,845,246.00"
"Wells, Jennie","Medicine","2001/08","2003/08","Grants","Funded","True","False","Co-Investigator","Synthesis Research in Geriatric Rehabilitation.","Borrie, MJ","Borrie MJ, Stolee P, Wells JL, Knoefel F.","$22,842,001.00"
"Wells, Jennie","Medicine","2001/01","2004/01","Clinical Trials","Funded","True","True","Co-Investigator","A Randomized, 26 week, Double-blind, placebo-controlled Trial to evaluate the Efficacy and Safety of Galantamine in the treatment of dementia secondary to cerebrovascular Disease. (GAL-INT-26).","Borrie MJ","Wells JL, Borrie MJ","$49,823,086.00"
"Wells, Jennie","Medicine","2001/04","2003/04","Clinical Trials","Funded","True","True","Co-Investigator","A Randomized, Double blind placebo-controlled trial to Evaluate the Efficacy and Safety of Galantamine in Subjects with Mild Cognitive Impairment Clinically at Risk for development Probable Alzheimer’s Type Dementia (GAL-INT-18).","Borrie MJ","Wells JL, Borrie MJ","$23,639,373.00"
"Wells, Jennie","Medicine","2000/01","2001/01","Clinical Trials","Funded","True","True","Principal Site Investigator","A Phase III, Multi-centre, Randomized, Controlled, Double-Blind, Parallel Group Clinical Trial of Synsorb Cd for the Treatment of Recurrent C. difficile-Associated Disease.","Wells JL","Brymer CD, Crilly RG, Diachun LL, Hurwitz JS.","$35,629,596.00"
"Wells, Jennie","Medicine","1999/01","2000/01","Grants","Funded","True","False","Co-Investigator","A Randomized Controlled Trial of Anti-Chlamydia Antibiotic Therapy for Patients with Alzheimer’s Disease.","Molloy W","Borrie MJ, Wells JL et al.","$45,461,483.00"
"Wells, Jennie","Medicine","1999/01","2000/01","Clinical Trials","Funded","True","True","Co-Investigator","A Multi-centre, Randomized, Double-blind, Placebo-controlled Dose-ranging Study to Evaluate once daily dose of Neotrofin (AIT-082) over 24 weeks in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity.","Molloy W","Borrie MJ, Wells JL et al.","$27,248,692.00"
"Wells, Jennie","Medicine","2000/01","2007/01","Clinical Trials","Funded","True","True","Co-Investigator","Canadian Outcome Study of Dementia (COSID). (Multi-centre trial)","Borrie MJ","Wells JL et al.","$41,606,464.00"
"Wells, Jennie","Medicine","2000/07","2002/07","Clinical Trials","Funded","True","True","Co-Investigator","Long-term Safety and Efficacy of Galantamine in the Treatment of Vascular or Mixed Dementia (Multi-centre trial) (GAL-INT-14)","Borrie MJ","Borrie MJ, Wells JL et al.","$57,122,042.00"
"Wells, Jennie","Medicine","1999/01","2000/01","Clinical Trials","Funded","True","True","Co-Investigator","A Multi-centre, Randomized, Double-blind, Placebo-controlled Trial of Neotrofin (AIT-082) in Patients with Moderate to Mild Alzheimer’s Type Dementia.","Molloy W","Borrie MJ, Wells JL et al (Co-investigator)","$23,491,383.00"
"Wells, Jennie","Medicine","1997/01","1998/01","Clinical Trials","Funded","True","True","Co-Investigator","A Multi-centre, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients with Moderate to Moderately Severe Alzheimer’s Disease followed by an Open Label Treatment Phase.","Borrie MJ","Borrie MJ, Rabheru K, Wells JL","$53,598,786.00"
"Wells, Jennie","Medicine","1997/01","1999/01","Clinical Trials","Funded","True","True","Co-Investigator","A Compassionate Use Program of Donepezil Hydrochloride (E2020) in Patients with Alzheimer’s Disease.","Borrie MJ","Borrie MJ, Rabheru K, Wells JL.","$44,729,144.00"
"Wells, Jennie","Medicine","1997/01","1998/01","Clinical Trials","Funded","True","True","Co-Investigator","A Phase III Clinical Trial of the Safety and Efficacy of Cerebrolysin in Alzheimer’s Disease.","Borrie MJ","Borrie MJ, Rabheru K, Wells JL.","$13,498,832.00"
"Wells, Jennie","Medicine","1998/01","1998/01","Clinical Trials","Funded","True","True","Co-Investigator","An Open-labelled Clinical Trial of Propentofylline for patients with Alzheimer’s Disease or Multi-infarct Dementia.","Borrie MJ","Borrie MJ, Wells JL","$32,158,293.00"
"Wells, Jennie","Medicine","1998","1998","Clinical Trials","Funded","True","True","Co-Investigator","A Double blind Phase III Clinical Trial of Galantamine in Mixed-Vascular Dementia. (Gal-Int-6)","Borrie MJ","Wells JL.","$45,713,673.00"
"Wells, Jennie","Medicine","1998","1998","Grants","Funded","True","False","Principal Investigator","A Novel Clinical Pharmacy Experience for Third Year Medical Students.","Wells JL","Borrie MJ, Brymer CD, Crilly RG.","$4,454,387.00"
"Wells, Jennie","Medicine","1998","","Grants","Funded","False","False","Principal Investigator","Use of Alternative Medication in Community-dwelling Well-elderly in London, Ontario.","Wells JL","Martin J.","$40,656,776.00"
"Wells, Jennie","Medicine","1998","","Grants","Funded","False","False","Collaborator","The Frail Elderly Study.","Brymer CD","Wells JL, et al.","$52,463,253.00"
"Mehta, Sanjay","Medicine","1993/07","1994/06","Grants","Funded","True","False","Co-Applicant","The regulation of pulmonary vascular tone by the L-arginine-nitric oxide pathway.","RD Levy S Mehta","","$18,112,136.00"
"Mehta, Sanjay","Medicine","1997","1997/06","Grants","Funded","True","False","Principal Investigator","The Therapeutic effects of exogenous NO and surfactant in an animal model of acute bacterial pneumonia.","S. Mehta","","$64,910,696.00"
"Mehta, Sanjay","Medicine","1997/07","1998/06","Grants","Funded","True","False","Principal Investigator","Modulation of pulmonary inflammation by endogenous NO surfactant in an animal model of diffuse pneumonia. Grant-in-Aid.","S Mehta JF Lewis DG McCormack","","$67,399,874.00"
"Mehta, Sanjay","Medicine","1998","1998/06","Grants","Funded","True","False","Principal Investigator","Elucidation of the mechanisms of the systemic effects of inhaled NO.","S. Mehta","","$31,917,715.00"
"Mehta, Sanjay","Medicine","1998/07","1999/06","Grants","Funded","True","False","Principal Investigator","Therapeutic effect of NO donors in a rat model of lung injury. Grant-in-Aid.","S Mehta DG McCormack","","$59,521,763.00"
"Mehta, Sanjay","Medicine","1998/07","2001/06","Grants","Funded","True","False","Principal Investigator","Modulation of the adverse effects of endogenous NO overproduction in lung injury","S Mehta","","$69,648,044.00"
"Mahon, Jeffrey","Medicine","1994","1996","Clinical Trials","Funded","True","False","Co-Principal Investigator","Screening and prevention for insulin-dependent diabetes mellitus","John Dupre","","$19,983,578.00"
"Mahon, Jeffrey","Medicine","1994","1997","Clinical Trials","Funded","True","False","Co-Principal Investigator","The efficacy and cost-effectiveness of N of 1 studies compared to standard treatment with NSAIDs in osteoarthritis","Janet Pope, Jeffrey Mahon","","$769,818.00"
"Mahon, Jeffrey","Medicine","1994","1997","Clinical Trials","Funded","True","False","Principal Investigator","The cost and consequences of awaiting elective total hip replacement","Jeffrey Mahon","","$49,148,163.00"
"Mahon, Jeffrey","Medicine","1994","1997","Clinical Trials","Funded","True","False","Site Investigator","Propranolol for small abdominal aortic aneurysms","Andreas Laupacis","","$6,666,259.00"
"Mahon, Jeffrey","Medicine","1996","1999","Clinical Trials","Funded","True","False","Co-Principal Investigator","Screening and prevention of insulin dependent diabetes mellitus","Jeffrey Mahon, John Dupre","","$37,686,558.00"
"Mahon, Jeffrey","Medicine","1996","2001","Clinical Trials","Funded","True","False","Co-Investigator","Genetics of human diabetic autoimmunity","Leigh Field","","$48,070,628.00"
"Mahon, Jeffrey","Medicine","1999","2001","Clinical Trials","Funded","True","False","Co-Investigator","Facilitating the transition from pediatric to adult care:an intervention study with adolescents with type 1 diabetes mellitus","Grace Bradish, Leah-Anne Craig","","$52,836,383.00"
"Mahon, Jeffrey","Medicine","1998","1998","Clinical Trials","Funded","True","False","Co-Investigator","A randomized comparison of traditional and systematic reviews as guides to therapeutic decisions","John McDonald","","$7,022,220.00"
"Mahon, Jeffrey","Medicine","1999","2000","Clinical Trials","Funded","True","False","Principal Site Investigator","The Diabetes Prevention Trial-Type 1(DPT-1)","Jay Skyler","","$53,873,888.00"
"Mahon, Jeffrey","Medicine","2001","2003","Clinical Trials","Funded","True","False","Principal Investigator","A prospective cohort study of latent autoimmune diabetes of adulthood in Canada","Jeffrey Mahon","","$16,622,944.00"
"Mahon, Jeffrey","Medicine","2003","2005","Clinical Trials","Funded","True","False","Co-Investigator","Long-term risk of abnormal glucose homeostasis after E.coli 0157:H7 gastroenteritis: The Walkerton Health Study","Rita Suri","","$62,180,256.00"
"Mahon, Jeffrey","Medicine","2001/07","2009","Clinical Trials","Funded","True","False","Co-Investigator","Trial to reduce IDDM in the genetically at risk","John Dupre","","$64,017,468.00"
"Mahon, Jeffrey","Medicine","2001","2007","Clinical Trials","Funded","True","False","Co-Investigator","TrialNet: The impact of GAD on preservation of beta-cell function","Diane Wherrett","","$27,797,496.00"
"Mehta, Sanjay","Medicine","1998/07","2003/06","Grants","Funded","True","False","Principal Investigator","Modulation of the adverse effects of endogenous NO overproduction in lung injury.","S Mehta","","$13,322,963.00"
"Mehta, Sanjay","Medicine","1999","1999/06","Grants","Funded","True","False","Principal Investigator","Regulation of Nitric Oxide Synthase mRNA and protein expression in animal models of lung injury.","S Mehta","","$4,565,159.00"
"Mehta, Sanjay","Medicine","1999/07","2000/06","Grants","Funded","True","False","Principal Investigator","Adverse effects of nitric oxide overproduction in lung injury. Grant-in-Aid.","S Mehta","","$6,646,181.00"
"Mehta, Sanjay","Medicine","2000","2000/06","Grants","Funded","True","False","Principal Investigator","Cellular source-specific NO production modulates microvascular leak in lung injury.","S Mehta","","$25,210,884.00"
"Mehta, Sanjay","Medicine","1999/07","2000/06","Grants","Funded","True","False","Principal Applicant","Nitric Oxide-surfactant interactions in acute lung injury.","S Mehta JF Lewis DG McCormack R Veldhuizen","","$29,804,008.00"
"Mehta, Sanjay","Medicine","2000/07","2001/06","Grants","Funded","True","False","Principal Investigator","Nitric oxide-surfactant interactions in a mouse model of sepsis-induced lung injury. Grant-in-Aid.","S Mehta","","$18,888,979.00"
"Mehta, Sanjay","Medicine","2000/07","2003/06","Grants","Funded","True","False","Co-Investigator","Mechanisms of Nitric Oxide’s effects in sepsis induced lung injury.","DG McCormack S Mehta","","$12,011,825.00"
"Mehta, Sanjay","Medicine","2000/07","2003/06","Grants","Funded","True","False","Co-Applicant","Multiple organ dysfunction in the systemic inflammatory response syndrome.","Kvietys P","Cepinskas G, Potter R, Harris H, Lewis JF, Veldhuizen R, Feng QP, Sandig M, McCormack DG, Mehta S, Tyml K, Wilson J","$73,965,574.00"
"Mehta, Sanjay","Medicine","2000/07","2001/06","Grants","Funded","True","False","Principal Investigator","Cellular source-specific effect of nitric oxide in a mouse model of bacterial pneumonia Sean Weicker.","S Mehta","","$55,648,559.00"
"Mehta, Sanjay","Medicine","2000/07","2001/06","Grants","Funded","True","False","Principal Investigator","Role and cellular source of NO in acute lung injury associated with pneumonia.","DG McCormack S Mehta","","$67,239,543.00"
"Mehta, Sanjay","Medicine","2001/07","2002/06","Grants","Funded","True","False","Principal Investigator","Mechanisms of Nitric Oxide’s Effects in Sepsis-induced Lung Injury.","S Mehta","DG McCormack","$63,966,539.00"
"Mehta, Sanjay","Medicine","2001/07","2002/06","Grants","Funded","True","False","Principal Investigator","Differential effects of cell-specific NO on pulmonary microvascular leak in murine sepsis","S Mehta","DG McCormack","$46,247,913.00"
"Mehta, Sanjay","Medicine","2001","2001/06","Grants","Funded","True","False","Principal Investigator","A pilot clinical trial of inhaled NO in pneumonia.","S Mehta","","$13,957,427.00"
"Xenocostas, Anargyros","Medicine","2003","2004","Clinical Trials","Funded","True","False","Co-Investigator","Genomics-based analysis of AML treatment resistance.","Berg R.","Xenocostas A","$37,742,469.00"
"Gula, Lorne","Medicine","2005/06","2007","Grants","Funded","True","False","Principal Investigator","Implantable Cardioverter defibrillators: Assessment of patient characteristics, waiting times, and outcomes from a Canadian registry","Lorne Gula","R. Yee","$19,701,969.00"
"Xenocostas, Anargyros","Medicine","2004","2005","Clinical Trials","Funded","True","False","Principal Investigator","Treatment related changes in markers of neurodegeneration over time in the cerebrospinal fluid of adults with hematologic malignancies receiving chemotherapy.","A. Xenocostas","Stephen Pasternak, Jane Rylett and Kevin Kuo","$45,229,045.00"
"Gula, Lorne","Medicine","2006/06","2008/01","Grants","Funded","True","False","Principal Investigator","Maximum voltage targeted ablation of atrial flutter.","Lorne Gula","Andrew Krahn","$70,126,251.00"
"Xenocostas, Anargyros","Medicine","2004","2006","Clinical Trials","Funded","True","False","Co-Investigator","Optimal Hemoglobin and the Effect of Red Blood Cell Transfusion in Acute Myocardial Infarction.","Ian Chin-Yee","Qingping Feng and A. Xenocostas","$46,319,573.00"
"Xenocostas, Anargyros","Medicine","2005","2006","Clinical Trials","Funded","True","False","Co-Investigator","Genomics analysis of AML drug resistance","Randal Berg","Dr. A. Xenocostas","$10,661,401.00"
"Xenocostas, Anargyros","Medicine","2005","2006","Clinical Trials","Funded","True","False","Principal Investigator","Is Erythropoietin Cardioprotective during Anemia?","Xenocostas A","Qingping Feng and Ian Chin-Yee","$67,995,075.00"
"Xenocostas, Anargyros","Medicine","2006","2007","Clinical Trials","Funded","True","False","Co-Principal Investigator","Effect of rh-EPO on hemodynamics and microcirculatory perfusion of a hemorrhagic shock rat model.","Dr. R. Kao","Xenocostas A, Claudio Martin and Tao Rui","$60,750,440.00"
"Xenocostas, Anargyros","Medicine","2006","2009","Clinical Trials","Funded","True","False","Co-Investigator","New Metabolic Imaging Approaches to Assess Brain Tissue Viability.","Rob Bartha","A. Xenocostas and Ting Lee","$14,825,678.00"
"Xenocostas, Anargyros","Medicine","2006","2009","Clinical Trials","Funded","True","False","Co-Investigator","Oxygen Consumption is an Early Predictor of Brain Damage Following Hypoxia-Ischemia.","Keith St. Lawrence","Xenocostas A and Ting Lee","$486,796.00"
"Xenocostas, Anargyros","Medicine","2006","2010","Clinical Trials","Funded","True","False","Co-Investigator","Do coping styles and social climate of the treatment setting influence self-concept and subjective well being after bone marrow transplantation?","Gerald M. Devins","Xenocostas A., Jeff Lipton and Hans Messner","$51,898,401.00"
"McCormack, David","Medicine","2006/10","2011/03","Grants","Funded","True","False","Collaborator","Micro-imaging for Murine Models of Obstructive Lung Disease.","Giles Santyr","","$15,174,252.00"
"McCormack, David","Medicine","2005/10","2010/09","Grants","Funded","False","False","Collaborator","Multiple Organ Dysfunction in the Systemic Inflammatory Response Syndrome.","Peter Kvietys","","$40,742,923.00"
"McCormack, David","Medicine","2006/01","2006/12","Grants","Funded","False","False","Principal Investigator","Microvascular Endothelial Cell Injury in Murine Sepsis.","David McCormack","","$11,608,122.00"
"McCormack, David","Medicine","2005/01","2005/12","Grants","Funded","False","False","Collaborator","Xenon-enhanced Micro-Computed Tomography of the Ventilated Rat Lung.","David Holdsworth","","$60,012,535.00"
"McCormack, David","Medicine","2003/07","2005/06","Grants","Funded","False","False","Collaborator","Mechanisms of Septic Pulmonary Microvascular Endothelial Cell Barrier Dysfunction.","Sanjay Mehta","","$37,282,529.00"
"McCormack, David","Medicine","2003/09","2004/08","Grants","Funded","False","False","Principal Investigator","Mechanisms and pathophysiology of pulmonary inflammatory and abnormal pulmonary vascular responses in sepsis-induced lung injury.","David McCormack","Student: Miss J. Shelton","$42,593,803.00"
"McCormack, David","Medicine","2004/01","2004/06","Grants","Funded","False","False","Principal Investigator","Cell-source specific effects of iNOS in murine and human acute lung injury.","David McCormack","","$36,552,867.00"
"McCormack, David","Medicine","2002/09","2003/08","Grants","Funded","False","False","Collaborator","Cell-source specific effects of NO on endothelial cell barrier dysfunction.","Sanjay Mehta","","$59,160,343.00"
"McCormack, David","Medicine","2002/09","2003/08","Grants","Funded","False","False","Collaborator","Macrophage Targeting of iNOS Inhibition in Sepsis-induced Lung Injury.","Sanjay Mehta","","$43,860,100.00"
"McCormack, David","Medicine","2000/09","2003/03","Grants","Funded","False","False","Collaborator","Systemic Inflammatory Response Syndrome and Multiple Organ Dysfunction.","Peter Kvietys","","$2,436,438.00"
"McCormack, David","Medicine","2000/09","2003/03","Grants","Funded","False","False","Principal Investigator","Mechanisms of nitric oxide’s effects in sepsis-induced lung injury.","David McCormack","","$26,936,083.00"
"McCormack, David","Medicine","2001/07","2002/06","Grants","Funded","False","False","Collaborator","Differential effects of cell-specific NO on pulmonary microvascular leak in murine sepsis.","Sanjay Mehta","","$3,592,258.00"
"McCormack, David","Medicine","2000/07","2002/06","Grants","Funded","False","False","Collaborator","Mechanisms of nitric oxide’s effects in sepsis-induced lung injury.","Sanjay Mehta","","$67,991,557.00"
"Mehta, Sanjay","Medicine","2002/07","2003/06","Grants","Funded","True","False","Principal Investigator","Cell source specific effects of NO on endothelial cell barrier dysfunction.","S Mehta","DG McCormack","$15,508,014.00"
"McCormack, David","Medicine","2000/09","2001/06","Grants","Funded","False","False","Principal Investigator","Role and Cellular Source of Nitric Oxide in Acute Lung Injury Associated with Pneumonia.","David McCormack","","$45,526,175.00"
"McCormack, David","Medicine","2000/07","2001/06","Grants","Funded","False","False","Collaborator","Nitric oxide-surfactant interactions in a mouse model of sepsis-induced lung injury.","Sanjay Mehta","","$71,124,146.00"
"Mehta, Sanjay","Medicine","2002/07","2003/06","Grants","Funded","True","False","Principal Investigator","Macrophage Targeting of iNOS in Sepsis-Induced Lung Injury.","S Mehta","DG McCormack","$45,665,204.00"
"Mehta, Sanjay","Medicine","2003/01","2003/12","Grants","Funded","True","False","Principal Investigator","Nitric oxide synthase expression and activity in neutrophils of septic ICU patients.","S Mehta","","$35,657,040.00"
"Mehta, Sanjay","Medicine","2003/07","2005/06","Grants","Funded","True","False","Principal Investigator","Mechanisms of Septic Pulmonary Microvascular Endothelial Cell Barrier Dysfunction","S Mehta","DG McCormack","$14,655,946.00"
"Mehta, Sanjay","Medicine","2003/07","2005/06","Grants","Funded","True","False","Principal Investigator","Characterization of pulmonary microvascular endothelial cells from patients with pulmonary arterial hypertension.","S Mehta","","$62,468,920.00"
"Mehta, Sanjay","Medicine","2003/07","2004/06","Grants","Funded","True","False","Co-Principal Investigator","Mechanisms and pathophysiology of pulmonary inflammation and abnormal pulmonary vascular responses in sepsis –induced acute lung injury (Jen Shelton)","DG McCormack S Mehta","","$24,039,709.00"
"Mehta, Sanjay","Medicine","2003/07","2004/06","Grants","Funded","True","False","Principal Investigator","Specific role of neutrophil iNOS in murine sepsis-induced acute lung injury.","S Mehta","DG McCormack","$48,488,537.00"
"Mehta, Sanjay","Medicine","2003/07","2004/06","Grants","Funded","True","False","Principal Investigator","Septic responses of vascular-bed specific endothelial cells.","S Mehta","","$26,911,462.00"
"Mehta, Sanjay","Medicine","2004/01","2004/12","Grants","Funded","True","False","Principal Investigator","In vivo neutrophil targeting of iNOS inhibition therapy in murine septic lung injury.","S Mehta","","$17,987,389.00"
"Mehta, Sanjay","Medicine","2003/07","2004/06","Grants","Funded","True","False","Principal Investigator","Effects of neutrophil iNOS on neutrophil function.","R Taneja S Mehta","","$18,350,295.00"
"Mehta, Sanjay","Medicine","2004/07","2007/06","Grants","Funded","True","False","Principal Investigator","Prevalence and Severity of Pulmonary Hypertension in Systemic Lupus Erythematosus.","B Dias S Mehta","","$12,257,123.00"
"Mehta, Sanjay","Medicine","2005/01","2005/12","Grants","Funded","True","False","Principal Investigator","The specific effects of macrophage iNOS in murine septic lung injury.","S Mehta","","$40,386,231.00"
"Kovacs, Michael","Medicine","1997","2001","Grants","Funded","False","False","Co-Applicant","Canadian Dutch pulmonary embolism diagnosis study (CANPEDS)","","Ginsberg J, Kearon MC, Anderson DR, Wells PS","$70,086,364.00"
"Kovacs, Michael","Medicine","1997","1998","Grants","Funded","False","False","Principal Site Investigator","A phase II study of topotecan and etoposide in patients with refractory or relapsed acute myeloid leukemia.","Kovacs MJ","","$60,263,849.00"
"Kovacs, Michael","Medicine","1997","2000","Grants","Funded","False","False","Principal Site Investigator","Phase III study of SDZ PSC-833 in combination with vincristine, adriamycin, and dexamethasone (PSC/VAD) vs. VAD alone in patients with relapsing or refractory multiple myeloma-MY8.","Kovacs MJ","","$64,061,866.00"
"Kovacs, Michael","Medicine","1997","2001","Grants","Funded","False","False","Co-Applicant","An investigation of two intensities of warfarin for the prevention of recurrent thromboembolism in patients with antiphospholipid antibodies","","","$36,763,901.00"
"Kovacs, Michael","Medicine","1998","2000","Grants","Funded","False","False","Co-Applicant","D-dimer and IPG for recurrent DVT: A randomized trial","","","$64,101,134.00"
"Kovacs, Michael","Medicine","1998","2002","Grants","Funded","False","False","Co-Applicant","Extended low-intensity anticoagulation for idiopathic venous thromboembolism","","Kearon MC, Gent M, Ginsberg J, Wells PS, Anderson DR, Julian J.","$32,650,986.00"
"Kovacs, Michael","Medicine","2000","2002","Grants","Funded","False","False","Principal Site Investigator","Chimetric Anti-CD20 monoclonal antibody (Rituximab) in remission induction and maintenance treatment of relapsed follicular Non-Hodgkin's Lymphoma: A phase III randomized clinical trial NCIC CTG LY.7 (EORTC 20981)","","","$28,256,761.00"
"Kovacs, Michael","Medicine","1999","2000","Grants","Funded","False","False","Principal Site Investigator","A Phase II study of Flavopiridol (HMR 1275; NSC 649890) in patients with untreated or relapsed mantle cell lymphoma","","","$74,094,811.00"
"Kovacs, Michael","Medicine","2002","2007","Grants","Funded","True","False","Co-Applicant","A Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant In patients with Multiple Myeloma (MY-10).","","","$72,921,576.00"
"Kovacs, Michael","Medicine","2001","2005","Grants","Funded","False","False","Co-Applicant","A cohort study evaluating the safety of a diagnostic strategy involving D-dimer and compression ultrasonography in patients with suspected recurrent deep vein thrombosis","","Bates SM, Crowther M, Demers C, Geerts W, Ginsberg J, Julia J, Kahn S, Kearon C","$29,975,577.00"
"Kovacs, Michael","Medicine","2001","2004","Grants","Funded","False","False","Co-Applicant","Pulmonary embolism diagnosis study","","Anderson D, Wells P","$15,451,678.00"
"Kovacs, Michael","Medicine","2001","2005","Grants","Funded","False","False","Co-Applicant","Thrombophilia in Pregnancy Prophylaxis Study (TIPPS)","","Ginsberg J","$14,172,385.00"
"Kovacs, Michael","Medicine","2002","2004","Grants","Funded","False","False","Principal Site Investigator","A Phase II Study of Oral Fludarabine Phosphate in Patients with Previously Untreated B-Cell Chronic Lymphocytic Leukemia","","","$23,769,944.00"
"Kovacs, Michael","Medicine","2002","2004","Grants","Funded","False","False","Principal Applicant","A Phase II Study of ZD6474 in Patients with Relapsed Multiple Myeloma, IND.145","Kovacs M","","$32,836,819.00"
"Kovacs, Michael","Medicine","2002","2003","Grants","Funded","False","False","Co-Applicant","A Pilot Study to Assess the Feasibility of a Multicentre Trial Assessing Management of Asymptomatic Persons with a Thrombophilia.","","Wells P, Anderson DR, Kahn S, Crowther M, Rodger M.","$64,818,463.00"
"Kovacs, Michael","Medicine","2004/06","present","Clinical Trials","Funded","True","False","Co-Applicant","Compression stockings and COX-II Inhibitors to prevent post-thrombotic syndrome: The SOX trial.","Kovacs M","Kahn S,Wells P, Ginsberg J.","$67,693,203.00"
"Kovacs, Michael","Medicine","2003","2007","Grants","Funded","True","False","Principal Applicant","REVERSE-REcurrent VEnous thromboembolism Risk Stratification Evaluation: A study to develop a clinical prediction rule to predict low recurrence risk in patients with idiopathic venous thromboembolism.","Kovacs M","Rodger M, Anderson D, Kahn S, Wells P.","$23,959,390.00"
"Kovacs, Michael","Medicine","2003","2007","Grants","Funded","True","False","Co-Applicant","Association Study to Explore the Genetics of Elevated Levels of Factor VIII","Kovacs M","","$12,949,936.00"
"Kovacs, Michael","Medicine","2004","2008","Grants","Funded","True","False","Co-Applicant","Does low dose oral vitamin K reduce the risk of bleeding, without causing thrombosis, in patients with warfarin-associated coagulopathy: A randomized clinical trial.","Kovacs M","","$2,976,253.00"
"Kovacs, Michael","Medicine","2006","2014/03","Grants","Funded","True","False","Principal Applicant","A Double blind randomised control trial of post-operative low molecular weight heparin bridging therapy versus placebo bridging therapy for patients who are at high risk arterial thromboembolism (Periop 2)","Kovacs M","","$1,751,650.00"
"Kovacs, Michael","Medicine","2006","2011","Grants","Funded","True","False","Co-Applicant","Furthering Innovation in Thrombosis Research","Kovacs M","","$71,131,615.00"
"Mehta, Sanjay","Medicine","2005/07","2008/06","Grants","Funded","True","False","Principal Investigator","Microvascular endothelial cell injury in murine sepsis.","S Mehta","McCormack DG","$65,738,852.00"
"Mehta, Sanjay","Medicine","2005/07","2006/06","Grants","Funded","True","False","Principal Investigator","Effects of Neutrophil vs Macrophage iNOS in septic human endothelial cell injury.","S Mehta","McCormack DG","$40,514,352.00"
"Mehta, Sanjay","Medicine","2005/07","2010/06","Grants","Funded","True","False","Co-Applicant","Group Grant: Multiple organ dysfunction in the systemic inflammatory response syndrome.","","Kvietys P, Feng QP, Lewis JF, Veldhuizen R, Potter R, Mehta S, McCormack DG","$1,129,249.00"
"Mehta, Sanjay","Medicine","2005/07","2006/06","Grants","Funded","True","False","Principal Investigator","Direct assessment of role of iNOS in human pulmonary endothelial cell injury.","S Mehta","","$9,793,235.00"
"Mehta, Sanjay","Medicine","2006/01","2006/12","Grants","Funded","True","False","Principal Investigator","The specific effects of macrophage iNOS in murine septic lung injury.","S Mehta","","$45,739,753.00"
"Mehta, Sanjay","Medicine","2006/07","2007/06","Grants","Funded","True","False","Co-Principal Investigator","The specific effects of macrophage iNOS in murine septic lung injury (Kalamo Farley)","DG McCormack","S Mehta","$38,428,021.00"
"Mehta, Sanjay","Medicine","2006/07","2007/06","Grants","Funded","True","False","Principal Investigator","Mechanisms of cell-source specific effects of iNOS in septic human endothelial cell injury.","S Mehta","","$11,961,898.00"
"Mehta, Sanjay","Medicine","2008","2013","Grants","Funded","True","False","Principal Investigator","Complex Regulation of Microvascular Endothelial Cell Function in Sepsis.","S Mehta","","$23,137,477.00"
"Mehta, Sanjay","Medicine","2003/07","2004/06","Grants","Funded","False","False","Principal Investigator","The effects of nebulized doripenem vs tobramycin in a murine model of acute, severe Pseudomonas aeruginosa pneumonia.","S Mehta","","$36,866,352.00"
"Mehta, Sanjay","Medicine","2004/07","2006/06","Grants","Funded","False","False","Principal Investigator","Effects of cycling inhaled NO in a rat model of acute Pseudomonas aeruginosa pneumonia.","S Mehta","","$36,983,071.00"
"van Uum, Stanislaus","Medicine","2006/01","2007/01","Grants","Funded","True","False","Co-applicant","Acute Vascular Effects of Aldosterone","R Feldman","Stan van Uum","$3,069,427.00"
"van Uum, Stanislaus","Medicine","2006","2007","Grants","Funded","True","False","Co-applicant","Determinants of Adenylyl Cyclase-Mediated Vascular Responses","R Feldman","","$8,080,417.00"
"Kovacs, Michael","Medicine","2006","2009","Grants","Funded","True","False","Co-Applicant","Exercise Training for the Treatment of Post-thrombotic Syndrome: The EXPO Pilot Trial","","","$69,960,680.00"
"Kovacs, Michael","Medicine","2006","2007","Grants","Funded","True","False","Principal Site Investigator","C.M.1 – A phase IIb study of molecular responses to Imatinib at standard or increased doses for previously untreated patient with CML in chronic phase","Kovacs, M.","","$42,249,527.00"
"Kovacs, Michael","Medicine","2006","2007","Grants","Funded","True","False","Co-Applicant","MY-11 – A randomised Phase II dose finding study of Lenalidomide and melphalan in patients with previously untreated multiple myeloma.","Kovacs, M.","","$67,406,794.00"
"Kovacs, Michael","Medicine","2006","2012","Grants","Funded","True","False","Co-Applicant","The Thrombophilia in Pregnancy Prophylaxis Study","Kovacs, M.","","$29,542,457.00"
"Kovacs, Michael","Medicine","1992","1994","Grants","Funded","False","True","Principal Site Investigator","Efficacy and safety of an out-patient anticoagulant regimen consisting of a fixed dose of 1 mg/kg of enoxaparin administered subcutaneously twice daily with a standard in-patient anticoagulant regimen consisting of unfractionated heparin administered by continuous intravenous infusion: A randomized open-label study in patients with proximal deep vein thrombosis.","Kovacs, M.","","$34,050,730.00"
"Kovacs, Michael","Medicine","1992","1994","Grants","Funded","False","True","Principal Site Investigator","Comparative trial of Aredia versus placebo in the prevention of skeletal-related episodes in multiple myeloma patients with osteolytic lesions.","Kovacs, M.","","$40,666,182.00"
"Kovacs, Michael","Medicine","1993","1994","Grants","Funded","False","True","Principal Site Investigator","A multi-centre cohort study of the incidence of venous thromboembolism following initial enoxaparin thromboprophylaxis in patients who have undergone hip or knee arthroplasty.","Kovacs, M.","","$35,779,047.00"
"Kovacs, Michael","Medicine","1995","1996","Grants","Funded","False","True","Principal Site Investigator","Columbus Trial - A comparison of low molecular weight heparin with standard heparin in the treatment of patients with venous thromboembolism.","","","$58,431,452.00"
"Kovacs, Michael","Medicine","1995","2001","Grants","Funded","False","True","Principal Site Investigator","LAFIT Trial - Randomized Study of Long Term Warfarin or Placebo Following Three Months of Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism","Kovacs, M.","","$25,144,850.00"
"Kovacs, Michael","Medicine","1996","1996","Grants","Funded","False","True","Principal Site Investigator","A Phase III Clinical Trial Evaluating the Safety and Efficacy of Technetium Tc 99m P280 in the Detection and Localization of Acute Venous Thrombosis by Gamma Scintigraphy Compared with Contrast Venography.","Kovacs, M.","","$41,252,390.00"
"Kovacs, Michael","Medicine","1996","1997","Grants","Funded","False","True","Principal Site Investigator","Clinical Evaluation of the Safety of EPREX* Sterile Solution (epoetin alfa) in the Treatment of Anemia in Cancer Patients.","Kovacs, M.","","$19,174,036.00"
"Kovacs, Michael","Medicine","1996","1997","Grants","Funded","False","True","Principal Site Investigator","Prevention of DVT in Spinal-Cord-Injured Patients, Multi-centre Trial.","Kovacs, M.","","$58,830,381.00"
"Kovacs, Michael","Medicine","1996","1997","Grants","Funded","False","True","Principal Site Investigator","A Phase II study of 2-Cd (leustatin) in previously treated patients with chronic lymphocytic leukemia (CLL)","Kovacs, M.","","$44,131,959.00"
"Kovacs, Michael","Medicine","1996","1997","Grants","Funded","False","True","Principal Site Investigator","Prospective multi-centre uncontrolled study to test the efficacy and safety of oral fludarabine phosphate in previously treated patients with B-cell","Kovacs, M.","","$70,718,123.00"
"Kovacs, Michael","Medicine","1997","1999","Grants","Funded","False","True","Principal Site Investigator","An open-label randomized study in elderly subjects with previously untreated acute myelogenous leukemia comparing treatment groups randomized to daunorubicin, cytarabine and PSC 833.","Kovacs, M.","","$60,562,297.00"
"Kovacs, Michael","Medicine","1997","1998","Grants","Funded","False","True","Principal Site Investigator","Efficacy & Safety of Tinzaparin vs. ASA in treatment of Acute Ischaemic Stroke","Kovacs, M.","","$57,107,559.00"
"Kovacs, Michael","Medicine","1997","1999","Grants","Funded","False","True","Principal Site Investigator","A phase 3 open label, randomized, controlled study in subjects with poor prognosis acute myelo-genous leukemia randomized to SDZ PSC 833 + cytarabine, mitoxantrone and etoposide (AME) or AME alone.","Kovacs, M.","","$50,755,013.00"
"Kovacs, Michael","Medicine","1997","1998","Grants","Funded","False","True","Principal Site Investigator","L1057-77: A phase 3 randomized, controlled trial evaluating the efficacy of Panretin? (ALRT1057; 9-cis-Retinoic Acid) capsules in patients with newly diagnosed acute promyelocytic leukaemia","Kovacs, M.","","$57,620,373.00"
"Kovacs, Michael","Medicine","1997","1999","Grants","Funded","False","True","Principal Site Investigator","A Phase II assessment of outpatient peri-procedure treatment with low molecular weight heparin for patients on warfarin and at risk for thrombo-embolic complications","Kovacs, M.","","$16,121,161.00"
"Kovacs, Michael","Medicine","1998","1999","Grants","Funded","False","True","Principal Site Investigator","A Phase III, Open-label multi-centre, randomized, comparative study of topotecan, Ara-C (TAG) versus Idarubicin, Ara-C (IDAG) in MDS patients with RAEB(High Risk), RAEB-t or in patients with AML from a preceding phase of MDS","Kovacs, M.","","$4,209,334.00"
"Kovacs, Michael","Medicine","1998","1999","Grants","Funded","False","True","Principal Site Investigator","A dose-ranging study of 99m Tc-labelled fibrin binding domain of fibronectin in patients with deep vein thrombosis","Kovacs, M.","","$53,666,966.00"
"Kovacs, Michael","Medicine","1999","2000","Grants","Funded","False","True","Principal Site Investigator","A randomized, phase II/III trial of SCH54031 PEG interferon alfa-Ib (PEG intron) vs intron in subjects with newly diagnosed CML","Kovacs, M.","","$34,013,934.00"
"Kovacs, Michael","Medicine","1998","2002","Grants","Funded","False","True","Principal Site Investigator","Randomized comparison of low molecular weight heparin v.s. oral warfarin therapy for long term anticoagulation in cancer patients with venous thromboembolism","Kovacs, M.","","$15,624,595.00"
"Kovacs, Michael","Medicine","1999","2000","Grants","Funded","False","True","Principal Site Investigator","Randomized comparison of low molecular weight heparin v.s. oral warfarin therapy for long term anticoagulation in cancer patients with venous thromboembolism","Kovacs, M.","","$57,864,689.00"
"Kovacs, Michael","Medicine","2000","2001","Grants","Funded","False","True","Principal Investigator","Randomized comparison of low molecular weight heparin v.s. oral warfarin therapy for long term anticoagulation in cancer patients with venous thromboembolism","Kovacs, M.","","$17,415,206.00"
"Kovacs, Michael","Medicine","2001","2002","Grants","Funded","False","True","Principal Investigator","Randomized comparison of low molecular weight heparin v.s. oral warfarin therapy for long term anticoagulation in cancer patients with venous thromboembolism","Kovacs, M.","","$58,125,363.00"
"Kovacs, Michael","Medicine","1998","1999","Grants","Funded","False","True","Principal Site Investigator","Protocol 10: A randomized double-blind, multi-centre comparison trial of i.v. zoledronate (4 mg or 8 mg) vs i.v. Aredia (90 mg), as an adjunct to standard therapies, in the treatment of multiple myeloma and breast cancer patients with cancer-related bone lesions","Kovacs, M.","","$51,394,680.00"
"Kovacs, Michael","Medicine","1999","2000","Grants","Funded","False","True","Principal Site Investigator","Multi-centre randomized, open-level study to evaluate the safety and efficacy of immunotherapy with subcutaneous MaxamineTM (histamine dihydrochloride) Plus Proleukin (Interleukin-2) versus no treatment (standard of care) in patients with acute myleoide leukemia in first or subsequent complete remission (CR)","Kovacs, M.","","$66,549,603.00"
"Kovacs, Michael","Medicine","1999","2000","Grants","Funded","False","True","Principal Site Investigator","Oral thrombin inhibitor H 376/95 given to patients as prolonged prophylaxis after a six-month anti-coagulation treatment for venous thromboembolism An international multi-centre double-blind placebo controlled study (THRIVE III)","Kovacs, M.","","$21,955,863.00"
"Kovacs, Michael","Medicine","2000","2001","Grants","Funded","False","True","Principal Site Investigator","Oral thrombin inhibitor H 376/95 given to patients as prolonged prophylaxis after a six-month anti-coagulation treatment for venous thromboembolism An international multi-centre double-blind placebo controlled study (THRIVE III)","Kovacs, M.","","$15,089,962.00"
"Kovacs, Michael","Medicine","2000","2001","Grants","Funded","False","True","Principal Site Investigator","A phase III study of STI571 versus Interferon- (INF) combined with Cytarabine (Ana-C) in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Pb+)chronic myelogenous leukemia in chronic phase (CML-CP)","Kovacs, M.","","$30,453,542.00"
"Kovacs, Michael","Medicine","2000","2001","Grants","Funded","False","True","Principal Investigator","Outpatient perioperative thromboembolic prophylaxis with low molecular weight heparin for patients who are at high risk for arterial thromboembolism","Kovacs, M.","","$46,562,540.00"
"Kovacs, Michael","Medicine","2003","2004","Grants","Funded","False","True","Principal Site Investigator","Van Gogh – PE, A multicentre, international, randomized, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous SanOrg34006 with the combination of (LMW)Heparin and vit K antagonist (VKA) in the treatment of acute symptomatic pulmonary embolism","","","$20,394,700.00"
"Kovacs, Michael","Medicine","2003","2004","Grants","Funded","False","True","Principal Site Investigator","Van Gogh – DVT, A multicentre, international, randomized, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous SanOrg 34006 with the combination of (LMW)Heparin and vitamin K antagonist (VKA) in the treatment of acute symptomatic deep vein thrombosis","","","$8,520,120.00"
"Kovacs, Michael","Medicine","2003","2004","Grants","Funded","False","True","Principal Site Investigator","Regimen - Clinical outcomes with the use of unfractionated heparin or low-molecular-weight heparin as perioperative and periprocedural bridging therapy in patients on long-term oral anticoagulant treatment requiring interruption for an elective procedure","","","$64,568,762.00"
"Kovacs, Michael","Medicine","2003","2005","* Grant-n-Aid","Funded","False","False","Principal Applicant","A pilot study of central venous catheter survival in cancer patients using low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity (The Catheter Study)","","","$20,838,117.00"
"Kovacs, Michael","Medicine","2002","2003","Grants","Funded","False","True","Principal Site Investigator","M34101-039: An international, multi-center, randomized, open-label study of PS-341 versus high-dose dexamethasone in patients with relapsed or refractory multiple myeloma","Kovacs, M.","","$42,108,967.00"
"Kovacs, Michael","Medicine","2002","2003","Grants","Funded","False","True","Principal Site Investigator","M34101-040: An international, non-comparative, open label study of PS-341 administered to patients with multiple myeloma who experienced relapsed or progressive disease after receiving at least four previous treatment regimens or experienced progressive disease after receiving dexamethasone in Millennium Protocol M34101-039","Kovacs, M.","","$51,781,817.00"
"Kovacs, Michael","Medicine","2004","2005","Grants","Funded","False","True","Principal Site Investigator","Gleam - An open label, randomised multi-centre study comparing Gleevac at doses of 400mg and 800mg in obtaining major molecular response in chronic phase patients with Philidelphia Chromosome positive CML that have reached a complete cytogenetic response with 400mg","Kovacs, M.","","$10,328,421.00"
"Kovacs, Michael","Medicine","2005","2006","Grants","Funded","False","True","Principal Site Investigator","Once daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep vein thrombosis","Kovacs, M.","","$19,499,564.00"
"Kovacs, Michael","Medicine","2006/06","2009","Grants","Funded","False","True","Principal Site Investigator","A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. RE-COVER","Kovacs, M.","","$57,016,389.00"
"Kovacs, Michael","Medicine","2005","2006","Grants","Funded","False","True","Principal Site Investigator","Doxil - A phase II study to assess the safety & efficacy of DBd comination therapy of Doxil, Velcade and Deyanethasome for previously untreated M.M.","Kovacs, M.","","$34,269,552.00"
"Kovacs, Michael","Medicine","2006","2007","Grants","Funded","True","True","Principal Site Investigator","ANM-107 – A Canadian open label, multi-centre expanded access study of oral AMN-107 in adult patients with Imatinib-resistant or intolerant CML in blast crisis accelerated phase or chronic phase","Kovacs, M.","","$24,576,801.00"
"Kovacs, Michael","Medicine","2006","2007","Grants","Funded","False","True","Principal Site Investigator","CLL-001 – A multi-centre randomised, double-blinded parallel group study of the efficacy and safety of two Lenalidomide dose regimens in subjects with relapsed or B-cell refractory CLL","Kovacs, M.","","$51,933,478.00"
"Kovacs, Michael","Medicine","2006","2007","Grants","Funded","False","True","Principal Site Investigator","Protocol CV185-027-019: Double-blind, Placebo-controlled Study of Apixaban for the prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study","Kovacs, M.","","$905,822.00"
"Kovacs, Michael","Medicine","1993","1993","Grants","Funded","False","False","Principal Investigator","Purchase of new IPG machine for DVT studies","Kovacs, M.","","$70,796,927.00"
"Kovacs, Michael","Medicine","1993","1993","Grants","Funded","False","False","Principal Investigator","An assessment of the need to measure heparin activity in patients undergoing total knee or hip arthroplasty being treated with low molecular weight heparin prophylaxis to prevent venous thromboembolism","Kovacs, M.","","$40,507,154.00"
"Kovacs, Michael","Medicine","1994","1995","Grants","Funded","False","False","Principal Applicant","Assessment of Activated Protein C Cofactor Deficiency in Malignancy.","Kovacs, M.","","$33,106,017.00"
"Kovacs, Michael","Medicine","1994","1995","Grants","Funded","False","False","Co-Applicant","A randomized trial on the use of minidose warfarin to maintain patency of central venous access in patients with thrombocytopenia.","Kovacs, M.","","$62,578,810.00"
"Kovacs, Michael","Medicine","1995","1995","Grants","Funded","False","False","Principal Applicant","Measurement of Heparin Anti-Xa Levels for Columbus Trial.","Kovacs, M.","","$67,324,214.00"
"Kovacs, Michael","Medicine","1996","1997","Grants","Funded","False","False","Principal Applicant","A Phase IV assessment of a Pilot Hospital-Based Outpatient Venous Thromboembolism Program","Kovacs, M.","Dhawan R, Morrow B, Fulton M, Johnson N, Smith V","$73,965,712.00"
"Kovacs, Michael","Medicine","1997","1998","Grants","Funded","False","False","Principal Applicant","A comparison of 2 D-dimer methods for diagnosis of DVT or PE","Kovacs, M.","","$1,293,450.00"
"Kovacs, Michael","Medicine","1998","1999","Grants","Funded","False","False","Principal Applicant","A Randomized Trial Comparing Two Low Molecular Weight Heparins for the Treatment of VTE (Innohep v.s. Heparin)","Kovacs, M.","","$62,265,359.00"
"Kovacs, Michael","Medicine","1999","2000","Grants","Funded","False","False","Principal Applicant","Assessment of the role of Prothrombin Gene 20210A in patients with thrombosis and malignancy","Kovacs, M.","","$49,487,865.00"
"Kovacs, Michael","Medicine","1999","2000","Grants","Funded","False","False","Principal Applicant","Randomized Controlled Pilot Study Comparing Anticoagulation Clinics with Routine Medical Care for the Management of Patients Requiring Long-Term Sodium Warfarin.","Kovacs, M.","","$49,384,938.00"
"Kovacs, Michael","Medicine","2002","2003","Grants","Funded","False","False","Principal Investigator","REVERSE-Recurrent Venous thromboembolism Risk Stratification Evaluation-A study to develop a clinical prediction rule to predict low recurrence risk in patients with idiopathic venous thromboembolism","Kovacs, M.","","$51,782,950.00"
"Licskai, Christopher","Medicine","2004/10","2006/11","Grants","Funded","True","False","Principal Investigator","Essex County Community Asthma Care Strategy Demonstration Project","Dr. Christopher Licskai","Ivan Nicoletti, Todd Sands, Lisa Paolatto","$40,099,064.00"
"Licskai, Christopher","Medicine","2004","2006","Grants","Funded","False","True","Principal Investigator","The Primary Care Asthma PRIISME Project","Dr. Christopher Licskai","","$41,959,739.00"
"Licskai, Christopher","Medicine","2002","2004","Grants","Funded","False","False","Principal Investigator","Essex County Community Asthma Care Strategy – Pilot Study","Christopher Licskai","Todd Sands, Lisa Paolatto, Ivan Nicoletti","$8,779,588.00"
"van Uum, Stanislaus","Medicine","2006","2007","Grants","Funded","True","False","Principal Investigator","Polymorphisms of human adenylyl cyclase 6 and Gi protein in relation to venous tone","","","$40,787,312.00"
"van Uum, Stanislaus","Medicine","2005","2007","Grants","Funded","True","False","Co-applicant","Influence of fasting and post-prandial lipemia on endothelial function in adolescents and young adults with type 1 diabetes","F Mahmud","","$40,171,747.00"
"van Uum, Stanislaus","Medicine","2005","","Grants","Funded","True","False","Principal Investigator","Three methods for assessing endothelial function.","","","$26,637,098.00"
"van Uum, Stanislaus","Medicine","2005/03","","Grants","Funded","True","False","Principal Investigator","Effect of oral 5-HTP intake on urinary 5-HIAA excretion","","","$52,257,636.00"
"van Uum, Stanislaus","Medicine","2005","2007","Grants","Funded","True","False","Principal Investigator","Frequency of a single nucleotide variant of human adenylyl cyclase VI (ACVI) in specific patient groups","","","$39,479,623.00"
"van Uum, Stanislaus","Medicine","2003","2005","Grants","Funded","True","False","Principal Investigator","Assessment of Vascular Sensitivity to Aldosterone Antagonism","","","$4,391,653.00"
"Kovacs, Michael","Medicine","2001","2002","Grants","Funded","False","True","Principal Site Investigator","[EXULT] KNEE: Optimization of Dose (Study A) and Con-firmation of Safety and Efficacy (Study B) of H 376/95 (Oral Direct Thrombin Inhibitor) Compared to Warfarin (Coumadin) for the Prevention of Venous Thromboembolism Following Total Knee Arthro-plasty (TKA) Protocol No. 290","Kovacs, M.","","$7,582,542.00"
"Kovacs, Michael","Medicine","2002","2003","Grants","Funded","False","True","Principal Site Investigator","[EXULT] KNEE: Optimization of Dose (Study A) and Confirmation of Safety and Efficacy (Study B) of H 376/95 (Oral Direct Thrombin Inhibitor) Compared to Warfarin (Coumadin) for the Prevention of Venous Thromboembolism Following Total Knee Arthro-plasty (TKA) Protocol No. 290","Kovacs, M.","","$8,827,803.00"
"Martin, Claudio","Medicine","1990","1990","Grants","Funded","True","False","Co-applicant","Effect of pentoxifylline on tissue injury in sepsis.","","Co-applicant with Dr. W.J. Sibbald","$40,043,870.00"
"Martin, Claudio","Medicine","1991","1991","Grants","Funded","True","False","Co-Investigator","Mechanisms of altered vascular reactivity and regional blood flows in hyperdynamic sepsis.","","","$49,031,649.00"
"Martin, Claudio","Medicine","1991","1991","Grants","Funded","True","False","Co-Investigator","Gut microvascular blood flow in hyperdynamic sepsis.","","","$50,497,399.00"
"Martin, Claudio","Medicine","1993","1993","Grants","Funded","True","False","Principal Site Investigator","Transfusion requirements in critical care.","","Paul Hebert, Claudio Martin, John Marshall, Martin Tweedale, Joe Pagliarello.","$8,082,838.00"
"Martin, Claudio","Medicine","1994","1996","Grants","Funded","True","False","Co-applicant","Effect of Storage on the Ability of Erythrocyte Transfusion to Support Oxygen Uptake in Sepsis.","","Dr. W. Sibbald","$57,705,244.00"
"Martin, Claudio","Medicine","1994","1994","Grants","Funded","True","False","Co-Investigator","Pathophysiology of pneumonia: Role of oxygen delivery and injury to the gut in the development of sepsis.","","","$27,144,371.00"
"Martin, Claudio","Medicine","1994","1997","Grants","Funded","True","False","Co-Principal Investigator","Transfusion requirements in critical care - TRICC.","","Paul Hebert, Claudio Martin, John Marshall, Martin Tweedale, Joe Pagliarello, Morris Blajchman","$12,224,557.00"
"Martin, Claudio","Medicine","1994","1998","Grants","Funded","True","False","Principal Investigator","Characteristics and outcomes of patients requiring prolonged intensive care.","","","$37,723,610.00"
"Martin, Claudio","Medicine","1999","2001","Grants","Funded","True","False","Principal Investigator","Albumin compared to crystalloid for intravascular volume therapy of sepsis.","","","$49,467,374.00"
"Martin, Claudio","Medicine","1999","2002","Grants","Funded","True","False","Co-Investigator","The impact of group characteristics, work organization, and co-ordination processes on ICU performance.","","","$43,924,859.00"
"Martin, Claudio","Medicine","2001","2003","Clinical Trials","Funded","True","False","Co-applicant","A cluster randomized trial to improve weaning and extubation from mechanical ventilation.","","","$34,938,112.00"
"Martin, Claudio","Medicine","2002","2006","Grants","Funded","True","False","Co-applicant","Evidence-based practice identification and change (EPIC)in the ICU.","Dr. Shoo Kim Lee","","$35,255,563.00"
"Martin, Claudio","Medicine","2003","2006","Clinical Trials","Funded","True","False","Co-applicant","A randomized trial of a lung-open ventilation strategy in acute lung injury (LOVS).","Dr. Maureen Meade","","$29,104,303.00"
"Martin, Claudio","Medicine","2003","2005","Clinical Trials","Funded","True","False","Principal Site Investigator","Randomized Controlled Trial of Vasopressin vs Norepinephrine in Septic Shock.","","","$50,174,659.00"
"Martin, Claudio","Medicine","2003","2003","Grants","Funded","True","False","Principal Applicant","Predictors of Readmission to the ICU: a prospective cohort study.","","","$46,725,903.00"
"Martin, Claudio","Medicine","2005","2008","Grants","Funded","True","False","Co-applicant","Knowledge Innovation and Diffusion in Myocardial Infarction.","Femida Gwadry-Sridhar","","$12,399,954.00"
"Martin, Claudio","Medicine","2005","2005","Grants","Funded","True","False","Co-applicant","The Effect of Gender Upon the Delivery and Outcomes of Critical Care in Ontario.","Robert Fowler, MD","","$36,064,618.00"
"Martin, Claudio","Medicine","2007/03","2008/12","Grants","Funded","True","False","Principal Investigator","Critical Care Vital Signs Monitor: A Scorecard for Safe and Effective Patient Care in the ICU.","","","$7,111,743.00"
"Martin, Claudio","Medicine","2007/11","2012/06","Grants","Funded","True","False","Principal Site Investigator","A Randomized Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients: The REDOXS Study.","","","$6,163,899.00"
"Martin, Claudio","Medicine","1991","1991","Grants","Funded","False","False","Co-Investigator","Pathophysiology of organ dysfunction in sepsis.","","","$57,181,720.00"
"Martin, Claudio","Medicine","1992","1992","Grants","Funded","False","False","Co-Investigator","Labview data acquisition and data analysis system.","","","$451,310.00"
"Martin, Claudio","Medicine","1994","1994","Grants","Funded","False","False","Principal Investigator","Pathophysiology of pneumonia: Role of oxygen delivery and injury to the gut in the development of sepsis.","","","$41,999,215.00"
"Martin, Claudio","Medicine","1994","1994","Grants","Funded","False","False","Principal Investigator","Role of peripheral blood neutrophils and peritoneal macrophages in a rat pneumonia model of sepsis.","","","$71,228,470.00"
"Martin, Claudio","Medicine","1995","1995","Grants","Funded","False","False","Principal Investigator","Criteria for the admission to the ICU from the ER in teaching and non-teaching hospitals.","","","$6,506,150.00"
"Martin, Claudio","Medicine","1997","1997","Grants","Funded","False","False","Principal Investigator","Intravital measurement of cellular dysoxia in the small bowel of septic rats (student support).","","","$37,986,244.00"
"Martin, Claudio","Medicine","1997","1997","Grants","Funded","False","False","Principal Investigator","Gut Oxygen Delivery and Consumption during Systemic Hypoxia.","","","$20,824,387.00"
"Martin, Claudio","Medicine","1998","1998","Grants","Funded","False","False","Principal Investigator","Intravital measurement of cellular dysoxia in the small bowel of septic rats.","","","$16,695,377.00"
"Martin, Claudio","Medicine","2000","2000","Grants","Funded","False","False","Principal Investigator","Ventilator-Induced Lung Injury and Remote Organ Injury.","","","$51,794,462.00"
"Martin, Claudio","Medicine","2000","2000","Grants","Funded","False","False","Principal Investigator","Cefotaxime for prophylaxis of ventilator-associated pneumonia.","","","$47,650,332.00"
"Martin, Claudio","Medicine","2001","2001","Grants","Funded","False","False","Co-Investigator","Gut Perfusion, Dysoxia, and Mucosal Permeability in Sepsis.","","","$58,501,930.00"
"Martin, Claudio","Medicine","2001","2001","Grants","Funded","False","False","Co-applicant","A provincial survey of practice variability and the determinants of practice variability in the utilization of non-invasive ventilation in academic centres.","","","$48,832,717.00"
"Martin, Claudio","Medicine","1997","1997","Grants","Funded","False","False","Principal Investigator","Gut Oxygen Delivery and Consumption during Systemic Hypoxia.","","","$66,211,352.00"
"Martin, Claudio","Medicine","2002","2002","Grants","Funded","False","False","Principal Applicant","Prevention of Radiographic Contrast Induced Reductions in Renal Functioning and Length of ICU Stay in At-Risk Critically Ill Diabetic and Non-diabetic Patients.","","Drs. Karen Burns, Louise Moist","$56,162,935.00"
"Martin, Claudio","Medicine","2002","2002","Grants","Funded","False","False","Co-applicant","Preservation of Renal Function in High-Risk CABG Surgery Patients Exposed to Cardiopulmonary Bypass with N-acetylcysteine: A Pilot Study.","Dr. Louise Moist","","$36,101,074.00"
"Martin, Claudio","Medicine","2003","2003","Grants","Funded","False","False","Principal Applicant","Predictors of Readmission to the Intensive Care Unit: A Prospective Cohort Study.","","","$73,603,710.00"
"Martin, Claudio","Medicine","2006","2008","Grants","Funded","False","False","Co-applicant","Cardiac myocytes conditioned with septic plasma induce PMN transendothelial migration by generating the chemokines (LIX, KC and MIP-2) via activation of a MAPK-NF?B pathway.","T. Rui","","$13,287,718.00"
"Martin, Claudio","Medicine","1994","1996","Grants","Funded","False","False","Co-Investigator","Studies of the effects of dopexamine on the micro-circulation in hyperdynamic sepsis.","","Dr. W. Sibbald","$28,366,256.00"
"Martin, Claudio","Medicine","1995","1995","Grants","Funded","False","False","Co-Investigator","Anti-endotoxin therapy in an ovine model of sepsis.","","Dr. W. Sibbald","$55,689,583.00"
"Martin, Claudio","Medicine","1995","1997","Grants","Funded","False","False","Co-Investigator","A pre-clinical program to determine the efficacy of diaspirin cross-linked hemoglobin solution (DCL-Hb) in sepsis.","","Dr. Sibbald and Chin-Yee","$18,078,755.00"
"Martin, Claudio","Medicine","1995","1997","Grants","Funded","False","False","Co-Investigator","Physiologicial Effects of a Preclinical Program to Study the Effects of RSR13 on the Microcirculation of RSR Compounds.","","Dr. Sibbald and Chin-Yee","$38,120,568.00"
"Martin, Claudio","Medicine","1995","1996","Grants","Funded","False","False","Principal Investigator","A study to assess the clinical and economic performance of ICU’s in Southwestern Ontario.","","","$8,029,737.00"
"Martin, Claudio","Medicine","1995","1996","Grants","Funded","False","False","Principal Investigator","European Sepsis Study (European Consortium for Intensive Care Data).","","","$26,911,695.00"
"Martin, Claudio","Medicine","2001","2001","Grants","Funded","False","False","Principal Investigator","An open-labelled study of recombinant activated protein C in severe sepsis.","","","$56,755,417.00"
"Martin, Claudio","Medicine","2001","2001","Grants","Funded","False","False","Principal Investigator","Multicenter, double-blind, placebo controlled, randomized, phase 3 study of tifacogin (Recombinant tissue factor pathway inhibitor [rTFPI/SC – 59735]) in severe sepsis.","","","$29,407,544.00"
"Martin, Claudio","Medicine","2002","2002","Grants","Funded","False","False","Co-Investigator","A Phase 2, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) versus Placebo in the Preemptive Antifungal Therapy in Patients in the Intensive Care Unit.","","","$17,878,863.00"
"Martin, Claudio","Medicine","2003","2003","Grants","Funded","False","False","Principal Investigator","Sepsis Treatment And Response (STAR) Registry.","","","$55,432,513.00"
"Martin, Claudio","Medicine","2003","2003","Clinical Trials","Funded","False","False","Principal Site Investigator","A Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Heparin in Patients with Severe Sepsis and Higher Disease Severity Who Are Undergoing Treatment with Drotrecogin Alfa (Activated). (F1K-MC-EVBR).","","","$52,442,166.00"
"Martin, Claudio","Medicine","2003","2003","Grants","Funded","False","False","Principal Site Investigator","Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Early Stage Severe Sepsis.","Claudio Martin","","$58,518,114.00"
"Martin, Claudio","Medicine","2004","2004","Grants","Funded","False","False","Principal Site Investigator","A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-blind, Three-Arm study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant tissue Factor Pathway Inhibitor) Administration in Subjects with severe Community-acquired Pneumonia.","","","$19,863,205.00"
"Martin, Claudio","Medicine","2007","2007","Grants","Funded","False","True","Co-Investigator","Protocol F7Trauma-1711. A Multi-center, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy and safety of activated recombinant factor VII in severely injured trauma patients with bleeding refractory to standard treatment.","Dr. Neil Parry","","$13,282,592.00"
"Martin, Claudio","Medicine","2007","2007","Grants","Funded","False","True","Principal Investigator","A Phase 3 Randomized Double-Blind Study of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia.","","","$21,644,448.00"
"Martin, Claudio","Medicine","2007","2009","Grants","Funded","False","True","Principal Investigator","Protocol F1K-MC-EVDK. A Phase 2 Study to Evaluate Dose and duration of Treatment of Drotrecogin alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction.","","","$48,897,848.00"
"Martin, Claudio","Medicine","2004","2004","Grants","Funded","False","False","Co-Investigator","Effect of rh-EPO on Hemodynamics and Microcirculatory Perfusion of a Septic Rat Model (Completed).","Dr. Raymond Kao","","$51,807,255.00"
"Martin, Claudio","Medicine","2005","2005","Grants","Funded","False","False","Co-Investigator","Effect of rh-EPO on Hemodynamics and MicrocirculatoryPerfusion of a Hemorrahagic Shock Rat Model.","Dr. Raymond Kao","","$24,905,564.00"
"Martin, Claudio","Medicine","2007/01","2007/01","Grants","Funded","False","False","Site Investigator","The SAFE Translation of Research into Practice Study (SAFE-TRIPS).","Simon Finfer, Australia (ANZICS)","","$18,495,494.00"
"Levstik, Mark","Medicine","2006/10","2008","Clinical Trials","Funded","False","False","Principal Investigator","Molecular Absorbent Recirculation System ( MARS ) in the treatment of acute on chronic liver failure in Transplant Patients.","Mark Levstik","","$9,100,648.00"
"Levstik, Mark","Medicine","2007","2007/02","Clinical Trials","Funded","False","False","Principal Investigator","The use of Fibroscan in Pre and Post Liver Transplant Patients to determine fibrosis progression: Schering Plough.","Mark Levstik","","$8,573,905.00"
"Hegele, Robert","Medicine","1990/07","1992/06","Grants","Funded","True","False","Principal Investigator","Family-based approaches in the assessment of dyslipidemias.","Robert A. Hegele","","$64,758,119.00"
"Hegele, Robert","Medicine","1991/09","1992/08","Grants","Funded","True","False","Principal Investigator","Genetic analysis of aldolase B genes in hereditary fructose intolerance.","Robert A. Hegele","","$36,102,003.00"
"Hegele, Robert","Medicine","1992/04","1995/03","Grants","Funded","True","False","Principal Investigator","Genetic studies of dyslipidemias.","Robert A. Hegele","","$11,403,626.00"
"Hegele, Robert","Medicine","1993/07","1995/06","Grants","Funded","True","False","Principal Investigator","Modulation of plasma lipoprotein(a).","Robert A. Hegele","Dr. P. Armstrong","$27,716,271.00"
"Hegele, Robert","Medicine","1995/07","1998/06","Grants","Funded","True","False","Principal Investigator","Genetics of lipoprotein deficiency states.","Robert A. Hegele","","$68,938,179.00"
"Hegele, Robert","Medicine","1996/07","2001/06","Grants","Funded","True","False","Principal Investigator","Genetic determinants of blood pressure.","Robert A. Hegele","","$67,498,547.00"
"Leasa, David","Medicine","1990/01","1991/01","Grants","Funded","True","False","Co-Investigator","Risk factors for gastrointestinal bleeding in critically ill patients.","Dr. DJ Cook","","$1,999,983.00"
"Leasa, David","Medicine","1993/01","1993/12","Grants","Funded","False","False","Co-Investigator","Randomized Trial of Stress Ulcer Prophylaxis with Sucralfate vs Ranitidine - Effect on Nosocomial Pneumonia","Deborah J Cook","","$22,114,225.00"
"Leasa, David","Medicine","1993/01","1996/12","Clinical Trials","Funded","True","False","Co-Investigator","Randomized Trial of Stress Ulcer Prophylaxis with Sucralfate vs Ranitidine - Effect on Nosocomial Pneumonia","Deborah J Cook","","$71,894,284.00"
"Leasa, David","Medicine","1995/01","1995/12","Grants","Funded","False","False","Co-Investigator","Pilot Study: Lung Volume Reduction Surgery in Emphysema","Richard A Malthaner","","$67,580,604.00"
"Leasa, David","Medicine","1996/01","1996/12","Clinical Trials","Funded","True","False","Co-Investigator","Levels of Care for Critically Ill patients: A Multicentre Observational Study","Deborah J Cook","","$48,341,506.00"
"Leasa, David","Medicine","1997/01","1997/12","Grants","Funded","True","False","Co-Investigator","Influence of Body Position on the Cardiopulmonary Effects of Inhaled Nitric Oxide in Acute Respiratory Failure","David Leasa","Michael Sharpe","$23,923,979.00"
"Leasa, David","Medicine","2000/01","2005/12","Clinical Trials","Funded","True","False","Co-applicant","Lung Open Ventilation Study","Dr. Maureen Meade","","$49,959,391.00"
"Leasa, David","Medicine","2000/01","2001/12","Grants","Funded","False","False","Site sub-investigator","Moxifloxacin in Ambulatory Pneumonia (MAP) Study","Dr. Karl Theakston, Site Investigator LHSC","","$2,393,560.00"
"Leasa, David","Medicine","2001/10","2004/09","Clinical Trials","Funded","True","False","Principal Site Investigator","A Randomized Trial of Empiric Broad-Spectrum Antibiotics and Invasive Techniques in the Setting of Ventilator-Associated Pneumonia","Dr. Daren Heyland","BAXTER, Alan Dawson ; COOK, Deborah Joanne ; DODEK, Peter Murray ; HODDER, Richard V. ; LAM, Yuk-Miu ; LEASA, David John","$37,619,844.00"
"Kortas, Claude","Medicine","1993/01","1996/01","Grants","Funded","False","False","Principal Investigator","Masters' in Education","Self","","$36,932,359.00"
"Kortas, Claude","Medicine","1995/01","1996/01","Grants","Funded","False","False","Principal Investigator","Flaxseed in Hemodialysis: Effects on Atherogenic Risk Factors-Plasma Lipids, Apoproteins and Viscosity","C Kortas","","$67,731,939.00"
"Kortas, Claude","Medicine","1995/01","1996/01","Grants","Funded","False","False","Co-Investigator","Evaluation of a Blood Volume Monitor in Routine Hemodialysis","Dr. RM Lindsay","Dr. WF Clark, Dr. P Blake, Dr. C Kortas","$18,856,060.00"
"Kortas, Claude","Medicine","1996/01","1997/01","Grants","Funded","False","False","Co-Investigator","EFPO Award: Residents' Perceptions of Their Role As Teachers.","Dr. Paul Watson","Dr. P Watson","$64,096,024.00"
"Kortas, Claude","Medicine","1997/01","1999/01","Grants","Funded","False","False","Co-Investigator","Atherosclerosis in Uremia - A Longitudinal Study","Dr. A Fine","Dr. C. Kortas","$41,645,588.00"
"Kortas, Claude","Medicine","1998/01","2001/01","Grants","Funded","False","False","Co-Investigator","Daily/Nocturnal Home Dialysis","Dr. R Lindsay","Dr. C. Kortas","$2,773,654.00"
"Kortas, Claude","Medicine","1998/01","1999/01","Grants","Funded","False","False","Co-Investigator","Icodextrin Peritoneal Dialysis Solution in Patients Treated with Peritoneal Dialysis (PD) in North America","Dr P Blake","Dr. C. Kortas","$27,490,442.00"
"Kortas, Claude","Medicine","2006/01","2006/12","Grants","Funded","False","False","Co-Investigator","Spring Faculty Support for Research in Education: An Exploration of Residents' Experience and Perceptions of In-Training Evaluations.","Dr. C Watling - Principal Investigator","Dr. C. Kortas","$59,264,730.00"
"Gilbert, Kenneth","Medicine","2002/07","2007/07","Clinical Trials","Funded","True","False","Collaborator","Perioperative Ischemic Evaluation Study","Homer Yang & 35 others (includes K. Gilbert)","","$74,393,689.00"
"Gilbert, Kenneth","Medicine","","","Clinical Trials","Funded","True","False","Co-Principal Investigator","Randomized controlled trial of a point-score system for assigning patients having hip or knee replacement surgery to an autologous blood donation program.","Brian J Larocque, Kenneth Gilbert","","$39,051,372.00"
"Gilbert, Kenneth","Medicine","1999/07","2000/01","Clinical Trials","Funded","True","False","Co-Principal Investigator","Effects of perioperative anemia on perioperative cardiac events in hip and knee surgery.","Brian J Larocque, Kenneth Gilbert","","$7,621,437.00"
"Gilbert, Kenneth","Medicine","1996/11","1997/05","Clinical Trials","Funded","True","False","Collaborator","Prospective Validation of A Point Score System for Predicting the Likelihood of Blood Transfusion in Patients Undergoing Hip and Knee Replacement","Brian J Larocque, Kenneth Gilbert","","$6,915,448.00"
"Gregor, James","Medicine","1995/07","","Grants","Funded","False","False","Principal Investigator","","J Gregor","","$70,921,234.00"
"Gregor, James","Medicine","1998/06","1999/05","Grants","Funded","False","False","Principal Investigator","Physicians perception of the utility of patients with Crohn’s disease.","J Gregor","","$6,760,474.00"
"Gregor, James","Medicine","1998/12","2001/05","Grants","Funded","False","False","Principal Investigator","Utility measurements in chronically active Crohn’s disease","J Gregor","B Feagan","$14,934,587.00"
"Gregor, James","Medicine","","","Grants","Funded","False","False","Co-Investigator","Utility measurements in patients with chronic liver disease","P Marotta","J Gregor","$39,572,123.00"
"Gregor, James","Medicine","","","Grants","Funded","False","False","Principal Investigator","Utility measurements in patients with ulcerative colitis","J Gregor","B Feagan","$48,359,667.00"
"Gregor, James","Medicine","1997/01","1999/02","Grants","Funded","False","True","Principal Investigator","The long term tolerability, safety and efficacy of oral ridogrel 5mg daily administered to patients with ulcerative colitis.","J Gregor","","$34,382,693.00"
"Gregor, James","Medicine","1997/01","1998/08","Grants","Funded","False","True","Principal Investigator","The efficacy and safety of oral ridogrel (0.5mg O.D. 2.5mg E.D. and 5mg O.D.) in the treatment of active ulcerative colitis","J Gregor","","$44,780,150.00"
"Gregor, James","Medicine","1999/02","2000/07","Grants","Funded","False","True","Principal Investigator","CDP571-010: Open Treatment Period for…A Phase II, multi-national, double-blind, placebo-controlled, parallel group, 16 week study to assess the safety and potential of the engineered human anti-TNF antibody, CDP571, to prevent disease flare whilst allowing steroid withdrawal in steroid dependant patients with crohn’s disease following an intravenous dose of 20mg/kg and the 8 weeks later 10mg/kg of CDP571","J Gregor","","$26,070,870.00"
"Gregor, James","Medicine","1999/02","2000/07","Grants","Funded","False","True","Principal Investigator","CDP571-009: Open treatment period for…A Phase II, Multi-National, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Potential of the Engineered Human Anti-Tnf Antibody, CDP 571, to treat patients with moderately to severe crohn’s disease following an intravenous dose of 20 or 10 mg/kg) of CDP571 followed by 8 or 12 weekly dosing with 10 mg/kg CDP571 over 24 weeks.","J Gregor","","$23,559,842.00"
"Gregor, James","Medicine","1998/09","2000/07","Grants","Funded","False","True","Principal Investigator","CDP571-010: A phase II, multi-national, double-blind, placebo-controlled, parallel group, 16 week study to assess the safety and potential of the engineered human anti-TNF antibody, CDP571, to prevent disease flare whilst allowing steroid withdrawal in steroid dependant patients with crohn’s disease following an intravenous dose of 20 mg/kg and the 8 weeks later 10 mg/kg of CDP571","J Gregor","","$19,277,058.00"
"Gregor, James","Medicine","1998/09","2000/07","Grants","Funded","False","True","Principal Investigator","CDP571-009: A phase II, multi-national, double-blind, placebo-controlled, parallel group study to assess the safety and potential of the engineered human anti-TNF antibody, CDP 571, to treat patients with moderately to severe crohn’s disease following an intravenous dose of 20 or 10 mg/kg of CDP571 followed by 8 or 12 weekly dosing with 10mg/kg CDP571 over 24 weeks","J Gregor","","$30,198,398.00"
"Gregor, James","Medicine","2000/10","2001/06","Grants","Funded","False","False","Principal Investigator","Registry of upper gastrointestinal bleeds (RUGBE). Canadian Association of Gastroenterology","J Gregor","","$26,361,931.00"
"Gregor, James","Medicine","2000/10","2001/11","Grants","Funded","False","True","Principal Investigator","Efficacy and safety of intravenous pantoprazole in comparison to intravenous ranitidine in patients after endoscopic haemostasis of the peptic ulcer bleeding to prevent rebleeding","J Gregor","","$10,534,537.00"
"Gregor, James","Medicine","2001/07","2002/07","Grants","Funded","False","True","Principal Investigator","Proton pump inhibitor infusion as an adjunct to endoscopic therapy for bleeding ulcer disease","J Gregor","","$27,911,528.00"
"Gregor, James","Medicine","2001/05","2002/11","Grants","Funded","False","True","Principal Investigator","CDP571-015: A phase III, multi-national, multi-site, double-blind, placebo-controlled, 28 week study to assess the safety and efficacy of the engineered human anti-TNF antibody, CDP571 (10mg/kg), in patients with active crohn’s disease","J Gregor","","$58,629,596.00"
"Gregor, James","Medicine","2001/07","2003/07","Grants","Funded","False","True","Principal Investigator","CDP571-014: A phase III Multi-national, multi-site, open label, 32 week long term follow-up study to assess the safety and efficacy of the engineered human anti-TNF antibody, CDP571, in patients with Crohn’s Disease.","J. Gregor","","$58,458,667.00"
"Gregor, James","Medicine","2001/01","2002/09","Grants","Funded","False","True","Principal Investigator","CDP571-013: A Phase III, Multi-national, multi-site, double-blind, placebo-controlled, parallel group, 36 week study to assess the efficacy and safety of the engineered human anti-TNF antibody, CDP571, to prevent disease flare whilst allowing steroid withdrawal in steroid dependent patients with crohn’s disease following an intravenous dose of 10 mg/kg CPP-571, given at 8 week intervals","J Gregor","","$56,626,041.00"
"Gregor, James","Medicine","2002","2004","Grants","Funded","False","False","Principal Investigator","Capsule Endoscopy in the Diagnosis of Obscure Causes of Gastrointestinal Haemorrhage","J Gregor","T Ponich","$68,998,429.00"
"Gregor, James","Medicine","2002/04","present","Grants","Funded","False","False","Principal Investigator","ASCA Recombinant Serological Assay Test for Crohn’s Disease","J Gregor","","$14,926,368.00"
"Gregor, James","Medicine","","","Grants","Funded","False","False","Principal Investigator","Natural History of Ulcerative Colitis in Southwestern Ontario","J Gregor","L Roth","$35,807,684.00"
"Gregor, James","Medicine","2006/05","present","Grants","Funded","False","True","Principal Investigator","Treatment Response In Patients With Symptoms Due To Gastroesophageal Disease Either With Or Without Esophagitis Treated With Pantoprazole Sodium 40mg O.D. Over 8 Weeks. “Real Life” Protocol #: BY1023/M3-341 UWO REB#: 12482","J Gregor","T Ponich, N Chande","$57,046,414.00"
"Gregor, James","Medicine","2006/03","2008","Grants","Funded","False","True","Co-Investigator","A Double Blind, Randomized, Placebo-Controlled Multicenter Study To Assess The Safety And Efficacy Of AST-120 In Mild To Moderately Active Crohn’s Patients With Fistulas Protocol #: AST001-00 UWO REB#: 12248","T Ponich","J Gregor, N Chande, J Howard, W Barnett, B Feagan","$35,668,495.00"
"Gregor, James","Medicine","2006/03","present","Grants","Funded","False","True","Co-Investigator","A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Protocol #: 291-415 UWO REB#: 12121","B Feagan","J McDonald, W Barnett, J Howard, J Gregor, T Ponich, N Chande","$27,200,958.00"
"Gregor, James","Medicine","2005","present","Grants","Funded","False","False","Co-Investigator","A Prospective, Open-Label Study to Evaluate the Adacolumn Apherisis System for the Treatment of Moderate to Severe Ulcerative Colitis Protocol #: 512-04-207 UWO REB#: 11177","T Ponich","J Howard, J Gregor, N Chande","$20,807,367.00"
"Gregor, James","Medicine","2006/02","2007","Grants","Funded","False","True","Co-Investigator","A Prospective, Open-Label Study To Evaluate The Adacolumn Apheresis System For The Treatment Of Moderate To Severe Crohn's Disease Protocol #: 512-04-208 Sponsor: UWO REB#: 11847","T Ponich","J Gregor, J Howard, N Chande","$74,373,360.00"
"Gregor, James","Medicine","2006","2007","Grants","Funded","False","True","Co-Investigator","A Prospective, Randomized, Double-Blinded, Placebo (Sham)-Controlled Study To Evaluate The Safety And Effectiveness Of The Adacolumn Apheresis System For The Treatment Of Moderate To Severe Crohn's Disease Protocol #: 512-04-206 UWO REB#: 11595","T Ponich","J Gregor, J Howard, N Chande","$11,459,663.00"
"Gregor, James","Medicine","2005","2006","Grants","Funded","False","True","Co-Investigator","A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apherisis System for the Treatment of Moderate to Severe Ulcerative Colitis Protocol #: 512-04-205 UWO REB#: 10899","T Ponich","J Howard, J Gregor, N Chande","$39,723,883.00"
"Gregor, James","Medicine","2005/11","2008","Grants","Funded","False","False","Co-Investigator","A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study To Evaluate The Safety And Efficacy Of Infliximab In Combination With Methotrexate For The Long-Term Treatment Of Crohn’s Disease (CD). COMMIT (Combination Of Maintenance Methotrexate and Infliximab Trial) Protocol #: RP0401 UWO REB#: 11121","T Ponich","J Gregor, N Chande, J Howard","$10,498,882.00"
"Gregor, James","Medicine","2005/03","2007","Grants","Funded","False","True","Co-Investigator","Metronidazole and Ciprofloxacin in the Treatment of Colonic Crohn's Disease Protocol #: (MACINTOCC) UWO REB#: 11246","B Feagan","J McDonald, W Barnett, J Howard, J Gregor, T Ponich, N Chande","$21,488,536.00"
"Gregor, James","Medicine","2003","2006","Grants","Funded","False","True","Co-Investigator","A Randomized Placebo-Controlled Double-Blind Multicentre Study To Determine The Efficacy And Safety Of Vsl#3 Probiotic Food Supplement Mixture In Prevention Of Endoscopic Recurrence In Crohn's Disease Patients With Ileocolonic Surgical Resection And Small Intestine To Colon Anastomosis Protocol #: VSL #3 PROBIOTICS UWO REB#: 9126","B Feagan","J McDonald, W Barnett, J Howard, J Gregor, T Ponich, N Chande","$28,059,688.00"
"Gregor, James","Medicine","2003","2007","Grants","Funded","False","True","Co-Investigator","A One-Year, Multi-Centre, Randomized, Double-Blind Placebo-controlled Parallel Groups Assessment of the Tolerability, Safety and Efficacy of EpanovaTM Soft Gelatin Capsules 4g/day for Maintenance of Remission of Crohn’s Disease (CD) Protocol #: TP0307 UWO REB #: 10181","T Ponich","J Howard, J Gregor","$10,581,274.00"
"Gregor, James","Medicine","2003/10","2007/11","Grants","Funded","False","True","Co-Investigator","A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (EpanovaTM) for the Maintenance of Symptomatic Remission in Subjects with Crohn’s Disease (CD). EPIC - 2 Protocol #: TP0308 UWO REB#: 9270","T Ponich","J Howard, J Gregor","$44,128,754.00"
"Gregor, James","Medicine","2004/08","2006","Grants","Funded","False","True","Co-Investigator","A Multi-Centre Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease. Protocol #: M04-690 UWO REB#: 10846","B Feagan","J McDonald, W Barnett, J Howard, J Gregor, T Ponich","$50,730,165.00"
"Gregor, James","Medicine","2003/08","2006/06","Grants","Funded","False","True","Co-Investigator","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Crohn’s Disease Protocol #: M02-404 UWO REB#: 9803","B Feagan","J McDonald, W Barnett, J Howard, J Gregor, T Ponich","$26,172,670.00"
"Gregor, James","Medicine","2002","present","Grants","Funded","False","False","Principal Investigator","Capsule Endoscopy in the Diagnosis of Obscure Causes of Gastrointestinal Haemorrhage.","J Gregor","","$14,416,141.00"
"Gregor, James","Medicine","2005/02","2005/06","Grants","Funded","False","True","Principal Investigator","Infliximab Use In Fistulizing Crohn’s Disease: Impact on Healthcare Resource Protocol #: n/a UWO REB#: 11089E","J Gregor","","$53,246,319.00"
"Gregor, James","Medicine","2004/10","2006/05","Grants","Funded","False","True","Co-Investigator","A 12-Months, Randomized, Double-Blind, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease Protocol #: CRAD001F2201 Sponsor: UWO REB#: 10380","B Feagan","J McDonald, W Barnett, J Howard, J Gregor, T Ponich","$9,565,858.00"
"Gregor, James","Medicine","2004","2006","Grants","Funded","False","True","Co-Investigator","Randomized, Stratified, Double-Blind, Placebo-controlled Phase 2 Study of the Steroid-sparing Properties of Sargramostim(leukine)Therapy in Patients with Corticosteroid-Dependent Crohn’s Disease Protocol #: 307501 UWO REB#: 10006","B Feagan","J McDonald, W Barnett, J Howard, J Gregor, T Ponich","$53,833,174.00"
"Gregor, James","Medicine","2005/04","2006/02","Grants","Funded","False","False","Principal Investigator","Registry of Patients Undergoing Endoscopic and/or Acid Suppression Therapy and an Outcomes Analysis for Upper Gastrointestinal Bleeding (REASON): A Retrospective Medical Chart Review in Canadian Hospitals Protocol #: D6910L00003 UWO REB#: 11240E","J Gregor","","$25,705,040.00"
"Gregor, James","Medicine","2006/01","2006/12","Grants","Funded","False","False","Principal Investigator","Registry of Patients with Upper GI Bleeding and Assessment of ECG Changes and Troponin 1 level at Presentation. Retrospective Study of Medical Chart Review at London Health Sciences Centre Protocol #: n/a UWO REB#: 12067E","J Gregor","","$396,233.00"
"le Riche, Nicole","Medicine","2006/05","2009/08","Grants","Funded","False","False","Co-Investigator","Comprehensive care in rheumatoid arthritis. An outcomes based pilot project in an under serviced area. (Southwestern Ontario)","Dr. Janet Pope","","$12,228,195.00"
"Montero Odasso, Manuel","Medicine","2005/10","2006/09","Grants","Funded","True","False","Co-Investigator","""Understanding frailty and frail older persons' needs to design innovative models of care.""","Francois Beland","","$62,667,525.00"
"Montero Odasso, Manuel","Medicine","2003","2003","Grants","Funded","True","False","Principal Applicant","Falls Prevention program, Salary Award","Dr. Manuel Montero-Odasso","","$8,454,387.00"
"Montero Odasso, Manuel","Medicine","2004","2004","Grants","complete","False","False","Co-Investigator","Bourse de formation en gériatrie","","","$11,385,375.00"
"Montero Odasso, Manuel","Medicine","2005/01","2005/12","Grants","Funded","True","False","Principal Applicant","Bourse de formation en gériatrie","Dr. Manuel Montero-Odasso","","$46,834,673.00"
"Hegele, Robert","Medicine","2001/04","2006/03","Grants","Funded","True","False","Principal Investigator","Genetic determinants of blood pressure.","Robert A. Hegele","","$34,018,493.00"
"Hegele, Robert","Medicine","1996/04","2010/03","Grants","Funded","True","False","Principal Investigator","Genetic determinants of dyslipidemia and obesity.","Robert A. Hegele","","$52,614,685.00"
"Hegele, Robert","Medicine","1997/07","2003/06","Grants","Funded","True","False","Principal Investigator","Genetic determinants of diabetes in aboriginal Canadians.","Robert A. Hegele","","$70,511,966.00"
"Hegele, Robert","Medicine","1998/07","2006/06","Grants","Funded","True","False","Principal Investigator","Genetic determinants of CHD risk in ethnic groups.","Robert A. Hegele","","$60,748,062.00"
"Hegele, Robert","Medicine","1998/07","2005/06","Grants","Funded","True","False","Principal Investigator","Genetic determinants of atherosclerosis and diabetes.","Robert A. Hegele","","$24,743,819.00"
"Hegele, Robert","Medicine","2001/04","2006/03","Grants","Funded","True","False","Principal Investigator","Canada Research Chair in Human Genetics, Tier I.","Robert A. Hegele","","$73,313,255.00"
"Hegele, Robert","Medicine","2001/01","2001/12","Grants","Funded","True","False","Principal Investigator","Equipment Grant","Robert A. Hegele","","$14,923,649.00"
"Hegele, Robert","Medicine","2003/04","2006/03","Grants","Funded","True","False","Principal Investigator","Celera Genome Database Initiative.","Robert A. Hegele","","$39,815,727.00"
"Hegele, Robert","Medicine","2004/07","2006/06","Grants","Funded","True","False","Principal Investigator","Genetic determinants of diabetes complications in Aboriginal Canadians.","Robert A. Hegele","","$22,891,298.00"
"Hegele, Robert","Medicine","2003/04","2008/03","Grants","Funded","True","False","Co-Investigator","Interdisciplinary team for aboriginal diabetes (Young).","Kue Young","","$60,833,827.00"
"Hegele, Robert","Medicine","2003/09","2007/08","Grants","Funded","True","False","Co-Investigator","The facility for advanced genetic analysis (Bulman).","Dennis Bulman","","$2,628,007.00"
"Hegele, Robert","Medicine","2004/09","2008/08","Grants","Funded","True","False","Co-Investigator","MR Imaging of Myeloperoxidase.","Brian Rutt","","$69,346,083.00"
"Hegele, Robert","Medicine","2005/07","2010/06","Grants","Funded","True","False","Principal Investigator","Genetic determinants of coronary heart disease.","Robert A. Hegele","","$73,795,285.00"
"Hegele, Robert","Medicine","2005/04","2010/03","Grants","Funded","True","False","Principal Investigator","Genetic determinants of obesity, diabetes and lipoproteins.","Robert A. Hegele","","$48,630,052.00"
"Hegele, Robert","Medicine","2006/10","2011/09","Grants","Funded","True","False","Principal Investigator","Structural and functional annotation of the human genome for disease study.","Robert A. Hegele","","$33,046,189.00"
"Hegele, Robert","Medicine","2006/04","2011/03","Grants","Funded","True","False","Principal Investigator","Genetic determinants of metabolic syndrome in ethnic groups.","Robert A. Hegele","","$20,463,638.00"
"Hegele, Robert","Medicine","2006/09","2011/08","Grants","Funded","True","False","Co-Investigator","CIHR team in circumpolar chronic disease prevention.","Kue Young","","$60,705,347.00"
"Hegele, Robert","Medicine","2007/07","2009/06","Grants","Funded","True","False","Principal Investigator","Genomics of hypertriglyceridemia.","Robert A. Hegele","","$39,703,606.00"
"Hegele, Robert","Medicine","2007/07","2012/06","Grants","Funded","True","False","Principal Investigator","Phenomics and genomics of atherosclerosis in monogenic metabolic syndrome.","Robert A. Hegele","","$70,813,568.00"
"Sen, Mithu","Medicine","2000","2001","Clinical Trials","Funded","True","False","Principal Investigator","The Evaluation of High Frequency Oscillation and Exogenous Surfactant in Adult Respiratory Distress Syndrome","","Co-investigator. Dr. JF Lewis.","$27,640,426.00"
"Sen, Mithu","Medicine","1990","1991","Clinical Trials","Funded","False","False","Principal Investigator","The Effect of Topical Capsaicin on Mucosal Mast Cell Degranulation.","","","$35,706,099.00"
"Sen, Mithu","Medicine","2005","2006","Clinical Trials","Funded","True","False","Principal Investigator","Do sleep-related changes in cardiac rhythm and blood pressure adversely effect outcome in acute ischemic stroke?","Sen M.","Co-investigators: Hachinski V, Young B, Ozdemir O.","$27,775,087.00"
"Sen, Mithu","Medicine","2005","2006","Clinical Trials","Funded","True","False","Principal Investigator","Do sleep-related changes in cardiac rhythm and blood pressure adversely effect outcome in acute ischemic stroke?","Sen","Co-investigators: Hachinski V, Young B, Ozdemir O.","$297,995.00"
"Sen, Mithu","Medicine","2005/09","2007/09","Clinical Trials","Applied","False","False","Co-Investigator","Outcomes of Sleep Apnea Patients at St Joseph’s Health Care Centre","Thileep Kandasemy","Wright E, Fuller J.","$65,794,745.00"
"Moote, David William","Medicine","1982","","Grants","Funded","False","True","Co-Investigator","","","","$4,682,695.00"
"Moote, David William","Medicine","1983","","Grants","Funded","False","True","Co-Investigator","","","","$42,089,236.00"
"Moote, David William","Medicine","1985","1987","Grants","Funded","False","True","Co-Investigator","The comparison of Zaditen (ketotifen) and placebo in the prophylaxis of bronchial asthma in children age 5–17 years","","","$35,130,726.00"
"Moote, David William","Medicine","1985/11","1987","Grants","Funded","False","True","Co-Investigator","Double-blind, placebo-controlled clinical study of piriprost potassium in the treatment of late-phase antigen-induced bronchoconstricted asthmatics.","","NAM Paterson, JA Mazza, DW Moote, et. al","$1,827,376.00"
"Moote, David William","Medicine","1986","","Grants","Funded","False","True","Co-Investigator","Double-blind, parallel group, randomized study comparing the ef?cacy, safety, and onset of action of SCH-29581 10 mg once a day, astemizole 10 mg once a day, and placebo in seasonal allergic rhinitis","","DW Moote, J.A. Mazza, et. al","$54,409,036.00"
"Moote, David William","Medicine","1987","","Grants","Funded","False","True","Co-Investigator","A double-blind, randomized multi-centre study of the ef?cacy and safety of budesonide vs. placebo in adult patients with stable chronic asthma","","JA Mazza, DW Moote, et. al","$29,963,221.00"
"Moote, David William","Medicine","1987","","Grants","Funded","False","True","Co-Investigator","Ibuprofen as an adjunct to antihistamine treatment of hayfever","","DW Moote, JA Mazza, et. al","$63,076,062.00"
"Moote, David William","Medicine","1987","","Grants","Funded","False","True","Co-Investigator","Safety and ef?cacy of loratadine (10mg OD) vs. polaramine (6mg BID) in the management of perennial allergic rhinitis","","DW Moote, JA Mazza, et. al","$21,458,173.00"
"Moote, David William","Medicine","1987","","Grants","Funded","False","True","Co-Investigator","Multi-center, double-blind, between-patient comparison of multiple doses of 12 µg formoterol metered dose aerosol vs. multiple doses of 200 µg salbutamol metered dose aerosol in patients with bronchial asthma","","DW Moote, JA Mazza, et. al","$6,435,418.00"
"Moote, David William","Medicine","1988","","Grants","Funded","False","True","Co-Investigator","Astemizole in the treatment of ragweed hayfever: A clinical and pharmacodynamic study","","DW Moote, JA Mazza, et. al","$21,870,921.00"
"Moote, David William","Medicine","1988","1989","Grants","Funded","False","True","Co-Investigator","Multi-center double-blind group comparative study of 2% nedocromil sodium and placebo in the treatment of perennial allergic conjunctivitis","","DW Moote, JA Mazza, et. al","$28,431,732.00"
"Moote, David William","Medicine","1988","1989","Grants","Funded","False","True","Co-Investigator","Double-blind group comparative study to compare the ef?cacy of nedocromil sodium 1% aqueous nasal spray and placebo in the treatment of perennial allergic rhinitis","","DW Moote, JA Mazza, et. al","$35,793,447.00"
"Moote, David William","Medicine","1989","","Grants","Funded","False","True","Co-Investigator","To evaluate the effects of changing dosage forms from Theo-Dur twice daily to an evening 24-hour theophylline sustained-release tablet in patients with reversible airway obstruction","","DW Moote, JA Mazza, et. al","$52,641,352.00"
"Moote, David William","Medicine","1989","1990","Grants","Funded","False","True","Co-Investigator","A multicentre, double blind, comparative evaluation of ketotifen vs. placebo in the treatment of chronic idiopathic urticaria","","DW Moote, JA Mazza, et. al","$7,947,628.00"
"Moote, David William","Medicine","1990","","Grants","Funded","False","True","Co-Investigator","A multicentre diskhaler/Ventodisk system safety profile and handling study in patients with reversible airways obstruction","DW Moote, et. al","","$60,602,032.00"
"Moote, David William","Medicine","1990","","Grants","Funded","False","True","Co-Investigator","Efficacy of loratadine vs. placebo in the prophylactic treatment of seasonal allergic rhinitis","","DW Moote, JA Mazza, et. al","$68,785,016.00"
"Moote, David William","Medicine","1990","","Grants","Funded","False","True","Co-Investigator","Pulmicort (budesonide) Turbuhaler given once daily as a maintenance treatment in mild asthma: morning or evening administration in comparison with twice daily administration and placebo","","DW Moote, JA Mazza, et. al","$17,116,656.00"
"Moote, David William","Medicine","1990","","Grants","Funded","False","True","Co-Investigator","A multicentre, randomized, double blind placebo controlled, cross over comparison of 50 µg salmeterol administered twice daily, and 200 µg salbutamol administered four times daily","","DW Moote, JA Mazza,","$26,000,392.00"
"Moote, David William","Medicine","1990","","Grants","Funded","False","True","Co-Investigator","Efficacy of SCH 434 vs. chlorpheniramine maleate and pseudoephedrine sulfate combination in the treatment of seasonal allergic rhinitis","","DW Moote, JA Mazza, et. al","$609,661.00"
"Moote, David William","Medicine","1991","","Grants","Funded","False","True","Co-Investigator","Pulmicort (budesonide) Turbuhaler given once daily as a maintenance treatment in mild asthma. Morning or evening administration in comparison with twice daily administration","","DW Moote, JA Mazza, et. al","$63,674,582.00"
"Moote, David William","Medicine","1991","1991","Grants","Funded","False","True","Principal Investigator","Inhaled salmeterol in adolescent and adult patients with mild to moderate chronic reversible obstructive airways disease","DW Moote","JA Mazza, et. al","$6,476,267.00"
"Moote, David William","Medicine","1991","","Grants","Funded","False","True","Co-Investigator","A multi centre comparative study of the efficacy, safety of cetirizine versus loratadine & placebo in the treatment of seasonal allergic rhinitis","","DW Moote, JA Mazza, et. al","$45,860,641.00"
"Moote, David William","Medicine","1991","","Grants","Funded","False","True","Co-Investigator","A Multicentre, double-blind, double-dummy group comparative study to compare the efficacy of tipredane nasal spray at a dose level of 800 µg once daily, beclomethasone dipropionate nasal spray at a dose level of 200 µg twice daily, and placebo in adult patients with seasonal allergic rhinitis caused by ragweed pollen","","DW Moote, JA Mazza, et. al","$38,312,560.00"
"Moote, David William","Medicine","1991","","Grants","Funded","False","True","Co-Investigator","A double blind comparison of Rhinocort® (budesonide) aqua, MDI and placebo in the treatment of seasonal allergic rhinitis","","DW Moote, JA Mazza, et. al","$68,963,684.00"
"Moote, David William","Medicine","1992","","Grants","Funded","False","True","Co-Investigator","A double blind dummy group comparative study assessing the safety and efficacy of tipredane nasal spray at dose levels of 400 µg b.i.d., 1600 µg b.i.d., 6400 µg b.i.d., beclomethasone dipropionate nasal spray at a dose level of 200 µg b.i.d., and placebo in patients with seasonal allergic rhinitis","","DW Moote, JA Mazza, et. al","$10,857,559.00"
"Moote, David William","Medicine","1992","","Grants","Funded","False","True","Co-Investigator","Efficacy and safety of Long term inhaled salmeterol and beclomethasone dipropionate in corticosteroid naive children with mild to moderate, chronic, stable asthma","","DW Moote, JA Mazza, B Lyttle et. al","$857,856.00"
"Moote, David William","Medicine","1992","1993","Grants","Funded","False","True","Co-Investigator","Double-blind, comparative study of SCH 434 b.i.d. vs. components in the treatment of common cold","","DW Moote, JA Mazza, et. al","$35,873,500.00"
"Moote, David William","Medicine","1992","1993","Grants","Funded","False","True","Co-Investigator","A placebo-controlled, dose comparative study of Rhinocort Aqua in patients with perennial rhinitis","","DW Moote, JA Mazza, et. al","$38,037,086.00"
"Moote, David William","Medicine","1992","","Grants","Funded","False","True","Co-Investigator","Efficacy and safety of mometasone furoate aqueous nasal spray in treatment of seasonal allergic rhinitis","","JA Mazza, DW Moote, et. al","$30,916,400.00"
"Moote, David William","Medicine","1993","","Grants","Funded","False","True","Co-Investigator","Livostin® (levocabastine) nasal spray and eyedrops in the treatment of seasonal allergic rhinoconjunctivitis","","JA Mazza, DW Moote, et. al","$20,155,748.00"
"Moote, David William","Medicine","1993","","Grants","Funded","False","True","Co-Investigator","Nedocromil sodium—an anti-inflammatory asthma medication in the treatment of chronic cough","","DG McCormack, DW Moote, JA Mazza","$47,449,986.00"
"Moote, David William","Medicine","1993","","Grants","Funded","False","True","Co-Investigator","A multi-center, randomized, double-blind, double-dummy, parallel-group study to determine the clinical equivalence of salmeterol xinafoate 50 µg twice daily delivered via a Multi Dose Powder-Inhaler (MDPI) or Diskhaler®(DH) in adolescent and adult patients with reversible airways disease","","JA Mazza, DW Moote, et. al","$59,328,386.00"
"Moote, David William","Medicine","1993","","Grants","Funded","False","True","Co-Investigator","Study of effects of Zileuton 400 mg qid and 600 mg qid plus low dose of beclomethasone compared to high dose of beclomethasone in asthma outside the United States","","JA Mazza, DW Moote, et. al","$55,986,643.00"
"Moote, David William","Medicine","1994","","Grants","Funded","False","True","Principal Investigator","A multi-center, double-blind placebo controlled trial of Accolate in mild to moderate asthmat patients needing chronic treatment: 13 week efficacy and up to a one year open label safety extension","","","$53,394,272.00"
"Moote, David William","Medicine","1994","","Grants","Funded","False","True","Co-Investigator","Efficacy and safety of mometasone furoate aqueous nasal spray versus Beconase Aq. and placebo in the treatment of perennial allergic rhinitis","","","$46,486,321.00"
"Moote, David William","Medicine","1994","","Grants","Funded","False","True","Principal Investigator","Longterm safety of mometasone furoate aqueous nasal spray in perennial rhnitis patients","","","$64,310,269.00"
"Moote, David William","Medicine","1994","1995","Grants","Funded","False","True","Principal Investigator","Efficacy and safety of mometasone furoate aqueous nasal spray versus placebo and Flonase in seasonal allergic rhinitis patients","","","$41,628,000.00"
"Moote, David William","Medicine","1994","1995","Grants","Funded","False","True","Principal Investigator","A multi-centre, double-blind, randomized, 6 month, parallel-group study to compare the efficacy and safety of fluticasone propionate (FP) 2000µg daily via the diskhaler with budesonide (BUD) 2000 µg daily via the turbuhaler in adult patients with severe, reversible airways disease","","","$73,515,365.00"
"Moote, David William","Medicine","1995","","Grants","Funded","False","True","Principal Investigator","Multi-center randomized, double-blind, parallel-group study to determine the clinical equivalence between fluticasone propionate 500 µg once daily and fluticasone propionate 250 µg twice daily both delivered via the metered-dose inhaler (MDI) in patients with moderate asthma","","","$73,230,991.00"
"Moote, David William","Medicine","1995","","Grants","Funded","False","True","Principal Investigator","A studye of the safety and efficacy of Allervax Ragweed for treatment of allergy symptoms induced by natural exposure to a ragweed pollen season","","","$9,387,199.00"
"Moote, David William","Medicine","1995","","Grants","Funded","False","True","Principal Investigator","A multi-center, randomized, placebo-controlled, double-blind, tow period, parallel-group study to assess the clinical effect of MK-0476 with concomitant administration of a removal of inhaled beclomethasone in asthmatic patients","","","$27,672,692.00"
"Moote, David William","Medicine","1995","","Grants","Funded","False","True","Principal Investigator","A multicenter, double-blind, placebo-controlled, parallel-group comparison safety and efficacy of Pranlukast (SB 205312) 75 and 150 mg bid with Claritin 10 mg uid in patients with seasonal allergic rhinitis","","","$61,850,217.00"
"Moote, David William","Medicine","1995","","Grants","Funded","False","True","Principal Investigator","A multi-center, double-blind, efficacy trial to compare Accolate (CAC 204219) given at 160 mg/day with placebo over 13 weeks to subjects with chronic severe asthma","","","$69,078,360.00"
"Moote, David William","Medicine","1995/01","","Grants","Funded","False","True","Co-Investigator","A double-blind randomized, parallel study comparing the efficacy and safety of fexofenadine 60 mg bid, 120 mg qid, and placebo in treatment of perennial allergic rhinitis","","","$52,540,600.00"
"Moote, David William","Medicine","1995/03","","Grants","Funded","False","True","Co-Investigator","Comparison of fexofenadine versus loratadine in seasonal allergic rhinitis","","","$28,343,358.00"
"Moote, David William","Medicine","1996/08","","Grants","Funded","False","True","Co-Investigator","Comparative study of the safety and efficacy of a twice-daily fexofenadine HCI 60 mg-pseudoephedrine HCI 120 mg combination versus its components alone in the management of ragweed seasonal allergy","","","$65,948,270.00"
"Moote, David William","Medicine","1997/01","","Grants","Funded","False","True","Principal Investigator","One month, double-blind efficacy and safety study of mometasone furoate aqueous nasal spray vs. placebo, followed by six-month open-label safety in children with allergic rhinitis","","","$22,347,624.00"
"Moote, David William","Medicine","1997","","Grants","Funded","False","True","Principal Investigator","Efficacy and safety of three daily dose levels of mometasone furoate dry powder in the treatment of asthmatics requiring high dose inhaled corticosteroids","","","$73,444,889.00"
"Moote, David William","Medicine","1997","","Grants","Funded","False","True","Principal Investigator","A multi-centre, randomized, double-blind parallel group clinical trial to assess the long-term (52 weeks) safety of fluticasone propionate 500 µg bid administered by pressurized metered dose inhaler propelled by GR106642X propellant in comparison with propellants 11 and 12 in adolescent and adult subjects with asthma","","","$5,472,680.00"
"Moote, David William","Medicine","1997/09","","Grants","Funded","False","True","Principal Investigator","A clinical and economic comparison of formoterol turbuhaler versus salmeterol and salbutamol pMDI in asthmatic patients not well controlled on inhaled steroid therapy","","","$65,140,532.00"
"Moote, David William","Medicine","1997/09","","Grants","Funded","False","True","Co-Investigator","A multicenter randomized trial comparing the safety and efficacy of flunisolide administered with an AeroChamber and budesonide administered with a turbuhaler in patients with moderated asthma","","","$52,172,836.00"
"Moote, David William","Medicine","1997/11","","Grants","Funded","False","True","Principal Investigator","Efficacy and safety of mometasone furoate HFA-227 metered dose inhaler and fluticasone propionate CFC metered dose inhaler in the treatment of asthma in subjects maintained on inhaled corticosteroids","","","$66,402,033.00"
"Moote, David William","Medicine","1998/01","","Grants","Funded","False","True","Principal Investigator","12 Weeks treatment with 200 or 800 µg/d ciclesonide versus placebo followed by a 40 weeks treatment with ciclesonide in asthmatic patients. A double-blind, randomized parallel group study with an open label extension","","","$34,916,786.00"
"Moote, David William","Medicine","1998/01","","Grants","Funded","False","True","Co-Investigator","12 Weeks treatment with 200 or 800 µg/d ciclesonide versus placebo followed by a 40 weeks treatment with ciclesonide in asthmatic patients. A double-blind, randomized parallel group study with an open label extension","","","$32,940,976.00"
"Moote, David William","Medicine","1998/10","","Grants","Funded","False","True","Principal Investigator","A 12-month, open-label, stratified study to assess the long-term safety of salmeterol/fluticasone propionate/GR106642X inhalation aerosol at doses of 50/100µg, 50/250µg and 50/500µg bd in adolescent and adult subjects with asthma","","","$39,142,433.00"
"Moote, David William","Medicine","","","Grants","Funded","False","True","Co-Investigator","Inhaled ciclesonide 400 ug once daily versus inhaled budesonide 400 ug once daily in patients with mild to moderate asthma. A double-blind, randomized, parallel group study","","J Mazza, DW Moote, KB Payton","$38,100,403.00"
"Moote, David William","Medicine","","","Grants","Funded","False","True","Co-Investigator","A multicentre randomized double-blind, double-dummy parallel group study to assess the long-term (six months) safety of intranasal fluticasone propionate aqueous nasal spray (FPANS) 200 ug once daily in comparison with fluticasone propionate nasal aerosol in adults and adolescents with perennial allergic rhinitis","","J Mazza, DW Moote, KB Payton","$22,902,764.00"
"Moote, David William","Medicine","","","Grants","Funded","False","True","Co-Investigator","Efficacy and safety of SCH 34117 (descarboethoxy - loratadine or DCL) in the treatment of patients with chronic idiopathic urticaria","","J Mazza, DW Moote, KB Payton","$71,596,981.00"
"Moote, David William","Medicine","","","Grants","Funded","False","True","Co-Investigator","A Phase IIIB, randomized parallel group open study to compare the oropharyngeal topical safety, the acceptability and the clinical efficacy of triamcinolone acetonide HFA - 134A 225 mcg inhalation aerosol to budesonide dry powder inhaler in inhaled steroid dependent adult asthmatics","","J Mazza, DW Moote, KB Payton","$32,708,777.00"
"Moote, David William","Medicine","1999/07","","Grants","Funded","False","True","Co-Investigator","Efficacy and safety of SCH 34117 compared to Cetirizine in the treatment of patients with seasonal allergic rhinitis","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$66,826,043.00"
"Moote, David William","Medicine","2000/01","","Grants","Funded","False","True","Co-Investigator","A multicentre, double-blind, randomized, parallel-group study investigating the clinical effect of montelukast/loratadine in patients with seasonal allergic rhinitis - Spring study","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$66,675,694.00"
"Moote, David William","Medicine","2000/02","","Grants","Funded","False","True","Principal Investigator","A randomized, double-blind, parallel group comparison of the safety and efficacy of three once daily doses of BAY 19-8004 with placebo and montelukast 10 mg daily in patients with symptomatic asthma","","","$12,786,351.00"
"Moote, David William","Medicine","2000/08","","Grants","Funded","False","True","Co-Investigator","A 12 week, randomized, double-blind, parallel group study to compare the efficacy and safety of salmeterol/fluticasone propionate/GR106642X (25/50 µg x 2 inhalations) bid with fluticasone propionate (125 µg x 2 inhalations bid in adolescent and adult patients with mild to moderate asthma","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$60,603,442.00"
"Moote, David William","Medicine","2000/08","","Grants","Funded","False","True","Co-Investigator","Real life effectiveness of Oxeze turbuhaler as needed in asthmatic patients during six months (RELIEF)","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$62,903,238.00"
"Moote, David William","Medicine","2000/09","","Grants","Funded","False","True","Co-Investigator","An assessment of safety and efficacy in treating moderated to sever asthmatics with inhaled ciclesonide 400 µg bid (800 µg/day) versus inhaled fluticasone propionate 500 µg bid (1000 µg/day)","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$69,867,471.00"
"Moote, David William","Medicine","2001/04","","Grants","Funded","False","True","Co-Investigator","A Multicentre, double-blind, randomized, parallel-group study investigating the clinical effect of montelukast in patients with seasonal allergic rhinitis","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$47,001,817.00"
"Moote, David William","Medicine","2001/05","","Grants","Funded","False","True","Co-Investigator","Efficacy and Safety of Symbicort (budesonide/formoterol) turbuhaler as single therapy in patients with moderate–severe asthma (STEP study)","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$23,488,619.00"
"Moote, David William","Medicine","2001/09","","Grants","Funded","False","True","Co-Investigator","The effectiveness and safety of an individualized Symbicort turbuhaler maintenance dosing regimen versus Symbicort turbuhaler given as regular twice daily therapy (SMART study)","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$25,370,651.00"
"Moote, David William","Medicine","2002/04","","Grants","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo controlled, parallel group, 12-week trial evaluating the efficacy and safety of fluticasone propionate/salmeterol diskus combination product 250/50 µg once daily versus fluticasone propionate/salmeterol diskus combination product 100/50 µg twice daily versus fluticasone propionate diskus 250 µg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short-acting beta2-agonists alone","","","$5,977,743.00"
"Moote, David William","Medicine","2002/04","","Grants","Funded","False","True","Co-Investigator","comparison of fluticasone (250 µg bid) and ciclesonide (400 µg od in the morning or evening) in asthma therapy (COMFORT)","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$36,724,306.00"
"Moote, David William","Medicine","2003/09","","Grants","Funded","False","True","Co-Investigator","Comparison of ciclesonide (400µg od via MDI) and fluticasone propionate (200µg bid via Diskus in the treatment of moderate asthma. A randomized, open label, parallel group multi-centre study","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$35,255,855.00"
"Moote, David William","Medicine","2003/11","","Grants","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial to assess the safety and efficacy of ciclesonide (200 µg once daily) applied as a nasal spray in the treatment of perennial allergic rhinitis (PAR) in patients 12 years and older","","","$27,104,365.00"
"Moote, David William","Medicine","2004/04","","Grants","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial designed to assess the efficacy and safety of ciclesonide applied as a nasal spray at three dose levels (200µg, 100µg, or 25µg, once daily) in the treatment of perennial allergic rhinitis (PAR) in patients 6-11 years of age","","Dr. J.A. Mazza, Dr. D.W. Moote, Dr. K.B. Payton","$58,076,617.00"
"Moote, David William","Medicine","2004/05","","Grants","Funded","False","True","Co-Investigator","A comparison of Symbicort single inhaler therapy (Symbicort 200 Turbuhaler 1 inhaler b.i.d. plus as needed) and conventional best practice in the treatment of persistent asthma in adolescents and adults – 2 26 week randomized, open-label, parallel group, multicentre study","","Dr. J.A. Mazza, Dr. D.W. Mazza, Dr. K.B. Payton","$53,898,977.00"
"Moote, David William","Medicine","2006","","Grants","Funded","False","True","Principal Investigator","A Randomized, Double-blind, Placebo-controlled, Parallel Group, Stratified, Multi-center, 12-week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm 100/10µg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Placebo or Fluticasone (100 µg twice daily) and Formoterol (10 µg twice daily) Alone in Adolescent and Adult Patients with Mild To Moderate Asthma","","","$50,505,668.00"
"Moote, David William","Medicine","2006","","Grants","Funded","False","True","Co-Investigator","A 6-month randomized, double-blind, parallel-group-, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium) 40 mg twice daily or 40 mg once daily with placebo in adults with asthma","","","$24,240,116.00"
"le Riche, Nicole","Medicine","2005/06","2007/01","Grants","Funded","False","False","Co-Investigator","A 1-year safety study of Duloxetine in patients with fibromyalgia syndrome.","Dr. Manfred Harth","","$23,096,740.00"
"le Riche, Nicole","Medicine","2003/01","2007/12","Grants","Funded","False","False","Co-Investigator","A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis who have had an Inadequate Response to Anti-TNF? Therapies.","Dr. Janet Pope","","$47,574,335.00"
"le Riche, Nicole","Medicine","2004/01","2013/07","Grants","Funded","False","False","Co-Investigator","An open label study of the efficacy and safety of retreatments with rituximab (MabThera®/Rituxan®) in patients with active rheumatoid arthritis who have had an inadequate response to anti-TNF? therapies.","Dr. Janet Pope","","$34,338,124.00"
"le Riche, Nicole","Medicine","2005/01","2012/02","Grants","Funded","False","False","Co-Investigator","A randomized placebo-controlled, multicenter Phase I/II study of escalating single intravenous doses of Ocrelizumab (rhuMAb 2H7 (Ro 496-4913, PRO70769) in patients with moderate to severe rheumatoid arthritis receiving stable doses of methotrexate but with unsatisfactory clinical response.","Dr. Janet Pope","","$55,375,065.00"
"le Riche, Nicole","Medicine","2005/01","2012/08","Grants","Funded","False","False","Co-Investigator","Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.","Dr. Janet Pope","","$34,397,546.00"
"le Riche, Nicole","Medicine","2004/01","2005/08","Grants","Funded","False","False","Co-Investigator","Long term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic ulcers.","Dr. Janet Pope","","$8,741,132.00"
"le Riche, Nicole","Medicine","2005/01","2007/06","Grants","Funded","False","False","Co-Investigator","A randomized, double-blinded, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis and an inadequate response to previous anti-TNF therapy.","Dr. Janet Pope","","$48,307,797.00"
"le Riche, Nicole","Medicine","2005/01","2007/11","Grants","Funded","False","False","Co-Investigator","A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Parallel-Group Study to Assess the Tolerability, Safety and Efficacy of Three Doses of Edratide (TV-4710) Administered Subcutaneously to Patients with Systemic Lupus Erythematosus.","Dr. Janet Pope","","$31,822,498.00"
"le Riche, Nicole","Medicine","2006/01","2007/11","Grants","Funded","False","False","Co-Investigator","Randomized, multi-center, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout.","Dr. Janet Pope","","$2,121,218.00"
"le Riche, Nicole","Medicine","2006/01","2006/12","Grants","Funded","False","False","Co-Investigator","A Phase II multi-centre, randomized, blinded study of 14 weeks duration comparing the effects of CRx-139 plus DMARD therapy to that of steroid plus DMARD therapy using ACR-20 in subjects with active rheumatoid arthritis partially responsive to the DMARD.","Dr. Janet Pope","","$1,295,387.00"
"le Riche, Nicole","Medicine","2006/01","2013/02","Grants","Funded","False","False","Co-Investigator","A Randomized, Double-Blind, Parallel-Group, multi-center Study to Evaluate the Efficacy and Safety of Various Dosing Regimens of Rituximab in combination with Methotrexate in RA patients with and Inadequate Response to Methotrexate.","Dr. Janet Pope","","$61,070,580.00"
"le Riche, Nicole","Medicine","2003","2006","Grants","Funded","False","False","Co-Investigator","A Randomized, Multifactorial, Double-Blind, Parallel-Group, Dose-Ranging Study Of The Efficacy And Safety Of Rituximab (Mabtheraâ/Rituxanâ) In Combination With Methotrexate In Patients With Active Rheumatoid Arthritis.","Dr. Janet Pope","","$25,146,560.00"
"le Riche, Nicole","Medicine","2003","2006","Grants","Funded","False","False","Co-Investigator","A multi-centre open label continuation study with subcutaneous D2E7 for patients with rheumatoid arthritis who completed a preceding clinical study with D2E7 (adalimumab).","Dr. Janet Pope","","$29,142,713.00"
"le Riche, Nicole","Medicine","2005","2006","Grants","Funded","False","False","Co-Investigator","A Phase III multicentre, double blind, placebo-controlled, parallel group 52-week study to assess the efficacy and safety of 2 dose regimens of lyophilized CDP870 given subcutaneously as additional medication to methotrexate in the treatment of signs and symptoms and preventing structural damage in patients with active rheumatoid arthritis who have an incomplete response to Methotrexate.","Dr. Janet Pope","","$17,445,946.00"
"le Riche, Nicole","Medicine","2005","2006","Grants","Funded","False","False","Co-Investigator","A Phase 2A, randomized, double-blind, placebo-controlled, multicenter study to compare 3 dose levels of CP-690, 550 versus placebo, administered orally twice daily (bid) for 6 weeks, in the treatment of the signs and symptoms of subjects with active rheumatoid arthritis.","Dr. Janet Pope","","$60,654,248.00"
"le Riche, Nicole","Medicine","2005","2006","Grants","Funded","False","False","Co-Investigator","Phase III “In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503 and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon.","Dr. Janet Pope","","$35,117,562.00"
"le Riche, Nicole","Medicine","","2002/08","Grants","Funded","False","False","Co-Investigator","A 13-week, multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study of 2 doses of COX 189 (200 mg and 400 mg o.d.) in patients with rheumatoid arthritis using naproxen (500 mg b.i.d.) as comparator.","Dr. Janet Pope","","$62,166,310.00"
"le Riche, Nicole","Medicine","2008/01","2008/12","Grants","Funded","False","False","Participant","The S.M.I.L.E. Project, a Multicentre Randomized Double-Blind Placebo Controlled Study of Methotrexate and Folic Acid in Systemic Lupus Erythematosus, a Phase II Trial.","Dr. Janet Pope","","$45,667,854.00"
"le Riche, Nicole","Medicine","2008/01","2008/12","Grants","Funded","False","False","Participant","The Effects of Lansoprazole Compared with Ranitidine on NSAID Induced Gastric Ulcers in Patients Continuing to Take NSAIDs.","Dr. T. Ponich, Dr. J. Gregor, Dr. J. Howard","","$9,280,993.00"
"le Riche, Nicole","Medicine","1984","1986","Grants","Funded","False","False","Assistantship","Assistantship from the Arthritis Society to provide partial base salary support.","","","$14,618,402.00"
"le Riche, Nicole","Medicine","1984","1986","Grants","Funded","False","False","Collaborator","Arthritis Society Grant-in-Aid for ""Development of a Systemic Lupus Erythematosus Activity Index"".","","","$64,405,499.00"
"le Riche, Nicole","Medicine","1985","1987","Grants","Funded","False","False","Collaborator","Lupus Clinic Development Grant","","","$39,560,741.00"
"Paul, Terri","Medicine","2005","2008/12","Clinical Trials","Funded","False","False","Principal Investigator","The effect of thyroid hormone suppression on bone mineral density in patients treated for differentiated thyroid carcinoma.","Dr. T Paul","","$17,973,199.00"
"Paul, Terri","Medicine","2001/01","2006","Clinical Trials","Funded","False","True","Co-Investigator","Randomized, double-blind, safety and efficacy trial with intravenous zolendronic acid for treatment of Paget’s disease of bone using Risedronate as a comparator. (Novartis)","Dr. A Hodsman","Dr. T Paul Dr. R Crilly","$18,676,738.00"
"Paul, Terri","Medicine","2006/05","2010","Clinical Trials","Funded","False","True","Co-Investigator","Fracture Incidence Reduction and Safety of TSE-424 (Bazedoxifene Acetate) Compared to Placebo and Raloxifene in Osteoporotic Postmenopausal Women. EXTENSION STUDY","Dr. A Hodsman","Dr. T Paul Dr. R Crilly","$30,770,565.00"
"Paul, Terri","Medicine","2006/06","2010","Clinical Trials","Funded","False","True","Co-Investigator","The Effect of Teriparatide Compared with Risedronate on Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures. (ELI LILLY)","Dr. A Hodsman","Dr. T Paul Dr. R Crilly","$14,141,178.00"
"Paul, Terri","Medicine","2006/09","2010","Clinical Trials","Funded","False","True","Co-Investigator","A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density.","Dr. A Hodsman","Dr. T Paul Dr. R Crilly","$36,503,943.00"
"Paul, Terri","Medicine","2004/05","2007/05","Clinical Trials","Funded","False","True","Principal Investigator","A Multicenter Double-Blind Randomized Active-Controlled Parallel Group Noninferiority Study Comparing 75 mg Risedronate Dosed on Two Consecutive Days Monthly with 5 mg daily Risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed over 24 Months HMR 4003M/3001.","Dr. A Hodsman","Dr. T Paul Dr. R Crilly","$73,517,942.00"
"Paul, Terri","Medicine","2003/02","2007/04","Clinical Trials","Funded","False","True","Principal Investigator","Multinational multicenter double blind randomized placebo controlled parallel group study assessing the efficacy of intravenous zolendronic acid in preventing subsequent osteoporotic fractures after a hip fracture. Protocol no: CZOL446H2310.","Dr. A Hodsman","Dr. T Paul Dr. R Crilly","$64,169,148.00"
"Paul, Terri","Medicine","2004/11","2007/03","Clinical Trials","Funded","False","True","Principal Investigator","An Open-label study to determine how prior therapy with Alendronate or Risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of Teriparatide. HMR 4003B/4034.","Dr. A Hodsman","Dr. T Paul Dr. R Crilly","$69,150,095.00"
"Paul, Terri","Medicine","2006/02","2007/03","Clinical Trials","Funded","False","True","Principal Investigator","A Randomized, Double-blind, Placebo-controlled, Parallel Group, dose finding study to investigate the safety tolerability and efficacy of Ostabolin-C™ in post-menopausal female subjects with low bone mineral density. EXTENSION STUDY","Dr.A Hodsman","Dr. T Paul","$3,269,730.00"
"Paul, Terri","Medicine","2005/07","2006/06","Clinical Trials","Funded","False","False","Co-Investigator","Methadone and Opiates Related Osteoporosis Feasibility Study.","Dr T Paul, Dr. S van Uum","Morley-Forester P Mahon J McKeough L","$58,798,494.00"
"Paul, Terri","Medicine","2004","2006","Clinical Trials","Funded","False","True","Co-Investigator","Community Outreach Diabetes Education to Family Physicians CODE FP.","Dr T Paul Dr. S Harris","","$33,892,872.00"
"Paul, Terri","Medicine","2003","2004","Clinical Trials","Funded","False","True","Co-Investigator","An 18 month double-blind, placebo-controlled, phase III trial with a 12 month interim analysis of the effect of recombinant human parathyroid hormone (ALX1-11) on fracture incidence in women with postmenopausal osteoporosis. Protocol ALX1-11-93001.","Dr A Hodsman","Dr T Paul Dr R Crilly","$61,609,568.00"
"Paul, Terri","Medicine","2004","2004/06","Clinical Trials","Funded","False","True","Co-Investigator","An 18-month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone rhPTH (1-84) ALX1-11 in Women with Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 Protocol CL1-11-002. 18-month study only involving randomized patients from previous study.","Dr A Hodsman","Dr T Paul Dr R Crilly","$20,833,447.00"
"Paul, Terri","Medicine","2005","2008","Clinical Trials","Funded","False","True","Co-Investigator","Sequential Use of Teriparatide and Raloxifene HCL in the Treatment of Postmenopausal Women With Osteoporosis. PROTOCOL B3D-MC-GHBQ. 3 year study","Dr A Hodsman","Dr T Paul Dr R Crilly","$43,585,356.00"
"Paul, Terri","Medicine","","","Clinical Trials","Funded","False","True","Co-Investigator","Fracture Incidence Reduction and Safety of TSE-424 (bazedoxifene acetate) compared to placebo and raloxifene in osteoporotic postmenopausal women. Protocol 3068A1-301-CA. 3-year study.","Dr A Hodsman","TL Paul, R Crilly","$25,515,884.00"
"Paul, Terri","Medicine","","","Clinical Trials","Funded","False","True","Co-Investigator","Continuing Outcomes Relevant to EvistaR (CORE): a study of Raloxifene HCL and Placebo in the Prevention of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis. H3S-MC-GGJY.","Dr A Hodsman","TL Paul, R Crilly","$47,009,753.00"
"Paul, Terri","Medicine","","","Clinical Trials","Funded","False","True","Co-Investigator","Extended follow-up of patients in LY333334 trials. Protocol B3D-MC-GHBJ.","Dr A Hodsman","TL Paul, R Crilly","$17,342,968.00"
"Paul, Terri","Medicine","2001","2010","Grants","Funded","True","False","Co-Investigator","Action to Control Cardiovascular Risk in Diabetes (ACCORD).","Dr I Hramiak","Dr T Paul Dr Charlotte McDonald","$52,751,051.00"
"Paul, Terri","Medicine","2003","2003","Clinical Trials","Funded","False","True","Co-Investigator","HOE 1964 – 12-week multinational, multicentre, controlled open 1:1:1 randomized parallel clinical trial to assess noninferiority between pre- and post-meal administration of HMR 1964 and pre-meal regular human insulin in subjects with type 1 diabetes mellitus receiving insulin glargine as the basal insulin therapy.","Dr I Hramiak","Dr T Paul","$47,270,768.00"
"Paul, Terri","Medicine","","","Clinical Trials","Funded","False","True","Co-Investigator","HOE Retinopathy 4016 – Evaluation of diabetic retinopathy progression in subjects with type 2 diabetes mellitus treated with insulin.","Dr I Hramiak","Dr T Paul","$6,598,255.00"
"Paul, Terri","Medicine","2002","2008","Clinical Trials","Funded","False","True","Co-Investigator","Efficacy and safety of EXUBERA (inhaled insulin) compared with subcutaneous human insulin therapy in adult subjects with type 1 diabetes mellitus: a two-year outpatient open-label parallel-group comparative trial.217-1022","Dr I Hramiak","Dr T Paul","$47,049,223.00"
"Paul, Terri","Medicine","2004","2006","Clinical Trials","Funded","False","True","Co-Investigator","217-111-5069 (Ext Ext) Long term safety of EXUBERA (inhaled insulin): extension of therapy in subjects with type 1 or type 2 diabetes mellitus completing Phase III randomized treatment trials (trends in pulmonary function after discontinuation of EXUBERA (inhaled insulin).","Dr I Hramiak","Dr T Paul","$56,166,962.00"
"Paul, Terri","Medicine","2002","2008","Clinical Trials","Funded","False","True","Co-Investigator","Efficacy and safety of EXUBERA (inhaled insulin) compared with subcutaneous human insulin therapy in adult subjects with type 2 diabetes mellitus: a two-year, outpatient, open-label, parallel-group comparative trial. 212-1029","Dr I Hramiak","Dr T Paul","$33,790,445.00"
"Paul, Terri","Medicine","2004","2011/09","Clinical Trials","Funded","False","True","Co-Investigator","A multi-center, international, randomised, 2x2 factorial design study to evaluate the effects of Lantus (insulin glargine) versus standard care, and of omega-3 fatty acids versus placebo, in reducing cardiovascular morbidity and mortality in high risk people with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or early Type 2 diabetes mellitus: The Origin Trial (Outcome Reduction with Initial Glargine INtervention)","Dr I Hramiak","Dr T Paul","$52,398,740.00"
"Paul, Terri","Medicine","2004","2004/06","Clinical Trials","Funded","False","True","Co-Investigator","A multi-center, randomized, double-blind, placebo-controlled, parallel-group study of 3 fixed doses of EAA-090 in adult outpatients with neuropathic pain associated with diabetic neuropathy.","Dr I Hramiak","Dr T Paul","$2,271,676.00"
"Paul, Terri","Medicine","2005","2005","Clinical Trials","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo-controlled, parallel group, 16-week MICARDIS (160) mg) tablets, Proof-of-Concept Study, evaluating insulin sensitivity in overweight or obese, non-diabetic, normotensives, using the oral glucose tolerance test, with a clamp sub-group.","Dr I Hramiak","Dr T Paul","$51,192,111.00"
"Paul, Terri","Medicine","2002","2006/12","Clinical Trials","Funded","False","True","Co-Investigator","A one-year, open, randomized, parallel, three-arm study comparing Exubera (insulin dry powder pulmonary inhaler) vs. Avandia (rosiglitazone maleate) as add-on therapy vs. Exubera substitution of sulfonylurea in patients with type 2 diabetes, poorly controlled on combination sulfonylurea and Metformin treatment.","Dr I Hramiak","Dr T Paul","$68,193,080.00"
"Paul, Terri","Medicine","2004","2008","Clinical Trials","Funded","False","True","Co-Investigator","Efficacy and safety of inhaled human insulin (EXUBERA) compared with subcutaneous human insulin therapy of adult subject with type 1 or type 2 diabetes mellitus and chronic obstructive pulmonary disease: A one-year, multicentre, randomized, outpatient, open-label, parallel-group comparative trial.","Dr I Hramiak","Dr T Paul","$19,742,139.00"
"Paul, Terri","Medicine","2004","2008","Clinical Trials","Funded","False","True","Co-Investigator","Efficacy and safety of inhaled human insulin (EXUBERA) compared with subcutaneous human insulin in the therapy of adult subject with type 1 or type 2 diabetes mellitus and chronic asthma: a one-year, multicentre, randomized, outpatient, open-label, parallel-group comparative trial.","Dr I Hramiak","Dr T Paul","$25,014,622.00"
"Paul, Terri","Medicine","2004","2006/06","Clinical Trials","Funded","False","True","Co-Investigator","Safety and efficacy of Exenatide in patients with type 2 diabetes using Thiazlidinediones or Thiazolidinediones and Metformin.","Dr I Hramiak","Dr T Paul","$13,234,441.00"
"Paul, Terri","Medicine","2005","2009","Clinical Trials","Funded","False","True","Co-Investigator","A multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone.","Dr I Hramiak","Dr T Paul","$43,209,581.00"
"Paul, Terri","Medicine","2005","2010","Clinical Trials","Funded","False","True","Co-Investigator","Multicenter, double-blind, randomized, placebo-controlled, dose ranging Phase 2 Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of the DPPIV Inhibitor R00730699 in Patients with Type 2 Diabetes, Who are Treated with a Stable Dose of Metformin.","Dr I Hramiak","Dr T Paul","$72,451,715.00"
"Paul, Terri","Medicine","2006","2006/04","Clinical Trials","Funded","False","True","Co-Investigator","A Multicentre, open label, non-randomised, safety study in subjects using insulin detemir for the treatment of insulin dependent Type 1 or Type 2diabetes mellitus. The PREDICTIVE (Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Viability Evaluation) Study.","Dr I Hramiak","Dr T Paul","$18,393,133.00"
"Paul, Terri","Medicine","2006/03","2007/06","Clinical Trials","Funded","False","True","Co-Investigator","A multicenter, double-blind, randomized, placebo-controlled dose ranging-phase 2 study to investigate efficacy, safety, tolerability, and pharmacokinetics of RO4389620 in patients with type 2 diabetes mellitus treated with a stable dose of metformin. (BM18249).","Dr I Hramiak","Dr T Paul","$69,795,829.00"
"Paul, Terri","Medicine","2006/06","2007/12","Clinical Trials","Funded","False","True","Co-Investigator","A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249. (BM18249 Ext).","Dr I Hramiak","Dr T Paul","$48,534,577.00"
"Paul, Terri","Medicine","2006/05","2010/12","Clinical Trials","Funded","False","True","Co-Investigator","Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors (CRESCENDO).","Dr I Hramiak","Dr T Paul","$12,815,341.00"
"Paul, Terri","Medicine","2006/05","2007/09","Clinical Trials","Funded","False","True","Co-Investigator","Liraglutide effect and action in diabetes (lead 4): effect on glycemic control of liraglutide in combination with Rosiglitazone plus metformin versus Rosiglitazone plus metformin in type 2 diabetes (a twenty-six week double-blind parallel trial to investigate safety and efficacy).","Dr I Hramiak","Dr T Paul","$71,631,574.00"
"Paul, Terri","Medicine","2006","2008","Clinical Trials","Funded","False","True","Co-Investigator","Target glycemic control and the incidence of documented symptomatic hypoglycemia in insulin naïve subjects with type 2 diabetes failing on oral hypoglycemic agent(s) and treated with LANTUS (insulin glargine) or LEVEMIR (insulin detemir): multicenter, multicountry, randomized, open-label, parallel-group study L2T3 (Lantus Levemir Treat-To-Target).","Dr I Hramiak","Dr T Paul","$64,707,309.00"
"Paul, Terri","Medicine","2007","2008","Clinical Trials","Funded","False","True","Co-Investigator","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or in Combination With Metformin).","Dr I Hramiak","Dr T Paul","$28,051,949.00"
"Paul, Terri","Medicine","2004","2004","Clinical Trials","Funded","False","False","Co-Investigator","Peri-Operative Steroid Coverage: A randomized trial of individualized and lower doses of Hydrocortisone.","Dr K Zarnke","Dr T Paul","$16,831,737.00"
"Paul, Terri","Medicine","2004","2004","Clinical Trials","Funded","False","True","Co-Investigator","A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Rosigliatzone in Combination with Glimepiride Compared to Climepirided Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Non TZD Oral Monotherapy. Funding:","Dr R McManus","Dr T Paul","$35,690,359.00"
"Paul, Terri","Medicine","2004","2006","Clinical Trials","Funded","False","True","Co-Investigator","Action in Diabetes and Vascular Disease: A factorial randomised trial of blood pressure lowering with fixed low-dose perindopril-indapamide combination and intensive glucose control with modified-release gliclazide-based regimen for the prevention of vascular disease among high risk individuals with type 2 diabetes.","Dr N W Rodger","Dr T Paul, Dr R McManus","$8,756,627.00"
"McManus, Ruth","Medicine","1993","1998","Grants","Funded","True","False","Principal Investigator","Efficacy and Metabolic effects of antihypertensive agents in high renin vs low renin Hypertension","McManus","Drs JD Spence, PF Mercer, MG Cherian, JT Hamilton and Anna Hocking PhD student","$42,039,909.00"
"McManus, Ruth","Medicine","1995","1997","Grants","Funded","True","False","Principal Investigator","Effects of Lactation on insulin sensitivity and Visceral fat in women with a history of gestational diabetes","McManus","Drs M Edmonds, L Harker, B Atack, M Maruncic and L Brownscombe","$21,401,502.00"
"McManus, Ruth","Medicine","1996","1998","Grants","Funded","True","False","Principal Investigator","Lipid Clinic Outcomes research project","McManus","Dr D Miller","$28,477,309.00"
"McManus, Ruth","Medicine","1998","1999","Grants","Funded","True","False","Principal Investigator","Patient Education in atherosclerosis risk reduction clinic","McManus","","$17,918,762.00"
"McManus, Ruth","Medicine","2000","2002","Grants","Funded","True","False","Principal Investigator","Efficacy of metformin and clomiphene citrate on ovulation induction in oligomenorrheic women with polycystic ovarian syndrome.","McManus","Drs Killinger, Power, Nisker","$25,684,261.00"
"McManus, Ruth","Medicine","1998","1998","Grants","Funding not required","True","False","Principal Investigator","Survey of Alternative Medicine use in a Diabetes Clinic","McManus","Drs E Toth, D Miller","$7,460,611.00"
"McManus, Ruth","Medicine","","","Grants","Funded","True","False","Co-Principal Investigator","Chronic Exercise responses to a stair climber program in pregnant women (gestational diabetes women)","M Mottola","McManus","$31,849,541.00"
"McManus, Ruth","Medicine","2002","2003","Grants","Funded","False","False","Principal Investigator","Effects of Glucose, Insulin, potassium infusion in angioplasty outcomes","McManus","Drs W Tsui, P Teefy, D Almond, D Massel, K Sridar, A Gupta, A Dick, B Kidwani","$6,974,137.00"
"McManus, Ruth","Medicine","2002","2005","Grants","Funded","True","False","Principal Investigator","Diabetes Prevention London (1.): population survey","McManus","L Stitt, G Bargh","$3,212,038.00"
"McManus, Ruth","Medicine","2002","2007","Grants","Funded","True","False","Co-Investigator","Nutrition and Exercise Lifestyle Intervention Program (NELPI) for overweight and obese Aboriginal and Non-Aboriginal pregnant and postpartum women","M Mottola","McManus, Gratton, Giroux, Harris, Hammond, Sopper","$10,648,250.00"
"McManus, Ruth","Medicine","2004","","Grants","Funded","True","False","Principal Investigator","Free Fatty Acid effects on insulin resistance in skeletal muscle and adipose tissue","McManus","Drs T Y Lee, Mahon, Hramiak, Joy","$20,637,099.00"
"McManus, Ruth","Medicine","2006","2009","Grants","Funded","True","False","Co-Investigator","Capacity-building and participatory research development of a community-based Nutrition and Exercise lifestyle intervention program (NELIP) for pregnant and postpartum Aboriginal Women.","Dr M Mottola","McManus, Gratton, Giroux, Harris, Hammond, Sopper, Leiter","$31,111,878.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Principal Investigator","Glycemic control evaluation: national efficacy and safety of an insulin resistance reducing agent study. Genesis trial","McManus","J-P Halle, L Leiter, S Ross","$34,558,498.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Principal Investigator","Insulin Lispro: FIT (flexible Insulin Therapy)","McManus","G Bailey","$41,992,711.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Principal Investigator","Insulin Delivery using a new Lilly 30. reusable pen design: Humapen","McManus","H Tildesley","$1,571,235.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Co-Investigator","Use of insulin lispro mixture in patients with Type 2 diabetes with oral agent inadequacy","McManus","","$66,118,510.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Principal Investigator","CanADA: the Atorvastatin trial in Type 2 diabetes (a multicentre, 12 month, open-label study of atorvastatin 10-80 mg in patients with Type 2 diabetes, dyslipidemia, and symptomatic athersclerosis:efficacy and frequency of achieving LDL-cholesterol guidleine target levels in the presence of coronary heart disease or other atherosclerotic disease, identified by symptoms of angina)","McManus","Dr L Leiter","$42,704,364.00"
"McManus, Ruth","Medicine","","","Grants","Funded","True","False","Principal Investigator","Stop-NIDDM: A joint Canadian-german-Scandanavian controlled randomized clinical trial on the efficacy of acarbose to delay or prevent the development of NIDDM in subjects with IGT","Dr W Rodger","McManus, J-L Chaisson","$68,316,108.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Collaborator","A multicentre, double-blind placebo-controlled study investigating the efficacy and safety of Prandase (Acarbose) (Bay g 5421) in the treatment of elderly patients with non-insulin-dependent diabetes mellitus","Dr W Rodger","McManus, Dr R Josse","$71,406,862.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Collaborator","A multicentre, double-blind, placebo-controlled study investigating the efficacy and safety of Miglitol (Bay m 1099) in combination with metformin as compared to monotherapy in the treatment of patients with non-insulin-dependent diabetes mellitus (Type II) inadequately controlled with diet alone","Dr W Rodger","McManus, Dr J-L Chaisson","$22,159,003.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Collaborator","A double-blind, placebo-controlled, multicentre, phase II study to evaluate the effects of Pramlintide (AC 137) on glycemic control as determined by glycated hemoglobin in patients with Type II diabetes mellitus","Dr W Rodger","McManus","$17,919,623.00"
"McManus, Ruth","Medicine","","","Grants","Funded","True","False","Principal Investigator","HOPE (Heart outcomes prevention evaluation study).","","","$14,679,899.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Principal Investigator","Use of Insulin Lispro Low mixture (LM) compared to NPH twice daily in the treatment of Type 2 diabetes","McManus","Dr L Grossman","$36,193,401.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Principal Investigator","Pioglitazone compared with placebo in non-drug treated patients with Type 2 Diabetes","McManus","","$70,891,671.00"
"McManus, Ruth","Medicine","2000","2008/05","Grants","Funded","True","False","Co-Investigator","Advance Study: A factorial randomized trial of blood pressure lowering with fixed low-dose perindopril-indapamide combination and intensive glucose control with a modified-release glicalzide-based regimen for the prevention of vascular disease among high risk individuals with type 2 diabetes. Sponsor:","Dr W Rodger","Local coinvestigator: Dr R McManus Dr P Hamet, study PI","$50,584,753.00"
"McManus, Ruth","Medicine","2001","2002","Grants","Funded","False","False","Co-Investigator","H5N-MC-GFFH study: a Phase 11 randomized, parallel study: evaluation of the dose response relationship of LY307161 SR on fasting an postprandial blood glucose in patients with Type 2 diabetes","","","$30,845,996.00"
"McManus, Ruth","Medicine","2002","2008","Grants","Funded","False","False","Co-Investigator","DIRECT trials. Effects of Candesartan cilexetil (Candesartan) on diabetic retinopathy","McManus (local PI)","Dr J Gonder","$32,802,443.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Principal Investigator","Mercury Trial. An open label, randomized, multicentre, phase 111B parallel group switching study to compare the efficacy and safety of lipid lowering agents atorvastatin, pravastatin, simvastatin, cerivastsatin and rosuvastatin in subjects with type 11a and 11b hypercholesterolemia","McManus","","$67,159,843.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Co-Investigator","Discovery trial: Direct Statin Comparison of LDL-C values: an evaluation of rosuvastatin therapy","McManus","Dr J Davignon","$29,156,888.00"
"McManus, Ruth","Medicine","","","Grants","Funded","False","False","Principal Investigator","R-03-532. A multicentre randomized double-blind parallel group placebo controlled clinical evaluation of rosiglitazone in combination with glimepiride compared to glimepiride plus placebo for 24 weeks in subjects with Type 2 diabetes mellitus who are controlled on non-TZD monotherapy","McManus","Dr LE Porter","$56,522,437.00"
"McManus, Ruth","Medicine","2004","2008/01","Grants","Funded","False","False","Co-Investigator","Reduction in the Occurrence of Center-Threatening diabetic Macular Edema (Roboxistaurin Mesylate)","Dr J Gonder","Co Investigator McManus","$43,223,546.00"
"McManus, Ruth","Medicine","2005","2008/03","Grants","Funded","False","False","Principal Investigator","Approach Study: A phase II, 18 month multicentre, randomized, double-blind, active-controlled clinical trial to compare rosiglitazone versus glipizide on the progression of atherosclerosis in subjects with Type 2 diabetes and cardiovascular disease.","McManus (local PI)","Local Coinvestigators: Dr P Teefy, K Sridhar","$5,608,492.00"
"Rehman, Faisal","Medicine","2007","2010","Grants","Funded","False","True","Co-Investigator","Evaluation of Cinacalcet therapy to lower cardiovascular events","Muirhead, N","Rehman, F","$26,108,522.00"
"Rehman, Faisal","Medicine","2006","2011","Grants","Funded","False","False","Co-Investigator","Ace inhibition for the preservation of renal function and patient survival in kidney transplantation","Knoll, G","Rehman, F","$10,219,759.00"
"Rehman, Faisal","Medicine","2006","2010","Grants","Funded","False","True","Co-Investigator","A prospective, randomized, open-label, pilot study to compare the effect on carotid atherosclerosis of a tacrolimus based regimen with conversion from a tacrolimus to a sirolimus-based regimen at 3-4 months post-transplant in de novo renal transplant recipients","House.A","Rehman, F","$8,261,213.00"
"Rehman, Faisal","Medicine","2006","2009","Grants","Funded","False","True","Co-Investigator","A randomized, open-label, comparative evaluation of the safety and efficacy of Sirolimus versus cyclosporine when combined in a regimen containing Basiliximab, Mycophenolate Mofetil, and corticosteroids in primary de novo renal allograft recipients","Muirhead, N","Rehman, F","$29,666,693.00"
"Rehman, Faisal","Medicine","2005","2008","Grants","Funded","False","True","Co-Investigator","A two-year extension to a one-year, multicentre, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced dose or full dose Neoral and corticosteroids versus mycophenolate mofetil (MMF, Cellcept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipients","Muirhead, N","Rehman, F","$23,824,629.00"
"Rehman, Faisal","Medicine","2005","2008","Grants","Funded","False","True","Co-Investigator","A trial to reduce cardiovascular events with ARANESP therapy","Muirhead, N","Rehman, F","$55,089,112.00"
"Rehman, Faisal","Medicine","2005","2007","Grants","Funded","False","True","Co-Investigator","A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation.","Muirhead, N","Rehman, F","$53,647,480.00"
"Rehman, Faisal","Medicine","2005/07","2007/06","Grants","Funded","True","False","Co-Investigator","Better use of Bibliographic Databases for Kidney Diseases","Garg, A","McKibbon, A; Rehman, F; Wilczynski, NL","$29,318,893.00"
"Rehman, Faisal","Medicine","2002","2004","Grants","Funded","False","True","Co-Investigator","A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to Sirolimus 316 versus continued use of calcineurin inhibitors in renal allograft recipients","Muirhead, N","Rehman, F","$42,331,299.00"
"Rehman, Faisal","Medicine","2004","2006","Grants","Funded","False","True","Co-Investigator","A multi-centre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of ALISKIREN on proteinuria when added to standardized losartan therapy and optional antihypertensive therapy in patients with hypertension and Type II diabetes mellitus","Muirhead, N","Rehman, F","$74,627,988.00"
"Rehman, Faisal","Medicine","2003","2005","Clinical Trials","Funded","False","True","Co-Investigator","A double-blind, randomized, dose-ranging, multi-centre, phase IIIB study to evaluate the efficacy and safety of high doses of Candesartan Cilexetil (ATACAND) on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria","Muirhead, N","Rehman, F","$28,514,740.00"
"Rehman, Faisal","Medicine","2004","2006","Grants","Funded","False","True","Co-Investigator","An open label, randomized, multi-centre, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis","Muirhead, N.","Rehman, F","$35,295,061.00"
"Rehman, Faisal","Medicine","2004","2006","Grants","Funded","False","True","Co-Investigator","An open label, randomized, multi-centre, parallel group study to demonstrate correction of anemia using subcutaneous injections of RO0503821 every 4-weeks in patients with chronic kidney disease who are not on dialysis","Muirhead, N","Rehman, F","$51,071,484.00"
"Rehman, Faisal","Medicine","2004","2006","Grants","Funded","False","True","Co-Investigator","An open-label, randomized, controlled, open-label, multi-centre, parallel group study to demonstrate the efficacy and safety of RO0503821 when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis","Muirhead, N","Rehman, F","$71,220,910.00"
"Hackam, Daniel","Medicine","2004/04","2006/04","Grants","Funded","True","False","Co-Investigator","Statins and Sepsis","Donald A Redelmeier","William Sibbald, Daniel Hackam, Alex Kopp, Muhammad Mamdani","$40,020,342.00"
"Hackam, Daniel","Medicine","2004/07","2005/07","Grants","Funded","True","False","Principal Investigator","Statins and ischemic complications in peripheral vascular disease","Daniel Hackam","Mohammed Al-Omran, Chaim Bell, Muhammad Mamdani","$70,885,689.00"
"Rehman, Faisal","Medicine","2005","2007","Grants","Funded","False","True","Co-Investigator","An open-label, multi-centre study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia","Muirhead, N","Rehman, F","$37,510,873.00"
"Rehman, Faisal","Medicine","2004","2006","Grants","Funded","False","True","Co-Investigator","A one-year, multicentre, partially blinded, double dummy, randomized study to evaluate the efficacy of FTY720 combined with reduced dose or full dose neoral and corticosteroids versus mycophenolate mofetil (MMF, Cellcept) combined with full dose Neoral and corticosteroids, in de novo adult renal transplant recipients","Muirhead, N","Rehman, F","$3,908,565.00"
"Rehman, Faisal","Medicine","2004","2007","Clinical Trials","Funded","False","True","Co-Investigator","A randomized, prospective, double-blinded, placebo-controlled (Sham Controlled) study to evaluate the safety and effectiveness of the Adacolumn Apheresis system for the treatment of moderate to severe ulcerative colitis","Ponich, T; Barnett, William","Rehman, F","$25,176,560.00"
"Rehman, Faisal","Medicine","2004","2007","Grants","Funded","False","False","Principal Investigator","Predictive value of asymptomatic elevated troponins in renal failure; A study to define the relationship between serum troponin values in asymptomatic patients with renal failure and cardiovascular outcomes","Rehman, F","","$59,589,924.00"
"Rehman, Faisal","Medicine","2003","2006","Clinical Trials","Funded","False","True","Co-Investigator","A study to evaluate the use of ROSUVASTIN in subjects on regular hemodialysis; an assessment of survival and cardiovascular events. A double-blind, randomized, multi-centre, Phase III, parallel group study to compare the effects of FOSUVASTIN (10mgs oral) with placebo; an assessment of survival and cardiovascular events when given to subjects with end stage renal failure on chronic hemodialysis treatment","Muirhead, N","Rehman, F","$49,255,296.00"
"Rehman, Faisal","Medicine","2003","2005","Grants","Funded","False","True","Co-Investigator","An active surveillance plan to prospectively monitor the incidence and developmental history of PRCA among patients receiving Epoetin Alfa Therapy","N. Muirhead","","$49,149,951.00"
"Rehman, Faisal","Medicine","2003","2005","Grants","Funded","False","True","Co-Investigator","A double-blind, randomized dose-ranging, multi-centre, phase IIIB study to evaluate efficacy and safety of high doses of CANDESARTAN CILEXETIL on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria","N. Muirhead","","$46,763,740.00"
"Rehman, Faisal","Medicine","2002","2008","Grants","Funded","False","False","Co-Investigator","A study of Folic Acid for vascular outcome reduction in transplantation","House, A","Rehman, F","$30,296,311.00"
"McFadden, Robin","Medicine","1983/07","1986/06","Grants","Funded","False","False","Principal Investigator","Salary Support.","Dr R McFadden","","$33,490,219.00"
"McFadden, Robin","Medicine","1983/11","1984/06","Grants","Funded","False","False","Principal Investigator","Technician Salary Support.","Dr R McFadden","","$6,309,195.00"
"McFadden, Robin","Medicine","1983","1983/12","Grants","Funded","False","False","Principal Investigator","Material & Supplies.","Dr R McFadden","","$29,768,464.00"
"McFadden, Robin","Medicine","1984","1984/02","Grants","Funded","False","False","Principal Investigator","Equipment Support.","Dr R McFadden","","$71,122,212.00"
"McFadden, Robin","Medicine","1984","1984/04","Grants","Funded","False","False","Principal Investigator","Equipment Support.","Dr R McFadden","","$55,764,038.00"
"McFadden, Robin","Medicine","1984/07","1985/06","Grants","Funded","False","False","Principal Investigator","Technician Salary Support.","Dr R McFadden","","$45,287,184.00"
"McFadden, Robin","Medicine","1985/05","1987/06","Grants","Funded","False","False","Principal Investigator","Granulomatous Alveolitis: Lymphocyte Migration & Adherence.","Dr R McFadden","","$73,504,816.00"
"McFadden, Robin","Medicine","1986/04","1987/06","Grants","Funded","False","False","Co-Investigator","MRI Detection of Lung Injury from Cancer Treatments.","Dr R McFadden Dr J Skillings","","$22,797,568.00"
"McFadden, Robin","Medicine","1986/05","1987/12","Grants","Funded","False","False","Co-Investigator","NMR T1 and T2 Values of the Normal Lung.","Dr R McFadden Dr T Carr","","$31,811,642.00"
"McFadden, Robin","Medicine","1986/07","1987/12","Grants","Funded","False","False","Principal Investigator","Beryllium-Induced Lung Disease.","Dr R McFadden","","$68,101,641.00"
"McFadden, Robin","Medicine","1987/07","1988/03","Grants","Funded","False","False","Principal Investigator","Lymphocytic Alveolitis:Mechanisms of Lymphocyte Recruitment to the Lung.","Dr R McFadden","","$74,876,482.00"
"McFadden, Robin","Medicine","1987","1987/11","Grants","Funded","False","False","Principal Investigator","Visual Assay of Lymphocyte Migration.","Dr R McFadden","","$62,732,564.00"
"McFadden, Robin","Medicine","1987","1987/12","Grants","Funded","False","False","Principal Investigator","T Cell Subset Specificity and Migration Reactions.","Dr R McFadden","","$37,058,251.00"
"McFadden, Robin","Medicine","1988/09","1989/06","Grants","Funded","False","False","Principal Investigator","Control of Lymphocyte Accumulation by Chemokinetic Lymphokines.","Dr R McFadden","","$64,589,493.00"
"McFadden, Robin","Medicine","1989/07","1992/06","Grants","Funded","False","False","Co-Investigator","Interstitial Lung Disease Role for Chemokinetic Mediators.","Dr R McFadden Dr L Fraher","","$34,131,397.00"
"McFadden, Robin","Medicine","1991/07","1992/06","Grants","Funded","False","False","Principal Investigator","Signal Transduction Mechanisms of Cytokinetic Agents and Inhibitors in Lymphocyte.","Dr R McFadden","","$21,922,867.00"
"McFadden, Robin","Medicine","1991/07","1992/06","Grants","Funded","False","False","Principal Investigator","Signal Transduction Mechanisms of Cytokinetic Agonistis and Inhibitors in T Lymphocytes.","Dr. R McFadden","","$54,857,288.00"
"McFadden, Robin","Medicine","1992/07","1995/09","Grants","Funded","False","False","Co-Investigator","Lymphocyte Recruitment in the Interstitial Lung Disease.","Dr R McFadden Dr L Fraher","","$5,931,630.00"
"McFadden, Robin","Medicine","1992/09","1993/06","Grants","Funded","False","False","Co-Investigator","Personnel Training Award.","Dr R McFadden Mr P Borron","","$52,637,605.00"
"McFadden, Robin","Medicine","1993/07","1995/06","Grants","Funded","False","False","Principal Investigator","Surfactant-Associated Proteins and the Immune System.","","Dr L Fraher Dr J Lewis","$59,013,587.00"
"McFadden, Robin","Medicine","1993/07","1994/06","Grants","Funded","False","False","Co-Investigator","Personnel Training Award.","Dr R McFadden Mr P Borron","","$12,808,653.00"
"McFadden, Robin","Medicine","1993/07","1994/06","Grants","Funded","False","False","Co-Investigator","Personnel Training Award.","Dr R McFadden Mr. P. Borron","","$494,369.00"
"McFadden, Robin","Medicine","1994/07","1995/06","Grants","Funded","False","False","Co-Investigator","Personnel Training Award.","Dr R McFadden Mr P Borron","","$2,790,397.00"
"McFadden, Robin","Medicine","1994/07","1995/06","Grants","Funded","False","False","Co-Investigator","Personnel Training Award.","Dr R McFadden Mr P Borron","","$70,379,841.00"
"McFadden, Robin","Medicine","1995/07","1996/06","Grants","Funded","False","False","Co-Investigator","Personnel Training Award.","Dr R McFadden Mr P Borron","","$3,776,102.00"
"McFadden, Robin","Medicine","1995/07","1996/06","Grants","Funded","False","False","Co-Investigator","Personnel Training Award.","Dr R McFadden Mr P Borron","","$28,837,674.00"
"McFadden, Robin","Medicine","1989/01","1990/12","Grants","Funded","False","False","Co-Investigator","Clavulin in COLD Exacerbation Trial.","Dr R McFadden Dr O Hammerberg","","$72,475,883.00"
"McFadden, Robin","Medicine","1999/01","1999/06","Grants","Funded","False","False","Principal Investigator","New Quinolones in Acute Exacerbations of Chronic Bronchitis.","","","$2,915,934.00"
"Teefy, Patrick","Medicine","2004","2004","Grants","Funded","False","False","Co-Investigator","Development of web-based cardiology teaching modules","","","$14,930,531.00"
"Teefy, Patrick","Medicine","1995","1995","Grants","Funded","False","False","Principal Investigator","Grant for Collateral Blood Flow Reserve","","","$18,016,150.00"
"Teefy, Patrick","Medicine","","","Grants","Funded","False","False","Principal Investigator","Educational grant to aid in the development of Computer-Based Hemodynamic Teaching File.","","","$23,977,716.00"
"Teefy, Patrick","Medicine","","","Grants","Funded","False","False","Principal Investigator","Assisting in Treatment of Serious Heart Disease in Belarus.","","","$51,238,639.00"
"Dresser, George","Medicine","2008/03","2009/05","Grants","Funded","True","False","Principal Applicant","RATCHET: Risk assessment and treat compliance in hypertension education trial","Dr George Dresser","Dr Bryan Har","$20,981,424.00"
"Dresser, George","Medicine","2008/05","2008/11","Grants","Funded","False","True","Co-Investigator","Oral Bioavailability of Iron and Calcium from P-114","Dr David Bailey","","$48,456,689.00"
"Dresser, George","Medicine","2005/10","2008/09","Grants","Funded","True","False","Principal Applicant","Drug disposition in intestinal disease","Dr George Dresser","Dr David Bailey Dr Richard Kim","$55,386,836.00"
"Dresser, George","Medicine","2006/03","2007/10","Grants","Funded","True","False","Principal Applicant","Use of probiotics for the prevention of c difficile associated diarrhea","Dr George Dresser","Dr Z Hussain, Dr M John, Dr R Reyes, Dr G Reid","$24,738,070.00"
"Dresser, George","Medicine","2005/07","2007/06","Grants","Funded","True","False","Principal Applicant","Drug disposition in celiac disease","Dr George Dresser","Dr David Bailey","$9,499,183.00"
"Dresser, George","Medicine","2004/04","2007/04","Grants","Funded","True","False","Co-Investigator","Dietary constituents and drug uptake transporters","Dr David Bailey","","$64,628,761.00"
"Dresser, George","Medicine","2002/12","2003/12","Grants","Funded","True","False","Principal Investigator","Grapefruit juice and fexofenadine interaction: naringin as an inhibitor of drug uptake transporters","Dr George Dresser","","$66,320,849.00"
"Dresser, George","Medicine","2002/12","2004/12","Grants","Funded","True","False","Principal Investigator","Naringin as an inhibitor of fexofenadine uptake transport: comparison with grapefruit juice","Dr George Dresser","Dr David Bailey","$51,051,155.00"
"Dresser, George","Medicine","2000/10","2003/09","Grants","Funded","True","False","Principal Investigator","In vivo interaction of juice constituents with fexofenadine in wild type P-GP deficient mice","Dr George Dresser","Dr David Bailey","$12,167,382.00"
"Dresser, George","Medicine","2001/03","2003/03","Grants","Funded","True","False","Principal Investigator","Effects of common herbal preparations on p-glycoprotein mediated drug transport","Dr George Dresser","","$59,163,333.00"
"Wisenberg, Gerald","Medicine","2008/07","2010/06","Grants","Funded","True","False","Principal Applicant",": Evaluation in a large animal model of the use of Akt enhanced endothelial progenitor cells for augmenting healing after myocardial infarction","Gerald Wisenberg","Frank Prato, Qingping Feng","$49,559,205.00"
"Lazo Langner, Alejandro","Medicine","2008","2011","Grants","Funded","True","False","Co-Applicant","Etiologic role of inflammation, thrombophilia and fibrinolysis in the post-thrombotic syndrome: the Bio-SOX study","Susan R. Kahn, Philip Wells","David R. Anderson, Nancy Carson, Michael J. Kovacs, Marc Rodger, Stan Shapiro, Vicky Tagalakis, Stewart Whitman","$49,772,401.00"
"Lazo Langner, Alejandro","Medicine","2008","2011","Grants","Funded","True","False","Co-Applicant","Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism (SOME trial): a Study using Comprehensive Abdomen/Pelvis Computed Tomography","Marc Carrier, Marc A. Rodger","Agnes Lee, Tim Ramsay, Douglas Coyle,Vicky Tagalakis, Gregoire Le Gal, Hardy Tao, Philip Wells","$53,144,657.00"
"Lazo Langner, Alejandro","Medicine","2008/04","2011/03","Grants","Funded","True","False","Co-Applicant","Personalized Medicine and Optimal Warfarin Anticoagulant Therapy in Ontario","Richard B. Kim, Philip Wells","Ute I. Schwarz, Guang Yong Zou","$34,473,621.00"
"Lazo Langner, Alejandro","Medicine","2007/10","2009/09","Grants","Funded","True","False","Co-Investigator","Effect of erythropoietin (EPO) on breast cancer metastasis","Anargyros Xenocostas","Alison L. Allan","$42,068,277.00"
"Hegele, Robert","Medicine","1990/07","1995/06","Grants","Funded","True","False","Principal Investigator","McDonald Scholarship","Robert A. Hegele","","$18,141,571.00"
"Hegele, Robert","Medicine","2007/09","2010/08","Grants","Funded","True","False","Principal Investigator","Schulich Support for LRGC Microarray Core Facility","Robert A. Hegele","","$59,399,726.00"
"Bosma, Karen","Medicine","2007/03","2010/03","Grants","Funded","True","False","Principal Applicant","The Influence of ventilator mode and patient-ventilator interaction on sleep quality in the intensive care unit","Dr. Karen Bosma","Dr. Femida Gwadry-Sridhar Dr. Mithu Sen","$5,092,396.00"
"Bosma, Karen","Medicine","2007/01","2010/12","Grants","Funded","True","False","Principal Applicant","The influence of ventilator mode and patient-ventilator interaction on sleep quality in the intensive care unit","Dr. Karen Bosma","Dr. Mithu Sen, Dr. Femida Gwadry-Sridhar","$34,601,267.00"
"McManus, Ruth","Medicine","2008/05","2010/05","Grants","Funded","True","False","Co-Investigator","A Nutrition and Exercise Lifestyle Program (NELIP) for women with gestational diabetes","Dr M Mottola","Drs S Harris, H Prapavessis, I Giroux, J Hammond, R Gratton. Ms Margie Davenport PhD student","$58,939,696.00"
"Chow, Lawrence","Medicine","1989","1990","Grants","Funded","True","False","Principal Investigator","“Functional distinctions of immunocellular infiltrates in virus-induced murine myocarditis”","Chow LH","McManus BM","$7,099,196.00"
"Chow, Lawrence","Medicine","1990","1992","Grants","Funded","True","False","Principal Investigator","“Cellular immunity in mouse myocarditis: adoptive transfer into SCID mice""","Chow LH","","$3,904,032.00"
"Chow, Lawrence","Medicine","1990","1991","Grants","Funded","True","False","Principal Investigator","“Equipment grant for experimental studies on virus-induced myocarditis in mice”","Chow LH","","$16,461,872.00"
"Chow, Lawrence","Medicine","1991","1992","Grants","Funded","True","False","Principal Investigator","“Antimyosin cardiac imaging and gallium scanning in patients with suspected myocarditis: selection for re-biopsy”","Chow LH","","$28,456,607.00"
"Chow, Lawrence","Medicine","1992","1995","Grants","Funded","True","False","Principal Investigator","“Cellular immunity in mouse myocarditis"" (Grant Renewal)","Chow LH","","$20,347,868.00"
"Chow, Lawrence","Medicine","1992","1993","Grants","Funded","True","False","Principal Investigator","“Equipment grant for virus laboratory”","Chow LH","","$42,278,929.00"
"Chow, Lawrence","Medicine","1994","1995","Grants","Funded","True","False","Principal Investigator","“The role of host immunity in allograft arteriopathy”","Chow LH","","$64,638,280.00"
"Chow, Lawrence","Medicine","1996","1997","Grants","Funded","True","False","Principal Investigator","“Gene therapy of allograft vascular disease”","Chow LH","Pickering JG","$56,111,481.00"
"Chow, Lawrence","Medicine","1996","1998","Grants","Funded","True","False","Principal Investigator","“The immunopathogenesis of graft vascular disease”","Chow LH","","$36,577,830.00"
"Chow, Lawrence","Medicine","1998","2001","Grants","Funded","True","False","Principal Investigator","“The immunopathogenesis of graft vascular disease” (Grant Renewal)","Chow LH","","$9,338,542.00"
"Huff, Murray","Medicine","1982","1983","Grants","Funded","True","False","Principal Investigator","Role of apolipoprotein C and E in the catabolism of triglyceride-rich lipoproteins","Huff MW","","$48,736,701.00"
"Huff, Murray","Medicine","1983","1984","Grants","Funded","True","False","Principal Investigator","Studies of apolipoproteins C and triglyceride-rich lipoproteins","Huff MW","","$36,221,003.00"
"Huff, Murray","Medicine","1984","1985","Grants","Funded","True","False","Principal Investigator","Characterization and metabolism of very low density lipoprotein formation","Huff MW","","$4,605,912.00"
"Huff, Murray","Medicine","1985","1988","Grants","Funded","True","False","Principal Investigator","Regulation of low density lipoprotein formation","Huff MW","","$23,386,358.00"
"Huff, Murray","Medicine","1988","1991","Grants","Funded","True","False","Principal Investigator","Regulation of low density lipoprotein formation","Huff MW","","$2,031,912.00"
"Huff, Murray","Medicine","1991","1994","Grants","Funded","True","False","Principal Investigator","Regulation of low density lipoprotein formation","Huff MW","","$19,837,872.00"
"Huff, Murray","Medicine","1992","1992","Grants","Funded","True","False","Principal Investigator","Equipment: Ultracentrifuge Rotor","Huff MW","","$1,882,180.00"
"Huff, Murray","Medicine","1994","1997","Grants","Funded","True","False","Principal Investigator","Regulation of lipoprotein metabolism","Huff MW","","$1,124,107.00"
"Huff, Murray","Medicine","1997","2000","Grants","Funded","True","False","Principal Investigator","Regulation of lipoprotein metabolism: Relationship to atherosclerosis","Huff MW","","$9,318,696.00"
"Huff, Murray","Medicine","2000","2005","Grants","Funded","True","False","Principal Investigator","Regulation of lipoprotein metabolism: Relationship to atherosclerosis","Huff MW","","$55,496,118.00"
"Huff, Murray","Medicine","2001","2006","Grants","Funded","True","False","Principal Investigator","Vascular Cell Responses in Atherosclerosis: A Genomics Approach","Huff MW","RA Hegele, JG Pickering, AR Lucas, RD Feldman, SSG Ferguson","$44,052,985.00"
"Huff, Murray","Medicine","2005","2010","Grants","Funded","True","False","Principal Investigator","Regulation of lipoprotein metabolism: Relationship to atherosclerosis","Huff MW","","$57,468,109.00"
"Huff, Murray","Medicine","2006","2011","Grants","Funded","True","False","Principal Investigator","Cellular Programs and Responses in Atherosclerosis: Linking Genotype to Phenotype","Huff MW","JG Pickering, RA Hegele, SSG Ferguson","$8,925,700.00"
"Huff, Murray","Medicine","1983","1985","Grants","Funded","True","False","Principal Investigator","Metabolism of apolipoproteins C and B in man","Huff MW","","$48,352,333.00"
"Huff, Murray","Medicine","1985","1987","Grants","Funded","True","False","Principal Investigator","Metabolism of apolipoproteins C, B and E in man","Huff MW","","$18,287,511.00"
"Huff, Murray","Medicine","1987","1989","Grants","Funded","True","False","Principal Investigator","Metabolism of apolipoproteins B, C and E in man","Huff MW","","$61,063,530.00"
"Huff, Murray","Medicine","1989","1992","Grants","Funded","True","False","Principal Investigator","Metabolism of apolipoproteins B, C and E in man","Huff MW","","$32,059,121.00"
"Huff, Murray","Medicine","1992","1995","Grants","Funded","True","False","Principal Investigator","Metabolism of apolipoproteins B, C and E in man","Huff MW","","$15,238,988.00"
"Huff, Murray","Medicine","1995","1998","Grants","Funded","True","False","Principal Investigator","Metabolism of apolipoproteins B, C and E in man","Huff MW","","$4,770,577.00"
"Huff, Murray","Medicine","1998","2003","Grants","Funded","True","False","Principal Investigator","Metabolism of apolipoproteins B, C and E in man","Huff MW","","$2,802,861.00"
"Huff, Murray","Medicine","2003","2008","Grants","Funded","True","False","Principal Investigator","Regulation of foam cell formation: Relationship to atherosclerosis","Huff MW","","$36,796,181.00"
"Huff, Murray","Medicine","1985","1985","Grants","Funded","True","False","Principal Investigator","Liquid Chromatography System","Huff MW","Valberg LS, Flanagan PR and Wolfe BM","$23,413,176.00"
"Huff, Murray","Medicine","1990","1992","Grants","Funded","True","False","Principal Investigator","Effect of alpha blockade in hypertensive subjects on plasma lipids and lipoproteins","Huff MW, Rabkin SW","","$49,378,190.00"
"Huff, Murray","Medicine","1987","1987","Grants","Funded","True","False","Principal Investigator","Ultracentrifuge Rotor","Huff MW","","$68,087,219.00"
"Huff, Murray","Medicine","1988","1988","Grants","Funded","True","False","Principal Investigator","Ultracentrifuge Tube Slicer","Huff MW","","$27,271,079.00"
"Brown, James","Medicine","1982","1983","Grants","Funded","True","False","Principal Applicant","","","","$71,549,748.00"
"Brown, James","Medicine","1983","1984","Grants","Funded","True","False","Principal Applicant","","","","$51,178,196.00"
"Brown, James","Medicine","1984","1985","Grants","Funded","True","False","Principal Applicant","","","","$42,404,645.00"
"Brown, James","Medicine","1985","1986","Grants","Funded","True","False","Principal Applicant","","","","$67,653,964.00"
"Brown, James","Medicine","1986","1987","Grants","Funded","True","False","Principal Applicant","","","","$11,107,342.00"
"Brown, James","Medicine","1989","1990","Grants","Funded","True","False","Principal Applicant","","","","$74,619,817.00"
"Brown, James","Medicine","1990","1991","Grants","Funded","True","False","Principal Applicant","","","","$41,095,866.00"
"Brown, James","Medicine","1983","1989","Grants","Funded","False","False","Principal Applicant","","","","$5,636,536.00"
"Brown, James","Medicine","1988","1988","Grants","Funded","True","False","Principal Applicant","","","","$3,224,181.00"
"Brown, James","Medicine","1989","1989","Grants","Funded","True","False","Principal Investigator","","","","$37,295,780.00"
"Brown, James","Medicine","1991","1991","Clinical Trials","Funded","False","False","Principal Investigator","Altered beta-adrenergic responsiveness in hypertension","","","$20,150,674.00"
"Brown, James","Medicine","1991","1992","Grants","Funded","True","False","Co-Investigator","Insulin mediated regulation of vascular beta-adrenergic responsiveness","Dr Ross Feldman","","$1,015,987.00"
"Brown, James","Medicine","1992","1993","Grants","Funded","True","False","Co-Investigator","Insulin mediated regulation of vascular beta-adrenergic responsiveness","Dr. Ross Feldman","","$53,146,234.00"
"Brown, James","Medicine","1997","1998","Grants","Funded","False","False","Principal Site Investigator","Effect of micronized fenofibrate 20 mg in comparison with pravastatin 20 to 40 mg on total cholesterol/HDL cholesterol ratio in patients with hypercholesterolemia. A multicentric, randomized double blind trial.","at London Health Sciences - University Hospital","","$197,433.00"
"Brown, James","Medicine","1998","2004","Clinical Trials","Funded","False","False","Co-Investigator","The effect of LDL-Cholesterol lowering beyond currently recommended minimum targets on coronary heart disease (CHD) recurrence in patients with pre-existing CHD).","Dr. M. Arnold","","$15,246,677.00"
"Brown, James","Medicine","1998","2005","Grants","Funded","False","False","Principal Site Investigator","Raloxifene hydrochloride or placebo in post-menopausal women at risk for major cardiovascular events.","at London Health Sciences - University Hospital","","$4,491,816.00"
"Brown, James","Medicine","2002","2002","Grants","Funded","False","False","Co-Investigator","Double-blind, randomized, multicenter, placebo-group phase Iia study to evaluate the safety and tolerability of oral Mesopram (ZK117137) up to 1.0 mg/day for up to 14 weeks in an intraindividual dose-escalating regimen in patients with clinically definite relapsing-remitting or secondary progressive multiple sclerosis","Dr. George Rice","","$2,352,027.00"
"Brown, James","Medicine","2004","2004","Grants","Funded","False","False","Co-Investigator","N-acetylcysteine per and post CABG in high-risk patients","Dr. Louise Moist","","$34,548,863.00"
"Pope, Janet","Medicine","2007/08","2008/08","Clinical Trials","Funded","False","True","Principal Investigator","Fatigue in Rheumatoid Arthritis","","","$36,930,864.00"
"Pope, Janet","Medicine","2008/03","2011/10","Clinical Trials","Funded","True","False","Co-Investigator","The impact of orofacial manifestations of systemic sclerosis on health-related quality of life","Mervyn Gornitsky","Canadian Scleroderma Research Group (CSRG), Murray Baron","$4,125,484.00"
"Pope, Janet","Medicine","2008/06","2010/06","Clinical Trials","Funded","True","True","Principal Investigator","Canadian Methotrexate and Etanercept Outcome Study: An open label randomized trial of etanercept and mtx. vs. etanercept alone in the treatment of rheumatoid arthritis (CAMEO).","","","$32,840,524.00"
"McManus, Ruth","Medicine","2008/07","2008/07","Grants","Funded","False","False","Co-Investigator","A phase IIa Study of the safety and clinical proo-of-concept of NC-503 (Eprosidate dissodium) in patinets with Type 2 diabetes and features of the metabolic syndrome","Dr Pavel Hamet","","$35,822,387.00"
"Feagan, Brian","Medicine","1995","1996","Clinical Trials","Funded","False","True","Co-Investigator","A comparative study of the efficacy and safety of budesonide Enema vs betamethasone Enema in Active Ulcerative Colitis (UC)","J. Irvine","P. Adams, W. Barnett, D. Bondy, J. Gregor, J. Howard, JWD McDonald, T. Ponich, L. Valberg, W. Watson","$28,993,331.00"
"Feagan, Brian","Medicine","1995","1997","Clinical Trials","Funded","False","True","Principal Investigator","Canadian Orthopedic Perioperative Erythropoietin Study II (COPESII)","","","$60,864,541.00"
"Feagan, Brian","Medicine","1996","1997","Clinical Trials","Funded","False","True","Co-Investigator","IL-10 in Chronic Active Crohn’s Disease","RN Fedorak","G. Wild, AH Steinhart","$48,381,057.00"
"Feagan, Brian","Medicine","1996","1997","Clinical Trials","Funded","False","True","Principal Investigator","Utility Measurement in IBD","","Dr. J. Gregor, Mr. R. Wall","$69,315,592.00"
"Feagan, Brian","Medicine","1997","1998","Clinical Trials","Funded","False","True","Collaborator","Analysis of Health Related Quality of Life Data","","","$4,295,897.00"
"Feagan, Brian","Medicine","1997","1998","Clinical Trials","Funded","False","True","Collaborator","A phase I study of ACT-1 antibody in patients with active ulcerative colitis","","","$71,269,031.00"
"Feagan, Brian","Medicine","1998","2000","Clinical Trials","Funded","False","True","Co-Investigator","ACCENT 1: A randomized, double-blind, placebo-controlled trial of anti-TNF of patients with moderately to severely active Crohn’s disease","","Dr. S. Hanauer, Dr. J. Gregor","$2,436,159.00"
"Feagan, Brian","Medicine","1998","2000","Clinical Trials","Funded","False","True","Co-Investigator","ACCENT II:A randomized, double-blind, placebo-controlled trial of anti-TNF chimeric monoclonal antibody (infliximab, remicade) in the long term treatments of patients with fistulizing Crohn’s disease","","Dr. Rutgeerts, Dr. J. Gregor","$22,239,367.00"
"Feagan, Brian","Medicine","1999","2002","Clinical Trials","Funded","False","True","Co-Investigator","Phase II, randomized placebo-controlled, double-blind, parallel group study to determine the safety, pharmacokinetics, and effectiveness of MLN-02 in patients with mildly to moderately active Crohn’s disease","","Dr. JWD McDonald","$69,817,521.00"
"Feagan, Brian","Medicine","1999","2002","Clinical Trials","Funded","False","True","Co-Investigator","Phase II, randomized, placebo-controlled, double-blind, parallel group, multicentre study to determine the safety, pharmacokinetics and effectiveness of MLN-02 in patients with mildly to moderately active ulcerative colitis","","Dr. JWD McDonald","$52,006,571.00"
"Feagan, Brian","Medicine","2001/08","2002/08","Clinical Trials","Funded","False","True","Principal Investigator","Phase II, multicentre, double-blind, placebo-controlled, parallel-group, dose response study to assess the safety and efficacy of the engineered human anti-TNF PEG conjugate, CDP870, dosed subcutaneously in patients with active Crohn’s disease.","","","$71,289,386.00"
"Feagan, Brian","Medicine","2001/11","2001/11","Clinical Trials","Funded","False","True","Principal Investigator","Randomized, double-blind, placebo-controlled, four parallel groups dose finding study of BIRB 796BS","","","$195,289.00"
"Feagan, Brian","Medicine","2002/03","2002/03","Clinical Trials","Funded","False","True","Principal Investigator","Phase II, double-blind, placebo-controlled study to determine the safety and efficacy of a humanized anti-interferon-y monoclonal antibody (HuZaf) administered to patients with moderate to severe Crohn’s disease. ZAF 707","","","$650,024.00"
"Feagan, Brian","Medicine","2002/06","2002/06","Clinical Trials","Funded","False","True","Principal Investigator","Randomized, placebo-controlled, double-blind, trial to evaluate the safety and efficacy of infliximab in patients with active ulcerative colitis (ACT1)","","","$36,964,765.00"
"Feagan, Brian","Medicine","2002/03","2006/12","Clinical Trials","Funded","False","True","Principal Applicant","Remicade® Treatment Registry Across Canada in Crohn’s Disease","","","$58,670,958.00"
"Feagan, Brian","Medicine","2003/04","2006/03","Clinical Trials","Funded","False","True","Principal Investigator","Multicentre, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody (Adalimumab) for the induction and maintenance of clinical remission in subjects with Crohn’s disease","","","$69,341,544.00"
"Feagan, Brian","Medicine","2005/01","2009/01","Clinical Trials","Funded","False","True","Principal Investigator","Multicentre, open label study of the human anti TNF monoclonal antibody Adalimumab to evaluate the long term safety and tolerability of repeated administration of Adalimumab in subjects with Crohn’s disease (690)","","","$74,651,674.00"
"Feagan, Brian","Medicine","2003/06","2005/09","Clinical Trials","Funded","False","True","Principal Investigator","Phase I/II partially randomized, open label study of Visilizumab in patients with severe ulcerative colitis refractory to intravenous corticosteroids","","","$33,999,178.00"
"Feagan, Brian","Medicine","2003/07","2005/09","Clinical Trials","Funded","False","True","Principal Applicant","Multicentre International Study of the Long-term Safety of Infliximab (Remicade) in Ulcerative Colitis (Results in UC: Remicade Safety Under Long-term Study in Ulcerative Colitis","","","$63,195,921.00"
"Feagan, Brian","Medicine","2003/11","2005/09","Clinical Trials","Funded","False","True","Director, Coordinating Centre","EPIC 1: 1 year, multicenter, randomized, double-blind, placebo-controlled, parallel group assessment of the tolerability, safety and efficacy of EPANOVA soft gelatin capsules 4g/day for maintenance","","Dr. JWD McDonald","$74,904,631.00"
"Feagan, Brian","Medicine","2002/10","2005/06","Clinical Trials","Funded","False","True","Co-Investigator","EPIC 2: A phase III , randomized, placebo-controlled, double-blind, parallel group, multicentre study to assess the efficacy and safety of Omega-3 free fatty acids (EPANOVA) for the maintenance of symptomatic remission in subjects with CD","","Dr. JWD McDonald","$64,772,470.00"
"Feagan, Brian","Medicine","2002/10","2005/06","Clinical Trials","Funded","False","True","Director, Coordinating Centre","EPIC 2 A phase III, randomized, placebo-controlled, double-blind, parallel group, multicentre study to assess the efficacy and safety of Omega-3 free fatty acids (EPANOVA) for the maintenance of symptomatic remission in subjects with CD","","","$60,499,270.00"
"Feagan, Brian","Medicine","2003/06","2005/06","Clinical Trials","Funded","False","True","Principal Investigator","A randomized, stratified, double-blind, placebo-controlled phase II study of the steroid-sparing properties of Sargramostim (LEUKINE) therapy in patients with corticosteroid-dependent Crohn’s disease. 307-501","","","$43,918,998.00"
"Feagan, Brian","Medicine","2004/06","2006/06","Clinical Trials","Funded","False","True","Principal Investigator","Open-label trial of Sargramostim (LEUKINE). A recombinant human granulocyte-macrophage colony stimulator factor (GMCSF),in active Crohn’s disease. 307-340","","","$48,843,553.00"
"Feagan, Brian","Medicine","2004/10","2005/10","Clinical Trials","Funded","False","True","Principal Investigator","Phase III randomized, double-blind, placebo-controlled, induction study of Sagramostim (LEUKINE) in patients with active Crohn’s disease.","","","$35,061,716.00"
"Feagan, Brian","Medicine","2004/06","2007/12","Clinical Trials","Funded","False","True","Principal Investigator","Multi-centre, randomized, phase II study of human monoclonal antibody to IL-12p40 (CNTO 1275) in subjects with moderately to severely active Crohn’s Disease","","","$51,630,988.00"
"Feagan, Brian","Medicine","2004/06","2006/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Randomized, double-blind, parallel-group, multicentre, proof of concept study of the efficacy of oral RAD001 (6mg/day) vs. azathioprine and placebo in Crohn’s disease.","","","$47,541,652.00"
"Feagan, Brian","Medicine","2004/03","2007/03","Clinical Trials","Funded","False","True","Director of Coordinating Centre, Project Manager, Medical Monitor","Double Blind, Open Label Studies to evaluate an Apheresis System for the Treatment of Moderate to Severe Ulcerative Colitis and Crohn’s Disease","","","$2,185,882.00"
"Feagan, Brian","Medicine","2004/10","2007/09","Clinical Trials","Funded","False","True","Site Investigator","Phase III multicentre, 52-week, open-label, extension study of the safety and efficacy of 25 mg or 50 mg of OPC-6535 oral tablets in the treatment of subjects with ulcerative colitis. Protocol 219.","","","$55,493,722.00"
"Feagan, Brian","Medicine","2004/05","2005/05","Clinical Trials","Funded","False","True","Site Investigator","Phase III, multicentre, randomized, double-blind, parallel-arm, 52 week dose comparison study of the efficacy and safety of 25 mg. QD and 50mg QD of OPC-6535 oral tablets and 800 mg BID Asacol in the maintenance of remission in subjects with ulcerative colitis. Protocol 220.","","","$53,884,937.00"
"Feagan, Brian","Medicine","2005/09","2007/09","Clinical Trials","Funded","False","True","Principal Investigator","Randomized, double-blind, placebo-controlled clinical study of the oral IL12/23 inhibitor, STA-5326 mesylate, for the induction of clinical response in patients with Crohn’s disease Procotol 5326-07","","","$45,492,951.00"
"Feagan, Brian","Medicine","2005/03","2006/03","Clinical Trials","Funded","False","True","Director, Coordinating Centre Lead Investigator","Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients with Irritable Bowel Syndrome with Diarrhea. DDP225-04-006","","","$8,495,959.00"
"Feagan, Brian","Medicine","2005/03","2006/03","Clinical Trials","Funded","False","True","Director, Coordinating Centre Lead Investigator","Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients with Irritable Bowel Syndrome with Constipation DDP733-04-007","","","$62,673,691.00"
"Feagan, Brian","Medicine","2003/06","2005/09","Clinical Trials","Funded","False","True","Principal Investigator","A phase 2/3, randomized, double-blind, placebo-controlled, multicentre study of Visilizumab in subjects with intravenous steroid refractory ulcerative colitis Protocol 291-415","","","$42,389,032.00"
"Feagan, Brian","Medicine","2003/02","2005/08","Clinical Trials","Funded","False","True","Principal Investigator","A randomized, double-blind, multicentre study of Visilizumab versus placebo in subjects with intravenous steroid-refractory ulcerative colitis previously responsive in a Visilizumab study Protocol 291-417","","","$16,406,835.00"
"Feagan, Brian","Medicine","2003/03","2005/03","Clinical Trials","Funded","False","True","Principal Investigator","An observational follow-up study for subjects receiving salvage therapy after previous treatment in a Visilizumab study for intravenous steroid-refractory ulcerative colitis. Protocol 291-420","","","$28,537,272.00"
"Feagan, Brian","Medicine","","","Clinical Trials","Funded","False","True","Collaborator","The Development and Evaluation of an Anemia Management Carepath in Breast Cancer Patients Receiving Adjuvant Chemotherapy AMAZE: A Feasibility Chart Review Study","","","$71,566,321.00"
"Feagan, Brian","Medicine","2006/06","2009/06","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase IIIB multicentre, open label induction and double-blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab over 26 wks in patients suffering from Crohn’s disease Welcome Study","","","$59,552,651.00"
"Feagan, Brian","Medicine","2007/04","2008/04","Clinical Trials","Funded","False","True","Director, Coordinating Centre","A Randomized Multicentre study to compare the effects of CRx-401 to Bezafibrate plus placebo on plasma glucose levels when given to subjects with diabetes on metformin","","","$38,568,601.00"
"Feagan, Brian","Medicine","2007/05","2008/05","Clinical Trials","Funded","False","True","Site Investigator","A Phase III, multi-centre, randomized, placebo-controlled study to evaluate the clinical efficacy and safety of induction and maintenance therapy with Abatacept in subjects with active Crohn's Disease","","","$59,199,351.00"
"Feagan, Brian","Medicine","2007/05","2008/05","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase IIIB multi-centre, double-blind, placebo-controlled trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn’s Disease COSPAR I","","","$21,313,456.00"
"Feagan, Brian","Medicine","2007/05","2008/05","Clinical Trials","Funded","False","True","Principal Investigator","An open label, multi-centre trial to examine the long term safety, efficacy and corticosteroid sparing effect of certolizumab pegol in patients with moderate to severe Crohn’s disease who have failed tapering of corticosteroids COSPAR II","","","$61,509,189.00"
"Dias, Bryan","Medicine","","","Grants","Funded","False","False","Co-Investigator","The study is identifying the identification and management of risk factors in acute coronary syndromes in patients in a multicentre trial involving both tertiary care hospitals and community centers across Southwestern Ontario.","","","$5,197,019.00"
"Dias, Bryan","Medicine","","","Grants","Funded","False","False","Principal Investigator","This is looking at the incidence of pulmonary hypertension in patients with lupus erythematosis","B. Dias and S. Mehta","J. Pope","$54,254,695.00"
"Feagan, Brian","Medicine","2007/09","2011/02","Clinical Trials","Funded","False","True","Director, Coordinating Centre","A Phase 2, multiple dose, open-label study to determine the long term safety of MLN002 in patients with Ulcerative Colitis and Crohn’s Disease C13004","","","$59,357,927.00"
"Feagan, Brian","Medicine","2006/11","2008/05","Clinical Trials","Funded","False","True","Director, Coordinating Centre","A Phase 2 randomized, placebo-controlled double blind study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of MLN0002 following multiple doses in patients with active UC (C13002)","","","$73,291,119.00"
"Feagan, Brian","Medicine","2007/12","2008/12","Clinical Trials","Funded","False","True","Principal Investigator","Comparison of efficacy and safety of infliximab as monotherapy or in combination with Azathioprine, versus Azathioprine monotherapy in moderate to severe active ulcerative colitis","","","$38,666,126.00"
"Feagan, Brian","Medicine","2007/12","2008/12","Clinical Trials","Funded","False","True","Principal Site Investigator","Phase 3 study to evaluate the safety and efficacy of Golimumab maintenance therapy in subjects with moderate to severe ulcerative colitis C0524T18","","","$55,067,972.00"
"Feagan, Brian","Medicine","2007/12","2008/12","Clinical Trials","Funded","False","True","Principal Site Investigator","Phase 2/3 study of Golimumab induction therapy in subjects with moderate to severe ulcerative colitis C0524T16","","","$28,128,537.00"
"Feagan, Brian","Medicine","2004/11","2008/03","Clinical Trials","Funded","False","True","Director, Data Coordinating Centre","Open label extension of EPIC 1- Study with Epanova for the maintenance of symptomatic remission in subjects with CD","","","$74,603,954.00"
"Feagan, Brian","Medicine","2006/01","2008/01","Clinical Trials","Funded","False","True","Principal Investigator","A Phase III, Randomized, Placebo-Controlled, Double-blind, Parallel Group, Multicentre Study to evaluate the Safety and Efficacy of Infliximab in Combination with MTX for the Long Term Treatment of Crohn’s Disease COMMIT","","","$64,172,671.00"
"Feagan, Brian","Medicine","2008/03","2009/03","Clinical Trials","Funded","False","True","Principal Site Investigator","Observational study of Biomarkers in Subjects with Inflammatory Bowel Disease compared with Non-IBD Control Subjects EMBARK","","","$10,931,659.00"
"Feagan, Brian","Medicine","1997","1998","Clinical Trials","Funded","True","False","Co-Investigator","Controlled trial of budesonide vs combination antibiotics vs budesonide plus antibiotics in the treatment of Crohn’s disease","","Dr. H. Steinhart","$49,562,484.00"
"Feagan, Brian","Medicine","1998","1998","Clinical Trials","Funded","True","False","Co-Investigator","Traditional systematic reviews as guides to therapeutic decisions.","","Dr. JWD McDonald","$67,124,003.00"
"Feagan, Brian","Medicine","1998","1999","Clinical Trials","Funded","True","True","Co-Investigator","Randomized controlled trial of a critical pathway to improve the management of patients with community-acquired pneumonia","","","$36,922,870.00"
"Feagan, Brian","Medicine","1999","2000","Clinical Trials","Funded","False","True","Co-Investigator","Safety, tolerance and efficacy of treatment with subcutaneous IL-10 (SCH52000) in subjects with steroid dependent Crohn’s disease","","Dr. S. Schreiber","$6,262,791.00"
"Feagan, Brian","Medicine","1999","2001","Clinical Trials","Funded","False","True","Site Investigator","Quality of life in fistulizing Crohn’s disease","","","$4,305,601.00"
"Feagan, Brian","Medicine","1999","2001","Clinical Trials","Funded","False","True","Site Investigator","Utility measurement in fistulizing Crohn’s disease","","","$61,203,864.00"
"Feagan, Brian","Medicine","1999","2001","Clinical Trials","Funded","True","False","Co-Investigator","Arthroscopy versus no surgery for osteoarthritis of the knee","","Dr. S. Kirkley","$18,887,351.00"
"Feagan, Brian","Medicine","2005/01","2006/06","Clinical Trials","Funded","True","False","Co-Investigator","Arthroscopy Versus No Surgery for Osteoarthritis of the Knee (Extension)","","Dr. P. Fowler","$57,301,968.00"
"Feagan, Brian","Medicine","2000","2003","Clinical Trials","Funded","True","False","Co-Investigator","Improving Exercise Prescription Among Canadian Family Physicians. The PACE+STEP Project","","Dr. R. Petrella","$66,436,340.00"
"Feagan, Brian","Medicine","2001","2003","Clinical Trials","Funded","True","False","Co-Investigator","Utility assessment in patients with hepatitis C infection","","Dr. P. Marotta","$16,136,214.00"
"Feagan, Brian","Medicine","2001/01","2005/01","Clinical Trials","Funded","False","True","Co-Investigator","Canadian cohort of ALS subjects","","Dr. M. Strong","$46,347,512.00"
"Feagan, Brian","Medicine","2001","2004","Clinical Trials","Funded","True","False","Site Investigator","The development and Evaluation of a blood conservation program in patients undergoing primary total hip joint arthroplasty","","","$16,112,807.00"
"Feagan, Brian","Medicine","2001","2003","Clinical Trials","Funded","True","False","Co-Investigator","Randomized, double-blind, placebo-controlled trial of ciprofloxacin or metronidazole for the treatment of Crohn’s disease perianal fistulas","","Dr. W. Sandborn","$43,293,382.00"
"Feagan, Brian","Medicine","2002/07","2005/01","Clinical Trials","Funded","True","True","Director of Coordinating Centre","Randomized, controlled trial of VSL #3 for the prevention of endoscopic recurrence following surgery for Crohn’s Disease","","","$46,639,769.00"
"Feagan, Brian","Medicine","2002/07","2005/01","Clinical Trials","Funded","True","True","Co-Investigator","Randomized, controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn’s disease.","","Dr. R. Fedorak","$28,017,391.00"
"Feagan, Brian","Medicine","2004/06","2007/06","Clinical Trials","Funded","True","False","Principal Applicant","Crohn’s and Colitis Clinical Trials Consortium","","","$59,041,404.00"
"Feagan, Brian","Medicine","2004/03","2007/03","Clinical Trials","Funded","True","False","Principal Applicant","A Trial of Ciprofloxacin or Metronidazole for the Treatment of Fistulizing Crohn’s Disease","","","$61,271,164.00"
"Feagan, Brian","Medicine","2004/11","2007/08","Clinical Trials","Funded","False","True","Director, Coordinating Centre","Evaluation of a Primary Treatment Algorithm Using Fixed Dose Combination Therapy for the Management of Grade II Hypertension","Dr. Ross Feldman","","$17,134,493.00"
"Feagan, Brian","Medicine","2008/05","2011/05","Clinical Trials","Funded","False","True","Director of Coordinating Centre","Evaluation of a Primary Treatment Algorithm Using Combination Therapy for the Management of Patients with Hypertension and Hypercholesterolemia","Dr. Ross Feldman","","$70,241,183.00"
"Feagan, Brian","Medicine","2003/01","2004/04","Clinical Trials","Funded","True","False","Director of Coordinating Centre","Evaluation of a Computer – Based Education Strategy for Atherosclerosis Risk Factor Management","Dr. Ross Feldman","","$51,705,996.00"
"Feagan, Brian","Medicine","2005/09","2007/05","Clinical Trials","Funded","True","False","Principal Investigator","Metronidazole and Ciprofloxacin in the treatment of colonic Crohn’s disease (MACINTOCC) trial.","","","$1,141,260.00"
"Feagan, Brian","Medicine","2006/01","2009/01","Clinical Trials","Funded","True","False","Site Investigator","Multi-Site Trial of Azathioprine Dosing in Crohn’s Disease","","","$20,063,558.00"
"Feagan, Brian","Medicine","2006/07","2009/07","Clinical Trials","Funded","True","False","Director, Coordinating Centre","A Phase III, Randomized, Placebo-Controlled, Double-blind, Parallel Group, Multicentre Study to evaluate the Safety and Efficacy of Infliximab in Combination with MTX for the Long Term Treatment of Crohn’s Disease COMMIT","","","$31,479,888.00"
"Sridhar, Krishnakumar","Medicine","2000/07","2000/07","Grants","Funded","False","False","Principal Investigator","A decision analytic model examining the cost-effectiveness of Glycoprotein IIa/IIIb receptor antagonists","","","$28,167,003.00"
"Sridhar, Krishnakumar","Medicine","2000/07","2000/07","Grants","Funded","False","False","Principal Investigator","The treatment of atrial fibrillation using anti-coagulants: Scenarios to investigate the gap between evidence and practice","","","$28,561,729.00"
"Sridhar, Krishnakumar","Medicine","2005/01","2005/01","Grants","Funded","False","False","Co-Investigator","Knowledge Innovation and Diffusion in Myocardial Infarction (KIDME)","Femida Gwadry-Sridhar","","$16,376,377.00"
"Huff, Murray","Medicine","1988","1989","Grants","Funded","False","True","Principal Investigator","Effect of alpha blockade in hypertensive subjects on plasma lipids and lipoproteins","Huff MW","","$71,149,872.00"
"Huff, Murray","Medicine","2007","2009","Grants","Funded","False","True","Principal Investigator","Regulation of hepatic lipoprotein secretion and glucose homeostasis by the citrus flavonoid nobiletin: Relationship to Atherosclerosis","Huff MW","","$41,399,884.00"
"Huff, Murray","Medicine","2007","2008","Grants","Funded","False","True","Principal Investigator","Regression of atherosclerosis by ETC-A in NZW rabbits","Huff MW","","$21,791,484.00"
"Huff, Murray","Medicine","1993","1995","Grants","Funded","False","True","Principal Investigator","Effect of ACAT inhibitors on hepatic lipoprotein metabolism","Huff MW","","$25,223,186.00"
"Huff, Murray","Medicine","1995","1996","Grants","Funded","False","True","Principal Investigator","Effect of Atorvastatin on hepatic lipoprotein metabolism","","","$71,086,118.00"
"Huff, Murray","Medicine","1996","1998","Grants","Funded","False","True","Principal Investigator","Comparison of Atorvastatin and Simvastatin on hepatic apoB secretion in vivo","","","$29,824,112.00"
"Huff, Murray","Medicine","1997","1999","Grants","Funded","False","True","Principal Investigator","The effect of Atorvastatin and simvastatin on post-prandial lipoprotein metabolism in vivo","","","$67,189,003.00"
"Huff, Murray","Medicine","1998","1999","Grants","Funded","False","True","Principal Investigator","Regulation of apolipoprotein B metabolism, in vivo, by atorvastatin and avasimibe (CI-1011)","","","$57,941,938.00"
"Huff, Murray","Medicine","1996","1997","Grants","Funded","False","True","Co-Investigator","Effects of Valsartan on plasma lipids and lipoproteins in patients with diabetic nephropathy","","","$25,879,059.00"
"Huff, Murray","Medicine","1999","2000","Grants","Funded","False","True","Principal Investigator","Regulation of apoB metabolism, in vivo, by an inhibitor of intestinal bile acid transport","","","$12,070,751.00"
"Huff, Murray","Medicine","2000","2002","Grants","Funded","False","True","Principal Investigator","Regulation of apoB metabolism, in vivo, by a combination of an ASBT inhibitor and a HMG-CoA reductase inhibitor","","","$9,714,355.00"
"Huff, Murray","Medicine","2000","2002","Grants","Funded","False","True","Principal Investigator","Lipid modulation and apoB kinetics, in vivo, by inhibitors of oxidosqualene cyclase","","","$71,296,166.00"
"Huff, Murray","Medicine","2001","2002","Grants","Funded","False","True","Principal Investigator","Regulation of HDL metabolism in the miniature pig by niacin or a fibrate: A genomic approach","","","$45,629,435.00"
"Huff, Murray","Medicine","2004/01","2006/01","Grants","Funded","False","True","Principal Investigator","Regulation of apoB metabolism by inhibitors of cholesterol absorption","","","$58,480,949.00"
"Huff, Murray","Medicine","2008/04","2008/12","Grants","Funded","False","True","Principal Investigator","Regulation of lipoprotein metabolism by Extended Release Niacin","","","$24,180,713.00"
"Huff, Murray","Medicine","2004/10","2005/09","Grants","Funded","False","True","Principal Investigator","Hepatocyte Cholesterol Metabolism","","","$28,679,460.00"
"Huff, Murray","Medicine","2007/10","2007/12","Grants","Funded","False","True","Principal Investigator","Pharmacokinetics of a PPAR? agonist (MBX8025)","","","$57,735,686.00"
"Huff, Murray","Medicine","2008/03","2008/05","Grants","Funded","False","True","Principal Investigator","The PPAR? agonist (MBX8025) as a cholesterol absorption inhibitor","","","$13,910,356.00"
"Rohekar, Sherry","Medicine","2007/02","2010/11","Grants","Funded","True","True","Principal Investigator","The Workforce in Rheumatology Issues STudy.","","","$62,719,391.00"
"Rohekar, Sherry","Medicine","2007/11","2009/06","Grants","Funded","True","False","Principal Investigator","Assessment Of Work Disability In Ankylosing Spondylitis","","","$30,647,024.00"
"Huff, Murray","Medicine","1987","1987","Grants","Funded","True","False","Principal Investigator","Ultracentrifuge with 2 rotors","Huff MW","","$54,170,543.00"
"Jevnikar, Anthony","Medicine","2007/07","2012/06","Grants","Funded","True","False","Principal Investigator","Non-Human Primate Islet/Kidney Transplantation Tolerance","Dr. A. Jevnikar","","$21,033,411.00"
"Jevnikar, Anthony","Medicine","2005/04","2010/03","Grants","Funded","True","False","Principal Investigator","Regulation of Renal Tubular Epithelial Cell Injury to Promote Kidney Allograft Survival","Dr. A. Jevnikar","","$50,736,025.00"
"Jevnikar, Anthony","Medicine","2002/07","2007/06","Grants","Funded","True","False","Principal Investigator","Induction of Transplant Tolerance by Synergy of Monoclonal Antibody Against CD45RB LF 15-0195, an Analogue of 15-Deoxyspergualin Analogue (DSG) in a Non-Human Primate Kidney Transplant Model","Dr. A. Jevnikar","","$57,120,468.00"
"Jevnikar, Anthony","Medicine","2004","2005","Grants","Funded","True","False","Principal Investigator","Production of Transgenic Plants Expressing Human Cytokines for Immunomodulation of Disease by Topical and Oral Application (Proof of Principle)","Dr. A. Jevnikar","","$62,214,191.00"
"Jevnikar, Anthony","Medicine","2004/07","2006/06","Grants","Funded","True","False","Co-Investigator","Prolongation of Renal Allograft Survival by Inhibition of MEK/ERK Activation","Dr. C. Du","","$25,049,678.00"
"Jevnikar, Anthony","Medicine","2003","2005","Grants","Funded","True","False","Principal Investigator","SR9137 Plant Recombinant Antibodies for Pseudomonas Aeruginosa for the Topical Prevention of Hospital Acquired Infections","Dr. A. Jevnikar","","$4,882,852.00"
"Jevnikar, Anthony","Medicine","2002","2004","Grants","Funded","True","False","Principal Investigator","Limitation of Epithelial Cell and Renal Allograft Injury by FLICE Inhibitory Protein (FLIP) and Endogenous Apoptosis Regulatory Proteins","Dr. A. Jevnikar","","$71,080,789.00"
"Jevnikar, Anthony","Medicine","1999","2002","Grants","Funded","True","False","Co-Investigator","Induction of Transplant Tolerance by Antibody against CD45RB","Dr. R. Zhong","","$30,496,289.00"
"Jevnikar, Anthony","Medicine","2002","2009","Clinical Trials","Funded","False","True","Principal Investigator","Prograf as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure.","","","$40,489,205.00"
"Jevnikar, Anthony","Medicine","2002","2008","Clinical Trials","Funded","False","True","Principal Investigator","Rapamune Outcomes Assessment Registry","","","$63,198,451.00"
"Jevnikar, Anthony","Medicine","2002","2012","Clinical Trials","Funded","False","True","Principal Investigator","A Prospective, Multi-centre Study for the Determination of the Incidence of Cardiovascular Events and the Prevalence of Risk Factors for Cardiovascular Disease in Renal Transplantation.","","","$34,662,109.00"
"Jevnikar, Anthony","Medicine","2004","2005","Clinical Trials","Funded","False","True","Principal Investigator","FKC-010 Clinical Regional transplant programs study of immunosuppressive therapy related toxicities in renal transplant recipients managed at regional or satellite community nephrology clinics.","","","$21,868,436.00"
"Jevnikar, Anthony","Medicine","2004","2005","Clinical Trials","Funded","False","True","Principal Investigator","FKC-010 Data Management Regional transplant programs study of immunosuppressive therapy related toxicities in renal transplant recipients managed at regional or satellite community nephrology clinics.","","","$20,112,614.00"
"Jevnikar, Anthony","Medicine","2002","2011","Clinical Trials","Funded","False","True","Principal Investigator","FK0-003 Data Management A Prospective, Multi-centre Study for the Determination of the Incidence of Cardiovascular Events and the Prevalence of Risk Factors for Cardiovascular Disease in Renal Transplant Patients.","","","$70,091,312.00"
"Jevnikar, Anthony","Medicine","2000","2003","Clinical Trials","Funded","False","True","Principal Investigator","A Phase 2 Randomized Multicenter Open-Label Safety of ISA 247 and Cyclosporine (Neoral) in Post-Renal Transplant Patients.","","","$20,300,204.00"
"Jevnikar, Anthony","Medicine","2006","2009","Clinical Trials","Funded","False","False","Principal Investigator","A Phase 2 B Randomized, Multicenter, Open-Label Concentration Controlled Safety Study of ISA247 and Tacrolimus in De Novo Renal Transplant Patients","","","$45,088,086.00"
"Jevnikar, Anthony","Medicine","2004","2008","Clinical Trials","Funded","False","True","Principal Investigator","Evaluation of the long-term safety and efficacy of a Tacrolimus-based 5-day steroid rapid withdrawal immunoprophylactic regimen in de novo renal transplantation.","","","$13,681,544.00"
"Jevnikar, Anthony","Medicine","2003","2009","Clinical Trials","Funded","False","True","Principal Investigator","A multicentre 1:1 randomized, double blind, two arm parallel group study to evaluate and compare the efficacy and safety of modified release Tacrolimus FK506E (MR4) versus Tacrolimus FK506.","","","$28,919,914.00"
"Jevnikar, Anthony","Medicine","2007","2009","Clinical Trials","Funded","False","True","Principal Investigator","A multicentre 1:1 randomized, double blind, two arm parallel group study to evaluate and compare the efficacy and safety of modified release Tacrolimus FK506E (MR4) versus Tacrolimus FK506. Above study but in an extension.","","","$53,656,036.00"
"Jevnikar, Anthony","Medicine","2006","2010","Clinical Trials","Funded","False","True","Co-Principal Investigator","A prospective, randomized, open-label, pilot study to compare the effect on carotid atherosclerosis of a Tacrolimus-based regimen with conversion from a Tacrolimus-to a Sirolimus-based regimen at 3-4 months post-transplant in de novo renal transplant recipients.","","","$34,349,673.00"
"Jevnikar, Anthony","Medicine","2002","2003","Clinical Trials","Funded","False","True","Co-Principal Investigator","Immunosuppression without calcineurin inhibition in renal transplantation: a pilot study of a novel non-nephrotoxic regimen","","","$21,473,551.00"
"Jevnikar, Anthony","Medicine","2004","2006","Clinical Trials","Funded","False","True","Co-Principal Investigator","A one year, multicentre, partially blinded, double dummy, randomized study to evaluate the efficacy of FTY720 combined with reduced dose or full dose neural and corticosteroids versus mycophenolate mofetil (MMF< Cellcept) combined with full dose Neoral and corticosteroids, in de novo adult renal transplant recipients.","","","$11,289,620.00"
"Siu, Samuel","Medicine","2002/07","2004/06","Clinical Trials","Funded","True","False","Co-Principal Investigator","Effect of ACEI Therapy in Patients with Systemic Right Ventricles","Dr. Judith Therrien","","$26,909,355.00"
"Siu, Samuel","Medicine","2002/07","2007/06","Clinical Trials","Funded","True","False","Principal Investigator","Pregnancy and long term prognosis in women with heart disease","","Gary Webb, Jack Colman, Judith Therrien","$39,252,441.00"
"Siu, Samuel","Medicine","2002/07","2004/06","Clinical Trials","Funded","True","False","Co-Principal Investigator","Adults with Tetralogy of Fallot: Right ventricular abnormalities","Dr. Brian McCrindle","","$11,294,659.00"
"Siu, Samuel","Medicine","2003/04","2006/03","Grants","Funded","True","False","Co-Investigator","Living better with Lupus: The health improvement and prevention program (HIPP) in systemic lupus erythematosus","Dr Paul Fortin","","$32,812,612.00"
"Siu, Samuel","Medicine","2003/07","2004/06","Clinical Trials","Funded","True","False","Principal Investigator","Time Effectiveness, Diagnostic Agreement, and Reproducibility of Digital vs Videotape Acquisition of Echocardiographic Images","Dr Samuel Siu","Dr. Eric Yu","$28,255,038.00"
"Siu, Samuel","Medicine","2003/07","2004/06","Clinical Trials","Funded","True","False","Supervisor of Dr Doris Basic, Supervisor","Prognostic value of myocardial perfusion imaging in patients with suspected coronary artery disease","D. Basic","","$15,597,906.00"
"Siu, Samuel","Medicine","2003/07","2005/06","Clinical Trials","Funded","True","False","Supervisor of Dr Doris Basic, Supervisor","Cardiac output and fetal outcome in pregnant women with heart disease","D. Basic","","$34,068,696.00"
"Siu, Samuel","Medicine","2004/07","2005/06","Clinical Trials","Funded","True","False","Supervisor of Dr Doris Basic, Supervisor","Realtime assessment of myocardial perfusion by contrast echocardiography","","","$63,983,466.00"
"Siu, Samuel","Medicine","2005","2007","Clinical Trials","Funded","True","False","Principal Investigator","Cardiac output and fetal well being in pregnant women with heart disease","","Jack Colman, Mathew Sermer","$28,772,458.00"
"Siu, Samuel","Medicine","2005/03","2008/04","Clinical Trials","Funded","True","False","Co-Investigator","A population-based study of Hodgkin’s lymphoma: Opportunities to reduce cardiac late effects (ORaCLE)","David Hodgson","","$31,061,069.00"
"Siu, Samuel","Medicine","2005/08","2006/07","Clinical Trials","Funded","True","False","Supervisor","Myocardial perfusion in patients with suspected graft vasculopathy","","","$60,101,529.00"
"Siu, Samuel","Medicine","2006/05","2009/10","Clinical Trials","Funded","True","False","Principal Investigator","Pregnancy and long term prognosis in women with congenital heart disease","Samuel Siu","Jack Colman, Mathew Sermer, Candice Silversides, Omid Salehian, Bryan Dias, Luc Beauchesne","$52,395,101.00"
"Siu, Samuel","Medicine","2007/07","2009/06","Clinical Trials","Funded","True","False","Principal Investigator","Neurodevelopmental outcomes in children of women with heart disease","Samuel Siu","Venera Bruto, Rachel Wald, Jack Colman, Candice Silversides, Mathew Sermer","$37,958,914.00"
"Siu, Samuel","Medicine","2000/07","2001/06","Grants","Funded","False","False","Principal Investigator","Contrast echocardiographic evaluation of left ventricular mass","","","$35,005,095.00"
"Rohekar, Gina","Medicine","2006/08","2007/12","Grants","Funded","True","True","Principal Investigator","3e Initiative In Rheumatology. Canadian National Question 4: Strategies To Reduce Nuisance Side Effects of Methotrexate. A Systematic Review","","","$23,497,440.00"
"Rohekar, Gina","Medicine","2007/11","2010","Grants","Funded","True","True","Principal Investigator","The Workforce in Rheumatology Issues STudy","","","$58,756,617.00"
"Rohekar, Gina","Medicine","2008/02","2010/06","Grants","Funded","True","False","Principal Investigator","Test-Retest Reliability Of Patient Global Assessment In Rheumatoid Athritis","","","$72,385,083.00"
"Muirhead, Norman","Medicine","1986/07","1987/06","Grants","Funded","False","True","Principal Site Investigator","A randomized, double-blind placebo-controlled dose-ranging multicentre study of rHuEPO in patients treated with chronic hemodialysis for end-stage renal disease","N. Muirhead","","$4,580,472.00"
"Muirhead, Norman","Medicine","1987/01","1987/06","Grants","Funded","False","True","Principal Investigator","An open intravenous dose titration and long term maintenance study of rHuEPO in nephric patients on chronic hemodialysis","N.Muirhead","","$34,508,759.00"
"Muirhead, Norman","Medicine","1986/07","1987/06","Grants","Funded","False","True","Principal Investigator","Double-blind placebo-controlled single and multiple dose safety and pharmacokinetic study of rHuEPO in nephric patients on chronic hemodialysis. Double blind placebo-controlled safety and efficacy study of rHuEPO in neprhic patients on chronic hemodialysis","N. Muirhead","","$59,629,588.00"
"Muirhead, Norman","Medicine","1987/07","1988/06","Grants","Funded","False","True","Principal Investigator","Study of erythropoietin in quality of life","N. Muirhead","","$21,342,330.00"
"Muirhead, Norman","Medicine","1987/07","1988/06","Grants","Funded","False","True","Principal Investigator","Studies of erythropoietin in anemia of chronic renal failure","N. Muirhead","","$59,209,548.00"
"Muirhead, Norman","Medicine","1987/07","1988/06","Grants","Funded","False","True","Principal Site Investigator","Erythropoietin in chronic renal failure - Multicentre study","N. Muirhead","","$40,042,810.00"
"Muirhead, Norman","Medicine","1987/07","1988/06","Grants","Funded","False","True","Principal Investigator","Erythropoietin in renal failure - Pilot study","N. Muirhead","","$55,155,337.00"
"Muirhead, Norman","Medicine","1988/08","1989/10","Grants","Funded","False","True","Principal Investigator","Phase II/III safety efficacy study of erythropoietin in high risk hemodialysis patients","N. Muirhead","","$33,869,013.00"
"Muirhead, Norman","Medicine","1989/04","1991/08","Grants","Funded","False","True","Principal Investigator","Study of long-term morbidity in patients on maintenance hemodialysis","N. Muirhead","","$19,012,874.00"
"Muirhead, Norman","Medicine","1989/06","1991/03","Grants","Funded","False","True","Principal Investigator","A study of rHuEPO in the treatment of anemia in high risk hemodialysis","N. Muirhead","","$11,024,899.00"
"Muirhead, Norman","Medicine","1988/09","1993/09","Grants","Applied","False","True","Principal Investigator","A study of the quality of life and cost effectiveness of renal transplantation","N. Muirhead","","$48,223,657.00"
"Muirhead, Norman","Medicine","1991/07","1993/06","Grants","Funded","False","True","Principal Investigator","An open study to determine the safety and efficacy of EPREX in correcting anemia in renal transplant patients with chronic graft dysfunction","N. Muirhead","","$12,037,638.00"
"Muirhead, Norman","Medicine","1992/03","1994/01","Grants","Funded","False","True","Principal Investigator","A study of recombinant human erythropoietin in pre-dialysis ESRD patients","N. Muirhead","","$71,137,347.00"
"Muirhead, Norman","Medicine","1992/06","1995/06","Grants","Funded","False","True","Principal Investigator","Randomized, double-blind, placebo-controlled study of the safety and tolerance of ascending single and multiple doses of intravenous rapamycin administered to renal transplant patients with chronic rejection","N. Muirhead","","$71,895,078.00"
"Muirhead, Norman","Medicine","1992/06","1995/06","Grants","Funded","False","True","Principal Investigator","(1) ""Randomized, double-blind comparative study of mycophenolate mofetil versus standard therapy in renal transplant recipients experiencing their first episode of acute cellular rejection"". (2) ""Randomized, open label comparison study of mycophenolate mofetil versus intravenous corticosteroids for treatment of refractory acute cellular allograft rejection in renal transplant recipients"". (3) ""Randomized, double-blind comparative study of mycophenolate mofetil versus azathioprine as adjunctive therapy with cyclosporine and steroids in prevention of renal allograft rejection","N. Muirhead","","$51,834,361.00"
"Muirhead, Norman","Medicine","1994/11","1996/12","Grants","Funded","False","True","Co-Investigator","A multicentre, randomized, open-label pharmaco-epidemiologic study to compare the pharmacokinetic, safety, therapeutic, clinical and economic benefits of sandimmune neoral to sandimmune","C.R. Stiller","N. Muirhead.","$42,583,248.00"
"Muirhead, Norman","Medicine","1994/12","1996/02","Grants","Funded","False","True","Co-Investigator","A single-blind pilot study of the effects of oral rapamycin on the occurrence of acute rejection episodes in renal allograft recipients","C.R. Stiller","N. Muirhead","$5,330,482.00"
"Muirhead, Norman","Medicine","1995/04","1997/01","Grants","Funded","False","True","Principal Investigator","A single centre, randomized, double-blind, placebo controlled, parallel group trial comparing the effect of treatment for 12 months with Valsartan 80mg and 160mg once daily, and Captopril 25mg three times a day, on urinary albumin exretion, renal function and plasma lipid profile, in normotensive patients with type II diabetes mellitus and nephropathy","N. Muirhead","B. Fegan, J. Mahon.","$47,615,070.00"
"Muirhead, Norman","Medicine","1995/04","1996/12","Grants","Funded","False","True","Principal Investigator","A randomized controlled trial to assess the effect of normalization of hemoglobin using epoetin alfa, on cardiomyopathy in hemodialysis patients without symptomatic cardiac disease","N. Muirhead","","$8,293,305.00"
"Muirhead, Norman","Medicine","1996/06","1997/07","Grants","Funded","False","True","Principal Investigator","A randomized double-blind placebo-controlled multicentre phase III clinical trial to evaluate the safety and efficacy of auriculin anaritide in the treatment of oliguric acute tubular necrosis","N. Muirhead","","$7,175,771.00"
"Muirhead, Norman","Medicine","1995","1999","Grants","Funded","False","True","Co-Investigator","The effect of irbesartan on morbidity and mortality in hypertensive patients with Type II diabetes and diabetic nephropathy","B. Wolfe","N. Muirhead","$186,680.00"
"Muirhead, Norman","Medicine","1996","2002","Grants","Funded","False","True","Principal Investigator","A randomized double-blind, placebo-controlled study of the long term effects of Fuvastatsn (LESCOL) on major adverse cardiac event (MACE) and progression of chronic transplant dysfunction in renal transplanted patients","N. Muirhead","","$71,780,114.00"
"Muirhead, Norman","Medicine","2002","2003","Grants","Funded","False","True","Principal Investigator","A randomized double-blind, placebo-controlled study of the long term effects of Fluvastatsn (LESCOL) on major adverse cardiac event (MACE) and progression of chronic transplant dysfunction in renal transplanted patients","Dr. N. Muirhead","","$45,402,442.00"
"Muirhead, Norman","Medicine","1996/10","2000/01","Grants","Funded","False","True","Principal Investigator","A placebo-controlled, double-blind study of the effect of two dose levels of Sirolimus plus standard immunosuppressive therapy in renal allograft recipients (RAP-IV)","N. Muirhead","","$25,829,301.00"
"Muirhead, Norman","Medicine","1997/08","2002/08","Grants","Funded","False","True","Principal Investigator","A study to determine the impact of hemoglobin maintenance and other interventional strategies to prevent or delay the progression of left ventricular mass increase in subjects with early renal insufficiency (PRI/EPO-CAN-10)","N. Muirhead","","$46,582,587.00"
"Muirhead, Norman","Medicine","1998/04","1999/12","Grants","Funded","False","True","Principal Investigator","Open-label study to examine the change in cyclosporine-pharmacokinetics during the first two weeks after renal transplantation in patients receiving neoral","N. Muirhead","","$38,814,060.00"
"Muirhead, Norman","Medicine","1998/10","1999/12","Grants","Funded","False","True","Principal Investigator","Open, randomized, parallel group pilot study to evaluate the feasibility of ‘sparse sampling AUC’ monitoring of cyclosporine as compared to conventional ‘trough’ monitoring in patients treated with Neoral and Simulect and steroids for the prevention of acute rejection in de novo kidney transplantation” (NEO-07)","N. Muirhead","","$53,110,867.00"
"Muirhead, Norman","Medicine","2001/10","2002","Grants","Funded","False","True","Principal Investigator","A three-year, randomized, multicenter, double-blind, double-dummy, parallel group study of the efficacy and safety of SDZ RAD tablets versus mycophenolate mofetil as part of triple immunosuppressive therapy in de novo renal transplant recipients","N. Muirhead","","$66,777,761.00"
"Muirhead, Norman","Medicine","1998/10","2002","Grants","Funded","False","True","Principal Investigator","A three-year, randomized, multicenter, double-blind, double-dummy, parallel group study of the efficacy and safety of SDZ RAD tablets versus mycophenolate mofetil as part of triple immunosuppressive therapy in de novo renal transplant recipients","N. Muirhead","","$58,885,828.00"
"Muirhead, Norman","Medicine","1997","2001","Grants","Funded","False","True","Co-Investigator","A phase III randomized, double-blind placebo-controlled multicentre study of the efficacy of odulimomab (AntiLFATM) in preventing delayed graft function (DGF) of cadaveric renal allografts in patients not receiving biological induction immunosuppression therapy","A. Jevnikar","N. Muirhead, D. Hollomby, A. House.","$46,599,416.00"
"Muirhead, Norman","Medicine","1999","2000","Grants","Funded","False","True","Co-Investigator","Prograf (tacrolimus) as secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure Protocol FKC-003","A. Jevnikar","N. Muirhead, D. Hollomby, A. House.","$23,062,602.00"
"Muirhead, Norman","Medicine","1999/08","2000/08","Grants","Funded","False","True","Principal Investigator","Valsartan in the treatment of chronic renal allograft dysfunction","N. Muirhead","","$47,127,064.00"
"Muirhead, Norman","Medicine","2000","2003","Grants","Funded","False","True","Principal Investigator","Double blind study to assess the impact of normalization of hemoglobin compared to partial correction of hemoglobin with Eprex/Erypro on left ventricular structure in early hemodialysis patients” (PRI/EPO-INT68)","N. Muirhead","A. House","$45,416,180.00"
"Muirhead, Norman","Medicine","2000","2003","Grants","Funded","False","True","Co-Investigator","A randomized double-blind parallel group evaluation of usual care plus cerivastatin 0.4mg once daily compared with usual care (placebo) alone in patients with end stage renal disease (ESRD) new to hemodialysis: Cerivastatin heart outcomes in renal disease: Understanding survival (CHORUS)","A. House","N. Muirhead","$53,307,638.00"
"Muirhead, Norman","Medicine","2000/10","2002/10","Grants","Funded","False","True","Principal Investigator","Open, multicentre study to evaluate the proportion of hemodailysis patients maintaining constant hemoglobin values when switching from 2x or 3x weekly intravenous or subcutaneous application to once weekly application of epoetin alfa” (PRI/EPO-INT-77)","N. Muirhead","A. House","$68,980,139.00"
"Muirhead, Norman","Medicine","2000","2002","Grants","Funded","False","True","Principal Investigator","Cerivastatin and heart outcomes in renal disease understanding survival","N. Muirhead","A. House, P. Cordy and C. Kortas.","$32,900,935.00"
"Muirhead, Norman","Medicine","2001","2005","Grants","Funded","False","True","Principal Investigator","Effect of early correction of anemia on the progression of chronic renal insufficiency (ECAP)","N. Muirhead","A. House","$45,387,424.00"
"Muirhead, Norman","Medicine","2002","2008","Grants","Funded","False","True","Principal Investigator","A study to determin the impact of hemoglobin maintenance and other interventional strategies to prevent or delay the progression of left ventricular mass increase in subjects with early renal insufficiency (PRE/EPO-CAN-27)","N. Muirhead","A. House","$60,380,159.00"
"Muirhead, Norman","Medicine","2002","2003","Grants","Funded","False","True","Principal Investigator","A 1 year multicentre, randomized, open label, parallel group pilot study of the efficacy and safety of RAD with early versus possibly delayed initiation of neoral in de novo renal transplant recipients at increased risk of delayed graft dysfunction","N.Muirhead","A. House, A. Jevnikar and D. Hollomby","$57,810,506.00"
"Muirhead, Norman","Medicine","2003","2008","Grants","Funded","False","True","Principal Investigator","A study to evaluate the use of rosuvastatin in subjects on regular hemodialysis: an assessment of survival and cardiac events: a double blind randomized multicentre phase 3b parallel group study to compare the effects of rosuvastatin (10mg oral) with placebo assessment of survival and cardiovascular events when given to subjects with end stage renal failure on chronic hemodialysis treatment","N. Muirhead","A. House.","$71,032,784.00"
"Muirhead, Norman","Medicine","2001","2006","Grants","Funded","False","True","Co-Investigator","Rapammune outcomes assessment registry (ROAR)","A. Jevnikar","N. Muirhead, D. Hollomby and A. House.","$26,008,533.00"
"Muirhead, Norman","Medicine","2002","2003","Grants","Funded","False","True","Co-Investigator","A phase 2, randomized, multicentre, open-label safety study of ISA 247 and cyclosporine (neoral) in post renal transplant patients","A. Jevnikar","N. Murihead, D. Hollomby and A. House.","$31,775,082.00"
"Muirhead, Norman","Medicine","2002","2004","Grants","Funded","False","True","Principal Investigator","A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continual use of calcineurin inhibitors in renal allograft recipients","N. Muirhead","A. Jevnikar, D. Hollomby and A. House","$4,461,775.00"
"Muirhead, Norman","Medicine","2002","2009","Grants","Funded","True","False","Co-Investigator","Folic acid for vascular outcome reduction in transplantation (FAVORIT)","A. House","N. Muirhead, A. Jevnikar, D. Hollomby, A. Hodsman and R. Bullas.","$33,976,679.00"
"Muirhead, Norman","Medicine","2005","2008","Grants","Funded","False","True","Principal Investigator","A trial to Reduce Cardiovascular Events with Aranesp Therapy","N. Muirhead","A. House, F. Rehman.","$7,648,002.00"
"Muirhead, Norman","Medicine","2004","2006","Grants","Funded","False","True","Principal Investigator","An open label, randomized, multi-center, parallel group study to demonstrate correction of anemia using subcutaneous injections of RO0503821 in patients with chronic kidney disease who are not on dialysis","N. Muirhead","A. House, F. Rehman.","$12,919,770.00"
"Muirhead, Norman","Medicine","2004","2006","Grants","Funded","False","True","Principal Investigator","An open label, randomized, multicentre, parallel group study to demonstrate correction of anemia using intravenous injections of R00503821 in patients with chronic kidney disease who are on dialysis","N. Muirhead","A. House, F. Rehman.","$28,563,662.00"
"Muirhead, Norman","Medicine","2004","2006","Grants","Funded","False","True","Principal Investigator","An open label, randomized, multicentre, parallel group study to determine the efficacy and safety of R00503821 when administered to patients with chronic kidney disease who are on dialysis","N. Muirhead","A. House, F. Rehman.","$1,202,570.00"
"Muirhead, Norman","Medicine","2005","2007","Grants","Funded","False","True","Principal Investigator","An Open-label, Multi-center Study to Document the Efficacy, Safety and Tolerability of Long-term Administration of RO0503821 in Patients with Chronic Renal Anemia","N. Muirhead","A. House, F. Rehman.","$51,217,833.00"
"Muirhead, Norman","Medicine","2004","2006","Grants","Funded","False","True","Principal Investigator","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the effects of Aliskiren on Proteinuria when Added to Standardized Losartan Therapy and Optional Antihypertensive Therapy in Patients with Hypertension and Type 2 Diabetes Mellitus","N. Muirhead","A. House, F. Rehman.","$41,454,159.00"
"Muirhead, Norman","Medicine","2005","2008","Grants","Funded","False","True","Principal Investigator","A Two-year Extension to a One-year, Multicenter, Partially Blinded, Double -Dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined with Reduced-dose or Full-dose Neoral and corticosteroids Versus Mycophenolate Mofetil (MMF, Cellcept) Combined with Full-dose Neoral and Corticosteroids, in De Novo Adult Renal Transplant Recipients","N. Muirhead","A. House, F. Rehman.","$40,274,611.00"
"Muirhead, Norman","Medicine","2004","2006/06","Grants","Funded","False","True","Principal Investigator","A one year, multicentre, partially blinded, double dummy, randomized study to evaluate the efficacy of FTY720 combined with reduced dose or full dose neural and corticosteroids versus mycophenolate mofetil (MMF< Cellcept) combined with full dose Neoral and corticosteroids, in de novo adult renal transplant recipients","N. Muirhead","A. House, F. Rehman","$14,591,021.00"
"Muirhead, Norman","Medicine","2007","2010","Grants","Funded","False","True","Principal Investigator","Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events","N. Muirhead","A. House, F. Rehman.","$17,851,874.00"
"Muirhead, Norman","Medicine","2006","2009","Grants","Funded","False","True","Principal Investigator","A Randomized, Open Label, Comparative Evaluation of Safety and Efficacy of Sirolimus versus Cyclosporine when compared in a Regimen Containing Basiliximab, Mycophenolate Mofetil, and Corticosteroids in Primary De Novo Renal Allograft Recipients","N. Muirhead","A. House, F. Rehman.","$27,146,757.00"
"Muirhead, Norman","Medicine","2005","present","Grants","Funded","False","True","Principal Investigator","A Facilitated Access Program to Provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in Solid organ transplantation","N. Muirhead","A. House, F. Rehman","$65,150,251.00"
"Muirhead, Norman","Medicine","2006","2012","Clinical Trials","Funded","False","True","Co-Investigator","A prospective, randomized, open-label, pilot study to compare the effect on carotid atherosclerosis of a tacrolimus based regimen with conversion form a tacrolimus to a sirolimus-based regimen at 3-4 months post-transplant in de novo renal transplant recipients","A. House","N. Muirhead, F. Rehman","$64,825,446.00"
"Muirhead, Norman","Medicine","2002","2003","Grants","Funded","False","True","Co-Investigator","Immunosuppression without calcineurin inhibition in renal transplantation: a pilot study of a novel non-nephrotoxic regimen","A. House","N. Muirhead, F. Rehman","$33,064,707.00"
"Muirhead, Norman","Medicine","2006","2011","Grants","Funded","True","False","Principal Investigator","ACE- Inhibition for the preservation of renal function and patient survival in kidney transplantation","N. Muirhead","G. Knoll, A. House, F. Rehman.","$48,540,125.00"
"Muirhead, Norman","Medicine","2006","2008","Grants","Funded","False","False","Principal Investigator","Resistance to Erythropoietin Effectiveness Algorithm Trial (A strategy for optimizing erythropoietin therapy in patients with erythropoietin resistance: A Randomized Controlled Trial)","N. Muirhead","A. House, F. Rehman","$425,025.00"
"Muirhead, Norman","Medicine","2002","2006","Grants","Funded","False","True","Co-Investigator","Prograf as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure","Dr. Anthony Jevnikar","","$40,493,933.00"
"Muirhead, Norman","Medicine","2002","2006","Grants","Funded","False","True","Co-Investigator","Rapamune Outcomes Assessment Registry","Dr. Anthony Jevnikar","","$13,229,327.00"
"Muirhead, Norman","Medicine","2002","present","Grants","Funded","False","True","Co-Investigator","A Prospective, Multi-centre Study for the Determination of the Incidence of Cardiovascular Events and the Prevalence of Risk Factors for Cardiovascular Disease in Renal Transplantation","Dr. Anthony Jevnikar","Astellas Pharma Canada","$14,465,458.00"
"Muirhead, Norman","Medicine","2004","2009","Grants","Funded","False","True","Co-Investigator","FKC-010 Clinical regional transplant programs study of immunosuppressive therapy related toxicities in renal transplant recipients managed at regional or satellite community nephrology clinics","Dr. Anthony Jevnikar","Astellas Pharma Canada","$50,390,270.00"
"Muirhead, Norman","Medicine","2004","2009","Grants","Funded","False","True","Co-Investigator","FKC-010 Data Management Regional transplant programs study of immunosuppressive therapy related toxicities in renal transplant recipients managed at regional or satellite community nephrology clinics","Dr. Anthony Jevnikar","Astellas Pharma Canada","$35,758,946.00"
"Muirhead, Norman","Medicine","2002","present","Grants","Funded","False","True","Co-Investigator","Multi-centre Study for the Determination of the Incidence of Cardiovascular Events and the Prevalence of Risk Factors for Cardiovascular Disease in Renal Transplant Patients","Dr. Anthony Jevnikar","Astellas Pharma Canada","$44,822,476.00"
"Muirhead, Norman","Medicine","2006","2009","Grants","Funded","False","True","Co-Investigator","A phase 2 B randomized, multicentre, open-label concentration controlled safety study os ISA247 and Tacrolimus in de novo renal transplant patients","Dr. Anthony Jevnikar","Isotechnika","$20,858,697.00"
"Muirhead, Norman","Medicine","2004","2007","Grants","Funded","False","True","Co-Investigator","Evaluation of the long-term safety and efficacy of a tacrolimus-based 5-day steroid rapid withdrawal immunoprophylactic regimen in de novo renal transplantation","Dr. Anthony Jevnikar","","$7,776,878.00"
"Muirhead, Norman","Medicine","2003","2007","Grants","Funded","False","True","Co-Investigator","A multicentre 1:1 randomized, double blind, two arm parallel group study to evaluate and compare the efficacy and safety of modified release tacrolimus FK506E (MR4) versus Tacrolimus FK506","Dr. Anthony Jevnikar","","$50,208,797.00"
"Muirhead, Norman","Medicine","2007","2009","Grants","Funded","False","True","Co-Investigator","A multicentre 1:1 randomized, double blind, two arm parallel group study to evaluate and compare the efficacy and safety of modified release tacrolimus FK506E (MR4) versus Tacrolimus FK506","Dr. Anthony Jevnikar","Astellas Pharma Canada","$42,028,187.00"
"Muirhead, Norman","Medicine","1987/07","1988/06","Grants","Funded","False","False","Principal Investigator","Risk factors for post renal transplant hypercalcemia","N. Muirhead","","$29,125,073.00"
"Muirhead, Norman","Medicine","1990/06","1991/06","Grants","Funded","False","False","Principal Investigator","Mannitol in the prevention of ATN post cadaveric renal transplant: A randomized controlled trial","N. Muirhead","","$45,978,894.00"
"Pickering, J. Geoffrey","Medicine","2001/07","2004/06","Grants","Funded","True","False","Co-Investigator","Cytokine Regulation of Transplantation Injury","D. Kelvin","J.G. Pickering","$41,081,786.00"
"Pickering, J. Geoffrey","Medicine","1995","1997","Grants","Funded","True","False","Principal Investigator","Role of beta-1 integrins in vascular remodeling","J.G. Pickering","B.M.C. Chan","$36,891,492.00"
"Pickering, J. Geoffrey","Medicine","2004","2004/09","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Eric van der Veer","J.G. Pickering","","$48,716,779.00"
"Pickering, J. Geoffrey","Medicine","2008/09","2008/09","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Theodore Small","J.G. Pickering","","$10,915,628.00"
"McManus, Ruth","Medicine","2008/08","2010/08","Grants","Funded","True","False","Principal Investigator","Vitamin D and Cytokine levels in women with and without gestational diabetes","Dr R McManus","Dr I Grioux, Dr K Summers, Dr B DeVrijer","$37,762,230.00"
"Kostuk, William","Medicine","2000","2004","Grants","Funded","False","True","Principal Site Investigator","IMAGINE – Ischemia Management with Accupril Post Bypass Graft via Inhibition with CoNverting Enzyme","","","$8,656,836.00"
"Rehman, Faisal","Medicine","2008/02","2009/12","Grants","Funded","False","False","Co-Investigator","Vitamin D Deficiency and the Risk of Acute Rejection Post-Renal Transplantaion: a study to determine whether Vitamin D deficiency, as quantified by the concentration of 25-hydroxyvitamin D, is associated with acute rejection in renal transplant patients.","House, A","","$21,139,906.00"
"Rehman, Faisal","Medicine","2008/01","2010/01","Grants","Funded","False","True","Co-Investigator","A Randomized, double blind, placebo-controlled, parallel group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, Aliskiren, on top of the conventional treatment, reduces cardiovascular and renal morbidity and mortality.","Muirhead, N","","$17,895,438.00"
"Rehman, Faisal","Medicine","2007/11","2008/09","Clinical Trials","Funded","False","True","Co-Investigator","Study to Assess Renal Replacement Therapy: A multicentre retrospective chart review to evaluate the incidence, hemoglobin levels and demographics of subjects who start renal replacement therapy in Canadian facilities.(STARRT EPR-C-07-CAN-016 Phase IV)","Muirhead, N","Rehman, F","$73,536,130.00"
"Rehman, Faisal","Medicine","2007","2009","Clinical Trials","Funded","False","False","Co-Investigator","Resistence to Erythroprotein Effectiveness Algorithm Trial. A strategy for optimizing erythroprotein therapy in patients with erythroprotein resistance: A randomized controlled trial.","","Rehman, F","$72,737,238.00"
"Rehman, Faisal","Medicine","2003","2003","Grants","Funded","False","True","Co-Investigator","Immunosuppression without calcineurin inhibition in renal transplantation: A pilot study of a novel non-nephrotoxic regimen.","House, A","Rehman, F","$45,790,725.00"
"Kostuk, William","Medicine","2008/03","2011/06","Grants","Funded","False","True","Co-Investigator","SATURN - Study of coronary atheroma by the intravascular ultrasound: effect of losuvastatin vs atorvastatin.","","","$36,505,900.00"
"Kostuk, William","Medicine","2007","present","Grants","Funded","False","False","Co-Investigator","CURRENT/OASIS 7 - Clopidogrel optimal loading dose usage to reduce recurrent events/optimal antiplatelet strategy for interventions.","","","$48,911,291.00"
"Kostuk, William","Medicine","2008","2009","Grants","Funded","False","True","Principal Site Investigator","RE-DEEM - Randomized dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving ASA and clopidogrel multicentred, prespective, placebo controlled, group dose escalation trial.","","","$35,263,801.00"
"Diamantouros, Pantelis","Medicine","2007","2009","Grants","Funded","False","False","Co-Investigator","CURRENT/OASIS 7 - Clopidogrel optinal loading dose usage to reduce recurrent events/optimal antiplatelet strategy for interventions.","Dr. William. J. Kostuk","Dr. P. Diamantouros","$38,650,439.00"
"Diamantouros, Pantelis","Medicine","2008/03","2011/06","Grants","Funded","False","True","Principal Site Investigator","SATURN - Study of coronary atheroma by the intravascular ultrasound; effect of losuvastatin vs. atorvastatin.","Dr. P. Diamantouros","","$69,088,154.00"
"Diamantouros, Pantelis","Medicine","2006","2012/02","Grants","Funded","False","False","Co-Investigator","FREEDOM - Future revascularization evaluation in patienst with diabetes mellitus","Dr. William J. Kostuk","Dr. P. Diamantouros","$69,716,998.00"
"Hill, David","Medicine","2006/07","2010/06","Grants","Funded","True","False","Principal Investigator","“Control of regeneration of the endocrine pancreas”","","","$65,205,781.00"
"Hill, David","Medicine","2007/07","2012/06","Grants","Funded","True","False","Co-Investigator","“Prevention of Cardiovascular Complications of Diabetes”","","","$47,968,954.00"
"Hill, David","Medicine","2005/07","2010/06","Grants","Funded","True","False","Co-Investigator","""Fetal Growth restriction: Mechanisms and Outcomes”","","","$34,340,032.00"
"Hill, David","Medicine","2007/07","2009/06","Grants","Funded","True","False","Co-Principal Investigator","""Early-life origins of visceral obesity”.","","K Yang and E Arany","$50,039,206.00"
"Hill, David","Medicine","2001/07","2007/06","Grants","Funded","True","False","Co-Investigator","Individual Operating Grant","","","$49,447,199.00"
"Hill, David","Medicine","2005/07","2007/06","Grants","Funded","True","False","Principal Investigator","Jessie’s Journey. “Duchenne’s Research Initiative”.","","","$51,514.00"
"Hill, David","Medicine","2005/07","2007/06","Grants","Funded","True","False","Co-Investigator","“Strategies to prevent progression to Type 2 diabetes in an at-risk pediatric population”.","","Ms Linda McKay RN, Bluewater Diabetes and Clinical Nutrition Centre, Sarnia; C. Clarson","$57,956,336.00"
"Hill, David","Medicine","2002/07","2007/06","Grants","Funded","True","False","Principal Investigator","“ Pancreatic Islet Generation from Human Stem Cells”.","","","$32,854,610.00"
"Hill, David","Medicine","2001/07","2006/06","Grants","Funded","True","False","Principal Applicant","“Maternal Hyperinsulinemia and Fetal Programming”.","","Dr Mulchand Patel","$25,611,323.00"
"Hill, David","Medicine","2003/07","2006/06","Grants","Funded","True","False","Principal Investigator","“Insulin-like growth factors and beta cell ontogeny”.","","","$26,404,284.00"
"Hill, David","Medicine","2004/07","2006/06","Grants","Funded","True","False","Co-Investigator","“Plasticity of adult neuronal and pancreatic progenitor cells”.","","A. Logan, D.J.Hill and S. Minger.","$14,694,189.00"
"Hill, David","Medicine","2002/07","2006/06","Grants","Funded","False","False","Principal Investigator","“Control of development of the endocrine pancreas”.","","","$16,615,003.00"
"Hill, David","Medicine","1999/07","2004/06","Grants","Funded","True","False","Principal Investigator","Study of the prevention of Type 1 diabetes.","","","$61,517,234.00"
"Hill, David","Medicine","1998","2002","Grants","Funded","False","False","Principal Investigator","“Regulation of pancreatic beta cell growth and susceptibility to IDDM by IGFs”.","","","$64,170,045.00"
"Hill, David","Medicine","1998","2003","Grants","Funded","False","False","Principal Investigator","","","","$9,670,190.00"
"Hill, David","Medicine","1999","2002","Grants","Funded","False","False","Principal Investigator","“Control of development of the endocrine pancreas”.","","","$30,345,500.00"
"Hill, David","Medicine","1996","2001","Grants","Funded","False","False","Principal Investigator","“Molecular mechanisms of the development of insulitis and its regulation in IDDM”.","","","$60,646,148.00"
"Hill, David","Medicine","1993","1999","Grants","Funded","False","False","Collaborator","“Fetal and neonatal health and development”.","","","$10,473,964.00"
"Hill, David","Medicine","1997","1997","Grants","Funded","False","False","Collaborator","“Evaluation of the clinical utility of IGF-I and IGFBP-3 in screening for growth hormone deficiency in children with short stature. Prospective evaluation of IGF-I and IGFBP-3 in screening for growth hormone deficiency in children with brain tumors. Influence of synthetic HGH on growth of malignant cerebral tumors: Influence of in vitro and in vivo model systems.”","","Dr C. Clarson and Dr R. Del Maestro","$22,745,833.00"
"Hill, David","Medicine","1996","2003","Grants","Funded","False","False","Principal Investigator","“Growth Factors and beta cell hyperplasia”.","","","$11,129,229.00"
"Hill, David","Medicine","1994","1995","Grants","Funded","False","False","Principal Investigator","”The trophic control of pancreatic islet growth and development”.","","","$61,024,245.00"
"Hill, David","Medicine","1989","1993","Grants","Funded","False","False","Collaborator","“Fetal and neonatal health and development”.","","","$74,385,661.00"
"Hill, David","Medicine","1989","1992","Grants","Funded","False","False","Principal Investigator","“Possible role for insulin-like growth factors as autocrine stimuli on pancreatic B cell growth in the rat fetus”.","","","$52,550,203.00"
"Hill, David","Medicine","1990","1991","Grants","Funded","False","False","Collaborator","“Hepatic release of somatomedin binding proteins: implications for metabolic control”.","","","$21,862,142.00"
"Hill, David","Medicine","1989","1991","Grants","Funded","False","False","Collaborator","“Growth and differentiation in thyroid neoplasia: an evaluation of the involvement of peptide growth factors”.","","","$57,902,760.00"
"Hill, David","Medicine","1988","1990","Grants","Funded","False","False","Collaborator","“Transforming growth factor expression in human colon carcinoma: Possible association with metastatic capability”.","","","$64,248,880.00"
"Hill, David","Medicine","1987","1989","Grants","Funded","False","False","Collaborator","“Growth factors and compensatory organ growth”.","","","$45,697,406.00"
"Hill, David","Medicine","1987","1989","Grants","Funded","False","False","Principal Investigator","“The role of peptide growth factors in the development and progression of experimental hepatocarcinogenesis”.","","","$19,210,416.00"
"Hill, David","Medicine","1986","1988","Grants","Funded","False","False","Principal Investigator","“The study of somatomedin/insulin-like growth factor synthesis and presence in the early gestation human fetus”.","","","$25,517,446.00"
"Hill, David","Medicine","1984","1988","Grants","Funded","False","False","Principal Investigator","“Somatomedin gene expression and peptide action during human fetal growth”.","","","$13,283,691.00"
"Hill, David","Medicine","1985","1986","Grants","Funded","False","False","Principal Investigator","“The paracrine role of somatomedins/insulin- like growth factors and other peptide growth factors on the growth and function of the pancreatic ß-cell”.","","","$43,517,989.00"
"Hill, David","Medicine","1984","1986","Grants","Funded","False","False","Collaborator","“The actions of transforming growth factors on the course of tissue differentiation in vitro and a possible growth factor abnormality associated with lymphoblastic leukemia”.","","","$65,288,701.00"
"Hill, David","Medicine","1983","1985","Grants","Funded","False","False","Collaborator","“The occurrence, nature and biological actions of transforming growth factors in the mammalian fetus”.","","","$67,868,581.00"
"Zhang, Zhu-Xu","Medicine","2004/06","2004/06","Grants","Funded","False","False","Principal Investigator","Multi Organ Transplantation Program,","","","$57,143,618.00"
"Zhang, Zhu-Xu","Medicine","2004/07","2004/07","Grants","Funded","False","False","Principal Investigator","","","","$18,503,689.00"
"Zhang, Zhu-Xu","Medicine","2005/04","2005/04","Grants","Funded","False","False","Principal Investigator","Multi Organ Transplantation Program,","","","$57,330,306.00"
"Zhang, Zhu-Xu","Medicine","2006/09","2006/09","Grants","Funded","False","False","Principal Investigator","","","","$56,203,940.00"
"Zhang, Zhu-Xu","Medicine","2006/09","2006/09","Grants","Funded","False","False","Principal Investigator","Infrastructure Operation Fund","","","$13,852,132.00"
"Zhang, Zhu-Xu","Medicine","2007/05","2007/05","Grants","Funded","False","False","Principal Investigator","Multi Organ Transplantation Program,","","","$182,131.00"
"Zhang, Zhu-Xu","Medicine","2007/07","2007/07","Grants","Funded","False","False","Principal Investigator","","","","$632,576.00"
"Zhang, Zhu-Xu","Medicine","2008/05","2008/05","Grants","Funded","False","False","Principal Investigator","Multi Organ Transplantation Program,","","","$30,470,570.00"
"Zhang, Zhu-Xu","Medicine","2008/07","2008/07","Grants","Funded","False","False","Principal Investigator","","","","$65,629,053.00"
"McCauley, William","Medicine","","","Grants","Funded","False","False","Principal Investigator","","","","$23,564,497.00"
"Shepherd, Lisa","Medicine","1999","","Grants","Funded","False","False","Principal Investigator","Confined Space Accidents on the Farm: Hydrogen Sulphide, Nitrogen Dioxide Exposures","Lisa Shepherd","","$66,443,265.00"
"Mehta, Sanjay","Medicine","2008/07","2009/06","Grants","Funded","True","False","Principal Investigator","Human pulmonary microvascular endothelial cell injury: role of neutrophil-endothelial cell interactions.","S Mehta","","$36,695,865.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Risk of death and acute care hospital utilization by emergency department patients without a family physician","","","$55,899,362.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Psychological and occupational impact of the SARS outbreak on healthcare workers","","","$24,865,043.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Expansion of Primary Angioplasty in an Integrated and Step-Wise Manner to Patients Presenting to Community Hospitals with Myocardial Infarction","","","$59,605,258.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Validation of a geriatric assessment tool","","","$11,932,000.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Predictive Validity Comparison of Two Five-Level Triage Acuity Scales in Canadian Emergency Departments","","","$16,440,850.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Principal Investigator","Measurement of violence in the emergency department and assessment of a strategy to reduce health care worker risk","","","$5,799,226.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Early discharge of patients with presumed opioid overdose: derivation and validation of a clinical decision rule","","","$52,833,477.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Early discharge of patients with presumed opioid overdose: derivation and validation of a clinical decision rule","","","$57,023,845.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Early discharge of patients with presumed opioid overdose: derivation and validation of a clinical decision rule","","","$15,319,199.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Early discharge of patients with presumed opioid overdose: derivation and validation of a clinical decision rule","","","$17,973,061.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Early discharge of patients with presumed opioid overdose: derivation and validation of a clinical decision rule","","","$64,626,236.00"
"Fernandes, Christopher","Medicine","","","Grants","Funded","False","False","Co-Investigator","Early discharge of patients with presumed opioid overdose","","","$64,912,727.00"
"Flanagan, Peter","Medicine","1979","1981","Grants","Funded","True","False","Principal Investigator","Intestinal Lead Absorption in Human Subjects","","","$56,395,288.00"
"Flanagan, Peter","Medicine","1980","1982","Grants","Funded","True","False","Principal Investigator","Transport of Zinc in Intestinal Brush Border and Basolateral Membranes","","","$37,566,877.00"
"Flanagan, Peter","Medicine","1985","1987","Grants","Funded","True","False","Principal Investigator","The Absorption of Zinc from Food in Human Subjects","","","$6,455,417.00"
"Flanagan, Peter","Medicine","1983","1984","Grants","Funded","True","False","Principal Investigator","Intestinal Absorption of Iron and Related Metals","","L.S. Valberg","$32,866,091.00"
"Flanagan, Peter","Medicine","1984","1986","Grants","Funded","True","False","Principal Investigator","Intestinal Absorption of Iron and Related Metals","","L.S. Valberg","$45,502,029.00"
"Flanagan, Peter","Medicine","1986","1989","Grants","Funded","True","False","Principal Investigator","Intestinal Absorption of Iron and Related Metals","","L.S. Valberg","$54,263,144.00"
"Flanagan, Peter","Medicine","1992","1997","Grants","Funded","True","False","Principal Investigator","Hemochromatosis","","","$1,291,894.00"
"Flanagan, Peter","Medicine","1993","1995","Grants","Funded","True","False","Principal Investigator","Iron Regulatory Factor in Hemochromatosis","","P.C. Adams","$37,166,168.00"
"Flanagan, Peter","Medicine","","2004","Grants","Funded","True","False","Principal Investigator","Analysis of ePCL Learning","","","$22,788,081.00"
"Flanagan, Peter","Medicine","2003","2004","Grants","Funded","True","False","Principal Investigator","Medical Education Online: An Exploratory Study of Medical Students’ Self-Directed and Collaborative Learning Through The Electronic Patient-Centered Learning Course","","","$48,862,336.00"
"Flanagan, Peter","Medicine","","1997","Grants","Funded","True","False","Principal Investigator","Just-In-Time Pedagogy for Videoconferencing and Webcasting: An Online Module for Faculty Development","","P. Paolucci","$63,822,690.00"
"Montero Odasso, Manuel","Medicine","2008/01","2009/01","Grants","Funded","True","False","Principal Investigator","""Effect of high doses of vitamin D on muscle and mobility in frail older adults. A pilot study.""","Dr. Manuel Montero-Odasso","Crilly R, Doherty T, Kloseck M, Speechley M, Fraher L, Duque G, and Petrella R.","$27,674,339.00"
"Montero Odasso, Manuel","Medicine","2007/07","2009/07","Grants","Funded","True","False","Principal Investigator","Reliability of quantitative gait analysis in older persons with Mild Cognitive Impairment: Pilot Study","Manuel Montero-Odasso","","$48,413,741.00"
"Montero Odasso, Manuel","Medicine","2008/07","2009/07","Grants","Funded","True","False","Co-Investigator","""Pattern of brain activation during working memory with and without emotional interference in patients with Mild Cognitive Impairment""","Amer Burham","","$3,138,492.00"
"Montero Odasso, Manuel","Medicine","2005","2005","Grants","Funded","True","False","Principal Investigator","""Falls prevention program in a long term care institution.""","","","$65,313,988.00"
"Montero Odasso, Manuel","Medicine","1998","1998","Grants","complete","False","False","Principal Applicant","""Mobility, gait and falls in elderly people""","","","$72,187,569.00"
"Wells, Jennie","Medicine","2008/01","present","Grants","Funded","True","False","Co-Investigator","Reliability of quantitative gait analysis in older persons with Mild Cognitive Impairment: A pilot study. Glenn E. Pratt Endowment Fund","Montero-Odasso M","Montero-Odasso M, Borrie M, Gutmanis I, Wells J.","$19,279,146.00"
"Hramiak, Irene","Medicine","2008/03","2009/12","Clinical Trials","Funded","False","True","Principal Investigator","A 12-week phase 2A, randomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 on glucose control and body weight in overweight adult subjects with Type 2 diabetes mellitus.","IM Hramiak","CG McDonald, TL Paul","$5,500,304.00"
"Licskai, Christopher","Medicine","2006/07","2008/06","Grants","Funded","True","False","Principal Investigator","Spirometry Quality Project","Dr. Christopher Licskai","Todd Sands, Ivan Nicoletti, Lisa Paolatto, Madonna Ferrone","$11,280,930.00"
"Licskai, Christopher","Medicine","2006/07","2008/06","Grants","Funded","True","False","Principal Investigator","Spirometry in Primary Care","Dr. Christopher Licskai","","$60,458,632.00"
"Crilly, Richard","Medicine","2005/06","2010/07","Grants","Funded","True","False","Co-Investigator","Aging and Community Health Research and Laboratory","Kloseck, M.","","$21,873,887.00"
"Crilly, Richard","Medicine","2008","2009","Grants","Funded","True","False","Co-Investigator","The Effect of High Doses of Vitamin D on Muscle and Mobility in Frail Older Adults: A Pilot Study.","MonteroOdasso, M.","Crilly, R., Doherty, T., Kloseck, M., Speechley, M., Fraher, L., Duque, G., and Petrella, R.","$62,333,393.00"
"Crilly, Richard","Medicine","2008","2011","Grants","Funded","True","True","Co-Principal Investigator","Application of GIS Mapping Methodology to the Analysis of Age Distribution, Hip Fracture Distribution and Prescribing of Bisphosphonates in Southwestern Ontario.","","Kloseck, M. (Co-PI)","$63,392,294.00"
"Crilly, Richard","Medicine","1998/01","2001/12","Grants","Funded","True","False","Co-Principal Investigator","Building the Cherryhill Healthy Aging Program: Community Development Co-ordinator Position","Crilly, R. and Kloseck, M.","","$16,460,918.00"
"Crilly, Richard","Medicine","1999/01","1999/12","Grants","Funded","True","False","Co-Investigator","Evaluation of the Cherryhill Healthy Aging Program","Kloseck, M.","","$63,677,571.00"
"Crilly, Richard","Medicine","2001/01","2001/12","Grants","Funded","True","True","Co-Investigator","Bone Densitometer Screening Program: A Self-Referral Osteoporosis Screening Program for Community Seniors","Platt, N.","Crilly, R., Kloseck, M.","$47,741,602.00"
"Crilly, Richard","Medicine","2004","2005","Grants","Funded","True","True","Principal Investigator","Funding for Part-Time Hip Fracture System Co-ordinator","","Overend, T., Simon, K., Speechley, M., Kloseck, M., and Jones, G.","$5,517,426.00"
"Crilly, Richard","Medicine","2006","2010/06","Grants","Funded","True","True","Co-Principal Investigator","""Points of Opportunity"" to Optimize the Treatment and Diagnosis of Osteoporosis","Crilly, R. and Kloseck, M.","Paul, T.","$10,970,642.00"
"Borrie, Michael","Medicine","2008","","Grants","Funded","True","False","Co-Investigator","Canadian dementia Knowledge Translation Network.","Rockwood K","Rockwood K, Borrie M, Gutmanis I, Gibson M, Orange JB, Forbes D, Connelly D.","$63,567,696.00"
"Borrie, Michael","Medicine","2008","","Grants","Funded","True","False","Co-Investigator","Centres of Excellence in Inter-professional Practice and Collaborative Geriatric Care","David Ryan","Borrie MJ, Gutmanis I","$46,567,337.00"
"Borrie, Michael","Medicine","2008/01","present","Grants","Funded","True","False","Co-Investigator","Reliability of quantitative gait analysis in older persons with Mild Cognitive Impairment: A pilot study. Glenn E. Pratt Endowment Fund","Montero Odasso M","Borrie M, Gutmanis I, Wells J.","$71,542,422.00"
"Borrie, Michael","Medicine","2003","2004","Clinical Trials","Funded","False","True","Principal Site Investigator","An 80-week, randomized, multi-centre, parallel-group, double-blind study of the efficacy and safety of Atorvastatin 80 MG plus an acetylcholinesterase inhibitor vesus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate alzheimer's disease","","Borrie MJ, Wells JL (co-investigator)","$40,122,549.00"
"Siu, Samuel","Medicine","2000","2005","Clinical Trials","Funded","True","False","Co-Investigator","Astronomer Study: Effect of cholesterol lowering on progression of aortic stenosis in patients with mild to moderate aortic stenosis","Dr. Kwan-Leung Chan","","$69,300,537.00"
"Lewis, James","Medicine","2007/07","2012/06","Grants","Funded","True","False","Principal Investigator","The role of the surfactant system in acute lung injury and progression to multi-organ failure","J Lewis","R Veldhuizen","$29,843,139.00"
"Lewis, James","Medicine","2008/07","2011/07","Grants","Funded","True","False","Co-Applicant","Pulmonary delivery of surfactant for treatment of lung diseases","J Zhu","","$73,162,415.00"
"Sen, Mithu","Medicine","2007","2008","Grants","Funded","True","False","Co-Investigator","The influence of ventilator mode and patient-ventilator interaction on sleep quality in the intensive care unit","Karen Bosma","Mithu Sen, Femida Gwadry-Sridhar","$52,443,466.00"
"Sen, Mithu","Medicine","2007","2008","Grants","Funded","True","False","Co-Investigator","A prospective assessment of the hospital stay of patients undergoing surgery for obstructive sleep apnea (FG07-9)","Rotenberg B","PI: Rotenberg B. Co-investigator: Sen M.","$43,203,003.00"
"Kostuk, William","Medicine","2008/09","2012","Grants","Funded","False","True","Principal Applicant","A comparison of prasugrel and clopidogrel in acute coronary syndrome (ACS) subjects with unstable angina/non-ST-elevation myocardial infarction (UA?STEMI) who are medically managed. TRILOGY ACS","William Kostuk","","$70,714,868.00"
"Borrie, Michael","Medicine","2008/05","2011/07","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase III, multicentre, randomized, double-blind, placebo-controlled, parallel group, efficiency and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease","Borrie MJ","Sub-investigator: Wells, J","$54,496,034.00"
"Wells, Jennie","Medicine","2008/05","2011/07","Clinical Trials","Funded","True","True","Co-Investigator","A Phase III, multicentre, randomized, double-blind, placebo-controlled, parallel group, efficiency and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease","Borrie MJ","Borrie MJ, Wells JL","$57,441,656.00"
"van Uum, Stanislaus","Medicine","2006/07","2008/06","Grants","Funded","True","False","Principal Applicant","Hair Levels of Cortisol and Testosterone as Biomarkers for Depression and Hypogonadism","","","$53,345,589.00"
"van Uum, Stanislaus","Medicine","2005/07","2007/06","Grants","Funded","True","False","Principal Applicant","Frequency of a single nucleotide variant of human adenylyl cyclase VI (ACVI) in specific patient groups","","","$54,088,187.00"
"van Uum, Stanislaus","Medicine","2008/07","2010/06","Grants","Funded","True","False","Principal Applicant","Pharmacogenomics of Levothyroxine Therapy: Role of Transporter Genetic Polymorphisms in Intestinal and Hepatic Hormone Uptake","Stan van Uum","Rommel Tirona, Richard Kim","$64,437,557.00"
"Myers, Kathryn","Medicine","2003/07","2007/06","Grants","Funded","False","False","Principal Investigator","Improving the quality of vital statistics through education","","","$16,674,298.00"
"Myers, Kathryn","Medicine","2004/07","2005/06","Grants","Funded","True","False","Co-Investigator","Competencies of the specialist physician: the residents' perspective","Donald Farquhar","","$17,936,744.00"
"Myers, Kathryn","Medicine","2000/07","2003/06","Grants","Funded","True","False","Co-Applicant","Development of an educational program in effective consultation letter writing","","","$37,486,403.00"
"Gula, Lorne","Medicine","1997/09","2003/10","Clinical Trials","Funded","False","True","Principal Applicant","Ejection fraction assessment and survival: An analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)","Lorne Gula","","$74,994,911.00"
"Chande, Nilesh","Medicine","2007","","Grants","Funded","False","False","Co-Applicant","","","Co-applicant as part of Department of Medicine Undergraduate Medical Education Committee","$359,822.00"
"Montero Odasso, Manuel","Medicine","2009/10","2011/12","Grants","Funded","True","False","Co-Investigator","Taoist Tai Chi and a Memory Intervention for Individuals with Mild Cognitive Impairment - A Randomized Control Trial.","Jennifer Fogarty","Jennifer Fogarty, Manuel MonteroOdasso, Kevin Hansen, Jennie Wells","$6,386,381.00"
"Montero Odasso, Manuel","Medicine","2007/04","2009/04","Grants","Funded","True","False","Co-Investigator","Clinical Utility of the Montreal Cognitive Assessment (MoCA) in a Community Geriatric Population","Jennifer Fogarty","Co-Investigators: Iris Gutmanis, Manuel Montero Odasso, Robert Roth","$40,863,985.00"
"Goldszmidt, Mark","Medicine","2008","2009","Grants","Funded","True","False","Collaborator","Engagement in the in-training evaluation (ITE) process: an exploration of faculty perspectives","Watling C.,","Kenyon C., Singh I, Kortas C.,Haddara W, Schultz V., Zibrowski E., Lingard L., Goldszmidt M.","$49,453,999.00"
"Goldszmidt, Mark","Medicine","2008","2009","Grants","Funded","True","False","Collaborator","Engagement in the in-training evaluation (ITE) process: an exploration of faculty perspectives at two learning sites","Watling C.,","Kenyon C., Singh I, Kortas C.,Haddara W, Schultz V., Zibrowski E., Lingard L., Goldszmidt M.","$39,898,024.00"
"Goldszmidt, Mark","Medicine","2008","2011","Grants","Funded","True","False","Collaborator","Establishing a Network for the Interdisciplinary Scholarship of Professional Education","Pitman A and Kinsella E,","MacMillan B, Chhem R, Hibbert K, Goldszmidt M, Orchard C, Wamsley K, Nisker J, Bartlett D, DeLuca S, Kirkwood K, Van Deven T,","$3,467,973.00"
"Goldszmidt, Mark","Medicine","2008","2009","Grants","Funded","True","False","Collaborator","Development of an Advanced Organizer and Interactive, Electronic Seminar Series for the Medicine Clerkship Block.","Moist, L.","Goldszmidt M., Rehman F., Chande N., Malbrecht A","$31,677,833.00"
"Gregor, James","Medicine","2009/07","2009/12","Grants","Funded","False","False","Co-Investigator","Colonoscopy Simulator Project","Dr. Nitin Khanna","Keith McIntosh, Resident","$68,629,599.00"
"Adams, Paul","Medicine","2010/01","2012/06","Grants","Funded","True","False","Co-Principal Investigator","Simultaneous Non-invasive quantification of hepatic steatosis and iron concentration with MRI","Beaton, Melanie","Melanie Beaton, Charles Mackenzie","$42,297,072.00"
"Adams, Paul","Medicine","2009/01","2012/01","Grants","Funded","True","False","Co-Principal Investigator","Evaluation of phlebotomy as a treatment of non-alcoholic fatty liver disease","","Melanie Beaton, Paul Marotta, Mark Levstik","$72,906,662.00"
"Adams, Paul","Medicine","2008/11","2009/11","Grants","Funded","True","False","Co-Principal Investigator","Physician billing costs attributable to ambiguous genetic tests.","","Mark Speechley, David Alter","$74,925,798.00"
"Adams, Paul","Medicine","2005/11","2007/11","Grants","Funded","False","True","Principal Site Investigator","A double-blind, randomized, placebo-controlled multi-center, phase II, parallel dose-ranging study to assess the antifibrotic activity of G1262570 in chronic hepatitis C subjects with hepatic fibrosis who have failed antiviral therapy","Paul Adams","","$54,550,057.00"
"Adams, Paul","Medicine","2007/07","2008/06","Grants","Funded","False","True","Principal Site Investigator","A phase 1/II open label, dose-escalation trial to explore the safety and efficacy of ICL670 (Exjade) in patients with iron overload resulting from hereditary hemochromatosis","Paul Adams","","$10,650,237.00"
"Hackam, Daniel","Medicine","2008/12","2009/12","Grants","Funded","True","False","Co-Investigator","Improving Renal Codes Within Health Administrative Data: Two Systematic Reviews","Amit X Garg","OLIVER, Matthew J; QUINN, Robert R; HACKAM, Daniel G","$73,736,973.00"
"Hackam, Daniel","Medicine","2009/04","2010/04","Grants","Funded","True","False","Principal Investigator","Closing care gaps in cardiovascular medicine","Daniel Hackam","Kaveh Shojania, David Alter, George Dresser, David Spence","$16,796,017.00"
"Hackam, Daniel","Medicine","2009/04","2010/11","Grants","Funded","True","False","Principal Investigator","Statins and Renovascular Disease","Daniel Hackam","Amit Garg; Muhammad Mamdani; Sheldon Tobe; Peter Austin","$35,405,449.00"
"House, Andrew","Medicine","1997/07","2004/06","Grants","Funded","True","False","Co-Investigator","Atherosclerosis in Uremia","Adrian Fine","A House","$14,811,836.00"
"House, Andrew","Medicine","2005/02","2007/01","Grants","Funded","True","False","Co-Investigator","Carotid atherosclerosis progression measurement tools: Comparison of specificity and sensitivity of 2D US and 3D US imaging biomarkers","Grace Parraga","A House","$4,971,815.00"
"House, Andrew","Medicine","2007/09","2008/08","Grants","Funded","True","False","Co-Investigator","Cardiac gating of 3-dimensional ultrasound imaging of carotid atherosclerosis in rheumatoid arthritis","Grace Parraga","A House, Christiane Mallett (Masters student)","$72,006,482.00"
"House, Andrew","Medicine","2007/07","2012/06","Grants","Funded","True","False","Principal Site Investigator","Vitamin D deficiency and the risk of acute rejection post renal transplantation","Dr. D. Zimmerman","A House","$8,587,930.00"
"House, Andrew","Medicine","2008/07","2010/06","Grants","Funded","False","True","Principal Site Investigator","Randomized, open-label 2-arm parallel design comparator study of the effect of Adalat XL compared to Tiazac XC on proteinuria and blood pressure in patients with diabetes and mild to moderate hypertension","A House","","$40,761,000.00"
"House, Andrew","Medicine","2008/07","2010/06","Grants","Funded","False","True","Co-Investigator","Observational study of late post renal transplant anemia and secondary hyperparathyroidism","Norman Muirhead","N Muirhed, A House, J Johnson","$55,492,800.00"
"House, Andrew","Medicine","2008/07","2011/06","Grants","Funded","False","True","Co-Investigator","(CERA) An open-label, randomized, multicenter, parallel-group study to demonstrate corection of anemia using once every four weeks subcutaneous injections of RO0503821 in patients with chronic kidney disease who are not on dialysis","Norman Muirhead","A House","$20,184,416.00"
"House, Andrew","Medicine","2008/07","2010/06","Grants","Funded","False","True","Co-Investigator","A phase 4, randomized, parallel group, multi-center study to assess the safety and efficacy of multiple dosing regimens of IV Conivaptan in subjects with euvolemic or hypervolemic hyponatremia","Norman Muirhead","A House","$60,750,102.00"
"House, Andrew","Medicine","2008/07","2011/06","Grants","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo-controlled, parallel group study in patients with type 2 diabetes at high risk for cardiovascular and renal events of aliskirin vs placebo (ALTITUDE)","Norman Muirhead","A House","$26,194,512.00"
"Gregor, James","Medicine","2009/01","present","Clinical Trials","Funded","False","False","Principal Investigator","Safety of Purified Oats in Celiac Disease","J Gregor","M Sey","$19,980,533.00"
"House, Andrew","Medicine","2007/07","2008/06","Grants","Funded","False","True","Sub Investigator","Study to assess renal replacement: A multicentre retrospective chart review to evaluate the incidence, hemoglobin levels, and demographics of subjects who start renal replacement therapy in Canadian facilities","Norman Muirhead","N Muirhead, A House, J Johnson","$8,231,218.00"
"House, Andrew","Medicine","2005/07","2006/06","Grants","Funded","False","True","Co-Investigator","A randomized, double-blind study to evaluate the impact of Rosiglitazone 8 mg/day versus placebo. IMT and carotid plaque volume and plaque roughness in patients with insulin resistance and carotid artery disease","Grace Parraga","A House","$54,621,385.00"
"House, Andrew","Medicine","2005/07","2006/06","Grants","Funded","False","True","Co-Investigator","Measuring atherosclerosis: Comparison of 3D US plaque volume, 2D US intima media thickness and MRI vessel wall volume","Grace Parraga","A House","$34,212,748.00"
"House, Andrew","Medicine","2009/09","2012/08","Grants","Funded","True","False","Co-Investigator","Cardiac gating of 3-dimensional ultrasound imaging of carotid atherosclerosis in rheumatoid arthritis","Grace Parraga","A House, Christiane Mallett (PhD student)","$35,700,381.00"
"House, Andrew","Medicine","2009/07","2012/06","Grants","Funded","False","True","Co-Investigator","Cardiac gating of 3-dimensional ultrasound imaging of carotid atherosclerosis in rheumatoid arthritis","Grace Parraga","A House, Christiane Mallett (PhD student)","$44,191,280.00"
"Adams, Paul","Medicine","2007/07","2008/06","Grants","Funded","False","True","Collaborator","A compassionate access, open label protocol to assess the safety and efficacy of telbivudine in adults > 16 years old with chronic hepatitis B in Canada.","","","$5,794,648.00"
"Adams, Paul","Medicine","2007/07","2008/06","Clinical Trials","Funded","False","True","Co-Investigator","A multicentre randomized double blind active control 96 week phase 3 trial of the efficacy and safety of clevudine compared to Adefovir at weeks 48 and 96 in nucleoside treatment naive patients with HBeAg positive chronic hepatitis due to Hepatitis B Virus.","","Paul Marotta, Mark Levstik","$24,833,387.00"
"Adams, Paul","Medicine","2007/07","2008/06","Grants","Funded","False","False","Co-Investigator","A phase 3 safety and efficacy study of Boceprevir in previously untreated subjects with chronic hepatitis C, genotype 1","","Paul Marotta, Mark Levstik","$41,461,420.00"
"Adams, Paul","Medicine","2007/07","2008/06","Clinical Trials","Funded","False","False","Co-Investigator","IMPROVE- a randomized open label multi-centre study evaluating the efficacy and safety of 48 or 72 weeks of treatment with Pegasys plus Copegus combination therapy in non-genotype 2/3 patients with chronic hepatitis C virus infection who have undetectable HCV-RNA or a 2 log drop at week 12.","","Paul Marotta, Mark Levstik","$65,838,575.00"
"Adams, Paul","Medicine","2007/07","2008/06","Grants","Funded","False","False","Co-Investigator","PO5101-A phase 3 safety and efficacy study of Boceprivir in subjects with chronic hepatitis C who failed prior treatment with Peginterferon/Ribavirin","","Paul Marotta, Mark Levstik","$21,732,597.00"
"Adams, Paul","Medicine","2007/07","2008/06","Grants","Funded","False","False","Co-Investigator","HGS 1008-C1067 - A phase 3 randomized multi-centre study to evaluate the efficacy and safety of albumin interferon Alfa 2b in combination with Ribavirin compared with Peginterferon 2a in combination with Ribavirin in Interferon alpha naive subjects with chronic hepatitis C.","","Paul Marotta, Mark Levstik","$13,494,796.00"
"Muirhead, Norman","Medicine","2008","2010","Grants","Funded","False","True","Principal Investigator","Observational study of late post renal transplant anemia and secondary hyperparathyroidism","N. Muirhead","","$9,190,777.00"
"Muirhead, Norman","Medicine","2003/07","2005/06","Grants","Funded","False","True","Principal Investigator","A double-blind, randomized, dose-ranging multi-centre, phase IIIB study to evaluate the efficacy and safety of high doses of candesartan cilexetil (ATACAND) on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria","N. Muirhead","","$39,935,007.00"
"Muirhead, Norman","Medicine","2003/07","2006/06","Grants","Funded","False","True","Principal Investigator","A study to evaluate the use of ROSUVASTATIN in subjects on regular hemodialysis: an assessment of survival and cardiovascular events. A double-blind, randomized, multi-centre, Phase III, parallel group study to compare the effects of FOSUVASTIN (10mgs oral) with placebo: an assessment of survival and cardiovascular events when given to subjects with end stage renal failure on chronic hemodialysis treatment","N. Muirhead","","$5,429,591.00"
"Muirhead, Norman","Medicine","2003/07","2005/06","Grants","Funded","False","True","Principal Investigator","An active surveillance plan to prospectively monitor the incidence and developmental history of PRCA among patients receiving Epoetin Alfa Therapy","N. Muirhead","","$26,515,941.00"
"Muirhead, Norman","Medicine","2003/07","2005/06","Grants","Funded","False","True","Principal Investigator","An active surveillance plan to conduct serologic testing for anti-erythropoietin antibodies, and prospectively monitor the incidence and development history of PRCA among patients receiving Epoetin Alfa Therapy","N. Muirhead","","$36,748,827.00"
"Muirhead, Norman","Medicine","2006/07","2008/06","Grants","Funded","False","True","Principal Investigator","A double-blind, randomized, placebo-controlled, multi-centre trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients","N. Muirhead","","$41,650,344.00"
"Muirhead, Norman","Medicine","2007/07","2010/06","Grants","Funded","False","True","Principal Investigator","A randomized, single-blind study to improve health related quality of life measured by the SF-36 vitality score by correcting anemia of chronic kidney disease with aranesp in the elderly","N. Muirhead","","$47,459,100.00"
"Muirhead, Norman","Medicine","2007/07","2010/06","Grants","Funded","False","True","Principal Investigator","Outcome trial evaluating the efficacy and safety of Norditropin in adult patients on chronic hemodialysis. A randomized, double-blind, parallel group, placebo controlled, multi-centre trial","N. Muirhead","","$12,713,676.00"
"Muirhead, Norman","Medicine","2007/07","2012/07","Grants","Funded","False","True","Co-Investigator","A randomized study to evaluate the effects of cinacalcet plus low dose vitamind D on vascular calcification in subjects with chronic kidney disease (CKD) receiving hemodialysis","N. Muirhead","","$69,714,916.00"
"Muirhead, Norman","Medicine","2004/07","2007/06","Grants","Funded","True","False","Principal Investigator","The long-term medical psychological implications of becoming a living related kidney donor: A historical matched cohort study","N. Muirhead","","$63,879,588.00"
"Muirhead, Norman","Medicine","2008/07","2012/07","Grants","Funded","True","False","Co-Investigator","Vitamin D deficiency and the risk of acute rejection post renal transplantation","Ottawa Health Research Institute","","$2,814,180.00"
"Muirhead, Norman","Medicine","2008/07","2012/07","Grants","Funded","False","True","Principal Investigator","A Randomized, double-blind, placebo-controlled, parallel group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskerin, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality","N. Muirhead","","$46,215,344.00"
"Muirhead, Norman","Medicine","2004/07","2010/06","Grants","Funded","True","False","Co-Investigator","The long-term medical and psychological implications of becoming a living kidney donor: A prospective pilot study","A. Garg","N. Muirhead","$68,131,541.00"
"Muirhead, Norman","Medicine","2007/07","2008/06","Grants","Funded","True","False","Co-Investigator","The long-term medical and psychological implications of becoming a living kidney donor: An international prospective study","A. Garg","N. Muirhead","$32,290,133.00"
"Muirhead, Norman","Medicine","2007/07","2008/06","Grants","Funded","False","True","Principal Investigator","Study to assess renal replacement: A multicentre retrospective chart review to evaluate the incidence, hemoglobin levels, and demographics of subjects who start renal replacement therapy in Canadian facilities","N. Muirhead","","$64,393,058.00"
"Siu, Samuel","Medicine","2009/01","2014/12","Grants","Funded","True","False","Program Leader","Translational Research Centre for Cardiovascular Research (TRICORE)","Dr. Samuel Siu and Dr. James White","","$63,576,270.00"
"Beaton, Melanie","Medicine","2009/01","2010/12","Grants","Funded","True","False","Principal Investigator","Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease","Beaton, MD","Adams, PA Marotta, P Levstik, M","$19,819,456.00"
"Beaton, Melanie","Medicine","2009/01","2011/12","Grants","Funded","True","False","Principal Investigator","Simultaneous non-invasive quantification of hepatic steatosis and iron concentration with MRI","Beaton, MD","McKenzie, C Adams, P.","$41,257,693.00"
"Beaton, Melanie","Medicine","2009/01","2010/12","Grants","Funded","True","False","Principal Investigator","Simultaneous non-invasive quantification of hepatic steatosis and iron concentration with Magnetic Resonance Imaging (MRI)","Beaton, MD","McKenzie, C.","$61,782,984.00"
"Beaton, Melanie","Medicine","2009/01","2010/12","Grants","Funded","True","False","Principal Investigator","Simultaneous non-invasive quantification of hepatic steatosis and iron concentration with MRI","Beaton, MD","McKenzie, CA","$68,658,782.00"
"van Uum, Stanislaus","Medicine","2009/07","2010/06","Grants","Funded","True","False","Co-Investigator","Hair Cortisol as a Biomarker of Chronic HPA Axis Response to Stress","Anne Saunders","Bill Maixner, L. Diatchenko, Gary D Slade, Gideon Koren","$7,062,747.00"
"van Uum, Stanislaus","Medicine","2006/07","","Grants","Funded","True","False","Principal Applicant","Hair Levels of Cortisol and Testosterone as Biomarkers for Depression and Hypogonadism","","","$44,238,537.00"
"Mangel, Joy","Medicine","2008/07","2010/07","Grants","Funded","False","False","Local Principal Investigator LHSC","An open-label, multi-centre, dose escalating, phase I/II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malingant disease.","","","$65,622,335.00"
"Montero Odasso, Manuel","Medicine","2001","2003","Grants","Funded","True","True","Site Investigator","Randomized, prospective and double blind study controlled with Ro 64-0769 (gs4104) in the treatment of influenza infection.","Dr. Manuel Montero-Odasso","","$26,095,017.00"
"Clark, William","Medicine","2009/01","2009/12","Grants","Funded","True","False","Co-Applicant","Opioid and benzodiazepine use in dialysis patients: a prospective study","Wyne A","Wyne A, Suri R, Clark WF","$65,098,523.00"
"Montero Odasso, Manuel","Medicine","1999","2002","Grants","completed","False","False","Principal Investigator","Evaluacion Funcional del Anciano. EFA Study.","","","$45,512,673.00"
"Montero Odasso, Manuel","Medicine","2004","2005","Grants","completed","False","False","Principal Investigator","Mobility profile as a predictor of adverse events in frail elderly population","","","$11,626,701.00"
"Montero Odasso, Manuel","Medicine","2004/01","2006/01","Grants","completed","True","False","Principal Investigator","MCI and gait velocity cross-sectional analysis of MCI cohort at the memory clinic at JGH, McGill Division of Geriatrics.","Manuel Montero-Odasso","","$46,979,950.00"
"Montero Odasso, Manuel","Medicine","2001","2003","Grants","completed","False","True","Co-Investigator","Study of the effects of Irbesartan SR47436 (BMS-186295) on Microalbuminuria in hypertensive patients with type II Diabetes Mellitus.","","","$62,294,579.00"
"Montero Odasso, Manuel","Medicine","2001","2003","Grants","completed","False","False","Co-Investigator","Prospective observational study of post-surgery complications in a teaching hospital that included 500 in-patients.","","","$17,617,000.00"
"Montero Odasso, Manuel","Medicine","1995","1996","Grants","Complete","False","False","Principal Investigator","Longitudinal study in a cohort of in-patients evaluated for a geriatric consultation service in Argentina.","","","$68,486,474.00"
"Edmonds, Marcia","Medicine","2009/01","2009/01","Grants","Funded","False","False","Co-Investigator","The Utility of Renal Ultrasound in Predicting Urologic Intervention for ED patients with suspected Renal Colic","Sedran R","Edmonds ML, Theakston K","$57,018,415.00"
"Peddle, Michael","Medicine","2006/11","2010","Grants","Funded","False","False","Co-Investigator","A Prospective Evaluation of Ketamine/Propofol vs. Ketamine alone for Procedural Sedation for Isolated Orthopedic Injury in the Paediatric Emergency Department","Shah, A","Reider, M Peddle, M Lehnhardt,K Mosdossy, G McLeod, S","$19,101,857.00"
"Peddle, Michael","Medicine","2006/11","2010","Grants","Funded","False","False","Co-Investigator","A Prospective Evaluation of Ketamine/Propofol vs. Ketamine alone for Procedural Sedation for Isolated Orthopedic Injury in the Paediatric Emergency Department","Shah, A","Reider, M Peddle, M Lehnhardt,K Mosdossy, G McLeod, S","$51,538,012.00"
"Peddle, Michael","Medicine","2006/11","2010","Grants","Funded","False","False","Co-Investigator","A Prospective Evaluation of Ketamine/Propofol vs. Ketamine alone for Procedural Sedation for Isolated Orthopedic Injury in the Paediatric Emergency Department","Shah, A","Reider, M Peddle, M Lehnhardt,K Mosdossy, G McLeod, S","$23,113,836.00"
"Theakston, Karl","Medicine","","1998","Grants","Funded","False","False","Site Co-Investigator","ASSENT II","","","$67,271,998.00"
"Theakston, Karl","Medicine","","1998","Grants","Funded","False","False","Site Co-Investigator","capitaL Study","","","$63,751,366.00"
"Theakston, Karl","Medicine","1997","1998","Grants","Funded","False","False","Principal Site Investigator","FASTRAK II","","","$36,033,523.00"
"Theakston, Karl","Medicine","1996","1997","Grants","Funded","False","False","Co-Investigator","GUSTO III","","","$16,174,995.00"
"Theakston, Karl","Medicine","1994","1996","Grants","Funded","False","False","Principal Site Investigator","FASTRAK","","","$46,600,107.00"
"Theakston, Karl","Medicine","","1996","Grants","Funded","False","False","Regional Co-Ordinator","Implementation of Ottawa Ankle Rules","","","$14,994,953.00"
"Theakston, Karl","Medicine","1998","present","Grants","Funded","False","False","Principal Site Co-Investigator","Blood Pressure Manipulation in Acute Stroke","","","$22,158,430.00"
"Theakston, Karl","Medicine","","1999","Grants","Funded","False","False","Site Co-investigator","CAP (Community-Acquired Pneumonia) Clinical Trial","","","$29,070,779.00"
"Theakston, Karl","Medicine","","1999","Grants","Funded","False","False","Principal Site Investigator","Regranex Trial","","","$29,218,263.00"
"Theakston, Karl","Medicine","","1999","Grants","Funded","False","False","Principal Site Co-investigator","LIMIT Trial","","","$47,166,954.00"
"Theakston, Karl","Medicine","","2000","Grants","Funded","False","False","Principal Site Investigator","MAP (Moxifloxacin in Ambulatory Pneumonia) Trial","","","$34,642,424.00"
"Theakston, Karl","Medicine","","2000","Grants","Funded","False","False","Site Co-investigator","ASSENT III(Assessment of the Safety and Efficacy of New Thrombolytic regimens)","","","$24,909,010.00"
"Theakston, Karl","Medicine","","2001/02","Grants","Funded","False","False","Principal Site Investigator","CATSAT (Computed Axial Tomography for Suspected Appendicitis Trial)","","","$65,853,237.00"
"Theakston, Karl","Medicine","","2007","Grants","Funded","False","False","Co-Investigator","Ultrasound for Renal Colic Study","","","$53,258,999.00"
"Myers, Kathryn","Medicine","2009/01","2011/01","Grants","Funded","False","True","Co-Investigator","ACCESSATION A pragmatic study evaluating the impact of access to smoking cessation treatment reimbursement on the proporation of successful quitters in a Canadian population of smokers motivated to quit","Tom Forbes","Tom Forbes - MD, Vascular Surgery Teresa Novick - Smoking cessation counsellor","$23,825,188.00"
"Diachun, Laura","Medicine","2009/01","2011/12","Grants","Funded","True","False","Co-Principal Investigator","Care of Older Adults, Educating our Future Physicians: An Undergraduate Schulich School of Medicine and Dentistry Integrated Geriatric Curriculum Initiative.","","Diachun L, VanBussel L.","$46,098,756.00"
"Hegele, Robert","Medicine","2008/09","2011/08","Grants","Funded","True","False","Principal Investigator","Schulich support for LRGC DNA Sequencing Core Facility","Robert A. Hegele","","$11,148,169.00"
"Hegele, Robert","Medicine","2008","2010","Grants","Funded","True","True","Principal Investigator","Genomic copy number variation in dyslipidemia and metabolic disease. The Jean Davignon Distinguished Cardiovascular & Metabolic Research Award","Robert A. Hegele","","$74,074,051.00"
"Moist, Louise","Medicine","2008/01","2011/12","Grants","Funded","True","False","Principal Investigator","Comparison of quality of life and clinical performance targets in Southwestern Ontario incentre and satellite unit dialysis patients","Dr. Louise Moist","","$14,497,630.00"
"Moist, Louise","Medicine","2008/09","2010/06","Grants","Funded","True","False","Principal Investigator","Development of an Advanced Organizer and Interactive, Electronic Seminar Series for the Medicine Clerkship Block","Dr. Louise Moist","","$26,269,185.00"
"Moist, Louise","Medicine","2009/01","2015/12","Grants","Funded","True","False","Co-Principal Investigator","Best Extremity Survival Times and Concurrent Complications Examination of Secondary Access Study","Dr. Louise Moist","","$50,690,130.00"
"Moist, Louise","Medicine","2008/03","2010/12","Grants","Funded","True","False","Principal Investigator","Best Extremity Survival Times and Concurrent Complications Examination of Secondary Access Study - Pilot Study","Dr. Louise Moist","","$9,793,215.00"
"Moist, Louise","Medicine","2009/03","2011/12","Grants","Funded","True","False","Co-Investigator","Detection of Acute Kidney Injury after AAA Repair - Role of New Biomarkers","Dr. Amit Garg","","$64,706,308.00"
"Hramiak, Irene","Medicine","2009/08","2016/12","Clinical Trials","Funded","False","True","Principal Investigator","Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS): A phase III, randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control on mono- or dual combination antihyperglycemic therapy.","IM Hramiak","CG McDonald, TL Paul, N Suskin, ME Weingert","$48,594,634.00"
"Hramiak, Irene","Medicine","2009/05","2010/03","Clinical Trials","Funded","False","True","Principal Investigator","A mutli-center, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/tolerability and pharmacokinetics of five dose levels of RO4998452 in patients with type 2 diabetes mellitus.","IM Hramiak","CG McDonald, TL Paul","$58,168,738.00"
"Hramiak, Irene","Medicine","2008/09","2011/12","Clinical Trials","Funded","False","True","Principal Investigator","GLP-1 agonist AVE0010 in paTients with type 2 diabetes mellitus for Glycemic cOntrol and sAfety evaLuation, on top of Metformin. A randomized, double-blind, placebo-controlled, parallel group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin in patients with type 2 diabetes not adequately controlled with metformin.","IM Hramiak","CG McDonald, TL Paul","$25,153,119.00"
"Hramiak, Irene","Medicine","2008/10","2012/12","Clinical Trials","Funded","False","True","Principal Investigator","Effect of Exenatide on Abdominal Fat Distribution in Patients with Type 2 Diabetes Pretreated with Metformin.","IM Hramiak","CG McDonald, TL Paul","$70,930,185.00"
"Hramiak, Irene","Medicine","2009/03","2011/12","Clinical Trials","Funded","False","True","Principal Investigator","A multicenter, randomized, double-blind, phase 3b trial to evaluate the efficacy and safety of Saxagliptin added to insulin monotherapy or to insulin in combination with metformin in subjects with Type 2 diabetes who have inadequate glycemic control on insulin alone or on insulin in combination with metformin.","IM Hramiak","CG McDonald, TL Paul","$74,660,970.00"
"Wells, Jennie","Medicine","2008/01","2011/01","Clinical Trials","Funded","True","True","Principal Investigator","Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer’s Disease","Wells JL","Wells JL, Borrie MJ, Burhan A, Clarke J, Alaama T","$2,018,943.00"
"Johnson, John","Medicine","2009","2013","Grants","Funded","True","True","Co-Investigator","Canadian study of predication of risk and evolution to dialysis, death and interim cardiovascular events over time","Norman Muirhead","Norman Muirhead, Andrew House, Faisal Rehman, John Johnson","$14,591,907.00"
"Kim, Richard","Medicine","2008/10","2013/09","Grants","Funded","True","False","Principal Investigator","Hepatic Organic Anion Transporting Polypeptide (OATP) drug uptake transporters as determinants of drug disposition","Richard B. Kim","Rommel G. Tirona George K. Dresser","$21,808,604.00"
"Kim, Richard","Medicine","2008/06","2009/11","Grants","Funded","True","False","Principal Applicant","Personalized Medicine and Optimal Warfarin Anticoagulant Therapy in Ontario","Richard B. Kim","Ute Schwarz George Dresser Alejandro LazoLangner Gong-Yong Zou Philip Wells","$51,706,223.00"
"Kim, Richard","Medicine","2008/05","2009/04","Grants","Funded","True","False","Principal Investigator","Drug Level Analysis Laboratory for Personalized Medicine Research","Richard B. Kim","","$27,225,381.00"
"Kim, Richard","Medicine","2008/08","2010/07","Grants","Funded","True","False","Principal Investigator","Personalized Medicine and Colon Cancer Chemotherapy: Bench to Bedside","Richard B. Kim","Eric Winquist Stephen Welch Scott Ernst Glenn Bauman Ute Schwarz Rommel Tirona Gong Yong Zou","$60,681,925.00"
"Kim, Richard","Medicine","2008/06","2010/05","Clinical Trials","Funded","False","True","PI of Pharmacogenomics component of this trial","CAnadian Methotrexate and Etanercept Outcome Study: An open label randomized trial of etanercept and methotrexate versus etanercept alone in the treatment of rheumatoid arthritis (CAMEO)","Janet Pope","","$20,372,152.00"
"Kim, Richard","Medicine","2008/07","2013/06","Grants","Funded","True","False","Co-Investigator","Pharmacogenomics of HIV Therapy","David Haas","","$42,032,866.00"
"Kim, Richard","Medicine","2008/04","2011/03","Grants","Funded","True","False","Co-Investigator","Role of Skeletal Muscle Transporters in Statin-Induced Myopathy","Rommel G. Tirona","","$19,279,336.00"
"McManus, Ruth","Medicine","2008/10","2011/10","Grants","Funded","True","False","Co-Investigator","Preventing childhood obesity; early intervention and first year postpartum for overweigth and obese women using a two-pronged family-based nutrition and exercise lifestyle intervention (NELIP)","Dr M Mottola","Drs I giroux, S Harris, ER Gratton, J Hammond, H Parapavessis, A Hanley","$29,247,087.00"
"van Uum, Stanislaus","Medicine","","","Grants","Applied","True","False","Principal Applicant","Role of Organic Anion Transporters in Individual Levothyroxine Dose Variation and Levothyroxine-Drug Interactions","","Richard Kim, Rommel Tirona","$74,846,381.00"
"Goldszmidt, Mark","Medicine","2009/07","2011/06","Grants","Funded","True","False","Co-Applicant","The Use of Goal-Oriented Categories in Medical Thinking and Reasoning","Minda, J.P.","Goldszmidt, M., Haddara, W.","$74,036,631.00"
"Dasgupta, Monidipa","Medicine","2009/05","2011/05","Grants","Funded","True","False","Principal Applicant","Prognostication of delirium in acutely medically ill older adults.","Dr. M. Dasgupta","Dr. Michael Borrie, Dr. Chris Brymer, Iris Gutmanis","$62,769,524.00"
"Myers, Kathryn","Medicine","2009/04","2011/04","Grants","Funded","True","False","Co-Principal Investigator","Vascular health and personalized medicine at LHSC/SJHC: Right place, right time, right people","Richard Kim","Richard Kim George Dresser","$13,078,431.00"
"Johnson, John","Medicine","2008","2010","Grants","Funded","False","True","Collaborator","A randomized, double-blind, placebo-controlled, parallel group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskirin, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality (ALTITUDE)","Norman Muirhead","N. Muirhead, A. House","$49,586,846.00"
"Johnson, John","Medicine","2008/06","present","Grants","Funded","True","False","Collaborator","Vitamin D deficiency and the risk of acute rejection post renal transplantation.","Zimmerman","A House, Principal Site Investigator","$29,049,867.00"
"Johnson, John","Medicine","2005","2010","Grants","Funded","False","True","Collaborator","A randomized, open-label, comparative evaluation of the safety and efficacy of Sirolimus versus Cyclosporine when combined in a regimen containing Basiliximab, Mycophenolate Mofetil, and corticosteroids in primary de novo renal allograft recipients","Norman Muirhead","N. Muirhead, A. House","$39,038,165.00"
"Johnson, John","Medicine","2008","2010","Grants","Funded","False","True","Collaborator","Observational study of late post renal transplant anemia and secondary hyperparathyroidism.","N Muirhead","N Muirhead, A House","$4,922,638.00"
"Johnson, John","Medicine","2008","2009","Grants","Funded","False","True","Collaborator","Study to assess renal replacement: A multicentre retrospective chart review to evaluate the incidence, hemoglobin levels, and demographics of subjects who start renal replacement therapy in Canadian facilities.","Norman Muirhead","N Muirhead, A House","$5,325,521.00"
"Johnson, John","Medicine","2006","2008","Grants","Funded","False","True","Collaborator","Outcome Trial evaluating the Efficacy and Safety of Norditropin® in Adult Patients on Chronic Haemodialysis. A Randomized, Double-Blind, Parallel group, Placebo controlled, Multi-centre trial.","Norman Muirhead","N Muirhead, A House","$20,043,537.00"
"House, Andrew","Medicine","2006/07","2008/06","Grants","Funded","False","True","Co-Investigator","Outcome Trial evaluating the Efficacy and Safety of Norditropin® in Adult Patients on Chronic Haemodialysis. A Randomized, Double-Blind, Parallel group, Placebo controlled, Multi-centre trial.","Norman Muirhead","N Muirhead, A House, J Johnson","$39,136,441.00"
"House, Andrew","Medicine","2009/01","2013/01","Grants","Funded","True","True","Co-Investigator","Canadian study of predication of risk and evolution to dialysis, death and interim cardiovascular events over time.","Norman Muirhead","Norman Muirhead, Andrew House, Faisal Rehman, John Johnson","$11,610,600.00"
"van Uum, Stanislaus","Medicine","2008/07","2010/06","Grants","Funded","True","False","Collaborator","Baseline Biomonitoring Studies and a Survey of Child-Youth Health as Prerequisites to Epidemiological Studies to Assess the Health Risk of the Attawapiskat First Nation and Walpole Island First Nation Communities from Exposure to Environmental Contaminants","","","$63,173,013.00"
"Myers, Kathryn","Medicine","2007/07","2008/06","Grants","Funded","True","False","Principal Applicant","Feedback is a two-way street: A qualitative analysis of written comments by residents on their assessments of clinical teachers","Kathryn Myers","Elaine Zibrowski, Lorelei Lingaard","$72,694,891.00"
"Diachun, Laura","Medicine","2009/06","2010/06","Grants","Funded","True","False","Principal Investigator","Comprehensive Geriatric Assessment Guide: Development and validation of a patient-completed feedback tool on student performance.","Diachun L.","Janet Gordon, Kim Blake (Dal)","$59,067,828.00"
"Licskai, Christopher","Medicine","2009/03","2011/03","Grants","Funded","True","False","Principal Investigator","Community Implementation and Validation of the Air Quality Health Index","Christopher Licskai","Teresa To, Brian Stocks","$67,615,402.00"
"Mehta, Sanjay","Medicine","2009","2013","Grants","Funded","True","False","Co-Applicant","Evaluation of Long-term Outcomes in Pulmonary Embolism","","S. Kahn, J.T. Granton, A. Hirsch, S. Mehta","$5,076,817.00"
"Montero Odasso, Manuel","Medicine","2009/07","2014/07","Grants","Funded","True","False","Principal Investigator","Can cognitive enhancers reduce the risk of falls in older people with Mild Cognitive Impairment: A randomized controlled trial.","Manuel Montero-Odasso","Michael Borrie, Jennie Wells, Mark Speechley","$58,682,728.00"
"Montero Odasso, Manuel","Medicine","2009/03","2010/03","Grants","Funded","True","False","Principal Investigator","Can cognitive enhancers reduce the risk of falls in older people with dementia? An open label study with age-matched controls","Manuel Montero-Odasso","Michael Borrie, Mark Speechley, Jennie Wells","$63,672,449.00"
"Borrie, Michael","Medicine","2009/06","2011/06","Grants","Funded","True","False","Co-Investigator","Can cognitive enhancers reduce the risk of falls in older people with Mild Cognitive Impairment? A Randomized Control Trial","Manuel Montero Odasso","Jennie Wells, Mark Speechley","$39,301,077.00"
"Wells, Jennie","Medicine","2009/06","2011/06","Grants","Funded","True","False","Co-Investigator","Can cognitive enhancers reduce the risk of falls in older people with Mild Cognitive Impairment? A Randomized Control Trial","Manuel MonteroOdasso","Michael Borrie, Mark Speechley, Jennie Wells","$58,392,130.00"
"Lewis, James","Medicine","2008/06","2009/07","Grants","Funded","True","False","Principal Investigator","In vitro mechanisms on lung-liver interactions in acute lung injury","J Lewis","N Markovic","$32,694,519.00"
"Adams, Paul","Medicine","2008/12","2010/12","Clinical Trials","Funded","True","False","Co-Investigator","Simultaneous Non-Invasive Quantification of Hepatic Steatosis and Iron Concentration with MRI","","M Beaton, C McKenzie","$39,237,419.00"
"Adams, Paul","Medicine","2009/01","2011/01","Clinical Trials","Funded","False","False","Co-Principal Investigator","Evaluation of Phlebotomy as a treatment of non-alcoholic fatty liver disease","Beaton, Melanie","M Beaton, P Marotta, M Levstik","$53,378,934.00"
"Kostuk, William","Medicine","2009/05","2012","Grants","Funded","False","True","Principal Site Investigator","ATLAS 2 - A randomized double-blind placebo controlled event driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome.","","","$38,504,208.00"
"Kostuk, William","Medicine","2006/07","present","Grants","Funded","False","False","Principal Site Investigator","FREEDOM - Future revascluarization evaluation in pateinst with diabetes mellitus","","","$57,509,285.00"
"Kostuk, William","Medicine","2009/06","","Grants","Funded","False","True","Principal Site Investigator","FUTURA OASIS 8 - Fondaparinux trial with UFH during revascularization in acute coronary syndrome: a prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high risk patients with UA/NSTEMI initally treated with subcutaneous fondaparinux and referred for early coronary angiography.","","","$49,902,864.00"
"Kostuk, William","Medicine","2009/05","2010","Grants","Funded","False","True","Principal Site Investigator","The TIMI 38 Coronary Stent Registry: Long term followup of subjects with PCI and stenting for ACS.","William Kostuk","","$70,639,924.00"
"Kostuk, William","Medicine","2009/06","2011/06","Grants","Funded","False","True","Co-Investigator","A 104 week, randomized double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary artery disease when added to optimal background therapy.","","","$55,393,460.00"
"Diamantouros, Pantelis","Medicine","2008/09","present","Grants","Funded","False","True","Co-Investigator","A comparison of prasugrel and clopidogrel in acute coronary syndrome (ACS) subjects with unstable angina/non-ST-elevation myocardial infarction (UA?NSTEMI) who are medically managed - The TRILOGY Study.","Dr. William J. Kostuk","Dr. P. Diamantouros","$66,009,560.00"
"Diamantouros, Pantelis","Medicine","2009/05","2012/01","Grants","Funded","False","True","Co-Investigator","The ATLAS ACS 2 TIMI 51 Trial. A randomized double-blind, placebo-controlled, event driven multicentre study to evaluate the efficacy and safety of rivaroxaban in subjects with a receont acute coronary syndrome.","Dr. William J. Kostuk","Dr. Pantelis Diamantouros","$38,244,463.00"
"Diamantouros, Pantelis","Medicine","2009/06","2010","Grants","Funded","False","True","Co-Investigator","FondaparinUx Trial with UFH during Revascularization in Acute coronary syndrome (FUTURA OASIS 8): A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high risk patients with UA/NSTEMI initially treated iwith subcutaneous fondaparinux and referred for early coronary angiography.","Dr. William J. Kostuk","Dr. P. Diamantouros","$43,298,933.00"
"Diamantouros, Pantelis","Medicine","2009/06","present","Grants","Funded","False","True","Co-Investigator","A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicentre study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary artery disease when added to optimal background therapy.","Dr. William J. Kostuk","Dr. Pantelis Diamantouros","$33,641,427.00"
"Gula, Lorne","Medicine","2009/02","present","Grants","Funded","True","False","Principal Applicant","Monitoring of Ventricular Rhythm & Exercise - ICD sTudy (MOVE-IT)","Lorne Gula","Peter Leong-Sit","$17,809,833.00"
"Gula, Lorne","Medicine","2010/07","present","Clinical Trials","Funded","False","True","Principal Investigator","Development of a Dedicated Atrial Fibrillation Clinic and Research Database.","Lorne Gula","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$40,927,414.00"
"Moist, Louise","Medicine","2009/01","2015/12","Grants","Funded","True","False","Co-Principal Investigator","Best Extremity Survival Times and Concurrent Complications: Examination of Secondary Access Study","Dr. Charmaine Lok","","$17,940,057.00"
"Bosma, Karen","Medicine","2009/07","2010/06","Grants","Funded","True","False","Co-Applicant","Correlation between sleep disruption and delirium in critically ill patients","Dr. Karen Bosma","Dr. George Dresser, Dr. Mithu Sen","$18,899,224.00"
"Yee, Raymond","Medicine","2001/07","2005/06","Grants","Funded","True","False","Principal Investigator","Ventricular Irregularity in Atrial Fibrillation","Raymond Yee","","$51,870,291.00"
"Hodsman, Anthony","Medicine","2009/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic,Efficacy and Safety Study of CTA018 Injection in Subjects with Stage 5 Chronic Kidney Disease with Secondary Hyperparathyroidism on Hemodialysis","","","$56,128,729.00"
"Hodsman, Anthony","Medicine","2009/01","2010/08","Grants","Funded","False","True","Principal Site Investigator","A 12-week, open label, multicentre, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCL in lowering serum phosphate levels in Chronic Kidney Disease patients on haemodialysis.","","","$25,780,372.00"
"Pope, Janet","Medicine","2008/01","2013/01","Grants","Funded","True","False","Co-Investigator","Lupus Nephritis New Emerging Team (LuNNET)-A New Look at Lupus Nephritis","Dr. Paul Fortin","CaNIOS Investigators","$47,754,063.00"
"Pope, Janet","Medicine","2007/10","2012/10","Grants","Funded","True","False","Co-Investigator","Learning to Live Better with Lupus: The Health Improvement and Prevention Program (HIPP) in Systemic Lupus Erythematosus","Dr. Paul Fortin, Dr. Deborah Dacosa","CaNIOS Investigators","$53,739,553.00"
"Pope, Janet","Medicine","2008","2010","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis – C87094","","Dr. Georgy Genov (UCB), Dr. Andrew Thompson, Dr. Gina Rohekar, Dr. Sherry Rohekar, Dr. Nicole LeRiche","$50,967,615.00"
"Pope, Janet","Medicine","2007","2009","Clinical Trials","Funded","False","True","Principal Site Investigator","A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-? therapy","","Pennelope Ward (Roche), Dr. Nicole LeRiche","$45,545,176.00"
"Pope, Janet","Medicine","2007","2009","Clinical Trials","Funded","False","True","Principal Site Investigator","A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment","","Pennelope Ward (Roche), Dr. Nicole LeRiche","$48,631,450.00"
"Pope, Janet","Medicine","2005","2010","Clinical Trials","Funded","False","True","Principal Site Investigator","Long-Term Extension Study of Safety During Treatment with Tocilizumab (MRA) in patients completing treatment in MRA core studies (WA18062)","","David Musselman (Roche), Dr. Nicole LeRiche, Donna McBain","$73,702,951.00"
"Pope, Janet","Medicine","2006","2008","Clinical Trials","Funded","False","True","Co-Principal Investigator","Long-Term Extension Study of Safety During Treatment with Tocilizumab (MRA) in patients completing treatment in MRA core studies (WA18062)","Dr. Carter Thorne","Dr. Andy Thompson, Dr. Gina Rohekar, Dr. Sherry Rohekar, Dr. Nicole LeRiche","$63,119,567.00"
"Pope, Janet","Medicine","2008","2010","Clinical Trials","Funded","False","True","Principal Investigator","An Observational Study to Determine if 3D Ultrasound Provides Quantifiable and Reproducible Measurement of Plaque Progression in Patients with Mild to Moderate RA and to Evaluate the Contribution of Traditional and Nontraditional Risk Factors Including Biomarkers for Cardiovascular Disease Regarding the Potential Contribution to the Occurrence of Plaque and Rate of Plaque Progression in these Patients","","","$4,085,674.00"
"Pope, Janet","Medicine","2005","2010","Clinical Trials","Funded","False","True","Principal Site Investigator","A randomized, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate response to methotrexate.","","Tim Shaw MD, Roche Products Ltd. Dr. Nicole Le Riche, Donna McBain, Research Coordinator","$45,064,648.00"
"Pope, Janet","Medicine","2009","2011","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 2, Randomized, Double-blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of 12 Weeks of Treatment with ARRY-371797 in Patients with Active Ankylosing Spondylitis and Inadequate Response to Conventional Therapy","","Dr. Sandra Rojas-Caro, Dr. Sherry Rohekar","$71,937,777.00"
"Pope, Janet","Medicine","2006","2008","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with Moderate to Severe Systemic Lupus Erythematosus- U2971g","","Dr. Dafna Gladman, Dr. Nicole LeRiche","$60,454,265.00"
"Pope, Janet","Medicine","2009","2010","Clinical Trials","Funded","False","True","Principal Site Investigator","DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: A randomized, double-blind, placebo-controlled, multicenter study","Dr. James Seibold, University of Michigan","","$32,953,938.00"
"Pope, Janet","Medicine","2008","2011","Clinical Trials","Funded","False","True","Principal Site Investigator","A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension, AC-052-510 (DETECT study)","","Fabrice Kiefer- Actelion Pharmaceuticals Ltd, Dr. Gerard Shoemaker","$6,106,622.00"
"Pope, Janet","Medicine","2007","2012","Clinical Trials","Funded","False","True","Principal Site Investigator","The Canadian Arthritis Cohort (CATCH): A prospective Cohort Study of Adults with New-Onset Inflammatory Arthritis Symptoms","Dr. Vivian Bykerk","","$69,931,729.00"
"Wells, Jennie","Medicine","2009/01","2010/01","Grants","Funded","True","False","Co-Investigator","Gait and Cognition as Gateways to understanding Mobility in Aging.","Montero-Odasso M.","Burhan A, Wells J, Borrie M.","$41,378,261.00"
"Hegele, Robert","Medicine","2009/07","2014/06","Grants","Funded","True","False","Principal Investigator","The genomics of elevated plasma triglycerides.","Robert A. Hegele","","$72,062,334.00"
"Hackam, Daniel","Medicine","2005/07","2009/07","Grants","Funded","True","False","Principal Investigator","Oral anticoagulation in elderly patients following major trauma: risks and benefits of continuing therapy","Daniel G Hackam","Donald Redelmeier; Alex Kopp","$28,320,387.00"
"Hackam, Daniel","Medicine","2007/07","2012/07","Grants","Funded","False","False","Principal Investigator","Startup funding","Daniel Hackam","","$39,000,780.00"
"Rohekar, Sherry","Medicine","2009/07","2011/07","Grants","Funded","True","False","Principal Investigator","Arthritis Expert Program: Improving Quality of Care in Chronic Disease.","","","$38,976,747.00"
"Rohekar, Sherry","Medicine","2009/03","2010/09","Grants","Funded","True","False","Principal Investigator","Assessment of Work Disability In Rheumatiod Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS)","","","$57,131,402.00"
"Rohekar, Gina","Medicine","2008/12","2008/12","Grants","Funded","True","False","Principal Investigator","Factors Influencing Physician Global Assessment in Early and Established Rheumatoid Arthris","Dr. Gina Rohekar","","$40,029,874.00"
"Crilly, Richard","Medicine","2000/01","2000/12","Grants","Funded","True","False","Co-Investigator","The Influence of Falling and Fear of Falling on Engagement in Self-Care, Productivity and Leisure Activities for Community Dwelling Elderly.","Hobson, S.","Kloseck, M., Crilly, R.G., Robbins, B., Vandervoort, A. and Ward-Griffin, C.","$72,253,949.00"
"Garg, Amit","Medicine","2009/10","2014/10","Grants","Funded","True","False","Principal Investigator","Canadian Living Kidney Donor Safety Study","Garg, Amit","","$45,896,293.00"
"Garg, Amit","Medicine","2008/07","2013/06","Grants","Funded","True","False","Co-Investigator","Ancillary Studies in the Natural History of Acute Kidney Injury","Parikh, Chirag","Garg AX, Deverajan P, Shilpak M","$15,331,970.00"
"Garg, Amit","Medicine","2007/04","2012/03","Grants","Funded","True","False","Co-Investigator","Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney Injury","Parikh, Chirag","Garg AX, Deverajan P, Shilpak M","$51,710,872.00"
"Crilly, Richard","Medicine","1998","2002","Grants","Funded","False","False","Co-Principal Investigator","Free Commercial Space Cherryhill Health Promotion and Information Centre in Cherryhill Mall.","Kloseck, M. (Co-PI)","","$24,031,155.00"
"Garg, Amit","Medicine","2009/03","2012/02","Grants","Funded","True","False","Principal Investigator","Detection of Acute Kidney Injury after Abdominal Aortic Aneurysm Repair: Role of New Biomarkers","Garg, Amit","","$33,017,002.00"
"Lewis, James","Medicine","2009/01","2009/12","Grants","Funded","True","False","Principal Applicant","Lung-liver interactions and exogenous surfactant treatment in an acid-induced model of acute lung injury","Jim Lewis","Ruud Veldhuizen","$18,264,758.00"
"Crilly, Richard","Medicine","1991/01","1991/12","Grants","Funded","True","False","Co-Principal Investigator","Validity, Reliability and Feasibility Testing of the Leisure Competence Measure: Phase I","Kloseck, M.","","$17,051,303.00"
"Crilly, Richard","Medicine","1994/01","1994/12","Grants","Funded","True","False","Co-Principal Investigator","Validity, Reliability and Feasibility Testing of the Leisure Competence Measure: Phase II","Kloseck, M.","","$19,465,618.00"
"Crilly, Richard","Medicine","2008","2009","Grants","Funded","True","True","Principal Investigator","Measurement of Bone Mass in Hip Fracture Patients","","","$55,794,845.00"
"Mangel, Joy","Medicine","2007/01","present","Grants","Funded","False","False","Co-Investigator","Cardiovascular Disease Assessment in Asymptomatic Young Survivors of Hodgkin's Lymphom: Influence of Mediastinal Radiation","Dr. S. Zelcer","","$4,688,915.00"
"Mangel, Joy","Medicine","2007/07","2009","Grants","Internal","False","False","Principal Investigator","The Cancer Care Centre Pathway in Patients with Newly Diagnosed Hodgkin and Non-Hodgkin Lymphoma.","Dr. Joy Mangel","","$32,600,646.00"
"Mangel, Joy","Medicine","2007/07","2008/06","Grants","Funded","False","False","Principal Investigator","Treatment of Hodgkin Lymphoma with ABVD without routine growth factor support - a quality assurance study.","Dr. Joy Mangel","","$495,539.00"
"Hramiak, Irene","Medicine","2009/07","2010/12","Clinical Trials","Funded","False","True","Principal Investigator","Evaluation of the use of a new re-usable insulin pen device (ClikSTAR) in Canadian patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM).","IM Hramiak","CG McDonald, TL Paul","$64,490,461.00"
"Crilly, Richard","Medicine","2007","2010","Grants","Funded","True","False","Collaborator","Strategies for Prevention of Hip Fracture in Elderly Nursing Home Residents","Sawka, A.M.","Josse R, Perrier L, Adachi J, Raina P, Crilly R, Woodhouse L, Hanley D.","$7,859,316.00"
"van Uum, Stanislaus","Medicine","2009/07","2011/06","Grants","Funded","True","False","Principal Applicant","Role of Organic Anion Transporters in Levothyroxine-Drug Interactions","","Rommel Tirona, Richard Kim","$54,404,955.00"
"Garg, Amit","Medicine","2010/01","2016/12","Grants","Funded","True","False","Co-Investigator","Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomized controlled trial","Clark, William","","$5,939,110.00"
"Garg, Amit","Medicine","2009/11","2010/10","Grants","Funded","True","False","Principal Investigator","Cardiovascular disease after acute gastrointestinal infection: Etiology and risk reduction with preventitive care","Garg, Amit","Clark W, Young A, Austin P","$33,322,471.00"
"Garg, Amit","Medicine","2009/07","2011/06","Grants","Funded","True","False","Principal Investigator","Risk of hypertensive disorders in pregnancy after living kidney donation","Garg, Amit","","$53,149,705.00"
"Garg, Amit","Medicine","2009/04","2011/04","Grants","Funded","True","False","Co-Investigator","Statins and Renovascular Disease","Hackam, Daniel","","$37,830,246.00"
"Garg, Amit","Medicine","2009/03","2010/02","Grants","Funded","True","False","Principal Investigator","Impact of MEDLINE filters on evidence retrieval","Garg, Amit","","$27,210,071.00"
"Garg, Amit","Medicine","2009","2010","Grants","Funded","True","False","Principal Investigator","A Research Conference on Living Organ Donor Reimbursement Policies","Garg, Amit","","$55,700,616.00"
"Garg, Amit","Medicine","2009","2010","Grants","Funded","True","False","Co-Investigator","A Consensus Workshop on Managing Misattributed Paternity in Living Kidney Donation","Young, Ann","","$49,717,281.00"
"Garg, Amit","Medicine","2008/11","2009/10","Grants","Funded","True","False","Co-Investigator","Computerized Clinical Decision Support: A Collaborative Research Synthesis","Haynes, Brian","Garg AX, McKibbon A, Wilcynski N","$3,663,978.00"
"Garg, Amit","Medicine","2008/11","2009/10","Grants","Funded","True","False","Principal Investigator","Improving Renal Codes Within Health Administrative Data: Two Systematic Reviews","Garg, Amit","Hackam D, Oliver M, Quinn R","$71,623,860.00"
"Garg, Amit","Medicine","2008/09","2009/08","Grants","Funded","True","False","Principal Investigator","Impact of eGFR reporting on healthcare utilization","Garg, Amit","Jain A, McLeod I","$22,600,769.00"
"Garg, Amit","Medicine","2007/07","2009/06","Grants","Funded","True","False","Co-Investigator","Home care assisted peritoneal dialysis: Risk of invasive procedures to maintain access for dialysis","Oliver, Matthew","","$4,340,105.00"
"Garg, Amit","Medicine","2009/01","2010/06","Grants","Funded","True","False","Co-Investigator","Pregnancy and the Kidney","Nevis, Immaculate","","$24,907,238.00"
"Garg, Amit","Medicine","2007/07","2009/06","Grants","Funded","True","False","Principal Investigator","The science of handling renal practice evidence: optimizing the retrieval of information from EMBASE and the internet","Garg, Amit","","$50,604,778.00"
"Garg, Amit","Medicine","2007/07","2009/06","Grants","Funded","True","False","Co-Investigator","The impact of expanding the eligibility for peritoneal dialysis on rates of hospitalization.","Quinn, Rob","","$45,953,158.00"
"Garg, Amit","Medicine","2009","2010","Grants","Funded","True","False","Principal Investigator","A Research Conference on Acute Kidney Injury in a Surgical Setting","Garg, Amit","","$52,250,949.00"
"Garg, Amit","Medicine","2008/11","2009/05","Grants","Funded","True","False","Co-Investigator","The role of carotid endarterectomy in patients with chronic kidney disease","Matthew, Anna","","$34,622,212.00"
"Garg, Amit","Medicine","2008/01","2009/01","Grants","Funded","True","False","Principal Investigator","A Research Conference to Enhance Living Kidney Donation","Garg, Amit","Knoll G, Gill J","$63,272,122.00"
"Garg, Amit","Medicine","2004/07","2008/06","Grants","Funded","True","False","Principal Investigator","The long-term medical and psychosocial implications of becoming a living kidney donor: A prospective pilot study (Vanguard phase)","Garg, Amit","","$46,957,047.00"
"Feagan, Brian","Medicine","2008/10","2013/10","Grants","Funded","True","False","Co-Applicant","Promoting Adherence to Regimen of Risk Factor Modification by Trained Non-Medical Personnel Evaluated Against Regular Practice Study","","","$32,359,709.00"
"Feagan, Brian","Medicine","2008/05","2013/04","Grants","Funded","True","False","Site Investigator","Genetic, Environmental and Microbiologic Factors in IBD Project","","","$51,841,138.00"
"Feagan, Brian","Medicine","2008/01","2013/01","Grants","Funded","False","True","Co-Applicant","A 5 Year, Registry Study of Humira (Adalimumab) in Patients with Moderately to Severely Active Crohn's Disease","","","$22,417,077.00"
"Feagan, Brian","Medicine","2009/09","2012/09","Grants","Funded","False","True","Principal Applicant","Randomized Evaluation of an Algorithm for Crohn's Treatment","","","$12,998,367.00"
"Feagan, Brian","Medicine","2009/04","2011/04","Grants","Funded","True","False","Co-Applicant","Effect of Lowering the Dialysate Sodium on Ambulatory Blood Pressure in Hemodialysis Patients: A Blinded Randomized Controlled Trial","","","$21,415,034.00"
"Feagan, Brian","Medicine","2009/01","2011/01","Grants","Funded","False","True","Site Investigator","A Phase 3, Open Label Study to Determine the Long-term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease","","","$335,530.00"
"Feagan, Brian","Medicine","2008/11","2010/11","Grants","Funded","False","True","Site Investigator","Optimization of Treatment with Infliximab in a Medical Setting","","","$70,113,800.00"
"Feagan, Brian","Medicine","2005/10","2010/09","Grants","Funded","True","False","Co-Applicant","Knowledge Synthesis and Translation by the Cochrane Collaboration in Canada","","","$3,153,685.00"
"Feagan, Brian","Medicine","2008/08","2010/08","Grants","Funded","False","True","Site Investigator","A Phase IIB, Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Patients with Moderate-Severe Active Crohn's Disease Previously Treated with Anti TNF Therapy","","","$28,273,493.00"
"Feagan, Brian","Medicine","2009/01","2010/06","Grants","Funded","False","True","Site Investigator","A Phase 3, Randomized, Placebo-controlled, Blinded, Multicentre study of the induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis","","","$54,753,031.00"
"Feagan, Brian","Medicine","2011/01","2013/06","Clinical Trials","Funded","False","True","Principal Investigator","A Phase 3, Randomized, Placebo-controlled, Blinded, Multicentre Study of the induction of Clinical Response and Remission by Vedolizumab in Patients with Moderate to Severe Crohn's Disease","","","$69,781,341.00"
"Feagan, Brian","Medicine","2008/06","2010/06","Grants","Funded","False","True","Site Investigator","A Multicentre, Double-blind, Placebo-controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability of Two Single IV Infusions of AIN 457 10mg/kg in Patients with Moderate-Severe Active Crohn's Disease","","","$58,138,201.00"
"Feagan, Brian","Medicine","2008/05","2010/05","Grants","Funded","False","True","Site Investigator","A Phase III, Multicentre, Placebo-controlled, Randomized, Double-blind, Study to evaluate the Safety and Efficacy of PROCHYMAL Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-Severe Crohn's Disease","","","$21,093,685.00"
"Feagan, Brian","Medicine","2008/04","2010/04","Grants","Funded","False","True","Site Investigator","A Phase I Study to Assess the Safety of Intravenous and Subcutaneous RhuMab Beta 7 Administered in a Single-Dose, Escalation Stage Followed by a Multi-dose, Parallel-Treatment Stage in Patients with Ulcerative Colitis","","","$15,260,207.00"
"Feagan, Brian","Medicine","2008/04","2010/04","Grants","Funded","True","False","Co-Applicant","Double-Blind, Placebo-Controlled, Randomized, Multicentre, Pilot Study on Safety and Efficacy of Ciprofloxacin for Prophylactic Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease Patients","","","$28,556,153.00"
"Feagan, Brian","Medicine","2008/04","2010/04","Grants","Funded","False","True","Site Investigator","A Phase II B, Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics in Intravenous Infusions of ABT-874 vs Placebo in Subjects with Moderate to Severe Active Crohn's Disease","","","$62,745,282.00"
"Feagan, Brian","Medicine","2008/02","2010/02","Grants","Funded","False","True","Site Investigator","A Phase IIIB, Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol in Subjects with Moderate to Severe Crohn's Disease","","","$10,522,348.00"
"Feagan, Brian","Medicine","2008/02","2010/02","Grants","Funded","False","True","Site Investigator","A Phase IIIB, Multinational, Open-label, Follow-up Trial to C87085 Designed to Assess the Long Term Safety of Certolizumab, in Subjects with Moderate to Severe Active Crohn's Disease who have Participated in Study C87085","","","$43,279,552.00"
"Feagan, Brian","Medicine","2008/01","2010/01","Grants","Funded","False","True","Director, Coordinating Centre","A Phase 2A, Randomized Placebo-Controlled, Double-Blind, Multi-Centre Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy of AG011 in Subjects with Active Ulcerative Colitis","","","$40,105,668.00"
"Feagan, Brian","Medicine","2007/05","2008/10","Grants","Funded","False","True","Site Investigator","A Phase III, Multicentre, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis","","","$33,509,576.00"
"Feagan, Brian","Medicine","2007/05","2008/05","Grants","Funded","False","True","Site Investigator","A Multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects with Moderate to Severe Crohn's Disease","","","$74,234,556.00"
"Feagan, Brian","Medicine","2006/12","2008/05","Grants","Funded","False","True","Principal Applicant","A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multicentre Study of Infliximab in Combination with Methotrexate for the Long Term Treatment of Crohn's Disease","","","$160,752.00"
"Feagan, Brian","Medicine","2004/03","2008/02","Grants","Funded","False","True","Director, Coordinating Centre","A Randomized Double-blind, Sham Controlled Study to Evaluate the Safety and Efficacy of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease","","","$15,688,653.00"
"Feagan, Brian","Medicine","2004/10","2007/09","Grants","Funded","False","True","Site Investigator","A Phase 3, Multi-Centre, 52 Week, Open Label, Extension Study of the Safety and Efficacy of 25 mg or 50 mg of OPC-6535 Oral Tablets with the Treatment of Subjects with Ulcerative Colitis","","","$29,651,141.00"
"Clark, William","Medicine","2010/01","2016/12","Grants","Funded","True","False","Principal Investigator","Plasma exchange and glucocorticoid dosing in patients with severe ANCA associated vasculitis: an international randomized control trial.","William F. Clark/ Michael Walsh","","$2,005,474.00"
"Hill, David","Medicine","2010/07","2012/06","Grants","Funded","True","False","Co-Investigator","Vitamin D and Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention","Director: G. Desoye","","$24,152,337.00"
"Hill, David","Medicine","2008/07","2011/06","Grants","Funded","True","False","Co-Principal Investigator","Reduction of Adolescent Risk Factors for Type-2 Diabetes and Diabetes-related Cardiovascular Disease (REACH)","","","$48,295,447.00"
"Hill, David","Medicine","2008/07","2010/06","Grants","Funded","True","False","Co-Investigator","Non-invasive assessment of stem cell therapy in dystrophic mice","Lisa Hoffman","","$19,039,115.00"
"Kao, Raymond","Medicine","2005/01","2005/12","Grants","Funded","True","False","Co-Applicant","Evaluation of Pulmonary Surfactant in mechanically Ventilated Trauma patients","","Bosma K, Lewis J.","$22,772,007.00"
"Kao, Raymond","Medicine","2000/07","2003/06","Grants","Funded","True","False","Principal Applicant","The Effect of Vitamin A on the Healing of Abdominal Wall and intestinal Perforations in a Rat Model.","","Yuen D.","$69,718,785.00"
"Kao, Raymond","Medicine","2002/07","2004/06","Grants","Funded","True","False","Principal Applicant","A Biological Marker of PTSD: A fMRI Study in Canadian forces personnel with PTSD.","","Lanius R.","$55,882,877.00"
"Kao, Raymond","Medicine","2005/07","2006/06","Grants","Funded","True","False","Principal Applicant","Effect of rh-EPO on Hemodynamics and Microcirculatory Perfusion of a Septic Rat Model.","Kao R","","$34,456,775.00"
"Kao, Raymond","Medicine","2006/07","2007/06","Grants","Funded","True","False","Principal Applicant","Effect of rh-EPO on Hemodynamics and Microcirculatory Perfusion of a Hemorrhagic Shock Rat Model.","Kao R","","$27,970,005.00"
"Boughner, Derek","Medicine","1987/11","1989/11","Grants","Funded","True","False","Co-Investigator","Design of a new bioprosthetic heart valve","G Campbell","A Menkis, I Vesely","$3,125,520.00"
"Boughner, Derek","Medicine","1990/03","1991/03","Grants","Funded","True","False","Co-Investigator","Valvular abnormalities, antiphospholipid antibodies and neuropsychiatric manifestations in systemic lupus erythmatosus","D Bell","W Brien, W. Clark,P Cheung, C Graffagnino, V Hachinski, L Melendez, T Ostbye, W Bloembergen","$23,849,113.00"
"Boughner, Derek","Medicine","2008/07","2010/06","Grants","Funded","True","False","Principal Investigator","Early imaged based diagosis of aortic valve sclerosis in a rabbit model","","Dr. K. Rogers","$67,821,133.00"
"Boughner, Derek","Medicine","1981/07","","Grants","Funded","True","False","Principal Investigator","Research Associateship - Personal support","Dr. Derek Boughner","","$22,829,547.00"
"Boughner, Derek","Medicine","1979/07","1984/06","Grants","Funded","True","False","Co-Investigator","Coronary artery disease","WJ Kostuk","","$63,740,196.00"
"Boughner, Derek","Medicine","2008/07","2010/07","Grants","Funded","True","False","Co-Applicant","CIHR Training program in vascular research","A Fenster","","$50,512,541.00"
"Huff, Murray","Medicine","2008/07","2012/06","Grants","Funded","True","False","Principal Investigator","Regulation of foam cell formation: Relationship to atherosclerosis","Huff MW","","$50,292,402.00"
"Dresser, George","Medicine","2008/03","2013/03","Grants","Funded","True","False","Co-Applicant","Hepatic Organic Anion Transporting Polypeptide OATP Drug Uptake Transporters as Determinants of Drug Disposition","Dr Richard Kim","","$39,995,719.00"
"Dresser, George","Medicine","2008/12","2010/12","Clinical Trials","Funded","True","False","Principal Investigator","Therapeutic drug monitoring and polysomnography in the management of sedation and delirium in critical care patients","Dr George Dresser","","$6,605,390.00"
"Diamantouros, Pantelis","Medicine","2009/08","2011/08","Grants","Funded","False","True","Co-Investigator","Randomized Evaluation of Recurrent Stroke comparing PFO Closure to Established Current Standard of Care Treatment (IDE #G990318)","Dr. David Spence","Dr. P. Diamantouros","$4,386,296.00"
"Lazo Langner, Alejandro","Medicine","2008/07","2011/07","Grants","Funded","True","False","Co-Applicant","Treatment of Hodgkin Lymphoma with ABVD without routine growth factor support – a Quality Assurance study","Joy E Mangel","Leonard Minuk, Ian Chin-Yee, Kang Howson-Jan, Reinhardt Lohman, Alejandro Lazo-Langner","$44,792,692.00"
"Pickering, J. Geoffrey","Medicine","2009/04","2010/03","Grants","Funded","True","False","Principal Investigator","Skin Protection by Enhancing NAD-mediated Cellular Fitness","J.G. Pickering","","$57,729,165.00"
"Haddara, Wael","Medicine","2009/07","present","Grants","Funded","True","False","Co-Principal Investigator","The Use of Goal-oriented Categories in Medical Thinking and Reasoning.","John Paul Minda","Mark Goldszmidt","$22,135,843.00"
"Haddara, Wael","Medicine","2007/07","2008/06","Grants","Funded","False","False","Co-Investigator","How Clinicians Think: An Investigation of the Cognitive Psychology of Medical Thinking and Reasoning.","","","$54,853,267.00"
"Kim, Richard","Medicine","2009/06","2011/05","Grants","Funded","True","False","Co-Principal Investigator","Vascular Health & Personalized Medicine Clinic at LHSC/SJHC: Right Place, Right Time, Right People","Richard Kim","Kathy Myers and George Dresser","$55,356,536.00"
"Kim, Richard","Medicine","2009/05","2010/05","Grants","Funded","False","True","Principal Applicant","Drug Disposition in Tumour Tissue","Richard B Kim","","$7,370,967.00"
"Kim, Richard","Medicine","2008/05","2009/04","Grants","Funded","False","True","Principal Applicant","Drug Uptake Transporters and the renal elimination of a Lilly prodrug and its active metabolite","Richard B. Kim","","$66,802,988.00"
"Kim, Richard","Medicine","2007/09","2008/08","Grants","Funded","False","True","Principal Applicant","Expression and subcellular localization transporters in human intestine","Richard B. Kim","","$40,818,348.00"
"Kim, Richard","Medicine","2007/07","2008/06","Grants","Funded","True","False","Co-Applicant","Hepatic Drug Transporters in Drug Disposition","Dan Roden","","$41,247,641.00"
"Kim, Richard","Medicine","2006/07","2007/06","Grants","Funded","True","False","Principal Applicant","Determinants of Individual Responsiveness to Drugs","Richard B Kim","","$23,596,806.00"
"Kim, Richard","Medicine","2005/01","2006/12","Grants","Funded","True","False","Co-Applicant","Drug Disposition in intestinal Disease","George Dresser","","$31,629,996.00"
"Kim, Richard","Medicine","2009/05","2010/05","Grants","Funded","False","True","Principal Applicant","Drug Uptake transporters and the renal elimination and Oatp transport potential of Lilly prodrug and its active metabolite","Richard B Kim","Rommel G. Tirona","$74,639,343.00"
"Lazo Langner, Alejandro","Medicine","2008","2009","Grants","Funded","True","False","Site Investigator","The Thrombophilia in Pregnancy Prophylaxis Study","M Rodger","","$3,114,744.00"
"Lazo Langner, Alejandro","Medicine","2008/08","2012","Grants","Funded","True","False","Site Investigator","Treatment registry of unusual site thrombosis (TRUST)","SR Kahn","","$90,103.00"
"Lazo Langner, Alejandro","Medicine","2008/08","present","Grants","Funded","True","False","Site Investigator","Developement and validation of clinical prediction rules for bleeding for patients on antiocagulant therapy for venous thromboembolism","PS Wells","","$62,363,482.00"
"Lazo Langner, Alejandro","Medicine","2006","2007","Clinical Trials","Funded","True","False","Site Investigator","International, multicentre, randomised, parallel group double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E","H Buller","","$55,513,652.00"
"Lazo Langner, Alejandro","Medicine","2007","2012","Clinical Trials","Funded","True","True","Site Investigator","Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism","M Kovacs","","$30,948,156.00"
"Lazo Langner, Alejandro","Medicine","2008","2012","Clinical Trials","Funded","True","True","Site Investigator","A prospective study of upper extremity deep vein thrombosis to determine the prevalence of Post-thrombotic Syndrome in patients managed with anticoagulation - EUDVT","SR Kahn","","$17,206,505.00"
"Lazo Langner, Alejandro","Medicine","2008","present","Clinical Trials","Funded","True","True","Site Investigator","AVF406g: A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma","L Minuk","","$71,020,571.00"
"Skanes, Allan","Medicine","2006/07","2008/06","Grants","Funded","True","False","Co-Applicant","Maximum Voltage Targeted Ablation of Atrial Flutter","Andrew Krahn","","$58,355,437.00"
"Yee, Raymond","Medicine","2008/07","2010/06","Grants","Funded","True","False","Principal Site Investigator","His bundle and para-hisian pacing: Acute and chronic benefits","Raymond Yee","","$1,842,576.00"
"Garg, Amit","Medicine","2010/03","2011/03","Grants","Funded","True","False","Principal Investigator","Organ Donor Registries: A Global Scoping Review","Garg, Amit","Markel F, Young K, Horvat L, Rosenblum A, Shemie S","$48,354,102.00"
"Montero Odasso, Manuel","Medicine","2009/10","2010/10","Grants","Funded","True","False","Co-Principal Investigator","Gait and Cognition as Gateways to understanding Mobility in Aging. CIHR Emerging Team Grant: Alliances in Mobility in Aging (LoI Research Grant)","Rob Petrella","","$35,029,842.00"
"van Uum, Stanislaus","Medicine","2009/05","2011/01","Grants","Funded","True","False","Principal Applicant","Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples","Stan Van Uum","Walter Kocha, Alan Dennis","$50,553,037.00"
"Skanes, Allan","Medicine","1999/07","2000/06","Grants","Funded","True","False","Co-Investigator","Ablation in Atrial Fibrillation","George Klein","","$21,867,606.00"
"Yee, Raymond","Medicine","1993/07","1996/06","Grants","Funded","True","False","Co-Investigator","Electrophysiology Studies in WPW","George Klein","","$69,775,239.00"
"Yee, Raymond","Medicine","2003/12","2005/12","Grants","Funded","False","False","Principal Investigator","Electrical features of screw-in lead fixation","Raymond Yee","","$28,108,955.00"
"Yee, Raymond","Medicine","2004/01","2004/09","Grants","Funded","True","False","Principal Investigator","Magnetic resonance imaging assessment of pacing intervention in heart failure: Prediction of response to biventricular pacing","Raymond Yee","","$28,314,334.00"
"Yee, Raymond","Medicine","1999/07","2001/06","Grants","Funded","True","False","Principal Investigator","Atrial fibrillation ventricular irregularity and atrial remodelling issues","Raymond Yee","","$68,545,546.00"
"Pope, Janet","Medicine","2010/04","2012/04","Grants","Funded","True","False","Principal Applicant","Facilitating Patient Utilization of Multidisciplinary Care in Inflammatory Arthritis","","Warren Nielson","$11,796,465.00"
"Garg, Amit","Medicine","2008/04","2009/03","Grants","Funded","True","False","Co-Principal Investigator","Preventing chronic kidney disease by avoiding acute, transient elevations in serum creatinine","Garg, Amit / Lamy, Andre","Coca S, Cuerden M, Cook R, Devereaux PJ, Hu S, Jain A, Novick R, Parikh C, Walsh M, Yusuf S","$35,017,363.00"
"Myers, Kathryn","Medicine","2009/05","2010/06","Grants","Funded","True","False","Principal Investigator","It's all in what you say: A corpus linguistic analysis of written comments made by medical residents about their clinical supervisors","Kathryn Myers","Elaine Zibrowski Lorelei Lingard","$13,980,922.00"
"McManus, Ruth","Medicine","2009/10","2014/01","Grants","Funded","False","True","Principal Site Investigator","Action in Diabetes and Vascular Disease: Preterax and Diamicron MR controlled Evaluation post-trial Observational Study (ADVANCE-ON)","Professors Stephen MacMahon and John Chalmers,","Advance Collaborative Group","$67,717,252.00"
"Lavi, Shahar","Medicine","2009/03","2012/03","Grants","Funded","True","False","Co-Principal Investigator","Sevoflurane sedation during primary percutaneous coronary intervention","Shahar Lavi","Ronit Lavi","$61,530,616.00"
"Lavi, Shahar","Medicine","2009/07","2011/06","Grants","Funded","True","False","Principal Investigator","Remote ischemic postconditioning during percutaneous coronary interventions","Shahar Lavi","","$42,340,928.00"
"Lavi, Shahar","Medicine","2009/07","2010/06","Grants","Funded","True","False","Principal Investigator","Leg versus arm ischemic postconditioning during percutaneous coronary interventions - effect on myocardial injury","Shahar Lavi","","$50,633,051.00"
"Lavi, Shahar","Medicine","2009/06","2010/05","Grants","Funded","True","False","Co-Investigator","Remote ischemic preconditioning before coronary artery bypass grafting surgery and the prevalance of perioperative atrial fibrilation","Ronit Lavi","Shahar Lavi","$73,864,829.00"
"Garg, Amit","Medicine","2004/04","2009/03","Grants","Funded","True","False","Principal Investigator","A data management facility for kidney diseases","Garg, Amit","","$55,789,349.00"
"Garg, Amit","Medicine","2004/04","2009/03","Grants","Funded","True","False","Principal Investigator","A data management facility for kidney diseases","Garg, Amit","","$25,998,172.00"
"Garg, Amit","Medicine","2006/04","2009/03","Grants","Funded","True","False","Principal Investigator","Clinician Scientist Training Award Phase 2","Garg, Amit","","$19,624,835.00"
"Lavi, Shahar","Medicine","2009/10","2012","Clinical Trials","Funded","False","True","Principal Site Investigator","AQUARIUS - A 104-week, randomized double blind, placebo controlled, parallel-group, multicentre study to evaluate the efficacy of Aliskiren on the progression of atherosclerosis in patients with coronary artery disease when added to optimal background therapy","Stephen Nicholls","","$65,914,256.00"
"Lavi, Shahar","Medicine","2009/07","present","","Funded","True","False","Principal Site Investigator","Genesis praxy - Sex and Gender Differences in Premature Acute Coronary Syndrome","","","$52,414,543.00"
"Garg, Amit","Medicine","2009","2012","Grants","Funded","True","False","Principal Investigator","Clinician Scientist Training Award Phase 2 (Renewal)","Garg, Amit","","$20,374,764.00"
"Gula, Lorne","Medicine","2005/01","2009/01","Clinical Trials","Funded","False","True","Co-Investigator","Randomized Controlled Trial of the Efficacy and Safety of Electroanatomical versus Circumferential Potential Guided Pulmonary Vein Isolation with and without Intracardiac Ultrasound","Allan Skanes","","$35,654,954.00"
"Gula, Lorne","Medicine","2005/01","2006/01","Clinical Trials","Funded","False","True","Co-Investigator","Acute Coupled Pacing Study","Raymond Yee","","$34,920,176.00"
"Gula, Lorne","Medicine","2005/01","2007/01","Clinical Trials","Funded","False","True","Co-Investigator","Select Secure Lead Post-Market Pilot Study","Raymond Yee","","$23,624,494.00"
"Gula, Lorne","Medicine","2006/01","2007/01","Clinical Trials","Funded","False","True","Co-Investigator","A Study of the Effects of GAP-486 on Ventricular Tachyarrhythmia Induction","Allan Skanes","","$1,526,420.00"
"Gula, Lorne","Medicine","2006/01","2008/01","Clinical Trials","Funded","False","True","Co-Investigator","Canadian Registry of ICD Implant Testing Procedures","Raymond Yee","","$20,198,451.00"
"Gula, Lorne","Medicine","2006/01","2009/01","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Lead Nav Clinical Research Study","Raymond Yee","","$39,651,155.00"
"Gula, Lorne","Medicine","2007/01","2008/01","Clinical Trials","Funded","False","True","Co-Investigator","A Randomized, Double-Blind, Placebo Controlled Study of At1-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities","Raymond Yee","","$7,790,468.00"
"Gula, Lorne","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Co-Investigator","Acute Refractory Pacing Site Study","Raymond Yee","","$28,303,319.00"
"Gula, Lorne","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Co-Investigator","Dynamic Discrimination Chronic Download Study","Raymond Yee","","$6,161,625.00"
"Gula, Lorne","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Medtronic Lead Model 10538 Chronic Research Study","Raymond Yee","","$37,123,455.00"
"Gula, Lorne","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Co-Investigator","Implant sans Fluora","Raymond Yee","","$43,711,976.00"
"Gula, Lorne","Medicine","2008/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Selective Strategy to Manage Arrhythmia Risk and Therapy with ICD","Paul Dorian","","$31,193,735.00"
"Skanes, Allan","Medicine","2004/01","2007/01","Clinical Trials","Funded","False","True","Site Investigator","Reveal Plus Alternate Implant Site Study","Andrew Krahn","","$52,563,638.00"
"Skanes, Allan","Medicine","2004/01","2008/01","Clinical Trials","Funded","False","True","Co-Investigator","The Electrode Configuration CRT Study","Andrew Krahn","George Klein, Allan Skanes, Raymond Yee","$16,858,517.00"
"Skanes, Allan","Medicine","2006/01","2007/01","Clinical Trials","Funded","False","True","Principal Site Investigator","A Study of the Effects of GAP-486 on Ventricular Tachyarrhythmia Induction","Allan Skanes","","$39,016,602.00"
"Skanes, Allan","Medicine","2003/01","2008/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Percutaneous Left Atrial Appendage Trans-catheter Occlusion (PLAATO) using the X-Caliber System: A Feasability Study","Allan Skanes","","$16,028,287.00"
"Skanes, Allan","Medicine","2005/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Randomized Controlled Trial of the Efficacy and Safety of Electroanatomical versus Circumferential Potential Guided Pulmonary Vein Isolation with and without Intracardiac Ultrasound","Allan Skanes","","$11,246,105.00"
"Skanes, Allan","Medicine","2004/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","Prospective, Non Randomized, Multi Centre Trial to Determine if Implant Device Data are Indicators of Clinical Outcomes","George Klein","","$48,583,200.00"
"Skanes, Allan","Medicine","2003/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","Canadian Registry of Atrial Fibrillation","George Klein","","$27,684,863.00"
"Skanes, Allan","Medicine","2008/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Selective Strategy to Manage Arrhythmia Risk and Therapy with ICD","Lorne Gula","George Klein, Allan Skanes, Raymond Yee","$22,101,938.00"
"Skanes, Allan","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Site Investigator","Resynchronization Therapy Outcomes Registry","Raymond Yee","","$69,832,318.00"
"Skanes, Allan","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Site Investigator","Model 6949 Lead Study","Raymond Yee","","$15,370,694.00"
"Skanes, Allan","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Site Investigator","Dynamic Discrimination of SVT/VT","Raymond Yee","","$37,234,137.00"
"Skanes, Allan","Medicine","2005/01","2006/01","Clinical Trials","Funded","False","True","Site Investigator","Acute Coupled Pacing Study","Raymond Yee","","$60,852,133.00"
"Skanes, Allan","Medicine","2005/01","2007/01","Clinical Trials","Funded","False","True","Site Investigator","Select Secure Lead Post-Market Pilot Study","Raymond Yee","","$4,475,137.00"
"Skanes, Allan","Medicine","2006/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","Canadian Registry of ICD Implant Testing Procedures","Raymond Yee","","$48,091,613.00"
"Skanes, Allan","Medicine","2007/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","A Randomized, Double-Blind, Placebo Controlled Study of At1-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities","Raymond Yee","","$53,729,667.00"
"Skanes, Allan","Medicine","2006/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Medtronic Lead Nav Clinical Research Study","Raymond Yee","","$29,281,378.00"
"Skanes, Allan","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Acute Refractory Pacing Site Study","Raymond Yee","","$12,714,405.00"
"Skanes, Allan","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Dynamic Discrimination Chronic Download Study","Raymond Yee","","$70,015,405.00"
"Skanes, Allan","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Medtronic Lead Model 10538 Chronic Research Study","Raymond Yee","","$48,534,292.00"
"Skanes, Allan","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Attain Starfix Model 4195 Left Ventricular Lead Study","Raymond Yee","","$32,790,946.00"
"Skanes, Allan","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Implant sans Fluora","Raymond Yee","","$30,551,398.00"
"Klein, George","Medicine","2004/01","2007/01","Clinical Trials","Funded","False","True","Site Investigator","Reveal Plus Alternate Implant Site Study","Andrew Krahn","","$18,066,946.00"
"Klein, George","Medicine","2004/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","The Electrode Configuration CRT Study","Andrew Krahn","George Klein, Allan Skanes, Raymond Yee","$779,203.00"
"Klein, George","Medicine","2006/01","2007/01","Clinical Trials","Funded","False","True","Site Investigator","A Study of the Effects of GAP-486 on Ventricular Tachyarrhythmia Induction","Allan Skanes","","$12,636,643.00"
"Klein, George","Medicine","2003/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","Percutaneous Left Atrial Appendage Trans-catheter Occlusion (PLAATO) using the X-Caliber System: A Feasability Study","Allan Skanes","","$21,473,942.00"
"Klein, George","Medicine","2005/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Randomized Controlled Trial of the Efficacy and Safety of Electroanatomical versus Circumferential Potential Guided Pulmonary Vein Isolation with and without Intracardiac Ultrasound","Allan Skanes","","$12,066,974.00"
"Klein, George","Medicine","2004/01","2008/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Prospective, Non Randomized, Multi Centre Trial to Determine if Implant Device Data are Indicators of Clinical Outcomes","George Klein","","$74,835,361.00"
"Klein, George","Medicine","2003/01","2008/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Canadian Registry of Atrial Fibrillation","George Klein","","$52,123,843.00"
"Klein, George","Medicine","2008/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Selective Strategy to Manage Arrhythmia Risk and Therapy with ICD","Lorne Gula","George Klein, Allan Skanes, Raymond Yee","$69,575,201.00"
"Klein, George","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Site Investigator","Resynchronization Therapy Outcomes Registry","Raymond Yee","","$43,172,866.00"
"Klein, George","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Site Investigator","Model 6949 Lead Study","Raymond Yee","","$65,989,944.00"
"Klein, George","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Site Investigator","Dynamic Discrimination of SVT/VT","Raymond Yee","","$50,094,282.00"
"Klein, George","Medicine","2005/01","2006/01","Clinical Trials","Funded","False","True","Site Investigator","Acute Coupled Pacing Study","Raymond Yee","","$15,382,615.00"
"Klein, George","Medicine","2005/01","2007/01","Clinical Trials","Funded","False","True","Site Investigator","Select Secure Lead Post-Market Pilot Study","Raymond Yee","","$70,616,868.00"
"Klein, George","Medicine","2006/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","Canadian Registry of ICD Implant Testing Procedures","Raymond Yee","","$38,180,548.00"
"Klein, George","Medicine","2007/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","A Randomized, Double-Blind, Placebo Controlled Study of At1-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities","Raymond Yee","","$10,129,404.00"
"Klein, George","Medicine","2006/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Medtronic Lead Nav Clinical Research Study","Raymond Yee","","$70,408,733.00"
"Klein, George","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Acute Refractory Pacing Site Study","Raymond Yee","","$4,333,299.00"
"Klein, George","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Dynamic Discrimination Chronic Download Study","Raymond Yee","","$58,602,434.00"
"Klein, George","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Medtronic Lead Model 10538 Chronic Research Study","Raymond Yee","","$64,893,102.00"
"Klein, George","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Attain Starfix Model 4195 Left Ventricular Lead Study","Raymond Yee","","$52,867,013.00"
"Klein, George","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Implant sans Fluora","Raymond Yee","","$34,400,926.00"
"Yee, Raymond","Medicine","2004/01","2007/01","Clinical Trials","Funded","False","True","Site Investigator","Reveal Plus Alternate Implant Site Study","Andrew Krahn","","$68,466,686.00"
"Yee, Raymond","Medicine","2004/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","The Electrode Configuration CRT Study","Andrew Krahn","George Klein, Allan Skanes, Raymond Yee","$23,178,185.00"
"Yee, Raymond","Medicine","2006/01","2007/01","Clinical Trials","Funded","False","True","Site Investigator","A Study of the Effects of GAP-486 on Ventricular Tachyarrhythmia Induction","Allan Skanes","","$53,992,645.00"
"Yee, Raymond","Medicine","2003/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","Percutaneous Left Atrial Appendage Trans-catheter Occlusion (PLAATO) using the X-Caliber System: A Feasability Study","Allan Skanes","","$34,514,771.00"
"Yee, Raymond","Medicine","2005/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Randomized Controlled Trial of the Efficacy and Safety of Electroanatomical versus Circumferential Potential Guided Pulmonary Vein Isolation with and without Intracardiac Ultrasound","Allan Skanes","","$68,880,686.00"
"Yee, Raymond","Medicine","2004/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","Prospective, Non Randomized, Multi Centre Trial to Determine if Implant Device Data are Indicators of Clinical Outcomes","George Klein","","$38,346,645.00"
"Yee, Raymond","Medicine","2003/01","2008/01","Clinical Trials","Funded","False","True","Site Investigator","Canadian Registry of Atrial Fibrillation","George Klein","","$68,648,473.00"
"Yee, Raymond","Medicine","2008/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Selective Strategy to Manage Arrhythmia Risk and Therapy with ICD","Lorne Gula","George Klein, Allan Skanes, Raymond Yee","$29,368,356.00"
"Yee, Raymond","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Resynchronization Therapy Outcomes Registry","Raymond Yee","","$66,257,639.00"
"Yee, Raymond","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Model 6949 Lead Study","Raymond Yee","","$39,185,259.00"
"Yee, Raymond","Medicine","2003/01","2006/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Dynamic Discrimination of SVT/VT","Raymond Yee","","$22,262,981.00"
"Yee, Raymond","Medicine","2005/01","2006/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Acute Coupled Pacing Study","Raymond Yee","","$19,011,454.00"
"Yee, Raymond","Medicine","2005/01","2007/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Select Secure Lead Post-Market Pilot Study","Raymond Yee","","$22,637,831.00"
"Yee, Raymond","Medicine","2003/09","2007/09","Clinical Trials","Funded","True","False","Principal Site Investigator","Home Automatic External Defibrillator Trial, Site 079","Dr. Gus Bardy","","$51,034,820.00"
"Yee, Raymond","Medicine","2006/01","2008/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Canadian Registry of ICD Implant Testing Procedures","Raymond Yee","","$24,311,273.00"
"Yee, Raymond","Medicine","2007/01","2008/01","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized, Double-Blind, Placebo Controlled Study of At1-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities","Raymond Yee","","$56,176,971.00"
"Yee, Raymond","Medicine","2006/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Lead Nav Clinical Research Study","Raymond Yee","","$61,498,531.00"
"Yee, Raymond","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Acute Refractory Pacing Site Study","Raymond Yee","","$17,148,437.00"
"Yee, Raymond","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Dynamic Discrimination Chronic Download Study","Raymond Yee","","$49,461,834.00"
"Yee, Raymond","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Lead Model 10538 Chronic Research Study","Raymond Yee","","$17,374,578.00"
"Yee, Raymond","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Attain Starfix Model 4195 Left Ventricular Lead Study","Raymond Yee","","$72,623,643.00"
"Yee, Raymond","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Implant sans Fluora","Raymond Yee","","$40,765,989.00"
"Skanes, Allan","Medicine","2008/11","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Discerning Symptomatic and Asymptomatic Episodes Pre & Post Radiofrequency Ablation of Atrial Fibrillation","David Birnie","Lorne Gula, Raymond Yee","$915,091.00"
"Skanes, Allan","Medicine","2007/05","present","Clinical Trials","Funded","False","True","Principal Site Investigator","First line Radiofrequency Ablation vs. Antiarrhythmic Drugs for Atrial Fibrillation Treatment","Andrea Natale & Carlos Morillo","Lorne Gula","$62,418,878.00"
"Skanes, Allan","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Site Investigator","Borealis","George Klein","","$38,441,763.00"
"Skanes, Allan","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Site Investigator","A randomized, controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation","Lorne Gula","","$9,640,291.00"
"Skanes, Allan","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Site Investigator","Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy","Raymond Yee","","$17,758,420.00"
"Skanes, Allan","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Site Investigator","Left Ventricular Capture Management","Raymond Yee","Lorne Gula, George Klein, Allan Skanes","$74,163,241.00"
"Skanes, Allan","Medicine","2007/01","present","Clinical Trials","Funded","False","True","Site Investigator","EnRhythm MRI Surescan Pacing System","Raymond Yee","","$63,709,523.00"
"Klein, George","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Site Investigator","Discerning Symptomatic and Asymptomatic Episodes Pre & Post Radiofrequency Ablation of Atrial Fibrillation","Allan Skanes","","$64,485,054.00"
"Klein, George","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Site Investigator","First line Radiofrequency Ablation vs. Antiarrhythmic Drugs for Atrial Fibrillation Treatment","Allan Skanes","","$489,155.00"
"Klein, George","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Borealis","George Klein","","$3,697,940.00"
"Klein, George","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Site Investigator","A randomized, controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation","Lorne Gula","","$21,066,332.00"
"Klein, George","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Site Investigator","Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy","Raymond Yee","","$24,253,642.00"
"Klein, George","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Site Investigator","Left Ventricular Capture Management","Raymond Yee","Lorne Gula, George Klein, Allan Skanes","$29,487,772.00"
"Klein, George","Medicine","2007/01","present","Clinical Trials","Funded","False","True","Site Investigator","EnRhythm MRI Surescan Pacing System","Raymond Yee","","$8,945,865.00"
"Gula, Lorne","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Co-Investigator","Borealis","George Klein","","$5,658,200.00"
"Gula, Lorne","Medicine","2009/06","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Shockless Implant Evaluation: A Prospective Randomised Clinical Trial","Jeff Healey","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$39,841,699.00"
"Gula, Lorne","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A randomized, controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation","Douglas L. Packer","","$4,659,328.00"
"Gula, Lorne","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Co-Investigator","Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy","Raymond Yee","","$36,256,462.00"
"Gula, Lorne","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Co-Investigator","Left Ventricular Capture Management","Raymond Yee","Lorne Gula, George Klein, Allan Skanes","$5,662,438.00"
"Gula, Lorne","Medicine","2005/01","present","Clinical Trials","Funded","False","True","Co-Investigator","Right Ventricular Apical Versus Septal Pacing Trial","Raymond Yee","","$27,038,976.00"
"Gula, Lorne","Medicine","2007/01","present","Clinical Trials","Funded","False","True","Co-Investigator","EnRhythm MRI Surescan Pacing System","Raymond Yee","","$6,214,357.00"
"Yee, Raymond","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Site Investigator","First line Radiofrequency Ablation vs. Antiarrhythmic Drugs for Atrial Fibrillation Treatment","Allan Skanes","","$5,127,172.00"
"Yee, Raymond","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Site Investigator","Borealis","George Klein","","$18,567,913.00"
"Yee, Raymond","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Site Investigator","A randomized, controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation","Lorne Gula","","$23,744,716.00"
"Yee, Raymond","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy","Raymond Yee","","$32,954,818.00"
"Yee, Raymond","Medicine","2007/12","2010/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Universal Antitachycardia Therapy Study","Paul Belk","Lorne Gula, Allan Skanes","$40,316,499.00"
"Yee, Raymond","Medicine","2008/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Left Ventricular Capture Management","Raymond Yee","","$27,958,895.00"
"Yee, Raymond","Medicine","2005/01","2016/12","Clinical Trials","Funded","False","True","Principal Investigator","Right Ventricular Apical Versus Septal Pacing Trial","Raymond Yee","George Klein","$71,916,649.00"
"Yee, Raymond","Medicine","2007/01","2010/08","Clinical Trials","Funded","False","True","Principal Site Investigator","EnRhythm MRI Surescan Pacing System","Nathalie Odryzynski","","$34,268,848.00"
"Siu, Samuel","Medicine","2010/07","2012/06","Grants","Funded","True","False","Co-Principal Investigator","Prognostic role of neurohormones in pregnant women with heart disease","Dr. Samuel Siu","Dr. C. Silversides","$62,426,532.00"
"Siu, Samuel","Medicine","2008/07","2011/06","Grants","Funded","True","False","Co-Applicant","Multi-modality imaging assessment for pacing interventions in heart failuRE (MAPIT-HF)","James White","","$58,673,568.00"
"Siu, Samuel","Medicine","2008/07","2010/06","Grants","Funded","True","False","Co-Applicant","His Bundle and ParaHisian Pacing: Acute and Chronic Benefits","Raymond Yee","","$34,410,900.00"
"Garg, Amit","Medicine","2010/04","2015/03","Grants","Funded","True","False","Principal Investigator","Preventing chronic kidney disease by avoiding acute, transient elevations in serum creatinine","Garg, Amit","Coca S, Cook R, Cuerden M, Devereaux PJ, Hu S, Jain A, Lamy A, Novick R, Parikh C, Walsh M","$12,953,434.00"
"Garg, Amit","Medicine","2010/04","2011/03","Grants","Funded","True","False","Principal Investigator","Accepting Kidneys from Older Donors: Impact on Transplant Recipient Outcomes","Garg, Amit","Kim SJ, Knoll G, Prasad R, Speechley M, Treleaven D, Young A","$56,684,016.00"
"Garg, Amit","Medicine","2010/01","2010/12","Grants","Funded","True","False","Principal Investigator","An International Conference to Enhance Living Kidney Donation","Garg, Amit","","$55,051,009.00"
"Jevnikar, Anthony","Medicine","2008/09","2013/08","Grants","Funded","True","False","Principal Applicant","Clinical Research Chair in Transplantation (CIHR/Pfizer) Regulation of Tissue Injury and Novel Approaches to Tolerance Induction to Promote Long Term Renal Transplant","Dr. A. Jevnikar","","$36,178,866.00"
"Wisenberg, Gerald","Medicine","2008","2011","Grants","Funded","True","False","Co-Investigator","Multimodality imaging Assessment of Pacing InTerventions in Heart Failure MAPIT-HF) Study","White, J.","Drangova M, Yee R, Wisenberg G.","$50,682,441.00"
"Wisenberg, Gerald","Medicine","2009/11","2011/10","Grants","Funded","True","False","Co-Applicant","Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imagin (Rb-ARMI)","DeKemp, RA","Prato, FS, Lee, TY, Beanlands, R, Gulenchyn, K., Iwanochko, I.","$12,415,985.00"
"Wisenberg, Gerald","Medicine","2009/09","2014/08","Grants","Funded","True","False","Collaborator","Imaging Modalities to Assist with Guiding Therapy and the Evaluation of Patients with Heart Failure (IMAGE-HF)","Beanlands R","multiple investigators across Canada (20)","$36,170,335.00"
"Kovacs, Michael","Medicine","2006","2010","Grants","Funded","True","False","Co-Applicant","Extended Prophylaxis comparing low molecular weight heparin (LMWH) to aspirin in total hip arthroplasty (EPCAT study).","","","$30,827,577.00"
"Kovacs, Michael","Medicine","2008/08","present","Grants","Funded","True","False","Co-Applicant","Treatment and risk factors for unusual site thrombosis registry study. (TRUST)","Dr. S. Kahn","","$58,945,347.00"
"Kovacs, Michael","Medicine","2008","present","Grants","Funded","True","False","Co-Applicant","The etiologic role of inflammation, thrombophilia and fibrinolysis in the post-thrombotic syndrome: The Bio-SOX Study (Grant#MOP 89349)","Dr. Susan Kahn","","$27,008,858.00"
"Kovacs, Michael","Medicine","2008/08","2013/12","Grants","Funded","True","False","Co-Applicant","Development and validation of prediction rules for bleeding for patients on anticoagulant therapy for venous thromboembolism.","Dr. Phil S. Wells","","$22,349,190.00"
"Kovacs, Michael","Medicine","2008/11","present","* Grant-in-Aid","Funded","True","False","Principal Applicant","A prospective study of upper extremity deep vein thrombosis to determine the prevalence of post-thrombotic syndrome in patients managed with anticoagulation - UEDVT","","","$33,485,850.00"
"Kovacs, Michael","Medicine","2009","present","Grants","Funded","True","True","Principal Site Investigator","Dalteparin Sodium injection (Fragmin), Multi-centre, open label, single arm, Long-term (52 weeks) study for understanding safetly and efficacy in subjects with malignancies and symptomatic venous thromboembolism (FRAGMIN)","","","$69,021,012.00"
"Hussain, Nadeem","Medicine","2007/07","","Clinical Trials","Industry funded","False","True","Principal Site Investigator","A Phase 2a, Randomized, Double-Blind, Placebo-Conrolled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiples Doses and Dose Levels of DDP733 in Patients with Irritable Bowel Syndrome and Constipation","","","$10,775,463.00"
"Hussain, Nadeem","Medicine","2007/07","","Clinical Trials","Industry funded","False","True","Principal Site Investigator","A Phase 2, Randomized, Double-Blind, Placebo-Conrolled Study to evaluate the Safety, Tolerability, and Pharmocodynamics of Multiples Doses and Dose Levels of DDP225 in Female subjects with Irritable Bowel Syndrome with Diarrhea","","","$25,770,043.00"
"Hussain, Nadeem","Medicine","2007/07","","Clinical Trials","Industry funded","False","True","Principal Site Investigator","Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of DDP733 in Female Patients with Irritable Bowel Syndrome with Constipation","","","$70,788,025.00"
"Hussain, Nadeem","Medicine","2007/07","","Clinical Trials","Industry funded","False","True","Principal Site Investigator","Linaclotide Clinical study in Chronic constipation and Irritable bowel syndrome with constipation in collaboration with Forest Research Institute.","","","$9,938,110.00"
"Pickering, J. Geoffrey","Medicine","2009/05","2015/04","Grants","Funded","True","False","Co-Investigator","CIHR Strategic Training Program in Vascular Research","Aaron Fenster","","$67,027,454.00"
"Bosma, Karen","Medicine","2009/01","2010/12","Grants","Funded","True","False","Co-Applicant","Therapeutic drug monitoring and polysomnography in the management of sedation and delirium in critical care patients","Dr. George Dresser","Dr. Karen Bosma, Dr. Bryan Young, Dr. Valerie Schulz","$42,481,688.00"
"McDonald, Charlotte","Medicine","2008/03","2009/12","Grants","Funded","False","True","Co-Investigator","A 12-week, phase 2A, randomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 on glucose control and body weight in overweight adult subjects with Type 2 diabetes mellitus.","IM Hramiak","CG McDonald, TL Paul","$32,604,077.00"
"McDonald, Charlotte","Medicine","2008/09","2011/12","Grants","Funded","False","True","Co-Investigator","GLP-1 agonist AVE0010 in patients with type 2 diabetes mellitus for glycemic control and safety evaluation, on top of metformin. A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin in patients with type 2 diabetes not adequately controlled with metformin.","IM Hramiak","CG McDonald, TL Paul","$5,099,580.00"
"McDonald, Charlotte","Medicine","2008/10","2012/12","Clinical Trials","Funded","False","True","Co-Investigator","Effect of Exenatide on Abdominal Fat Distribution in Patients with Type 2 Diabetes Pretreated with Metformin.","IM Hramiak","CG McDonald, TL Paul","$28,421,103.00"
"McDonald, Charlotte","Medicine","2009/03","2012/03","Grants","Funded","False","True","Co-Investigator","A multicenter, randomized, double-blind, phase 3b trial to evaluate the efficacy and safety of Saxagliptin added to insulin monotherapy or to insulin in combination with metformin in subjects with Type 2 diabetes who have inadequate glycemic control on insulin alone or on insulin in combination with metformin.","IM Hramiak","CG McDonald, TL Paul","$25,418,752.00"
"McDonald, Charlotte","Medicine","2009/04","2010/06","Grants","Funded","False","True","Co-Investigator","An observational follow-up study of patients previously enrolled in Exubera controlled clinical trials.","IM Hramiak","CG McDonald, TL Paul","$26,777,730.00"
"McDonald, Charlotte","Medicine","2009/03","2010/12","Grants","Funded","False","True","Co-Investigator","EMERGE 4. A multicenter, randomized, double-blind, double-dummy, placebo and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO507031) compared to sitagliptin and placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin.","IM Hramiak","CG McDonald, TL Paul","$2,298,601.00"
"McDonald, Charlotte","Medicine","2009/08","2016/12","Grants","Funded","False","True","Co-Investigator","Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS): A phase III, randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control on mono- or dual combination antihypergrlycemic therapy.","IM Hramiak","CG McDonald, TL Paul, N Suskin, ME Weingert","$16,875,756.00"
"McDonald, Charlotte","Medicine","2009/05","2010/03","Clinical Trials","Funded","False","True","Co-Investigator","A multi-center, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/tolerability and pharmacokinetics of five dose levels of RO4998452 in patients with type 2 diabetes mellitus.","IM Hramiak","CG McDonald, TL Paul","$71,135,934.00"
"McDonald, Charlotte","Medicine","2009/08","2012/01","Grants","Funded","False","True","Co-Investigator","Thiazolidinedione intervention with vitamin D evaluation (TIDE). A multicenter, randomized, double-blind, placebo-controlled trial of a thiazolidinedione or placebo and of vitamin D or placebo in people with Type 2 diabetes at risk for cardiovascular disease.","IM Hramiak","CG McDonald, TL Paul, N Suskin, ME Weingert","$23,996,608.00"
"McDonald, Charlotte","Medicine","2009/07","2010/12","Grants","Funded","False","True","Co-Investigator","Evaluation of the Use of a New Re-usable Insulin Pen Device (ClikSTAR™) in Canadian Patients with Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM). (sanofi-aventis – LANTU L 03912 EasEE Clik)","IM Hramiak","CG McDonald, TL Paul","$55,701,968.00"
"Paul, Terri","Medicine","2001/07","2007/03","Clinical Trials","Funded","False","True","Co-Investigator","Evaluation of diabetic retinopathy progression in subjects with Type 2 diabetes mellitus. (Aventis Pharma – HOE 4016)","IM Hramiak,","TL Paul, J Gonder","$65,601,221.00"
"Paul, Terri","Medicine","2007/04","2010/12","Clinical Trials","Funded","False","True","Co-Investigator","A randomised, parallel-group, open-labelled, multinational trial comparing the efficacy and safety of insulin detemir (levemir) versus human insulin (NPH insulin), used in combination with insulin aspart as bolus insulin, in the treatment of pregnant women with type 1 diabetes.","IM Hramiak","CG McDonald, TL Paul","$19,530,336.00"
"Paul, Terri","Medicine","2007/08","2009/03","Clinical Trials","Funded","False","False","Co-Investigator","Efficacy and safety of 2 mg/day of M100907 on sleep maintenance insomnia with a sub-study of the effect of M100907 on stable Type 2 diabetes mellitus: a 12-week, multi-center, randomized, double-blind, placebo-controlled study.","IM Hramiak","CG McDonald, TL Paul","$71,549,354.00"
"Paul, Terri","Medicine","2008/09","2010/06","Clinical Trials","Funded","False","True","Co-Investigator","GLP-1 agonist AVE0010 in paTients with type 2 diabetes mellitus for Glycemic cOntrol and sAfety evaLuation, on top of Metformin. A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin in patients with type 2 diabetes not adequately controlled with metformin.","IM Hramiak","CG McDonald, TL Paul","$20,919,325.00"
"Paul, Terri","Medicine","2009/07","2010/12","Clinical Trials","Funded","False","True","Co-Investigator","Evaluation of the Use of a New Re-usable Insulin Pen Device (ClikSTAR™) in Canadian Patients with Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).","IM Hramiak","CG McDonald, TL Paul","$64,657,475.00"
"Paul, Terri","Medicine","2007/08","2008/07","Clinical Trials","Funded","False","True","Co-Investigator","The effect of treatment interruption on safety of Exenatide in patients with Type 2 diabetes.","IM Hramiak,","CG McDonald, TL Paul","$52,260,877.00"
"Paul, Terri","Medicine","2008/10","2011/12","Clinical Trials","Funded","False","True","Co-Investigator","Effect of Exenatide on Abdominal Fat Distribution in Patients with Type 2 Diabetes Pretreated with Metformin.","IM Hramiak,","CG McDonald, TL Paul","$3,405,771.00"
"Paul, Terri","Medicine","2008/03","2009/12","Clinical Trials","Funded","False","True","Co-Investigator","A 12-week, phase 2A, randomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 on glucose control and body weight in overweight adult subjects with Type 2 diabetes mellitus.","IM Hramiak,","CG McDonald, TL Paul","$4,640,005.00"
"Paul, Terri","Medicine","2009/03","2009/12","Clinical Trials","Funded","False","True","Co-Investigator","A multicenter, randomized, double-blind, phase 3b trial to evaluate the efficacy and safety of Saxagliptin added to insulin monotherapy or to insulin in combination with metformin in subjects with Type 2 diabetes who have inadequate glycemic control on insulin alone or on insulin in combination with metformin.","IM Hramiak,","CG McDonald, TL Paul","$48,875,792.00"
"Paul, Terri","Medicine","2009/04","2009/06","Clinical Trials","Funded","False","True","Co-Investigator","An observational follow-up study of patients previously enrolled in Exubera controlled clinical trials.","IM Hramiak,","CG McDonald, TL Paul","$47,091,341.00"
"Paul, Terri","Medicine","2009/03","2010/12","Clinical Trials","Funded","False","True","Co-Investigator","EMERGE 4. A multicenter, randomized, double-blind, double-dummy, placebo and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO507031) compared to sitagliptin and placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin.","IM Hramiak,","CG McDonald, TL Paul","$21,816,187.00"
"Paul, Terri","Medicine","2009/04","2010/03","Clinical Trials","Funded","False","True","Co-Investigator","A multi-center, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/tolerability and pharmacokinetics of five dose levels of RO4998452 in patients with type 2 diabetes mellitus.","IM Hramiak,","CG McDonald, TL Paul","$51,528,069.00"
"Paul, Terri","Medicine","2009/08","2016/03","Clinical Trials","Funded","False","True","Co-Investigator","Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS): A phase III, randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control on mono- or dual combination antihypergrlycemic therapy.","IM Hramiak,","CG McDonald, TL Paul","$37,570,991.00"
"Paul, Terri","Medicine","2009/08","2011/06","Clinical Trials","Funded","False","True","Co-Investigator","Thiazolidinedione intervention with vitamin D evaluation (TIDE). A multicenter, randomized, double-blind, placebo-controlled trial of a thiazolidinedione or placebo and of vitamin D or placebo in people with Type 2 diabetes at risk for cardiovascular disease.","IM Hramiak,","CG McDonald, TL Paul","$2,882,670.00"
"Feldman, Ross","Medicine","2007/01","2010/03","Grants","Funded","False","True","Principal Investigator","STITCH (2) Study","Ross D. Feldman","","$71,405,074.00"
"Feldman, Ross","Medicine","2007/07","2009/06","Grants","Funded","True","False","Principal Investigator","Determinants of adenylyl cyclase mediated vascular responses","Ross D. Feldman","","$74,671,410.00"
"Feldman, Ross","Medicine","2004/11","2006/07","Grants","Funded","False","True","Principal Investigator","STITCH","Ross D. Feldman","","$57,452,424.00"
"Feldman, Ross","Medicine","2003/07","2006/06","Grants","Funded","True","False","Principal Investigator","Vascular adenylyl cyclase regulation","Ross D. Feldman","","$30,284,867.00"
"Feldman, Ross","Medicine","2001/07","2006/06","Grants","Funded","True","False","Co-Investigator","HSFO Group Grant : Vascular Cell Responses in Altherosclerosis: A Genomic Approach","Murray Huff","Ross D. Feldman","$41,767,750.00"
"Feldman, Ross","Medicine","2001/03","2006/06","Grants","Funded","True","False","Principal Investigator","Determinants of G-Protein Coupled Receptor-Mediated Vascular Disease","Ross D. Feldman","","$42,989,235.00"
"Feldman, Ross","Medicine","2002/07","2004/12","Grants","Funded","True","False","Principal Investigator","Career Investigator Award","Ross D. Feldman","","$2,722,934.00"
"Dresser, George","Medicine","2004/07","2006/06","Clinical Trials","Funded","True","False","Co-Investigator","Perioperative Ischemic Evaluation","P.J.Devereaux","","$58,540,344.00"
"Dresser, George","Medicine","2007/07","2010/06","Grants","Funded","False","True","Co-Principal Investigator","Simplified Therapeutic Intervention To Control Hypertension and Hypercholesterolemia","Ross Feldman","","$59,381,743.00"
"Mahon, Jeffrey","Medicine","2010","2012","Clinical Trials","Funded","True","False","Co-Investigator","Trial to reduce IDDM in the genetically at-risk.","John Dupre","","$17,563,514.00"
"Mahon, Jeffrey","Medicine","2010","2012","Clinical Trials","Funded","True","False","Co-Investigator","Type 1 diabetes TrialNet:Toronto Clinical Centre","Diane Wherrett","","$57,323,675.00"
"Suskin, Neville","Medicine","2009/07","2012/06","Grants","Funded","True","False","Co-Investigator","MOVE-IT, Monitoring Of Ventricular rhythm & Exercise - ICD Trial","Gula","","$71,647,132.00"
"Suskin, Neville","Medicine","2008/07","2011/06","Grants","Funded","True","False","Co-Investigator","Plasticity of cortical cardiovascular interactions in vascular disease.","Shoemaker","","$71,015,597.00"
"Suskin, Neville","Medicine","2008/07","2011/06","Grants","Funded","True","False","Co-Investigator","Comparing paper versus electronic transmission of cardiac rehabilitation summaries to primary care physicians: A multi-method study of information flow and content","Grace","","$17,658,586.00"
"Sen, Mithu","Medicine","2010/01","2012/12","Grants","Funded","True","False","Principal Investigator","Assessment and management of delirium in the intensive care unit: a quality improvement initiative.","Sen M.","Co-investigators: Bosma KJ, Schulz V.","$9,853,101.00"
"Sen, Mithu","Medicine","2007","2008","Grants","Funded","True","False","Co-Investigator","The influence of ventilator mode and patient-ventilator interaction on sleep quality in the intensive care unit","Karen Bosma","Mithu Sen, Femida Gwadry-Sridhar","$66,299,904.00"
"Muirhead, Norman","Medicine","2009/07","2013/06","Grants","Funded","False","True","Principal Investigator","Canadian study of prediction of risk and evolution to dialysis, death and interim cardiovascular events over time.","","A. House, F. Rehman, J. Johnson","$36,796,478.00"
"Moist, Louise","Medicine","2011","2014","Grants","Funded","True","False","Principal Investigator","Comparison of the effect of a fistula vs. graft on left ventricular mass and function over 1 year: a randomized controlled trial","Dr. Louise Moist","","$20,512,674.00"
"Clark, William","Medicine","2009/11","2011/12","Grants","Funded","True","False","Co-Principal Investigator","Cardiovascular disease after acute gastrointestinal infection: Etiology and risk reduction with preventative care","GARG, Amit X","Garg AX, Clark WF, Young A, Austin P","$15,352,061.00"
"Hramiak, Irene","Medicine","2005","2010","Grants","Funded","True","False","Principal Investigator","The Canadian Obesity Network (CON-RCO)","AM Sharma","IM Hramiak","$57,464,007.00"
"Hramiak, Irene","Medicine","2008/04","2009/09","Clinical Trials","Funded","False","True","Co-Investigator","The effect of liraglutide compared to sitagliptin, both in combination with metformin in subjects with type 2 diabetes. A 26 week randomized, open-label, comparator, three-armed, parallel-group, multi-centre, multi-national trial. Trial phase 3b.","S Harris","IM Hramiak","$8,876,550.00"
"Hegele, Robert","Medicine","2008/07","2010/06","Grants","Funded","True","False","Co-Investigator","Identification of Causal Variants at Novel GWAS Loci Associated with Lipid Traits","Daniel Rader","","$68,649,601.00"
"Lindsay, Robert","Medicine","2010/04","2012/05","Grants","Funded","True","False","Co-Investigator","Comparison of the effect of a fistula vs. graft on left ventricular mass and function over 1 year: a randomized controlled trial","Louise Moist","","$46,534,429.00"
"Lindsay, Robert","Medicine","2008/01","2011/07","Grants","Funded","True","False","Principal Site Investigator","Cognitive function in dialysis patients: Ancillary study to the FHN trial","Michael Rocco","","$58,303,147.00"
"Lindsay, Robert","Medicine","2010/04","2012/09","Grants","Funded","True","False","Co-Investigator","Effect of lowering the dialysate sodium on ambulatory blood pressure in hemodialysis patients: A randomized controlled trial","Rita Suri","","$69,714,284.00"
"Borrie, Michael","Medicine","2009/03","2011/02","Grants","Funded","False","True","Principal Investigator","A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-centre study of RO5313534 used as add-on to Donepezil treatment in patients with mild to moderate symptoms of Alzheimer Disease.","Borrie MJ","Wells JL","$46,745,345.00"
"Borrie, Michael","Medicine","2009/08","2011/03","Clinical Trials","Funded","False","True","Principal Investigator","A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer's Disease.","M. Borrie","","$38,960,130.00"
"Borrie, Michael","Medicine","2009/05","2011/01","Clinical Trials","Funded","False","True","Co-Principal Investigator","Phase III, Parallel, Randomized, Placebo-controlled, dose-response, delayed-start 88 week Study for the Effect of LY450139, a y-Secretase Inhibitor, on the progression of Alzheimer's Disease as Compared with Placebo.","Jennie Wells","","$62,184,606.00"
"Wells, Jennie","Medicine","2009/05","2011/01","Clinical Trials","Funded","True","True","Principal Investigator","Phase III, Parallel, Randomized, Placebo-controlled, dose-response, delayed-start 88 week Study for the Effect of LY450139, a y-Secretase Inhibitor, on the progression of Alzheimer's Disease as Compared with Placebo.","Wells Jennie L.","Borrie MJ, Wells JL.","$32,463,301.00"
"Martin, Claudio","Medicine","2010/01","2011/12","Grants","Funded","False","True","Principal Site Investigator","A Randomized Double-Blinded, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation","Claudio Martin","Sponsor PI: Dr. May Orfali","$42,087,929.00"
"Martin, Claudio","Medicine","2009/07","2012/06","Clinical Trials","Funded","True","False","Principal Site Investigator","ABLE - Age of Blood Evaluation Study","Dr. Jacques Lacroix, Centre Hospit Univ St.Justine","","$31,859,908.00"
"Martin, Claudio","Medicine","2009/07","2010/07","Clinical Trials","Funded","False","False","Principal Site Investigator","Calfactant Therapy for Direct Acute Respiratory Distress Syndrome and Direct Acute Lung Injury in Adults and Children","","","$6,976,541.00"
"Martin, Claudio","Medicine","2007/07","2009/08","Clinical Trials","Funded","False","True","Principal Investigator","A Phase 2 Study to Evaluate Dose and duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction","","","$30,141,253.00"
"Martin, Claudio","Medicine","2009/07","2012/06","Grants","Funded","False","False","Collaborator","the Effect of rHu-EPO on microcirculatory alterations in ICU patients","Dr. Raymond Kao","Xenocostas A, Parry N, Tao R, Badhwar A, Kelly L","$18,755,800.00"
"Kao, Raymond","Medicine","2008/07","2009/06","Grants","Funded","True","False","Principal Applicant","EPO and No Phosphorlation in Septic Mice","","","$64,090,778.00"
"Kao, Raymond","Medicine","2009/07","2011/06","Grants","Funded","True","False","Principal Investigator","The Effect of rHuEPO on Microcirculatory alterations in ICU patients","","Martin CM, Xenocostas A, Parry N, Tao R, Badhwar A, Kelly L","$70,606,254.00"
"Joy, Tisha","Medicine","2008","present","Clinical Trials","Funded","False","True","Co-Investigator","A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients with Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy","Dr. Hegele","Dr. T. Joy","$58,966,139.00"
"Joy, Tisha","Medicine","2008","present","Clinical Trials","Funded","False","True","Co-Investigator","An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 in Subjects with Familial Hypercholesterolemia","Dr. Hegele","Dr. T. Joy","$33,529,283.00"
"Joy, Tisha","Medicine","2008","present","Clinical Trials","Funded","False","True","Co-Investigator","A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients with Severe Hypercholesterolemia on a Maximally Tolerated Lipid Lowering Regimen and Who are Not on Apheresis","Dr. Hegele","Dr. T. Joy","$39,628,218.00"
"Kane, Sheri-Lynn C","Medicine","2009/07","2010/10","Grants","Funded","False","False","Co-Principal Investigator","Seniors and Delirium: Knowledge Transfer and Exchange Think Tank and Consensus Conference","Dr. SheriLynn Kane","Dr. Iris Gutmanis; Dr. Lisa Van Bussel","$30,951,470.00"
"Suskin, Neville","Medicine","2008/07","2014/09","Grants","Funded","True","False","Co-Investigator","Heart Outcomes Prevention Evaluation (HOPE-3): a large simple randomized trial of combined cholesterol modifications and blood pressure lowering in middle aged people at average risk","Yusuf S","","$1,550,177.00"
"Suskin, Neville","Medicine","2006/07","2009/12","Grants","Funded","True","False","Co-Investigator","Reliable change in cardiac rehabilitation","Prior P","","$43,962,735.00"
"Skanes, Allan","Medicine","2003/09","2007/09","Clinical Trials","Funded","True","False","Site Investigator","Home Automatic External Defibrillator Trial, Site 079","Dr. Gus Bardy","","$27,529,985.00"
"Klein, George","Medicine","2003/09","2007/09","Clinical Trials","Funded","True","False","Site Investigator","Home Automatic External Defibrillator Trial, Site 079","Dr. Gus Bardy","","$45,075,766.00"
"Klein, George","Medicine","2004/10","2009/09","Clinical Trials","Funded","True","False","Site Investigator","A Randomized Clinical Trial of Fludrocortisone for the Prevention of Vasovagal Syncope POST II","Robert Sheldon","","$17,289,137.00"
"Skanes, Allan","Medicine","2004/10","2009/09","Clinical Trials","Funded","True","False","Site Investigator","A Randomized Clinical Trial of Fludrocortisone for the Prevention of Vasovagal Syncope POST II","Robert Sheldon","","$54,813,930.00"
"Yee, Raymond","Medicine","2004/10","2009/09","Clinical Trials","Funded","True","False","Site Investigator","A Randomized Clinical Trial of Fludrocortisone for the Prevention of Vasovagal Syncope POST II","Robert Sheldon","","$44,271,891.00"
"Yee, Raymond","Medicine","2003/03","2010/12","Grants","Funded","True","False","Site Principal Co-Investigator","Resynchronization/defibrillation for Ambulatory heart failure","Anthony Tang","Other Site Principal Co-Investigator is Dr. Malcolm Arnold","$15,022,975.00"
"Thompson, Andrew","Medicine","2009/01","2012/01","Grants","Funded","True","False","Principal Investigator","Creation of a Validated Web-Based Curriculum in Rheumatology: Improving Education of Our Family Physicians, Family Medicine Residents, and Medical Students","","","$46,648,191.00"
"Thompson, Andrew","Medicine","2007/07","2008/06","Grants","Funded","True","False","Principal Investigator","Creation of a Validated Web-Based Curriculum in Rheumatology: Improving Education of our Allied Health Practitioners","","","$31,219,906.00"
"Thompson, Andrew","Medicine","2007/07","2008/06","Grants","Funded","False","True","Principal Investigator","Multi-Centre Canadian Arthritis Referral Study","","","$49,208,257.00"
"Thompson, Andrew","Medicine","2008/07","2009/07","Grants","Funded","True","False","Principal Investigator","Instructional Musculoskeletal Education Videos","","","$45,740,228.00"
"Borrie, Michael","Medicine","2009/01","2010/01","Grants","Funded","True","False","Co-Investigator","Gait and Cognition as Gateways to understanding Mobility in Aging.","Montero Odasso M.","Burhan A, Wells J, Borrie M.","$592,033.00"
"Borrie, Michael","Medicine","2008","2011","Clinical Trials","Funded","False","True","Co-Investigator","Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer’s Disease","J. Wells","Borrie M, Burhan A, Clarke J, Al Aama T","$9,625,785.00"
"Wells, Jennie","Medicine","2004/01","2008/03","Grants","Funded","True","False","Co-Investigator","The Canadian Alzheimer's Disease Quality of Life Study (CADQOL)","Borrie MJ","Borrie MJ, Wells JL","$27,864,514.00"
"Borrie, Michael","Medicine","2002/09","2005/09","Grants","Funded","True","False","Principal Investigator","The Canadian Alzheimer's Disease Quality of Life Study (CADQOL)","Borrie MJ","Borrie MJ, Wells JL","$34,623,768.00"
"Borrie, Michael","Medicine","2002","2003","Clinical Trials","Funded","False","True","Principal Investigator","Extend Program. Participant in recruiting for this observational, nonrandomized trial assessing the success of switching patients to Exelon.","Borrie MJ","Wells JL","$1,949,792.00"
"Borrie, Michael","Medicine","2000/07","2002/07","Clinical Trials","Funded","False","True","Principal Investigator","Long-term Safety and Efficacy of Galantamine in the Treatment of Vascular or Mixed Dementia (Multi-centre trial) (GAL-INT-14)","Borrie MJ","Borrie MJ, Wells JL et al.","$21,400,729.00"
"Clark, William","Medicine","2010/07","2017/06","Clinical Trials","Funded","True","False","Principal Investigator","Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis: an International Controlled Trial","Clark WF","Clark WF, Carette S, Clase C, Gangji A, Garg AX, Jayne D, Khalidi N, Manns B, Merkel P, Muruve D, Pannu N, Pavenski K, Reich D, Wald R, Walsh M.","$70,102,558.00"
"Borrie, Michael","Medicine","1998","1998","Clinical Trials","Funded","False","True","Principal Investigator","A Double blind Phase III Clinical Trial of Galantamine in Mixed-Vascular Dementia. (Gal-Int-6)","Borrie MJ","Wells JL.","$55,120,705.00"
"Borrie, Michael","Medicine","1998","1998","Clinical Trials","Funded","False","True","Co-Investigator","An Open-labelled Clinical Trial of Propentofylline for patients with Alzheimer’s Disease or Multi-infarct Dementia.","","Borrie MJ, Wells JL","$69,232,862.00"
"Borrie, Michael","Medicine","1998","1998","Grants","Funded","True","False","Co-Investigator","A Novel Clinical Pharmacy Experience for Third Year Medical Students.","Wells JL","Borrie MJ, Brymer CD, Crilly RG.","$72,602,286.00"
"Borrie, Michael","Medicine","1997","1999","Clinical Trials","Funded","False","True","Co-Investigator","A Compassionate Use Program of Donepezil Hydrochloride (E2020) in Patients with Alzheimer’s Disease.","","Borrie MJ, Rabheru K, Wells JL.","$63,021,449.00"
"Borrie, Michael","Medicine","1997","1998","Clinical Trials","Funded","False","True","Principal Investigator","A Multi-centre, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients with Moderate to Moderately Severe Alzheimer’s Disease followed by an Open Label Treatment Phase.","Borrie MJ","Rabheru K, Wells JL","$24,030,115.00"
"Borrie, Michael","Medicine","1997","1998","Clinical Trials","Funded","False","True","Principal Investigator","A Phase III Clinical Trial of the Safety and Efficacy of Cerebrolysin in Alzheimer’s Disease.","Borrie MJ","Rabheru K, Wells JL.","$35,016,438.00"
"Borrie, Michael","Medicine","1999","2000","Clinical Trials","Funded","False","True","Co-Investigator","A Multi-centre, Randomized, Double-blind, Placebo-controlled Dose-ranging Study to Evaluate once daily dose of Neotrofin (AIT-082) over 24 weeks in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity.","Molloy W","Borrie MJ, Wells JL et al.","$28,550,967.00"
"Borrie, Michael","Medicine","1999","2000","Clinical Trials","Funded","True","False","Co-Investigator","A Randomized Controlled Trial of Anti-Chlamydia Antibiotic Therapy for Patients with Alzheimer’s Disease.","Molloy W","Borrie MJ, Wells JL et al.","$56,463,639.00"
"Wells, Jennie","Medicine","2009/03","2011/02","Grants","Funded","True","True","Co-Investigator","A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-centre study of RO5313534 used as add-on to Donepezil treatment in patients with mild to moderate symptoms of Alzheimer Disease.","Borrie MJ","Borrie MJ, Wells JL","$74,602,865.00"
"Joy, Tisha","Medicine","2009","2011","Clinical Trials","Funded","False","True","Co-Investigator","Phase 2a study for the Safety and Clinical Proof-of-Concept of NC-503 (eprosidate disodium) in Patients with Type 2 Diabetes and Features of Metabolic Syndrome.","Dr. R. McManus","Dr. T. Joy","$16,275,578.00"
"Joy, Tisha","Medicine","2009","2010","Clinical Trials","Funded","False","True","Co-Investigator","NN1250-3724: A 26-week randomized, confirmatory, controlled, open-label, multicentre, multinational treat-to-target trial comparing the efficacy and safety of SIBA 200 U/mL 3 times/weekly injected in the morning and insulin glargine once daily in a population of insulin naive subjects with type 2 diabetes mellitus currently treated with OADS qualifying for intensified treatment.","Dr. R. McManus","Dr. T. Joy","$51,238,661.00"
"Joy, Tisha","Medicine","2009","present","Clinical Trials","Funded","False","True","Co-Investigator","A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who are Not on Apheresis.","Dr. R. Hegele","Dr. T. Joy","$9,291,641.00"
"McCormack, David","Medicine","2008/07","2013/06","Clinical Trials","Funded","False","True","Principal Investigator","Safety and efficacy of airway bypass in severely hyperinflated COPD","","","$42,078,062.00"
"McCormack, David","Medicine","2007/07","2008/06","Clinical Trials","Funded","False","True","Co-Principal Investigator","3He MRI of Exercise-induced Bronchospasm - a placebo-controlled stufy of montelukast effects on 3He MRI phenotypes of asthma","","","$49,321,035.00"
"McCormack, David","Medicine","2007/07","2010/06","Grants","Funded","False","False","Co-Investigator","Noninvasive Imaging Biomarkers of Respiratory Disease for Early Detection, Monitoring Disease Progression, and Development of New Treatments and Interventions - London Lung Imaging Reasearch Team","","McCormack DG, Etemad-Rezai R, Santyr G, and Parraga G","$34,922,885.00"
"McCormack, David","Medicine","2005/12","2006/08","Clinical Trials","Funded","False","False","Co-Principal Investigator","A Study Exploring the use of Magnetic Resonance Imaging in Patients with Chronic Obstructive Pulmonary Disease (COPD)","Grace Parraga, David McCormack","Etemad-Rezai R, Licskai C, Santyr G","$49,911,249.00"
"Montero Odasso, Manuel","Medicine","2010/02","2015/01","Grants","Funded","True","False","Principal Investigator","""Gait Variability as a Predictor of Cognitive Decline and Risk of Falls in MCI. The Gait and Brain Cohort Study""","Manuel Montero-Odasso","Vladimir Hachinski, Mark Speechley, Robert Bartha, Michael Borrie","$26,990,669.00"
"Garg, Amit","Medicine","2010/10","2011/09","Grants","Funded","True","False","Co-Investigator","Steroids In caRdiac Surgery trial (SIRS)","Teoh, Kevin","","$52,031,938.00"
"Muirhead, Norman","Medicine","2010/07","2012/06","Clinical Trials","Funded","False","True","Principal Investigator","A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of using cinacalcet to correct hypercalcemia in renal transplant recipients with autonomous hyperparathroidism","Norman Muirhead","A. House, R. Rehman, J. Johnson","$65,780,534.00"
"Muirhead, Norman","Medicine","2010/07","2012/06","Grants","Funded","False","True","Principal Investigator","An open, randomized, controlled, parallel group, phase III study to investigate the safety and efficacy of fermagate comparison in hemodialysis patients with hyperphosphatemia","Norman Muirhead","A. House, F. Rehman, J. Johnson","$768,661.00"
"Muirhead, Norman","Medicine","2010/07","2017/06","Clinical Trials","Funded","False","True","Co-Investigator","A comparison of effects of standard dose vs low dose advagraf with IL-2 receptor antibody induction, MMF and steroids, with or without an ACEi/ARB-based antihypertensive therapy on renal allograft histology, function, and immune response","Anthony Jevnikar","A. House, F. Rehman, J. Johnson","$61,923,323.00"
"Crilly, Richard","Medicine","2007/07","2008/06","Grants","Funded","True","False","Co-Applicant","Vitamin D and Osteoporosis (ViDOS) Long-Term Care (LTC) Study","Alexandra Papaioannou","Jonathan Adachi, Lisa Dolovich, Lora Giangregorio et al","$31,189,374.00"
"Skanes, Allan","Medicine","2010/01","present","Clinical Trials","Funded","False","False","Principal Site Investigator","Adenosine following pulmonary vein isolation to target dormant conduction elimination.","Laurent Macle","Lorne Gula, Peter Leong-Sit","$31,413,920.00"
"Gula, Lorne","Medicine","2009/12","2011/10","Clinical Trials","Funded","False","True","Co-Investigator","Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 1000 or 300mg OD with amiodarone as calibrator for the prevention of ICD interventions or death (protocol DRI10936).","Peter Kowey","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$55,411,250.00"
"Klein, George","Medicine","2009/12","2011/10","Clinical Trials","Funded","False","True","Principal Site Investigator","Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 1000 or 300mg OD with amiodarone as calibrator for the prevention of ICD interventions or death (protocol DRI10936).","Peter Kowey","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$44,734,473.00"
"Leong-Sit, Peter","Medicine","2009/12","2011/10","Clinical Trials","Funded","False","True","Site Investigator","Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 1000 or 300mg OD with amiodarone as calibrator for the prevention of ICD interventions or death (protocol DRI10936).","Peter Kowey","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$68,594,279.00"
"Skanes, Allan","Medicine","2009/12","2011/10","Clinical Trials","Funded","False","True","Co-Investigator","Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 1000 or 300mg OD with amiodarone as calibrator for the prevention of ICD interventions or death (protocol DRI10936).","Peter Kowey","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$4,896,058.00"
"Yee, Raymond","Medicine","2009/12","present","Clinical Trials","Funded","False","True","Site Investigator","Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 1000 or 300mg OD with amiodarone as calibrator for the prevention of ICD interventions or death (protocol DRI10936).","Peter Kowey","","$61,472,154.00"
"Yee, Raymond","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Acute Endovascular Vagus Nerve Stimulation Study.","Raymond Yee","","$12,879,658.00"
"Skanes, Allan","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Acute Endovascular Vagus Nerve Stimulation Study.","Raymond Yee","","$40,127,787.00"
"Klein, George","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Acute Endovascular Vagus Nerve Stimulation Study.","Raymond Yee","","$22,656,958.00"
"Gula, Lorne","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Co-Investigator","Acute Endovascular Vagus Nerve Stimulation Study.","Raymond Yee","","$32,736,354.00"
"Yee, Raymond","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Lead Model 3830 Clinical Investigation.","Raymond Yee","","$46,559,046.00"
"Skanes, Allan","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Medtronic Lead Model 3830 Clinical Investigation.","Raymond Yee","","$19,351,874.00"
"Klein, George","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Medtronic Lead Model 3830 Clinical Investigation.","Raymond Yee","","$43,844,579.00"
"Gula, Lorne","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Lead Model 3830 Clinical Investigation.","Raymond Yee","","$74,757,633.00"
"Yee, Raymond","Medicine","2004","2010","Grants","Funded","False","False","Site Investigator","Multidisciplinary Study of Right Ventricular Dysplasia.","Andrew Krahn","","$26,545,282.00"
"Skanes, Allan","Medicine","2004/01","2010/01","Clinical Trials","Funded","False","False","Site Investigator","Multidisciplinary Study of Right Ventricular Dysplasia.","Andrew Krahn","","$15,308,046.00"
"Klein, George","Medicine","2004/01","2010/01","Clinical Trials","Funded","False","False","Site Investigator","Multidisciplinary Study of Right Ventricular Dysplasia.","Andrew Krahn","","$6,468,148.00"
"Yee, Raymond","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events.","Salim Yusuf","","$42,629,104.00"
"Skanes, Allan","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events.","Andrew Krahn","","$39,823,120.00"
"Klein, George","Medicine","2004/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events.","Andrew Krahn","","$6,657,061.00"
"Skanes, Allan","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","A Study of One Lead Defibrillation Efficacy.","Raymond Yee","","$27,764,528.00"
"Yee, Raymond","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Principal Site Investigator","A Study of One Lead Defibrillation Efficacy.","Raymond Yee","","$60,422,311.00"
"Klein, George","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Site Investigator","A Study of One Lead Defibrillation Efficacy.","Raymond Yee","","$50,284,070.00"
"Gula, Lorne","Medicine","2007/01","2009/01","Clinical Trials","Funded","False","True","Co-Investigator","A Study of One Lead Defibrillation Efficacy.","Raymond Yee","","$36,325,476.00"
"Johnson, John","Medicine","2010","2012","Grants","Funded","False","True","Co-Investigator","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism","N Muirhead","F Rehman, AA House, JF Johnson","$14,403,183.00"
"Johnson, John","Medicine","2010","2012","Grants","Funded","False","True","Co-Investigator","An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate together with a randomized placebo controlled double blind fermagate comparison in hemodialysis patients with hyperphosphatemia.","N Muirhead","F Rehman, AA House, JF Johnson","$60,801,911.00"
"Johnson, John","Medicine","2010","2017","Grants","Funded","False","True","Co-Investigator","A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® with IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without an ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response","A Jevnikar","F Rehman, AA House, N Muirhead, JF Johnson","$14,523,472.00"
"Crilly, Richard","Medicine","2009","2010/07","Grants","Funded","True","True","Co-Principal Investigator","Brogan Database Access for GIS Mapping Project","","Kloseck, M.","$44,228,677.00"
"Rehman, Faisal","Medicine","2010","2012","Grants","Funded","False","True","Co-Investigator","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism","Muirhead, N","House, A; Rehman, F; Johnson, J","$21,780,404.00"
"Rehman, Faisal","Medicine","2010","2012","Grants","Funded","False","True","Co-Investigator","An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate together with a randomized placebo controlled double blind fermagate comparison in hemodialysis patients with hyperphosphatemia.","Muirhead, N","House, A; Rehman, F; Johnson, J","$42,789,121.00"
"Rehman, Faisal","Medicine","2010","2017","Clinical Trials","Funded","False","True","Co-Investigator","A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® with IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without an ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response.","Jevnikar, A","House, A; Johnson, J; Muirhead, N; Rehman, F","$57,074,854.00"
"Thompson, Andrew","Medicine","2007/02","2007/02","Grants","Funded","False","False","Principal Investigator","The Arthritis Society Living Well Series","","","$32,648,796.00"
"Hussain, Nadeem","Medicine","2009","2010","Clinical Trials","Non-funded research","False","False","Principal Investigator","Eosinophilic esophagitis and Schatzki ring - ongoing recruitment","","","$67,113,268.00"
"Hussain, Nadeem","Medicine","2009","present","Clinical Trials","Applied","False","False","Principal Investigator","Epigenetic and Genetic Analysis of Pancreatic Disease","","Dr. Terry Ponich Christopher Pin","$46,682,694.00"
"Hodsman, Anthony","Medicine","2010/02","2010/07","Clinical Trials","Funded","False","True","Principal Site Investigator","A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab versus Placebo in Males with Low Bone Mineral Density","","","$62,961,089.00"
"Hodsman, Anthony","Medicine","2009/12","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized Open-Label Study to evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy","","","$8,518,723.00"
"Garg, Amit","Medicine","2009/04","2012/03","Grants","Funded","True","False","Co-Principal Investigator","REnal Function as a predictor of Vascular events in noncardiac Surgery patients cOhort evaluation (RE-VISION)","Devereaux, PJ (Nominated PI)","","$70,757,174.00"
"Garg, Amit","Medicine","2010","2011","Grants","Funded","True","False","Co-Investigator","POISE-2","Devereaux, PJ","","$32,996,369.00"
"Rehman, Faisal","Medicine","2003","2005","Grants","Funded","False","True","Co-Investigator","An active surveillance plan to conduct serologic testing for anti-erythropoetin antibodies, and prospectively monitor the incidence and developmental history of PRCA among patients receiving Epoetin Alfa Therapy","N. Muirhead","","$27,954,139.00"
"Rehman, Faisal","Medicine","2009","2013","Clinical Trials","Funded","False","True","Co-Investigator","Canadian study of predication of risk and evolution to dialysis, death and interim cardiovascular events over time.","Muirhead, N","House, A; Johnson, J; Rehman, F","$51,917,398.00"
"Rehman, Faisal","Medicine","2008","2011","Grants","Funded","False","True","Co-Investigator","An open label, randomized, multi-centre, parallel group study to demonstrate correction of anemia using once every four weeks subcutaneous injections of RO0503821 in patients with chronic kidney disease who are not on dialysis","Muirhead, N.","Rehman, F","$51,250,252.00"
"Crilly, Richard","Medicine","2009/07","2010/06","Grants","Funded","True","False","Co-Applicant","Vitamin D and Osteoporosis (ViDos) Long-term Care Study","Papaioannou, A","","$61,761,503.00"
"Rohekar, Sherry","Medicine","2009/11","2011/11","Grants","Funded","True","False","Principal Investigator","Regional Rheumatology Strategy: Facilitating Patient Access to Multidisciplinary Care","","","$52,271,456.00"
"Blake, Peter","Medicine","2009/05","2010/04","Grants","Funded","False","False","Principal Investigator","Global Trends in Peritoneal Dialysis Utilization","Blake PG","Jain AK","$32,883,100.00"
"Lavi, Shahar","Medicine","2011/04","2013","Clinical Trials","Funded","False","True","Principal Site Investigator","Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus. (ALECARDIO)","Jean-Claude Tardif","","$52,925,604.00"
"Lavi, Shahar","Medicine","2010/04","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Canadian Atherosclerosis Imaging Network (CAIN) – Correlation Between Coronary and Carotid Atherosclerotic Disease and Links with Clinical Outcomes.","Jean-Claude Tardif","","$47,115,336.00"
"Lavi, Shahar","Medicine","2010/03","2012","Clinical Trials","Funded","False","True","Principal Site Investigator","A phase IIIb multicenter, double-blind, randomized, placebo-controlled study, evaluating the effect of treatment with dalcetrapib 600 mg on atherosclerotic disease as measured by Coronary intravascular ultrasound (IVUS), quantitative coronary angiography, carotid b-mode ultrasound intima medial thickness (IMT) and total plaque volume in subjects undergoing coronary angiography who have coronary artery disease (CAD). (Dal-Plaque II)","Jean-Claude Tardif","","$66,916,328.00"
"Chin-Yee, Ian","Medicine","2009/07","2013/06","Grants","Funded","True","False","Site Co-Investigator","ABLE STUDY","Lacroix J.","Chin-Yee I, Martin C.","$36,712,388.00"
"Diachun, Laura","Medicine","2010/05","2011/05","Grants","Funded","True","False","Principal Investigator","Validation of the Comprehensive Geriatric Assessment Guide (CGAG): A student performance evaluation tool.","Diachun L.","Diachun L, Gordon J, Blake K.","$54,462,364.00"
"Goldszmidt, Mark","Medicine","2010/07","2011/06","Grants","Funded","True","False","Co-Applicant","The hidden curriculum around patients who are ‘taking up beds’: Towards a deeper understanding of the CanMEDS manager and advocate roles","Weijer, C.","Lingard, L. Watling, C. Goldszmidt, M.","$32,522,040.00"
"Hramiak, Irene","Medicine","2010/05","2012/12","Clinical Trials","Funded","False","True","Principal Investigator","A multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, 26-week, multticenter study with a 26-week extension to evaluate the efficacy, safety, and tolerability of canagliflozin in the treatment of subjects with type 2 diabetes mellitus who have moderate renal impairment.","IM Hramiak","CG McDonald, TL Paul","$50,752,722.00"
"Hramiak, Irene","Medicine","2010/07","2013/07","Clinical Trials","Funded","False","True","Principal Investigator","SAVOR 53 Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes.","IM Hramiak","G Jablonsky, CG McDonald, TL Paul, N Suskin, ME Weingert","$10,760,421.00"
"Hramiak, Irene","Medicine","2010/07","2016/12","Clinical Trials","Funded","False","True","Principal Investigator","LEADER Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results. A long-term, multi-centre, international, randomised double-blind, placebo-controlled trial to determine liraglutide effects on cardiovascular events","IM Hramiak","G Jablonsky, CG McDonald, TL Paul, ME Weingert","$23,502,121.00"
"Moist, Louise","Medicine","2011","2014","Grants","Funded","True","False","Co-Investigator","Curcumin to prevent perioperative complications after elective abdominal aortic aneurysm repair: a randomized controlled trial","Dr. Amit Garg","","$12,277,557.00"
"Dresser, George","Medicine","2010/07","2012/06","Grants","Funded","True","False","Co-Investigator","Coffee-cardiovascular drug interactions","Dr David Bailey","Dr Malcolm Arnold","$3,739,318.00"
"Hackam, Daniel","Medicine","2010/07","2015/07","Grants","Funded","True","False","Principal Investigator","Statins and renovascular disease","Daniel Hackam","","$13,050,332.00"
"Hackam, Daniel","Medicine","2010/03","2011/05","Grants","Funded","True","False","Principal Investigator","POEM Researcher Award","Daniel Hackam","","$40,108,512.00"
"Dresser, George","Medicine","2010/07","2011/07","Grants","Funded","True","False","Co-Investigator","Perioperative Inhibition of the Renin Angiotensin System: A Randomized Controlled Trial","Dr Marko Mrkobrada","","$33,727,835.00"
"Lewis, James","Medicine","2010/09","2011/09","Grants","Funded","True","False","Co-Applicant","The effects of mechanical ventilation on the biophysical properties of pulmonary surfactant","R Veldhuizen","J Lewis","$18,082,723.00"
"Lewis, James","Medicine","2010/07","2013/06","Grants","Funded","True","False","Mentor","The role of MMP-3 in acute lung injury and multiple organ failure","Cory Yamashita","","$44,928,499.00"
"Hramiak, Irene","Medicine","2009/03","2010/12","Clinical Trials","Funded","False","True","Principal Investigator","A multicenter, randomized, double-blind, placebo and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031), compared to sitagliptin and placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin.","IM Hramiak","CG McDonald, TL Paul","$65,366,329.00"
"Hramiak, Irene","Medicine","2009/04","2010/03","Clinical Trials","Funded","False","True","Principal Investigator","A multicenter, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/tolerability and pharmacokinetics of five dose levels of RO4998452 in NOVALIGHT BC21587 patients with type 2 diabetes mellitus.","IM Hramiak","CG McDonald, TL Paul","$63,333,991.00"
"Montero Odasso, Manuel","Medicine","2009/07","2010/06","Grants","Funded","True","False","Principal Investigator","""A simple and new approach for sub-categorization of mild cognitive impairment""","Manuel Montero-Odasso","Principal investigator: Manuel Montero Odasso Co-investigators: Susan, Muir, Jennifer Fogarty, Michael Borrie","$65,005,072.00"
"Montero Odasso, Manuel","Medicine","2009/07","2010/06","Grants","In preparation","False","False","Principal Investigator","""Identification of dementia and fall risk in mild cognitive impairment:","","Principal investigator: Manuel Montero Odasso, Post doctoral fellow: Susan Muir","$56,978,871.00"
"McCormack, David","Medicine","2010/10","2015/09","Grants","Funded","True","False","Co-Principal Investigator","Hyperpolarized Helium-3 Magnetic Resonance Imaging of Healthy Aging Lung","Grace Parraga","Santyr G, McCormack DG","$45,605,505.00"
"Pickering, J. Geoffrey","Medicine","2010/10","2015/06","Grants","Funded","True","False","Principal Investigator","Regulation of vascular stability by FGF9","J.G. Pickering","","$16,097,637.00"
"Pickering, J. Geoffrey","Medicine","2010/07","2013/06","Grants","Funded","True","False","Principal Investigator","Control of smooth muscle cell motility and vascular stabilization","J.G. Pickering","","$73,344,873.00"
"Pope, Janet","Medicine","2011/10","2015/10","Grants","Funded","True","False","Principal Investigator","Development of a composite index for efficacy in SSc RCTs and determining the values of patient reported outcomes for patients in an acceptable symptom state (PASS) 10-SRP-IJD-23","","","$44,491,205.00"
"Pope, Janet","Medicine","2009/07","2011/07","Grants","Funded","True","False","Co-Investigator","Two Stage Genome Wide Scan in Systemic Sclerosis (GWAS)","Maureen Mayes/Murray Baron","","$28,381,128.00"
"Pope, Janet","Medicine","2009/09","2013/01","Grants","Funded","True","False","Co-Principal Investigator","The Development of Classification Criteria for Scleroderma","","ACR/EULAR","$7,057,347.00"
"Pope, Janet","Medicine","2009/08","2010/12","Clinical Trials","Funded","False","True","Principal Site Investigator","A global multicentre observational study in RA patients who are non-responders or intolerant to a single tumour necrosis factor (TNF) inhibitor MA22401 (Switch)","","","$2,628,292.00"
"Pope, Janet","Medicine","2010/07","2011/07","Clinical Trials","Funded","False","True","Principal Site Investigator","A randomized double-blind placebo controlled dose ranging study to evaluate the efficacy and safety of SAR15391 in patients with ankylosing spondylitis (AS) – DRI11073","","","$1,333,201.00"
"Pope, Janet","Medicine","2010/03","2011/03","Clinical Trials","Funded","False","True","Principal Site Investigator","A long-term, open-label, follow-up study of CP-690,550. A moderately selective janus-kinase-3 inhibitor, for treatment of rheumatoid arthritis – A3921024","","","$46,500,693.00"
"Pope, Janet","Medicine","","","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase IIa, multicenter, randomized placebo-controlled study to evaluate the safety, tolerability biomarkers, and clinical effect of laquinimod in systemic lupus erythematosus patients with active lupus arthritis","","","$52,910,531.00"
"Pope, Janet","Medicine","2010/09","2011/09","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase IIa, multicenter, randomized placebo-controlled study to evaluate the safety, tolerability biomarkers, and clinical effect of laquinimod in systemic lupus erythematosus patients with active lupus arthritis","","","$2,986,744.00"
"Pope, Janet","Medicine","2010/09","2011/09","Clinical Trials","Funded","False","True","Principal Site Investigator","A phase 1, double blind, randomized, single ascending dose study of the safety and tolerability of MEDI-570in SLE-CP209","","","$50,152,513.00"
"Yamashita, Cory","Medicine","2010/01","2010/12","Grants","Funded","True","False","Principal Investigator","The Role of MMP-3 in Acute Lung Injury and Multiple Organ Failure","Cory Yamashita","","$13,415,483.00"
"Yamashita, Cory","Medicine","2010/07","2013/06","Grants","Funded","True","False","Principal Investigator","The Role of Matrix Metalloproteinase-3 in Acute Lung Injury and Multiple Organ Failure","Cory Yamashita","","$57,085,624.00"
"Yamashita, Cory","Medicine","2010/07","2010/07","Grants","Funded","True","False","Principal Investigator","The Role of Matrix Metalloproteinase-3 in Acute Lung Injury and Multiple Organ Failure","Cory Yamashita","","$22,018,059.00"
"Yamashita, Cory","Medicine","2010/07","2011/07","Grants","Funded","True","False","Principal Investigator","The Role of Matrix Metalloproteinase-3 in Acute Lung Injury and Multiple Organ Failure","Cory Yamashita","","$59,852,334.00"
"Yamashita, Cory","Medicine","2010/07","2011/06","Grants","Funded","True","False","Principal Investigator","The Role of MMP-3 in Acute Lung Injury","Cory Yamashita","","$26,415,375.00"
"Beaton, Melanie","Medicine","2011/01","2012/12","Grants","Funded","True","False","Co-Investigator","Sitagliptin for the treatment of Non-alcoholic Steatohepatitis in Patients with Type 2 Diabetes","Joy, T","Beaton, MD","$21,048,871.00"
"Lavi, Shahar","Medicine","2010/09","2011/09","Clinical Trials","Funded","False","True","Principal Site Investigator","Phase 2b randomized, partially-blinded, multi-center, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 Snticoagulation System (RADAR trial).","Thomas J Povsic","","$54,826,582.00"
"Suskin, Neville","Medicine","2009/07","2010/06","Grants","Funded","True","False","Co-Applicant","CIHR Team in Physical Activity, Mobility and Neural Health - LOI","Kevin Shoemaker","","$15,748,959.00"
"Jain, Arsh","Medicine","2009/05","2010/04","Grants","Funded","True","False","Co-Principal Investigator","Global trends in peritoneal dialysis utilization","Blake, Peter","","$4,872,829.00"
"Lavi, Shahar","Medicine","2008/10","2010/06","Clinical Trials","Funded","False","True","Site Investigator","Study of coronary Atheroma by inTravascular Ultrasound: effect of Rosuvastatin versus atorvastatiN (SATURN)","Stephen Nicholls","","$33,940,218.00"
"Lavi, Shahar","Medicine","2008/09","2009/06","Clinical Trials","Funded","False","True","Site Investigator","Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs (CURRENT)","Shamir Mehta","","$29,405,518.00"
"Lavi, Shahar","Medicine","2008/09","2009/11","Clinical Trials","Funded","False","True","Site Investigator","INNOVATE - PCI","Robert Welsh","","$59,921,854.00"
"Lavi, Shahar","Medicine","2009/07","2010","Clinical Trials","Funded","False","True","Site Investigator","FondaparinUx Trial With UFH During Revascularization in Acute Coronary Syndromes (FUTURA- OASIS 8).","Shamir Mehta","","$16,366,024.00"
"Lavi, Shahar","Medicine","2009/07","2010/07","Clinical Trials","Funded","False","True","Site Investigator","Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)","Michael C Gibson","","$17,917,376.00"
"Lavi, Shahar","Medicine","2010/07","present","Clinical Trials","Funded","True","False","Site Investigator","PeriOperative ISchemic Evaluation-2 Trial (POISE-2)","Philip J Devereaux","","$24,106,578.00"
"Lavi, Shahar","Medicine","2010/04","2013/03","Clinical Trials","Funded","False","True","Site Investigator","A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects. (TRILOGY ACS)","Paul A Gurbel","","$5,906,150.00"
"Jain, Arsh","Medicine","2009/05","2010/04","Grants","Funded","True","False","Principal Investigator","Impact of eGFR reporting.","Garg, Amit","","$45,723,886.00"
"Jain, Arsh","Medicine","2009/05","2010/04","Grants","Funded","True","False","Co-Principal Investigator","Impact of Lab Prompts on Chronic Disease Management: The Case of Kidney Disease","Garg, Amit","","$48,501,565.00"
"Jain, Arsh","Medicine","2008/09","2009/08","Grants","Funded","True","False","Co-Principal Investigator","Impact of eGFR reporting on healthcare utilization","Garg, Amit","","$24,210,316.00"
"Jain, Arsh","Medicine","2011/04","2012/09","Grants","Funded","True","False","Principal Applicant","Randomized Controlled Trial of Bimodal Solution for Peritoneal Dialysis: 24-Hour UF Efficiency Using Bimodal PD Solutions","Jain, Arsh","","$67,355,172.00"
"Bosma, Karen","Medicine","2010/01","2012/12","Grants","Funded","True","False","Co-Applicant","Assessment and management of delirium in the intensive care unit: a quality improvement initiative","Dr. Mithu Sen","Dr. Karen Bosma, Dr. Valerie Schulz","$39,148,143.00"
"Suskin, Neville","Medicine","2010/10","2014/03","Grants","Funded","True","False","Co-Investigator","Reliable Changes Indices in Cardiac Rehabilitation","Peter Prior","","$33,272,763.00"
"Joy, Tisha","Medicine","2011","2013/12","Grants","Funded","True","False","Principal Investigator","Sitagliptin for the Treatment of Non-Alcoholic Steatohepatitis in Patients with Type 2 Diabetes","Dr. T. Joy","M. Beaton","$68,864,915.00"
"Joy, Tisha","Medicine","2010","2013","Grants","Funded","False","False","Principal Investigator","Evaluation of patients with statin myopathy using an N of 1 trial design","T. Joy","Drs. C. McDonald, J.L. Mahon, R.A. Hegele","$55,127,769.00"
"House, Andrew","Medicine","2010/07","2012/07","Grants","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of using cinacalcet to correct hypercalcemia in renal transplant recipients with autonomous hyperparathyroidism.","N Muirhead","A House, F Rehman, J Johnson","$3,899,024.00"
"House, Andrew","Medicine","2010/07","2012/07","Grants","Funded","False","True","Co-Investigator","An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate in hemodialysis","N Muirhead","A House, F Rehman, JJ Johnson","$34,381,710.00"
"House, Andrew","Medicine","2010/07","2017/07","Grants","Funded","False","True","Co-Investigator","A comparison of effects of standard dose vs low dose advagraf with IL-2 receptor antibody induction, MMF and steroids, with or without an ACEi/ARB-based antihypertensive therapy on renal allograft histology, function, and immune response.","A Jevnikar","N Muirhead, A House, F Rehman, J Johnson","$20,078,413.00"
"Garg, Amit","Medicine","2010/10","2015/04","Grants","Funded","True","False","Co-Investigator","Steroids In caRdiac Surgery (SIRS)","Teoh, Kevin & Whitlock, Richard","","$11,169,648.00"
"Garg, Amit","Medicine","2010/10","2013/09","Grants","Funded","True","False","Principal Investigator","Reimbursing Living Kidney Donors for their Non-Medical Expenses","Garg, Amit & Klarenbach, Scott","Cuerden, Meaghan S; Jacobs, Philip","$59,881,445.00"
"Garg, Amit","Medicine","2010/06","2012/05","Grants","Funded","True","False","Co-Principal Investigator","Drug safety in impaired kidney function","Garg, Amit (Nominated PI)","Weir M, Juurlink D, Mamdani M, Paterson M","$52,872,827.00"
"Garg, Amit","Medicine","2010/06","2011/05","Grants","Funded","True","False","Co-Investigator","A Research Conference on the Canadian Experience with Quotidian Dialysis","Nesrallah, Gihad","Garg A, Lindsay R, Moist L, Suri R","$39,395,269.00"
"Garg, Amit","Medicine","2002/01","2008/06","Grants","Funded","True","False","Co-Investigator","A 7 year health care study and follow-up of long-term medical complications from contaminated water in Walkerton, Ontario","Clark, William","Garg AX, Howard J, Matsell D, Salvadori M","$4,001,694.00"
"Garg, Amit","Medicine","2012/04","2016/03","Grants","Funded","True","False","Co-Investigator","POISE-2","Devereaux, PJ","","$65,722,122.00"
"Moist, Louise","Medicine","2010/04","2013/04","Grants","Funded","True","True","Co-Investigator","A Comparative Survival Study of Two Competing Home Dialysis Modalities: Short-Daily Hemodialysis versus Peritoneal Dialysis","Dr. Gihad Nesrallah","","$29,561,339.00"
"Moist, Louise","Medicine","2010/01","2011/01","Grants","Funded","True","False","Co-Investigator","A Research Conference on the Canadian Experience with Quotidian Dialysis","Dr. Gihad Nesrallah","","$48,964,636.00"
"Garg, Amit","Medicine","2011/04","2014/03","Grants","Funded","True","False","Co-Investigator","Clinical search retrieval and dissemination from large internet databases such as MEDLINE","Haynes, Robert","","$58,266,308.00"
"Garg, Amit","Medicine","2011/01","2013/03","Grants","Funded","True","False","Principal Investigator","Electrolyte Disorders from Common Medications: Risk and Mitigation","Garg, Amit","Beyea M, Gandi S, Gomes T, Hackam D, Juurlink D, Lam N, Mamdani M, McLachlan R, Minuk L, Paterson M, Reiss J, Weir M","$62,795,811.00"
"Garg, Amit","Medicine","2011/07","2013/06","Grants","Funded","True","False","Co-Investigator","Standard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRRT-AKI)","Wald, Ron","","$54,337,175.00"
"Garg, Amit","Medicine","2011/01","2013/03","Grants","Funded","True","False","Principal Investigator","Acute kidney injury from antiviral drugs for herpes infections: A population-based study of older adults","Garg, Amit","Beyea M, Blake P, Gandhi S, Gomes T, Hackam D, Juurlink D, Lam N, Mamdani M, Weir M","$52,291,910.00"
"Garg, Amit","Medicine","2011/01","2013/03","Grants","Funded","True","False","Principal Investigator","Preoperative Medications and Acute Kidney Injury: A VISION sub-study","Garg, Amit","Devereaux PJ, Walsh M, Molnar A, Mrkobrada M, Shah M","$56,356,041.00"
"Garg, Amit","Medicine","2011/04","2013/03","Grants","Funded","True","False","Principal Investigator","Filtering Medline for Renal Information: Renal Sub-Filters","Garg, Amit","Haynes R, McKibbon K, Shariff S, Wilczynski N","$6,566,997.00"
"Jevnikar, Anthony","Medicine","2007/07","2012/06","Grants","Funded","True","False","Co-Investigator","Therapeutic Potential and Mechanism of Double-Negative Regulatory T (DN-Treg) Cells Mediated Tolerance in Heart Transplantation","Dr. Z. Zhang","","$37,126,842.00"
"Jevnikar, Anthony","Medicine","2008/07","2010/06","Grants","Funded","True","False","Co-Investigator","The Role NK Cell in Kidney Injury","Dr. Z. Zhang","","$67,500,997.00"
"Kostuk, William","Medicine","2010/02","2013","Grants","Funded","False","True","Principal Site Investigator","A comparison of prasugrel at the time of percutaneous coronary intervention (PCI) or as pretreatment at the time of diagnosis in patients with non-ST-elevation myocardial infarction (NSTEMI): The ACCOAST study.","William Kostuk","","$55,705,466.00"
"Diamantouros, Pantelis","Medicine","2008","2009","Grants","Funded","False","True","Co-Applicant","Randomized dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving ASA and clopidogrel multicentred, prespective, placebo-controlled, group dose escalation trial.","Dr. Willliam J. Kostuk","Dr. P. Diamantouros","$4,485,468.00"
"Diamantouros, Pantelis","Medicine","2010/02","","Grants","Funded","False","True","Co-Investigator","A comparison of prasugrel at the time of percutaneous coronary intervention (PCI) or as pretreatment at the time of diagnosis in patients with non-ST-elevation myocardial infarction (NSTEMI).","Dr. William J. Kostuk","Dr. P. Diamantouros","$68,771,736.00"
"Diamantouros, Pantelis","Medicine","2010/10","2013/10","Grants","Funded","False","True","Co-Investigator","A randomized trial of routine aspiration ThrOmbecTomy with Percutaneous coronary Intervention (PCI) versus PCI ALone in in patients with ST Elevation Myocardial Infarction (STEMI) undergoing primary PCI.","Dr. Shahar Lavi","Dr. P. Diamantouros","$40,856,146.00"
"Kostuk, William","Medicine","2010/10","2013/10","Grants","Funded","False","True","Co-Investigator","A randomized trial of routine aspiration ThrOmbecTomy with Percutaneous coronary Intervention (PCI) versus PCI alone in patients with ST Elecation Myocardial infarction (STEMI) undergoing primary PCI","Dr. Shahar Lavi","","$47,296,517.00"
"Hackam, Daniel","Medicine","2010/10","2013/10","Grants","Funded","True","False","Co-Investigator","Translation of 3D carotid ultrasound to point-of-care atherosclerosis measurement","David Spence","Daniel Hackam; Grace Parraga; Aaron Fenster","$36,149,404.00"
"Hackam, Daniel","Medicine","2010/04","2012/04","Grants","Funded","True","False","Co-Investigator","Drug safety in impaired kidney function","Amit Garg","Matthew A. Weir; Arsh K. Jain; Jeffrey L. Mahon; Daniel G. Hackam; Muhammad Mamdani;David Juurlink; Michael Paterson","$23,746,091.00"
"Hackam, Daniel","Medicine","2010/04","2013/04","Grants","Funded","True","False","Co-Investigator","An ICES (Institute for Clinical Evaluative Sciences) Research Facility for the University of Western Ontario","Amit Garg, Claire Temple","Dan Hackam; Muriel Brackstone; Richard Malthaner; Chris Vinden; Stewart Harris","$49,570,115.00"
"Siu, Samuel","Medicine","2006/07","2008/07","Grants","Funded","True","False","Co-Principal Investigator","Hemodynamics and hormonal changes in pregnant women with cardiac disease: understanding the effects of pregnancy on the diseased heart.","Silversides, Candice","Siu, SC","$52,747,802.00"
"Minuk, Leonard","Medicine","2010/07","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A phase III, randomized, open-label, 3-arm study to determine the efficacy and safety of Lenalidomide (Revlimid) plus low-dose dexamethasone when given until progressive disease or for 18 four-week cycles versus the combination of Melphalan, Prednisone, and Thalidomide given for 12 six-week cycles in patients with previously untreated Multiple Myeloma who are either 65 years of age or older or not candidates for stem cell transplantation.","Dr. Leonard Minuk","","$67,850,834.00"
"Hackam, Daniel","Medicine","2011/06","2012/12","Grants","Funded","True","False","Principal Investigator","Statins and intracerebral hemorrhage","Daniel G Hackam","Moira K Kapral; David N Juurlink; Peter C Austin; Muhammad M Mamdani; Vladimir Hachinksi; J Michael Paterson","$46,412,809.00"
"Hackam, Daniel","Medicine","2011/04","2014/04","Grants","Funded","True","False","Co-Investigator","Animals, Humans, and the Continuity of Evidence: A Study of Clinical Translation","Jonathan Kimmelman (McGill)","GRIMSHAW, Jeremy M; HACKAM, Daniel G; KNOLL, Gregory; LONDON, Alex J; MARSHALL, John C; MOHER, David; RAMSAY, Timothy O; SAMPSON, Margaret; STEWART, Duncan J; WEIJER, Charles","$14,188,538.00"
"Hackam, Daniel","Medicine","2011/04","2013/04","Grants","Funded","True","False","Co-Investigator","Electrolyte Disorders from Common Medications: Risk and Mitigation","Amit X Garg","BEYEA, Michael M; GANDHI, Sonja; GOMES, Tara; HACKAM, Daniel G; JUURLINK, David N; LAM, Ngan; MAMDANI, Muhammad; MCLACHLAN, Richard; MINUK, Leonard; PATERSON, J. Michael; REISS, Jeffrey; WEIR, Matthew A","$62,677,451.00"
"Hackam, Daniel","Medicine","2011/07","2012/07","Grants","Funded","True","False","Co-Investigator","Beta blockers, dialyzability and outcomes","Matthew Weir","Amit Garg, Matthew Oliver, Robert Quinn, Matthew Roberts, Rita Suri, Dan Hackam, David Juurlink, Muhammad Mamdani, Tara Gomes, Michael Paterson","$38,408,881.00"
"Hackam, Daniel","Medicine","2011/04","2013/04","Grants","Funded","True","False","Co-Investigator","Acute kidney injury from antiviral drugs for herpes infections: A population-based study of older adults","Amit Garg","BEYEA, Michael M; BLAKE, Peter G; GANDHI, Sonja; GOMES, Tara; HACKAM, Daniel G; JUURLINK, David N; LAM, Ngan; MAMDANI, Muhammad; WEIR, Matthew A","$30,934,323.00"
"Mrkobrada, Marko","Medicine","2009/07","2012/01","Grants","Funded","True","False","Principal Applicant","PASS: Peri-Operative Inhibition of the Angiotensin System Study","Marko Mrkobrada","","$45,204,579.00"
"Mrkobrada, Marko","Medicine","2009/07","2012/01","Clinical Trials","Funded","True","False","Co-Investigator","POISE-2: Perioperative Ischemic Evaluation Trial - 2","PJ Devereaux","","$28,852,164.00"
"Suskin, Neville","Medicine","2011/03","2012/02","Grants","Funded","True","False","Co-Applicant","Promoting Systematic Inpatient Cardiac Rehabilitation Referral","Dr. Sherry Grace","","$67,894,926.00"
"Bosma, Karen","Medicine","2009/11","2012/10","Clinical Trials","Funded","True","False","Principal Site Investigator","The Oscillation for ARDS Treated Early Trial","Niall Ferguson and Maureen Meade","The Canadian Critical Care Trials Group","$65,762,705.00"
"Johnson, John","Medicine","2010","2012","Grants","Funded","False","True","Co-Investigator","Advagraf/Prograf Conversion Study A Randomized, open-label, cross over study to examine the impact of Prograf and Advagraf on tacrolimus exposure, mycophenolic acid pharmacokinetics, renal allograft function of adverse effects","Norman Muirhead","","$43,843,174.00"
"Johnson, John","Medicine","2010","2015","Grants","Funded","False","True","Co-Investigator","Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomized, Double-Blind, Placebo Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes.","Norman Muirhead","","$13,646,893.00"
"House, Andrew","Medicine","2010/07","2015/06","Grants","Funded","False","True","Co-Investigator","A Multicentre, Randomized, Double-Blind, Placebo Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes.","Norman Muirhead","","$13,486,728.00"
"House, Andrew","Medicine","2010/07","2012/06","Grants","Funded","False","True","Co-Investigator","A Randomized, open-label, cross over study to examine the impact of Prograf and Advagraf on tacrolimus exposure, mycophenolic acid pharmacokinetics, renal allograft function of adverse effects","Norman Muirhead","","$10,540,391.00"
"Suskin, Neville","Medicine","2010/11","2015/11","Grants","Funded","True","False","Co-Principal Investigator","CIHR Team in Physical Activity, Mobility and Neural Health","Kevin Shoemaker","","$18,742,081.00"
"Beaton, Melanie","Medicine","2009/12","2010/06","Grants","Funded","False","True","Co-Investigator","Fibroscan and Their Dedicated Probes Efficiency in Obese Patients","Dr. Mark Levstik","Dr. Melanie Beaton Dr. Paul Marotta","$16,022,832.00"
"House, Andrew","Medicine","2011/07","2017/06","Grants","Funded","True","False","Principal Site Investigator","Effect of Immunosuppressive Medication Use one Patient Outcomes Following Kidney Transplantation Failure","Andrew House","","$68,350,394.00"
"Muirhead, Norman","Medicine","2010/07","2012/07","Grants","Funded","False","True","Principal Investigator","A randomized, open-label, cross over study to examine the impact of Prograf and Advagraf on tacrolimus exposure, mycophenolate acid pharmacokinetics, renal allgraft function of adverse effects","Muirhead, Norman","A. House, J. Johnson and F. Rehman","$62,757,335.00"
"Muirhead, Norman","Medicine","2010/07","2015/07","Grants","Funded","False","True","Principal Investigator","A multicentre, randomized, double-blind, placebo controlled phase IV trial to evaluate the effect of Saxagliptin on the incidence of cardiovascular death, myocardial infarction or ischaemic stroke in patients with Type 2 Diabetes","Muirhead, Norman","A. House, J. Johnson and F. Rehman","$33,614,238.00"
"Feagan, Brian","Medicine","2010/12","2012/12","Grants","Funded","True","False","Principal Applicant","Oral Methotrexate for Crohn's Disease","","","$5,759,017.00"
"Feagan, Brian","Medicine","2009/07","2012/06","Grants","Funded","False","True","Director, Coordinating Centre","","","","$19,702,219.00"
"Feagan, Brian","Medicine","2009/07","2010/06","Grants","Funded","False","True","Director, Coordinating Centre","Hydros Joint Therapy and Hydros Joint TA Therapy for Pain Associated with Knee OA","","","$69,918,467.00"
"Feagan, Brian","Medicine","2010/07","2012/07","Grants","Funded","False","True","Director, Coordinating Centre","A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohn’s Disease","","","$43,018,450.00"
"Feagan, Brian","Medicine","2010/07","2012/07","Grants","Funded","False","True","Director, Coordinating Centre","A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn’s Disease","","","$27,970,007.00"
"Feagan, Brian","Medicine","2010/07","2012/07","Grants","Funded","False","True","Director, Coordinating Centre","An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn’s Disease","","","$59,127,648.00"
"Feagan, Brian","Medicine","2010/07","2012/07","Grants","Funded","False","True","Director, Coordinating Centre","A Randomized, Double-Blind, Placebo-Controlled induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately-severely active Crohn’s Disease – CIMS only","","","$7,518,103.00"
"Feagan, Brian","Medicine","2010/07","2012/07","Grants","Funded","False","True","Director, Coordinating Centre","A Multicentre, Randomized, Double-blind, Placebo Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability of Baminercept in Subjects with Moderate to Severe Active Ulcerative Colitis – CIMS only","","","$60,661,753.00"
"Garg, Amit","Medicine","2010","2013","Grants","Funded","True","True","Principal Investigator","Canadian Living Kidney Donor Safety Study","Garg, Amit","","$13,504,237.00"
"Garg, Amit","Medicine","2009/07","2010/06","Grants","Funded","True","True","Principal Investigator","Canadian Living Kidney Donor Safety Study","Garg, Amit","","$74,852,620.00"
"McManus, Ruth","Medicine","2010/11","2016/12","Grants","Funded","True","False","Collaborator","Metformin in Women with Type 2 diabetes in Pregnancy Trial (MiTy)","Dr Denice Feig","Drs Lois Donovan, E Ryan, J Booth, R Houlden, A Godbut, T Kader, S Meltzer, J Lee, H Clark, J Weisnagel, G Carson, A Galway, M Wolfs, L Lipscombe, J Low, S Gandhi, D Thompson, J Shaban, S Ludwig, D Miller.","$48,573,192.00"
"Jevnikar, Anthony","Medicine","2010/07","2012/07","Grants","Funded","True","False","Co-Investigator","The Role NK Cell in Kidney Injury","Dr. Z. Zhang","","$1,696,234.00"
"Feldman, Ross","Medicine","2012/04","2014/03","Grants","Funded","True","False","Co-Investigator","Reducing the risk with E-based support for Adherence to lifestyle Change in Hypertension: REACH","Robert Nolan","Ross D. Feldman","$30,596,484.00"
"Feldman, Ross","Medicine","2010/03","2011/02","Grants","Funded","False","False","Principal Investigator","","Ross D. Feldman","","$4,232,384.00"
"Hramiak, Irene","Medicine","2009/03","2009/12","Clinical Trials","Funded","False","True","Principal Investigator","A multicenter, randomized, double-blind, randomized, placebo and active-controlled study to assess the efficacy, safety, and tolerability of taspoglutide (RO5073031), compared to sitagliptin and placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin.","IM Hramiak","CG McDonald, TL Paul","$11,132,094.00"
"Mehta, Sanjay","Medicine","2008","2010","Grants","Funded","False","True","Principal Investigator","Role of monitoring exercise induced changes in BNP in pulmonary arterial hypertension","S Mehta","","$32,223,550.00"
"Kim, Richard","Medicine","2010/07","2015/06","Grants","Funded","True","False","Principal Applicant","Cancer Care Ontario Research Award in Experimental Therapeutics","Richard Kim","","$48,314,023.00"
"Kim, Richard","Medicine","2010/10","2013/09","Grants","Funded","True","False","Co-Applicant","Translational Research Team","Eric Winquist","","$16,050,822.00"
"Siu, Samuel","Medicine","2008/01","2013/07","Grants","Funded","True","False","Program Leader","Translational Imaging Centre for Cardiovascular Outcomes Research Fund (ORF)","Dr. Samuel Siu and Dr. James White","","$14,994,839.00"
"Shah, Amit P","Medicine","2007/07","2008/08","Grants","Funded","True","False","Principal Investigator","A Prospective Evaluation of Ketamine/Propofol vs. Ketamine alone for Procedural Sedation for Isolated Orthopedic Injury in the Paediatric Emergency Department","Dr. Amit Shah","","$60,167,147.00"
"Shah, Amit P","Medicine","2007/07","2008/08","Grants","Funded","True","False","Principal Investigator","A Prospective Evaluation of Ketamine/Propofol vs. Ketamine alone for Procedural Sedation for Isolated Orthopedic Injury in the Paediatric Emergency Department","Dr. Amit Shah","","$12,921,267.00"
"Shah, Amit P","Medicine","2007/07","2008/08","Grants","Funded","True","False","Principal Investigator","A Prospective Evaluation of Ketamine/Propofol vs. Ketamine alone for Procedural Sedation for Isolated Orthopedic Injury in the Paediatric Emergency Department","Dr. Amit Shah","","$58,993,573.00"
"Shah, Amit P","Medicine","2003/01","2007/06","Grants","Funded","True","False","Principal Site Investigator","Implementation of the Canadian C-spine Rule (Phase III).","Dr. Ian Stiell","","$8,134,857.00"
"Shah, Amit P","Medicine","2003/01","2007/06","Grants","Funded","True","False","Principal Site Investigator","Evaluation of an Active Strategy to Implement the Canadian CT Head Rule: Phase III.","Dr. Ian Stiell","","$11,695,863.00"
"Xenocostas, Anargyros","Medicine","2008/01","2010/12","Clinical Trials","Funded","True","False","Principal Investigator","Effect of Erythropoietin (EPO) on Breast Cancer Metastasis","","Alison Allan and Alejandro Lazo-Langner","$22,138,787.00"
"Xenocostas, Anargyros","Medicine","2007","2012/06","Clinical Trials","Funded","True","False","Co-Investigator","Cardioprotection by Erythropoietin: Role of nitric oxide.","Qingping Feng","Anargyros Xenocostas","$35,672,867.00"
"Lewis, James","Medicine","2011/01","2014/12","Grants","Funded","True","False","Co-Principal Investigator","Functional and metabolic magnetic resonance imaging of lung inflammation","Giles Santyr","","$49,643,673.00"
"Feldman, Ross","Medicine","2010/06","2012/05","Grants","Funded","False","True","Principal Investigator","","Ross D. Feldman","","$70,903,077.00"
"Gregor, James","Medicine","2009/10","2011/07","Grants","Funded","False","False","Co-Applicant","The effect of intestinal proton-coupled folate transporter (PCFT) expression on the disposition of methotrexate","J. Gregor","Vishal Patel","$29,514,382.00"
"Hegele, Robert","Medicine","2010/04","2015/03","Grants","Funded","True","False","Principal Investigator","Genetic determinants of plasma lipoproteins","Robert A. Hegele","","$74,974,986.00"
"Hegele, Robert","Medicine","2010/09","2013/08","Grants","Funded","True","False","Principal Investigator","Schulich support for LRGC Microarray Core Facility","Robert A. Hegele","","$26,081,968.00"
"Hegele, Robert","Medicine","2010/09","2012/08","Grants","Funded","True","False","Principal Investigator","Program of Experimental Medicine","Robert A. Hegele","","$18,839,064.00"
"Borrie, Michael","Medicine","2010/04","2015/03","Grants","Funded","True","False","Co-Investigator","Gait Variability as Predictor of Cognitive Decline and Risk of Falls in MCI. A Cohort Study","Manuel Montero Odasso","Co Investigators: R. Bartha, M. Speechley, V. Hachinski, MJ Borrie","$51,842,735.00"
"Moist, Louise","Medicine","2011/01","2013/01","Grants","Funded","True","False","Principal Investigator","Infrastructure Support","Dr. Louise Moist","","$21,910,276.00"
"Hegele, Robert","Medicine","2011/04","2016/03","Grants","Funded","True","False","Principal Investigator","Genetic architecture of cardiometabolic risk in families and communities","Robert A. Hegele","","$59,187,490.00"
"Borrie, Michael","Medicine","2005/07","2008/06","Clinical Trials","Funded","False","True","Principal Investigator","Longitudinal Imaging Substudy of GenADA","","Bartha R, Smith M, Wells JL","$49,688,370.00"
"Borrie, Michael","Medicine","2006/01","2009/01","Grants","Funded","True","False","Principal Investigator","Alzheimer Disease Neuroimaging Initiative (ADNI)","Borrie MJ","Wells JL","$61,575,528.00"
"Borrie, Michael","Medicine","2004/07","2008/06","Clinical Trials","Funded","False","True","Principal Investigator","NeuroImaging component of genotype-phenotype associations in Alzheimer Disease","Borrie MJ","Wells JL","$64,849,920.00"
"Wells, Jennie","Medicine","2005/01","2006/01","Grants","Funded","True","False","Co-Investigator","Info Rehab: Better Information for Better MSK Health and Quality of Life for Older Persons Summary of Research Proposal","Stolee P.","Stolee P, Wells JL, Borrie MJ, et al","$42,240,750.00"
"Wells, Jennie","Medicine","2006/01","2010/12","Grants","Funded","True","False","Co-Investigator","Alzheimer Disease Neuroimaging Initiative (ADNI)","Borrie M.","Borrie MJ","$23,621,288.00"
"Borrie, Michael","Medicine","2011/02","2013/02","Clinical Trials","Funded","False","True","Principal Investigator","A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the dose of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy.","M. Borrie","J. Wells, T. AlAama","$39,145,327.00"
"Wells, Jennie","Medicine","2011/02","2013/02","Clinical Trials","Funded","True","True","Co-Principal Investigator","A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the dose of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy.","Michael Borrie","T. AlAama","$505,118.00"
"Borrie, Michael","Medicine","2010/05","2013/05","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized, double-blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer Disease.","M. Borrie","Wells JL (sub-investigator)","$19,319,001.00"
"Wells, Jennie","Medicine","2010/05","2013/05","Clinical Trials","Funded","True","True","Co-Principal Investigator","A Randomized, double-blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer's Disease.","Borrie MJ","Wells JL, Borrie MJ","$46,015,585.00"
"Wells, Jennie","Medicine","2009/10","2011/12","Grants","Funded","True","False","Co-Investigator","Taoist Tai Chi and a Memory Intervention for Individuals with Mild Cognitive Impairment - A Randomized Control Trial.","Jennifer Fogarty","Jennie Wells, Manuel MonteroOdasso, Kevin Hansen","$56,131,457.00"
"Gunaratnam, Lakshman","Medicine","2011/03","2012/02","Grants","Funded","True","False","Principal Applicant","Exploiting KIM-1 signalling to ameliorate acute kidney injury through clearance of apoptotic cells","Lakshman Gunaratnam","Dr. Bradley Denker, Dr. Jospeh Bonventre, Dr. Hao Wang","$37,577,354.00"
"Gunaratnam, Lakshman","Medicine","2011/10","2016/03","Grants","Funded","True","False","Principal Applicant","Exploiting KIM-1 signalling to ameliorate acute kidney injury through clearance of apoptotic cells","Lakshman Gunaratnam","Dr. Bradley Denker, Dr. Jospeh Bonventre, Dr. Hao Wang, Dr. Gilles Lajoie","$52,712,695.00"
"Gunaratnam, Lakshman","Medicine","2010/01","2012/12","Grants","Funded","False","False","Principal Applicant","Role of Kidney Injury Molecule-1 in the regulation of renal inflammation in ischemia reperfusion injury","Lakshman Gunaratnam","","$63,590,746.00"
"Minuk, Leonard","Medicine","2010/09","2013","Clinical Trials","Funded","False","True","Principal Investigator","An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.","Dr. Leonard Minuk","","$60,239,206.00"
"Minuk, Leonard","Medicine","2010/09","present","Clinical Trials","Funded","False","True","Principal Site Investigator","An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma.","Dr. Leonard Minuk","","$31,786,380.00"
"Crilly, Richard","Medicine","2011/10","2014/03","Grants","Funded","True","False","Co-Applicant","A Knowledge to Action Intervention for Long-term Care: A Feasibility Study Focusing on the Uptake of Osteoporosis and Fracture Prevention Best Practices","Alexandra Papaioannou","JD Adachi, L Dolovich, LM Giangregorio, G Ioannidis, R Josse, L Lohfeld, S Marr, S Morin, A Sawka","$3,094,028.00"
"Minuk, Leonard","Medicine","2010/05","present","Clinical Trials","Funded","False","True","Site Investigator","A randomized, double-blind, placebo controlled study of the JAK inhibitor INCB 18424 tablets administered orally to subjects with primary myelofibrosis (PMF), post polycythemia Vera-myelofibrosis (PPV-MF) or essential thombocythemia myelofibrosis (PET-MF).","Dr. Kang Howson-Jan","L. Minuk","$9,628,127.00"
"Minuk, Leonard","Medicine","2009/07","2010/06","Grants","Funded","True","False","Co-Investigator","Treatment of Hodgkin Lymphoma with ABVD without Routine Growth Factor Support - A Quality Assurance Study.","Dr. Joy Mangel","L. Minuk, A. Lazo-Langner, I. Chin-Yee, K. Howson-Jan","$65,540,857.00"
"Minuk, Leonard","Medicine","2010/09","present","Clinical Trials","Funded","True","False","Principal Site Investigator","An open-label Phase II Study of the efficacy of combination bortezomib-containing regiments in the treatment of newly diagnosed patients with t(4;14) positive multiple myeloma.","Dr. Donna Reece","L. Minuk, A. Belch, C. Shustik, C. Chen, D. White, D. Szwajcer, V. Kukreti, M. Sebag, R. Tiedemann, S. Trudel","$29,137,464.00"
"Minuk, Leonard","Medicine","2010/09","present","Clinical Trials","Funded","True","False","Site Investigator","Alemtuzumab and CHOP Chemotherapy for aggressive histological peripheral T-Cell Lymphomas: A multi-centre Phase I and II Study.","Dr. Joy Mangel","L. Minuk","$6,171,139.00"
"Minuk, Leonard","Medicine","2010/06","2010/10","Clinical Trials","Funded","False","True","Co-Investigator","Phase II study of temozolomide in previously untreated acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) subjects unsuitable for standard induction therapy exhibiting low MGMT expression.","Dr. Kang Howson-Jan","L. Minuk","$1,696,188.00"
"Minuk, Leonard","Medicine","2010/01","present","Clinical Trials","Funded","True","False","Site Investigator","A Phase III study of gemcitabine, dexamethasone, and cisplatin compared to dexamethasone, cytarabine and cisplatin plus/minus rituximab [(R)-GDP VS (R)-DHAP] as salvage chemotherapy for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma prior to autologous stem cell transplant and followed up maintenance rituximab versus observation.","Dr. Kang Howson-Jan","L. Minuk","$23,213,946.00"
"Gunaratnam, Lakshman","Medicine","2011/07","2014/06","Grants","Funded","True","False","Principal Applicant","Exploiting KIM-1 signalling to ameliorate renal ischemia reperfusion injury through clearance of apoptotic cells","Lakshman Gunaratnam","","$610,015.00"
"Lewis, James","Medicine","2011/09","2016/08","Grants","Funded","True","False","Co-Applicant","The effects of mechanical ventilation on the biophysical properties of pulmonary surfactant","Ruud Veldhuizen","","$36,478,800.00"
"Kostuk, William","Medicine","2011/02","2015/02","Grants","Funded","False","True","Principal Site Investigator","PEGASUS-TIMI 54: A randomized double-blind, placebo controlled, parallel group, multinational trial to asses the prevention of thrombotic events with Ticagrelor compared to placebo on a background of acetyl salicyclic acid (ASA). Therapy in patients with history of myocardial infarction.","William Kostuk","","$913,122.00"
"Kostuk, William","Medicine","2011/02","2012/11","Grants","Funded","True","True","Co-Investigator","Can HDL infusions significantly quicken atherosclerosis regression? (CHI SQUARE): A phase II multi-center, double-blind, ascending dose, placebo-controlled, dose-finding trial of CER 001 or placebo in subjects with acute coronary syndrome.","","","$20,376,061.00"
"Kostuk, William","Medicine","2011/03","2012/12","Grants","Funded","True","True","Co-Investigator","Evaluation of the safety and efficacy of short-term A-002 treatment in subjects with acute coronary syndrome (VISTA-16)","","","$51,726,078.00"
"Diamantouros, Pantelis","Medicine","2011/03","2012/12","Grants","Funded","True","True","Co-Investigator","Evaluation of the safety and efficacy of short-term A-002 treatment in subjects with acute coronary syndromes (VISTA-16)","Dr. Shahar Lavi","Dr. P. Diamantouros","$67,185,202.00"
"Diamantouros, Pantelis","Medicine","2011/03","2012/10","Grants","Funded","True","True","Co-Investigator","Can HDL infusions signficiantly quicken atherosclerosis regression? (CHI SQUARE): A phase II multi-centre, double-blind, ascending dose, placebo-controlled, dose-finding trial of CER 001 or placebo in subjects with acute coronary syndrome.","Dr. S. Lavi","Dr. P. Diamantouros","$70,005,996.00"
"Diamantouros, Pantelis","Medicine","2011/03","2012/12","Grants","Funded","True","True","Co-Investigator","PEGASUS-TIMI 54: A randomized, double-blind, placebo controlled, parallel group, multinational trial to assess the prevention of thrombotic events with Ticagrelor compared to placebo on a background of Acetyl Salicylic Acid (ASA) therapy in patients with history of myocardial infarction.","Dr. William J. Kosuk","Dr. P. Diamantouros","$19,734,400.00"
"Millard, Wanda","Medicine","2007","","Grants","Funded","True","False","Principal Investigator","Intra-articular Lidocaine versus Conscious Sedation for the Reduction of Anterior Shoulder Dislocations in the Emergency Department.","","","$32,984,346.00"
"Thompson, Guy","Medicine","2004/10","2006/02","Clinical Trials","Funded","False","False","Co-Investigator","A Study to Assess Long-Term Antiviral Activity, Safety, Including Serum Lipids, and Tolerability of BMS-232632 in Combination with Stavudine (D4T) and Lamivudine (3TC) in Subjects Previously Treated with Nelfinavir or BMS-232632.","Ralph, Edward","Thompson, Bill, Hammerberg, Ole","$2,769,387.00"
"Thompson, Guy","Medicine","2001/02","2005/06","Clinical Trials","Funded","True","False","Principal Investigator","A prospective randomized trial of Structured Treatment Interruption (STI) followed by initiation of a new antiretroviral regimen versus immediate switching to a new antiretroviral regimen in HIV-infected patients experiencing virologic failure on HAART (CTN #164)","Thompson, Bill","Ralph, Edward, Hammberger, Ole","$47,890,010.00"
"Thompson, Guy","Medicine","2001/11","2008/01","Clinical Trials","Funded","True","False","Principal Investigator","A Tri-National (Canada, UK, USA) Randomized Controlled Trial To Determine The Optimal Management Of Patients With HIV Infection For Whom First And Second-Line Highly Active Antiretroviral Therapy Has Failed","Thompson, Bill","Ralph, Edward, Hammerberg, Ole","$72,286,115.00"
"Thompson, Guy","Medicine","2004/04","2011/06","Clinical Trials","Funded","True","False","Principal Investigator","A large, simple trial comparing two strategies for management of anti-retroviral therapy (The SMART Study)","Thompson, Bill","Ralph, Edward, Hammberg, Ole","$14,479,177.00"
"Thompson, Guy","Medicine","2002/10","2007/09","Clinical Trials","Funded","True","False","Principal Investigator","A Pilot Study Assessing the Efficacy of Pneumococcal Vaccine in HIV Patients: Delayed versus Immediate Immunization","Thompson, Bill","Ralph, Edward, Hammberg, Ole","$21,852,129.00"
"Thompson, Guy","Medicine","2005/04","2006/06","Clinical Trials","Funded","False","False","Principal Investigator","An Open-Label Safety Study of Tipranavir Co-administered with Low-dose Ritonavir in Patients with advanced HIV-1 Infection and Limited Treatment Options","Thompson, Bill","Ralph, Edward, Hammerberg, Ole","$19,102,308.00"
"Thompson, Guy","Medicine","2002/03","2004/02","Clinical Trials","Funded","False","False","Principal Investigator","An Expanded Access Program for Tenofovir Disoproxil Fumarate (Tenofovir DF) in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options","Thompson, Bill","Ralph, Edward, Hammerberg, Ole","$43,838,932.00"
"Thompson, Guy","Medicine","2007/01","2007/12","Clinical Trials","No funds received","True","False","Principal Investigator","Early access of TMC 114 in combination with low dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options","Thompson, Bill","Ralph, Edward, Hammerberg, Ole","$52,887,393.00"
"Thompson, Guy","Medicine","2009/07","2010/06","Clinical Trials","Funded","False","False","Principal Investigator","Prospective study to assess patient satisfaction, quality of life and adverse events of patients using the Biojector versus standard needles for enfuvirtide administration.","Thompson, Bill","Ralph, Edward, Hammerberg, Ole","$48,565,896.00"
"Thompson, Guy","Medicine","2009/09","2012/03","Clinical Trials","Funded","True","False","Co-Investigator","A Randomized Control Clinical Trial of Micronutrient & Antioxidant supplementation in persons with untreated HIV infection.","Ralph, Edward","Thompson, Bill, Elsayed, Sameer, Hammerberg, Ole","$32,688,855.00"
"Thompson, Guy","Medicine","2009/07","2010/06","Clinical Trials","Funded","False","False","Co-Investigator","Babies born to HIV positive mothers","Ralph, Edward","Thompson, Bill, Elsayed, Sameer, Hammerberg, Ole","$21,722,437.00"
"Thompson, Guy","Medicine","2009/08","present","Clinical Trials","Funded","False","False","Co-Investigator","OCS: Ontario HIV Treatment Network Cohort Study","Ralph, Edward","Thompson, Bill, Elsayed, Sameer, Hammerberg, Ole","$31,669,042.00"
"Thompson, Guy","Medicine","2011/04","present","Clinical Trials","Funded","False","False","Principal Investigator","A Study of Host and Viral Factors Associated with Disease Progression in Long Term HIV Infected Subjects.","Thompson, Bill","Ralph, Edward, Elsayed, Sameer, Hammerberg, Ole","$20,581,632.00"
"Thompson, Guy","Medicine","2011/04","","Clinical Trials","Funded","False","False","Co-Investigator","The psychosocial experiences and needs of HIV-positive women during their first year of motherhood","Ralph, Edward","Thompson, Bill, Elsayed, Sameer, Hammerberg, Ole","$575,386.00"
"Thompson, Guy","Medicine","2000/08","2009/12","Clinical Trials","Funded","True","False","Co-Investigator","A Randomized, Open Label, Phase III, International Study of Subcutaneous Recombinant IL-2 Proleukin in Patients With HIV-1 Infection and CD4 Cell Counts 300/mm3: Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT)","Ralph, Edward","Thompson, Bill, Hammerberg, Ole","$52,368,181.00"
"Thompson, Guy","Medicine","2002/05","2005/12","Clinical Trials","Funded","True","False","Co-Investigator","Therapeutic Drug Monitoring Guided Protease Inhibitor Therapy in People Living with the Human Immunodeficiency virus (HIV)","Reider, M.","Thompson, Bill, Ralph, Edward, Hammerberg, Ole","$49,442,569.00"
"Thompson, Guy","Medicine","2000/12","2005/12","Clinical Trials","Funded","False","False","Principal Investigator","Collect Information about HIV disease in the province of Ontario on an on-going basis.","Thompson, Bill","Ralph, Edward, Hammerberg, Ole","$23,102,746.00"
"Thompson, Guy","Medicine","2002/03","2004","Clinical Trials","Funded","False","False","Principal Investigator","An expanded access program for Tenofovir Disoproxil Fumarate (Tenofovir DF) in the Treatment of HIV-1 infected patients who have limited treatment options.","Thompson, Bill","Ralph, Edward, Hammerberg, Ole","$48,611,538.00"
"Thompson, Guy","Medicine","2002/08","2004","Clinical Trials","no funds","False","False","Principal Investigator","Atazanavir (BMS-232632) for HIV infected individuals: An early access program.","Thompson, Bill","Ralph, Edward, Hammberg, Ole","$41,457,910.00"
"Gregor, James","Medicine","2007/01","2011/01","Grants","Funded","False","True","Co-Investigator","A Phase 2, Multiple Dose, Open-label Study to Determine the Long Term Safety of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease. Protocol #C13004.","Dr. T. Ponich","","$60,653,458.00"
"Gregor, James","Medicine","2009","present","Grants","Funded","False","True","Co-Investigator","A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical response and remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis. Protocol #: C13006.","Dr. T. Ponich","","$38,433,899.00"
"Gregor, James","Medicine","2009","present","Grants","Funded","False","True","Co-Investigator","A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN 0002 in Patients with Moderate to Severe Crohn's Disease. Protocol: #C13007.","Dr. T. Ponich","","$64,014,377.00"
"Gregor, James","Medicine","2009","present","Grants","Funded","False","True","Co-Investigator","A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease. Protocol #: C13008","Dr. T. Ponich","","$42,672,800.00"
"Gregor, James","Medicine","2009","present","Grants","Funded","False","True","Co-Investigator","A Phase 111b, Multinational, Randomized, Double-Blind, Placebo Controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, A Pegylated Fab' Fragment of a Humanized Anti-TNf-Alpha Monoclonal Antibody, Administered Subcutaneously at Weeks 0, 2 and 4 in Subjects with Moderately to Severely Active Crohn's Disease. Protocol Number: C87085.","Dr. B. Feagan","","$27,403,944.00"
"Gregor, James","Medicine","2009","present","Grants","Funded","False","True","Co-Investigator","A Phase 111b, Multinational, Open-Label, Follow-On Trial to C87085 Designed to Assess the Long-Term Safety of Certolizumab Pegol, A Pegylated Fab' Fragment of a Humanized Anti-Tnf-Alpha Monoclonal Antibody, Administered at Weeks 1, 2 and 4, and then every 4 weeks thereafter, In subjects with Moderately to Severely Active Crohn's Disease who have Participated in Study C87085. Protocol Number C87088.","Dr. B. Feagan","","$15,818,766.00"
"Gregor, James","Medicine","2007","2008","Grants","Funded","False","True","Co-Investigator","A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately to Severely Active Ulcerative Colitis. Protocol Number: C0524T16","Dr. B. Feagan","","$24,793,425.00"
"Gregor, James","Medicine","2009","2010","Grants","Funded","False","True","Co-Investigator","A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis. Protocol Number: C0524T17","Dr. B. Feagan","","$42,383,556.00"
"Gregor, James","Medicine","2009","present","Grants","Funded","False","True","Co-Investigator","A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis. Protocol #: C0524T18.","Dr. B. Feagan","","$42,460,071.00"
"Xenocostas, Anargyros","Medicine","2003","2004","Grants","Funded","True","False","Co-Principal Investigator","Effect of Recombinant Human Erythropoietin on Hemodynamics and Microcirculatory Perfusion of a Septic Rat Model.","Raymond Kao","Claudio Martin and Tao Rui","$54,046,267.00"
"Xenocostas, Anargyros","Medicine","2007","","Clinical Trials","Funded","True","False","Co-Investigator","Effect of Anemia and RBC Transfusion in Acute Myocardial Infarction","Anargyros Xenocostas","Ian Chin-Yee and Qingping Feng","$1,285,346.00"
"Xenocostas, Anargyros","Medicine","2005","2007","Clinical Trials","Funded","False","True","Principal Investigator","Erythropoietin as a cardioprotectant.","Xenocostas, A","","$54,320,013.00"
"Xenocostas, Anargyros","Medicine","2008","2010","Clinical Trials","Funded","False","True","Principal Investigator","Effect of erythropoietin (EPO) on Breast Cancer Metastasis.","Xenocostas, A","","$16,310,803.00"
"Xenocostas, Anargyros","Medicine","2003","2004","Clinical Trials","Funded","False","True","Principal Investigator","Can Recombinant Human Erythropoietin Prevent Mortality, Myocardial Dysfunction and the Development of Heart Failure after Myocardial Infarction: A Pre-Clinical Maurine Model.","Xenocostas, A.","","$14,102,137.00"
"Xenocostas, Anargyros","Medicine","2002","2003","Clinical Trials","Funded","False","True","Co-Principal Investigator","Prevention of SAH Associated Vasospasm in Rabbits by Erythropoietin: A Preclinical Neuroprotection Trial.","","","$31,520,003.00"
"Xenocostas, Anargyros","Medicine","2001","2003","Clinical Trials","Funded","False","True","Co-Principal Investigator","A Phase I/II Study of Recombinant Human Erythropoietin in the Treatment of Transplant-Associted Thrombotic Microangiopahty.","","","$57,110,725.00"
"Gula, Lorne","Medicine","2010/09","2013/08","Clinical Trials","Funded","False","True","Co-Investigator","Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic ARVC Patients","Andrew Krahn","","$39,924,082.00"
"Klein, George","Medicine","2010/11","2013/08","Clinical Trials","Funded","False","True","Principal Site Investigator","Prolonged Monitoring to Detect Ventricular Arrhythmias Presymptomatic ARVC Patients","Andrew Krahn","Raymond Yee","$48,829,058.00"
"Leong-Sit, Peter","Medicine","2010/09","2013/08","Clinical Trials","Funded","False","True","Co-Investigator","Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic ARVC Patients","Andrew Krahn","","$17,316,297.00"
"Yee, Raymond","Medicine","2010/09","2015/09","Clinical Trials","Funded","False","True","Co-Applicant","Prolonged Monitoring to Detect Ventricular Arrhythmias Presymptomatic ARVC Patients","Andrew Krahn","","$57,199,341.00"
"Skanes, Allan","Medicine","2010/09","2015/09","Clinical Trials","Funded","False","True","Co-Applicant","Prolonged Monitoring to Detect Ventricular Arrhythmias Presymptomatic ARVC Patients","Andrew Krahn","","$6,571,453.00"
"Wisenberg, Gerald","Medicine","2011/07","2015/06","Clinical Trials","Funded","True","False","Co-Investigator","Quantitative Myocardial CT Perfusion Imaging","Ting Yim Lee","Brett Heilbron, Jonathan Leipisc (UBC), James Min (Cornell), Aaron So (UWO), James White (UWO)","$34,584,238.00"
"Klein, George","Medicine","2010","","Grants","Funded","False","False","Principal Applicant","Dis. Ed. Award","","","$50,408,203.00"
"Garg, Amit","Medicine","2011/03","2014/02","Grants","Funded","True","False","Co-Investigator","The Ontario Drug Policy Research Network (ODPRN)","Muhammad Mamdani, David Juurlink","Andreas Laupacis, Anne Holbrook, Douglas Coyle, David Henry, Tara Gomes, Onil Bhattacharyya, Michael Evans, Amit Garg, Gerald Evans, Michael Paterson, Peter Austin, Irfan Dhalla, Sharon Straus, Matthew Weir","$20,751,767.00"
"Lindsay, Robert","Medicine","2010/11","2013/11","Grants","Funded","True","True","Co-Principal Investigator","A comparative survival study of two competing home dialysis modalities: short-daily hemodialysis versus peritoneal dialysis","Gihad Nesrallah, Rita Suri, Robert Lindsay","Peter Blake, Amit Garg, Louise Moist","$20,207,821.00"
"Lindsay, Robert","Medicine","2005/03","2010/09","Grants","Funded","False","True","Co-Principal Investigator","Home hemodialysis: Alternative therapies","Robert Lindsay, Rita Suri, Amit Garg","","$70,776,878.00"
"Member, Test","Medicine","2011/01","2012/01","Grants","Funded","True","True","Principal Applicant","Weight Control in Lab Mice when subjected to unhealthy eating choices","Member, Test","Dr. Strange","$40,655,451.00"
"Member, Test","Medicine","2010/01","2011/02","Grants","Funded","False","True","Principal Investigator","Documentation for research from past","Member, Test","Dr. Strange","$1,263,963.00"
"Member, Test","Family Medicine","2009/07","2010/06","Clinical Trials","Applied","False","True","Co-Applicant","Measuring weight in lab mice","Member, Test","Dr. Strange","$11,955,752.00"
"McDonald, Charlotte","Medicine","2011","2014","Grants","Funded","True","False","Collaborator","Families Defeating Diabetes: Canadian Intervention for Family-centered Diabetes Prevention following Gestational Diabetes (GDM)","Dr. Ruth McManus","Dr. Tisha Joy, Dr. Charlotte McDonald, Dr. S Ludwig, Dr. G Shen, Dr. J McGavock, Dr. L Donovan, Dr. D Miller.","$26,079,908.00"
"Jain, Arsh","Medicine","2011/07","2012/06","Grants","Funded","True","False","Principal Applicant","The Impact of eGFR reporting on antibiotic dosing errors in chronic kidney disease patients.","Jain, Arsh","","$32,207,048.00"
"Chin-Yee, Ian","Medicine","2011/03","2014/02","Grants","Funded","False","True","Principal Investigator","Detection of Paroxysmal Nocturnal Hemoglobinuria in Idiopathic Deep Vein Thrombosis/Pulmonary Embolism","Dr. Ian Chin-Yee","Dr. Alejandro Lazo-Langner Dr. Michael J. Kovacs","$55,687,305.00"
"Hramiak, Irene","Medicine","2011/04","2014/12","Clinical Trials","Funded","True","False","Principal Investigator","ACCORDION Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-ON study","IM Hramiak","CG McDonald, TL Paul","$14,531,956.00"
"Hramiak, Irene","Medicine","2011/04","2016/03","Clinical Trials","Funded","True","False","Principal Investigator","Reducing with MetfOrmin Vascular Adverse Lesions in T1DM","IM Hramiak","CG McDonald, TL Paul","$50,113,251.00"
"MacDonald, Christine","Medicine","1999/07","2001/08","Grants","Funded","False","False","Principal Applicant","National Health Research and Development Program Health Canada","Christine MacDonald","","$3,761,500.00"
"MacDonald, Christine","Medicine","2000/07","2001/08","Grants","Funded","False","False","Principal Applicant","Ministry of Training, Colleges and Universities","Christine MacDonald","","$54,939,709.00"
"MacDonald, Christine","Medicine","1999/05","2001/08","Grants","Funded","False","False","Principal Applicant","Funding for Master of Science","Christine MacDonald","","$9,151,267.00"
"Hramiak, Irene","Medicine","2009/04","2011/12","Clinical Trials","Funded","False","True","Principal Investigator","An Observational follow-up study of patients previously enrolled in Exubera controlled clinical trials.","IM Hramiak","CG McDonald, TL Paul","$17,791,346.00"
"Hackam, Daniel","Medicine","2012/01","2012/12","Grants","Funded","True","False","Principal Investigator","Program on Experimental Medicine Researcher Award","Daniel G Hackam","","$1,408,150.00"
"Hackam, Daniel","Medicine","2011/04","2013/04","Grants","Funded","True","False","Co-Investigator","Effect of aldosterone antagonism on carotid atherosclerosis","David Spence","Dan Hackam, George Dresser, Aaron Fenster, Grace Parraga, David McCarty, Alan Dennis, Atef Rizkallah","$44,679,591.00"
"Montero Odasso, Manuel","Medicine","2011/07","2013/06","Clinical Trials","Funded","True","False","Co-Investigator","Quantitative and clinical measurement of balance function in community-dwelling older adults with Alzheimer Disease.","Susan Muir","","$61,090,674.00"
"Montero Odasso, Manuel","Medicine","2010/06","2015/07","Grants","Funded","True","False","Principal Investigator","POEM grant for research productivity","Manuel Montero-Odasso","","$33,978,252.00"
"McDonald, Charlotte","Medicine","2010/05","2012/12","Clinical Trials","Funded","False","True","Co-Investigator","A multicenter, double-blind, placebo-controlled, 3-arm, parallel-group, 26 week, multicenter study with a 26 week extension to evaluate the efficacy, safety, and tolerability of canagliflozin in the treatment of subjects with type 2 diabetes mellitus who have moderate renal impairment.","IM Hramiak","CG McDonald, TL Paul","$64,820,473.00"
"McDonald, Charlotte","Medicine","2010/07","2013/07","Clinical Trials","Funded","False","True","Co-Investigator","SAVOR Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomised, Double-Blind, PLacebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Pateints with Type 2 Diabetes","IM Hramiak","G Jablonsky, CG McDonald, TL Paul, N Suskin, ME Weingert","$55,320,250.00"
"McDonald, Charlotte","Medicine","2010/07","2016/12","Clinical Trials","Funded","False","True","Co-Investigator","LEADER Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results. A long-term, multi-centre, international, randomised double-blind, placebo-controlled trial to determine liraglutide effects on cardiovascular events.","Dr. Irene Hramiak","G Jablonsky, CG McDonald, TL Paul, ME Weingert","$780,456.00"
"McDonald, Charlotte","Medicine","2009/03","2010/12","Clinical Trials","Funded","False","True","Co-Investigator","A multicenter, randomized, double-blind, placebo and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031), compared to sitagliptin and placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin.","IM Hramiak","CG McDonald, TL Paul","$2,127,831.00"
"McDonald, Charlotte","Medicine","2011/04","2014/12","Clinical Trials","Funded","True","False","Site Investigator","Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-ON study","IM Hramiak","CG McDonald, TL Paul","$50,349,943.00"
"McDonald, Charlotte","Medicine","2011/04","2016/03","Clinical Trials","Funded","True","False","Site Investigator","Reducing with Metformin Vascular Adverse Lesions in T1DM","IM Hramiak","CG McDonald, TL Paul","$61,072,481.00"
"McDonald, Charlotte","Medicine","2011/10","2016/12","Clinical Trials","Funded","True","False","Co-Investigator","PSO3 - Reduction of nocturnal hypoglycemia by using predictive algorithms and pump suspension: an outpatient pilot feasibility and efficacy study. PSO4 - Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children","IM Hramiak","CG McDonald, TL Paul, J Lum","$1,329,058.00"
"McDonald, Charlotte","Medicine","2011/03","2011/12","Clinical Trials","Funded","True","False","Co-Investigator","Feasibility of Assessment of Prototype Nocturnal Hypoglycemia Reduction System(Inpatient)","IM Hramiak","CG McDonald, TL Paul, J Lum","$74,776,469.00"
"McDonald, Charlotte","Medicine","2009/04","2011/06","Clinical Trials","Funded","False","True","Co-Investigator","An Observational follow-up study of patients previously enrolled in Exubera controlled clinical trials.","IM Hramiak","CG McDonald, TL Paul","$54,712,699.00"
"Minuk, Leonard","Medicine","2011/01","present","Grants","Funded","True","False","Co-Applicant","Electrolyte disorders from Common Medications: Risk and Mitigation.","Dr. Amit Garg","L. Minuk, M. Weir, M. Beyea, S. Gandhi, T. Gomes, D. Hackam, D.. Juurlink, N. Lam, M. Mamdani, R. McLachlan, M. Paterson, J. Reiss","$28,163,439.00"
"Goldszmidt, Mark","Medicine","2011/07","2014/12","Grants","Funded","True","False","Principal Investigator","Improving care for complex patients: Influencing the communication practices that shape care","Goldszmidt, M.","Lingard, L.","$38,406,120.00"
"Goldszmidt, Mark","Medicine","2011/07","2013/07","Grants","Funded","True","False","Principal Investigator","The Education Research Fellowship: A Strategy for Developing the Clinician-Educator-Researcher Role""","Goldszmidt, M.","Lingard, L. Zibrowski, E. Ross, D.","$2,750,100.00"
"Weir, Matthew","Medicine","2010/09","2012/08","Grants","Funded","True","False","Co-Principal Investigator","Drug Safety in Impaired Renal Function","Matthew Weir","Amit X. Garg, David N. Juurlink, Muhammad Mamdani, Michael Paterson, Jeffrey L. Mahon, Daniel G. Hackam, Arsh K. Jain","$39,022,256.00"
"Weir, Matthew","Medicine","2011/04","2013/03","Grants","Funded","True","False","Co-Investigator","Acute kidney injury from antiviral drugs for herpes infections: A population-based study of older adults","Amit X. Garg","Michael Beyea, Peter Blake, Tara Gomes, David N. Juurlink, Muhammad Mamdani","$60,600,844.00"
"Weir, Matthew","Medicine","2011/04","2013/09","Grants","Funded","True","False","Co-Investigator","Electrolyte Disorders from Common Medications: Risk and Mitigation","Amit X. Garg","Michael Beyea, Tara Gomes, David N. Juurlink, Muhammad Mamdani,","$55,168,964.00"
"Weir, Matthew","Medicine","2011/09","2012/05","Grants","Funded","True","False","Principal Investigator","Beta-blockers, Dialyzability and Outcomes","Matthew Weir","Amit X. Garg, Michael Beyea, Abhijat Kitchlu, Daniel G. Hackam, Matthew Oliver, Rita Suri","$61,553,064.00"
"Weir, Matthew","Medicine","2011/04","2014/03","Grants","Funded","True","False","Co-Investigator","The Ontario Drug Policy Research Network (ODPRN)","Muhammad Mamdani, David N. Juurlink","Andreas Laupacis, Anne Holbrook, Douglas Coyle, David Henry, Tara Gomes, Onil Bhattacharyya, Michael Evans, Amit Garg, Gerald Evans, Michael Paterson, Peter Austin, Irfan Dhalla, Sharon Straus","$29,673,980.00"
"Hodsman, Anthony","Medicine","2010/11","2012/07","Grants","Funded","True","False","Co-Investigator","A Knowledge Translation Tool f or Estimating Fracture Risk: The Use of FRAX® in Primary Care","Karen Beattie","J Adachi, R Grewal, G Ioannidis, J Macdermid, A Hodsman","$10,378,343.00"
"Louzada, Martha de Lacerda","Medicine","2008/09","2015/09","Clinical Trials","Funded","False","True","Co-Investigator","A Phase III, Randomized, Open-Label, 3-Arm Study To Determine the Efficacy and Safety of Lenalidomide (Revlimid?) Plus Low-Dose Dexamethasone When Given Until Progressive Disease or for 18 Four-Week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-Week Cycles in Patients with Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation","Dr. Leonard Minuk","","$5,461,206.00"
"Louzada, Martha de Lacerda","Medicine","2009/07","","Clinical Trials","Funded","False","True","Co-Investigator","Dalteparin sodium injection, multicentre, Open label, single arm, long-term (52 weeks) study for understanding safety and efficacy in subjects with malignancies and symptomatic venous thromboembolism.","Dr. Michael Kovacs","","$5,411,646.00"
"Louzada, Martha de Lacerda","Medicine","2010/12","","Clinical Trials","Funded","False","True","Co-Investigator","A phase 3 randomized, double blind, double dummy, parallel group, multicenter, multi-national study for the evaluation of efficacy and safety of LMWH/Edoxaban versus LMWH/warfarin in subjects with symptomatic DVT and/or PE.","Dr. Michael Kovacs","","$59,906,966.00"
"Weir, Matthew","Medicine","2012/10","2017/09","Grants","Funded","True","False","Co-Principal Investigator","ICES Kidney, Transplantation and Dialysis Program","Amit X. Garg","","$66,994,404.00"
"Hodsman, Anthony","Medicine","2012/04","2014/03","Grants","Funded","True","False","Co-Investigator","Reduced kidney function and fragility fractures (Ranked 4/57, Rated 4.49)","GARG, Dr. Amit","J Adachi, S Cadarette, L-A Fraser, A. Hodsman, W. Leslie, C. Lok, K. Naylor, J Pouget, A Young","$42,497,338.00"
"McManus, Ruth","Medicine","2011/09","2014/09","Grants","Funded","True","False","Principal Investigator","FDD: Families Defeating Diabetes: Canadian Intervention for family-centered diabetes prevention following Gestational Diabetes (GDM)","Dr R McManus","Drs Tisha Joy, Charlotte McDonald, M Mottola, I Giroux, Sora Ludwig, Garry Shen, J McGavock, L Donovan, D Miller","$44,891,579.00"
"Pickering, J. Geoffrey","Medicine","2011/09","2011/09","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Alanna Watson","J.G. Pickering","","$19,624,691.00"
"Pickering, J. Geoffrey","Medicine","2011/07","2011/07","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Dr. Hao Yin","J.G. Pickering","","$30,686,606.00"
"van Uum, Stanislaus","Medicine","2010/10","2012/10","Grants","Funded","True","False","Co-Applicant","Can cortisol in saliva and hair predict recovery following acute musculoskeletal trauma?","David M. walton","Joy C. MacDermid","$59,713,687.00"
"van Uum, Stanislaus","Medicine","2009/10","2014/10","Grants","Funded","True","False","Co-Applicant","CIHR Team in using a mobile community research laboratory to improve understanding, treatment and prevention of addiction and mental illness co-morbidities at the individual and community level : The Ontario Communities Project","Jon Carney","Principle Investigators: CAIRNEY, John ; GRAHAM, Kathryn (Kate) Marie ; KENNEDY, James Lowery ; REHM, Juergen T. ; WELLS, Samantha Lynn Co-Investigators: CHAITON, Michael Oliver ; KATES, Nick ; KOREN, Gideon ; LOBO, Daniela Sabbatini Silva ; MENZIES, Peter Michael ; TYNDALE, Rachel Fynvola ; VAN UUM, Stanislaus ; VERJEE, Zulfikarali","$42,425,243.00"
"Hackam, Daniel","Medicine","2013/04","2016/04","Grants","Funded","True","False","Co-Investigator","Usual care vs Physiologically Individualized Therapy Resistant Hypertension in South Africa","David Spence","Femida Gwadry-Sridhar, Muhammad Mamdani, Jorge Cruz, Daniel Hackam, John Koval, Brian Rayner, Clint Cupido, Krish Vallabhjee, Charles Hongoro, Maurice Mars","$61,765,112.00"
"Hackam, Daniel","Medicine","2012/03","2015/03","Grants","Funded","True","False","Co-Investigator","Signal, Safety, and Success: An Analysis of Risk, Benefit, and Translation after Detection of Clinical Activity in Drug Development","Jonathan Kimmelman","Dean Fergusson, Jeremy Grimshaw, Dan Hackam, Alex John London, Tim Ramsay, Duncan Stewart, Charles Weijer","$58,406,744.00"
"Gunaratnam, Lakshman","Medicine","2011/07","2012/06","Grants","Funded","True","False","Principal Applicant","Exploiting KIM-1 signalling to ameliorate renal ischemia reperfusion injury through clearance of apoptotic cells","Lakshman Gunaratnam","","$37,235,503.00"
"Licskai, Christopher","Medicine","2011/07","2012/11","Grants","Funded","True","False","Collaborator","Correlation of Air Quality Health Index (AQHI) and Chronic Disease Morbidities","Dr. Teresa To","Christopher Licskai, Sharon Dell, Sanja Stanojevic, Richard Foty","$70,998,881.00"
"Mahon, Jeffrey","Medicine","2010","2012","Grants","Funded","True","False","Principal Investigator","Juvenile Diabetes Research Foundation - Canadian Clinical Trial Network (JDRF-CCTN) Type 1 Diabetes Clinical Trial Network - Coordinating Center.","Jeffrey Mahon","Dr. Brian Feagan","$64,704,355.00"
"Rohekar, Sherry","Medicine","2010/12","2012/03","Grants","Funded","True","False","Principal Investigator","""Work Instability in a Large Multicentre Cohort of Patients with Ankylosing Spondylitis""","","","$33,327,616.00"
"Clark, William","Medicine","2012/04","2014/03","Grants","Funded","True","False","Co-Investigator","Hypertensive disorder of pregnancy after bacterial gastroenteritis","Clark WF","Clark WF, Macnab JJ, McDonald S, Moist LM, Nevis I, Sontrop JM, Suri R, Thabane L.","$43,709,119.00"
"Pope, Janet","Medicine","2011/10","2014/06","Grants","Funded","True","True","Principal Investigator","Closing the Gap in Care in Seronegative Inflammatory Arthritis (PsA, SpA) from Identification to Implementation of Treating to Target: A Randomized Trial of Feedback, Education, and Behavioural Change (Metrix II)","","","$14,603,141.00"
"Pope, Janet","Medicine","","","Clinical Trials","Funded","True","False","Co-Investigator","Develop Methods to Measure Fatigue and to Identify Factors Related to Fatigue in Scleroderma (CSRG substudy)","Brett Thombs","","$45,811,453.00"
"Pope, Janet","Medicine","2011/05","2012/07","Clinical Trials","Funded","True","False","Co-Investigator","Develop Methods to Measure Fatigue and to Identify Factors Related to Fatigue in Scleroderma (CSRG substudy)","Brett Thombs","","$17,032,810.00"
"Pope, Janet","Medicine","2010/11","2011/11","Clinical Trials","Funded","False","True","Principal Site Investigator","A randomized double blind- placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) – LTS11298","","","$13,730,542.00"
"Pope, Janet","Medicine","2010/12","2012/12","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 2A Randomized Double-Blinded, Placebo and Active Controlled Two Cohort Two Doses Cross-Over Multi-Centre Clinical Study to Assess Efficacy of a Once Daily Administration of a Phosphodiesterase 5 Inhibitor (PF 00489791) for the Treatment of Vasospasm in Primary and Secondary Raynaud’s Phenomenon (Protocol #A7331010)","","","$71,763,832.00"
"Pope, Janet","Medicine","2010/12","2012/12","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis (Protocol # CC-10004-PSA-002)","","","$58,005,326.00"
"Pope, Janet","Medicine","2011/01","2011/07","Clinical Trials","Funded","False","True","Principal Investigator","Closing the Gap for Good Care in SSc in Canada","","","$45,862,946.00"
"Pope, Janet","Medicine","2011/03","2013/03","Clinical Trials","Funded","False","True","Principal Site Investigator","Plasma Collection for Biomarker Screening in Rheumatoid Arthritis Patients.","","","$74,346.00"
"Pope, Janet","Medicine","2011/03","2014/04","Clinical Trials","Funded","False","True","Principal Site Investigator","A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis – NA25220/open label","","","$61,867,140.00"
"Pope, Janet","Medicine","2011/09","2018/12","Clinical Trials","Funded","False","True","Principal Site Investigator","A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA) – WA25204","","","$15,824,400.00"
"Pope, Janet","Medicine","2011/05","2013/05","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Four 12-Week Treatment Cycles (48 weeks total) of Epratuzumab in Systemic Lupus Erythematosus Subjects with Moderate to Severe Disease (EMBODY 2) – SL0010","","","$30,124,096.00"
"Pope, Janet","Medicine","2011/10","2013/10","Clinical Trials","Funded","False","True","Principal Site Investigator","Prediction of early non response to etanercept (Enbrel®) and methotrexate combination therapy in rheumatoid arthritis patients eligible to first line anti-TNF treatment based on gene expression analysis of whole blood","","","$522,137.00"
"Pope, Janet","Medicine","2011/08","2012/08","Clinical Trials","Funded","False","True","Principal Investigator","RELATES: Retrospective Analysis of Abatecept Effectiveness and Safety – A Canadian Experience (BMS ID 101-289)","","","$9,894,032.00"
"Pope, Janet","Medicine","2012/01","2014/01","Clinical Trials","Funded","False","True","Principal Investigator","A Canadian Randomized Controlled Trial (RCT) of real world Cimzia treatment in RA: Randomizing to Stop vs Continue DMARDs","","","$41,861,053.00"
"Pope, Janet","Medicine","2012/01","2013/01","Clinical Trials","Funded","False","True","Principal Investigator","A randomized trial of active Psoriatic Arthritis (PsA): Randomizing to treat to a target vs. usual care","","","$42,628,549.00"
"Pope, Janet","Medicine","2011/11","2013/06","Clinical Trials","Funded","False","True","Principal Investigator","The durability of ERA disease control after tocilizumab withdrawal: A Canadian Experience","","","$27,965,287.00"
"Rohekar, Sherry","Medicine","2010/07","2011/07","Grants","Funded","False","True","Principal Investigator","Spondyloarthritis Research Clinic","","","$69,179,206.00"
"Beaton, Melanie","Medicine","2010/10","2013/10","Grants","Funded","True","False","Principal Investigator","Evaluation of Therapy and the Quantification of Hepatic Steatosis and Liver Disease using Magnetic Resonance Imaging in Non-alcoholic Fatty Liver Disease","Beaton, MD.","McKenzie, C. Tirona, R.","$60,261,645.00"
"House, Andrew","Medicine","2011/07","2013/06","Grants","Funded","True","False","Principal Site Investigator","Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study","AA House","","$58,975,521.00"
"House, Andrew","Medicine","2011/07","2011/12","Grants","Funded","True","False","Principal Site Investigator","Effect of immunosuppressive medication use on patient outcomes following kidney transplantation failure.","AA House","","$57,174,795.00"
"House, Andrew","Medicine","2011/09","2013/01","Grants","Funded","False","True","Co-Investigator","Randomized open label trial of Oral Sirolimus for decrease of stenosis in Arteriovenous fistula in hemodialysis patients when compared with standard therapy.","A Jevnikar","A House","$49,855,825.00"
"Rui, Tao","Medicine","2006/10","2009/09","Grants","Funded","True","False","Principal Investigator","Cardiac myocytes as a cellular source of chemokines in sepsis and its regulation pathways: role of NADPH oxidase and p38 kinase","Tao Rui","","$37,965,929.00"
"Rui, Tao","Medicine","2008/07","2011/06","Grants","Funded","True","False","Principal Investigator","Role of HMGB1 in ischemia/reperfusion-induced myocardial injury","Tao Rui","","$30,236,158.00"
"Lewis, James","Medicine","2012/03","2017/02","Grants","Funded","True","False","Co-Applicant","The Role of Hypercholesterolemia in Acute Lung Injury","Ruud Veldhuizen","Jim Lewis, Cory Yamashita","$73,459,980.00"
"Garg, Amit","Medicine","2012/04","2017/03","Grants","Funded","True","False","Principal Investigator","Preventing Peri-operative Acute Kidney Injury: SIRS & POISE-2 Sub-studies","Garg, Amit","Alonso P, Biccard B, Botto F, Chan M, Cuerden M, Devereaux PJ, Kurz A, Lamontagne F, Lamy A, Malaga G, Paparella D, Parikh C, Pogue J, Quantz M, Sessler D, Shah M, Shah P, Walsh M, Whitlock R, Xavier D, Zuo Y","$70,593,429.00"
"Garg, Amit","Medicine","2011/12","2016/11","Grants","Funded","True","False","Co-Investigator","Measuring and Improving the Quality of Ambulatory Care for People with Cardiovascular Risk Factors and/or chronic Cardiovascular Disesease","Tu, Jack","","$24,517,753.00"
"Garg, Amit","Medicine","2012/04","2014/03","Grants","Funded","True","False","Principal Investigator","Reduced kidney function and fragility fractures","Garg, Amit","Adachi J, Cadarette S, Hodsman A, Leslie W, Lok C, Pouget J, Young A","$69,829,743.00"
"Garg, Amit","Medicine","2012/04","2014/03","Grants","Funded","True","False","Co-Investigator","Optimizing the allocation of 'high-risk' deceased donor kidneys: A Canadian perspective","Kim, Joseph","","$8,226,395.00"
"Garg, Amit","Medicine","2011/10","2013/09","Grants","Funded","True","False","Principal Investigator","Hypertensive Disorders of Pregnancy after Bacterial Gastroenteritis","Garg, Amit","Clark W, Macnab J, McDonald S, Moist L, Nevis I, Sontrop V, Suri R, Thabane L","$51,737,823.00"
"McCormack, David","Medicine","2009/07","2014/06","Grants","Funded","True","False","Collaborator","CIHR Team Thoracic Imaging Network of Canada","N. Mueller","","$19,894,464.00"
"McCormack, David","Medicine","2009/10","2012/09","Grants","Funded","True","False","Co-Principal Investigator","Hyperpolarized Helium-3 Magnetic Resonance Imaging Phenotypes of COPD","Grace Parraga","","$51,482,020.00"
"Kim, Richard","Medicine","2011/09","2014/08","Grants","Funded","True","False","Principal Investigator","Drug Safety and Effectiveness Network (DSEN) Pharmacogenomics of Adverse Events National Team(PREVENT)","Richard Kim","","$50,920,945.00"
"Kim, Richard","Medicine","2011/03","2011/06","Grants","Funded","True","False","Principal Investigator","Infrastructure Funding for CCO Research Chairs","Richard Kim","","$70,865,018.00"
"Kim, Richard","Medicine","2011/01","2011/12","Clinical Trials","Funded","True","False","Principal Investigator","Docetaxel Weight-based Dosing Study","Richard Kim","","$45,218,355.00"
"Kim, Richard","Medicine","2010/12","2011/07","Grants","Funded","True","False","Principal Investigator","Drug Level Analysis Laboratory for Personalized Medicine Research","Richard Kim","","$46,461,129.00"
"Huff, Murray","Medicine","2010/07","2013/06","Grants","Funded","False","False","Principal Investigator","Regulation of ApoB metabolism: Relationship to atherosclerosis","Huff MW","","$45,284,300.00"
"Lazo Langner, Alejandro","Medicine","2011/01","2014/01","Grants","Funded","True","True","Co-Principal Investigator","Detection of PNH clones in patients with idiopathic deep vein thrombosis pulmonary embolism","Ian Chin-Yee, A Lazo-Langner","Mike Keeney, Michael Kovacs","$72,030,013.00"
"Mehta, Sanjay","Medicine","2006","2010","Clinical Trials","Funded","False","True","Principal Investigator","A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension","S Mehta","","$18,192,652.00"
"Mehta, Sanjay","Medicine","2009","2010","Clinical Trials","Funded","False","True","Principal Investigator","A Phase 2A, randomized, double blind, placebo-controlled, parallel group, study investigating the dose-response of PF-00489791 on acute hemodynamics in subjects with idiopathic and familial pulmonary hypertension","S Mehta","","$7,180,411.00"
"Mehta, Sanjay","Medicine","2009","2011","Clinical Trials","Funded","False","True","Principal Investigator","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension","S Mehta","","$27,704,722.00"
"Mehta, Sanjay","Medicine","2009/01","2012/01","Clinical Trials","Funded","False","True","Principal Investigator","A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension","S Mehta","","$30,216,538.00"
"Mehta, Sanjay","Medicine","2009","2012","Clinical Trials","Funded","False","True","Principal Investigator","Study with Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome; A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension","S Mehta","","$23,137,083.00"
"Mehta, Sanjay","Medicine","2009","2012","Clinical Trials","Funded","False","True","Principal Investigator","A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension","S Mehta","","$29,933,422.00"
"Mehta, Sanjay","Medicine","2009/01","2013/01","Clinical Trials","Funded","False","True","Principal Investigator","Study with Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve Clinical outcome: open-label long-term extension","S Mehta","","$28,684,937.00"
"Mehta, Sanjay","Medicine","2010/07","2013","Clinical Trials","Funded","False","True","Principal Investigator","A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study","S Mehta","","$17,399,152.00"
"Mehta, Sanjay","Medicine","2010/07","2013","Clinical Trials","Funded","False","True","Principal Investigator","Open label long-term extension multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension","S Mehta","","$71,207,103.00"
"Mehta, Sanjay","Medicine","2010","2012","Clinical Trials","Funded","False","True","Principal Investigator","Randomized, double-blind, placebo-controlled, multicentre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).","S Mehta","","$22,993,606.00"
"Mehta, Sanjay","Medicine","2010/01","2013/01","Clinical Trials","Funded","False","True","Principal Investigator","Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","S Mehta","","$22,317,947.00"
"Mehta, Sanjay","Medicine","2008/07","2012","Clinical Trials","Funded","False","True","Principal Investigator","A Post Marketing Observational Surveillance Programme for Ambrisentan in PAH; 2008 - ongoing","S Mehta","","$57,059,929.00"
"Jain, Arsh","Medicine","2011/06","2014/06","Grants","Funded","True","False","Principal Investigator","eGFR Reporting Award Funding","Jain, Arsh","","$6,223,388.00"
"Bosma, Karen","Medicine","2011/01","2013/12","Grants","Funded","True","False","Principal Applicant","Mechanisms of Arousals from Sleep in Mechanically Ventilated Patients","Dr. Karen Bosma","","$69,036,455.00"
"Bosma, Karen","Medicine","2011/01","2013/11","Grants","Funded","True","False","Principal Applicant","Mechanisms of Arousals from Sleep in Mechanically Ventilated Patients","Dr. Karen Bosma","","$46,835,080.00"
"Bosma, Karen","Medicine","2009/06","2013/08","Grants","Funded","True","True","Principal Applicant","Is respiratory rate an adequate indicator of respiratory distress during weaning from mechanical ventilation?","Dr. Karen Bosma","","$12,136,697.00"
"Chin-Yee, Ian","Medicine","2011/12","2014/01","Grants","Funded","True","False","Co-Principal Investigator","Application of Liposomes to Improve the Hypothermic Storage of Red Blood Cells","Dr. Jelena Holovati and Co-PI Dr. Ian Chin-Yee","Dr. Jason Acker, Dr. Q. Feng, Dr. I. Chin-Yee","$38,035,189.00"
"Hsia, Cyrus","Medicine","2009/12","2010/06","Grants","Funded","False","True","Co-Investigator","A phase III, randomized open-label, 3-arm study to determine the efficacy and safety of Lenalidomide (Revlimid) plus low-dose dexamenthasone when given until progressive disease or for 18 four-week cycles versus the combination of Melphalan, Prednisone, and Thalidomide given for 12 six-week cycles in patients with previously untreated Multiple Myeloma who are either 65 years of age or older or not candidates for stem cell transplantation.","","","$60,602,038.00"
"Hsia, Cyrus","Medicine","2007/06","present","Grants","Funded","False","True","Co-Investigator","A Randomized, double blind, placebo controlled pilot trial of Rituximab for Adults with Immune Thombodytopenic Purpura at Initial presentation or at relapse following medical treatments who are receiving standard therapy","","","$68,603,913.00"
"Hsia, Cyrus","Medicine","2011/10","present","","Funded","False","False","Principal Applicant","Plasma Utilization Following Cardiac Surgery","","","$66,600,997.00"
"Hsia, Cyrus","Medicine","2009/07","2010/06","Grants","Funded","False","True","Co-Investigator","An international, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma.","","","$66,701,351.00"
"Hsia, Cyrus","Medicine","2009/07","2010/06","Grants","Funded","False","True","Co-Investigator","An international, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.","","","$25,655,038.00"
"Hsia, Cyrus","Medicine","2009/07","2010/06","Grants","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo controlled study of the JAK inhibitor INCB 18424 tablets administered orally to subjects with primary myelobibrosis (PMF), post polycythemia Ver-myelofibrosis (PPV-MF) or Essential thrombodythemia myelofibrosis (PET-MF).","","","$50,639,336.00"
"Hodsman, Anthony","Medicine","2012/07","2015/06","Clinical Trials","Funded","True","False","Co-Investigator","Build Better Bones with Exercise (B3E): A pilot, multi-centre randomized controlled trial to examine whether exercise can prevent fractures among women with vertebral fractures (Ranked 5/40, Rated 4.11)","Lora Giangregorio","J Adachi, M Ashe, A Cheung, L-A Fraser, K Hill, A Hodsman, D Kendler, N Mittmann, A Papaioannou, L Thabane, J Wark","$54,775,072.00"
"Hodsman, Anthony","Medicine","","","Grants","applying March 2012","True","False","Co-Investigator","Assessment of the Independent and Joint Effects of Dietary Calcium and Vitamin D on Arterial Calcification, and Osteoporosis","David Goltzman","","$3,410,171.00"
"Hodsman, Anthony","Medicine","2012/07","2017/06","Clinical Trials","Funded","True","False","Co-Investigator","Evidence-based fracture management supports to optimize fracture recovery, future bone health and optimal physical after distal radius fracture. (Ranked 2/11, Rated 4.18)","MACDERMID, Joy","R. Grewal, G King, J Johnson, A. Hodsman, L Ferreira, K Chung","$59,382,405.00"
"Hodsman, Anthony","Medicine","2012/06","2015/02","Grants","Applied","True","False","Co-Investigator","Assessment of the Independent and Joint Effects of Dietary Calcium and Vitamin D on Arterial Calcification, and Osteoporosis","GOLTZMAN, Dr. Daivd","J. Genest, D. Hanley, A. Hodsman, A. Jamal, C. Kovacs, N. Kreiger, B. Lentle, W. Olszynski, J. Prior, E. Rahme, B. Richards.","$17,150,471.00"
"Minuk, Leonard","Medicine","2011/06","present","Grants","Funded","True","False","Co-Investigator","Multicentre Canadian Study of Prophylaxis in Older Adults with Severe Hemophilia.","Dr. Shannon Jackson","L. Minuk, M. Yang, K. Brose, K. Webert, R. Card, MC Poon","$327,444.00"
"Minuk, Leonard","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 3 Randomized Open Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma CA204-004.","Dr. Leonard Minuk","","$13,250,797.00"
"Minuk, Leonard","Medicine","2011/11","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 3 Randomized Open Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Subjects with previously untreated Multiple Myeloma CA-204-006.","Dr. Leonard Minuk","","$17,539,653.00"
"Minuk, Leonard","Medicine","2011/11","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 3 Multicenter Randomized Open Label Study to Compare the Efficacy and Safety of Pomalidomide in combination with Low - Dose Dexamethasone versus High Dose Dexamethasone in subjects with Refractory or Relapsed and Refractory Multiple Myeloma.","Dr. Leonard Minuk","","$73,491,057.00"
"Kovacs, Michael","Medicine","2011/07","present","","Funded","True","False","Co-Applicant","The OVWAC II study: a multicentre study of low dose oral vitakin K for INR control in patients receiving warfarin.","Dr. Mark Crowther","","$28,110,291.00"
"Kovacs, Michael","Medicine","2011/09","present","","Funded","True","False","Co-Applicant","The Management of Subsegmental Pulmonary Embolism: prospective cohort study (SUSPECT study)","Dr. Marc Carrier","","$30,742,451.00"
"Kovacs, Michael","Medicine","2010/12","2014/12","Grants","Funded","False","True","Principal Site Investigator","A Phase 3, randomized double-blind, double-dummy, parallel-group, multi-centre, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus LMW heparin/warfarin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism. Protocol DU176B-D-U305 (HOKUSAI)","Dr. Michael J. Kovacs","","$14,052,333.00"
"Kovacs, Michael","Medicine","2007/07","2011/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. (Einstein)","","","$48,687,427.00"
"Kovacs, Michael","Medicine","2009/07","present","* Grant-in-aid","Funded","True","False","Co-Applicant","REVERSE (Recurrent Venous Thromboembolism Risk Stratification Evaluation) II: validation of the ""Men and HERDOO2"" - A clinical decision rule to identify patients with ""unprovoked"" venous thromboembolism who can discontinue anticoagulants after 6 months of treatment.","Dr. Marc Rodger","","$2,711,870.00"
"Moist, Louise","Medicine","2012/04","2014/04","Grants","Funded","True","False","Co-Investigator","Hypertensive disorder of pregnancy after bacterial gastroenteritis","Dr.","","$6,785,524.00"
"Kovacs, Michael","Medicine","2011/01","present","","Funded","True","False","Co-Applicant","Prospective evaluation of long-term outcomes after pulmonary embolism: The ELOPE Study","Dr. Susan Kahn","","$7,824,574.00"
"Kao, Raymond","Medicine","2010","2013","Grants","Funded","True","False","Principal Investigator","Comparing effect of Normal Saline, Ringer's Lactate and 75% Hypertonic Saline with rHuEPO on microcirculatory perfusion and tissue bioenergetics of the small intestines in a hemorrhegic shock rat model.","","","$6,438,290.00"
"Jevnikar, Anthony","Medicine","2011/01","2016/03","Grants","Funded","True","False","Principal Investigator","Regulation of Renal Tubular Epithelial Cell Injury to Promote Kidney Allograft Survival","Dr. A. Jevnikar","","$53,370,028.00"
"Jevnikar, Anthony","Medicine","2011/09","present","Clinical Trials","Funded","False","True","Principal Investigator","Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemodialysis Patients when Compared with Standard Therapy (SAVE)","Dr. Anthony M. Jevnikar","","$38,948,036.00"
"Jevnikar, Anthony","Medicine","2011/10","2014/09","Grants","Funded","True","False","Co-Investigator","Regulation of Pre-Transplant Ischemic Injury and Cardiac Allograft Vasculopathy","Dr. Z. Zhang","","$41,052,573.00"
"Kovacs, Michael","Medicine","2011/03","2012/02","Clinical Trials","Funded","False","True","Co-Investigator","Detection of paroxysmal nocturnal hemoglobinuria (PNH) clones in patients with idiopathic deep vein thrombosis/pulmonary embolism (DVT/PE).","Dr. Ian Chin-Yee","","$16,869,321.00"
"Hramiak, Irene","Medicine","2009/08","2011/12","Clinical Trials","Funded","False","True","Principal Investigator","Thiazolidinedione Intervention with vitamin D Evaluation (TIDE). A multicenter randomized double-blind placebo-controlled trial of a thiazolidinedione or placebo and of vitamin D or placebo in people with type 2 diabtes at risk for cardiovascular disease.","IM Hramiak","GC McDonald, TL Paul, N Suskin, ME Weingert","$7,078,354.00"
"Lazo Langner, Alejandro","Medicine","2009/07","present","Grants","Funded","True","False","Site Investigator","Study of red blood cell transfusion triggers in patients undergoing hematopoietic stem cell transplantation (TRIST).","Jason Tay, Alan Tinmouth","","$43,975,780.00"
"Lazo Langner, Alejandro","Medicine","2010/07","present","Clinical Trials","Funded","True","True","Site Investigator","BMS 004 Study. Lenalidomide/dexamethasone with or without elotuzumab for relapsed Multiple Myeloma patients.","L Minuk","","$1,391,680.00"
"Lazo Langner, Alejandro","Medicine","2010/07","present","Clinical Trials","Funded","True","True","Site Investigator","BMS 006 Study. Lenalidomide/dexamethasone with or without elotuzumab for newly diagnosed Multiple Myeloma patients","L Minuk","","$9,036,200.00"
"Lazo Langner, Alejandro","Medicine","2010/07","present","Clinical Trials","Funded","True","True","Site Investigator","A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone Versus High-Dose Dexamethaseone in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma","L Minuk","","$61,198,513.00"
"Lazo Langner, Alejandro","Medicine","2010/07","present","Clinical Trials","Funded","True","True","Site Investigator","Open-Label, Multi-Center, Single-Arm Study for the Safety and Efficacy of Pomalidomide (CC-4047) Monotherapy for Subjects with Refractory or Relapsed and Refractory Multiple Myeloma A Comparison Study for Clinical Trial CC-4047-MM-003","L Minuk","","$69,242,383.00"
"Lazo Langner, Alejandro","Medicine","2011/09","present","Clinical Trials","Funded","True","True","Site Investigator","A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase (ENEST study)","A Xenocostas","","$10,093,897.00"
"Lazo Langner, Alejandro","Medicine","2010/07","present","Clinical Trials","Funded","True","True","Site Investigator","Comparative investigation of low molecular weight heparin/edoxoban tosylate (DU176b) versus (LMWH)heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots (The Edoxoban Hokusai-VTE Study).","H Buller","","$23,204,895.00"
"Lazo Langner, Alejandro","Medicine","2009/07","2011/06","Clinical Trials","Funded","True","True","Site Investigator","Frag 001 study. Safety and efficacy of long term administration of dalteparin in patients with cancer-related thrombosis","M Kovacs","","$22,573,031.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2011/01","2013/01","Grants","Funded","True","False","Co-Principal Investigator","2011-2013 AHSC AFP Innovation Fund, MOHLTC Perioperative Evidence-Based Decision-Making & Health Technology Assessment in Anesthesia & Surgery: Building a Centre of Excellence Co-Principal Investigator (Dr. Janet Martin) $196, 250 (Year 1) $176, 250 (Year 2)",".","","$34,912,279.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2009","2011","Grants","Funded","True","False","Principal Investigator","2009-2011 Ontario AFP Innovation Grant Project: Evidence-Based Perioperative Drug Therapy: Getting Evidence into Policy & Practice Principal Investigator $112,500 (year 1) $92,500 (year 2)","","","$12,870,193.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2009","2011","Grants","Funded","True","False","Co-Investigator","2009-2011 Ontario AFP Innovation Grant Project: Evidence Embedded Clinical Decision Support and Collaboration to Enhance Patient Safety and Outcomes. Co-Investigator with Dr. Ian Herrick (Principal Investigator) $227, 500 (year 1) $187,500 (year 2)","","","$41,441,635.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2007","2008","Grants","Funded","True","False","Co-Investigator","2007-2008 Lawson Health Research Institute, Internal Research Fund (IRF) Project: Perioperative Cardiac Anesthesia Database Co-Investigator with Dr. Ravi Taneja (Principal Investigator) $35,880","","","$16,600,784.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2005","2007","Grants","Funded","True","False","Co-Investigator","2005-2007 Canadian Patient Safety Institute Project: The Effect of a Merger of a Two Site Cardiac Surgery and Cardiac Anesthesia Service on Patient Outcomes and Institutional Safety Culture Co-Investigator with Dr. Richard Novick (Principal Investigator) $46,000","","","$27,590,081.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2005","2006","Grants","Funded","True","False","Principal Investigator","2005-2006 Anemia Institute for Research & Education (AIRE) Project: Multicenter Benchmark study on Volume Therapy and Blood Transfusion in Surgical Patients (Principal Investigator) and Coordinating Center $25,500","","","$9,324,082.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2005","2006","Grants","Funded","True","False","Co-Investigator","2005-2006 Lawson Health Research Institute, Internal Research Fund (IRF) Project: Cost Analysis and Economic Analysis of Post-Operative Nausea and Vomiting in a Canadian Teaching Hospital Co-Investigator with Dr. Janet Martin (Principal Investigator) $7,600","","","$30,678,075.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2005","2006","Grants","Funded","True","False","Principal Investigator","2005-2006 Canadian Institutes of Health Research Project: Predictors of Massive Blood Loss in Cardiac Surgery: Development and Validation of a Simple Prediction Rule Site Collaborator with Dr. Keyvan Karkouti (Principal Investigator) $15,000","","","$44,278,902.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2002","2006","Grants","Funded","True","False","Co-Investigator","2002-2006 Canadian Institutes of Health Research & Ontario Ministry of Health & Long Term Care Project: Blood Conservation using Antifibrinolytics: A Randomized Trial in Cardiac Surgery Population (BART Study) Co-Investigator at TGH with Dr. Paul Hebert (Principal Investigator) $2,209,327 (total all sites)","","","$7,284,070.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2002","2004","Grants","Funded","True","False","Principal Investigator","2002-2004 Heart and Stroke Foundation of Ontario Canada Grant # NA 4915 Project: Continuous Cell-Saver, Neurocognitive Outcome and Cardiac Surgery Co-Investigator with Dr. George Djaiani (Principal Investigator) $199,995","","","$73,850,769.00"
"Gunaratnam, Lakshman","Medicine","2013/06","2018/05","Grants","Funded","True","False","Principal Applicant","“Simulation and Imaging Laboratory for the Study of Ischemia Reperfusion Injury and Inflammation in Transplantation”","Dr. Lakshman Gunaratnam","","$35,237,540.00"
"Rui, Tao","Medicine","2010/07","2012/06","Grants","Funded","True","False","Principal Investigator","","Tao Rui","","$50,936,911.00"
"Rui, Tao","Medicine","2012/07","2015/06","Grants","Funded","True","False","Principal Applicant","MicroRNA380-5p/IL-33 in the development of diabetic cardiomyopathy","Tao Rui","","$51,056,199.00"
"Rui, Tao","Medicine","2012/04","2015/03","Grants","Funded","True","False","Co-Applicant","THE EFFECT OF RESUSCITATION WITH C-PEPTIDE ON THE SMALL INTESTINE MICROCIRCULATION PERFUSION, TISSUE BIOENERGETICS, GUT INJURY AND LUNG INFLAMMATION IN ACUTE AND 24 HOURS MOUSE MODEL OF HEMORRHAGIC SHOCK AND RESUSCITATION","Raymond Kao","","$11,490,850.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2002","2004","Grants","Funded","True","False","Co-Investigator","2002-2004 Lawson Health Research Institute. Internal Research Fund (IRF). Project: The effect of a merger on a two site cardiac surgery and anesthesia service on patient outcomes and institutional safety culture Co-Investigator with Dr. Richard Novick (Principal Investigator) $12,500","","","$65,406,847.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2001","2002","Grants","Funded","True","False","Principal Investigator","2001-2002 Anemia Institute for Research & Education, Canada Project: The role of bradykinin post cardiopulmonary bypass on bleeding and hypotension. Principal Investigator $30,000","","","$47,439,320.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2001","2002","Grants","Funded","True","False","Co-Investigator","2001-2002 Anemia Institute for Research & Education, Canada Project: Efficacy of ANH in reducing the incidence of allogenic blood transfusion in cardiac surgery. Co-Investigator with Dr. Keyvan Karkouti (Principal Investigator) $30,000","","","$73,950,631.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2001","2002","Grants","Funded","True","False","Collaborator","2001-2002 NIH Clinical Trial Pilot Grant, USA Project: Randomized Off Bypass Outcome Trial (ROBOT) Collaborative Investigator with Dr. Mark Newman (Principal Investigator), Duke University Medical Center US$120,000","","","$4,046,968.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2000","2001","Grants","Funded","True","False","Principal Investigator","2000-2001 Canadian Anesthesiologists’ Society Research Award: Dr. Earl Wynands Research Award in Cardiovascular Anesthesia Project: Prevention of acute renal failure in patients with preoperative renal impairment undergoing CABG surgery without cardiopulmonary bypass (Principal Investigator) $20,000","","","$28,228,756.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2000","2001","Grants","Funded","True","False","Principal Investigator","2000-2001 Bayer/Canadian Blood/Services/Hema-Quebec Partnership Grant, Canada Project: Antithrombin treatment in heparin-resistance patients undergoing CABG surgery. Collaborative Investigator with Dr. Jean-Francois Hardy (Principal Investigator), University of Montreal $62,000","","","$49,455,223.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1998","1999","Grants","Funded","True","False","Co-Investigator","1998-1999 Canadian Anesthesiologists’ Society Research Award: Zeneca Pharma Inc Canadian Research Award Project: Postoperative sleep disturbances: incidence and correlation with myocardial ischemia Co-Investigator with Dr. Keyvan Karkouti (Principal Investigator) $10,000","","","$3,961,004.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1998","1999","Grants","Funded","True","False","Co-Investigator","1998-1999 Canadian Anesthesiologists’ Society Research Award: Astra Pharma Inc Canadian Research Award in Regional Anesthesia/Acute Pain Management Project: The effects of perioperative analgesic techniques on outcome after thoracic surgery. Co-Investigator with Dr. Peter Slinger (Principal Investigator) $15,000","","","$5,063,430.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1995","1996","Grants","Funded","True","False","Co-Principal Investigator","1995-1996 Ontario Thoracic Society, Canada Project: The effect of hypercapnia and hypocapnia on regional perfusion in a swine model of coronary artery disease. Co-Principal Investigator with Dr. Ramiro Arellano $17,000","","","$16,640,013.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1995","1996","Grants","Funded","True","False","Principal Investigator","1995-1996 Anesthesia Patient Safety Foundation, American Society of Anesthesiologists, USA Project: Is early extubation safe in patients following coronary artery bypass surgery? A prospective randomized controlled outcome study. (Principal Investigator) US$50,000","","","$64,673,438.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1995","1996","Grants","Funded","True","False","Principal Investigator","1995-1996 Centre for Cardiovascular Research, The Toronto Hospital – Promising Pilot Project Grant Project: Esmolol or subhypnotic dose of propofol reduces post extubation myocardial ischemia in early extubated patients after CABG surgery. (Principal Investigator) $9,000","","","$18,000,256.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1995","1996","Grants","Funded","True","False","Principal Investigator","1995-1996 Centre for Cardiovascular Research, The Toronto Hospital – Equipment Grant Project: Nitric Oxide on Pulmonary Hypertension Before and After Heart Transplant Principal Investigator $4,250","","","$27,702,455.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1995","1996","Grants","Funded","True","False","Principal Investigator","1995-1996 Society of Cardiovascular Anesthesiologists, USA, Project: Postoperative myocardial ischemia and infarction in early versus late extubation for patients following CABG surgery. (Principal Investigator) US$10,000","","","$9,795,412.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1994","1995","Grants","Funded","True","False","Co-Investigator","1994-1995 Ontario Thoracic Society, Canada Project: Postoperative allograft gas exchange in sequential single lung transplant: Identification of rejection by volume based capnography. Co-Investigator with Dr. Karen McRae (Principal Investigator) $17,000","","","$40,768,278.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1993","1995","Grants","Funded","True","False","Principal Investigator","1993-1995 Heart & Stroke Foundation of Ontario, Canada, Project: Cardiac medications and propofol Anesthesia in a chronic swine model. (Principal Investigator) $124,088","","","$2,253,161.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1994","1995","Grants","Funded","True","False","Co-Investigator","1994-1995 Canadian Anesthesiologists’ Society Research Award: David S. Sheridan Canadian Research Award Project: Effect of permissive hypercapnia on regional myocardial blood flow, metabolism and contractility of collateral-dependent and normal myocardium in a chronic swine model. Co-Investigator with Dr. Ramiro Arellano (Principal Investigator) $10,000","","","$58,533,907.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1991","1993","Grants","Funded","True","False","Principal Investigator","1991-1993 Heart & Stroke Foundation of Ontario, Canada Project: Cardiac medications and controlled ischemia in a chronic swine model under isoflurane Anesthesia. (Principal Investigator) $115,897","","","$5,625,948.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1992","1993","Grants","Funded","True","False","Principal Investigator","1992-1993 Physicians’ Services Incorporated Foundation, Ontario, Canada Project: Coagulopathies in spinal vs. general Anesthesia in TURP patients. (Principal Investigator) $15,000","","","$53,529,759.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1991","1991","Grants","Funded","True","False","Principal Investigator","1991-1992 Heart and Stroke Foundation of Ontario, Canada Project: Effects preoperative sedation and oxygen saturation on silent myocardial ischemia. Principal Investigator $24,836","","","$40,311,475.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1989","1990","Grants","Funded","True","False","Principal Investigator","1989-1990 The Physicians’ Services Incorporated Foundation, Ontario Project: Hemodynamic and postoperative respiratory functions of narcotic agonists and antagonist. (Principal Investigator) $36,000","","","$32,055,548.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1989","1990","Grants","Funded","True","False","Principal Investigator","1989-1990 Dean’s Fund Award, Faculty of Medicine, U of Toronto. Project: Hemodynamic and catecholamine responses of narcotics agonists /antagonist during general anesthesia. (Principal Investigator) $4,000","","","$74,379,885.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1989","1990","Grants","Funded","True","False","Principal Investigator","1989-1990 Canadian Anesthesiologists’ Society Research Award: David S. Sheridan Canadian Research Award Project: Preoperative cardiac medication and controlled ischemia in chronic collateral coronary stenosis in swine. (Principal Investigator) $10,000","","","$4,285,353.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2007","2008","Grants","Funded","True","True","Co-Principal Investigator","2007-2008 Novo-Nordisk Inc. Project: A randomized, double blind, placebo-controlled, multi-center study to evaluate the efficacy of activated recombinant factor VVIIa for early control of hemorrhage in high-risk cardiac surgery. (USA and Canada) Site Principal Investigator with Dr. Keyvan Karkouti (Principal Investigator) $15,000","","","$73,442,624.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2005","2007","Grants","Funded","True","True","Principal Investigator","2005-2007 Organon Pharmaceuticals Project: A multicenter, randomized, parallel group, comparative, safety-assessor blinded, phase IIIa trial in adult surgical subjects under general anesthesia at increased risk for pulmonary complications. Site Principal Investigator $61,994","","","$5,533,793.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2003","2004","Grants","Funded","True","True","Co-Principal Investigator","2003-2004 EISAI Inc. Project: Lipid A antagonist in CABG and or valve surgery with Cardiopulmonary Bypass Site Principal Investigator $20,000","","","$24,244,114.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2002","2003","Grants","Funded","True","True","Co-Principal Investigator","2002-2003 Baxter Healthcare Corporation Project: Maintenance Anesthesia with Desflurane or Propofol for OPCAB Surgery Co-Principal Investigator with Dr. D Bainbridge US $90,000","","","$63,201,811.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2002","2003","Grants","Funded","True","True","Co-Principal Investigator","2002-2003 Pharmacia Project: Safety and efficacy of Parecoxib/Valdecoxib compared to placebo treatment in patients who have coronary artery bypass graft via median sternotomy Co-Investigator with Dr. F Ralley (Principal Investigator) $50,000","","","$40,181,559.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2000","2001","Grants","Funded","True","True","Principal Investigator","2000-2001 Hemosol Inc. Project: Canada/USA – Phase III multicenter randomized controlled, blind study of the safety & efficacy of Hemolink in CABG patients. Principal Investigator $150,000","","","$22,876,729.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2000","2001","Grants","Funded","True","True","Principal Investigator","2000-2001 Alliance Pharmaceutical Corp. Project: Phase III single blind, randomized, multicenter, controlled study of the effectiveness of Perflubron to augment intraoperative autologous donation and avoid allogeneic blood transfusion in CABG patients. Principal Investigator $100,000","","","$42,410,055.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2000","2001","Grants","Funded","True","True","Co-Principal Investigator","2000-2001 Abbott Laboratories. Project: Sevoflurane induction and maintenance of anesthesia for patients with impaired left ventricular function undergoing CABG surgery: a prospective randomized clinical trial Co-Principal Investigator with Dr. George Djaiani $74,321","","","$70,058,752.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2000","2001","Grants","Funded","True","True","Principal Investigator","2000-2001 GD Searle & Co. Project: A clinical evaluation of the safety and efficacy of Paracoxib in CABG patient post median sternotomy. Principal Investigator $81,000","","","$7,991,817.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2000","2001","Grants","Funded","True","True","Co-Investigator","2000-2001 Jannsen Ortho Inc. Project: Risks of blood transfusion in women undergoing CABG surgery. Co-Investigator with Dr. Keyvan Karkouti (Principal Investigator) $40,000","","","$73,463,455.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1999","2000","Grants","Funded","True","True","Principal Investigator","1999-2000 Hemosol Inc. Project: Canada/Europe – Phase III multicenter randomized controlled, blind study of the safety & efficacy of Hemolink in CABG patients. Principal Investigator $150,000","","","$6,005,215.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1998","1999","Grants","Funded","True","True","Principal Investigator","1998-1999 Pharmacia & Upjohn. Project: A Phase III dose escalation study to evaluate safety and efficacy of Freedox for the prevention or amelioration of acute renal failure in patients with renal impairment undergoing elective cardiovascular surgery. Principal Investigator $70,000","","","$53,777,393.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1998","1999","Grants","Funded","True","True","Principal Investigator","1998-1999 Hemosol Inc. Project: A Phase II multi-centre randomized controlled, single blind study to evaluate the safety and efficacy of Hemolink in elective CABG patients. Principal Investigator $75,000","","","$36,292,866.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1996","1997","Grants","Funded","True","True","Principal Investigator","1996-1997 Ortho-McNeil Inc. Project: Multi-centre randomized, controlled trial of Epoetin for autologous blood procurement before cardiac surgery. Principal Investigator $30,000","","","$22,636,094.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1996","1997","Grants","Funded","True","True","Principal Investigator","1996-1997 Glaxo Wellcome Inc. Project: Multi-centre randomized, controlled trial of Remifentanil vs. Fentanyl in CABG patients. Principal Investigator $150,000","","","$22,705,451.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1994","1995","Grants","Funded","True","True","Principal Investigator","1994-1995 Ohmeda Pharma, Canada. Project: Predictors and risk scoring system in CVICU database. Principal Investigator $25,000","","","$6,012,925.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1994","1995","Grants","Funded","True","True","Principal Investigator","1994-1995 Abbott Laboratories, Canada Project: A randomized clinical trial of PCA vs. IV morphine for early and conventional extubated patients post CABG surgery. Principal Investigator $65,000","","","$1,266,521.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1993","1995","Grants","Funded","True","True","Principal Investigator","1993-1995 Zeneca, Canada. Project: Propofol sedation in geriatric patients following CABG surgery. Co-Investigator with Dr. Jacek Karski (Principal Investigator) $70,000","","","$50,733,472.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1994","1995","Grants","Funded","True","True","Principal Investigator","1994-1995 Glaxo, Canada. Project: Pharmaco-economics of Anesthesia in surgery. Principal Investigator $28,000","","","$5,116,669.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1993","1994","Grants","Funded","True","True","Co-Investigator","1993-1994 Janssen Pharmaceutical, Canada. Project: Evaluation of postoperative alfentanil infusion in cardiac surgical patients: effects on hemodynamics, sedation and shivering. Co-Investigator with Dr. Jacek Karski (Principal Investigator) $50,000","","","$45,933,197.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1993","1994","Grants","Funded","True","True","Co-Investigator","1993-1994 Burroughs Wellcome, Canada. Project: Evaluation the safety and efficacy of Mivacurium chloride compared to succinylcholine in ambulatory surgical patients. Co-Investigator with Dr. Frances Chung (Principal Investigator) $70,000","","","$25,508,236.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1993","1994","Grants","Funded","True","True","Co-Investigator","1993-1994 Gensia Pharmaceutica, Inc., USA. Project: A randomized double-blind placebo controlled study of the effect of Acadesine on myocardial infarction and adverse cardiovascular outcome in patients undergoing CABG surgery. Co-Investigator with Dr. Richard Weisel (Principal Investigator) US$50,000","","","$42,053,738.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1992","1993","Grants","Funded","True","True","Co-Investigator","1992-1993 Burroughs Wellcome, Canada. Project: Dose response study of Doxacurium in a pithed rat model. Co-Investigator with Dr. Ramiro Arellano (Principal Investigator) $10,000","","","$30,809,462.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1992","1993","Grants","Funded","True","True","Principal Investigator","1992-1993 Burroughs Wellcome, Canada. Project: Pharmacokinetics of Doxacurium in CABG patients (normothermic vs. hypothermic). Principal Investigator $50,000","","","$72,171,559.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1988","1989","Grants","Funded","True","True","Co-Investigator","1988-1989 Hoffmann La Roche, Canada. Project: Midazolam and diazemul in cataract surgery. Co-Investigator with Dr. Frances Chung (Principal Investigator) $25,900","","","$39,856,179.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","1987","1988","Grants","Funded","True","True","Co-Investigator","1987-1988 Janssen Pharmaceutica, Canada. Project: Hemodynamic and respiratory functions of sufentanil for short surgical procedure. Co-Investigator with Dr. Frances Chung (Principal Investigator) $8,500","","","$34,104,060.00"
"Martin, Claudio","Medicine","2011/07","2013/06","Grants","Funded","True","False","Co-Applicant","Sepsis Associated Encephalopathy","Douglas Fraser","","$36,892,581.00"
"Joy, Tisha","Medicine","2011","present","Clinical Trials","Funded","False","True","Co-Investigator","A Phase II, Double-Blind Randomized, Placebo-Controlled, Multicenter, Dose-Ranging study to evaluate the tolerability and efficacy of AMG 145 on LDL-C in Combination with HMG-Co A Reductase Inhibitors in Hypercholesterolemia subjects. AMGEN 20101155/TIMI57","Dr. R. Hegele","Dr. T. Joy","$32,111,630.00"
"Joy, Tisha","Medicine","2011","present","Clinical Trials","Funded","False","True","Co-Investigator","A Phase II, Double-Blind Randomized, Placebo-Controlled, Multicenter, Dose-Ranging study to evaluate the tolerability and efficacy of AMG 145 on LDL-C in combination with HMG-Co A Reductase Inhibitors in patients with Heterozygous Familial Hypercholesterolemia. AMGEN 20090158","Dr. Robert Hegele","Dr. Tisha Joy","$70,589,486.00"
"Lavi, Shahar","Medicine","2010/09","present","Clinical Trials","Funded","True","False","Co-Investigator","A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI (TOTAL)","Sanjit Jolly","","$20,115,206.00"
"Lavi, Shahar","Medicine","2011/03","2012","Clinical Trials","Funded","False","True","Principal Site Investigator","VISTA-16 (Vascular Inflammation Suppression to Treat Acute coronary syndrome for 16 weeks)","Stephen Nicholls","","$71,676,950.00"
"Lavi, Shahar","Medicine","2010/10","2012","Clinical Trials","Funded","False","True","Principal Site Investigator","CHI SQUARE- Can HDL Infusions Significantly Quicken Atherosclerosis Regression?","Jean-Claude Tardif","","$45,087,171.00"
"Lavi, Shahar","Medicine","2011/04","present","Clinical Trials","Funded","False","True","Site Investigator","A randomized, double-blind, placebo contolled, parallel group, multinational trial, to assess the prevention of thrombotic events with ticagrelor compared to placebo on background of acetylsalicylic acid therapy in patients with history of myocardial infarction. (PEGASUS TIMI 54)","Eugene Braunwald","","$18,789,278.00"
"Lavi, Shahar","Medicine","2009/04","2010/11","Clinical Trials","Funded","False","True","Site Investigator","APPRAISE-2 (Apixaban for Prevention of Acute Ischemic Events - 2)","John H Alexander","","$54,713,973.00"
"Lavi, Shahar","Medicine","2009/04","2010/11","Clinical Trials","Funded","False","True","Site Investigator","Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)","Edoardo Camenzind","","$40,593,083.00"
"Lavi, Shahar","Medicine","2011/04","2013","Clinical Trials","Funded","False","False","Site Investigator","Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents (VELETI II)","Josep Rodes-Cabau","","$68,620,830.00"
"Lavi, Shahar","Medicine","2011/10","present","","Funded","False","False","Principal Site Investigator","Canadian Observational AntiPlatelet sTudy (COAPT): Description of the Length of Dual Antiplatelet Therapy, Patient Characteristics, Treatment Patterns, and Processes of Care in Canadian Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention","","","$3,058,406.00"
"Lavi, Shahar","Medicine","2012/07","2015/07","Clinical Trials","Funded","True","False","Co-Investigator","A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI (TOTAL).","Sanjit Jolly","","$27,404,809.00"
"Lavi, Shahar","Medicine","2012/07","2014/06","Grants","Funded","True","False","Principal Investigator","Remote Ischemic Postconditioning During Percutaneous Coronary Interventions","Shahar Lavi","","$24,446,297.00"
"Lavi, Shahar","Medicine","2010/07","2011/06","","Funded","False","False","Principal Investigator","Support for investigator initiated research.","","","$4,134,384.00"
"Lavi, Shahar","Medicine","2011/07","2012/06","","Funded","False","False","Principal Investigator","Support for investigator initiated research.","","","$33,614,062.00"
"Kovacs, Michael","Medicine","2009/03","2013/03","Grants","Funded","True","False","Co-Applicant","Recurrent venous Thromboembolism risk stratification evaluation (REVERSE): long term follow-up to define if lifelong anticoagulation is required in high risk patients with a first unprovoked venous thromboembolism","Dr. Marc Rodger","","$11,055,461.00"
"Lazo Langner, Alejandro","Medicine","2009/07","present","Grants","Funded","True","False","Site Investigator","The OVWAC II Study: A Multicentre Study of Low Dose Oral Vitamin K for INR Control in Patients Receiving Warfarin","Mark Crowther","","$15,589,891.00"
"Lazo Langner, Alejandro","Medicine","2009/07","present","Grants","Funded","True","False","Site Investigator","Prospective Evaluation of Long-term Outcomes after Pulmonary Embolism: The ELOPE Study","Susan R Kahn","","$36,123,755.00"
"Lazo Langner, Alejandro","Medicine","2009/07","2010/06","Grants","Funded","True","False","Site Investigator","A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who are at High Risk for Arterial Thromboembolism","Michael Kovacs","","$14,371,742.00"
"Lazo Langner, Alejandro","Medicine","2009/07","2010/06","Grants","Funded","True","False","Site Investigator","REcurrent VEnous thromboembolism Risk Stratification Evaluation (REVERSE): Long Term Follow-up to Define if Lifelong Anticoagulation is Required in High Risk Patients with a First Unprovoked VTE","Marc Rodger","","$65,907,888.00"
"Crilly, Richard","Medicine","2012/02","2013/01","","Funded","True","False","Co-Investigator","Development of Consensus Recommendations and Research Priorities for Osteoporosis Management and Fracture Prevention in Long-Term Care","","Alexandra Papaioannou, JD Adachi, AM Cheung, RG Crilly, L. Giangregorio, S. Jaglal et a.","$51,970,527.00"
"Diachun, Laura","Medicine","2012","2013","Grants","Funded","True","False","Principal Investigator","""Comparing the Characterization of Geriatric Care by Medical Teams at Two Short-Term Inpatient Care Sites""","Diachun L.","","$4,899,942.00"
"Muirhead, Norman","Medicine","2010/07","2012/07","Clinical Trials","Funded","False","True","Principal Investigator","A randomized, open label, cross over study to examine the impact of Prograf and Advagraf on tacrolimus exposure, mycophenolic acid pharmacokinetics, renal allograft function or adverse effects","Dr. Norman Muirhead","Dr. A. House, Dr. A. Jevnikar & Dr. F. Rehman","$2,648,020.00"
"Muirhead, Norman","Medicine","2011/07","2013/07","Grants","Funded","False","False","Co-Investigator","Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A pilot study","Dr. A. House","Dr. N. Muirhead, Dr. A. Jevnikar & Dr. F. Rehman","$5,603,077.00"
"Muirhead, Norman","Medicine","2011/07","2013/07","Grants","Funded","False","False","Co-Investigator","Effect of Immunosuppressive Medication Use on Patient Outcomes Following Kidney Transplantation Failure","Dr. A. House","Dr. N. Muirhead, Dr. A. Jevnikar & Dr. F. Rehman","$28,530,713.00"
"Muirhead, Norman","Medicine","2011/09","2013/01","Clinical Trials","Funded","False","True","Co-Investigator","Randomized Open Label Trial of Oral Sirolimus for Decrease of stenosis in Arteriovenous Fistula in Hemodialysis Patients When Compared with Standard Therapy","Dr. A. Jevnikar","Dr. N. Muirhead, Dr. A. House & Dr. F. Rehman","$12,626,173.00"
"Muirhead, Norman","Medicine","2009/01","","Clinical Trials","Funded","False","True","Co-Investigator","Assessment of Immune Status Using the Cylex Assay as an Adjunct to Study FKC-014","Dr. P. Luke","Dr. N. Muirhead","$14,996,169.00"
"Hramiak, Irene","Medicine","2011/11","2013/12","Clinical Trials","Funded","False","True","Principal Investigator","6-Month, Multi-center, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes with a 6-Month Safety Extension Period.","IM Hramiak","CG McDonald, TL Paul","$39,921,232.00"
"Hramiak, Irene","Medicine","2012/02","2019/12","Clinical Trials","Funded","False","True","Principal Investigator","The Effect of LY2189265 on major Cardiovascular Events in Patients with Type 2 Diabetes: Reducing Cardiovascular Events with a Weekly Incretin in Diabetes.","IM Hramiak","CG McDonald, TL Paul","$38,550,627.00"
"Leasa, David","Medicine","2009/09","2010/08","Grants","Funded","True","False","Collaborator","Improving the Experience of Patients Requiring or at Risk of Long-Term Mechanical Ventilation","ROSE, Louise","FRASER, Ian; GOLDSTEIN, Roger; LEASA, David; MAWDSLEY, Cathy; MCKIM, Douglas","$67,584,699.00"
"Leasa, David","Medicine","2011/10","2012/09","Grants","Funded","True","False","Collaborator","Mechanical ventilator weaning: a knowledge synthesis to guide practice and improve outcome","FRASER, Ian Murray ; ROSE, Louise","BLACKWOOD, Bronagh ; BRYAN, Robert Edward James ; BURNS, Karen Elizabeth Ann ; CHOONG, Karen ; CLARKE, Sean P. ; DAINTY, Katie Naismith ; DIAL, Mary Sandra ; JORDAN, Joanne Elizabeth ; JOUVET, Philippe André ; LEASA, David John ; LEMPHERS, Michael ; MCAULEY, Danny ; MCKIM, Douglas ; NOYES, Jane ; SCHULTZ, Marcus","$4,022,526.00"
"Leasa, David","Medicine","2011/04","2014/04","Grants","Funded","True","False","Collaborator","Understanding Long-Term Mechanical Ventilation in Canada: A Programmatic Approach","DIAL, Mary Sandra ; ROSE, Louise","AMIN, Reshma ; FAN, Eddy ; FOWLER, Robert Allston ; FRASER, Ian Murray ; GOLDSTEIN, Roger S. ; KATZ, Sherri Lynne ; KING, Judith Ann ; LEASA, David John ; MAWDSLEY, Cathy ; MCKIM, Douglas ; NONOYAMA, Mika Laura ; ROAD, Jeremy David ; RUBENFELD, Gordon","$39,018,742.00"
"Leasa, David","Medicine","2009/05","2011/10","Grants","Funded","True","False","Principal Applicant","System of interprofessional care for patients requiring long-term mechanical ventilation","LEASA, David","","$70,698,373.00"
"Goldszmidt, Mark","Medicine","2011/05","2012/09","","Funded","False","False","Principal Applicant","Improving care for complex patients: Influencing the communication practices that shape care teaching perspective","","","$10,381,322.00"
"Lewis, James","Medicine","2012/07","2013/06","Grants","Funded","True","False","Co-Applicant","Imaging pulmonary exacerbations in patients with cystic fibrosis","Grace Parraga","","$8,865,948.00"
"Garg, Amit","Medicine","2010","2015","Grants","Funded","True","False","Co-Investigator","Long-Term Implications Of Becoming A Living Kidney Donor: An International Prospective Study","Boudville, Neil","","$32,793,947.00"
"Garg, Amit","Medicine","2010","2012","Grants","Funded","True","False","Co-Applicant","Economic consequences of living kidney donation in Australia: the donor perspective.","Boudville, Neil","","$11,319,636.00"
"Rehman, Faisal","Medicine","2011/09","2013/01","Grants","Funded","False","True","Co-Investigator","Open label trial of oral sirolimus for decrease of stenosis in arteriovenous fistula in hemodialysis patients when compared with standard therapy:","Jevnikar, A","","$12,050,704.00"
"Rehman, Faisal","Medicine","2011/10","2017/01","Grants","Funded","True","False","Co-Investigator","Effect of immunosuppressive medication use on patient outcomes following kidney transplantation”. (66,500). Oct.2011-Jan.2017 (Co-investigator) Peer reviewed.","House, A","","$33,211,373.00"
"Rehman, Faisal","Medicine","2010","2015","Clinical Trials","Funded","False","True","Co-Investigator","A multicenter, randomized, double-blind, placebo controlled phase IV trial to evaluate the effect of Saxagliptin on the incidence of cardiovascular death, myocardial infarction or ischaemic stroke in patients with Type 2 Diabetes.","Muirhead, N","House, A; Johnson, J; Rehman, F","$5,855,851.00"
"Rehman, Faisal","Medicine","2010","2012","Clinical Trials","Funded","False","True","Co-Investigator","A randomized, open-label, cross over study to examine the impact of Prograf and Advagraf on tacrolimus exposure, mycophenolate acid pharmacokinetics, renal allograft function of adverse effects.","Muirhead, N","House, A; Johnson, J; Rehman, F","$13,267,161.00"
"Rehman, Faisal","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Co-Investigator","Assessment of immune status using the cylex assay as an adjunct to study FKC-014.","Luke, P","","$46,454,780.00"
"Rehman, Faisal","Medicine","2008","2009","Grants","Funded","False","True","Co-Investigator","Surveillance for CMV disease – A comparison of two different molecular amplification assays.","Rehman, F","","$10,934,107.00"
"Rehman, Faisal","Medicine","2008/10","2010/10","Grants","Funded","False","True","Co-Investigator","Randomized, open-label 2-arm parallel design comparator study of the effect of Adalat® XL® compared to diltiazem (Tiazac® XC) on proteinuria and blood pressure in patients with diabetes and mild to moderate hypertension, when used as an add-on to Avalide® (angiotensin-receptor blocker (ARB) irbesartan and hydrochlorothiazide).","House, A","","$37,535,262.00"
"Rehman, Faisal","Medicine","2008","2010","Grants","Funded","False","True","Co-Investigator","Observational Study of Late Post Renal Transplant Anemia and Secondary Hyperparathyroidism.","Muirhead, N","","$58,702,176.00"
"Rehman, Faisal","Medicine","2007","2010","Clinical Trials","Funded","False","True","Co-Investigator","Outcome trial evaluating the efficacy and safety of Norditropin in adult patients on chronic haemodialysis. A randomized, double-blind, parallel group, placebo controlled, multi-centre trial” ($57,900) 2007-2010","Muirhead, N","","$61,796,074.00"
"Rehman, Faisal","Medicine","2011","2013","Grants","Funded","True","False","Co-Investigator","Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: a pilot study","House, A","","$48,651,601.00"
"Diachun, Laura","Medicine","2012/01","2013/01","Grants","Funded","True","False","Research Supervisor","Yin Hui, summer student: Research project ""Teaching and Learning Elder Care: How is the ""Older Patient"" Presented to Medical Students by Geriatric and Non-Specialist Clinical Teachers"".","Laura Diachun","","$67,551,018.00"
"Montero Odasso, Manuel","Medicine","2011/06","2013/01","Grants","Funded","True","False","Principal Investigator","A Simple and New Approach for Sub-categorization of Mild Cognitive Impairment.","Manuel Montero-Odasso","Michael Borrie, Karen Gopaul, Susan Muir","$24,754,318.00"
"Lavi, Shahar","Medicine","2012/09","2014/09","Grants","Funded","True","True","Principal Investigator","Effect of Ticagrelor on endothelial dysfunction.","Shahar Lavi","","$49,870,739.00"
"Louzada, Martha de Lacerda","Medicine","2011/01","2021/01","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma.","Dr. Len Minuk","","$66,739,545.00"
"Louzada, Martha de Lacerda","Medicine","2011/01","2021/01","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in combination with Low-dose Dexamethasone Versus High-Dose Dexamethasone in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma.","Dr. Len Minuk","","$15,005,451.00"
"Garg, Amit","Medicine","2011/06","2014/05","","Funded","True","False","Co-Investigator","Canadian Kidney Knowledge Translation and Generation Network","Manns, Braden","","$73,173,246.00"
"Garg, Amit","Medicine","2011/04","2014/03","","Funded","True","False","Principal Investigator","Curcumin to prevent perioperative complications from elective abdominal aortic aneurysm repair","Garg, Amit","","$16,781,510.00"
"Skanes, Allan","Medicine","2011/10","2016","Grants","Funded","True","False","Co-Applicant","Advanced techniques for image assisted cardiac investigations","Maria Drangova","","$38,506,721.00"
"Skanes, Allan","Medicine","2008/04","2013","Grants","Funded","True","False","Co-Applicant","Imaging for cardiovascular therapeutics","Maria Drangova","","$64,002,399.00"
"Skanes, Allan","Medicine","2005/04","2009","Grants","Funded","True","False","Co-Applicant","Interventional Cardiovascular MRI","Maria Drangova","","$28,723,328.00"
"Yee, Raymond","Medicine","2011/10","2016","Grants","Funded","True","False","Co-Applicant","Advanced techniques for image assisted cardiac investigations","Maria Drangova","","$74,621,030.00"
"Yee, Raymond","Medicine","2008/04","2013","Grants","Funded","True","False","Co-Applicant","Imaging for cardiovascular therapeutics","Maria Drangova","","$51,550,802.00"
"Yee, Raymond","Medicine","2005/04","2009","Grants","Funded","True","False","Co-Applicant","Interventional Cardiovascular MRI","Maria Drangova","","$62,610,290.00"
"Skanes, Allan","Medicine","2010/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Atrial Fibrillation Program Database","Lorne Gula","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$15,062,888.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2012","2013","Grants","Funded","True","False","Co-Investigator","2012 - 2013 AHSC AFP Innovation Fund Integrating Vision Care into the MEDICI Framework (Medical Evidence, Decision Integrity and Clinical Impact Co-Investigator (Dr. Janet Martin) Principal Investigator (Dr. William Hodge) $181, 281","","","$35,367,652.00"
"House, Andrew","Medicine","2012/07","2017/06","","Funded","True","False","Principal Site Investigator","Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study","AA House","","$23,911,272.00"
"House, Andrew","Medicine","2011/07","2013/06","","Funded","False","True","Co-Investigator","Randomized Open label trial of Oral Sirolimus for decrease of stenosis in Arteriovenous fistula in hemodialysis patients when compared with standard therapy","A Jevnikar","","$24,408,012.00"
"Johnson, John","Medicine","2011","2013","","Funded","False","True","Co-Investigator","Randomized Open label trial of Oral Sirolimus for decrease of stenosis in Arteriovenous fistula in hemodialysis patients when compared with standard therapy","A Jevnikar","","$54,728,781.00"
"Huff, Murray","Medicine","2012/07","2015/06","Grants","Funded","True","False","Principal Investigator","Regulation of intestinal lipoprotein overproduction in insulin resistant states by citrus flavonoids.","Huff MW","","$72,744,431.00"
"Hegele, Robert","Medicine","2012/07","2015/06","Grants","Funded","True","False","Principal Investigator","Phenomics of monogenic cardiometabolic syndrome","Robert A. Hegele","","$74,200,645.00"
"Garg, Amit","Medicine","2011/10","2012/09","Grants","Funded","True","False","Co-Principal Investigator","Beta blockers, dialyzability and outcomes","Weir, Matthew (Nominated PI)","","$60,446,440.00"
"Garg, Amit","Medicine","2011/10","2012/09","Grants","Funded","True","False","Co-Investigator","Randomized Controlled Trial of Bimodal Solution for Peritoneal Dialysis: 24-Hour Ultra-Filtration Efficiency Using Bimodal PD Solutions During the Long Dwell","Jain, Arsh","","$42,621,942.00"
"McDonald, Charlotte","Medicine","2012/06","present","Clinical Trials","Funded","True","False","Principal Site Investigator","A Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Gluten-Free Diet in Patients with Asymptomatic Celiac Disease and Type 1 Diabetes Celiac disease and Diabetes - Dietary Intervention and Evaluation Trial (CD-DIET)","Dr. Farid Mahmud","Dr. Patricia Gallego","$59,962,193.00"
"Myers, Kathryn","Medicine","2012/07","2014/06","Grants","Funded","True","False","Principal Investigator","Faculty perceptions of their clinical teaching assessments by residents","Kathryn Myers","Elaine Zibrowski","$32,682,970.00"
"Mrkobrada, Marko","Medicine","2012","2013","Clinical Trials","Funded","True","False","Co-Investigator","Preoperative Medications and Acute Kidney Injury: A VISION sub-study","AX Garg","","$70,727,098.00"
"Mrkobrada, Marko","Medicine","2011/01","2012/01","Grants","Funded","True","False","Co-Principal Investigator","Pilot Study: NeuroVISION: Covert Stroke After Noncardiac SurgeryPASS: Peri-Operative Inhibition of the Angiotensin System Study","Marko Mrkobrada","","$25,787,045.00"
"Mrkobrada, Marko","Medicine","2011","2013","Clinical Trials","Funded","True","False","Co-Investigator","POISE-2: Perioperative Ischemic Evaluation Trial - 2","PJ Devereaux","","$19,366,184.00"
"Adams, Paul","Medicine","2011/09","2014/08","Grants","Funded","True","False","Co-Principal Investigator","Genetic modifiers of hemochromatosis disease expression in HFE C282Y homozygotes","Christine McLaren, UC Irvine","Gordon McLaren, Jim Barton, Prad Phatak, Nathan Subramaniam, Lyle Gurrin, Chad Garner","$66,450,324.00"
"Moist, Louise","Medicine","2011/01","2013/01","","Funded","False","True","Co-Investigator","Randomized Open label trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemodialysis Patients when Compared with Standard Therapy","","","$50,295,075.00"
"Feagan, Brian","Medicine","2010/02","2012/06","Clinical Trials","Funded","False","True","Principal Investigator","a Double-blind, double-dummy, placebo-controlled dose escalation study to evaluate the safety, tolerability and pharmacokinetics and anti-inflammatory effects of GSK 1399686 in patients with mild to moderate active ulcerative colitis","","","$21,926,336.00"
"Feagan, Brian","Medicine","2009/03","2011/03","Clinical Trials","Funded","False","True","Principal Investigator","Phase 2/3 multi-centre, randomized, placebo-controlled, double-blind, study to evaluate the safety and efficacy of Golimumab induction therapy, administered subcutaneously in subjects with moderately to severely active ulcerative colitis","","","$5,643,294.00"
"Feagan, Brian","Medicine","2011/12","2013/12","Clinical Trials","Funded","False","False","Site Investigator","A multi-country Psychometric Validation of a Newly Developed Questionnaire: to assess the satisfaction with treatment of patients with severe active Crohn's disease.","","","$39,768,924.00"
"Feagan, Brian","Medicine","2008/07","2013/06","Clinical Trials","Funded","False","True","Site Investigator","A long-term, non-interventional Registry: to assess safety and effectiveness of Humira (Adalimumab) in subjects with moderately to severely active Crohn's disease","","","$58,465,187.00"
"Feagan, Brian","Medicine","2011/07","2013/07","Clinical Trials","Funded","False","True","Principal Investigator","A Double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of PF-04236921 in subjects with Crohn's Disease who are anti-TNF inadequate responders.","","","$57,942,923.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Principal Investigator","A multicentre open-label extension study for subjects who participated in Study B0151003","","","$58,537,686.00"
"Feagan, Brian","Medicine","2011/07","2013/07","Clinical Trials","Funded","False","True","Site Investigator","A phase IIa, randomized, double-blind, sponsor unblinded, placebo-controlled, parallel, multiple dose study to evaluate the pharmacodynamics, pharmacokinetics and safety of Anrukinzumab in patients with active ulcerative colitis","","","$63,750,189.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Principal Investigator","An open-label, multicentre study to evaluate the impact of Adalimumab on quality of life, healthcare utilization and costs of ulcerative colitis subjects in the usual clinical practice setting","","","$73,701,146.00"
"Feagan, Brian","Medicine","2011/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A prospective, multicentre, randomized, double-blind, placebo-controlled, trial to compare REMICADE (infliximab) and placebo to the prevention of recurrence in Crohn's disease patients undergoing surgical resection who are at an increased risk of recurrence","","","$11,010,411.00"
"Feagan, Brian","Medicine","2011/07","2013/07","Clinical Trials","Funded","False","False","Site Investigator","A randomized, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNCO142-0000-0002 in subjects with moderately to severely active Crohn's disease.","","","$18,084,072.00"
"Feagan, Brian","Medicine","2008/07","2012/06","Clinical Trials","Funded","False","True","Site Investigator","A phase III, multicentre, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of Golimumab maintenance therapy administered subcutaneously in subjects with moderately to severely active ulcerative colitis","","","$26,257,367.00"
"Feagan, Brian","Medicine","2011/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A phase II, randomzied, double-blind, placeo-controlled study to evaluate the efficacy and safety of rhuMab Beta 7 in patients with moderate to severe ulcerative colitis","","","$61,681,597.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A phase III, randomized, double-blind, placebo-controlled parallel-group, multicentre study to evaluate the safety and efficacy of Ustekinumab induction therapy in subjects with moderately to severely active Crohn's disease who have failed or are intolerant of TNF antagonist therapy","","","$44,054,868.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of Ustekinumab induction therapy in subjects with moderately to severely active Crohn's disease","","","$27,074,531.00"
"Feagan, Brian","Medicine","2012/07","2016/07","Clinical Trials","Funded","False","True","Site Investigator","A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of Ustekinumab maintenance therapy in subjects with moderately to severely active Crohn's disease","","","$34,167,933.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A phase 2b, double-blind, randomized, placebo-controlled, double-dummy, dose ranging study to evaluate the clinical efficacy and safety of induction and maintenance therapy with BMS-945429 in subjects with moderate to severe Crohn's disease","","","$63,274,084.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A randomized, double-blind, multiple dose placebo controlled study to evaluate the safety, tolerability and efficacy of AMG 181 in subjects with moderate to severe Ulcerative Colitis","","","$38,997,114.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral CP-690, 550 as an induction therapy in subjects with moderate to severe ulcerative colitis","","","$47,715,813.00"
"Feagan, Brian","Medicine","2008/03","2010/04","Grants","Funded","False","False","Co-Applicant","Promoting Adherence to Regimen of Risk Factor Modifications by Trained Non-Medical Personnel (Volunteers) Evaluated Against Regular Practice Study","","","$50,600,840.00"
"Feagan, Brian","Medicine","2005/10","2010/09","Grants","Funded","False","False","Co-Applicant","Knowledge Synthesis and Translation by the Cochrane Collaboration in Canada","","","$35,222,145.00"
"Feagan, Brian","Medicine","2010/10","2015/09","Grants","Funded","False","False","Co-Applicant","Knowledge Synthesis and Translation by the Cochrane Collaboration in Canada","Dr. Brian Feagan","","$74,805,722.00"
"Feagan, Brian","Medicine","2009/04","2011/03","Grants","Funded","False","False","Co-Applicant","Effect of Lowering the Dialysate Sodum on Ambulatory Blood Pressure in Hemodialysis Patients: A Blinded Randomized Controlled Trial","","","$43,458,682.00"
"Feagan, Brian","Medicine","2010/07","2012/07","Grants","Funded","False","False","Principal Applicant","Oral Methotrexate for the Treatment of Crohn's disease (Bridge Funding)","","","$52,022,651.00"
"Feagan, Brian","Medicine","2010/07","2012/07","Grants","Funded","False","False","Principal Applicant","Oral Methotrexate for the Treatment of Crohn's Disease","","","$37,179,611.00"
"Feagan, Brian","Medicine","2009/07","2012/06","Grants","Funded","False","False","Director, Coordinating Centre","Canadian Type 1 Diabetes Clinical Trial Network","","","$55,304,693.00"
"Montero Odasso, Manuel","Medicine","2012/04","2017/03","Grants","Funded","True","False","Principal Investigator","Ontario Early Researcher Award: A Novel Approach to Understand Cognitive Decline and Risk of Falls in Older Ontarians","Manuel Montero-Odasso","","$58,454,720.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-04236921 in Subjects with Crohn's Disease who are Anti-TNF Inadequate Responders (ANDANTE)","","","$42,069,621.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Multicenter Open-Label Extension Study for Subjects who Participated in Study B0151003 (ANDANTE II)","","","$19,803,314.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 2A, Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, Parallel, Multiple Dose Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Anrukinzumab in Patients with Active Ulcerative Colitis","","","$38,378,813.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Principal Investigator","A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK 1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohn's Disease","","","$3,907,009.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Principal Investigator","A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn's Disease-","","","$7,060,845.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Principal Investigator","An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn's Disease","","","$34,064,444.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","Vision: Multi-country Psychometric validation of a newly developed questionnaire assessing the satisfaction with treatment of patients with severe active Crohn's disease","","","$32,666,248.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, multi-center Study to Investigate the Safety and Efficacy of Multistem (PF-05285401) in Subjects with Moderate to Severe Ulcerative Colitis","","","$55,132,195.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","An Open Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting – INSPIRE","","","$59,505,235.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase IIb Randomized, Placebo Controlled Study to evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in subjects with Active Ulcerative Colitis","","","$28,278,966.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","UNITI-1 A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicentre study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy","","","$43,304,089.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","UNITI-2 A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicentre study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to severely Active Crohn’s Disease","","","$29,221,689.00"
"Barnett, William","Medicine","2011","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohn’s Disease (IMUNITI) -","","","$72,188,518.00"
"Barnett, William","Medicine","2010","present","Clinical Trials","Funded","False","False","Sub-Investigator","PREVENT - Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence","","","$1,082,661.00"
"Barnett, William","Medicine","2009","2010","Clinical Trials","Funded","False","False","Sub-Investigator","A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Therapeutic Activity of ORE1001 in Subjects with Ulcerative Colitis","","","$55,568,232.00"
"Barnett, William","Medicine","2009","2010","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis","","","$7,684,615.00"
"Barnett, William","Medicine","2009","2011","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 3, Randomized, Placebo-controlled, Blinded, Multicentre Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis","","","$15,040,049.00"
"Barnett, William","Medicine","2009","2011/04","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 3, Randomized, Placebo-controlled, Blinded, Multicentre Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn's Disease","","","$903,459.00"
"Barnett, William","Medicine","2009","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 3, Open-Label Study to determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease","","","$64,173,563.00"
"Barnett, William","Medicine","2009","2010","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn's Disease Previously Treated with TNF Antagonist Therapy (CERTIFI)","","","$48,597,428.00"
"Barnett, William","Medicine","2008","2009","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Mulit-Center Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderately Active Ulcerative Colitis","","","$31,443,507.00"
"Barnett, William","Medicine","2008","2011","Clinical Trials","Funded","False","False","Principal Investigator","A Phase 2, Multiple-Dose, Open-label Study to Determine the Long Term Safety of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease","","","$31,221,814.00"
"Barnett, William","Medicine","2008","2010","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase IIB, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease","","","$7,597,882.00"
"Barnett, William","Medicine","2008","2010","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase IIIb, Multinational, Randomized, double-blind, placebo controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn's disease","","","$2,504,740.00"
"Barnett, William","Medicine","2008","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase IIIb, Multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn's disease who have participated in study C87085","","","$32,226,949.00"
"Barnett, William","Medicine","2008","2010","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta7 Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients with Ulcerative Colitis - ABS4262g","","","$24,990,984.00"
"Barnett, William","Medicine","2008","present","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis","","","$65,724,243.00"
"Barnett, William","Medicine","2008","2010","Clinical Trials","Funded","False","False","Sub-Investigator","A multicenter, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to assess the efficacy, safety and tolerability of two single IV infusions of AIN457 10mg/kg (anti IL-17 monoclonal antibody) in patients with moderate to severe active Crohn's disease.","","","$37,411,638.00"
"Barnett, William","Medicine","2008","present","Clinical Trials","Funded","False","False","Sub-Investigator","Crohn's and Colitis Foundation of Canada Inflammatory Bowel Disease GEM (Genetic, Environmental, and Microbiological Factors in IBD) Project","","","$42,660,518.00"
"Barnett, William","Medicine","2008","2009","Clinical Trials","Funded","False","False","Sub-Investigator","A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately to Severely Active Ulcerative Colitis - PURSUIT","","","$51,978,134.00"
"Barnett, William","Medicine","2007","2010","Clinical Trials","Funded","False","False","Sub-Investigator","(ABS4261g) Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects","","","$66,721,495.00"
"Barnett, William","Medicine","2006","2009","Clinical Trials","Funded","False","False","Sub-Investigator","Certolizumab in Crohn’s Disease","","","$12,314,304.00"
"Barnett, William","Medicine","2005","2008","Clinical Trials","Funded","False","False","Principal Investigator","Adacolumn in Crohn’s Disease","","","$39,298,336.00"
"Barnett, William","Medicine","2005","2008","Clinical Trials","Funded","False","False","Sub-Investigator","Azathioprine in Crohn’s Disease","","","$27,809,838.00"
"Barnett, William","Medicine","2005","2007","Clinical Trials","Funded","False","False","Sub-Investigator","Visilizumab in Ulcerative Colitis","","","$30,373,594.00"
"Barnett, William","Medicine","2005","2007","Clinical Trials","Funded","False","False","Sub-Investigator","COMMIT (Infliximab with Methotrexate/Placebo)","","","$70,026,278.00"
"Barnett, William","Medicine","2005","2006","Clinical Trials","Funded","False","False","Sub-Investigator","VSL#3 (Probiotic) in Crohn’s Disease","","","$70,247,965.00"
"Barnett, William","Medicine","2005","2006","Clinical Trials","Funded","False","False","Sub-Investigator","Anti-IL12/23 in Crohn’s Disease","","","$39,749,974.00"
"Barnett, William","Medicine","2004","2007","Clinical Trials","Funded","False","False","Sub-Investigator","OPC6535 in Ulcerative Colitis","","","$33,533,092.00"
"Barnett, William","Medicine","2004","2006","Clinical Trials","Funded","False","False","Sub-Investigator","Berlex (Sargramostim) in Crohn’s Disease","","","$73,550,985.00"
"Barnett, William","Medicine","2004","2005/01","Clinical Trials","Funded","False","False","Sub-Investigator","Anti IL-12 in Crohn’s Disease","","","$29,337,476.00"
"Barnett, William","Medicine","2002","2008","Clinical Trials","Funded","False","False","Sub-Investigator","Adalimumab in Crohn’s Disease","","","$57,488,933.00"
"Barnett, William","Medicine","2002","2004","Clinical Trials","Funded","False","False","Sub-Investigator","Infliximab in Ulcerative Colitis","","","$16,580,192.00"
"Barnett, William","Medicine","2002","2004","Clinical Trials","Funded","False","False","Sub-Investigator","Daclizumab in Ulcerative Colitis","","","$1,639,920.00"
"Barnett, William","Medicine","2001","2006","Clinical Trials","Funded","False","False","Sub-Investigator","EPIC-2 (Epanova) Omega 3 Fatty Acids","","","$444,743.00"
"Barnett, William","Medicine","2001","2004","Clinical Trials","Funded","False","False","Sub-Investigator","Huzaf in Crohn’s Disease","","","$23,719,044.00"
"Barnett, William","Medicine","2001","2003","Clinical Trials","Funded","False","False","Sub-Investigator","BIRB in Crohn’s Disease","","","$63,785,823.00"
"Barnett, William","Medicine","2000","2002","Clinical Trials","Funded","False","False","Sub-Investigator","CDP 870 in Crohn’s Disease","","","$66,978,036.00"
"Barnett, William","Medicine","1999","2002","Clinical Trials","Funded","False","False","Sub-Investigator","LDP02 in Crohn’s Disease and Ulcerative Colitis","","","$65,446,970.00"
"Barnett, William","Medicine","1999","2002","Clinical Trials","Funded","False","False","Sub-Investigator","Accent I and Accent II in Crohn’s Disease","","","$17,343,668.00"
"Blake, Peter","Medicine","2011/01","2013/03","","Funded","False","False","Collaborator","Acute kidney injury from antiviral drugs for herpes infections: A population-based study of older adults.","","","$54,889,806.00"
"Yan, Brian","Medicine","2003/06","2006/06","Grants","Funded","True","False","Co-Principal Investigator","Preliminary Study on the effect of Inflixmab on bone turnover in Crohns Disease","Brian Yan and Harold Preiksaitis","Brian Yan, Lisanne Laurier, Harold Preiksaitis","$46,914,729.00"
"Yan, Brian","Medicine","2005/07","2006/06","Grants","Funded","True","False","Co-Principal Investigator","Epidemiology of Gastrointestinal stroma tumors (GIST) in the Calgary Health Region: a population based study","Brian Yan, Paul Beck","Brian Yan, Gil Kaplan, Carla Nash, Stephan Urbanski, Paul Beck","$24,908,965.00"
"Yan, Brian","Medicine","2006/11","2007/10","* Clinical Fellowship","Funded","True","False","Collaborator","Phase I/II Trial of Combined Intratumoral Injection of Dendritic Cell Immunotherapy with Chemoradiation Therapy in Patients with Unresectable Pancreatic Cancer","George Fisher","brian Yan, Jacques Van Dam, George Fisher, Edgar Engleman, Timothy Kuo, Wenru Song, Albert Koong, Karyn Goodman, Joan Frisoli, Claudia Benike, Yaso Natkunam, Kevin Sheehan,","$25,233,080.00"
"Yan, Brian","Medicine","2006/11","2007/10","* Clinical Fellowship","Funded","False","True","Co-Applicant","Phase I/II Trial of Combined Intratumoral Injection of dendritic cell immunotherapy with chemoradiation therapy in patients with unresectable pancreatic cancer","Jacques Van Dam","Brian Yan, Jacques Van Dam","$69,469,546.00"
"Yan, Brian","Medicine","2012/07","","Grants","Funded","False","False","Principal Investigator","EUS Guided Ethanol with Paclitaxel Ablation for Pancratic Mucinous Cystic Neoplasms.","Brian Yan","Nadeem Hussain, Zahra Kassam, Aaron Haig, Roberto Hernandez-Alejandro, Vivian McAlister, Ken Leslie","$35,319,446.00"
"Minuk, Leonard","Medicine","2012/06","present","Grants","Funded","True","False","Co-Principal Investigator","The Prevelance and Management of Cardiovascular Disease in Older Patients with Hemophelia - A Multicenter Retrospective Cohort Study.","Dr. L. Minuk and Dr. M. Louzada","","$55,365,189.00"
"Taabazuing, Mary-Margaret","Medicine","2011/01","present","* Research","Funded","False","False","Principal Site Investigator","CAHO ARTIC MOVE ON Project","LHSC Site Lead - Dr. Margaret Taabazuing","Dr. M. Dasgupta","$736,167.00"
"Ponich, Terry","Medicine","2010","present","","Funded","True","False","Co-Applicant","Novel Approaches to Assess Epigenetic and Genetic Changes Associated with Human Pancreatic Disease.","Dr. Chris Pin","","$38,063,931.00"
"Ponich, Terry","Medicine","2008","2013","Grants","Funded","True","False","Collaborator","Signaling Networks in Pancreatic Disease.","Dr. Chris Pin","","$2,836,602.00"
"Ponich, Terry","Medicine","2012","","","Applied","True","False","Co-Applicant","A Novel Mouse Model to Identify Early Events in Pancreatic Ductal Adenocarcinoma.","Dr. Chris Pin","","$59,700,618.00"
"Lavi, Shahar","Medicine","2012/07","2013/06","","Funded","False","False","Principal Investigator","Support for investigator initiated research.","","","$34,931,817.00"
"Crilly, Richard","Medicine","1994/07","1995/06","Grants","Funded","True","False","Co-Principal Investigator","Validity, Reliability and Feasibility Testing of the Leisure Competence Measure: Phase II","","","$34,469,125.00"
"Yamashita, Cory","Medicine","2012/07","2014/06","Grants","Funded","True","False","Co-Applicant","The Role of Hypercholesterolemia in Susceptibility to Acute Lung Injury","Dr. Cory Yamashita","","$52,017,072.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2006","2009","Grants","Funded","True","False","Principal Investigator","2006-2009 Academic Medical Organization of Southwestern Ontario (AMOSO). Project: Anesthesia and Clinical Pharmacology Academic Joint Recruitment Fund – Dr. Craig Railton $120,000, Funded","","","$47,784,231.00"
"Mehta, Sanjay","Medicine","2012","2013","Grants","Funded","True","False","Co-Investigator","TIMP3 Regulates Macrophage Function Following Acute Lung Injury","S Gill","","$39,414,621.00"
"Mehta, Sanjay","Medicine","2012","2013","Grants","Funded","True","False","Co-Investigator","Endothelial dysfunction/injury in murine sepsis is mediated through TIMP3","S Gill","","$13,107,997.00"
"Mehta, Sanjay","Medicine","2012","2014","Grants","Funded","True","False","Co-Investigator","Mechanisms Of Neutrophil-Induced Murine Septic Lung Injury","R Taneja","S Gill (Co-I)","$9,384,299.00"
"Mehta, Sanjay","Medicine","2012","2013","Clinical Trials","Funded","False","True","Principal Investigator","Clinical Importance and Treatment of COPD-Associated Pulmonary Hypertension","S Mehta","","$7,451,356.00"
"Shepherd, Lisa","Medicine","2012/09","2013/08","Grants","Funded","True","False","Principal Applicant","Improving the Emergency Medicine Clinical Clerkship: Impact on the Medical Student, the Emergency Physician and Emergency Department patient flow.","Lisa Shepherd","Christine Richardson, Marilyn Innes, Lorelei Lingard, Elaine Zibrowski","$61,186,569.00"
"Borrie, Michael","Medicine","2012/08","2012/12","Clinical Trials","Funded","False","True","Principal Investigator","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease.","Michael Borrie","","$14,106,571.00"
"Moist, Louise","Medicine","2012/07","2014/06","Grants","Funded","True","False","Co-Investigator","Hemodialysis infection prevention with polysporin triple ointment versus shower technique in satellite centres (HIPPOS-SAT)","Dr. Charmaine Lok","","$1,237,463.00"
"Moist, Louise","Medicine","2008/12","2015/12","Grants","Funded","False","False","Collaborator","CanPREDDICT study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular events over time","Dr. Adeera Levin","","$17,114,378.00"
"Moist, Louise","Medicine","2008/12","2015/12","Grants","Funded","True","False","Collaborator","Bioimpediance as a Predictor of Cardiovascular Outcomes in Subjects with Chronic Kidney Disease","Dr. Catherine Clase","","$22,515,061.00"
"Garg, Amit","Medicine","2012/10","2017/09","Grants","Funded","True","False","Co-Principal Investigator","ICES Kidney, Dialysis and Transplantation Program","Garg, Amit (Nominated PI)","","$64,706,307.00"
"Garg, Amit","Medicine","2012/04","2013/03","","Funded","True","False","Principal Investigator","Comparing PubMed and Google Scholar on evidence retrieval","Garg, Amit","","$14,130,288.00"
"Garg, Amit","Medicine","2013/04","2015/03","Grants","Funded","True","False","Co-Investigator","Predicting the need for community care for chronic kidney disease following hospitilization with acute kidney injury","James, Matthew","","$73,212,509.00"
"Garg, Amit","Medicine","2013/04","2019/03","Grants","Funded","True","False","Principal Investigator","Safety and outcomes of accepting hypertensive individuals as living kidney donors","Garg, Amit","","$60,120,635.00"
"Jain, Arsh","Medicine","2012/10","2017/09","Grants","Funded","True","False","Co-Principal Investigator","ICES Kidney, DIalysis and Transplantation Program","Garg, Amit","","$9,258,082.00"
"House, Andrew","Medicine","2012/07","2014/06","","Funded","False","True","Co-Investigator","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study of the Efficacy and Safety of Once-Daily Phosphodiesterase 5 Inhibitor (PF-00489791) in Adults with Type 2 Diabetes and Overt Nephropathy","N Muirhead","","$55,939,854.00"
"House, Andrew","Medicine","2012/07","2015/06","","Funded","False","True","Co-Investigator","Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study (TEMPO)","N Muirhead","","$12,782,051.00"
"House, Andrew","Medicine","2012/07","2014/06","","Funded","False","True","Co-Investigator","A Prospective, Observational, Randomized Comparative Study of Case Managed Versus Non-Case Managed Initiation of Hemodialysis","N Muirhead","","$29,713,006.00"
"Mehta, Sanjay","Medicine","2013/01","2015/01","Clinical Trials","Funded","False","True","Principal Investigator","A Phase 2, Placebo Controlled, Doubleblind, Randomized, Clinical Study To Determine Safety, Tolerability And Efficacy Of Pulsed, Inhaled Nitric Oxide (Ino) Versus Placebo As Add-On Therapy In Symptomatic Subjects With PAH","S Mehta","","$19,188,115.00"
"Mehta, Sanjay","Medicine","2012","2015","Grants","Funded","True","False","Co-Investigator","Randomized, double-blind, placebo-controlled, multi-center, proof of concept study to evaluate the effect of sildenafil citrate (Revatio) 20 mg TID on hemodynamics in patients with Portal- Pulmonary Arterial Hypertension (PPAH) (RePo1 trial)","","","$73,968,000.00"
"Lindsay, Robert","Medicine","2012/01","2014/12","Grants","Funded","True","False","Principal Applicant","Use of cardiac imaging modalities to reduce sudden cardiac death in hemodialysis pateitns","Benjamin Thompson","Robert Lindsay","$25,409,026.00"
"Lindsay, Robert","Medicine","2013/01","2014/01","Grants","Funded","True","False","Co-Applicant","Cystatin C as a marker in dialysis","Dr. Shi-Han (Susan) Huang","Robert Lindsay","$70,032,562.00"
"Lindsay, Robert","Medicine","2009/07","2010/06","Grants","Funded","True","False","Co-Investigator","Predicting mortality, technique survival and training failure for a Canadian multicentre home hemodialysis cohort","Robert Pauly","","$61,612,878.00"
"Pope, Janet","Medicine","2012/06","2013/06","Grants","Funded","True","False","Principal Applicant","Scleroderma and Lupus Research","","","$38,144,462.00"
"Pope, Janet","Medicine","2012/01","2014/01","Clinical Trials","Funded","False","True","Site Investigator","A phase II/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis – WA27788","","","$31,972,325.00"
"Pope, Janet","Medicine","2012/01","2014/01","Clinical Trials","Funded","False","True","Site Investigator","A phase II/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis – WA27788 Open Label Extension","","","$47,595,851.00"
"Pope, Janet","Medicine","2011/05","2013/05","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4) – SL0012","","","$2,569,857.00"
"Pope, Janet","Medicine","2011/12","2013/12","Clinical Trials","Funded","False","False","Site Investigator","Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety, and tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis. – AC-055C301","","","$28,811,271.00"
"Lewis, James","Medicine","2012/12","2014/12","Grants","Funded","True","False","Co-Applicant","Imaging pulmonary exacerbations of cystic fibrosis","Grace Parraga","","$66,748,255.00"
"Lindsay, Robert","Medicine","2012/01","2012/12","Grants","Funded","True","False","Principal Investigator","Cystatin C as a marker for dialysis adequacy","Dr. Susan Huang","","$8,063,999.00"
"Lindsay, Robert","Medicine","2011/07","2013/07","Clinical Trials","Funded","True","False","Co-Investigator","Relationship between skeletal muscle strength and size in people with end-stage renal disease on haemodialysis","Dr. Tom Overend","","$73,232,256.00"
"Lindsay, Robert","Medicine","2009/07","2011/06","Grants","Funded","False","False","Principal Applicant","Cystatin C as a marker for dialysis marker","Dr. Susan Huang","","$28,749,774.00"
"Siu, Samuel","Medicine","2011/04","2016/03","Grants","Funded","True","False","Program Leader","Pregnancy and subsequent cardiovascular risk in women with heart disease","Dr. Samuel Siu, Dr. Candice Silversides","","$61,967,435.00"
"Spaic, Tamara","Medicine","2012/04","2016/12","Grants","Funded","True","False","Co-Principal Investigator","Multicenter Randomized Controlled Trial of Structured Transition on Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults with Type 1 Diabetes","Dr Cheril Clarson and Dr. Tamara Spaic","Dr Irene Hramiak Dr Jeffrey Mahon","$2,798,083.00"
"Boughner, Derek","Medicine","2012/06","2014/07","Grants","Funded","True","False","Principal Applicant","POEM","D. Boughner","","$45,965,463.00"
"Chin-Yee, Ian","Medicine","2010/07","2015/07","Grants","Funded","False","False","Co-Investigator","A National Multicenter Study, Appropriateness of Frozen Plasma Use in Canada","Cyrus Hsia","","$12,273,628.00"
"Chin-Yee, Ian","Medicine","2011/07","2021/06","Clinical Trials","Funded","False","False","Co-Investigator","A phase 3, Multicenter Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma.","Len Minuk","","$57,029,164.00"
"Chin-Yee, Ian","Medicine","2011/07","2021/06","Clinical Trials","Funded","False","False","Co-Investigator","A Phase 3 Randomized OPen Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma.","Len Minuk","","$39,553,835.00"
"Borrie, Michael","Medicine","2012/10","2014/02","Grants","Funded","True","False","Co-Investigator","Lewy Body Spectrum Disorders: A Pharmacogenomic Study of Cholinesterase Inhibitors Investigating Cognitive Benefit, Motor Worsening, and Brain Imaging","Borrie, MJ","Lewy Body Spectrum Disorders Collaborative Research Group (Masellis M, Caldwell C, Finger E, Warrington J, Bartha R, Stodilka R, Pasternak S, Wells J, Gill D.)","$56,902,715.00"
"Lewis, James","Medicine","2012/01","2014/12","* Salary support","Funded","True","False","Mentor","The protective role of TIMP3 in acute lung injury","Cory Yamashita","","$15,323,451.00"
"Lewis, James","Medicine","2012/06","2013/05","Grants","Funded","True","False","Co-Applicant","The role of hypercholesterolemia in susceptibility to acute lung injury","Cory Yamashita","","$18,084,041.00"
"Mangel, Joy","Medicine","2012/06","present","Grants","Funded","True","False","Principal Investigator","R-mini-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma in the Elderly - A Quality Assurance Study","Mangel J","Lam S, Minuk L, Howson-Jan K, Chin-Yee I Louzada M, Lohmann R, Lazo-Langer A.","$13,516,079.00"
"Spaic, Tamara","Medicine","2012/09","2016/12","Grants","Funded","True","False","Site Investigator","A Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Gluten-Free Diet in Patients with Asymptomatic Celiac Disease and Type 1 Diabetes","Dr Farid Mahmud","Dr Charlotte McDonald","$27,685,499.00"
"Pickering, J. Geoffrey","Medicine","2012/02","2015/01","* Innovation Grant","Funded","True","False","Principal Investigator","Stabilization of Tumor Vessels","J.G. Pickering","","$56,814,461.00"
"Fernandes, Christopher","Medicine","2009/07","2010/06","Grants","Funded","True","False","Co-Investigator","The Obstetrical Triage and Acuity Scale","","","$65,446,686.00"
"Fernandes, Christopher","Medicine","2011/07","2013/06","Grants","Funded","True","False","Co-Investigator","The Obstetrical Triage and Acuity Scale","","","$10,435,123.00"
"Fernandes, Christopher","Medicine","2011/10","2013/06","Grants","Funded","True","False","Co-Investigator","The Obstetrical Triage and Acuity Scale","","","$25,642,303.00"
"Barra, Lillian","Medicine","2012/09","2015/09","Grants","Funded","True","False","Principal Investigator","The Establishment of a Multidisciplinary Team for Systemic Vasculitis","Lillian Barra","Collaborators: W. Clark, J. Pope and M. Strong","$60,171,021.00"
"Kostuk, William","Medicine","2012/10","2017/01","Grants","Funded","False","True","Co-Investigator","Ischemia Trial: International Study of Comparative Health Effectiveness with Medical and Invasive Approaches. Optional Research Study - Genetic and Biomarker Biorepository","Dr. William Kostuk - Principal Site Investigaotr","Dr. Shahar Lavi, Dr Aashish Goela, Dr. Bob Kiaii, Dr. Jonathan Romsa, Dr. Gerald Wisenberg, Dr. W. J. Kostuk","$48,097,518.00"
"Pickering, J. Geoffrey","Medicine","2012/07","2012/07","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Yiwen Xu","J.G. Pickering","","$51,449,239.00"
"Pickering, J. Geoffrey","Medicine","2011/05","2011/05","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Giovanni-Michele Arpino","J.G. Pickering","","$37,781,835.00"
"Pickering, J. Geoffrey","Medicine","2012/09","2012/09","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Alanna Watson","J.G. Pickering","","$46,178,568.00"
"Johnson, John","Medicine","2012","2014","","Funded","False","True","Collaborator","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Phosphodiesterase 5 Inhibitor (PH-00489791) in Adults with Type 2 Diabetes and Overt Nephropathy","N Muirhead","","$42,871,534.00"
"Johnson, John","Medicine","2012","2015","","Funded","False","True","Collaborator","Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study (TEMPO)","N Muirhead","","$46,619,672.00"
"Johnson, John","Medicine","2012","2014","","Funded","False","True","Collaborator","A Prospective, Observational Randomized Comparative Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis","N Muirhead","","$49,878,932.00"
"Diamantouros, Pantelis","Medicine","2008/11","2015/01","Grants","Funded","False","True","Co-Investigator","Patient Related Outcomes with Endeavour Versus Cypher Stenting Trial","Dr. Patrick Teefy - Principal Site Investigator","Dr. Kumar Sridhar, Dr. Pantelis Diamantouros, Dr. Jaffer Syed, Dr. WIlliam Kostuk, Dr. George Jablonsky","$8,326,575.00"
"Diamantouros, Pantelis","Medicine","2012/08","2014/12","Grants","Funded","False","True","Co-Investigator","Sealing Moderate Coronary Saphenous Vein Graft Lesions with Paclitaxel-eluting Stents as a New Approach to Maintaining Vein Graft Patency and Reducing Cardiac Events.","Dr. Patrick Teefy - Site Principal Investigator","Dr. Kumar Sridhar, Dr. Pallav Garg, Dr. George Jablonsky, Dr. Pantelis Diamantouros, Dr. Shahar Lavi, Dr. Jaffer Syed","$44,258,044.00"
"Diamantouros, Pantelis","Medicine","2011/03","2012/09","Grants","Funded","False","True","Co-Investigator","Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks.. Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes.","Dr. Shahar Lavi","Dr. Kumar Sridhar, Dr. George Jablonsky, Dr. Pantelis Diamantouros, Dr. Jaffer Syed.","$45,317,533.00"
"Kostuk, William","Medicine","2008/11","2015/01","Grants","Funded","False","True","Co-Investigator","Patient Related Outcomes with Endeavour Versus Cypher Stenting Trial","Principal Site Investigator - Dr. Patrick Teefy","Dr. Kumar Sridhar, Dr. Pantelis Diamantouros, Dr. Jaffer Syed, Dr. William Kostuk, Dr. George Jablonsky,","$66,030,352.00"
"Kostuk, William","Medicine","2012/08","2014/12","Grants","Funded","False","True","Co-Investigator","Sealing Moderate Coronary Saphenous Vein Graft Lesions with Paclitaxel0eluting Stents as a New Approach To Maintaing Vein Graft Patency and Reducing Cardiac Events.","Principal Site Investigator - Dr. Patrick Teefy","Dr. Kumar Shridhar, Dr. George Jablonsky, Dr. Pantelis Diamantouros, Dr. William Kostuk, Dr. Jaffer Syed, Dr. Shahar Lavi","$39,850,443.00"
"Garg, Amit","Medicine","2012/07","2013/07","Grants","Funded","True","False","Principal Investigator","ICES Kidney, Dialysis and Transplantation Program","Garg, Amit","","$30,080,684.00"
"Jevnikar, Anthony","Medicine","2006/07","2010/06","Clinical Trials","Funded","False","True","Co-Investigator","Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: the Immuknow Assay","Dr. Patrick Luke","","$28,647,377.00"
"Jevnikar, Anthony","Medicine","2010/07","2013/07","","Funded","False","True","Co-Investigator","Assessment of Immune Status Using the Cylex Assay as an Adjunct to Study FKC-014","Dr. Patrick Luke","","$17,101,156.00"
"Jevnikar, Anthony","Medicine","2010/07","2017/06","","Funded","False","True","Principal Investigator","A Comparison of Effects of Standard Dose vs Low Dose Advagraf with IL-2 Receptor Antib ody Induction, MMF and Steroids, with or Without an ACE/ARB-Based Antihypertensive Therapy on Renal Allograft Histology Function and Immune Response","Dr. Anthony Jevnikar","","$40,087,103.00"
"Xenocostas, Anargyros","Medicine","2011/01","2013/01","Clinical Trials","Funded","True","False","Collaborator","Application of Liposomes to Improve the Hypothermic Storage of Red Blood Cells. Sponsor: Canadian Blood Services. Funding:","Jelena Holovati","Jason Acker and Ian Chin-Yee, Qingping Feng and Anargyros Xenocostas (Co-PI).","$67,564,266.00"
"Diamantouros, Pantelis","Medicine","2011","present","Grants","Funded","False","True","Co-Investigator","Canadian Observational AntiPlatelet Study: Description of the Length of Dual Antiplatelet Therapy, Patient Characteristics, Treatment Patterns and Processes of Care in Canadian Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention.","Principal Site Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. Pallav Garg, Dr. George Jablonsky, Dr. Jaffer Syed","$35,959,797.00"
"Diamantouros, Pantelis","Medicine","2011/04","2012","Grants","Funded","False","True","Co-Investigator","Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus","Principal Site Investigator - Dr.Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. George Jablonsky, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. Pallav Garg, Dr. Jaffer Syed","$42,739,580.00"
"Diamantouros, Pantelis","Medicine","2010/04","present","Grants","Funded","False","True","Co-Investigator","Canadian Atherosclerosis Imaging Network (CAIN) - Correlation Between Coronary and Carotid Atherosclerotic Disease and Links with Clnical Outcomes.","Principal SIte Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. Jaffer Syed, Dr. Patrck Teefy, Dr. Kumar Sridhar, Dr. Pallav Garg, Dr. George Jablonsky","$52,184,118.00"
"Diamantouros, Pantelis","Medicine","2010/03","2012","Grants","Funded","False","True","Co-Investigator","A Phase IIIb Multicentre, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Effect of Treatment with Dalcetraphib 600 mg on Atherosclerotic Disease as Measured by Coronary Intravascular Ultrasound (IVUS), Quantitative Coronary Angiography, Cartoid b-mode Ultrasound Intima Medial Thickness (IMT) and Total Plaque Volume in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease (CAD).","Principal Site Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. Pallav Garg, Dr. Jaffer Syed","$44,541,309.00"
"Diamantouros, Pantelis","Medicine","2009/07","present","Grants","Funded","False","True","Co-Investigator","Sex and Gender Differences in Premature Acute Coronary Syndrome.","Principal Site Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. George Jablonsky, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. Jaffer Syed, Dr. Pallav Garg","$31,295,585.00"
"Kostuk, William","Medicine","2010/10","present","Grants","Funded","False","True","Co-Investigator","Canadian Observational AntiPlatelet Study. Description of the Length of Processes of Care in Canadian Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention.","Principal Site Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. George Jablonsky, Dr. Jaffer Syed, Dr. Palllav Garg","$20,892,715.00"
"Kostuk, William","Medicine","2011/04","2012","Grants","Funded","False","True","Co-Investigator","Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus.","Principal Site Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. George Jablonsky, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. Jaffer Syed, Dr. Pallav Garg","$57,191,715.00"
"Kostuk, William","Medicine","2010/04","present","Grants","Funded","False","True","Co-Investigator","Canadian Atherosclerosis Imaging Network (CAIN) - Correlation Between Coronary and Carotid Atherosclerotic Disease and Links with Clinical Outcomes.","Principal Site Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. George Jablonsky, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. Jaffer Syed, Dr. Pallav Garg","$10,498,821.00"
"Kostuk, William","Medicine","2010/03","2012","Grants","Funded","False","True","Co-Investigator","A phase IIIb Multicentre, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Effect of Treatment with Dalcetrapib 600 mg on Atherosclerotic Disease as Measured by Coronary Intravascular Ultrasound (IVUS), Quantitative Coronary Angiography, Carotid b-mode Ultrasound Intima Medial Thickness (IMT) and Total Plaque Volume in Subjects Undergoing Coronary Angiography Who have Coronary Artery Disease (CAD).","Principal Site Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. Pallav Garg, Dr. Jaffer Syed","$5,455,170.00"
"Kostuk, William","Medicine","2009/07","present","Grants","Funded","False","True","Co-Investigator","Sex and Gender Differences in Premature Acute Coronary Syndrome.","Principal Site Investigator - Dr. Shahar Lavi","Dr. William Kostuk, Dr. Pantelis Diamantouros, Dr. George Jablonsky, Dr. Patrick Teefy, Dr. Kumar Sridhar, Dr. Pallav Garg, Dr. Jaffer Syed","$24,041,642.00"
"Jain, Arsh","Medicine","2012/02","2014/09","Grants","Funded","False","False","Principal Applicant","Risk of acute kidney injury following the use of tenofovir for HIV infection.","Jain, Arsh","","$53,041,989.00"
"Jain, Arsh","Medicine","2011/02","","Grants","Funded","False","False","Principal Applicant","The Impact of eGFR Reporting on Antibiotic Errors in Chronic Kidney Disease Patients","Jain, Arsh","","$71,940,970.00"
"Pope, Janet","Medicine","2008","2017/12","Grants","Funded","False","True","Principal Investigator","CRA-Roche Research Summer Studentship","","","$35,222,803.00"
"Pope, Janet","Medicine","2012/02","2017/01","Grants","Funded","True","False","Co-Investigator","Emerging Team: The Scleroderma Patient-Centred Intervention Network","","","$58,898,803.00"
"Elsayed, Sameer","Medicine","2005","2007","Grants","Funded","True","False","Co-Investigator","A comparison of methods for the rapid detection of MRSA in blood cultures","Dr. Dan Gregson","Dr. Sameer Elsayed and Dr. Deirdre Church","$46,807,281.00"
"Elsayed, Sameer","Medicine","2005","2008","Grants","Funded","True","False","Principal Investigator","DNA Sequencing of Novel Bacteria Implicated In Human Infection","Dr. Sameer Elsayed","Dr. Kunyan Zhang","$12,588,186.00"
"Elsayed, Sameer","Medicine","2006/01","2007/01","Grants","Funded","True","False","Co-Investigator","Emergence of the Streptococcus milleri group as the Major Cause of Invasive Pyogenic Streptococcal Infections","Dr. Kevin Laupland","Dr. Sameer Elsayed and Dr. Daniel Gregson","$9,859,955.00"
"Elsayed, Sameer","Medicine","2004","2006","","Funded","False","False","Principal Investigator","Utility of 28S Ribosomal RNA Gene Sequence Analysis for the Routine Identification of Clinically-Important Fungi","Dr. Sameer Elsayed","Dr. Kunyan Zhang","$47,509,094.00"
"Elsayed, Sameer","Medicine","2004","2006","Grants","Funded","True","False","Co-Investigator","Development of a Multiplex PCR Assay for Detection of Staphylococcal Virulence Gene PVL and Methicillin Resistance (MR) with Simultaneous Discrimination of Staphylococcus aureus (SA) from CoNS","Dr. Kunyan Zhang","Dr. Sameer Elsayed and Dr. John Conly","$34,166,563.00"
"Elsayed, Sameer","Medicine","2003","2003","Grants","Funded","False","False","Principal Investigator","Comparison of PCR versus microscopy for the diagnosis of acute malaria","Dr. Sameer Elsayed","Dr. Kunyan Zhang","$53,236,861.00"
"Elsayed, Sameer","Medicine","2003/01","2003/01","Grants","Funded","True","False","Co-Investigator","The first longitudinal study on the prevalence of mupirocin-resistant staphylococci in the Calgary Health Region, Calgary, Alberta, Canada","Dr. Kunyan Zhang","Dr. Sameer Elsayed and Dr. John Conly","$51,168,129.00"
"Elsayed, Sameer","Medicine","2003","2003","Grants","Funded","True","False","Co-Investigator","Development of a multiplex PCR assay for simultaneous identification of methicillin and mupirocin-resistant Staphylococcus aureus (SA)","Dr. Kunyan Zhang","Dr. Sameer Elsayed and Dr. John Conly","$26,183,142.00"
"Elsayed, Sameer","Medicine","2003","2003","Grants","Funded","True","False","Principal Investigator","Development and Validation of a Molecular Beacon Fluorescent Probe-Based Real-Time PCR Assay for Rapid Detection of Vancomycin-resistant Enterococci","Dr. Sameer Elsayed","Dr. Kunyan Zhang, Dr. Daniel Gregson, and Dr. Deirdre Church","$11,716,142.00"
"Elsayed, Sameer","Medicine","2003","2005","Grants","Funded","True","False","Co-Investigator","Development of a multiplex PCR assay for simultaneous identification of methicillin and mupirocin-resistant Staphylococcus aureus (SA)","Dr. Kunyan Zhang","Dr. Sameer Elsayed and Dr. John Conly","$45,302,114.00"
"Elsayed, Sameer","Medicine","2003","2005","Grants","Funded","True","False","Co-Investigator","Surveillance and identification of Pseudomonas aeruginosa producing metallo-?-lactamases (MBLs) in the Calgary Health Region","Dr. Johann Pitout","Dr. Sameer Elsayed, Dr. Daniel Gregson, Dr. Deirdre Church, Dr. Kevin Laupland, Dr. Kunyan Zhang, Dr. John Conly","$70,296,907.00"
"Elsayed, Sameer","Medicine","2002","2004","Grants","Funded","True","False","Co-Investigator","Multilocus Sequence Typing (MLST) of Serotype III Group B Streptococcus and correlation with pathogenic potential","Dr. Dele Davies","Dr. Sameer Elsayed, Dr. Nicola Jones, and Dr. Carol Baker.","$45,189,034.00"
"Elsayed, Sameer","Medicine","2002","2006","Grants","Funded","True","False","Principal Investigator","Real-Time Polymerase Chain Reaction-Based Assays for the Rapid Diagnosis of Neonatal Sepsis","Dr. Sameer Elsayed","Dr. Dele Davies","$24,111,432.00"
"Elsayed, Sameer","Medicine","2002","2004","Grants","Funded","True","False","Principal Investigator","Utility of DNA Sequencing for the Identification of Clinically-Significant Bacteria","Dr. Sameer Elsayed","Dr. Kunyan Zhang","$16,633,365.00"
"Elsayed, Sameer","Medicine","2002","2005","Grants","Funded","True","False","Principal Investigator","Development of Real-Time Multiplex PCR for the Diagnosis of Acute Malaria","Dr. Sameer Elsayed","Dr. Kunyan Zhang and Dr. Deirdre Church","$31,796,862.00"
"Elsayed, Sameer","Medicine","2001","2003","Grants","Funded","True","False","Principal Investigator","Comparison of Polymerase Chain Reaction (PCR) Versus Phenotypic Methods for the detection of Vancomycin-Resistant Enterococci (VRE)","Dr. Sameer Elsayed","Dr. Daniel Gregson and Dr. Deirdre Church","$25,929,899.00"
"Lazo Langner, Alejandro","Medicine","2013/03","2016/06","Grants","Funded","True","False","Co-Applicant","D-dimer testing, tailored to clinical pretest probability, to minimize initial and follow-up ultrasound testing in suspected deep vein thrombosis: A management study","Clive Kearon","","$55,156,203.00"
"Lazo Langner, Alejandro","Medicine","2011","2016","Grants","Funded","True","False","Co-Applicant","Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism (SOME trial): a Study using Comprehensive Abdomen/Pelvis Computed Tomography","Marc Carrier, Marc A. Rodger","Agnes Lee, Tim Ramsay, Douglas Coyle,Vicky Tagalakis, Gregoire Le Gal, Hardy Tao, Philip Wells","$39,185,879.00"
"Pope, Janet","Medicine","2012/04","2012/06","Grants","Funded","True","False","Co-Investigator","Personalized Medicine in ERA - indentifying disease trajectories using cluster analysis of clinically available markers","","","$47,344,375.00"
"Kane, Sheri-Lynn C","Medicine","2011","2013","Grants","Funded","False","False","Co-Investigator","Working with Seniors Improve Transitions from Hospital.","Dr. Christopher Frank","","$28,804,027.00"
"Kao, Raymond","Medicine","2007/07","2009/06","Grants","Funded","True","False","Principal Investigator","Effect of rh-EPO improves gut barrier function in a hemorrhagic shock and resuscitation model","","","$63,782,032.00"
"Kao, Raymond","Medicine","2012/07","2015/06","Grants","Funded","True","False","Principal Investigator","To study the effect of resuscitation with C-Peptide on the small intestine microcirculation perfusion, tissue bioenergetics, gut injury and lung inflammation in an acute and 24 hour mouse model of hemorrhagic shock and resuscitation.","","","$40,689,075.00"
"Kovacs, Michael","Medicine","2012/04","2016/03","Grants","Funded","True","False","Co-Applicant","Extended venous thromboembolism prophylaxis comparing Rivaroxaban to aspirin following total hip and knee arthroplasty.","David Anderson","","$50,283,140.00"
"Kovacs, Michael","Medicine","2010/04","2013/03","Grants","Funded","True","False","Co-Applicant","A randomized, placebo-controlled trial of compression stockings to prevent the post-thrombotic syndrome.","Susan Kahn","","$33,967,636.00"
"Pickering, J. Geoffrey","Medicine","2012/07","2014/06","Grants","Funded","True","False","Co-Applicant","Dual energy micro-CT for angiography and cardiovascular histology.","Maria Drangova","","$14,475,704.00"
"Elsayed, Sameer","Medicine","2005","2006","Grants","Funded","False","True","Co-Investigator","Invasive Candida species Infections: A Five-Year Population-Based Assessment","Dr. Kevin Laupland","Dr. Sameer Elsayed and Dr. Michael Parkins","$66,758,011.00"
"Elsayed, Sameer","Medicine","2005","2006","Grants","Funded","False","True","Co-Investigator","Activity of Linezolid Against Coagulase-negative Staphylococci Using Agar Dilution","Dr. Zafar Hussain","Dr. Sameer Elsayed and Dr. Michael John","$29,670,621.00"
"Paul, Terri","Medicine","2010/07","2015/06","Clinical Trials","Funded","False","True","Co-Investigator","SAVOR Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes.","IM Hramiak","TL Paul, CG McDonald","$5,111,055.00"
"Paul, Terri","Medicine","2010/05","2010/12","Clinical Trials","Funded","False","True","Co-Investigator","A multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, 26-week, multticenter study with a 26-week extension to evaluate the efficacy, safety, and tolerability of canagliflozin in the treatment of subjects with type 2 diabetes mellitus who have moderate renal impairment.","IM Hramiak","TL Paul","$53,969,698.00"
"Paul, Terri","Medicine","2010/07","2016/07","Clinical Trials","Funded","False","True","Co-Investigator","LEADER Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results. A long-term, multi-centre, international, randomised double-blind, placebo-controlled trial to determine liraglutide effects on cardiovascular events","IM Hramiak","TL Paul, CG McDonald","$72,271,383.00"
"Paul, Terri","Medicine","2011/04","2016/06","Clinical Trials","Funded","True","False","Co-Investigator","Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-ON study","IM Hramiak","TL Paul, CG McDonald","$14,514,008.00"
"Paul, Terri","Medicine","2011/01","2015/03","Clinical Trials","Funded","True","False","Co-Investigator","Reducing with MetfOrmin Vascular Adverse Lesions in T1DM","IM Hramiak","TL Paul, CG McDonald","$24,729,812.00"
"Paul, Terri","Medicine","2011/02","2013/01","Clinical Trials","Funded","True","False","Co-Investigator","Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension","I Hramiak","TL Paul","$65,437,220.00"
"Paul, Terri","Medicine","2011/03","2012/12","Clinical Trials","Funded","True","False","Co-Investigator","Feasibility Assessment of Prototype Nocturnal Hypoglycemia Reduction System (Inpatient)","IM Hramiak","TL Paul","$34,270,718.00"
"Paul, Terri","Medicine","2009/04","2011/06","Clinical Trials","Funded","False","True","Co-Investigator","An Observational follow-up study of patients previously enrolled in Exubera controlled clinical trials.","IM Hramiak","TL Paul","$46,443,403.00"
"Paul, Terri","Medicine","2010/05","2013/05","Clinical Trials","Funded","False","True","Principal Investigator","A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of Cinacalcet for the treatment of hypercalcemia in subjects with primary hyperparathyroidism unabel to undergo parathyroidectomy","TL Paul","A Hodsman, R Crilly, L Fraser","$7,364,759.00"
"Clark, William","Medicine","2012/09","2013/09","","Funded","False","True","Principal Investigator","Danone - NHANES","Clark WF","","$30,052,717.00"
"Clark, William","Medicine","2012/09","2013/09","","Funded","False","True","Principal Investigator","Danone - S-London Pilot Study - EAU-6607-GD","Clark WF","","$17,927,775.00"
"Clark, William","Medicine","2013/09","2017/09","Clinical Trials","Funded","False","True","Principal Investigator","Chronic Kidney Disease - Water Intake Trial Study","Clark WF","","$8,533,413.00"
"Clark, William","Medicine","2013/01","present","Grants","Funded","True","False","Co-Investigator","The Therapeutic Evaluation of STeroids in IgA Nephropathy Global (TESTING) Study - Canadian Network","HLADUNEWICH, Michelle","Hladunewich M, Cattran D, Levin A, Reich H, Barbour S, Clark W, Clase C, Hemmelgarn B, Pannu N, Rigatto C, Sood M.","$29,838,789.00"
"Moist, Louise","Medicine","2013/01","2013/12","Grants","Funded","True","False","Principal Investigator","A Needle Attachment Fixture for Measuring the Force of Needle Penetration During Arteriovenous Fistula Cannulation","Dr. Louise Moist","","$68,955,099.00"
"Spaic, Tamara","Medicine","2012/11","2013/11","Grants","Funded","True","False","Site Investigator","Outpatient Reduction of Nocturnal Hypoglycemia By Using Predictive Algorithms and Pump Suspension","Dr B. Buckingham/ Dr Irene Hramiak","Dr Terri Paul","$26,073,147.00"
"Spaic, Tamara","Medicine","2013/02","2016/12","Grants","Funded","True","False","Co-Investigator","Continuous Glucose Monitoring in Women with Type 1 Diabetes in Pregnancy Trial","Dr. Denice S. Feig / Dr Ruth McManus","Dr Selina Liu","$29,086,810.00"
"Louzada, Martha de Lacerda","Medicine","2012/04","2015/03","Grants","Funded","True","False","Co-Principal Investigator","Analysis of Pro-coagulant and Thrombin-generation markers for the prediction of therepeutic failure during anticoagulation in cancer patients at high-risk for recurrence of venous thromboembolism: A pilot study (REMARK).","Dr. Philip Stephen Wells and Dr. Martha Louzada","P.S. Wells, M.A. Rodger, T.O. Ramsay, P.L. Gross, A.L. Lazo-Langner, M. Carrier","$17,166,397.00"
"Louzada, Martha de Lacerda","Medicine","2012/03","2014/03","Clinical Trials","Funded","False","True","Co-Principal Investigator","The prevalence and Management of Cardiovascular Disease in Older Adults with Hemophilia - A Multicentre Retrospective Cohort Study (ARCHER).","Len Minuk/Co-Principal Martha Louzada","Jackson S, Saidenberg E, Tinmouth A, Poon M, Brose K, Card R, Laudenbach L, Chin-Yee I.","$27,432,093.00"
"Chin-Yee, Ian","Medicine","2012/03","","Clinical Trials","Funded","False","False","Co-Investigator","The Prevalence and Management of Cardiovascular Disease in Older Adults with Hemophilia - A Multicentre Retrospective Cohort Study.","Len Minuk","Louzada M, Jackson S, Saidenberg E, Tinmouth A, Poon M, Brose K, Card R, Laudenbach L, Chin-Yee I.","$4,960,173.00"
"Adams, Paul","Medicine","2013/03","2016/03","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)","","","$38,312,812.00"
"Adams, Paul","Medicine","2013/03","2016/03","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)","","","$7,540,301.00"
"Garg, Pallav","Medicine","","","","Applied","False","False","Co-Applicant","Prevention of adverse drug reactions through integration of pharmacogenomics and drug interactions","Dr Richard B. Kim MD FRCPC","","$8,289,626.00"
"Paul, Terri","Medicine","2010/07","2012/12","Grants","Funded","True","False","Co-Applicant","The Development and validation of a multimedia computer based learning module for teaching Otolaryngology physical exam skills","Terri Paul, Kevin Fung","","$62,459,315.00"
"Huang, Shih-Han Susan","Medicine","2013/04","2016/03","Grants","Funded","False","True","Co-Investigator","The CKD Water Intake Trial (WIT)","W.F. Clark","Garg A, Moist L, House AA, Weir M","$33,941,069.00"
"Bosma, Karen","Medicine","2004/07","present","Grants","Funded","False","False","Principal Investigator","Department of Medicine Start-up Funds","Dr. Karen Bosma","","$40,633,618.00"
"Huff, Murray","Medicine","2013/04","2018/03","Grants","Funded","True","False","Principal Investigator","Inhibition of foam cell formation and the inflammatory response: Relationship to atherosclerosis.","Huff MW","","$40,651,351.00"
"Lazo Langner, Alejandro","Medicine","2014/03","2017/06","Grants","Funded","True","False","Co-Applicant","D-dimer testing, tailored to clinical pretest probability, to reduce use of CT pulmonary angiography in suspected pulmonary embolism: A management study. (PE Graduated D-dimer [PEGeD] Study)","Clive Kearon","","$6,763,906.00"
"Hramiak, Irene","Medicine","2012/08","2015/07","Clinical Trials","Funded","True","False","Co-Principal Investigator","The LONGevity in Type I diabetes and Macrovascular disease Epidemiology study.","I Hramiak & S Liu","S Liu (Co-PI) R Gurfinkel J Mahon M Weingert","$57,865,990.00"
"Hramiak, Irene","Medicine","2013/05","2016/02","Clinical Trials","Funded","False","True","Principal Investigator","Long term outcomes. A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes.","IM Hramiak","T Joy, CG McDonald, TL Paul","$1,248,638.00"
"Fraser, Lisa-Ann","Medicine","2012/10","2015/09","Grants","Funded","True","False","Co-Investigator","Building Better Bones with Exercise (B3E)","Lora Giangregorio","Lisa-Ann Fraser, Jonathon Adachi, Anthony Hodsman, Anne Braun, Angela Cheung, David Kendler, John Wark, Keith Hill, Nicole Mittmann, Maureen Ashe, Robert Bleakney, Alexandra Papaioannou, and Lehana Thabane","$38,950,343.00"
"Fraser, Lisa-Ann","Medicine","2012/07","2014/06","Grants","Funded","True","False","Co-Investigator","Reduced Kidney Function and Fragility Fractures","Amit Garg","Lisa-Ann Fraser","$38,205,103.00"
"Pickering, J. Geoffrey","Medicine","1997","1997","Grants","Funded","True","False","Principal Investigator","Personnel support for post-doctoral fellow, Dr. Shaohua Li","J.G. Pickering","","$33,530,622.00"
"Member, Test","Family Medicine","2011/01","2011/12","Grants","Funded","True","True","Principal Investigator","Weight Control in Lab Mice","Member, Test","Dr. Strange","$72,088,829.00"
"Member, Test","Family Medicine","2009/01","present","Grants","Funded","True","False","Principal Investigator","Weight Control in Lab Mice","Member, Test","Dr. Strange","$51,583,568.00"
"Member, Test","Family Medicine","2009/01","2009/02","Grants","Funded","False","False","Principal Applicant","Weight Control in Lab Mice","Member, Test","Dr. Strange","$14,591,830.00"
"Johnson, John","Medicine","2013","2020","","Funded","False","True","Co-Investigator","Multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect of Dapagliflozin 10 mg once daily on the incidence of cardiovascular death, myocardial infarction","N Muirhead","","$30,412,545.00"
"Johnson, John","Medicine","2013","2015","","Funded","False","True","Co-Investigator","A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy","N Muirhead","","$8,018,679.00"
"Johnson, John","Medicine","2013","2018","","Funded","False","True","Co-Investigator","Kinase Inhibition to Decrease Nephropathy Intervention Trial. Randomized to Sirolimus.Leflunomide or standard of care","A House","","$38,032,586.00"
"House, Andrew","Medicine","2013/07","2018/06","","Funded","True","False","Principal Site Investigator","Kinase Inhibition to Decrease Nephropathy Intervention Trial. Randomized to Sirolimus.Leflunomide or standard of care","AA House","","$58,093,413.00"
"House, Andrew","Medicine","2013/07","2015/06","","Funded","False","True","Co-Investigator","A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy","N Muirhead","","$36,879,037.00"
"House, Andrew","Medicine","2013/07","2020/06","","Funded","False","True","Co-Investigator","Multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect of Dapagliflozin 10 mg once daily on the incidence of cardiovascular death, myocardial infarction","N Muirhead","","$13,785,277.00"
"Xenocostas, Anargyros","Medicine","2010/07","","Clinical Trials","Funded","False","False","Co-Investigator","Study of red blood cell transfusion triggers in patients undergoing hematopoietic stem cell transplantation (TRIST)","","","$16,879,273.00"
"Mehta, Sanjay","Medicine","2013","2016","Grants","Funded","True","False","Principal Investigator","Mechanisms of microvascular endothelial cell apoptosis in sepsis","S Mehta","Gill, SE","$41,904,351.00"
"Minuk, Leonard","Medicine","2013/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Randomized Double-Blind Placebo controlled phase 3 study of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor in combination with Bendamustine and Rituximab in subjects with Relapsed or Refractory CLL","Dr. Leonard Minuk","","$10,362,922.00"
"Minuk, Leonard","Medicine","2013/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized Open Label Phase 3 study of Cardilzomib plus Dexamathasone vs Bortezomib Plus Dexamethasone in patients with relapsed multiple myeloma.","Dr. Leonard Minuk","","$15,745,371.00"
"Minuk, Leonard","Medicine","2012/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase II/III multicentre partially randomized open label trial investigating safety and efficacy of on demand and prophylactic treatment with BAY94-9027 in servere hemophilia A","Dr. Leonard Minuk","","$70,388,217.00"
"Minuk, Leonard","Medicine","2013/01","present","Clinical Trials","Funded","True","False","Principal Site Investigator","A Phase II study of using a combination of Busulfan and Melphalan as conditioning regimen for autologous stem cell transplantation in patients who has received Bortezomib based induction for newly diagnosed multiple myeloma followed by lenalidomide maintenance until disease progression.","Dr. Leonard Minuk","","$33,391,576.00"
"Minuk, Leonard","Medicine","2007/01","present","Grants","Funded","True","False","Co-Investigator","A randomized, double blind, placebo controlled pilot trial of Rituximab for adults with immune thrombocytopenic purpura at initial presentation or at relapse following medical treatments who are receiving standard therapy (R-ITP)","Dr. Donald Arnold","","$23,963,746.00"
"Louzada, Martha de Lacerda","Medicine","2009/12","present","Clinical Trials","Funded","False","True","Co-Investigator","REVERSE II (Recurrent Venous Thromboembolism Risk STratification Evaluation): validation of the ""Men and HERDOO2"" - A clinical decision rule to identify patients with ""unprovoked"" venous thromboembolism who can discontinue anticoagulants after 6 months of treatment.","Dr. Mike Kovacs","M. Louzada","$70,910,382.00"
"Louzada, Martha de Lacerda","Medicine","2008","","Clinical Trials","Funded","False","True","Co-Investigator","A prospective study of upper extremity deep vein thrombosis to determine the prevalence of post-thrombotic syndrome in patients managed with anticoagulation - UEDVT","Dr. Mike Kovacs","M. Louzada","$40,300,585.00"
"Louzada, Martha de Lacerda","Medicine","2013/03","present","Clinical Trials","Funded","False","True","Co-Investigator","A randomized open-label, parallel-group, multi-center study for the evaluation of efficacy and safety of edoxaban monotherapy versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis - edoxaban thrombus reduction imaging study (eTRIS)","Dr. Mike Kovacs","Martha Louzada","$28,019,076.00"
"Louzada, Martha de Lacerda","Medicine","2011/07","present","Grants","Funded","True","False","Co-Investigator","The OVWAC II study: A multicentre study of low dose oral vitamin K for INR control in patients receiving warfarin","Dr. Mike Kovacs","M. Louzada","$73,487,251.00"
"Louzada, Martha de Lacerda","Medicine","2012/07","present","Grants","Funded","True","False","Co-Investigator","The management of subsegmental pulmonary embolism: A cohort study (SSPE)","Dr. Mike Kovacs","Co-investigator","$55,149,089.00"
"Louzada, Martha de Lacerda","Medicine","2006/07","2014/03","Grants","Funded","True","False","Co-Investigator","A double blind randomised control trial of post-operative low molecular weight heparin bridging therapy versus placebo bridging therapy for patients who are at high risk arterial thromboembolism (PERIOP 2)","Dr. Mike Kovacs","M. Louzada","$9,274,894.00"
"Chin-Yee, Ian","Medicine","2013/02","2016/06","Clinical Trials","Funded","False","True","Principal Site Investigator","PNH REGISTRY","Dr. Ian Chin-Yee","Dr. Cyrus Hsia","$7,000,794.00"
"Chin-Yee, Ian","Medicine","2013/02","2015/01","Grants","Funded","True","False","Co-Applicant","Design of kinosensors as novel tools for cancer diagnosis","Dr. David Litchfield/H. Kraatz","A. Xenocostas, C. Hsia,","$70,535,157.00"
"Hramiak, Irene","Medicine","2013/01","2014/12","Clinical Trials","Funded","False","True","Principal Investigator","ORIGIN (Outcome Reduction with Initial Glargine Intervention) and Legacy Effects: An Obervational Study","IM Hramiak","CG McDonald, TL Paul","$74,023,242.00"
"Louzada, Martha de Lacerda","Medicine","2013/01","present","Clinical Trials","Funded","False","True","Co-Investigator","Randomized Double-Blind Placebo controlled phase 3 study of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor in combination with Bendamustine and Rituximab in subjects with Relapsed or Refractory CLL.","Dr. Len Minuk","","$73,777,499.00"
"Louzada, Martha de Lacerda","Medicine","2013/07","present","Clinical Trials","Funded","False","True","Co-Investigator","A randomized open label phase 3 study of Cardilzomib plus Dexamethasone vs Bortezomib plus Dexamethasone in patients with relapsed multiple myeloma.","Dr. Len Minuk","","$32,669,744.00"
"Louzada, Martha de Lacerda","Medicine","2011/07","2012","","Funded","False","True","Co-Investigator","A phase 3 randomized open label trial of Lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma CA-204-006.","Dr. Len Minuk","","$30,658,936.00"
"Louzada, Martha de Lacerda","Medicine","2013/07","","Clinical Trials","Funded","False","True","Co-Investigator","ELOQUENT 2 - (relapsed)","Dr. Len Minuk","","$69,627,116.00"
"Hramiak, Irene","Medicine","2011/10","2016/12","Clinical Trials","Funded","True","False","Principal Investigator","PSO3 - Reduction of nocturnal hypoglycemia by using predictive algorithms and pump suspension. an outpatient pilot feasibility and efficacy study. PSO4 - Outpatient reduction of nocturnal hypoglycemia by using predictive algorithms and pump suspension in children.","I Hramiak","CG McDonald, TL Paul, J Lum","$28,565,344.00"
"Shepherd, Lisa","Medicine","2012/12","2013/11","Grants","Funded","False","False","Principal Applicant","Development of Podcasts to support the Emergency Medicine Clinical Clerkship Experience","Lisa Shepherd","","$23,275,301.00"
"Mura, Marco","Medicine","2009/07","2010/06","Grants","Funded","True","True","Co-Applicant","Impact of recipient lung gene expression profiles on primary graft dysfunction incidence and survival after lung transplantation for pulmonary fibrosis","Marc de Perrot","Marco Mura Masaki Anraku Shaf Keshavjee","$63,121,901.00"
"Mura, Marco","Medicine","2010/07","2011/06","* Scholarship","Funded","True","False","Principal Applicant","A gene expression profile based on Pulmonary Artery Pressures in Pulmonary Fibrosis to identify distinct phenotypes of the disease and predict Primary Graft Dysfunction after Lung Transplantation","John T. Granton","","$2,574,804.00"
"Mura, Marco","Medicine","2011/07","2014/12","Grants","Funded","True","True","Principal Investigator","Osteopontin in Idiopathic Pulmonary Arterial Hypertension, A Biomarker and Therapeutic Target","Marco Mura","John T. Granton","$64,337,983.00"
"Mura, Marco","Medicine","2012/07","2015/06","Grants","Funded","False","False","Principal Investigator","Start-up research funds, Western University, Department of Medicine","Marco Mura","","$42,285,374.00"
"Mura, Marco","Medicine","2013/09","2018/08","Grants","Funded","True","False","Principal Investigator","European Respiratory Society 2013 IPF Research Award","Marco Mura","","$60,052,829.00"
"Mehta, Sanjay","Medicine","2013","2016","Clinical Trials","Funded","False","True","Principal Investigator","TDE-PH-310 - A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Event Driven Study to Compare the Time to First Clinical Worsening in Subjects with Pulmonary Arterial Hypertension Receiving UT-15C in Combination with a PDE5-I or ERA Compared with a PDE5-I or ERA Alone","S Mehta","","$4,490,647.00"
"Mehta, Sanjay","Medicine","2014/01","2016/01","Clinical Trials","Funded","False","True","Principal Investigator","TDE-PH-311 - An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension","S Mehta","","$6,743,479.00"
"Beaton, Melanie","Medicine","2013/06","2018/09","Grants","Funded","True","False","Co-Investigator","A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)","Adams, PC","Beaton, MD Marotta, P Levstik, M Al-Judaibi, B","$42,292,341.00"
"Beaton, Melanie","Medicine","2013/06","2016/06","Grants","Funded","True","False","Co-Investigator","Celiac disease and Diabetes - Dietary Intervention and Evaluation Trial (CD-DIET)","Mahmud, FH","Beaton, MD Marcon, M Assor, E Cutz, E Cino, M Lawson, M Gallego, P McDonald, C Mack, D Bax, K","$50,868,605.00"
"Beaton, Melanie","Medicine","2013/06","2018/09","Grants","Funded","True","False","Co-Investigator","A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2(LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)","Adams, PC","Beaton, MD Marotta, P Levstik, M Al-Judaibi, B","$26,108,034.00"
"Hramiak, Irene","Medicine","2013/07","2019/06","Clinical Trials","Funded","False","True","Principal Investigator","Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.","IM Hramiak","T Joy, C McDonald and T Paul","$37,551,822.00"
"Yamashita, Cory","Medicine","2012/09","2013/09","Grants","Funded","True","False","Co-Principal Investigator","Antimicrobial Peptide Fortified Surfactant for the Treatment of Cystic Fibrosis","Dr. Cory Yamashita","Dr. Ruud Veldhuizen","$48,180,543.00"
"Diamantouros, Pantelis","Medicine","2013/07","2015/07","Clinical Trials","Funded","False","True","Co-Investigator","Surgical Replacement and Transcatheter Aortic Valve Implantation","Dr. B. Kiaii","Dr. M. Chu, Dr. P. Teefy, Dr. P. Diamantouros","$25,547,587.00"
"Montero Odasso, Manuel","Medicine","2013/01","2018/01","Grants","Funded","True","False","Co-Principal Investigator","Gait and Ambulation Team, Ontario Brain Institute Integrated Discovery Neurodegeneration Project.","Michael Strong","","$53,395,617.00"
"Licskai, Christopher","Medicine","2012/01","2014/12","Grants","Funded","False","True","Principal Investigator","Windsor-Essex/Chatham-Kent Collaborative COPD Management Program","Christopher Licskai","Madonna Ferrone, Natalie Malus, Todd Sands","$53,364,635.00"
"Licskai, Christopher","Medicine","2011/10","2017/03","Grants","Funded","True","False","Principal Investigator","Consumer Access to Personal Health Information for Asthma Self-Management","Christopher Licskai","Teresa To, Diane Lougheed, Joseph Cafazzo, Samir Gupta","$5,069,468.00"
"Licskai, Christopher","Medicine","2006/04","2016/03","Grants","Funded","True","False","Principal Investigator","Asthma Plan of Action - Primary Care Asthma Program","Christopher Licskai","Todd Sands, Lisa Paolatto, Dorothy Pardalis, Rob Modestino, Rosa Marra, Natalie Malus","$73,705,019.00"
"Licskai, Christopher","Medicine","2011/01","2012/12","Grants","Funded","False","True","Principal Investigator","Learning to COPE with COPD","Christopher Licskai","Madonna Ferrone, Natalie Malus, Todd Sands","$2,775,115.00"
"Licskai, Christopher","Medicine","2008/01","2015/12","Grants","Funded","True","False","Principal Investigator","Asthma Diagnosis Protocol","Christopher Licskai","Nigel Paterson, Abdul Gari, Allen Greenwald, Dilshad Moosa, Keith Payton","$72,013,797.00"
"Muirhead, Norman","Medicine","2013/07","2020/07","Clinical Trials","Funded","False","True","Principal Investigator","Multicentre, randomized, double-bline, placebo controlled trial to evaluate the effect of Dapagliflozin 10mg once daily on the incidence of cardiovascular death, myocardial infarction","Norman Muirhead","Dr. Andrew House, Dr. F. Rehman, Dr. M. Weir & Dr. J. Johnson","$62,429,388.00"
"Muirhead, Norman","Medicine","2013/07","2015/07","Clinical Trials","Funded","False","True","Principal Investigator","A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy","Norman Muirhead","Dr. A. House, Dr. F. Rehman, Dr. M. Weir & Dr. J. Johnson","$35,015,631.00"
"Muirhead, Norman","Medicine","2012/07","2013/07","Clinical Trials","Funded","False","True","Principal Investigator","Evaluation of genetic markers predicting tac dose requirements","Norman Muirhead/Richard Kim","","$28,935,796.00"
"Muirhead, Norman","Medicine","2013/07","2018/07","Grants","Funded","True","False","Co-Investigator","Kinase inhibition to decrease nephropathy intervention trial randomized to Sirolimus, Leflunomide or standard of care","Andrew House","Dr. N. Muirhead, Dr. M. Weir, Dr. F. Rehman & Dr. J. Johnson","$14,580,960.00"
"Kostuk, William","Medicine","2011/07","2014/06","Grants","Funded","False","False","Co-Investigator","The Implantable Counter Pulsation Device (CPD) Safety and Efficacy Clinical Trial","Dr. Mac Quantz","Dr. Bob Kiaii, Dr. Peter Pflugfelder, Dr. W. Kostuk","$60,977,362.00"
"Garg, Amit","Medicine","2013/04","2018/03","Grants","Funded","True","False","Co-Investigator","Canadian National Transplant Research Program: Increasing Donation and Improving Transplantation Outcomes","West, Lori","","$9,613,025.00"
"Garg, Amit","Medicine","2013/10","2017/09","Grants","Funded","True","False","Co-Investigator","Do Primary Care Reforms Influence Physician Performance and Patient Outcomes? Econometric Analyses of Ontario’s Primary Healthcare Delivery Models","Sarma, Sisira","Rose Anne Devlin, Amit Garg, Salimah Shariff, Amardeep Thind, Gregory Zaric","$39,362,790.00"
"Garg, Amit","Medicine","2013/04","2015/03","Grants","Funded","True","False","Principal Investigator","Risk of kidney stones and bleeding in living kidney donors","Garg, Amit","","$10,414,058.00"
"Garg, Amit","Medicine","2013/10","2018/09","Grants","Funded","True","False","Principal Investigator","Standard Criteria Living Kidney Donor Safety Study","Garg, Amit","","$20,314,029.00"
"van Uum, Stanislaus","Medicine","2013/01","2014/12","Grants","Funded","True","True","Principal Applicant","Thyroid Cancer in the Canadian context: description of care patterns during last decade, and analysis of socioeconomic determinants of stage at presentation and outcome","Stan Van Uum","Steve Burrell Jason Franklin Robert Hart Ali Imran Ted McDonald Deric Morrison Terri Paul Irina Rachinsky John Yoo","$65,237,199.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral CP-690, 550 as a maintenance therapy in subjects with moderate to severe ulcerative colitis","","","$44,251,247.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral CP-690, 550 as an open-label therapy in subjects with moderate to severe ulcerative colitis","","","$68,637,216.00"
"Feagan, Brian","Medicine","2008/01","2010/01","Grants","Funded","False","True","Site Investigator","A Phase III, Multicentre, Placebo-controlled, Randomized, Double-blind, Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL Intravenous Infusion for the Maintenance of Re-Induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-Refractory Moderate-Severe Ulcerative Colitis","","","$55,591,654.00"
"Feagan, Brian","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Site Investigator","A randomized, double-blind, multiple dose placebo controlled study to evaluate the safety, tolerability and efficacy of AMG 181 in subjects with moderate to severe Crohn's Disease.","","","$22,009,552.00"
"Feagan, Brian","Medicine","2012/05","2014/05","Clinical Trials","Funded","False","True","Site Investigator","C2011-0401 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients with Active Mild or Moderate Ulcerative Colitis not Adequately Controlled on a Background Oral 5-ASA Regimen","","","$25,532,827.00"
"Feagan, Brian","Medicine","2012/03","2014/03","Clinical Trials","Funded","False","True","Site Investigator","A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multi-center study to Investigate the Safety and Efficacy Of Multistem (PF-05285401) in Subjects With Moderate to Severe Ulcerative Colitis","","","$73,252,018.00"
"Feagan, Brian","Medicine","2013/04","2015/04","Clinical Trials","Funded","False","True","Site Investigator","A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn’s Disease CCX114643","","","$26,732,964.00"
"Feagan, Brian","Medicine","2013/04","2015/04","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 2a Study to evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or are Intolerant to Anti-tumor Necrosis Factor-alpha","","","$23,692,647.00"
"Feagan, Brian","Medicine","2013/07","2015/07","Clinical Trials","Funded","False","True","Site Investigator","A randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC).","","","$66,356,862.00"
"Feagan, Brian","Medicine","2013/04","2015/05","Clinical Trials","Funded","False","True","Site Investigator","A Double-Blind, Randomized, Placebo-Controlled, Parallel, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-00547659 In Subjects With Moderate To Severe Ulcerative Colitis (Turandot)","","","$44,009,220.00"
"Feagan, Brian","Medicine","2013/04","2015/04","Clinical Trials","Funded","False","True","Site Investigator","A Multicenter Open-Label Extension Study To Assess Long-Term Safety Of PF-00547659 In Subjects With Ulcerative Colitis (Turandot II)","","","$28,033,426.00"
"Feagan, Brian","Medicine","2013/09","2015/09","Clinical Trials","Funded","False","True","Co-Principal Investigator","A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicentre Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects with Moderate to Severe Ulcerative Colitis","","","$46,512,688.00"
"Feagan, Brian","Medicine","2013/07","2015/07","Clinical Trials","Funded","False","True","Co-Principal Investigator","A Randomized, Active-Controlled, Double-Blind, and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2g/day for the Treatment of Active Ulcerative Colitis","","","$67,140,391.00"
"Barra, Lillian","Medicine","2013/10","2014/09","Grants","Funded","True","False","Co-Investigator","The role of anti-homocitrullinated protein/peptide immune responses in Rheumatoid Arthritis","Ewa Cairns","L. Barra, D. Bell","$58,451,813.00"
"Jain, Arsh","Medicine","2012/07","2014/06","Grants","Funded","True","False","Co-Investigator","ICES Kidney, Dialysis and Transplantation Program","Garg, Amit","","$38,805,755.00"
"Member, Test","Family Medicine","2009/07","present","Clinical Trials","Funded","True","False","Principal Investigator","","Member, Test","","$43,775,472.00"
"Member, Test","Family Medicine","2009/07","2010/06","Clinical Trials","Funded","True","False","Co-Applicant","","Member, Test","","$63,440,645.00"
"Member, Test","Family Medicine","2009/07","2010/06","Clinical Trials","Funded","True","True","Co-Applicant","","Member, Test","","$40,463,454.00"
"Kim, Richard","Medicine","2013/10","2018/10","Grants","Funded","True","False","Principal Investigator","Hepatic bile acid and Organic Anion Transporting Polypeptide drug uptake transporters as determinants of drug disposition","Richard B. Kim","Yun-Hee Choi","$12,207,677.00"
"Kim, Richard","Medicine","2013/04","2014/03","Clinical Trials","Funded","True","False","Principal Investigator","Genetic markers of ototoxicity with cisplatin chemotherapy in head and neck cancer","Richard Kim","","$26,790,831.00"
"Kim, Richard","Medicine","2012/06","2013/05","Grants","Funded","True","False","Principal Investigator","Personalized medicine Team for the Prevention of Adverse Drug Response (ADR) at LHSC","Richard Kim","","$30,347,873.00"
"Pickering, J. Geoffrey","Medicine","2013/05","2013/05","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Alanna Watson","J.G. Pickering","","$61,970,717.00"
"Pickering, J. Geoffrey","Medicine","2013/04","2015/06","Grants","Funded","True","False","Principal Investigator","Control of vascular smooth muscle cell aging","J.G. Pickering","","$67,615,187.00"
"Khanna, Reena","Medicine","2013/09","2013/09","Grants","Funded","True","False","Principal Investigator","Young Clinicians Program for Gastro 2013 APDW/WCOG","Khanna, R.","","$54,747,619.00"
"Kovacs, Michael","Medicine","2013/10","2017/09","Grants","Funded","True","False","Co-Applicant","D-dimer testing, tailored to clinical pretest probability, to reduce use of CT pulmonary angiography in suspected pulmonary embolism: A management study","Kearon, Clive","","$35,009,331.00"
"Kovacs, Michael","Medicine","2013/03","2016/06","Grants","Funded","False","False","Co-Applicant","D-dimer testing, tailored to clinical pretest probability, to minimize initial and followup ultrasound testing in suspected deep vein thrombosis. A management study.","Kearon, Clive","","$61,875,162.00"
"Kovacs, Michael","Medicine","2013/03","2014/02","","Funded","False","True","Principal Site Investigator","A randomized, open-label, parallel-group, multi-center study for the evaluation of efficacy and safety of edoxaban monotherapy versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis","","","$45,883,508.00"
"Lazo Langner, Alejandro","Medicine","2013/07","2015/06","Grants","Funded","True","False","Principal Applicant","Immigration and the epidemiology of venous thromboembolism","Alejandro Lazo-Langner","","$11,700,862.00"
"Lazo Langner, Alejandro","Medicine","2013/07","2015/06","Grants","Funded","True","False","Principal Applicant","Immigration and the epidemiology of venous thromboembolism","A Lazo-Langner","","$9,813,349.00"
"Lazo Langner, Alejandro","Medicine","2008/07","2011/07","Grants","Funded","True","False","Collaborator","Remote Ischemic Postconditioning During Percutaneous Coronary Intervention (RIP–PCI trial). Effect on Coronary Flow Reserve and Ischemic Complications","Shahar Lavi","Samuel Siu, Geoffrey Pickering, Murray Huff, Patrick Teefy, Michael Keeney, Alejandro Lazo-Langner","$32,666,820.00"
"Lazo Langner, Alejandro","Medicine","2015","2017/06","Grants","Funded","True","False","Co-Applicant","Analysis of pro-coagulant and thrombin generation markers for the prediction of therapeutic failure during anticoagulation in cancer patients at high risk for recurrence of venous thromboembolism: a pilot study (REMARK)","PS Wells","","$65,452,243.00"
"Lazo Langner, Alejandro","Medicine","2010/07","present","Clinical Trials","Funded","True","True","Site Investigator","Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST)","L Minuk","","$50,625,633.00"
"Lazo Langner, Alejandro","Medicine","2011/07","2012/06","Clinical Trials","Funded","True","True","Site Investigator","A Phase II Study of using a combination of Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients who have received Bortezomib based induction for Newly Diagnosed Multiple Myeloma followed by Lenalidomide Maintenance until Disease Progression","L Minuk","","$6,189,907.00"
"Lazo Langner, Alejandro","Medicine","2013/07","present","Clinical Trials","Funded","True","False","Site Investigator","Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (12-049)","L Minuk","","$49,625,084.00"
"Lazo Langner, Alejandro","Medicine","2013/07","present","Grants","Funded","True","False","Co-Investigator","EINSTEIN PTS STUDY. Incidence of the post-thrombotic syndrome in patients with proximal deep vein thrombosis treated for the first 3 to 12 months with rivaroxaban or conventional anticoagulation (enoxaparin followed by vitamin K antagonists). Retrospective investigator-initiated study on patients recruited in a randomized clinical trial (Einstein DVT)","P Prandoni","","$73,008,020.00"
"Lazo Langner, Alejandro","Medicine","2013/07","present","Clinical Trials","Funded","True","True","Site Investigator","A randomized, open-label, parallel-group, multi-center study for the evaluation of efficacy and safety of edoxaban monotherapy versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis – edoxaban thrombus reduction imaging study (eTRIS)","M Kovacs","","$60,226,755.00"
"Lazo Langner, Alejandro","Medicine","2013/07","present","Clinical Trials","Funded","True","True","Site Investigator","A Randomized, Open-Label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma","L Minuk","","$14,342,871.00"
"Leong-Sit, Peter","Medicine","2013/03","2016/01","Clinical Trials","Funded","False","True","Principal Investigator","Rhythm Evaluation for AntiCoagulaTion with COntinuous Monitoring","Peter Leong-Sit","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$48,637,690.00"
"McManus, Ruth","Medicine","2013/01","2016/07","Grants","Funded","True","False","Collaborator","MiTy Kids (Metformin in women with Type 2 diabetes in pregnancy Kids trial)","Dr Denice Feig","L Donovan, E Ryan, J Booth, R Houlden, A Godbut, Kader, S Meltzer, J Lee, H Clark, J Wiesnagel, G Garso, A Galway, M Wolfs, L Lipscombe, J Low, S Gandhi, D Thompson, J Shaban, S Ludwig, D Miller.","$67,548,158.00"
"McManus, Ruth","Medicine","2013/01","2016/07","Grants","Funded","True","False","Principal Site Investigator","Conceppt: Continuous glucose monitoring in women with type 1 diabetes in pregnancy trial","Dr D Feig","","$7,827,460.00"
"Licskai, Christopher","Medicine","2013/09","2014/09","Grants","Funded","True","False","Co-Applicant","A Smartphone App Which Helps Patients with Asthma to Help Their Doctors To Help Them","Dr. Samir Gupta","Sharon Strauss, Louis-Philippe Boulet, Anthony Levinson, David Chan, Gina Agarwal, Muhammad Mamdani, Joseph Cafazzo, Joanna Sale","$45,705,148.00"
"Licskai, Christopher","Medicine","2010/07","2011/06","Grants","Funded","True","False","Principal Applicant","AQHI - Integrating AQHI into Asthma Action Plans to Improve Asthma Outcomes","Christopher Licskai","Madonna Ferrone, Todd Sands","$7,237,613.00"
"Licskai, Christopher","Medicine","2011/07","2012/02","Grants","Funded","True","False","Principal Applicant","AQHI - Integrating AQHI into Asthma Action Plans to Improve Asthma Outcomes - Phase 2","Christopher Licskai","Madonna Ferrone, Todd Sands","$49,084,787.00"
"Licskai, Christopher","Medicine","2010/06","2011/05","Grants","Funded","False","True","Principal Investigator","Clinical Pilot to Evaluate the Reliability and Accuracy of ThinPrep Sputum Differential Cell Counts in Patients with Moderate to Severe Asthma","Christopher Licskai","Michelle Weir","$18,613,203.00"
"user, name","Medicine","2013/07","2016/06","Grants","Funded","True","False","Principal Investigator","This is the long title that I am entering in.","Paul Malcomson","","$33,550,203.00"
"Borrie, Michael","Medicine","2014/07","2016/07","Clinical Trials","Funded","True","False","Co-Investigator","Prediction Progression to Dementia in the Alzheimer Disease and Neuroimaging Initiative Cohort","Rob Bartha","Michael Borrie","$34,458,064.00"
"Borrie, Michael","Medicine","2011/07","2012/06","Grants","Funded","True","False","Clinician/Scientist","The role of ischemic vasculopathy in adult onset neurodegenerative diseases and the creation of the Dementia Network of Ontario Research Database (DNORD)","","","$62,014,944.00"
"Moist, Louise","Medicine","2013","2015","Grants","Funded","True","False","Principal Investigator","","Dr. Louise Moist","","$36,980,842.00"
"Moist, Louise","Medicine","2012","2014","Grants","Funded","True","False","Co-Investigator","","Dr. Immaculate Nevis","","$11,022,313.00"
"Moist, Louise","Medicine","2010","2011","Grants","Funded","True","False","Co-Investigator","","Dr. Gihad Nesrallah","","$74,633,319.00"
"Moist, Louise","Medicine","2008","2015","Grants","Funded","True","True","Collaborator","","Dr. Adeera Levin","","$30,626,715.00"
"Moist, Louise","Medicine","2011","2013","Grants","Funded","True","True","Co-Investigator","","Dr. Anthony Jevnikar","","$61,828,565.00"
"Moist, Louise","Medicine","2006","2007","Grants","Funded","False","True","Principal Investigator","","Dr. Louise Moist","","$3,247,579.00"
"Barra, Lillian","Medicine","2014/04","2018/05","Grants","Funded","True","False","Co-Investigator","The role of anti-homocitrullinated protein/peptide immune responses in Rheumatoid Arthritis","Ewa Cairns","D. Bell and L. Barra","$22,537,520.00"
"Yee, Raymond","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Principal Site Investigator","ALternate Site Cardiac ReSYNChronization","Mireille van Ginneken","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$45,579,405.00"
"Yee, Raymond","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Risk Estimation Following Infarction Non-invasive Evaluation - ICD efficacy","Derek Exner","Skanes, Allan Manlucu, Jaimie Leong-Sit, Peter Gula, Lorne Tang, Anthony","$15,959,295.00"
"Yee, Raymond","Medicine","2012/05","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Syncope: Pacing or Recording in the Later Years","Robert Sheldon","Peter Leong-Sit, Jaimie Manlucu","$51,461,104.00"
"Yee, Raymond","Medicine","2010/05","2013/05","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Adaptive CRT Study","Dave Munneke","Lorne Gula, Peter Leong-Sit, Allan Skanes","$16,352,969.00"
"Yee, Raymond","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Model 20066 LV Lead Study","Mark Lazeroms, Senior Scientist","Peter Leong-Sit","$51,866,769.00"
"Yee, Raymond","Medicine","2011/08","present","Clinical Trials","Funded","False","True","Principal Site Investigator","PainFree SST Clinical Study","Dan Lexcen","Lorne Gula, Peter Leong-Sit, Allan Skanes","$48,071,197.00"
"Yee, Raymond","Medicine","2011/11","2013/09","Clinical Trials","Funded","False","True","Principal Site Investigator","Universal Antitachycardia Pacing 2.0 Download Study","Paul Belk","Skanes, Allan Leong-Sit, Peter","$53,145,475.00"
"Yee, Raymond","Medicine","2010/06","2013/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Fidelis Lead Canadian X-ray Study","Josee Morissette","","$16,904,527.00"
"Yee, Raymond","Medicine","2011/12","2012/08","Clinical Trials","Funded","False","True","Principal Site Investigator","High Septal Pacing for Cardiac Resynchronization Therapy (HISTORY) Acute Research Study","Dorothee Marossero","Peter Leong-Sit","$42,551,359.00"
"Martin, Claudio","Medicine","2013/03","2014/02","Grants","Funded","True","False","Principal Applicant","Critical Care Vital Signs Monitor: Performance Indicators and Quality Improvement in Critical Care","Claudio Martin","Nayib Ayas, Carla Chrusch, Dev Jayaraman, Denny Laporta, John Muscedere, Kendiss Olafson, Clare Ramsey, Tom Stelfox,","$73,586,526.00"
"Yee, Raymond","Medicine","2007/08","2013/04","Clinical Trials","Funded","False","True","Principal Site Investigator","International Study on Syncope of Uncertain Etiology 3","Michele Brignole","Klein, George","$24,512,528.00"
"Yee, Raymond","Medicine","2010/10","2012/08","Clinical Trials","Funded","False","True","Principal Site Investigator","Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT device","Angelo Auricchio","George Klein","$20,357,150.00"
"Yee, Raymond","Medicine","2013/08","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography (ICSY01)","Francois Philippon","Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$10,977,600.00"
"Yee, Raymond","Medicine","2011/02","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Safety of Sports for Patients with Implantable Cardioverter-Defibrillators: A Multicentre Registry","Rachel Lampert","Peter Leong-Sit, Jaimie Manlucu","$52,213,902.00"
"Skanes, Allan","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","ALternate Site Cardiac ReSYNChronization","Mireille van Ginneken","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$47,504,765.00"
"Manlucu, Jaimie","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","ALternate Site Cardiac ReSYNChronization","Mireille van Ginneken","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$13,881,680.00"
"Gula, Lorne","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","ALternate Site Cardiac ReSYNChronization","Mireille van Ginneken","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$1,368,015.00"
"Leong-Sit, Peter","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","ALternate Site Cardiac ReSYNChronization","Mireille van Ginneken","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$43,865,367.00"
"Spaic, Tamara","Medicine","2014","","Grants","Funded","False","False","Co-Investigator","Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes","Dr. Irene Hramiak","","$26,196,464.00"
"Adams, Paul","Medicine","2014/07","2017/06","Grants","Applied","False","False","Co-Principal Investigator","Genetic modifiers of iron status in hemochromatosis HFE C282Y homozygotes","Christine McLaren","McLaren C, McLaren G, Barton J, Emond M, Gurrin L, Nickerson D, Parker C, Phatak P, Powell L, Subramanian L","$74,875,311.00"
"Adams, Paul","Medicine","2011/07","2012/06","Grants","Applied","False","False","Co-Principal Investigator","Function and role in virulence of novel proteins from Helicobacter pylori.","","Creuzenet C","$67,723,323.00"
"Hegele, Robert","Medicine","2013/01","2017/01","Grants","Funded","True","False","Co-Principal Investigator","Personalized medicine strategies for molecular diagnostics and targeted therapeutics of cardiovascular diseases.","Jean-Claude Tardif","Marie-Pierre Dubé, Robert A. Hegele","$66,477,203.00"
"Yamashita, Cory","Medicine","2014/06","2015/05","Grants","Funded","True","False","Principal Investigator","Antimicrobial Peptide Fortified Surfactant for the Treatment of Cystic Fibrosis","Dr. Cory Yamashita","Dr. Veldhuizen, Dr. Lewis, Dr. Delport, Dr. Haagsman","$28,972,646.00"
"Lewis, James","Medicine","2014/05","2016/04","Grants","Funded","True","False","Co-Applicant","Antimicrobial peptide fortified surfactant for the treatment of cystic fibrosis","Cory Yamashita","Jim Lewis, Ruud Veldhuizen","$50,716,891.00"
"Rohekar, Sherry","Medicine","2013/02","2013/12","Grants","Funded","True","False","Principal Investigator","CRA/SPARCC Spondyloarthritis Guidelines","Sherry Rohekar","","$29,369,464.00"
"Kostuk, William","Medicine","2005/04","2015/06","Grants","Funded","False","True","Principal Site Investigator","Multicentre, double-blind, randomized study to establish the clinical benefit and safety of vytorin (ezetimibe/simvastatn tablet) vs simvastatn monotherapy in high-risk subjects presenting with acute coronary syndrome (IMPROVE-IT).","Dr. William J. Kostuk","None","$1,711,388.00"
"Martin, Claudio","Medicine","2013/10","2016/09","Grants","Funded","True","False","Principal Investigator","Targeted Exercise Intervention to Reduce Morbidity and Mortality in Sepsis","Claudio Martin","Chris Ellis, Gedas Cepinskas, Rob Hammond, Tina Mele, Michael Sharpe, Keith St Lawrence, Daniel Goldman, Doug Fraser, Kevin Shoemaker","$11,311,440.00"
"Hegele, Robert","Medicine","2007/04","2014/03","Grants","Funded","True","False","Principal Investigator","Canada Research Chair in Human Genetics, Tier 1 (Renewal) (for 7 years)","Robert A. Hegele","","$66,542,732.00"
"Feagan, Brian","Medicine","2013/09","2015/09","Clinical Trials","Funded","False","True","Co-Investigator","A Study to Evaluate the Pharmacokinetics of Adalimumab in Combination with Methotrexate for the Treatment of Patients with Ulcerative Colitis","Dr. Barnett","","$74,882,651.00"
"Khanna, Reena","Medicine","2013/04","2015/07","Clinical Trials","Funded","False","True","Co-Investigator","A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn’s Disease","Brian Feagan","","$27,045,570.00"
"Khanna, Reena","Medicine","2013/04","2015/07","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 2a Study to evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or are Intolerant to Anti-tumor Necrosis Factor-alpha","Brian Feagan","","$20,659,632.00"
"Khanna, Reena","Medicine","2013/07","2015/07","Clinical Trials","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC)","Brian Feagan","","$6,942,505.00"
"Khanna, Reena","Medicine","2013/04","2015/04","Clinical Trials","Funded","False","True","Co-Investigator","A Double-Blind, Randomized, Placebo-Controlled, Parallel, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-00547659 In Subjects With Moderate To Severe Ulcerative Colitis (Turandot)","Brian Feagan","","$40,368,015.00"
"Khanna, Reena","Medicine","2011/07","2012/06","Clinical Trials","Funded","False","True","Co-Investigator","A Multicenter Open-Label Extension Study To Assess Long-Term Safety Of PF-00547659 In Subjects With Ulcerative Colitis (Turandot II)","Brian Feagan","","$1,086,620.00"
"Khanna, Reena","Medicine","2013/07","2015/07","Clinical Trials","Funded","False","True","Principal Investigator","A Randomized, Active-Controlled, Double-Blind, and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2g/day for the Treatment of Active Ulcerative Colitis","Khanna, R.","","$9,609,441.00"
"Khanna, Reena","Medicine","2012/11","2014/11","Clinical Trials","Funded","False","True","Co-Investigator","A randomized, double-blind, multiple dose placebo controlled study to evaluate the safety, tolerability and efficacy of AMG 181 in subjects with moderate to severe ulcerative colitis","Brian Feagan","","$24,209,561.00"
"Khanna, Reena","Medicine","2012/11","2014/11","Clinical Trials","Funded","False","True","Co-Investigator","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn’s Disease","Brian Feagan","","$73,723,866.00"
"Khanna, Reena","Medicine","2012/11","2014/11","Clinical Trials","Funded","False","True","Co-Investigator","• OCTAVE A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral CP-690, 550 as an induction, therapy in subjects with moderate to severe ulcerative colitis","Brian Feagan","","$43,442,747.00"
"Khanna, Reena","Medicine","2012/11","2014/11","Clinical Trials","Funded","False","True","Co-Investigator","• OCTAVE A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral CP-690, 550 as a maintenance therapy in subjects with moderate to severe ulcerative colitis","Brian Feagan","","$7,140,988.00"
"Khanna, Reena","Medicine","2012/11","2014/11","Clinical Trials","Funded","False","True","Co-Investigator","OCTAVE A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral CP-690, 550 as an open-label therapy in subjects with moderate to severe ulcerative colitis","Brian Feagan","","$12,020,101.00"
"Khanna, Reena","Medicine","2013/01","2015/01","Clinical Trials","Funded","False","True","Co-Investigator","RPC01-202 - A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study To Evaluate The Clinical Efficacy And Safety Of Induction Therapy With Rpc1063 In Patients With Moderately To Severely Active Ulcerative Colitis","Brian Feagan","","$19,158,245.00"
"van Uum, Stanislaus","Medicine","2012/10","2014/10","Grants","Funded","True","True","Co-Applicant","The Effect of an Inter-Disciplinary Program, Including Mindfulness Based Stress Reduction, on Psychosocial Function, Pain and Metabolism in Patients with Painful Diabetic Peripheral Neuropathy.","JHOward Nathan","Samantha Lynn Co-Investigators: CHAITON, Michael Oliver ; KATES, Nick ; KOREN, Gideon ; LOBO, Daniela Sabbatini Silva ; MENZIES, Peter Michael ; TYNDALE, Rachel Fynvola ; VAN UUM, Stanislaus ; VERJEE, Zulfikarali","$27,591,198.00"
"Skanes, Allan","Medicine","2011/12","2016/05","Clinical Trials","Funded","False","True","Principal Applicant","Dabigatran for Peri-Procedural Anticoagulation during Radiofrequency Ablation of Atrial Fibrillation","Allan Skanes","Lorne Gula, George Klein, Jaimie Manlucu, Peter Leong-Sit, Raymond Yee","$21,886,329.00"
"Gula, Lorne","Medicine","2011/12","present","Clinical Trials","Funded","False","True","Co-Investigator","Dabigatran for Peri-Procedural Anticoagulation during Radiofrequency Ablation of Atrial Fibrillation","Allan Skanes","Lorne Gula, George Klein, Jaimie Manlucu, Peter Leong-Sit, Raymond Yee","$19,154,807.00"
"Klein, George","Medicine","2011/12","present","Clinical Trials","Funded","False","True","Co-Investigator","Dabigatran for Peri-Procedural Anticoagulation during Radiofrequency Ablation of Atrial Fibrillation","Allan Skanes","Lorne Gula, George Klein, Jaimie Manlucu, Peter Leong-Sit, Raymond Yee","$11,737,463.00"
"Leong-Sit, Peter","Medicine","2011/12","present","Clinical Trials","Funded","False","True","Co-Investigator","Dabigatran for Peri-Procedural Anticoagulation during Radiofrequency Ablation of Atrial Fibrillation","Allan Skanes","Lorne Gula, George Klein, Jaimie Manlucu, Peter Leong-Sit, Raymond Yee","$5,360,183.00"
"Manlucu, Jaimie","Medicine","2011/12","present","Clinical Trials","Funded","False","True","Co-Investigator","Dabigatran for Peri-Procedural Anticoagulation during Radiofrequency Ablation of Atrial Fibrillation","Allan Skanes","Lorne Gula, George Klein, Jaimie Manlucu, Peter Leong-Sit, Raymond Yee","$11,856,336.00"
"Yee, Raymond","Medicine","2011/12","present","Clinical Trials","Funded","False","True","Co-Investigator","Dabigatran for Peri-Procedural Anticoagulation during Radiofrequency Ablation of Atrial Fibrillation","Allan Skanes","Lorne Gula, George Klein, Jaimie Manlucu, Peter Leong-Sit, Raymond Yee","$37,885,618.00"
"Gula, Lorne","Medicine","2009/12","present","Clinical Trials","Funded","True","False","Principal Investigator","Randomized trial of circumferential versus segmental antral isolation in paroxysmal atrial fibrillation","Lorne Gula","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$35,359,201.00"
"Klein, George","Medicine","2009/12","present","Grants","Funded","True","False","Co-Investigator","Randomized trial of circumferential versus segmental antral isolation in paroxysmal atrial fibrillation","Lorne Gula","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$51,694,155.00"
"Leong-Sit, Peter","Medicine","2009/12","2014/07","Grants","Funded","True","False","Principal Applicant","Randomized trial of circumferential versus segmental antral isolation in paroxysmal atrial fibrillation","Lorne Gula","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$62,724,115.00"
"Manlucu, Jaimie","Medicine","2009/12","present","Clinical Trials","Funded","True","False","Co-Investigator","Randomized trial of circumferential versus segmental antral isolation in paroxysmal atrial fibrillation","Lorne Gula","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$57,120,684.00"
"Skanes, Allan","Medicine","2009/12","present","Clinical Trials","Funded","True","False","Co-Investigator","Randomized trial of circumferential versus segmental antral isolation in paroxysmal atrial fibrillation","Lorne Gula","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$14,316,199.00"
"Yee, Raymond","Medicine","2009/12","present","Clinical Trials","Funded","True","False","Co-Investigator","Randomized trial of circumferential versus segmental antral isolation in paroxysmal atrial fibrillation","Lorne Gula","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$47,716,359.00"
"Klein, George","Medicine","2009/06","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Hospital Acquired Long QT Syndrome","Andrew Krahn","Lorne Gula, Allan Skanes, Raymond Yee","$22,256,649.00"
"Gula, Lorne","Medicine","2009/06","2014/03","Clinical Trials","Funded","True","False","Co-Investigator","Hospital Acquired Long QT Syndrome","Andrew Krahn","Lorne Gula, Allan Skanes, Raymond Yee","$72,872,780.00"
"Skanes, Allan","Medicine","2009/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Hospital Acquired Long QT Syndrome","Andrew Krahn","Lorne Gula, Allan Skanes, Raymond Yee","$18,037,930.00"
"Yee, Raymond","Medicine","2009/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Hospital Acquired Long QT Syndrome","Andrew Krahn","Lorne Gula, Allan Skanes, Raymond Yee","$55,635,382.00"
"Klein, George","Medicine","2011/11","present","Grants","Funded","True","False","Principal Site Investigator","Canadian National ARVC Registry","Andrew Krahn","Jaimie Manlucu, Raymond Yee, Anthony Tang","$65,000,296.00"
"Klein, George","Medicine","2010/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Development of a Dedicated Atrial Fibrillation Clinic and Research Database","Lorne Gula","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$65,006,166.00"
"Klein, George","Medicine","2004/04","present","Grants","Funded","False","True","Principal Site Investigator","Cardiac Arrest Survivors with Preserved Ejection fraction Registry","Andrew Krahn","Anthony Tang","$28,021,397.00"
"Yee, Raymond","Medicine","2004/01","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Implantable Cardiac Defibrillator (ICD) Database","Raymond Yee","George Klein, Allan Skanes","$70,422,557.00"
"Klein, George","Medicine","2004/01","present","Grants","Funded","True","False","Co-Investigator","Implantable Cardiac Defibrillator (ICD) Database","Raymond Yee","George Klein, Allan Skanes","$68,020,066.00"
"Skanes, Allan","Medicine","2004/01","present","Grants","Funded","True","False","Co-Investigator","Implantable Cardiac Defibrillator (ICD) Database","Raymond Yee","George Klein, Allan Skanes","$47,212,678.00"
"Mehta, Sanjay","Medicine","2013/01","2015/01","Clinical Trials","Funded","False","True","Principal Investigator","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Study of Ambrisentan in Subjects with Chronic Thromboembolic PH (CTEPH)","S Mehta","","$45,693,414.00"
"Mehta, Sanjay","Medicine","2013/01","2013/12","Clinical Trials","Funded","False","True","Principal Investigator","EAS – Early Access Study for Riociguat Treatment of Patients with Chronic Thromboembolic PH (CTEPH)","S Mehta","","$63,907,663.00"
"Jevnikar, Anthony","Medicine","2013/04","2018/03","Grants","Funded","True","False","Co-Applicant","Canadian National Transplant Research Program: Increasing Donation and Improving Transplantation Outcomes","Dr. L. West","Caulfield T, Hebert, MJ, Humar A, Knoll G, Levings M, Mital S, Roy DC, Schultz K, Shapiro J","$3,115,471.00"
"Blake, Peter","Medicine","2011/10","2012/09","Grants","Funded","False","True","Co-Investigator","","Jain AK","Blake PG","$48,604,730.00"
"Hramiak, Irene","Medicine","2014/11","2015/10","Clinical Trials","Funded","False","True","Principal Investigator","To assess the efficacy and safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus.","IM Hramiak","TL Paul, T Spaic","$62,772,233.00"
"Hramiak, Irene","Medicine","2013/09","2015/08","Clinical Trials","Funded","False","True","Principal Investigator","Efficacy and safety of FIAsp compared to insulin aspart both in conmbination with insulin detemir in adults with type 1 diabetes","IM Hramiak","TL Paul, T Spaic","$35,720,147.00"
"Montero Odasso, Manuel","Medicine","2014/04","2019/04","Grants","Funded","True","False","Co-Principal Investigator","Motor, Exercise and Cognition Team (MEC), Canadian Consortium on Neurodegeneration in Aging (CCNA)","Howard Chertkow","Co-Leader - Louis Bherer, Quincy Almeida, Richard Camicioli, Julien Doyon, Karen Li, Teresa Liu-Ambrose, Laura Middleton, Jose Morais, William McIlroy","$7,172,596.00"
"Montero Odasso, Manuel","Medicine","2013/07","2014/01","Grants","Funded","True","False","Co-Principal Investigator","Canadian Consortium on Neurodegeneration in Aging (CCNA) - Letter of Intent","Howard Chertkow","","$3,487,313.00"
"Pickering, J. Geoffrey","Medicine","2013/07","2015/11","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Dr. Hao Yin","J.G. Pickering","","$2,530,887.00"
"Pickering, J. Geoffrey","Medicine","2013/09","2014/03","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Krista Hawrylyshyn","J.G. Pickering","","$30,539,853.00"
"Blake, Peter","Medicine","2010/01","2014/01","Grants","Funded","False","False","Co-Investigator","A Comparative Study of Two Competing Home Dialysis Modalities: A prospective cohort study comparing short-daily hemodialysis and peritoneal dialysis survival, hospitalization and vascular access outcomes; a DaVita and USRDS Database Linkage Study","Nesrallah G","Lindsay R, Blake PG, Garg A, Suri R","$33,281,435.00"
"Sen, Mithu","Medicine","2013/10","2018/09","Grants","Funded","True","False","Collaborator","Using neuroimaging to assess cognitive function after serious brain injury","Adrian Owen","Rhodri Cusack, Gordon Bryan Young","$49,355,007.00"
"Kovacs, Michael","Medicine","2013/07","2013/06","Grants","Funded","True","False","Co-Investigator","The SOX Trial: Disseminating the unexpected results of a large, CIHR-funded North American RCT of elastic compression stockings to prevent the post-thrombotic syndrome.","","","$49,612,861.00"
"House, Andrew","Medicine","2011/06","2013/05","Grants","Funded","True","False","Co-Principal Investigator","Non-renal metabolism of drugs in patients with varying degrees of chronic kidney disease","Brad Urquhart","","$30,929,526.00"
"House, Andrew","Medicine","2012/02","2015/01","Grants","Funded","True","False","Principal Investigator","Novel Strategies for Lowering Plasma Homocysteine in Humans","House AA","Brad Urquhart","$44,791,283.00"
"Borrie, Michael","Medicine","2013/03","2016/12","Grants","Funded","False","True","Principal Investigator","A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer’s Disease. (Protocol No. MK-8931-017-07) (also known as SCH 900931, P07738)","Michael Borrie","Jennie Wells","$46,106,466.00"
"Borrie, Michael","Medicine","2013/10","2016/10","Grants","Funded","False","True","Co-Investigator","A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease","Dr. Jennie Wells","Dr. Elizabeth Finger Dr. Stephen Pasternak","$46,487,970.00"
"Borrie, Michael","Medicine","2013/11","2016/11","Grants","Funded","False","True","Principal Investigator","Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo","Dr. Michael Borrie","Dr. Jennie Wells","$9,354,965.00"
"Borrie, Michael","Medicine","2011/10","2014/06","Grants","Funded","False","True","Principal Investigator","A multicenter, open-label, long-term safety extension of phase II studies ABE4869g and ABE4955g in patients with mild to moderate Alzheimer’s disease","Michael Borrie","Jennie Wells","$10,937,297.00"
"Borrie, Michael","Medicine","2011/07","2016/06","Grants","Funded","True","False","Principal Investigator","Alzheimer's Disease Neuroimaging Initiative-2 (ADNI-2)","","Jennie Wells","$68,560,335.00"
"Borrie, Michael","Medicine","2014/12","2018/12","Grants","Funded","True","False","Co-Investigator","Canadian Consortium on Neurodegeneration in Aging Clinical Cohorts","Howard Chertkow","","$23,299,185.00"
"Mura, Marco","Medicine","2014/01","2015/12","Grants","Funded","True","False","Principal Investigator","Ascertainment of the best prognostic serum biomarker in idiopathic pulmonary fibrosis: a pilot study","Marco Mura","","$10,851,280.00"
"Sen, Mithu","Medicine","2009","2012/09","Grants","Funded","True","False","Site Investigator","Site grant = $1500/pt; 17 patients enrolled at Victoria Hospital for total of $25,500","Co-PI's - Drs. Maureen Meade & Niall Ferguson","Site Lead Victoria Hospital = Dr. Mithu Sen","$18,178,394.00"
"Licskai, Christopher","Medicine","2014/01","2016/09","Grants","Funded","True","False","Co-Investigator","Impact of Air Pollution and Climate Change on the Incidence, Exacerbation and Progression of Asthma and COPD","Dr. Shawn Aaron","To,T., Gershon, A., Lougheed, D., Villeneuve, P., Chen, H., Crighton, E., Su, Y.","$58,323,329.00"
"Diachun, Laura","Medicine","2013/01","2013/12","Grants","Funded","True","False","Research Supervisor","Yin Hui, summer student: Research project ""Teaching and Learning Elder Care: How is the 'Older Patient' Presented to Medical Students by Geriatric and Non-Specialist Clinical Teachers""","Laura Diachun","","$57,100,223.00"
"Diachun, Laura","Medicine","2011/01","2011/12","Grants","Funded","True","False","Principal Investigator","""Comparing the Characterization of Geriatric Care by Medical Teams at Two Short-Term Inpatient Care Sites""","Diachun L.","","$51,019,050.00"
"Diachun, Laura","Medicine","2012/01","2012/12","Grants","Funded","True","False","Research Supervisor","Yin Hui, summer student: Research project ""Teaching and Learning Elder Care: How is the 'Older Patient' Presented to Medical Students by Geriatric and Non-Specialist Clinical Teachers""","Laura Diachun","","$33,055,915.00"
"Fraser, Lisa-Ann","Medicine","2014/05","2016/05","Grants","Funded","False","False","Principal Applicant","A Pilot Clinic to Improve Osteoporosis Care and Outcomes for Patients Suffering a Non-Traumatic Fracture","Lisa-Ann Fraser","","$34,424,366.00"
"Lavi, Shahar","Medicine","2013/04","present","Clinical Trials","Funded","True","True","Site Investigator","Management of Myocardial Injury After Non Cardiac Surgery","Philip J Devereaux","","$8,488,671.00"
"Lavi, Shahar","Medicine","2013/10","present","Clinical Trials","Funded","False","True","Site Investigator","Long-Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease in post myocardial infarction patients","David Brieger","","$26,994,026.00"
"Lavi, Shahar","Medicine","2014/07","present","Clinical Trials","Applied","True","False","Co-Investigator","Exenatide for Myocardial Protection during RepErfusion Study: A double- blind, placebo-controlled trial","Vladimír Džavík","","$491,135.00"
"Lavi, Shahar","Medicine","2012/10","present","Clinical Trials","Funded","True","False","Principal Site Investigator","International Study of Comparative Health Effectiveness with Medical and Invasive Approaches","David J Maron","","$16,580,670.00"
"Lavi, Shahar","Medicine","2012/10","present","Clinical Trials","Funded","False","True","Site Investigator","GLobal Assessment of plaque reGression with a PCSK9 antibOdy as measured by intraVascular ultrasound","Amgen","","$18,137,427.00"
"Lavi, Shahar","Medicine","2012/10","present","Clinical Trials","Funded","True","False","Co-Investigator","Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Primary PCI for STEMI","Shamir Mehta","","$48,538,669.00"
"Lavi, Shahar","Medicine","2013/09","2014/09","Grants","Funded","False","True","Principal Investigator","Peripheral Stimulation Device to Improve Coronary Flow Reserve in Coronary Artery Disease (PERCCAD)","Shahar Lavi","","$4,729,785.00"
"Peddle, Michael","Medicine","2007","2011","Grants","Funded","False","False","Co-Investigator","A Prospective Evaluation of Ketamine/Propofol vs. Ketamine alone for Procedural Sedation for Isolated Orthopedic Injury in the Paediatric Emergency Department","Shah, A","Reider, M Peddle, M Lehnhardt,K Mosdossy, G McLeod, S","$14,009,575.00"
"Gula, Lorne","Medicine","2010/04","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Ventricular Tachycardia Ablation vs Enhanced Drug Therapy in Structural Heart Disease","John Sapp - QE II Health Sciences Centre","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$44,868,909.00"
"Leong-Sit, Peter","Medicine","2010/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Development of a Dedicated Atrial Fibrillation Clinic and Research Database","Lorne Gula","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$25,165,158.00"
"Skanes, Allan","Medicine","2010/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Development of a Dedicated Atrial Fibrillation Clinic and Research Database","Lorne Gula","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$16,028,742.00"
"Yee, Raymond","Medicine","2010/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Development of a Dedicated Atrial Fibrillation Clinic and Research Database","Lorne Gula","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$33,726,078.00"
"Gula, Lorne","Medicine","2012/03","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Atrial Substrate Modification with Aggressive Blood Pressure Control to Prevent Atrial Fibrillation","Ratika Parkash","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$42,645,900.00"
"Manlucu, Jaimie","Medicine","2012/10","present","Clinical Trials","Funded","False","False","Co-Investigator","Ventricular Repolarization Measurements in Right Ventricle Paced Rhythm","Peter Leong-Sit","Lorne Gula, Jaimie Manlucu","$37,311,132.00"
"Gula, Lorne","Medicine","2012/10","present","Clinical Trials","Funded","False","False","Co-Investigator","Ventricular Repolarization Measurements in Right Ventricle Paced Rhythm","Peter Leong-Sit","Lorne Gula, Jaimie Manlucu","$6,914,156.00"
"Leong-Sit, Peter","Medicine","2012/10","present","Clinical Trials","Funded","False","False","Principal Investigator","Ventricular Repolarization Measurements in Right Ventricle Paced Rhythm","Peter Leong-Sit","Lorne Gula, Jaimie Manlucu","$32,744,187.00"
"Joy, Tisha","Medicine","2013/08","2019/08","Clinical Trials","Funded","False","True","Co-Investigator","DECLARE (D1693C00001): Dapagliflozin Effect on CardiovascuLAR Events. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.","I. Hramiak","T. Joy T. Paul C. McDonald","$49,512,805.00"
"Fraser, Lisa-Ann","Medicine","2013/12","2014/12","Grants","Funded","True","False","Principal Investigator","Bone Health in Type 1 Diabetes","Lisa-Ann Fraser","Tayyab Khan, Tamara Spaic","$39,523,045.00"
"Wells, Jennie","Medicine","2014/07","2019/07","Grants","Funded","True","False","Co-Investigator","Curing dementia with cough Medicine: a proof of principle trial of Amboxol in Parkinson's Disease dementia","Stephen Pasternak","Robert Bartha, Jennie Wells, Michael Borrie, Elizabeth Finger, Mary Jenkins, Mandar Jog, Michael Kovacs, Don Mahuran, Penny MacDonald, Tony Rupar, Keith St. Lawrence, Peggy Vandervoort, GY Zhou","$65,549,030.00"
"Yamashita, Cory","Medicine","2011/07","2012/06","Grants","Funded","True","False","Principal Investigator","Antimicrobial Peptide Fortified Surfactant for the Treatment of Cystic Fibrosis","Cory Yamashita","","$47,674,094.00"
"Joy, Tisha","Medicine","2012/01","present","Clinical Trials","Funded","False","True","Co-Investigator","A Multicenter Controlled Open-Label Extension Study to Assess the Long-term Safety and Efficacy of AMG 145 (OSLER)","Dr. R. Hegele","Dr. T. Joy","$40,552,181.00"
"Joy, Tisha","Medicine","2013/04","present","Clinical Trials","Funded","False","True","Co-Investigator","A Double-Blind, Randomized, placebo-controlled, Multicenter study to Evaluate the Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia (RUTHERFORD-2)","Dr. R. Hegele","Dr. T. Joy","$4,974,821.00"
"Joy, Tisha","Medicine","2013/08","present","Clinical Trials","Funded","False","True","Co-Investigator","A Double-blind, Randomized, Placebo-controlled multicenter study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is Used in Combination with statin therapy in Patients with Clinically Evident Cardiovascular Disease (FOURIER)","Dr. R. Hegele","Dr. T. Joy","$31,359,211.00"
"Joy, Tisha","Medicine","2011/07","2013/12","Clinical Trials","Funded","False","True","Co-Investigator","A 2-Part, Phase 2/3 study to Assess the Safety, Tolerability, and Efficacy of AMG 145 in Subjects with Homozygous Familial Hypercholesterolemia","Dr. R. Hegele","Dr. T. Joy","$68,685,065.00"
"Joy, Tisha","Medicine","2013/11","present","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia","Dr. R. Hegele","Dr. T. Joy","$72,915,379.00"
"Joy, Tisha","Medicine","2013/09","present","Clinical Trials","Funded","False","True","Co-Investigator","A Multicenter Controlled Open-label Extension Study to Assess Long-term Safety and Efficacy of AMG 145 (OSLER 2)","Dr. R. Hegele","Dr. T. Joy","$28,041,780.00"
"Joy, Tisha","Medicine","2013/11","present","Clinical Trials","Funded","False","True","Co-Investigator","A Multicenter, Open-label study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects with Severe Homozygous Familial Hypercholesterolemia (TAUSSIG)","Dr. R. Hegele","Dr. T. Joy","$12,120,216.00"
"Leong-Sit, Peter","Medicine","2013/02","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients with Cardiovascular Risk Factors","Jeff Healey & Stuart Connolly","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$25,409,101.00"
"Manlucu, Jaimie","Medicine","2013/04","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Attain Performa Quadripolar Lead Clinical Study","Kara Southall - Worldwide Clinical Trial Leader","Raymond Yee","$15,542,291.00"
"Leong-Sit, Peter","Medicine","2011/02","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial","Douglas L. Packer","Lorne Gula, Jaimie Manlucu, Allan Skanes","$45,958,831.00"
"Leong-Sit, Peter","Medicine","2013/07","present","Clinical Trials","Funded","False","False","Principal Site Investigator","The Prospective, Multicenter Canadian Atrial Fibrillation PVAC Cohort Study","Vidal Essebag & Atul Verma","Lorne Gula, Allan Skanes","$74,317,899.00"
"Gula, Lorne","Medicine","2013/02","present","Clinical Trials","Funded","False","False","Principal Site Investigator","Cardiac Sarcoidosis Multi-Center Cohort","David Birnie & Pablo Nery","Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$18,459,722.00"
"Skanes, Allan","Medicine","2013/06","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia","Adam Cline - Worldwide Clinical Trial Leader","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$64,943,813.00"
"Yee, Raymond","Medicine","2012/09","present","Clinical Trials","Funded","True","False","Principal Site Investigator","MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy","James White","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$54,271,613.00"
"Gula, Lorne","Medicine","2012/09","present","Clinical Trials","Funded","True","False","Co-Investigator","MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy","James White","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$72,854,844.00"
"Leong-Sit, Peter","Medicine","2012/09","present","Clinical Trials","Funded","True","False","Co-Investigator","MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy","James White","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$37,681,250.00"
"Manlucu, Jaimie","Medicine","2012/09","present","Clinical Trials","Funded","True","False","Co-Investigator","MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy","James White","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$9,645,213.00"
"Manlucu, Jaimie","Medicine","2013/01","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study: A Cluster Crossover Trial Comparing Conventional vs. Incremental Antibiotic Therapy for the Prevention of Arrhythmia Device","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$69,858,625.00"
"Leong-Sit, Peter","Medicine","2012/01","present","Clinical Trials","Funded","True","False","Principal Site Investigator","A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation","Anthony Tang","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$24,156,814.00"
"Skanes, Allan","Medicine","2012/10","2014/04","Clinical Trials","Funded","False","True","Principal Investigator","Prospective, single-arm study evaluating safety and performance of Rhythmia Medical’s electroanatomical mapping system and catheter in patients undergoing catheter ablation procedures for the treatment of cardiac tachyarrhythmias","Allan Skanes","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu","$9,058,669.00"
"Gula, Lorne","Medicine","2010/01","present","Clinical Trials","Funded","False","False","Co-Investigator","Adenosine following pulmonary vein isolation to target dormant conduction elimination.","Laurent Macle","Lorne Gula, Peter Leong-Sit","$40,992,554.00"
"Leong-Sit, Peter","Medicine","2010/01","present","Clinical Trials","Funded","False","False","Co-Investigator","Adenosine following pulmonary vein isolation to target dormant conduction elimination.","Laurent Macle","Lorne Gula, Peter Leong-Sit","$12,628,952.00"
"Skanes, Allan","Medicine","2012/02","2013/12","Clinical Trials","Funded","False","True","Principal Site Investigator","A Single-Arm Multi-Center Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard Over-the-Wire Mesh Ablation System","Claire Williams","Lorne Gula, Peter Leong-Sit","$24,002,633.00"
"Leong-Sit, Peter","Medicine","2009/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Monitoring of Ventricular Rhythm & Exercise - ICD sTudy (MOVE-IT)","Lorne Gula","Peter Leong-Sit, Neville Suskin","$35,778,885.00"
"Skanes, Allan","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Part II","Atul Verma","Lorne Gula, Peter Leong-Sit","$71,962,846.00"
"Manlucu, Jaimie","Medicine","2010/01","present","Clinical Trials","Funded","True","False","Principal Site Investigator","BRidge or continUe coumadin for device SurgEry randomized CONTROLled Trial","David Birnie & Vidal Essebag","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$58,945,045.00"
"Klein, George","Medicine","2012/05","2013/03","Clinical Trials","Funded","False","True","Principal Site Investigator","Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with Catecholaminergic Polymorphic Ventricular Tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period – Phase II exploratory study","P. Schwartz","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$74,393,562.00"
"Gula, Lorne","Medicine","2012/05","2013/06","Clinical Trials","Funded","False","True","Principal Site Investigator","A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator","Donna McAfee","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$20,755,468.00"
"Borrie, Michael","Medicine","2014/07","2016/07","Grants","Funded","True","False","Co-Applicant","Catalyst Grant: Secondary Analysis of Neurimaging Databases","Rob Bartha","Rob Bartha, N. Rajakumar","$46,661,555.00"
"Lavi, Shahar","Medicine","2014/07","2019/06","Clinical Trials","Funded","True","False","Co-Investigator","Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Primary PCI for STEMI","Shamir Mehta","","$62,331,745.00"
"Klein, George","Medicine","2010/04","present","Clinical Trials","Funded","True","False","Co-Investigator","Ventricular Tachycardia Ablation vs Enhanced Drug Therapy in Structural Heart Disease","John Sapp - QE II Health Sciences Centre","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$72,897,509.00"
"Leong-Sit, Peter","Medicine","2010/04","present","Clinical Trials","Funded","True","False","Co-Investigator","Ventricular Tachycardia Ablation vs Enhanced Drug Therapy in Structural Heart Disease","John Sapp - QE II Health Sciences Centre","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$67,284,109.00"
"Manlucu, Jaimie","Medicine","2010/04","present","Clinical Trials","Funded","True","False","Co-Investigator","Ventricular Tachycardia Ablation vs Enhanced Drug Therapy in Structural Heart Disease","John Sapp - QE II Health Sciences Centre","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$70,499,491.00"
"Skanes, Allan","Medicine","2010/04","present","Clinical Trials","Funded","True","False","Co-Investigator","Ventricular Tachycardia Ablation vs Enhanced Drug Therapy in Structural Heart Disease","John Sapp - QE II Health Sciences Centre","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$18,560,922.00"
"Yee, Raymond","Medicine","2010/04","present","Clinical Trials","Funded","False","False","Co-Investigator","Ventricular Tachycardia Ablation vs Enhanced Drug Therapy in Structural Heart Disease","John Sapp - QE II Health Sciences Centre","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$57,054,889.00"
"Gula, Lorne","Medicine","2013/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients with Cardiovascular Risk Factors","Jeff Healey & Stuart Connolly","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$21,695,043.00"
"Manlucu, Jaimie","Medicine","2013/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients with Cardiovascular Risk Factors","Jeff Healey & Stuart Connolly","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$9,828,461.00"
"Skanes, Allan","Medicine","2013/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients with Cardiovascular Risk Factors","Jeff Healey & Stuart Connolly","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$73,543,122.00"
"Yee, Raymond","Medicine","2013/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients with Cardiovascular Risk Factors","Jeff Healey & Stuart Connolly","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$67,568,449.00"
"Yee, Raymond","Medicine","2013/04","present","Clinical Trials","Funded","False","True","Co-Investigator","Attain Performa Quadripolar Lead Clinical Study","Kara Southall - Worldwide Clinical Trial Leader","Raymond Yee","$71,145,072.00"
"Gula, Lorne","Medicine","2011/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial","Douglas L. Packer","Lorne Gula, Jaimie Manlucu, Allan Skanes","$58,745,258.00"
"Manlucu, Jaimie","Medicine","2011/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial","Douglas L. Packer","Lorne Gula, Jaimie Manlucu, Allan Skanes","$2,014,078.00"
"Skanes, Allan","Medicine","2011/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial","Douglas L. Packer","Lorne Gula, Jaimie Manlucu, Allan Skanes","$64,005,427.00"
"Yee, Raymond","Medicine","2013/12","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in patients with Permanent Atrial Fibrillation ( RAFT-PermAF)","Anthony Tang","Lorne Gula, George Klein, Peter Leong-Sit, Jaimie Manlucu","$44,752,009.00"
"Gula, Lorne","Medicine","2013/12","present","Clinical Trials","Funded","True","False","Co-Investigator","Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in patients with Permanent Atrial Fibrillation ( RAFT-PermAF)","Anthony Tang","Lorne Gula, George Klein, Peter Leong-Sit, Jaimie Manlucu","$29,947,288.00"
"Klein, George","Medicine","2013/12","present","Clinical Trials","Funded","True","False","Co-Investigator","Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in patients with Permanent Atrial Fibrillation ( RAFT-PermAF)","Anthony Tang","Lorne Gula, George Klein, Peter Leong-Sit, Jaimie Manlucu","$50,381,244.00"
"Leong-Sit, Peter","Medicine","2013/12","present","Clinical Trials","Funded","True","False","Co-Investigator","Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in patients with Permanent Atrial Fibrillation ( RAFT-PermAF)","Anthony Tang","Lorne Gula, George Klein, Peter Leong-Sit, Jaimie Manlucu","$50,733,770.00"
"Manlucu, Jaimie","Medicine","2013/12","present","Clinical Trials","Funded","True","False","Co-Investigator","Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in patients with Permanent Atrial Fibrillation ( RAFT-PermAF)","Anthony Tang","Lorne Gula, George Klein, Peter Leong-Sit, Jaimie Manlucu","$74,070,043.00"
"Gula, Lorne","Medicine","2013/07","present","Clinical Trials","Funded","False","False","Co-Investigator","The Prospective, Multicenter Canadian Atrial Fibrillation PVAC Cohort Study","Vidal Essebag & Atul Verma","Lorne Gula, Allan Skanes","$40,968,595.00"
"Skanes, Allan","Medicine","2013/07","present","Clinical Trials","Funded","False","False","Co-Investigator","The Prospective, Multicenter Canadian Atrial Fibrillation PVAC Cohort Study","Vidal Essebag & Atul Verma","Lorne Gula, Allan Skanes","$73,761,193.00"
"Leong-Sit, Peter","Medicine","2013/02","present","Clinical Trials","Funded","False","False","Co-Investigator","Cardiac Sarcoidosis Multi-Center Cohort","David Birnie & Pablo Nery","Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$52,578,289.00"
"Manlucu, Jaimie","Medicine","2013/02","present","Clinical Trials","Funded","False","False","Co-Investigator","Cardiac Sarcoidosis Multi-Center Cohort","David Birnie & Pablo Nery","Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$54,377,063.00"
"Skanes, Allan","Medicine","2013/02","present","Clinical Trials","Funded","False","False","Co-Investigator","Cardiac Sarcoidosis Multi-Center Cohort","David Birnie & Pablo Nery","Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$50,463,008.00"
"Gula, Lorne","Medicine","2013/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia","Adam Cline - Worldwide Clinical Trial Leader","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$71,979,285.00"
"Leong-Sit, Peter","Medicine","2013/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia","Adam Cline - Worldwide Clinical Trial Leader","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$62,322,573.00"
"Manlucu, Jaimie","Medicine","2013/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia","Adam Cline - Worldwide Clinical Trial Leader","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$35,367,366.00"
"Gula, Lorne","Medicine","2013/01","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study: A Cluster Crossover Trial Comparing Conventional vs. Incremental Antibiotic Therapy for the Prevention of Arrhythmia Device","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$4,594,327.00"
"Leong-Sit, Peter","Medicine","2013/01","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study: A Cluster Crossover Trial Comparing Conventional vs. Incremental Antibiotic Therapy for the Prevention of Arrhythmia Device","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$17,287,796.00"
"Klein, George","Medicine","2013/01","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study: A Cluster Crossover Trial Comparing Conventional vs. Incremental Antibiotic Therapy for the Prevention of Arrhythmia Device","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$40,686,313.00"
"Skanes, Allan","Medicine","2013/01","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study: A Cluster Crossover Trial Comparing Conventional vs. Incremental Antibiotic Therapy for the Prevention of Arrhythmia Device","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$21,995,456.00"
"Yee, Raymond","Medicine","2013/01","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study: A Cluster Crossover Trial Comparing Conventional vs. Incremental Antibiotic Therapy for the Prevention of Arrhythmia Device","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$58,096,074.00"
"Gula, Lorne","Medicine","2012/01","present","Clinical Trials","Funded","True","False","Co-Investigator","A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation","Anthony Tang","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$6,815,751.00"
"Klein, George","Medicine","2012/01","present","Clinical Trials","Funded","True","False","Co-Investigator","A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation","Anthony Tang","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$31,512,804.00"
"Manlucu, Jaimie","Medicine","2012/01","present","Clinical Trials","Funded","True","False","Co-Investigator","A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation","Anthony Tang","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$21,062,784.00"
"Skanes, Allan","Medicine","2012/01","present","Clinical Trials","Funded","True","False","Co-Investigator","A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation","Anthony Tang","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$5,032,197.00"
"Gula, Lorne","Medicine","2013/03","present","Clinical Trials","Funded","False","True","Co-Investigator","Rhythm Evaluation for AntiCoagulaTion with COntinuous Monitoring","Rod Passman","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$40,658,884.00"
"Manlucu, Jaimie","Medicine","2013/03","present","Clinical Trials","Funded","False","True","Co-Investigator","Rhythm Evaluation for AntiCoagulaTion with COntinuous Monitoring","Rod Passman","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$6,106,039.00"
"Skanes, Allan","Medicine","2013/03","present","Clinical Trials","Funded","False","True","Co-Investigator","Rhythm Evaluation for AntiCoagulaTion with COntinuous Monitoring","Rod Passman","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$12,756,085.00"
"Yee, Raymond","Medicine","2013/03","present","Clinical Trials","Funded","False","True","Co-Investigator","Rhythm Evaluation for AntiCoagulaTion with COntinuous Monitoring","Rod Passman","Lorne Gula, Jaimie Manlucu, Allan Skanes, Raymond Yee","$15,783,324.00"
"Gula, Lorne","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Risk Estimation Following Infarction Non-invasive Evaluation - ICD efficacy","Derek Exner","Skanes, Allan Manlucu, Jaimie Leong-Sit, Peter Gula, Lorne","$26,481,192.00"
"Leong-Sit, Peter","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Risk Estimation Following Infarction Non-invasive Evaluation - ICD efficacy","Derek Exner","Skanes, Allan Manlucu, Jaimie Leong-Sit, Peter Gula, Lorne","$32,942,554.00"
"Skanes, Allan","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Risk Estimation Following Infarction Non-invasive Evaluation - ICD efficacy","Derek Exner","Skanes, Allan Manlucu, Jaimie Leong-Sit, Peter Gula, Lorne","$43,453,575.00"
"Manlucu, Jaimie","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Risk Estimation Following Infarction Non-invasive Evaluation - ICD efficacy","Derek Exner","Skanes, Allan Manlucu, Jaimie Leong-Sit, Peter Gula, Lorne","$63,383,719.00"
"Gula, Lorne","Medicine","2012/10","present","Clinical Trials","Funded","False","True","Co-Investigator","Prospective, single-arm study evaluating safety and performance of Rhythmia Medical’s electroanatomical mapping system and catheter in patients undergoing catheter ablation procedures for the treatment of cardiac tachyarrhythmias","Allan Skanes","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu","$58,944,859.00"
"Leong-Sit, Peter","Medicine","2012/10","present","Clinical Trials","Funded","False","True","Co-Investigator","Prospective, single-arm study evaluating safety and performance of Rhythmia Medical’s electroanatomical mapping system and catheter in patients undergoing catheter ablation procedures for the treatment of cardiac tachyarrhythmias","Allan Skanes","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu","$58,258,704.00"
"Manlucu, Jaimie","Medicine","2012/10","present","Clinical Trials","Funded","False","True","Co-Investigator","Prospective, single-arm study evaluating safety and performance of Rhythmia Medical’s electroanatomical mapping system and catheter in patients undergoing catheter ablation procedures for the treatment of cardiac tachyarrhythmias","Allan Skanes","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu","$56,398,073.00"
"Klein, George","Medicine","2012/03","present","Clinical Trials","Funded","True","False","Co-Investigator","Atrial Substrate Modification with Aggressive Blood Pressure Control to Prevent Atrial Fibrillation","Ratika Parkash","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$50,025,848.00"
"Leong-Sit, Peter","Medicine","2012/03","present","Clinical Trials","Funded","True","False","Co-Investigator","Atrial Substrate Modification with Aggressive Blood Pressure Control to Prevent Atrial Fibrillation","Ratika Parkash","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$3,085,713.00"
"Manlucu, Jaimie","Medicine","2012/03","present","Clinical Trials","Funded","True","False","Co-Investigator","Atrial Substrate Modification with Aggressive Blood Pressure Control to Prevent Atrial Fibrillation","Ratika Parkash","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$70,568,587.00"
"Skanes, Allan","Medicine","2012/03","present","Clinical Trials","Funded","True","False","Co-Investigator","Atrial Substrate Modification with Aggressive Blood Pressure Control to Prevent Atrial Fibrillation","Ratika Parkash","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$23,142,261.00"
"Yee, Raymond","Medicine","2012/03","present","Clinical Trials","Funded","True","False","Co-Investigator","Atrial Substrate Modification with Aggressive Blood Pressure Control to Prevent Atrial Fibrillation","Ratika Parkash","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$46,256,072.00"
"Leong-Sit, Peter","Medicine","2013/08","present","Clinical Trials","Funded","False","True","Co-Investigator","Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography (ICSY01)","Francois Philippon","Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$16,874,551.00"
"Manlucu, Jaimie","Medicine","2013/08","present","Clinical Trials","Funded","False","True","Co-Investigator","Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography (ICSY01)","Francois Philippon","Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$70,292,448.00"
"Leong-Sit, Peter","Medicine","2012/05","present","Clinical Trials","Funded","True","False","Co-Investigator","Syncope: Pacing or Recording in the Later Years","Robert Sheldon","Peter Leong-Sit, Jaimie Manlucu","$47,828,523.00"
"Manlucu, Jaimie","Medicine","2012/05","present","Clinical Trials","Funded","True","False","Co-Investigator","Syncope: Pacing or Recording in the Later Years","Robert Sheldon","Peter Leong-Sit, Jaimie Manlucu","$46,201,351.00"
"Manlucu, Jaimie","Medicine","2011/11","present","Clinical Trials","Funded","True","False","Co-Investigator","Canadian National ARVC Registry","Andrew Krahn","Jaimie Manlucu, Raymond Yee, Anthony Tang","$8,445,626.00"
"Yee, Raymond","Medicine","2011/11","present","Clinical Trials","Funded","True","False","Co-Investigator","Canadian National ARVC Registry","Andrew Krahn","Jaimie Manlucu, Raymond Yee, Anthony Tang","$59,426,549.00"
"Leong-Sit, Peter","Medicine","2011/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Safety of Sports for Patients with Implantable Cardioverter-Defibrillators: A Multicentre Registry","Rachel Lampert","Peter Leong-Sit, Jaimie Manlucu","$11,970,964.00"
"Manlucu, Jaimie","Medicine","2011/02","present","Clinical Trials","Funded","True","False","Co-Investigator","Safety of Sports for Patients with Implantable Cardioverter-Defibrillators: A Multicentre Registry","Rachel Lampert","Peter Leong-Sit, Jaimie Manlucu","$67,759,193.00"
"Manlucu, Jaimie","Medicine","2014/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","ECG Feedback for CRT Response","Jackie Mittelstadt - Clinical Research Specialist","Peter Leong-Sit, Anthony Tang","$22,304,588.00"
"Leong-Sit, Peter","Medicine","2014/01","present","Clinical Trials","Funded","False","True","Co-Investigator","ECG Feedback for CRT Response","Jackie Mittelstadt - Clinical Research Specialist","Peter Leong-Sit, Anthony Tang","$50,220,094.00"
"Skanes, Allan","Medicine","2014/01","2016/09","Grants","Internally Funded","False","False","Principal Investigator","Anatomical measurements of the heart for radiofrequency catheter ablation","Allan Skanes","","$1,673,113.00"
"Gula, Lorne","Medicine","2008/11","present","Clinical Trials","Funded","False","True","Co-Investigator","Discerning Symptomatic and Asymptomatic Episodes Pre & Post Radiofrequency Ablation of Atrial Fibrillation","David Birnie","Lorne Gula, Raymond Yee","$70,438,558.00"
"Yee, Raymond","Medicine","2008/11","2011/10","Clinical Trials","Funded","False","True","Co-Investigator","Discerning Symptomatic and Asymptomatic Episodes Pre & Post Radiofrequency Ablation of Atrial Fibrillation","David Birnie","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$20,209,243.00"
"Gula, Lorne","Medicine","2012/02","2013/12","Clinical Trials","Funded","False","True","Co-Investigator","A Single-Arm Multi-Center Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard Over-the-Wire Mesh Ablation System","Claire Williams","Lorne Gula, Peter Leong-Sit","$29,194,769.00"
"Leong-Sit, Peter","Medicine","2012/02","2013/12","Clinical Trials","Funded","False","True","Co-Investigator","A Single-Arm Multi-Center Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard Over-the-Wire Mesh Ablation System","Claire Williams","Lorne Gula, Peter Leong-Sit","$15,122,740.00"
"Leong-Sit, Peter","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Model 20066 LV Lead Study","Mark Lazeroms, Senior Scientist","Peter Leong-Sit","$74,466,475.00"
"Skanes, Allan","Medicine","2011/08","present","Clinical Trials","Funded","False","True","Co-Investigator","PainFree SST Clinical Study","Dan Lexcen","Lorne Gula, Peter Leong-Sit, Allan Skanes","$47,439,733.00"
"Leong-Sit, Peter","Medicine","2011/08","present","Clinical Trials","Funded","False","True","Co-Investigator","PainFree SST Clinical Study","Dan Lexcen","Lorne Gula, Peter Leong-Sit, Allan Skanes","$69,072,060.00"
"Gula, Lorne","Medicine","2011/08","present","Clinical Trials","Funded","False","True","Co-Investigator","PainFree SST Clinical Study","Dan Lexcen","Lorne Gula, Peter Leong-Sit, Allan Skanes","$10,560,416.00"
"Klein, George","Medicine","2005/01","present","Clinical Trials","Funded","False","True","Co-Investigator","Right Ventricular Apical Versus Septal Pacing Trial","Raymond Yee","George Klein","$44,039,555.00"
"Klein, George","Medicine","2009/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Shockless Implant Evaluation: A Prospective Randomised Clinical Trial","Jeff Healey","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$27,900,884.00"
"Leong-Sit, Peter","Medicine","2009/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Shockless Implant Evaluation: A Prospective Randomised Clinical Trial","Jeff Healey","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$17,833,357.00"
"Skanes, Allan","Medicine","2009/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Shockless Implant Evaluation: A Prospective Randomised Clinical Trial","Jeff Healey","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$73,947,070.00"
"Yee, Raymond","Medicine","2009/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Shockless Implant Evaluation: A Prospective Randomised Clinical Trial","Jeff Healey","George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$15,316,320.00"
"Gula, Lorne","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Part II","Atul Verma","Lorne Gula, Peter Leong-Sit","$66,548,079.00"
"Leong-Sit, Peter","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Part II","Atul Verma","Lorne Gula, Peter Leong-Sit","$54,477,870.00"
"Gula, Lorne","Medicine","2012/05","2013/03","Clinical Trials","Funded","False","True","Co-Investigator","Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with Catecholaminergic Polymorphic Ventricular Tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period – Phase II exploratory study","P. Schwartz","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$34,327,536.00"
"Leong-Sit, Peter","Medicine","2012/05","2013/03","Clinical Trials","Funded","False","True","Co-Investigator","Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with Catecholaminergic Polymorphic Ventricular Tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period – Phase II exploratory study","P. Schwartz","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$34,128,230.00"
"Skanes, Allan","Medicine","2012/05","2013/03","Clinical Trials","Funded","False","True","Co-Investigator","Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with Catecholaminergic Polymorphic Ventricular Tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period – Phase II exploratory study","P. Schwartz","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$12,668,799.00"
"Yee, Raymond","Medicine","2012/05","2013/03","Clinical Trials","Funded","False","True","Co-Investigator","Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with Catecholaminergic Polymorphic Ventricular Tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period – Phase II exploratory study","P. Schwartz","Lorne Gula, Peter Leong-Sit, Allan Skanes, Raymond Yee","$3,054,528.00"
"Gula, Lorne","Medicine","2010/01","present","Clinical Trials","Funded","True","False","Co-Investigator","BRidge or continUe coumadin for device SurgEry randomized CONTROLled Trial","David Birnie & Vidal Essebag","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$19,187,843.00"
"Klein, George","Medicine","2010/01","present","Clinical Trials","Funded","True","False","Co-Investigator","BRidge or continUe coumadin for device SurgEry randomized CONTROLled Trial","David Birnie & Vidal Essebag","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$40,950,609.00"
"Leong-Sit, Peter","Medicine","2010/01","present","Clinical Trials","Funded","True","False","Co-Investigator","BRidge or continUe coumadin for device SurgEry randomized CONTROLled Trial","David Birnie & Vidal Essebag","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$16,422,248.00"
"Skanes, Allan","Medicine","2010/01","present","Clinical Trials","Funded","True","False","Co-Investigator","BRidge or continUe coumadin for device SurgEry randomized CONTROLled Trial","David Birnie & Vidal Essebag","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$74,548,790.00"
"Yee, Raymond","Medicine","2010/01","present","Clinical Trials","Funded","True","False","Co-Investigator","BRidge or continUe coumadin for device SurgEry randomized CONTROLled Trial","David Birnie & Vidal Essebag","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$54,992,178.00"
"Yee, Raymond","Medicine","2010/11","2013/08","Clinical Trials","Funded","False","True","Co-Investigator","Prolonged Monitoring to Detect Ventricular Arrhythmias Presymptomatic ARVC Patients","Andrew Krahn","Raymond Yee","$60,702,844.00"
"Gula, Lorne","Medicine","2007/05","present","Clinical Trials","Funded","False","True","Co-Investigator","First line Radiofrequency Ablation vs. Antiarrhythmic Drugs for Atrial Fibrillation Treatment","Andrea Natale & Carlos Morillo","Lorne Gula","$22,549,862.00"
"Klein, George","Medicine","2010/10","2012/08","Clinical Trials","Funded","False","True","Co-Investigator","Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT device","Angelo Auricchio","George Klein","$59,465,621.00"
"Leong-Sit, Peter","Medicine","2011/11","2013/09","Clinical Trials","Funded","False","True","Co-Investigator","Universal Antitachycardia Pacing 2.0 Download Study","Paul Belk","Skanes, Allan Leong-Sit, Peter","$36,078,121.00"
"Skanes, Allan","Medicine","2011/11","2013/09","Clinical Trials","Funded","False","True","Co-Investigator","Universal Antitachycardia Pacing 2.0 Download Study","Paul Belk","Skanes, Allan Leong-Sit, Peter","$72,274,179.00"
"Gula, Lorne","Medicine","2010/05","2013/05","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Adaptive CRT Study","Dave Munneke","Lorne Gula, Peter Leong-Sit, Allan Skanes","$57,037,661.00"
"Leong-Sit, Peter","Medicine","2010/05","2013/05","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Adaptive CRT Study","Dave Munneke","Lorne Gula, Peter Leong-Sit, Allan Skanes","$74,716,549.00"
"Skanes, Allan","Medicine","2010/05","2013/05","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Adaptive CRT Study","Dave Munneke","Lorne Gula, Peter Leong-Sit, Allan Skanes","$55,270,363.00"
"Yee, Raymond","Medicine","2010/06","2012/07","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Attain Success Clinical Trial and Attain Success Lead Placement Sub-Study","Ming Duanmu","Lorne Gula, Allan Skanes","$68,330,973.00"
"Gula, Lorne","Medicine","2010/06","2012/07","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Attain Success Clinical Trial and Attain Success Lead Placement Sub-Study","Ming Duanmu","Lorne Gula, Allan Skanes","$2,576,377.00"
"Skanes, Allan","Medicine","2010/06","2012/07","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Attain Success Clinical Trial and Attain Success Lead Placement Sub-Study","Ming Duanmu","Lorne Gula, Allan Skanes","$35,440,617.00"
"Leong-Sit, Peter","Medicine","2011/12","2012/08","Clinical Trials","Funded","False","True","Co-Investigator","High Septal Pacing for Cardiac Resynchronization Therapy (HISTORY) Acute Research Study","Dorothee Marossero","Peter Leong-Sit","$53,712,756.00"
"Klein, George","Medicine","2012/05","2013/06","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator","Donna McAfee","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$4,037,149.00"
"Leong-Sit, Peter","Medicine","2012/05","2013/06","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator","Donna McAfee","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$18,969,043.00"
"Manlucu, Jaimie","Medicine","2012/05","2013/06","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator","Donna McAfee","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$62,177,978.00"
"Skanes, Allan","Medicine","2012/05","2013/06","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator","Donna McAfee","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes","$43,906,492.00"
"Boughner, Derek","Medicine","1987/07","1990/06","Grants","Funded","True","False","Co-Investigator","NSERC Operating grant","G Campbell","G Campbell A Menkis, I Vesely","$73,238,439.00"
"Boughner, Derek","Medicine","1990/07","1991/06","Grants","Funded","True","False","Collaborator","PSI Grant","D Bell","D Bell, W Brien, W Clark, P Cheung, C Graffagnino, V Hachinski, L Melendez, T Ostbye, W Bloembergen","$38,001,344.00"
"Klein, George","Medicine","2007/08","2013/04","Clinical Trials","Funded","False","True","Co-Investigator","International Study on Syncope of Uncertain Etiology 3","Michele Brignole","Klein, George","$25,978,835.00"
"Gula, Lorne","Medicine","2007/12","2010/06","Clinical Trials","Funded","False","True","Co-Investigator","Universal Antitachycardia Therapy Study","Paul Belk","Lorne Gula, Allan Skanes","$43,150,081.00"
"Skanes, Allan","Medicine","2007/12","2010/06","Clinical Trials","Funded","False","True","Co-Investigator","Universal Antitachycardia Therapy Study","Paul Belk","Lorne Gula, Allan Skanes","$20,924,423.00"
"Yee, Raymond","Medicine","2010/07","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Evaluation of the Impact of Cardiovascular MRI on Therapeutic Decisions, Resource Utilization and Outcomes in Patients with Known or Suspected Cardiovascular Disease","James White","","$73,530,324.00"
"Yee, Raymond","Medicine","2011/05","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Multi-Modality Imaging Assessment for Pacing Interventions in Heart Failure: Targeting Optimal Sites and Outcomes","James White","","$42,536,987.00"
"Gula, Lorne","Medicine","2010/01","2012/07","Clinical Trials","Funded","True","False","Co-Investigator","A Simple Randomized Trial of Conventional vs. Aggressive Prevention of Arrhythmia Device Infection","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$69,225,814.00"
"Klein, George","Medicine","2010/01","2012/07","Clinical Trials","Funded","True","False","Co-Investigator","A Simple Randomized Trial of Conventional vs. Aggressive Prevention of Arrhythmia Device Infection","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$15,540,723.00"
"Leong-Sit, Peter","Medicine","2010/01","2012/07","Clinical Trials","Funded","True","False","Co-Investigator","A Simple Randomized Trial of Conventional vs. Aggressive Prevention of Arrhythmia Device Infection","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$30,134,878.00"
"Skanes, Allan","Medicine","2010/01","2012/07","Clinical Trials","Funded","True","False","Co-Investigator","A Simple Randomized Trial of Conventional vs. Aggressive Prevention of Arrhythmia Device Infection","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$19,175,235.00"
"Yee, Raymond","Medicine","2010/01","2012/07","Clinical Trials","Funded","True","False","Co-Investigator","A Simple Randomized Trial of Conventional vs. Aggressive Prevention of Arrhythmia Device Infection","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$17,515,984.00"
"Manlucu, Jaimie","Medicine","2011/06","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$51,860,061.00"
"Gula, Lorne","Medicine","2011/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$61,456,699.00"
"Klein, George","Medicine","2011/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$69,989,492.00"
"Leong-Sit, Peter","Medicine","2011/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$35,222,973.00"
"Skanes, Allan","Medicine","2011/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$30,723,880.00"
"Yee, Raymond","Medicine","2011/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study","Andrew Krahn","Lorne Gula, George Klein, Peter Leong-Sit, Allan Skanes, Raymond Yee","$15,572,254.00"
"Leong-Sit, Peter","Medicine","2011/01","2012/05","Clinical Trials","Funded","False","True","Co-Investigator","Mapping of ECG Signal for Optimal Sensing in a Reveal Implantable Cardiac Monitor","Jian Cao","Peter Leong-Sit, Raymond Yee","$961,926.00"
"Yee, Raymond","Medicine","2011/01","2012/05","Clinical Trials","Funded","False","True","Co-Investigator","Mapping of ECG Signal for Optimal Sensing in a Reveal Implantable Cardiac Monitor","Jian Cao","Peter Leong-Sit, Raymond Yee","$34,771,969.00"
"Leong-Sit, Peter","Medicine","2013/03","2014/02","Clinical Trials","Funded","True","False","Principal Site Investigator","Canadian Atrial Fibrillation Stroke Prevention Intervention Network","Jeff Healey et al","Jason Andrade et al","$13,026,257.00"
"Skanes, Allan","Medicine","2013/03","2014/02","Clinical Trials","Funded","True","False","Co-Applicant","Canadian Atrial Fibrillation Stroke Prevention Intervention Network","Jeff Healey et al","Jason Andrade et al","$39,951,680.00"
"Leong-Sit, Peter","Medicine","2009/12","2014/07","Grants","Funded","True","False","Principal Applicant","Randomized trial of circumferential versus segmental antral isolation in paroxysmal atrial fibrillation","Lorne Gula","George Klein, Peter Leong-Sit, Jaimie Manlucu, Allan Skanes, Raymond Yee","$56,993,597.00"
"Beaton, Melanie","Medicine","2014/10","2019/09","Grants","Funded","True","False","Co-Applicant","Drug Disposition in Non-Alcoholic Fatty Liver Disease","Rommel G. Tirona","Beaton MD","$39,553,325.00"
"Al-Judaibi, Bandar","Medicine","2013/03","2014/03","Grants","Funded","True","False","Co-Investigator","Optimizing Chronic HCV treatment using pharmacogenomic biomarkers","Richard KIm","","$72,419,153.00"
"Kostuk, William","Medicine","1990","1991","Grants","Funded","False","False","Principal Site Investigator","Evaluation of inotropic agents in patients with heart failure","William Kostuk","","$25,949,098.00"
"Joy, Tisha","Medicine","2014/01","2017/07","Clinical Trials","Funded","False","True","Principal Site Investigator","A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects","T. Joy","R. A. Hegele","$54,530,198.00"
"Kostuk, William","Medicine","1991","1992","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$50,770,988.00"
"Kostuk, William","Medicine","1991","1992","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$7,485,908.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","Dr. William Kostuk","","$32,404,845.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$3,754,487.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Evaluation of pharmacological testing to assess myocardial ischemia.","William Kostuk","","$4,166,177.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","Dr. William Kostuk","","$37,126,903.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Reduction of coronary artery risk factors","Dr. William Kostuk","","$72,519,857.00"
"Kostuk, William","Medicine","1992","1993","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","Dr. William Kostuk","","$29,973,528.00"
"Kostuk, William","Medicine","1993","1994","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$33,289,292.00"
"Kostuk, William","Medicine","1993","1994","Grants","Funded","False","True","Principal Site Investigator","Assessment of therapeutic interventions in patients with heart failure.","William Kostuk","","$73,049,017.00"
"Kostuk, William","Medicine","1994","1995","Grants","Funded","False","True","Principal Site Investigator","Assessment of antianginal agents","William Kostuk","","$35,807,391.00"
"Kostuk, William","Medicine","1994","1995","Grants","Funded","False","True","Principal Site Investigator","Evaluation of cardiac function and coronary vasculature in cardiac transplant patients","William Kostuk","","$31,789,088.00"
"Kostuk, William","Medicine","2000","2001","Grants","Funded","False","True","Co-Investigator","PLAATO - Percutaneous left atrial appendage transcatheter occlusion suing the X-caliber system. A feasibility study.","George Klein","","$18,974,623.00"
"Kostuk, William","Medicine","1989","1989","Grants","Funded","False","True","Principal Site Investigator","Grant","William Kostuk","","$17,207,620.00"
"Chin-Yee, Ian","Medicine","2008/09","2015/09","Clinical Trials","Funded","False","True","Co-Investigator","First Trial","Dr. Leonard Minuk","","$23,118,806.00"
"Myers, Kathryn","Medicine","2013/08","2015/06","Grants","Funded","True","False","Principal Investigator","The consequential validity of resident assessments of their clinical teachers: faculty perspectives","Kathryn Myers","Elaine Zibrowski","$45,451,597.00"
"Myers, Kathryn","Medicine","2011/06","2013/01","Grants","Funded","True","False","Principal Investigator","A qualitative study of resident and faculty perceptions of clinical teaching assessments","Kathryn Myers","Elaine Zibrowski Lorelei Lingard","$27,100,670.00"
"Myers, Kathryn","Medicine","2012/08","2014/12","Grants","Funded","True","False","Principal Investigator","Faculty reflection on their assessments of clinical teaching by resident","Kathryn Myers","Elaine Zibrowski","$60,869,456.00"
"Muirhead, Norman","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Principal Investigator","A phase 2 randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of phosphodiesterase 5 inhibitor (PF-00489791) in adults with the type 2 diabetes and overt nephropathy.","Dr. N. Muirhead","A. House, J. Johnson, F. Rehman, M. Weir","$68,156,198.00"
"Muirhead, Norman","Medicine","2012/07","2015/07","Clinical Trials","Funded","False","True","Principal Investigator","Transfusion management of incident dialysis patients in Canada: A prospective observational study (TEMPO)","Dr. N. Muirhead","A. House, J. Johnson, F. Rehman, M. Weir","$41,110,769.00"
"Muirhead, Norman","Medicine","2012/07","2014/07","Clinical Trials","Funded","False","True","Principal Investigator","A prospective observational, randomized comparative study of case managed versus non-case managed initiation of hemodialysis","Dr. N. Muirhead","A. House, J. Johnson, F. Rehman, M. Weir","$59,157,154.00"
"Wells, Jennie","Medicine","2013/10","2016/10","Clinical Trials","Funded","True","True","Principal Investigator","A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease","Wells JL","Borrie MJ, Finger E, Pasternak S, Wells JL","$9,100,752.00"
"Kostuk, William","Medicine","2014/04","2018/06","Grants","Funded","False","True","Principal Site Investigator","THEMIS - Effect of ticagrelor on health outcomes in diabetes mellitus patients intervention study","Dr. Philippe Gabriel Steg, Dr. Deepak Bhatt","","$50,970,896.00"
"Huang, Shih-Han Susan","Medicine","2014/05","2015/12","Grants","Funded","False","True","Co-Investigator","Vanguard Multi-Centre Feasibility Trial to Determine if Buttonhole vs. Step-Ladder Cannulation for Home Hemodialysis","Dr. Deb Zimmerman","","$19,546,381.00"
"Mura, Marco","Medicine","2014/05","2015/06","Grants","Funded","True","False","Principal Investigator","Immunohistochemistry markers of UIP and NSIP.","Marco Mura","Dr. Christopher Howlett","$11,095,552.00"
"Huang, Shih-Han Susan","Medicine","2013/07","2016/06","Grants","Funded","True","False","Principal Investigator","Cystatin C as a New Marker for Dialysis Adequacy","Shih-Han Susan Huang","","$27,040,470.00"
"Garg, Amit","Medicine","2011/07","2012/06","Grants","Funded","True","False","Principal Investigator","ICES KDT: Knowledge User Decision Support","Amit Garg","","$12,634,089.00"
"Weir, Matthew","Medicine","2013/10","2016/09","Grants","Funded","True","False","Principal Applicant","Nano-particle curcumin and proteinuric chronic kidney disease","Matthew Weir","","$9,383,119.00"
"Weir, Matthew","Medicine","2013/04","2016/03","Grants","Funded","True","False","Co-Investigator","The Ontario Drug Policy Research Network (ODPRN)","Muhammad Mamdani, David N. Juurlink","Andreas Laupacis, Anne Holbrook, Douglas Coyle, David Henry, Tara Gomes, Onil Bhattacharyya, Michael Evans, Amit Garg, Gerald Evans, Michael Paterson, Peter Austin, Irfan Dhalla, Sharon Straus","$44,230,916.00"
"Weir, Matthew","Medicine","2014/01","2015/12","Grants","Funded","True","False","Co-Principal Investigator","Beta blocker pharmacokinetics in hemodialysis","Matthew Weir","Brad Urquhart","$3,938,989.00"
"Clark, William","Medicine","2014/07","2016/07","Grants","Funded","True","False","Principal Investigator","Long-term vascular outcomes of idiopathic thrombotic microangiopathy treated with plasma exchange","William F. Clark","Foley SR, Gangji AS, George J, Hildebrand AM, Pavenski K, Thejeel B.","$72,205,007.00"
"Gunaratnam, Lakshman","Medicine","2014/07","2016/06","Grants","Funded","True","False","Co-Principal Investigator","Daily hemodilaysis, transplantation and mortality","Dr. Rita Suri","Dr. Peter Austin","$72,786,875.00"
"Khanna, Reena","Medicine","2013/09","2015/09","Grants","Funded","True","False","Principal Investigator","Validation of the Endoscopic Indices for Crohn's Disease","Khanna, R.","","$65,558,059.00"
"Chin-Yee, Ian","Medicine","2013/11","2014/05","Clinical Trials","Funded","False","False","Co-Investigator","A Multicenter, Single-Arm, Open-Label Treatment Use Program for Pomalidomide (POM) in combination with Low Dose Dexamethasone (LD-DEX) in Subjects with Relapsed or Refractory Multiple Myeloma.","Len Minuk","","$17,361,232.00"
"Chin-Yee, Ian","Medicine","2014/01","present","Clinical Trials","Funded","False","False","Co-Investigator","A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma.","Len Minuk","","$44,534,868.00"
"Chin-Yee, Ian","Medicine","2013/10","present","Clinical Trials","Funded","False","False","Co-Investigator","A Phase II Study using a combination of Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients who have received Bortezomib based induction for Newly Diagnosed Mutiple Myeloma followed by Lenalidomide Maintenance until Disease Progression.","Len Minuk","","$4,258,485.00"
"Louzada, Martha de Lacerda","Medicine","2014/01","present","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagnosed Multiple Myeloma.","Len Minuk","","$11,003,660.00"
"Louzada, Martha de Lacerda","Medicine","2013/11","2014/04","Clinical Trials","Funded","False","True","Co-Investigator","A Multicenter, Single-Arm, Open-Label Treatment Use Program for Pomalidomide (POM) in combinatin with Low Dose Dexamethasone (LD-DEX) in Subjects with Relapsed or Refractory Multiple Myeloma.","Len Minuk","","$64,139,110.00"
"Louzada, Martha de Lacerda","Medicine","2013/10","present","Clinical Trials","Funded","False","True","Co-Investigator","A Phase II Study using a combination of Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients who have received Bortezomib based induction for Newly Diagnosed Multiple Myeloma followed by Lenalidomide Maintenance until Disease Progression.","Len Minuk","","$73,288,591.00"
"Louzada, Martha de Lacerda","Medicine","2014/06","2019/01","Grants","Funded","False","True","Co-Applicant","Janssen Stewardship Fund: LRCP Leukemia Bank and Myeloma Database","Anargyros Xenocostas and Martha Louzada","","$32,236,531.00"
"Louzada, Martha de Lacerda","Medicine","2013/05","present","Grants","Funded","False","False","Principal Investigator","Assessment of Risk of Thromboprophylaxis failure in hospitalized patients with cancer (ARTIC Study).","Martha Louzada","Alejandro Lazo-Langner Michael Kovacs Fatimah Al-Ani","$21,315,993.00"
"Louzada, Martha de Lacerda","Medicine","2014/03","2014/12","* Department of Medicine Funds","Funded","False","False","Principal Investigator","Evaluating the need for anticoagulation beyond 6 months for patients with cancer-associated venous thromboembolism: a retrospect of real life.","Martha Louzada","Michael Kovacs Alejandro Lazo-Langner Fatimah Al-Ani","$50,050,537.00"
"Lazo Langner, Alejandro","Medicine","2014/01","2017/12","Grants","Funded","True","False","Principal Applicant","Immigration and the epidemiology of venous thromboembolism","A Lazo-Langner","","$56,137,697.00"
"Spaic, Tamara","Medicine","2013/06","2013/08","Grants","Funded","False","False","Principal Investigator","Predictors of Successful Transition in Young Adults with T1D","Rashmi Nedadur","Tamara Spaic, Cheril Clarson","$42,719,100.00"
"Leong-Sit, Peter","Medicine","2014/07","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Global Registry Program on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III)","Jeff Healey","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$26,355,211.00"
"Klein, George","Medicine","2014/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Global Registry Program on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III)","Jeff Healey","George Klein","$30,203,042.00"
"Mura, Marco","Medicine","2013/10","2015/06","Grants","Funded","True","False","Co-Investigator","Nutritional Status of Patients with Interstitial Lung Disease: A Cross-Sectional Study","Dr. Janet Madill","Dr. Janet Madill, PI, Brescia College Sylvia Rinaldi, Master Student, Research Assistant, Brescia College","$3,329,096.00"
"Lavi, Shahar","Medicine","2014/07","2016/06","Grants","Funded","True","False","Principal Investigator","Role of adjunctive mild therapeutic hypothermia and cardiac catheterization for acute coronary syndromes in cardiac arrest: Retrospective review of outcomes","Shahar Lavi","","$935,164.00"
"Licskai, Christopher","Medicine","2014/07","2017/06","Grants","Funded","True","False","Co-Investigator","The Ontario Chronic Obstructive Pulmonary Disease COPD Population Health Network","Dr. Andrea Gershon, Dr. Shawn Aaron","","$60,983,900.00"
"Licskai, Christopher","Medicine","2014/07","2015/06","Grants","Funded","True","False","Co-Investigator","The Electronic Asthma Action Plan System (eAAPS) for Implementation in Primary Care Study","Dr. Samir Gupta","Agarwal, G., Boulet, L, Chan, D., Dolovich, L., Goel, S., Kaplan, A., Lebovic, G., Levinson, A., Madeley, C., Mamdani, M., Oliphant, R., Straus, S., Van Dam, A.","$62,906,170.00"
"House, Andrew","Medicine","2014/01","2021/12","Grants","Funded","True","False","Principal Investigator","Multi-center Data Registry for Outcomes from Renal Replacement Therapy","Andrew House","","$74,171,708.00"
"House, Andrew","Medicine","2012/01","2015/01","Grants","Funded","False","True","Co-Investigator","Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study (TEMPO)","Norman Muirhead","","$50,029,092.00"
"House, Andrew","Medicine","2014/05","2015/01","Grants","Funded","False","True","Co-Investigator","A Prospective, Observational, Randomized Comparative Study of Case Managed Versus Non-Case Managed Initiation of Hemodialysis","Norman Muirhead","","$61,709,947.00"
"House, Andrew","Medicine","2013/10","2019/12","Grants","Funded","False","True","Co-Investigator","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg once daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes","Norman Muirhead","","$34,712,409.00"
"House, Andrew","Medicine","2013/10","2014/07","Grants","Funded","False","True","Co-Investigator","A Phase 2B, Randomized, Blinded, Dose-Ranging, Active-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Dose Response Relationship of GSK1278863 over the first 4 weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 over 24 weeks in Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease who Switch from Recombinant Human Erythropoietin","Norman Muirhead","","$50,285,737.00"
"House, Andrew","Medicine","2013/10","2015/10","Grants","Funded","False","True","Co-Investigator","A 24 week, Phase 2B, Randomized, Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects with Anemia Associated with Chronic Kidney Disease who are Not on Dialysis","Norman Muirhead","","$14,657,063.00"
"House, Andrew","Medicine","2014/07","2019/06","Grants","Funded","True","False","Co-Principal Investigator","Drug Disposition in Chronic Kidney Disease","Brad Urquhart","","$64,086,366.00"
"Adams, Paul","Medicine","2014/07","2017/06","Grants","Funded","True","False","Co-Principal Investigator","Genetic modifiers of hemochromatosis disease expression in C282Y homozygotes","Christine McLaren","Christine McLaren, Gordon McLaren, Lawrie Powell, Nathan Subramaniam, John Philips, Jim Barton, Prad Phatak","$20,983,482.00"
"Wisenberg, Gerald","Medicine","2014/07","2015/06","Grants","Funded","True","False","Principal Investigator","PET/MR assessment of post myocardial infarction inflammation and remodeling","Gerald Wisenberg","Frank Prato, James White, Rob de Kemp","$27,827,726.00"
"Huang, Shih-Han Susan","Medicine","2014/07","2016/06","Grants","Funded","True","False","Principal Applicant","MRI volume assessment in dialysis patients","Shih-Han Huang","","$14,477,069.00"
"Hegele, Robert","Medicine","2010/09","2015/08","Grants","Funded","True","False","Principal Investigator","Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function","Robert A. Hegele","","$35,467,881.00"
"Huff, Murray","Medicine","2013/03","2014/04","Grants","Funded","True","False","Principal Investigator","Regulation of dyslipidemia and insulin resistance by flavonoids: Relationship to atherosclerosis.","Huff MW","","$26,247,229.00"
"Huff, Murray","Medicine","2014/04","2017/03","Grants","Funded","True","False","Principal Investigator","Regulation of dyslipidemia and insulin resistance by flavonoids: Relationship to atherosclerosis.","Huff MW","","$34,522,316.00"
"Huff, Murray","Medicine","2014/04","2016/05","Grants","Funded","True","False","Principal Investigator","ETC-1002 Studies in LDR-/- Yucatan miniature pigs.","Huff MW","","$37,852,200.00"
"Huff, Murray","Medicine","2014/05","2016/04","Grants","Funded","True","False","Principal Investigator","Evaluation of in vivo efficacy of ETC-1002 in Ldlr-/- mice.","Huff MW","","$6,975,908.00"
"Barra, Lillian","Medicine","2014/07","2017/06","Grants","Funded","True","False","Principal Investigator","Elucidating the mechanism of accelerated atherosclerosis in Rheumatoid Arthritis: the role of citrullination and the Shared Epitope","Lillian Barra","Collaborators: E. Cairns, M. Huff, G. Pickering and D. Bell","$47,884,465.00"
"Siu, Samuel","Medicine","2009/01","2014/12","Grants","Funded","True","False","Program Leader","Translational Research Centre for Cardiovascular Research (TRICORE)","Dr. Samuel Siu and Dr. James White","","$14,054,710.00"
"Gill, Sean","Medicine","2013/07","2016/06","Grants","Funded","True","False","Co-Investigator","Mechanisms of Microvascular Endothelial Cell Apoptosis in Sepsis","Sanjay Mehta","Sean Gill, Tianqing Peng","$56,546,737.00"
"Gill, Sean","Medicine","2013/07","2014/06","Grants","Funded","True","False","Principal Investigator","TIMP3 Regulates Macrophage Function Following Lung Injury","Sean Gill","","$35,797,059.00"
"Gill, Sean","Medicine","2013/01","2013/12","Grants","Funded","True","False","Co-Principal Investigator","MMP3 regulates macrophage function following lung injury","Cory Yamashita","","$13,145,124.00"
"Gill, Sean","Medicine","2012/07","2014/06","Grants","Funded","True","False","Principal Investigator","Endothelial dysfunction/injury in murine sepsis is mediated through TIMP3","Sean Gill","Sanjay Mehta","$23,575,413.00"
"Gill, Sean","Medicine","2012/07","2014/06","Grants","Funded","True","False","Collaborator","Neutrophil-dependent mechanisms regulating endothelial death in ALI","Ravi Taneja","Sean Gill, Sanjay Mehta","$13,973,636.00"
"Diachun, Laura","Medicine","2014/06","2015/09","Grants","Funded","True","False","Research Supervisor","Radha Joseph, Summer Student. ""Third-year clinical clerks’ experiences with complex patients"".","Laura Diachun","","$368,362.00"
"Diachun, Laura","Medicine","2014/03","2015/03","Grants","Funded","True","False","Principal Investigator","Third Year Clinical Clerks Experiences with Complex Patients","Laura Diachun","","$18,381,273.00"
"Martin, Claudio","Medicine","2014/01","2016/12","Grants","Funded","True","False","Co-Investigator","Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation","Bosma, Karen J","Brochard, Laurent J; Burns, Karen E; Martin, Claudio M; Thorpe, Kevin E.","$2,698,481.00"
"Martin, Claudio","Medicine","2012/06","2015/05","Grants","Funded","True","False","Co-Investigator","Canadian Critical Care Knowledge Translation Network","Muscedere, John","CHANT, Clarence ; COOK, Deborah Joanne ; DODEK, Peter Murray ; GIBNEY, Noel ; HEYLAND, Daren Keith ; KEENAN, Sean Patrick ; LACROIX, Jacques ; LAWLESS, Bernard ; LEGARE, Martin ; MARTIN, Claudio Marcelo ; PATRICK, Ward D. ; PAUNOVIC, Bojan ; REYNOLDS, Steven Campbell ; SCALES, Damon Cole ; SHAW, Susan ; SINUFF, Tasnim ; TRPKOVSKI, Julie ; TURGEON, Alexis F","$29,612,645.00"
"Martin, Claudio","Medicine","2012/10","2016/09","Grants","Funded","True","False","Co-Investigator","Early Determination of long-term Prognosis in critically ill patients with Severe Traumatic Brain Injury (TBI-Prognosis multicenter prospective study","Turgeon, Alexis F","BAGSHAW, Sean M ; BERNARD, Francis ; BURNS, Karen Elizabeth Ann ; FERGUSSON, Dean A ; GREEN, Robert S ; GRIESDALE, Donald ; KUTSOGIANNIS, Demitrios James ; LAMONTAGNE, Francois ; LAUZIER, François ; MARTIN, Claudio Marcelo ; MCINTYRE, Lauralyn Ann ; MEADE, Maureen Ora ; MOORE, Lynne ; MOULIN, Véronique ; PAGLIARELLO, Giuseppe ; REYNOLDS, Steven Campbell ; RIGAMONTI, Andrea ; SAVARD, Martin ; SCALES, Damon Cole ; ZARYCHANSKI, Ryan ; ZYGUN, David Andrew","$10,800,333.00"
"Tang, Anthony","Medicine","1989/01","1990/12","Grants","Funded","True","False","Co-Investigator","Transesophageal atrial pacing to assess myocardial perfusion reserve","Terence Ruddy","Anthony Tang","$70,108,830.00"
"Tang, Anthony","Medicine","1994/01","1996/12","Grants","Funded","True","False","Co-Investigator","Quality of life comparison in a randomized trial of pacemaker recipients","David Newman","S. Connolly, Anthony Tang, P. Dorian, C. Lau","$16,523,713.00"
"Tang, Anthony","Medicine","1996/01","2000/12","Grants","Funded","True","False","Principal Investigator","The effect of chronotropic status on the alteration of life quality due to rate adaptive pacing: a prospective randomized cross-over study","Anthony Tang","Co-applicant - K. Woodend","$8,696,776.00"
"Tang, Anthony","Medicine","1997/01","1999/12","Grants","Funded","True","False","Principal Investigator","A systematic enquiry into the mechanisms of anti-arrhythmic drug effects on defibrillation","Anthony Tang","Greg Beatch","$55,763,938.00"
"Tang, Anthony","Medicine","1997/01","1999/12","Grants","Funded","True","False","Co-Investigator","A preliminary randomized controlled study to compare the clinical effects of vasopressin and epinephrine in the treatment of in hospital cardiac arrest","Ian Stiel","Anthony Tang, George Wells","$38,648,073.00"
"Tang, Anthony","Medicine","1999/01","2001/12","Grants","Funded","True","False","Principal Investigator","Influence of ventricular refractoriness on defibrillation","Anthony Tang","","$21,867,089.00"
"Tang, Anthony","Medicine","2000/01","2003/12","Grants","Funded","True","False","Co-Investigator","Molecular Basis and Genetic Epidemiology of Dilated Cardiomyopathy","F. Tesson","Anthony Tang, Kwan Chan","$59,253,925.00"
"Tang, Anthony","Medicine","2001/01","2002/12","Grants","Funded","True","False","Principal Investigator","The Effect of Cardiac Resynchronization on Oxidative Metabolism and Myocardial Efficiency in Patients with Advanced Heart Failure and Ventricular Conduction Abnormality","Anthony Tang","Robert Beanlands","$9,965,474.00"
"Tang, Anthony","Medicine","2003/01","2005/12","Grants","Funded","True","False","Principal Investigator","The effect of cellular telephones on patients with implantable cardioverter defibrillators","Anthony Tang","KS Tan, Mario Talajic","$53,790,579.00"
"Tang, Anthony","Medicine","2003/01","2008/12","Grants","Funded","True","False","Principal Investigator","Resynchronization/defibrillation for advanced heart Failure Trial","Anthony Tang & George Wells","Robert Sheldon, Mario Talajic, Stuart Connolly, Malcolm Arnold, John Parker, Jean-Lucian Rouleau, and Graham Nichol","$18,835,570.00"
"Tang, Anthony","Medicine","2004/01","2007/12","Grants","Funded","True","False","Co-Investigator","Importance of mechanical dyssynchrony and resynchronization therapy in advanced heart failure patients","David Birnie","Terence Ruddy, Anthony Tang","$914,846.00"
"Tang, Anthony","Medicine","2004/01","2006/12","Grants","Funded","True","False","Co-Investigator","Pathophysiologic characterization and therapeutic intervention in the PRKAG2 cardiac syndrome","Michael Gollob","Anthony Tang, Robert Beanlands","$72,460,502.00"
"Tang, Anthony","Medicine","2006/01","2007/12","Grants","Funded","True","False","Co-Investigator","Atrial fibrillation in the intensive care unit: a randomized controlled trial","Salmaan Kanji","Paul Hebert, Anthony Tang","$40,832,894.00"
"Tang, Anthony","Medicine","2006/01","2008/12","Grants","Funded","True","False","Co-Investigator","Genetic predictors of ventricular arrhythmias in patients with heart failure","Michael Gollob","Anthony Tang, David Birnie","$24,083,815.00"
"Tang, Anthony","Medicine","2006/01","2009/12","Grants","Funded","True","False","Co-Investigator","Pathophysiologic study of the role of AMPK in cardiac arrhythmias, conduction system development, and metabolic cardiomyopathy","Michael Gollob","Robert Beanlands, Anthony Tang","$47,897,676.00"
"Tang, Anthony","Medicine","2006/01","2009/12","Grants","Funded","True","False","Co-Investigator","Abnormalities in rhythm in the cardiac resynchronization/Defibrillation in advance heart failure trial","Ratika Parkash","John Sapp, Anthony Tang, George Wells","$35,233,749.00"
"Tang, Anthony","Medicine","2009/01","2012/12","Grants","Funded","True","False","Co-Investigator","Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial","David Birnie & Vidal Essebag","Doug Coyle, Jeff Healey, Andrew Krahn, Christopher Simpson, Soori Sivakumaran, Anthony Tang, George Wells","$17,016,539.00"
"Tang, Anthony","Medicine","2010/01","2015/12","Grants","Funded","True","False","Principal Investigator","Ventricular Tachycardia Ablation versus Enhanced Drug Therapy in Structural Heart Disease","John Sapp, Anthony Tang & George Wells","Douglas Coyle, Ratika Parkash, and William G Stevenson","$21,533,090.00"
"Tang, Anthony","Medicine","2011/01","2013/09","Grants","Funded","True","False","Principal Site Investigator","Atrial Substrate Modification with Aggressive Blood Pressure Control to Prevent Atrial Fibrillation","Ratika Parkash, Anthony Tang & George Wells","","$16,914,517.00"
"Tang, Anthony","Medicine","2010/01","2010/01","Grants","Funded","True","False","Principal Investigator","Planning meeting for a RCT grant on the treatment of Atrial Fibrillation in heart failure","Anthony Tang","George Wells, Mario Talajic, Atul Verma, and Ratika Parkash","$12,954,340.00"
"Tang, Anthony","Medicine","2010/01","2015/12","Grants","Funded","True","False","Principal Investigator","Long QT syndrome in Northern British Columbia: Understanding the impact","Laura Arbour, Anthony Tang","Lanora Field, Roderick McCormick","$45,222,875.00"
"Tang, Anthony","Medicine","2011/01","2016/12","Grants","Funded","True","False","Nominated Principal Investigator","A Randomized Ablation-based Atrial Fibrillation Rhythm Control versus Rate Control Trial in Patients with Heart Failure and High Burden Atrial Fibrillation","Anthony Tang et al","Co-applicants: M. Arnold, D. Birnie, D. Coyle, L. Macle, A. Skanes, J Healey, G. Newton, J. Rouleau, V. Essebag","$73,558,588.00"
"Tang, Anthony","Medicine","2011/01","2014/12","Grants","Funded","True","False","Principal Applicant","Atrial Substrate Modification with Aggressive Blood Pressure Control to Prevent Atrial Fibrillation","Ratika Parkash, Anthony Tang & George Wells","John Sapp, Jean-Clude Tardiff, and Jeff Healey","$544,663.00"
"Tang, Anthony","Medicine","2012/01","2015/12","Grants","Funded","True","False","Co-Investigator","MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy","James White","Matthias Friedrich, Eric Larose, Benard Thibault, Lorne Gula, Raymond Yee, Alexander Dick, Daivd Birnie, Anthony Tang","$38,325,750.00"
"Tang, Anthony","Medicine","2012/01","2015/12","Grants","Funded","True","False","Co-Investigator","Prevalence of sub-clinical atrial fibrillation in patients with cardiovascular risk factors detected using an implantable loop recorder","Jeff Healey","S. Connolly, P. Devereaux, H. Dokainish, R. Goeree, A. Ha, R. Hart, A. Krahn, A. Mehta, F. Philippon, J. Pogue, Anthony Tang","$13,248,613.00"
"Tang, Anthony","Medicine","2012/01","2012/12","Grants","Funded","True","False","Principal Investigator","Canadian Atrial Fibrillation Stroke Prevention Network","Jeff Healey et al","Jason Andrade, Stuart Connolly, Jafna Cox, Andrew Ha, Thao Huynh, Peter Leong-Sit, Ratika Parkash, Francois Philippon, Allan Skanes, Atul Verma","$6,179,811.00"
"Tang, Anthony","Medicine","2013/01","2016/12","Grants","Funded","True","False","Co-Investigator","Double Short vs Standard Exposure Duration During Cryoballoon Pulmonary Vein Isolation","Jason Andrade","Anthony Tang, George Wells","$7,323,028.00"
"Tang, Anthony","Medicine","2013/01","2016/12","Grants","Funded","True","False","Co-Investigator","CHRS Cardiac Implantable Electrical Device Surveillance System (CDSS) – A Pilot Study","Ratika Parkash","Jeff Healey, Andrew Krahn, Derek Exner, Raymond Yee, Chris Simpson, Eugene Crystal, Pabo Nery, Bernard Thibault, Elizabeth Stephenson, Vidal Essebag, Francois Phillippon, Anthony Tang, George Wells","$50,196,520.00"
"Tang, Anthony","Medicine","2013/01","2013/12","Grants","Funded","True","False","Nominated Principal Investigator","Resynchronization/defibrillation for Ambulatory Heart failure Trial in patients with Permanent Atrial Fibrillation","Anthony Tang et al","David Birnie, Douglas Coyle, Andrew Krahn, Gary Newton, Fancois Philippon, Damian Redfearn, Bernard Thibault, Raymond Yee","$20,508,072.00"
"Tang, Anthony","Medicine","2014/01","2019/12","Grants","Funded","True","False","Nominated Principal Investigator","Resynchronization/defibrillation for Ambulatory Heart failure Trial in patients with Permanent Atrial Fibrillation","Anthony Tang et al","David Birnie, Douglas Coyle,Vidal Essebag, Andrew Krahn, Gary Newton, Fancois Philippon, Damian Redfearn, Bernard Thibault, Raymond Yee","$15,376,929.00"
"Tang, Anthony","Medicine","2014/01","2014/12","Grants","Funded","True","False","Principal Investigator","Frequent Ventricular Premature Contractions in Heart Failure: Prevalence and Prognosis","Marc Deyell & Anthony Tang","John Sapp, George Wells","$57,046,157.00"
"Tang, Anthony","Medicine","2013/01","2018/12","Grants","Funded","True","False","Principal Investigator","Canadian Atrial Fibrillation Stroke Prevention Intervention Network","Jeff Healey et al","Jason Andrade, Clare Atzema, Stuart Connolly, Lisa Dolovich, Vidal Essebag, Derek Exner, David Gladstone, Ron Goeree, Andrew Ha, Robert Hart, Michael Hill, Thao Huynh, Paul Khairy, Andrew Krahn, Andrew McRae, Nazanin Meshkat, Carlos Morillao, Robby Nieuwlaat, Ratika Parkash, Francois Philippon, Francis Quinn, Damian Redfearn, Roopinder Sandhu, Mukul Sharma, Mario Talajic, Lehana Thabane, Sheldon Tobe, Atul Verma, Richard Whitlock, Stephen Wilton","$10,203,538.00"
"Jain, Arsh","Medicine","2013/10","2017/10","Grants","Funded","True","False","Co-Investigator","The Peritoneal Dialysis Outcomes and Practice Patterns Study (P-DOPPS)","Perl, Jeffery","","$10,266,391.00"
"Jain, Arsh","Medicine","2011/07","2012/06","Grants","Funded","True","False","Principal Applicant","Assessing the impact of eGFR reporting on process of care measures","Jain, Arsh","","$62,779,908.00"
"McCormack, David","Medicine","2014/07","2019/06","Grants","Funded","True","False","Co-Applicant","Structure-Function MRI of Asthma","Parraga, G.","Nair, P., Maksym, G., McCormack, D.","$8,700,796.00"
"Liu, Selina","Medicine","2012/12","present","Grants","Funded","False","True","Co-Principal Investigator","LONGTIME: The Longevity in Type 1 Diabetes and Macrovascular Disease Epidemiology Study","Irene Hramiak","Jeffery Mahon, Michael Weingert, Ronen Gurfinkel","$10,960,722.00"
"Bosma, Karen","Medicine","2014/10","2017/09","Grants","Funded","True","False","Principal Applicant","Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation","Dr. Karen J. Bosma","","$50,385,893.00"
"Bosma, Karen","Medicine","2014/10","2017/09","Grants","Funded","True","True","Principal Applicant","Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study","Dr. Karen J. Bosma","","$12,480,330.00"
"Bosma, Karen","Medicine","2014/07","2017/06","Grants","Funded","True","True","Co-Applicant","Sedation Practice in Intensive Care Evaluation (SPICE III) Sub-Study of: Early Goal Directed Sedation Compared with Standard Care in Mechanically Ventilated Patients in Intensive Care","Dr. Yoanna Skrobik","","$50,728,136.00"
"Gunaratnam, Lakshman","Medicine","2012/12","2017/11","Grants","Funded","True","False","Co-Investigator","Canadian National Transplant Research Program: Increasing Donation and Improving Transplantation Outcomes","Dr. Lori West","ESDALE, Barbara K; FAIRHEAD, Todd R; FIFIELD, Tammy; GAVSIE, Ronnie; MACDONALD, Nancy; MARCUS, Sharon; MARSHALL, John C; NICHOLAS, David B; RUSH, David N; SMITH, David A; WORTON, Kim; YOUNG, Kimberly P; ABBEY, Susan E; ALLEN, Upton D; ALWAYN, Ian P; BERGERON, John J; BERTHIAUME, Yves; BLYDT-HANSEN, Tom; BROADY, Raewyn; BUSQUE, Stephan; CAILHIER, Jean-Francois; CARDINAL, Héloise; CATTRAL, Mark S; CHANDLER, Jennifer A; CHASSE, Michael; CHRUSCINSKI, Andrzej J; COLLETTE, Suzon; DEVINS, Gerald M; DH","$39,458,656.00"
"Spaic, Tamara","Medicine","2014/05","2015/04","Grants","Funded","False","True","Co-Investigator","Data Gaps Web DR (Phase 1)","Stewart Harris","Nicole Mittmann","$39,325,876.00"
"Tang, Anthony","Medicine","2013/10","2014/10","Grants","Funded","True","False","Principal Investigator","Canadian Arrhythmia Network Full Application Preparation Fund","Anthony Tang","","$28,935,321.00"
"Suskin, Neville","Medicine","2014/06","2017/05","Clinical Trials","Funded","True","False","Co-Investigator","Patient-Centered Care Transitions in Heart Failure (PACT-HF): a pragmatic multi-center cluster randomized trial","CONNOLLY, Stuart James ; VAN SPALL, Harriette","GRAHAM, Ian D. ; HAYNES, Robert Brian ; HEFFERNAN, Michael L. ; LAMY, André ; MAINGI, Manish ; POREPA, Liane ; RICCI, Joseph A. ; SUSKIN, Neville Gordon ; TEO, Koon Kang ; THABANE, Lehana ; TJANDRAWIDJAJA, Michael","$15,559,097.00"
"Kovacs, Michael","Medicine","2014/09","2016/09","Grants","Funded","False","False","Co-Applicant","Clinical predictors for venous thromboembolism in patients with a history of thrombosis","G. Le Gal","","$37,578,014.00"
"Tang, Anthony","Medicine","1990/01","1998/12","Grants","Funded","True","False","Principal Site Investigator","Multi Unsustained Tachycardia Trial","Alfred Buxton","","$19,129,026.00"
"Tang, Anthony","Medicine","1990/01","1997/12","Grants","Funded","True","False","Site Co-Investigator","Canadian Implantable Defibrillator Study","Stuart Connolly","","$55,814,632.00"
"Tang, Anthony","Medicine","1993/01","1998/12","Grants","Funded","True","False","Principal Site Investigator","Canadian Trial for Physiologic Pacing","Robin S. Roberts","","$73,674,936.00"
"Tang, Anthony","Medicine","1997/01","2004/12","Grants","Funded","True","False","Principal Site Investigator","Sudden Cardiac Death in Congestive Heart Failure","Gust Bardy","","$34,405,714.00"
"Tang, Anthony","Medicine","1997/01","1999/12","Grants","Funded","True","False","Site Co-Investigator","Canadian Trial of Atrial Fibrillation","Mario Talajic","","$40,330,514.00"
"Tang, Anthony","Medicine","1997/01","2002/09","Grants","Funded","True","False","Site Co-Investigator","Atrial fibrillation follow-up investigation of rhythm management","H. Greene","","$72,151,629.00"
"Tang, Anthony","Medicine","2001/04","2007/10","Grants","Funded","True","False","Site Co-Investigator","Atrial Fibrillation and Congestive Heart Failure (AF-CHF) Trial","Luigi Padeletti","","$63,000,923.00"
"Tang, Anthony","Medicine","2003/10","2011/07","Grants","Funded","True","False","Principal Site Investigator","Evaluation of Resynchronization Therapy for Heart Failure","Bernard Thibault","","$8,274,855.00"
"Tang, Anthony","Medicine","2010/01","present","Grants","Funded","True","False","Site Co-Investigator","Adenosine following pulmonary vein isolation to target dormant conduction elimination.","Laurent Macle","Lorne Gula, Peter Leong-Sit","$12,330,866.00"
"Tang, Anthony","Medicine","2005/01","2006/12","Clinical Trials","Funded","False","True","Principal Investigator","Electrical remodeling in the failing heart","Anthony Tang","David Birnie","$32,828,805.00"
"Leong-Sit, Peter","Medicine","2014/03","present","Clinical Trials","Funded","False","True","Principal Site Investigator","The Comparison of Management Plan – Ablation plus Resynchronization for Efficacy in Atrial Fibrillation","Stephen Wilton, Anthony Tang, Derek Exner","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$48,185,485.00"
"Gula, Lorne","Medicine","2014/03","present","Clinical Trials","Funded","False","True","Site Co-Investigator","The Comparison of Management Plan – Ablation plus Resynchronization for Efficacy in Atrial Fibrillation","Stephen Wilton, Anthony Tang, Derek Exner","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$54,834,220.00"
"Klein, George","Medicine","2014/03","present","Clinical Trials","Funded","False","True","Site Co-Investigator","The Comparison of Management Plan – Ablation plus Resynchronization for Efficacy in Atrial Fibrillation","Stephen Wilton, Anthony Tang, Derek Exner","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$12,496,304.00"
"Manlucu, Jaimie","Medicine","2014/03","present","Clinical Trials","Funded","False","True","Site Co-Investigator","The Comparison of Management Plan – Ablation plus Resynchronization for Efficacy in Atrial Fibrillation","Stephen Wilton, Anthony Tang, Derek Exner","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$29,924,336.00"
"Tang, Anthony","Medicine","2011/01","2014/12","Clinical Trials","Funded","False","True","Principal Investigator","The Comparison of Management Plan – Ablation plus Resynchronization for Efficacy in Atrial Fibrillation","Stephen Wilton, Anthony Tang, Derek Exner","","$51,131,175.00"
"Skanes, Allan","Medicine","2014/03","present","Clinical Trials","Funded","False","True","Site Co-Investigator","The Comparison of Management Plan – Ablation plus Resynchronization for Efficacy in Atrial Fibrillation","Stephen Wilton, Anthony Tang, Derek Exner","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes","$31,193,940.00"
"Tang, Anthony","Medicine","2009/01","2011/12","Clinical Trials","Funded","False","True","Principal Site Investigator","Shockless Implant Evaluation: A Prospective Randomised Clinical Trial","Jeff Healey","","$53,211,611.00"
"Tang, Anthony","Medicine","2009/01","present","Clinical Trials","Funded","False","True","Site Co-Investigator","Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Part II","Atul Verma","","$30,506,069.00"
"Tang, Anthony","Medicine","2009/09","2011/05","Clinical Trials","Funded","False","True","Site Co-Investigator","Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 1000 or 300mg OD with amiodarone as calibrator for the prevention of ICD interventions or death (protocol DRI10936).","Peter Kowey","","$12,867,947.00"
"Tang, Anthony","Medicine","2010/01","2012/12","Clinical Trials","Funded","False","True","Site Co-Investigator","PainFree SST Clinical Study","Inge Kuijpers","","$62,939,499.00"
"Tang, Anthony","Medicine","2008/11","2011/10","Clinical Trials","Funded","False","True","Site Co-Investigator","Discerning Symptomatic and Asymptomatic Episodes Pre & Post Radiofrequency Ablation of Atrial Fibrillation","David Birnie","","$35,402,408.00"
"Borrie, Michael","Medicine","2015/01","2017/01","Clinical Trials","Funded","True","False","Co-Investigator","Curing dementia with cough medicine: A Proof of Principle Trial repurposing Ambroxol as a disease modifying treatment for Parkinsons's Disease dementia","Stephen Pasternak","Robert Bartha, Michael Borrie, Elizabeth Finger, Mandar Jog, Michael Kovacs, Penny MacDonald, Don Mahuran, Mary Jenkins, Keith St. Lawrence, Rommel Tirona, Jennie Wells, Guangyong Zou, Tony Rupar, R Terry Thompson, William Pavlosky","$60,261,697.00"
"Tang, Anthony","Medicine","2011/01","2012/09","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Adaptive CRT Study","Dave Munneke","","$7,185,840.00"
"Tang, Anthony","Medicine","2010/01","2012/12","Clinical Trials","Funded","False","True","Site Co-Investigator","Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming","Marc Silver","","$10,132,212.00"
"Tang, Anthony","Medicine","2010/01","2010/11","Clinical Trials","Funded","False","True","Site Co-Investigator","A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)","Unknown","","$48,857,428.00"
"Tang, Anthony","Medicine","2011/01","2011/09","Clinical Trials","Funded","False","True","Site Co-Investigator","Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy","Stuart Connolly","","$40,013,296.00"
"Tang, Anthony","Medicine","2009/10","2012/01","Clinical Trials","Funded","False","True","Site Co-Investigator","Clinical evaluation of a novel 12-hole irrigated tip catheter ablation system for the treatment of typical atrial flutter-results from the Duo FLAIR clinical study","Dhanunjaya Lakkireddy","","$23,759,410.00"
"Tang, Anthony","Medicine","2007/01","2011/06","Clinical Trials","Funded","False","True","Site Co-Investigator","Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation","Michael Hanna","","$28,348,908.00"
"Tang, Anthony","Medicine","2009/11","2010/08","Clinical Trials","Funded","False","True","Site Co-Investigator","Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation","Unknown","","$50,093,183.00"
"Tang, Anthony","Medicine","2007/09","2008/08","Clinical Trials","Funded","False","True","Site Co-Investigator","Reveal® XT Performance Trial","Guido H. Rieger","","$72,033,128.00"
"Tang, Anthony","Medicine","2007/12","2013/04","Clinical Trials","Funded","False","True","Principal Site Investigator","Study to Determine the Efficacy of Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension","Mario Talajic","","$33,483,667.00"
"Tang, Anthony","Medicine","2005/11","2009/04","Clinical Trials","Funded","False","True","Site Co-Investigator","Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate","Paul Reilly","","$21,674,119.00"
"Tang, Anthony","Medicine","2006/07","2008/12","Clinical Trials","Funded","False","True","Site Co-Investigator","Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers","Olga Bandman","","$2,623,343.00"
"Tang, Anthony","Medicine","2005/10","2006/04","Clinical Trials","Funded","False","True","Site Co-Investigator","Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr","Urszula Wisniewska","","$29,174,875.00"
"Tang, Anthony","Medicine","2004/10","2008/07","Clinical Trials","Funded","False","True","Principal Site Investigator","Managed Ventricular Pacing (""MVP"") Trial","Michael O. Sweeney","","$37,228,674.00"
"Tang, Anthony","Medicine","2011/07","2012/06","Clinical Trials","Funded","False","True","Site Co-Investigator","A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of an Extended Infusion of Tedisamil Sesquifumarate in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Subjects with Recent Onset Atrial Fibrillation or Flutter – sponsor Protocol number: S219.3.114","unknown","","$67,051,082.00"
"Tang, Anthony","Medicine","2004/01","2006/12","Clinical Trials","Funded","False","True","Site Co-Investigator","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events","Phillippe Yusuf","","$32,148,171.00"
"Tang, Anthony","Medicine","2004/01","2005/12","Clinical Trials","Funded","False","True","Principal Site Investigator","MAVRIC VR ICD Registry","George Klein","","$35,430,916.00"
"Tang, Anthony","Medicine","2007/02","2010/08","Clinical Trials","Funded","False","True","Principal Site Investigator","EnRhythm MRI™ SureScan™ Pacing System Clinical Investigation","Nathalie Odryzynski","","$11,402,952.00"
"Tang, Anthony","Medicine","2004/01","2006/01","Clinical Trials","Funded","False","True","Principal Site Investigator","Model 6949 Lead Study","Unknown","","$22,993,692.00"
"Diamantouros, Pantelis","Medicine","2014/02","2018/01","Grants","Funded","False","False","Co-Investigator","Chronic Remote Ischemic Conditioning Following Primary PCI for STEMI: A Multicentre, prospective, Phase II, Randomized, Double-blind, Placebo-controlled Clinical Study.","Dr. S. Lavi","Dr. P. Diamantouros, Dr. P. Teefy, Dr. K. Sridhar, Dr. P. Garg","$29,273,073.00"
"Diamantouros, Pantelis","Medicine","2013/11","2017/09","Grants","Funded","False","True","Co-Investigator","Exenatide for Myocardial Protection during RepErfusion Study: A double-blind, p0lacebo-controlled trial (EMPRES)","Dr. S. Lavi","Dr. P. Diamantouros, Dr. P. Teefy, Dr. K. Sridhar, Dr. P. Garg","$27,958,524.00"
"Diamantouros, Pantelis","Medicine","2013/04","2019/04","Grants","Funded","True","False","Co-Investigator","A randomized, comparative effectiveness study of complete versus culprit-only revascularization strategies to treat multi-vessel disease after percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI)","Dr. S. Lavi","Dr. P. Diamantouros, Dr. P. Teefy, Dr. K. Sridhar, Dr. P. Garg","$55,168,183.00"
"Diamantouros, Pantelis","Medicine","2010/07","2015/12","Grants","Funded","False","False","Co-Investigator","A randomized trial of routine aspiration Thrombectomy with PCI versus PCI Alone in patients with STEMI undergoing primary PCI","Dr. S. Lavi","Dr. P. Diamantouros, Dr. P. Teefy, Dr. K. Sridhar, Dr. P. Garg","$9,284,555.00"
"Kim, Richard","Medicine","2014/09","2017/08","Grants","Funded","True","False","Principal Investigator","Drug Safety and Effectiveness Network (DSEN) Pharmacogenomics of Adverse Events National Team(PREVENT)","Richard Kim","","$23,155,158.00"
"Kim, Richard","Medicine","2014/05","2016/04","Grants","Funded","True","False","Principal Investigator","Implementation of Pharmacogenomics Guided Warfarin Dosing and INR monitoring for Hospitalized Patients: Focus on Health Economics and Adverse Event Rates","Richard Kim","","$16,654,226.00"
"Kim, Richard","Medicine","2013/10","2014/11","Grants","Funded","True","False","Principal Investigator","Development of an innovative Personalized CApecitabine Pretreatment algorithm for optimal dosing and Adverse Drug Reaction prevention (CAP-ADR): Phase I: Defining an optimal single time point sampling strategy representative of overall pharmacokinetic response to capecitabine","Eric Winquist","","$36,599,079.00"
"Ball, Ian","Medicine","2011/07","2014/06","Grants","Funded","False","False","Principal Investigator","Queen's Research Initiation Grant","Ian Ball","","$72,091,898.00"
"Martin, Claudio","Medicine","2015/06","2018/05","Grants","Applied","False","False","Co-Investigator","Phase II, multi-centre, randomized control trial of beta-Hydroxy-Methyl-Butyrate (HMB) in improving physical muscle function, in nutritionally at risk, elderly patients","Adam Rahman","Claudio Martin, John Drover","$22,681,363.00"
"Lazo Langner, Alejandro","Medicine","2015/07","2017/06","Grants","Applied","True","False","Co-Principal Investigator","Population-Based Evaluation of Adjunctive Interventional Radiology Approaches to Treat Acute Deep Vein Thrombosis","Susan Kahn, Vicky Tagalakis, Alejandro Lazo-Langne","","$7,587,799.00"
"Lazo Langner, Alejandro","Medicine","2016/07","2021/07","Grants","Applied","True","False","Co-Principal Investigator","A prospective multi-centre cohort study of perioperative anticoagulation in patients on long-term warfarin or rivaroxaban for venous thromboembolic disease (PERIOP 3)","Michael J. Kovacs, Alejandro Lazo-Langner","","$67,594,521.00"
"Lazo Langner, Alejandro","Medicine","2015/07","2018/06","Grants","Applied","True","False","Co-Principal Investigator","Climate and Health Initiative – London (CHIL)","LisaAnn Fraser","(All co-principal investigators) Akshya Vasudev, Amit Garg, Blayne Welk, Dhenuka Radhakrishnan, James Howerad, Kristin Clemens, Lucie Richard, Micahel Silverman, Neville Suskin, Salimah Sharif, Alejandro Lazo-Langner,","$26,744,958.00"
"Lazo Langner, Alejandro","Medicine","2016/07","2021/06","Grants","Applied","True","False","Principal Applicant","Conditions, Determinants and Outcomes in Venous Thromboembolic Disease: the COVeTeD research program.","Alejandro Lazo-Langner","","$36,429,195.00"
"Gunaratnam, Lakshman","Medicine","2013/06","2017/05","Grants","Funded","True","False","Principal Applicant","“Simulation and Imaging Laboratory for the Study of Ischemia Reperfusion Injury and Inflammation in Transplantation”","Dr. Lakshman Gunaratnam","","$4,173,805.00"
"Montero Odasso, Manuel","Medicine","2012/01","2017/01","Grants","Funded","True","False","Principal Investigator","Gait Variability as Predictor of Cognitive Decline and Risk of Falls in MCI. A Cohort Study","Manuel Montero-Odasso","","$60,382,920.00"
"Montero Odasso, Manuel","Medicine","2014/07","2016/06","Grants","Funded","True","False","Co-Investigator","The Role of Anodal Transcranial Direct Current Stimulation in Drug Induced Parkinsonism of Schizophrenia","Priya Subramanian","Amer Burhan, Julien Modolo, Sreelatha Varapravan","$42,376,024.00"
"Ball, Ian","Medicine","2015/01","2017/07","Clinical Trials","Funded","False","False","Principal Investigator","Targetted Exercise Reduces Morbidity and Mortality in Exercise","Ian Ball","C Martin, D Fraser, M Sharpe, T Mele, K Shoemaker, G. Cepinskas, C.G. Ellis, D Goldman, K St-Lawrence, R Hammond","$38,481,268.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2012/01","2015/01","Grants","Funded","True","False","Co-Principal Investigator","2012 - 2015 Schulich School of Medicine & Dentistry Dean's Research Grant Initiative MEDICI Center: Transforming Early Successes into a Sustainable Program of Cross Departmental Health Technology Assessment, Evidence-Based Decision-Making, and Knowledge Translation Co-Principal Investigator (Dr. Davy Cheng) $570,000",".","","$63,113,492.00"
"Fraser, Lisa-Ann","Medicine","2015/06","2017/06","Grants","Funded","True","False","Principal Applicant","Western Ambient Temperature and Health Research (WeATHeR) Program at ICES","Lisa-Ann Fraser","K. Clemens, A. Garg, J. Howard, A. Lazo-Langner, Radhakrishnan, M. Silverman, N. Suskin, A. Vasudev, B. Welk, S. Shariff, K. Liu, L. Richard","$39,258,279.00"
"Liu, Selina","Medicine","2012/01","2014/11","Clinical Trials","Funded","True","False","Co-Principal Investigator","A Strategy to Improve the Care and Outcome of Diabetes in Pregnancy in On-Reserve First Nations Women","Co-Principal Investigator: Stewart Harris","","$32,887,587.00"
"Gula, Lorne","Medicine","2014/10","2015/10","Grants","Funded","False","False","Principal Applicant","Healthforce Ontario Grant to support Physician Assistant Hiring","Lorne Gula","","$30,812,338.00"
"Gula, Lorne","Medicine","2013/10","2015/10","Grants","Funded","False","False","Principal Applicant","Healthforce Ontario Grant to support Physician Assistant Hiring","Lorne Gula","","$13,830,876.00"
"Leasa, David","Medicine","2009/09","2010/08","Grants","Funded","True","False","Collaborator","Improving the Experience of Patients Requiring or at Risk of Long-Term Mechanical Ventilation","ROSE, Louise","FRASER, Ian Murray ; GOLDSTEIN, Roger S. ; LEASA, David John ; MAWDSLEY, Cathy ; MCKIM, Douglas","$30,092,814.00"
"Teefy, Patrick","Medicine","2012/09","2014/09","Grants","Funded","False","True","Collaborator","Ticagrelor and Endothelial Function","Shahar Lavi","","$49,930,998.00"
"Teefy, Patrick","Medicine","2012/07","2015/07","Grants","Funded","False","False","Co-Investigator","TOTAL trial","Dr. Sanjit Jolly","","$46,390,957.00"
"Teefy, Patrick","Medicine","2011/04","2013/04","Clinical Trials","Funded","False","False","Principal Investigator","VELETI II","Patrick Teefy","","$60,589,820.00"
"Huang, Shih-Han Susan","Medicine","2014/10","2016/10","Clinical Trials","Funded","True","False","Principal Site Investigator","Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study – Canadian Network","Michelle Hladunewich","","$52,409,521.00"
"Pope, Janet","Medicine","2014/11","2016/11","Grants","Funded","True","False","Co-Investigator","Systemic sclerosis subset classification criteria. Initiation of a multi-phase, international, collaborative study. Agency: World Scleroderma Foundation.","Sindhu Johnson MD PhD FRCPC","","$53,826,540.00"
"Hramiak, Irene","Medicine","2012/09","2014/08","Clinical Trials","Funded","True","False","Co-Principal Investigator","A Pilot Study. Non-Mydriatic Ultra-Widefield Retinal Imaging for Diabetic Retinopathy Screening.","I Hramiak & S Liu","S Liu (Co-PI) J Gonder JL Mahon Filek","$49,873,154.00"
"McDonald, Charlotte","Medicine","2015/05","2016/12","Clinical Trials","Funded","True","False","Principal Site Investigator","Epidemiology of Diabetes Interventions and Complications","Dr. Charlotte McDonald","","$72,134,566.00"
"Smith, Stuart","Medicine","2000/01","2001/12","Grants","Funded","True","True","Co-Investigator","Strategies for Optimizing Heart Failure in the Community.","Co-Investigator with Heather Sherrard","Co-Investigator with Heather Sherrard","$20,151,848.00"
"Smith, Stuart","Medicine","2000/01","2001/12","Grants","Funded","True","True","Co-Investigator","CHF Care in Community Family Practice.","Co-Investigator with Marcel Dore (CCFP)","Co-Investigator with Marcel Dore (CCFP)","$60,947,949.00"
"Smith, Stuart","Medicine","2004/01","2006/12","Grants","Funded","True","False","Co-Investigator","""Educating Care Providers on Cardiac Health” (EPOCH) on Heart Failure Management in Long-Term Care Institutions.","Co-Investigator with Dr. Erin Tjam","Co-Investigator with Dr. Erin Tjam","$52,445,334.00"
"Smith, Stuart","Medicine","2007/01","2008/12","Grants","Funded","True","False","Co-Investigator","Working Towards a Cohesive Journey for the Congestive Heart Failure Patient in Waterloo-Wellington","Co-Investigator with Jeannine Costigan / Don Shilt","Co-Investigator with Jeannine Costigan / Don Shilton","$66,609,425.00"
"Mura, Marco","Medicine","2014/12","2016/12","Grants","Funded","False","True","Principal Applicant","Interstitial Lung Disease Clinic Nurse Coordinator","Marco Mura","","$53,752,540.00"
"Yamashita, Cory","Medicine","2015/04","2017/03","Grants","Funded","True","False","Principal Applicant","Host-Defense Peptide Fortified Surfactant for the Treatment of Bacterial Lung Infections","Dr. Cory Yamashita","Dr. Jim Lewis","$6,626,901.00"
"Ball, Ian","Medicine","2015/03","2016/03","Clinical Trials","Funded","True","False","Co-Applicant","An Observational Study of Organ Donation Practices at Three Canadian Centres","Maureen Meade","Michael Sharpe, Christine Ribic, Sonny Dhanani, David Williamson","$68,537,116.00"
"Ball, Ian","Medicine","2015/02","2016/02","Clinical Trials","Funded","True","False","Principal Applicant","London Health Sciences Centre Critical Care Medicine Internal Research Fund","Ian Ball","Claudio Martin, Michael Sharpe, Kevin Shoemaker, Doug Fraser, Tina Mele, Keith St-Lawrence, Chris Ellis, G Cepinskas","$41,189,204.00"
"Leasa, David","Medicine","2014/10","2015/10","Grants","Funded","True","False","Co-Applicant","Cough augmentation techniques to optimize weaning success and present reintubation in critically ill patients","Louise Rose, Douglas McKIm","N. ADHIKARI, R. AMIN, D. FERGUSSON, I. FRASER, S. KATZ, D. LEASA, C. LEBLANC C. O'CONNELL","$31,617,055.00"
"Manlucu, Jaimie","Medicine","2015/04","2017/03","Grants","Funded","False","False","Principal Investigator","Reverse Remodeling in CRT Patients with Intermediate QRS and Transseptal Endocardial LV Leads","Dr. Jaimie Manlucu","Dr. Anthony Tang","$40,423,506.00"
"Woolfrey, Karen","Medicine","2012/07","2013/06","Grants","Funded","True","False","Principal Investigator","Emergency Medicine Post Graduate Education Program Sunnybrook Health Sciences Centre. In Situ Simulation Program Development Grant","K. Woolfrey","","$5,458,583.00"
"Woolfrey, Karen","Medicine","2010/07","2011/06","Grants","Funded","True","False","Principal Investigator","Department of Medicine Innovation Grant - In-situ Simulation for Procedural Skills Competency in Emergency Medicine Resident Training Program","K. Woolfrey","","$49,350,819.00"
"Woolfrey, Karen","Medicine","2011/07","2012/06","Grants","Funded","True","False","Principal Site Investigator","SAEMO Grant: Medical Simulation - Development of an Emergency Medicine OSCE for Postgraduate Medical Trainees","K. Woolfrey","D. Dagnone","$34,402,839.00"
"Woolfrey, Karen","Medicine","2010/07","2011/06","Grants","Funded","True","False","Principal Investigator","The DRFUS Trial: Distal Radius Fracture Reduction with Point of Care Ultrasound","K. Woolfrey","L. Cartier","$48,231,453.00"
"Woolfrey, Karen","Medicine","2007/07","2007/07","Grants","Funded","True","False","Principal Investigator","Ambulatory Visits to a Canadian Emergency Department - Why to patients come?","K. Woolfrey","J. Chu","$34,938,119.00"
"Woolfrey, Karen","Medicine","2005/07","2006/07","Grants","Funded","True","False","Principal Investigator","Emergency Department 72-hour returns - The Bounce Study","K. Woolfrey","A. Healey","$51,116,847.00"
"Barra, Lillian","Medicine","2011/09","present","Grants","Funded","False","False","Principal Site Investigator","Diagnostic and Classification Criteria for Primary Systemic Vasculitis","Rashid Luqmani","","$60,178,327.00"
"Barra, Lillian","Medicine","2013/01","present","Grants","Funded","False","False","Principal Investigator","MRI/FDG-PET for large vessel vasculitis","Lillian Barra","Collaborators: A. Islam, F. Prato, J. Mandel, W. Pavlosky","$61,981,961.00"
"Barra, Lillian","Medicine","2012/07","present","Grants","Funded","False","False","Principal Investigator","Department of Medicine Internal Funding","Lillian Barra","","$15,996,541.00"
"Barra, Lillian","Medicine","2014/07","present","Grants","Funded","False","False","Principal Investigator","Rheumatoid Arthritis-Associated Antibodies and Cardiovascular Disease","Lillian Barra","Collaborators: E. Cairns, M. Huff, G. Pickering and D. Bell","$73,163,295.00"
"Barra, Lillian","Medicine","2011/02","2014/01","Grants","Funded","False","False","Principal Investigator","Department of Medicine and Division of Rheumatology Start-up funds","Lillian Barra","","$24,555,908.00"
"van Uum, Stanislaus","Medicine","2011/09","2011/09","Grants","Applied","True","False","Collaborator","Unravelling the Biological, Psychological and Social Influences on Disability After Whiplash","Dr. David Walton","Dr. David Walton, Dr. C. Goldsmith, Dr. M. Pierrynowski, Dr. J. Elliott, L. Levesque PT","$17,124,418.00"
"van Uum, Stanislaus","Medicine","2009/10","2014/09","Clinical Trials","Funded","True","False","Co-Applicant","CIHR Team in Using a Mobile Community Research Laboratory to Improve Understanding, Treatment, and Prevention of Addiction and Mental Illness Co-Morbidities at the Individual and Community Level: The Ontario Communities Project","Cairney,J;Graham,K;Kennedy,J;Rehm,J;Wells,S","Chaiton, Michael; Kates, Nick; Koren, Gideon; Lobo, Daniela; Menzies, Peter; Tyndale, Rachel; van Uum, S; Verjee, Zulfikarali","$39,714,895.00"
"van Uum, Stanislaus","Medicine","2011/06","2011/06","Clinical Trials","Funded","True","False","Co-Investigator","Cortisol Study","David Walton PT","Koren, Gideon; Russel, Evan; van Uum, Stan","$40,670,554.00"
"Rahman, Adam","Medicine","2012/07","2014/07","Grants","Funded","True","False","Principal Investigator","Fellowship in Clinical Nutrition and Micronutrient Research, Institute of Nutrition, Metabolism and Diabetes","RAHMAN, A","N/A","$65,375,453.00"
"Rahman, Adam","Medicine","2014/10","2016/12","Clinical Trials","Funded","True","False","Principal Investigator","Pilot randomized control trial of Beta Hydroxy Methyl Butyrate in improving physical muscle function in critically ill patients","RAHMAN, A","Martin C, Heyland D, Pikul J, Vanderloo M","$62,229,843.00"
"Rahman, Adam","Medicine","2015/01","2016/12","Clinical Trials","Funded","True","False","Co-Investigator","A comprehensive evaluation of nutritional status in critically ill patients after extubation","MOISEY, L","Mourtzakis M, Keller H, Rahman A, Heyland D","$14,191,298.00"
"Rahman, Adam","Medicine","2015/02","2017/02","Clinical Trials","Funded","True","False","Co-Principal Investigator","Randomized control trial of Beta Hydroxy Methyl Butyrate in improving physical muscle function in critically ill patients","RAHMAN A ; HEYLAND D","Martin C, Drover D, Agarwala R","$51,481,372.00"
"Rahman, Adam","Medicine","2015/07","2017/06","Clinical Trials","Funded","True","False","Co-Principal Investigator","Randomized Control Trial of Nutritional Care Pathway in Malnourished Hospitalized Medical Patients: Pilot Study","RAHMAN A ; MRKOBRADA M","Armstrong D, Patel A, Chakroborty A","$15,690,718.00"
"Rahman, Adam","Medicine","2015/04","2017/04","Clinical Trials","Funded","True","False","Co-Principal Investigator","Transplantation of Microbes of Fecal Origin for Prevention and Treatment of Metabolic Syndrome and Non Alcoholic Fatty Liver Disease","RAHMAN A ; SILVERMAN M","Hegele R, Hramiak I McKenzie C, Nair S, Reid G, Burton J, Beaton M, Joy T","$46,979,630.00"
"Rahman, Adam","Medicine","2015/01","2017/12","Clinical Trials","Funded","True","False","Co-Principal Investigator","Enhancement of a diet low in FODMAPS with probiotic supplements – The FIBSpro study","RAHMAN A, SCHULTZ, M, HARVIE R","Burton J, Reid G, Coppell K","$36,055,820.00"
"Rahman, Adam","Medicine","2015/09","2017/09","Clinical Trials","Funded","True","False","Co-Principal Investigator","More-2-Eat: Nutrition care pathway and optimized protein supplementation for malnourished elderly patients","RAHMAN A, HELLER K","Heyland D, Mrkobrada M, Basualdo-Hammond, C, Liu B, Bernier P, Gramlich L, Ray S, Douglas P, Duerksen D, Laporte M, Curtis L.","$52,439,898.00"
"Rahman, Adam","Medicine","2015/03","2017/12","Clinical Trials","Applied","True","False","Co-Principal Investigator","Enhancement of a diet low in FODMAPS with probiotic supplements – The FIBSpro randomized control trial","RAHMAN A, BURTON J","Reid G, Schultz M, Harvie R, McIntosh K","$15,355,207.00"
"Rahman, Adam","Medicine","2015/09","2017/01","Clinical Trials","Funded","True","False","Co-Principal Investigator","Institute of Clinical and Evaluative Sciences Clinical Scientist Development Program (ICES Western): Hospitalization and Surgical Intervention Rates in Patients with Crohn’s Disease: A Population-Based Cohort Study","RAHMAN A, FEAGAN B","N/A","$72,078,812.00"
"Mrkobrada, Marko","Medicine","2014/01","2018/01","Grants","Funded","True","False","Co-Principal Investigator","NeuroVISION Study: Detection and Neurological Impact Of Cerebrovascular Events In Noncardiac Surgery Patients: A Cohort Evaluation Study","Marko Mrkobrada","","$24,206,850.00"
"Elsayed, Sameer","Medicine","2015/01","present","Grants","Applied","True","False","Co-Applicant","Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): A Pilot Randomized Controlled Clinical Trial","Dr. Claudio Martin","Dr. Sameer Elsayed","$46,450,157.00"
"Martin, Claudio","Medicine","2014/07","2020/06","Grants","Funded","True","False","Co-Applicant","The Canadian Critical Care Trials Group","Paul Hebert","","$15,918,490.00"
"Martin, Claudio","Medicine","2015/12","2016/12","Clinical Trials","Funded","True","False","Co-Principal Investigator","Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): A Piolot Randomized Controlled Clinical Trial","Claudio Martin and Sameer Elsayed","","$65,224,613.00"
"Martin, Claudio","Medicine","2013/10","2014/09","Grants","Funded","True","False","Co-Principal Investigator","Ancillary testing for diagnosis of brain death: a systematic review and meta-analysis","Dean Fergusson and Claudio Martin","Michael Chasse, Shane English, Gregory Knoll, Francois Lauzier, Jean-Francois Lize, Lauralyn McIntyre, Sam Shemie, Alexis Turgeon","$19,516,950.00"
"Martin, Claudio","Medicine","2014/09","2019/08","Grants","Funded","True","False","Co-Applicant","The Canadian Critical Care Trials Group","Karen Burns, Karen Choong, Deborah Cook, et al","Richard Hall, James Hutchison, Claudio Martin","$15,299,937.00"
"Rohekar, Sherry","Medicine","2011/07","2012/06","Grants","Funded","True","False","Co-Principal Investigator","Arthritis Expert Program: Improving Quality of Care in Chronic Disease","Sherry Rohekar","Janet Pope","$14,124,503.00"
"Lazo Langner, Alejandro","Medicine","2015/07","2020/07","Grants","Funded","True","False","Co-Principal Investigator","ICRH Community Development Program Grant: Can-VECTOR.","Susan R Kahn, Marc Rodger","","$62,511,176.00"
"Lazo Langner, Alejandro","Medicine","2016/07","2021/07","Grants","Applied","True","False","Principal Applicant","Identification of genetic polymorphisms of vein wall remodelling in chronic venous disease","Alejandro Lazo-Langner","","$51,918,631.00"
"Lazo Langner, Alejandro","Medicine","2015/07","2017/07","Grants","Applied","True","False","Co-Principal Investigator","A prospective multi-centre cohort study of perioperative anticoagulation in patients on long-term warfarin or rivaroxaban for venous thromboembolic disease (PERIOP 3)","Michael J. Kovacs, Alejandro Lazo-Langner","","$69,218,479.00"
"Muirhead, Norman","Medicine","2014/07","2014/09","Clinical Trials","Funded","False","True","Principal Investigator","Epidemioloigical Study Assessing the Burden of Illness of ADPKD in Canada","Norman Muirhead","","$60,227,198.00"
"Moist, Louise","Medicine","2015/01","2017/01","Grants","Funded","True","False","Principal Investigator","PISCES: Protection against Incidences of Serious Cardiovascular Events Study with Daily Fish Oil Supplementation in Dialysis Patient: A Pilot Study","Dr. Louise Moist","","$46,029,954.00"
"Pickering, J. Geoffrey","Medicine","2014/07","2014/07","Grants","Funded","True","False","Principal Investigator","Personnel support for graduate student, Yiwen Xu","J.G. Pickering","","$56,425,576.00"
"Pickering, J. Geoffrey","Medicine","2014/07","2017/06","Grants","Funded","True","False","Co-Applicant","Dual energy micro-CT for angiography and cardiovascular histology.","Maria Drangova","J.G. Pickering, E. Gillies","$58,638,915.00"
"Pickering, J. Geoffrey","Medicine","2006/05","2006/05","* Infrastructure Fund","Funded","True","False","Principal Investigator","Measures of gene expression (Real-time RT-PCR) and fluorescent micromanipulating infrastructure to examine stem cell function will provide unique abilities to London stem cell biologists","J.G. Pickering","","$71,318,919.00"
"Pickering, J. Geoffrey","Medicine","1999/09","2004/02","* Innovation Fund","Funded","True","False","Principal Investigator","Stem-cell transplantation and regenerative therapy","J.G. Pickering","","$38,615,369.00"
"Lewis, James","Medicine","2015/03","2017/02","Grants","Funded","False","False","Co-Applicant","Host defense peptide fortified surfactant for the treatment of bacterial lung infections","Cory Yamashita","","$37,819,421.00"
"Dias, Bryan","Medicine","2007/01","2010/12","Grants","Funded","True","False","Co-Investigator","Pregnancy and long term prognosis in woman with congenital heart disease","Bryan Dias","Jack Colman, Mathew Sermer, Candice Silversides, Omid Salehian, Bryan Dias, Luc Beauchesne","$61,709,469.00"
"Yamashita, Cory","Medicine","2015/07","2017/06","Grants","Funded","True","False","Principal Applicant","Host-Defense Peptide Fortified Surfactant for the Treatment of Cystic Fibrosis Associated Lung Infections","Dr. Cory Yamashita","","$26,042,752.00"
"Martin, Claudio","Medicine","2015/07","2016/06","Grants","Funded","True","False","Co-Applicant","Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): A Randomized Controlled Trial","Nick Daneman and Robert Fowler","Bagshaw, S., Coburn B., Cook D., Dodek, P., Hall R., Kumar A., Lamontagne F., Lauzier F., Marshall J., Martin C., McIntyre L., Muscedere J., Reynolds S., Stelfox H.","$26,239,829.00"
"Hackam, Daniel","Medicine","2014/01","2014/12","Grants","Funded","False","False","Principal Investigator","POEM Research Award","Daniel Hackam","","$40,752,197.00"
"Hackam, Daniel","Medicine","2013/01","2013/12","Grants","Funded","False","False","Principal Investigator","POEM Research Award","Daniel Hackam","","$47,283,491.00"
"Hackam, Daniel","Medicine","2015/01","2015/06","Grants","Funded","False","False","Principal Investigator","POEM Research Award","Daniel Hackam","","$12,765,445.00"
"Yamashita, Cory","Medicine","2015/07","2017/06","Grants","Applied","True","False","Co-Principal Investigator","Host-Defense Peptide Fortified Surfactant for the Treatment of Pediatric Tracheostomy-Associated Infections","Dr. Cory Yamashita","Dr. Ruud Veldhuizen","$16,773,326.00"
"Minuk, Leonard","Medicine","2011/11","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Open-label, Multi-center, Single-arm Study for the Safety and Efficacy of Pomalidomide","Leonard Minuk","I Chin-Yee, M Louzada","$38,178,881.00"
"Bosma, Karen","Medicine","2015/07","2020/06","Grants","Funded","True","False","Co-Applicant","The NEUROlogically-impaired extubation Timing Trial (NEURO-ETT)","Scale, Damon, Ferguson, Niall","Adhikari N, Alali A, Baker A, Bosma K, Brochard L, Chapman M, Charbonney E, Cuthbertson B, Fowler R, Griesdale D, Mainprize T, McCredie V, Meade M, Nathens A, Rubenfeld G, Seely A, Singh J, Turgeon A, Wilcox ME, Zygun D","$10,515,919.00"
"Gryn, Steven","Medicine","2015/03","present","Clinical Trials","Funded","False","True","Co-Investigator","A randomized, double-blind, placebo-controlled phase 3 study of ISIS 304801 administered subcutaneously to patients with hypertriglyceridemia","Robert Hegele (site PI)","","$53,186,912.00"
"Gryn, Steven","Medicine","2015/03","present","Clinical Trials","Funded","False","True","Site Investigator","Medically ill patient assessment of rivaroxaban versus placebo in reducing post-discharge venous thrombo-embolism risk","George Dresser (site PI)","","$21,669,546.00"
"Sen, Mithu","Medicine","2015/07","2019/06","Grants","Applied","True","False","Co-Investigator","Re-evalatuion Of Systematic Early neuromuscular blockade in ARDS (ROSE) Trial","Ferguson N, Lamontagne F","Knowledge Users: Fan E, Grondin K, Piraino T Co-I: Adhikari N, Archambault P, Bagshaw S, Bosma K, Charbonney E, Cook D, Dorscheid D, Friedrich J, Goligher E, Hall R, Herridge M, Hebert P, Lauzier F, Meade M, Mehta S, Muscedere J, Sen M, Slutsky A","$27,608,646.00"
"Silverman, Michael","Medicine","2015/05","2017/05","Grants","Funded","True","False","Principal Investigator","Transplantation of Microbes of Fecal Origin for Prevention and Treatment of Metabolic Syndrome and Non Alcoholic Fatty Liver Disease.","Dr.Michael Silverman","Dr.Adam Rahman, Dr.Tisha Joy, Dr.Irene Hramiak, Dr. Robert A. Hegele, Dr.Jeremy Burton, Dr. Gregor Reid, Dr.Seema Nair Parvathy, Dr. Charles A. McKenzie, Dr. Kelly Summers, Dr.Greg Gloor, Dr.Robert McIntyre","$34,436,618.00"
"Moist, Louise","Medicine","2015/07","2017/07","Grants","Funded","True","False","Co-Investigator","A Randomized Controlled Trial Comparing Arteriovenous Fistulas to Central Venous Catheters for Vaascular Access in Incident Hemodialysis Patients","Dr. Robert Quinn","","$1,030,733.00"
"Borrie, Michael","Medicine","2015/03","2019/12","Clinical Trials","Funded","True","False","Principal Investigator","The A4 (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) Study","Borrie, M.","Wells J, Finger E, Pasternak S.","$11,711,144.00"
"Wells, Jennie","Medicine","2015/03","2019/12","Clinical Trials","Funded","True","True","Co-Investigator","The A4 (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) Study Alzheimer Disease Cooperative Study (ADCS)","Borrie, M.","Finger E, Pasternak S, Wells J.","$64,450,126.00"
"Kostuk, William","Medicine","2013/08","2018/06","Grants","Funded","False","True","Principal Site Investigator","A randomized double-blind event driven multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with chronic heart failure and significant coronary artery disease following a hospitalization for exacerbation of heart failure (Commander HF study).","Dr. W. J. Kostuk","Dr. P. Pflugfelder","$7,805,221.00"
"Goldszmidt, Mark","Medicine","2014/07","2015/06","Grants","Funded","True","False","Co-Investigator","CTU Communication Research Project","DeLuca, S.","Hibbert, K., Faden, L., Goldszmidt, M.","$40,631,954.00"
"Goldszmidt, Mark","Medicine","2013/07","2014/06","Grants","Funded","True","False","Principal Investigator","The Role of Basic Sciences in Understanding and Retaining Clinical Knowledge","Goldszmidt, M.","Cowan, A.","$31,812,205.00"
"Goldszmidt, Mark","Medicine","2013/05","2015/09","Grants","Funded","True","False","Principal Investigator","Exploring Junior Trainees Approach to Clinical Documentation and Patient Follow-up","Goldszmidt, M.","Cadieux, D.","$5,785,305.00"
"Skanes, Allan","Medicine","2014/04","present","Grants","Funded","True","False","Co-Investigator","Image-guided device interventions for cardiovascular disease","Graham Wright","Kevan Anderson, Labonny Biswas, Brian Courtney, Isaac Jouraard, Natasha Alves-Kotzev, Eugene Crystal, Maria Drangova, Raymond Yee, Allan Skanes, Terry Peters","$39,642,185.00"
"Yee, Raymond","Medicine","2014/04","present","Grants","Funded","True","False","Co-Investigator","Image-guided device interventions for cardiovascular disease","Graham Wright","Kevan Anderson, Labonny Biswas, Brian Courtney, Isaac Jouraard, Natasha Alves-Kotzev, Eugene Crystal, Maria Drangova, Raymond Yee, Allan Skanes, Terry Peters","$62,204,494.00"
"Yamashita, Cory","Medicine","2014/07","2015/06","Grants","Funded","True","False","Principal Investigator","Antimicrobial Peptide Fortified Surfactant for the Treatment of Cystic Fibrosis","Dr. Cory Yamashita","","$51,020,707.00"
"Yee, Raymond","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Model 20105 Lead Study","Laura Manotta","Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$59,531,475.00"
"Leong-Sit, Peter","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Model 20105 Lead Study","Laura Manotta","Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$37,283,543.00"
"Manlucu, Jaimie","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Model 20105 Lead Study","Laura Manotta","Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$50,284,557.00"
"Tang, Anthony","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Model 20105 Lead Study","Laura Manotta","Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$1,714,331.00"
"Yee, Raymond","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Substernal Pacing Acute Clinical Evaluation (SPACE) Study","Marina Ostanniy","Bob Kiaii, Michael Chu, Dave Nagpal, Jaimie Manlucu, Peter Leong-Sit","$45,770,795.00"
"Manlucu, Jaimie","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","Substernal Pacing Acute Clinical Evaluation (SPACE) Study","Marina Ostanniy","Bob Kiaii, Michael Chu, Dave Nagpal, Jaimie Manlucu, Peter Leong-Sit","$29,737,660.00"
"Leong-Sit, Peter","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","Substernal Pacing Acute Clinical Evaluation (SPACE) Study","Marina Ostanniy","Bob Kiaii, Michael Chu, Dave Nagpal, Jaimie Manlucu, Peter Leong-Sit","$55,990,175.00"
"Yee, Raymond","Medicine","2014/06","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Canadian Registry of Cardiovascular Implantable Electronic Device Outcomes","Ratika Parkash","Jaimie Manlucu, Peter Leong-Sit","$42,079,233.00"
"Manlucu, Jaimie","Medicine","2014/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Canadian Registry of Cardiovascular Implantable Electronic Device Outcomes","Ratika Parkash","Jaimie Manlucu, Peter Leong-Sit","$24,797,240.00"
"Leong-Sit, Peter","Medicine","2014/06","present","Clinical Trials","Funded","True","False","Co-Investigator","Canadian Registry of Cardiovascular Implantable Electronic Device Outcomes","Ratika Parkash","Jaimie Manlucu, Peter Leong-Sit","$27,098,804.00"
"Gula, Lorne","Medicine","2014/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Global Registry Program on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III)","Jeff Healey","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$10,410,009.00"
"Manlucu, Jaimie","Medicine","2014/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Global Registry Program on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III)","Jeff Healey","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$7,085,955.00"
"Skanes, Allan","Medicine","2014/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Global Registry Program on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III)","Jeff Healey","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$58,709,072.00"
"Tang, Anthony","Medicine","2014/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Global Registry Program on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III)","Jeff Healey","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$5,926,431.00"
"Yee, Raymond","Medicine","2014/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Global Registry Program on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III)","Jeff Healey","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$40,050,631.00"
"Leong-Sit, Peter","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Protocol","Jonathan Piccini","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$11,312,153.00"
"Gula, Lorne","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Protocol","Jonathan Piccini","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$52,697,348.00"
"Manlucu, Jaimie","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Protocol","Jonathan Piccini","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$32,367,363.00"
"Skanes, Allan","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Protocol","Jonathan Piccini","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$31,902,581.00"
"Tang, Anthony","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Protocol","Jonathan Piccini","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$52,838,631.00"
"Yee, Raymond","Medicine","2015/04","present","Clinical Trials","Funded","False","True","Co-Investigator","A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Protocol","Jonathan Piccini","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$61,899,442.00"
"Tang, Anthony","Medicine","2013/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia","Adam Cline - Worldwide Clinical Trial Leader","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$19,390,574.00"
"Tang, Anthony","Medicine","2005/12","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","System Longevity Study: Monitoring Long-Term Function of Medtronic Heart-Related Products","Jean Russell","","$74,728,900.00"
"Tang, Anthony","Medicine","2009/06","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Model 4196 Left Ventricular (LV) Lead Chronic Performance Study","Jean Russell","","$70,458,002.00"
"Tang, Anthony","Medicine","2007/05","2011/02","Clinical Trials","Funded","False","True","Co-Investigator","EnRhythm MRI SureScan Pacing System Study","Sarah Willey","","$56,240,517.00"
"Tang, Anthony","Medicine","2009/04","2013/02","Clinical Trials","Funded","False","True","Co-Investigator","Medtronic Shock-Less Study","Dan Lexcen","","$8,711,893.00"
"Tang, Anthony","Medicine","2009/08","2013/10","Clinical Trials","Funded","False","True","Co-Investigator","PainFree SST - Protecta Clinical Study","Dan Lexcen","","$6,510,904.00"
"Tang, Anthony","Medicine","2005/08","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Lead Model 3830","CRHF Legacy Study","","$64,966,292.00"
"Tang, Anthony","Medicine","2004/11","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Sprint Fidelis Model 6949 RV/SVC Lead","CRHF Legacy Study","","$38,261,584.00"
"Tang, Anthony","Medicine","2004/03","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic InSync Marquis Model 7277","CRHF Legacy Study","","$29,161,842.00"
"Tang, Anthony","Medicine","1999/07","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Kappa 700","CRHF Legacy Study","","$48,650,923.00"
"Tang, Anthony","Medicine","2002/03","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Marquis DR Model 7274 Dual Chamber Implantable Cardioverter Defibrillator","CRHF Legacy Study","","$20,470,013.00"
"Tang, Anthony","Medicine","2006/08","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","MAVRIC VR ICD Registry","CRHF Legacy Study","","$38,414,465.00"
"Tang, Anthony","Medicine","2005/08","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic EnRhythm Implantable Pulse Generator Clinical Trial","CRHF Legacy Study","","$23,338,333.00"
"Tang, Anthony","Medicine","2004/08","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Worldwide Application Study of Marquis VR Enhancements","CRHF Legacy Study","","$58,112,976.00"
"Tang, Anthony","Medicine","2003/02","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Medtronic Model 7272 InSync ICD Cardiac Resynchronization System","CRHF Legacy Study","","$70,285,345.00"
"Tang, Anthony","Medicine","2009/03","2012/06","Clinical Trials","Funded","False","True","Principal Site Investigator","Model 4195 Left Ventricular (LV) Lead Chronic Performance Study","Jean Russell","","$74,547,016.00"
"Tang, Anthony","Medicine","2012/12","2014/03","Clinical Trials","Funded","False","True","Principal Site Investigator","Miracle Mid EF","Marina Ostanniy","","$39,279,292.00"
"Tang, Anthony","Medicine","2014/01","present","Clinical Trials","Funded","False","True","Co-Investigator","ECG Feedback for CRT Response","Jackie Mittelstadt - Clinical Research Specialist","Peter Leong-Sit, Anthony Tang","$48,434,008.00"
"Tang, Anthony","Medicine","2011/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Risk Estimation Following Infarction Non-invasive Evaluation - ICD efficacy","Derek Exner","Skanes, Allan Manlucu, Jaimie Leong-Sit, Peter Gula, Lorne Tang, Anthony","$56,961,606.00"
"Tang, Anthony","Medicine","2010/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure","Scott Sarazin","","$51,680,756.00"
"Tang, Anthony","Medicine","2012/06","present","Clinical Trials","Funded","False","True","Co-Investigator","Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study","Aleela Baune","","$48,815,691.00"
"Barra, Lillian","Medicine","2015/03","2016/02","Grants","Funded","True","False","Co-Investigator","Pathogenesis of Rheumatoid Arthritis-Associated Antibodies","Ewa Cairns","","$26,335,026.00"
"Barra, Lillian","Medicine","2015/06","2017/05","Grants","Funded","True","False","Co-Applicant","Improving the Care of Patients with Systemic Vasculitis through the Development of Management Recommendations and Educational Materials: A Canadian Vasculitis Network (CanVasc) Initiative","Christian Pagnoux","L.Barra","$43,346,810.00"
"Ball, Ian","Medicine","2015/07","2015/09","Grants","Funded","False","False","Supervisor","Retrospective analysis of glycemic variability's effect on delirium in the critically ill elderly patient","Spencer Chambers","Claudio Martin, Brenda Morgan","$39,239,907.00"
"Asfaha, Samuel","Medicine","2011/04","2015/04","Grants","Funded","True","False","Principal Investigator","Identification and characterization of intestinal and colonic stem cells.","Asfaha S","","$60,464,918.00"
"Asfaha, Samuel","Medicine","2009/04","2011/09","Grants","Funded","True","False","Principal Investigator","The role of bone marrow-derived stem cells (BMDCs) in the development of and progression to gastric cancer.","Asfaha S","","$15,006,435.00"
"Asfaha, Samuel","Medicine","2008/11","2010/11","Grants","Funded","True","False","Principal Investigator","The role of bone marrow-derived stem cells (BMDCs) in the development of and progression to gastric cancer.","Asfaha S","","$70,986,114.00"
"Asfaha, Samuel","Medicine","2009/03","2010/03","Grants","Funded","True","False","Principal Investigator","Detweiler Traveling Fellowship","Asfaha S","","$57,706,191.00"
"Asfaha, Samuel","Medicine","2007/01","2008/01","Grants","Funded","True","False","Principal Applicant","CAG Resident Research Training Grant","Asfaha S","","$46,253,976.00"
"Asfaha, Samuel","Medicine","2003/01","2003/01","Grants","Funded","True","False","Principal Applicant","Dr. Lydia Sikora Memorial Research Award","Asfaha S","","$14,652,126.00"
"Asfaha, Samuel","Medicine","2015/09","2017/08","Grants","Applied","True","False","Principal Applicant","Identifying Cancer Stem Cell Targets in Colon Cancer","Asfaha S","","$18,210,717.00"
"Asfaha, Samuel","Medicine","2015/09","2017/08","Grants","Funded","True","False","Principal Applicant","Dclk1+ tuft cells as a cellular origin for inflammation-associated cancer in the gut","Asfaha S","","$23,581,318.00"
"Iyer, Hariharan","Medicine","2015/01","2018/12","Clinical Trials","Funded","False","True","Co-Investigator","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis.","Dr. N. Muirhead","Dr. Hariharan Iyer","$64,015,573.00"
"McIntyre, Christopher","Medicine","2015/01","2017/12","Grants","Funded","True","False","Principal Investigator","Remote ischemic preconditioning for the prevention of dialysis induced injury","Chris McIntyre","","$55,622,309.00"
"McIntyre, Christopher","Medicine","2013/01","2016/12","Grants","Funded","True","False","Principal Investigator","Peritoneal Dialysis for the treatment of HF","Chris McIntyre","Phil Kalra; Simon Davies","$24,470,211.00"
"McIntyre, Christopher","Medicine","2013/01","2016/12","Grants","Funded","True","False","Principal Investigator","Clinical Impact of Utilising Cystatin C to estimate GFR","Chris McIntyre","Maarten Taal","$73,134,145.00"
"McIntyre, Christopher","Medicine","2012/01","2016/12","Grants","Funded","True","False","Principal Investigator","UoN URS PhD studentship, Scholarship","Chris McIntyre","Dr. Sue Francis","$47,959,624.00"
"McIntyre, Christopher","Medicine","2011/01","2013/12","Grants","Funded","True","False","Principal Investigator","Dialysis induced endotoxaemia","Chris McIntyre","","$13,937,231.00"
"McIntyre, Christopher","Medicine","2014/01","2016/12","Grants","Funded","True","False","Principal Investigator","Arts-based research to explore the experience and expectation of patients needing dialysis","Chris McIntyre","","$23,829,282.00"
"McIntyre, Christopher","Medicine","2013/12","2016/01","Grants","Funded","True","False","Principal Investigator","Prescription of intradialytic exercise to improve quality of life (PEDAL Trial)","Chris McIntyre","Chris Pugh; Iain Macdougall","$3,076,829.00"
"McIntyre, Christopher","Medicine","2014/01","2015/12","Grants","Funded","True","False","Principal Investigator","Effects of haemodialysis and haemodiafiltration on myocardial perfusion","Chris McIntyre","Dr. Sue Francis","$4,184,631.00"
"McIntyre, Christopher","Medicine","2013/01","2015/12","Grants","Funded","True","False","Principal Investigator","Intrarenal haemodynamics, oxygen metabolism and fibrosis in CKD","Chris McIntyre","Dr. Sue Francis","$62,487,571.00"
"McIntyre, Christopher","Medicine","2011/01","2013/12","Grants","Funded","True","False","Principal Investigator","Plasma toxicity manipulation and HD","Chris McIntyre","","$15,441,157.00"
"McIntyre, Christopher","Medicine","2012/01","2013/12","Grants","Funded","True","False","Principal Investigator","Cardio-renal effects of bardoxolone","Chris McIntyre","Dr. Sue Francis","$36,232,829.00"
"McIntyre, Christopher","Medicine","2011/01","2013/12","Grants","Funded","True","False","Principal Investigator","Ischaemic preconditioning in HD","Chris McIntyre","","$38,304,693.00"
"McIntyre, Christopher","Medicine","2009/01","2012/12","Grants","Funded","True","False","Principal Investigator","Dialysate cooling to prevent the development of Heart failure","Chris McIntyre","","$71,932,618.00"
"McIntyre, Christopher","Medicine","2011/01","2012/12","Grants","Funded","True","False","Principal Investigator","Renal perfusion in CRS","Chris McIntyre","","$8,837,853.00"
"McIntyre, Christopher","Medicine","2010/01","2011/12","Grants","Funded","True","False","Principal Investigator","Vitamin D and FGF 23 in progressive vascular aging in CKD 3","Chris McIntyre","Maarten Taal","$44,451,779.00"
"McIntyre, Christopher","Medicine","2009/01","2011/12","Grants","Funded","True","False","Principal Investigator","Myocardial Stunning in Paediatric Dialysis Patients","Chris McIntyre","","$66,150,505.00"
"McIntyre, Christopher","Medicine","2009/01","2011/12","Grants","Funded","True","False","Principal Investigator","Risk of renal function decline","Chris McIntyre","","$50,636,234.00"
"McIntyre, Christopher","Medicine","2008/01","2010/12","Grants","Funded","True","False","Principal Investigator","Cardiovascular Consequences of CKD in Older People","Chris McIntyre","","$53,244,246.00"
"McIntyre, Christopher","Medicine","2009/01","2010/12","Grants","Funded","True","False","Principal Investigator","Dialysis induced cardiac injury","Chris McIntyre","","$50,679,455.00"
"McIntyre, Christopher","Medicine","2008/01","2009/12","Grants","Funded","True","False","Principal Investigator","Investigation of the effects of dialysate magnesium concentration","Chris McIntyre","","$55,822,141.00"
"Silverman, Michael","Medicine","2015/05","2016/05","Clinical Trials","Funded","True","False","Principal Investigator","Prevention of Antibiotic overprescribing as a strategy for increasing clinical billings- an interventional study","Michael S Silverman","Dr.Salimah Shariff, Dr.Marcus Povitz and Dr.Amit Garg","$35,046,485.00"
"McIntyre, Christopher","Medicine","2007/01","2009/12","Grants","Funded","True","False","Co-Investigator","The effect of acidosis correction in CKD","Joh Feehally","Chris McIntyre","$5,867,128.00"
"McIntyre, Christopher","Medicine","2007/01","2009/12","Grants","Funded","True","False","Principal Investigator","Myocardial Stunning during Paediatric Dialysis","Chris McIntyre","Dr. Daljit Hothi","$67,307,282.00"
"Silverman, Michael","Medicine","2015/06","2016/06","Clinical Trials","Funded","True","False","Principal Investigator","Baseline Resistance Testing in Hepatitis C Care","Michael S Silverman","Dr.Eric Arts, Dr.P.Marotta, Dr.Karim Qusomani, Dr.P.Adams, Dr Bandar Aljudabi, Dr.Melanie Beaton","$6,054,022.00"
"Silverman, Michael","Medicine","2015/07","2017/07","Clinical Trials","Funded","True","False","Principal Investigator","Weather Changes and Health: Substudy on impact of temperature on incidence of Cellulitis","Michael S Silverman","","$44,924,818.00"
"Spaic, Tamara","Medicine","2015/01","2016/01","Clinical Trials","Funded","False","True","Co-Investigator","A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","Dr I. Hramiak","Dr T. Spaic Dr. T. Paul","$63,630,003.00"
"Spaic, Tamara","Medicine","2014/07","2015/06","Clinical Trials","Funded","False","False","Co-Investigator","A Randomized Phase 2, Doubleblind, Placebo controlled, Treat to Target, Parallel group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus","Dr. I. Hramiak","Dr. T. Spaic Dr. T. Paul","$9,731,518.00"
"Hegele, Robert","Medicine","2011/09","2016/08","Grants","Funded","True","False","Co-Principal Investigator","Molecular mechanisms of novel genes associated with plasma lipids and cardiovascular disease","Daniel Rader","Robert A. Hegele","$60,323,183.00"
"Hegele, Robert","Medicine","2014/07","2019/06","Grants","Funded","True","False","Co-Principal Investigator","Ontario Neurodegeneration Research Initiative","Michael Strong","Robert A. Hegele","$13,768,813.00"
"Huang, Shih-Han Susan","Medicine","2015/08","2016/07","Grants","Funded","False","True","Co-Principal Investigator","The CKD Water Intake Trial (WIT) Follow-Up study","W.F. Clark","","$49,969,560.00"
"Manlucu, Jaimie","Medicine","2015/04","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients with New-onset Persistent Left Bundle Branch Block after Transcatheter Aortic Valve Implantation.","Josep Rodes Cabau","Bob Kiaii, Michael Chu, Pantelis Diamantouros, Patrick Teefy","$45,562,217.00"
"Barra, Lillian","Medicine","2015/04","2016/03","Grants","Funded","True","False","Principal Applicant","Investigating citrullinated proteins in joint and vascular tissues using a mouse model of Rheumatoid Arthritis","Lillian Barra","","$34,194,711.00"
"Hramiak, Irene","Medicine","2015/01","2016/01","Clinical Trials","Funded","False","True","Principal Investigator","To evaluate the efficacy and safety of Dapagliflozin as an add-on therapy to insulin in the treatment of subjects with Type 1 diabetes mellitus.","IM Hramiak","TL Paul, T Spaic","$50,647,548.00"
"Wells, Jennie","Medicine","2013/11","2016/11","Clinical Trials","Funded","True","True","Co-Investigator","Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo.","Borrie MJ","Wells JL, Borrie MJ","$66,688,815.00"
"Licskai, Christopher","Medicine","2013/01","2016/03","Grants","Funded","True","False","Principal Applicant","Family Health Team Primary Care Innovation Collaborative","Christopher Licskai","","$36,477,588.00"
"Licskai, Christopher","Medicine","2015/03","2015/12","Grants","Funded","True","False","Co-Investigator","The Canadian Airway Disease Research Network","Shawn Aaron","Fitzgerald, J., Halayko, A., Lavoie, K., Plaxton, J., Licskai","$9,972,900.00"
"Licskai, Christopher","Medicine","2015/05","2016/03","Grants","Funded","False","True","Principal Investigator","breatheAgain Project","Christopher Licskai","Teresa To, Diane Lougheed, Joseph Cafazzo, Samir Gupta","$47,482,514.00"
"Basharat, Pari","Medicine","2015/05","2019/05","Grants","Funded","True","False","Principal Applicant","The Establishment of a Myositis Network to Advance Research, Collaboration, and Knowledge Translation in Skeletal Muscle Disease","Dr. Pari Basharat","","$50,247,471.00"
"Lavi, Shahar","Medicine","2015/04","2017/04","Grants","Funded","True","False","Principal Investigator","Role of Adjunctive Mild Therapeutic Hypothermia and Early Cardiac Catheterization for Acute Coronary Syndromes in Cardiac Arrest","Shahar Lavi","","$72,925,610.00"
"Khanna, Reena","Medicine","2014/01","2015/01","Grants","Funded","True","False","Principal Investigator","Future Leaders in IBD","Khanna, R.","","$68,559,872.00"
"Khanna, Reena","Medicine","2015/01","2016/12","Grants","Funded","True","False","Principal Investigator","Schulich Strategic Support Award","Khanna, R.","","$68,387,293.00"
"Khanna, Reena","Medicine","2014/01","2015/06","Grants","Funded","True","False","Principal Investigator","Faculty Development Mini Fellowship Application","Khanna, R.","","$28,447,729.00"
"Mura, Marco","Medicine","2015/05","2018/06","Grants","Funded","True","False","Principal Investigator","Early and Comprehensive Management of Interstitial Lung Disease to Improve Outcomes and Healthcare Resource Utilization","Dr. Marco Mura","","$34,310,187.00"
"Licskai, Christopher","Medicine","2014/07","2019/06","Grants","Funded","True","False","Co-Investigator","Structure-Function MRI of Asthma","Parraga, G., Nair, P.","Maksym, G., Mccormack, D., Licskai, C.","$49,249,224.00"
"Borrie, Michael","Medicine","2014/01","present","Clinical Trials","Funded","False","True","Co-Investigator","TRx-237-007: A Double-Blind, Placebo-Controlled, Randomized Parallel-Group, 12-Month Safety and Efficacy Study of Leuco-ethylthioninium bis(hydromethanesulfonate) in Subjects with Behavioural Variant Frontotemporal Dementia.","Finger, E.","Wells JL and Borrie MJ.","$63,708,181.00"
"Borrie, Michael","Medicine","2014/05","present","Clinical Trials","Funded","False","True","Co-Investigator","TRx-237-005: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-ethylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer's Disease.","Pasternak, S.","Wells JL and Borrie MJ.","$26,626,235.00"
"Borrie, Michael","Medicine","2015/02","present","Clinical Trials","Funded","False","True","Co-Investigator","TRx-237-020: An Open-Label, Extension Study of the Effects of Leuco-ethylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer's Disease or Behavioural Variant Frontotemporal Dementia.","Finger, E.","Wells JL and Borrie MJ.","$50,867,133.00"
"Borrie, Michael","Medicine","2014/07","2020/01","Grants","Funded","False","True","Principal Investigator","A Phase III, Randomized, Placebo Controlled, Parallel-Group, Double Blind Clinical Trial to study the Efficacy and Safety Trial of MK-8931 (SCH900931) in Subjects with Amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (Prodromal AD).","Borrie, MJ","Wells JL","$21,163,200.00"
"Borrie, Michael","Medicine","2015/05","2023/01","Clinical Trials","Funded","False","True","Principal Investigator","221AD302: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease.","Borrie MJ","Wells JL","$12,831,256.00"
"McDonald, Charlotte","Medicine","2011/11","2013/12","Clinical Trials","Funded","False","True","Co-Investigator","6-Month, Multi-centre, Randomized, Open-label, Parallel-Group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes with a 6-Month Safety Extension Period","IM Hramiak","CG McDonald, TL Paul","$2,302,240.00"
"McDonald, Charlotte","Medicine","2012/02","2019/12","Clinical Trials","Funded","False","True","Co-Investigator","The Effect of LY2189265 on Major Cardiovascular Events in Patients with Type 2 Diabetes: Reducing Cardiovascular Events with a Weekly Incretin in Diabetes.","IM Hramiak","CG McDonald, TL Paul","$47,472,465.00"
"Borrie, Michael","Medicine","2014/10","2020/01","Clinical Trials","Funded","False","True","Principal Investigator","A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, efficacy and safety study of gantenerumab in patients with mild Alzheimer's Disease.","Borrie MJ","Wells JL","$15,685,678.00"
"McDonald, Charlotte","Medicine","2013/01","2014/12","Clinical Trials","Funded","False","True","Co-Investigator","ORIGIN (Outcome Reduction with Initial Glargine Intervention) and Legacy Effects: An Observational Study)","IM Hramiak","CG McDonald, TL Paul","$51,425,960.00"
"McDonald, Charlotte","Medicine","2013/05","2016/02","Clinical Trials","Funded","False","True","Co-Investigator","Long term outcomes. A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes.","IM Hramiak","T Joy, CG McDonald, TL Paul","$43,808,122.00"
"Borrie, Michael","Medicine","2014/12","2018/01","Clinical Trials","Funded","False","True","Principal Investigator","Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-week, Phage 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moder Alzheimer's Diease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication.","Borrie MJ","Wells JL","$46,635,651.00"
"McDonald, Charlotte","Medicine","2013/07","2019/06","Clinical Trials","Funded","False","True","Co-Investigator","Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.","IM Hramiak","T Joy, C McDonald and T Paul","$48,541,565.00"
"Borrie, Michael","Medicine","2013/05","2020/01","Clinical Trials","Funded","False","True","Principal Investigator","Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE 38054 in patients with mild-moderate Alzheimer's Disease treated wtih donepezil.","Borrie MJ","Wells JL","$31,039,950.00"
"Borrie, Michael","Medicine","2014/11","2021/01","Clinical Trials","Funded","False","True","Principal Investigator","An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients with Mild-Moderate Alzheimer's Disease","Borrie MJ","Wells JL","$14,652,433.00"
"McDonald, Charlotte","Medicine","2011/07","2015/05","Clinical Trials","Funded","True","False","Site Investigator","Epidemiology of Diabetes Interventions and Complications","Dr. John Dupre","CG McDonald","$60,367,340.00"
"Gula, Lorne","Medicine","2014/10","2015/09","Grants","Funded","True","False","Co-Principal Investigator","The dual roles of exercise in fatal ventricular arrhythmias","Harpreet Chahal","Lorne Gula","$68,189,470.00"
"Wells, Jennie","Medicine","2014/01","present","Clinical Trials","Funded","True","False","Co-Investigator","TRx-237-007: A Double-Blind, Placebo-Controlled, Randomized Parallel-Group, 12-Month Safety and Efficacy Study of Leuco-ethylthioninium bis(hydromethanesulfonate) in Subjects with Behavioural Variant Frontotemporal Dementia.","Finger, E.","Borrie MJ, Wells JL","$44,808,075.00"
"Wells, Jennie","Medicine","2014/05","present","Clinical Trials","Funded","True","False","Co-Investigator","TRx-237-005: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-ethylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer's Disease","Pasternak S.","Wells JL, Borrie MJ","$23,670,904.00"
"Wells, Jennie","Medicine","2015/02","present","Clinical Trials","Funded","True","False","Co-Investigator","TRx-237-020: An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia.","Finger E.","Wells JL, Borrie MJ","$15,774,958.00"
"Wells, Jennie","Medicine","2014/07","2020/01","Clinical Trials","Funded","True","True","Co-Investigator","A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double- Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease(Prodromal AD).","Borrie MJ","Wells JL, Borrie MB","$17,658,033.00"
"Wells, Jennie","Medicine","2015/05","2023/01","Clinical Trials","Funded","True","True","Co-Investigator","221AD302: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease.","Borrie MJ","Wells JL, Borrie MJ","$32,628,514.00"
"Wells, Jennie","Medicine","2014/10","2020/01","Clinical Trials","Funded","True","True","Co-Investigator","A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, efficacy and safety study of gantenerumab in patients with mild Alzheimer’s disease.","Borrie MJ","Wells JL, Borrie MJ","$53,184,900.00"
"Wells, Jennie","Medicine","2014/12","2018/01","Clinical Trials","Funded","True","True","Co-Investigator","Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication.","Borrie MJ","Wells JL, Borrie MJ","$31,211,240.00"
"Wells, Jennie","Medicine","2013/05","2020/01","Clinical Trials","Funded","True","True","Co-Investigator","Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE 58054 in patients with mild-moderate Alzheimer’s Disease treated with donepezil.","Borrie MJ","Wells JL, Borrie MJ","$70,348,597.00"
"Wells, Jennie","Medicine","2014/11","2021/01","Clinical Trials","Funded","True","True","Co-Investigator","An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients with Mild-Moderate Alzheimer’s Disease (Lundbeck Open Label).","Borrie MJ","Wells JL, Borrie MJ","$39,989,038.00"
"Rahman, Adam","Medicine","2015/12","2019/12","Grants","Applied","True","False","Co-Investigator","CIHR Team Grant: Late Life Issues","Daren Heyland","","$24,902,549.00"
"Goldszmidt, Mark","Medicine","2015/06","present","Grants","Funded","True","False","Co-Principal Investigator","Investigating the Use of Cognitive Diagnostic Assessment in the Development and Assessment of Entrustable Professional Activities","Saad Chahine, Mark Goldszmidt","Collaborators: SheriLynn Kane, Noureen Huda","$58,131,607.00"
"Rahman, Adam","Medicine","2014/07","2017/06","Clinical Trials","Funded","False","True","Co-Investigator","Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Multiple Daily Intravenous (IV) Doses of Ulimorelin (LP-101) in Critically Ill Patients with Enteral Feeding Intolerance","D Heyland","S Harris","$1,934,877.00"
"House, Andrew","Medicine","2014/07","2016/07","Grants","Funded","True","False","Co-Investigator","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor","Seyed Hosseini","","$59,703,474.00"
"House, Andrew","Medicine","2013/06","2019/06","Grants","Funded","True","False","Principal Investigator","The BK:KIDNI Trial BK Viremia: Kinase Inhibition to Decrease Nephropathy Intervention Trial","Andrew House","","$42,669,086.00"
"Lindsay, Robert","Medicine","2014/10","2015/12","Grants","Funded","True","False","Principal Applicant","London Dialysis Course: Available to All","Robert Lindsay","","$17,264,103.00"
"Lindsay, Robert","Medicine","2015/06","2017/06","Grants","Funded","True","False","Principal Applicant","Assessment of kidney dialyzers using a novel in-vitro filtration/diffusion apparatus","Robert Lindsay","","$12,531,489.00"
"Suskin, Neville","Medicine","2015/09","2018/08","Grants","Funded","True","False","Co-Investigator","Cerebrovascular outcomes in ischemic heart disease patients undergoing cardiac rehabilitation","Kevin Shoemaker","Cepinskas, Gediminas; Daley, Mark J; Dekaban, Gregory A; Fraser, Douglas D; St. Lawrence, Keith S; Summers, Kelly; Suskin, Neville G","$33,687,059.00"
"Suskin, Neville","Medicine","2014/07","2015/06","Clinical Trials","Funded","False","True","Principal Site Investigator","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome","Neville Suskin","","$60,303,935.00"
"Hegele, Robert","Medicine","2015/09","2020/08","Grants","Funded","True","False","Principal Investigator","Edith Schulich Vinet Endowment","Robert A. Hegele","","$46,630,523.00"
"Hegele, Robert","Medicine","2015/07","2018/06","Grants","Funded","True","False","Principal Investigator","Genomics and phenomics of hypertriglyceridemia and cardiometabolic syndrome","Robert A. Hegele","","$67,342,754.00"
"Hegele, Robert","Medicine","2015/04","2022/03","Grants","Funded","True","False","Principal Investigator","Clinical translation of genomic understanding of cardiometabolic risk","Robert A. Hegele","","$63,785,533.00"
"Tang, Anthony","Medicine","2014/10","present","Grants","Funded","True","False","Co-Applicant","Reverse Remodeling in CRT Patients with Intermediate and Transseptal Endocardial LV Leads","Jaimie Manlucu","","$30,984,039.00"
"Tang, Anthony","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Co-Investigator","Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation","Jeff Healey","Lorne Gula, Jaimie Manlucu, Allan Skanes","$61,378,770.00"
"Leong-Sit, Peter","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation","Jeff Healey","Lorne Gula, Jaimie Manlucu, Allan Skanes","$13,758,216.00"
"Gula, Lorne","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Co-Investigator","Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation","Jeff Healey","Lorne Gula, Jaimie Manlucu, Allan Skanes","$70,489,620.00"
"Manlucu, Jaimie","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Co-Investigator","Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation","Jeff Healey","Lorne Gula, Jaimie Manlucu, Allan Skanes","$20,770,181.00"
"Skanes, Allan","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Co-Investigator","Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation","Jeff Healey","Lorne Gula, Jaimie Manlucu, Allan Skanes","$30,535,982.00"
"Tang, Anthony","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Co-Investigator","Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation","Lena Rivard","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang","$4,141,495.00"
"Leong-Sit, Peter","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation","Lena Rivard","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang","$40,440,796.00"
"Manlucu, Jaimie","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Co-Investigator","Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation","Lena Rivard","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang","$35,785,454.00"
"Skanes, Allan","Medicine","2015/07","present","Clinical Trials","Funded","True","False","Co-Investigator","Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation","Lena Rivard","Lorne Gula, Jaimie Manlucu, Allan Skanes, Anthony Tang","$13,034,991.00"
"Tang, Anthony","Medicine","2015/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Optisure Lead Post Approval Study","Grant Kim","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$62,953,992.00"
"Yee, Raymond","Medicine","2015/07","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Optisure Lead Post Approval Study","Grant Kim","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$36,706,123.00"
"Manlucu, Jaimie","Medicine","2015/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Optisure Lead Post Approval Study","Grant Kim","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$28,439,789.00"
"Gula, Lorne","Medicine","2015/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Optisure Lead Post Approval Study","Grant Kim","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$69,321,217.00"
"Leong-Sit, Peter","Medicine","2015/07","present","Clinical Trials","Funded","False","True","Co-Investigator","Optisure Lead Post Approval Study","Grant Kim","Lorne Gula, Peter Leong-Sit, Jaimie Manlucu, Anthony Tang","$73,121,281.00"
"Tang, Anthony","Medicine","2015/03","present","Clinical Trials","Funded","True","False","Co-Investigator","Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: The Effect of Double Short vs. Standard Exposure Cryoablation Duration During Pulmonary Vein Isolation","Jason Andrade","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$27,110,506.00"
"Leong-Sit, Peter","Medicine","2015/03","present","Clinical Trials","Funded","True","False","Principal Site Investigator","Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: The Effect of Double Short vs. Standard Exposure Cryoablation Duration During Pulmonary Vein Isolation","Jason Andrade","Lorne Gula, George Klein, Jaimie Manlucu, Allan Skanes, Anthony Tang, Raymond Yee","$68,438,203.00"
"Ball, Ian","Medicine","2015/07","2018/07","Clinical Trials","Funded","True","False","Principal Site Investigator","CYCLE Pilot-- A multi-centre pilot randomized clinical trial of early in bed leg cycling versus routine physiotherapy in mechanically ventilated patients.","Dr. Michelle Kho","A Fox-Robichaud, K Koo, M Mourtzakis, J Reid, J Tarride, K Burns, M Herridge, V Lo, J Pellizzari, J Rudkowski, D Cook, T Karachi, S Mathur, T Piraino, A Seely","$22,045,110.00"
"Lavi, Shahar","Medicine","2015/01","present","Grants","Funded","True","True","Co-Investigator","The Safety and Efficacy of Ticagrelor For CoronAry Stenting Post Thrombolysis Trial","Payam Dehghani","","$31,549,982.00"
"Beaton, Melanie","Medicine","2015/05","2017/05","Grants","Funded","True","False","Co-Investigator","Microbes of Fecal Origin for Prevention and Treatment of Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease","Silverman, M","Beaton, M Joy, T McIntyre, C Burton, J McKenzie, C Rahman, A Reid, G Hramiak, I Hegele, R Gloor, G Summers, K","$67,658,648.00"
"Huang, Shih-Han Susan","Medicine","2015/07","2017/07","Grants","Funded","True","False","Principal Applicant","Bedside ultrasound-based assessment of liver compliance to measure fluid status in hemodialysis patients","Dr. S. Huang","Dr. M. Levstik Dr. C. McIntyre Dr. C. Grant","$10,024,465.00"
"Huang, Shih-Han Susan","Medicine","2015/07","2017/07","Grants","Funded","True","False","Co-Investigator","Assessment of kidney dialyzers using a novel in-vitro filtration/diffusion apparatus","Dr. R. Lindsay","Dr. S. Huang Dr. G. Campbell","$65,024,399.00"
"Tang, Anthony","Medicine","2015/07","2016/12","Grants","Funded","True","False","Co-Investigator","Cardiac Sarcoidosis Multicenter Prospective Cohort","David Birnie, Rob Beanlands, Pablo Nery","S. Aaron S. Chakrabarti P. Cox, R. De Kemp, V. Essebag, M. Friedrich, L. Gula, A. Ha, J. Healey, T. Hruczkowski, P. Liu, F. Quinn, L. Rivard , J. Sapp, A. Tang, G. Wells, G. Wisenberg","$65,843,063.00"
"Tang, Anthony","Medicine","2014/01","2019/12","Grants","Funded","True","False","Scientific Director and CEO","Canadian Arrhythmia Network-Network of Centre of Excellence","Anthony Tang","","$66,939,295.00"
"Wisenberg, Gerald","Medicine","2015/07","2016/06","Grants","Funded","False","False","Co-Applicant","Cardiac Sarcoidosis Multicentre Prospective Cohort","David Birnie","Dr. S. Aaron Dr. S. Chakrabarti Prof. P. Cox, Dr. R. De Kemp Dr. V. Essebag Prof. M. Friedrich Dr. L. Gula Dr. A. Ha Dr. J. Healey, Dr. T. Hruczkowski Dr. P. Liu Dr. F. Quinn, Docteure L. Rivard Dr. J. Sapp Dr. A. Tang Dr. G. Wells Dr. G. Wisenberg","$38,155,141.00"
"Moist, Louise","Medicine","2015/07","2016/07","Grants","Funded","True","False","Co-Investigator","Assessment of kidney dialyzers using a novel in-vitro filtration/diffusion assaratus","Dr. Robert Lindsay","","$73,267,986.00"
"Tang, Anthony","Medicine","2009/11","2011/12","Clinical Trials","Funded","False","True","Co-Investigator","Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion","Sanofi","","$2,819,030.00"
"Moist, Louise","Medicine","2015/07","2016/06","Grants","Funded","False","True","Co-Investigator","Intermittent HEMOdialysis Antiocoagulation with TINzaparin versus Unfractinated Heparin: A Pilot Multicentre Randomised Control Trial (HEMO-TIN Trial)","Dr. Christine Ribic","","$52,138,320.00"
"Mrkobrada, Marko","Medicine","2015/07","2022/07","Grants","Funded","True","False","Co-Investigator","Predicting and Preventing the major vascular complications of surgery","P.J. Devereaux","Marko Mrkobrada","$71,168,967.00"
"Kao, Raymond","Medicine","2007/07","2008/06","Grants","Funded","True","False","Principal Investigator","Erythropoietin improves skeletal muscle microcirculation through the activation of eNOS in a mouse sepsis model","Kao R","","$15,092,250.00"
"Kao, Raymond","Medicine","2009/07","2011/07","Grants","Funded","True","False","Principal Investigator","Effect of rh-EPO on sublingual microcirculation and splanchnic central venous oxygen saturation in patients with severe sepsis and septic shock","Kao R","","$48,362,913.00"
"Kao, Raymond","Medicine","2009/01","2011/12","Grants","Funded","True","False","Principal Investigator","To determine and compare the effect of rh-EPO and crystalloid solutions on the small intestine microcirculation perfusion, tissue bioenergetics and gut injury in an acute and 24 hours hemorrhagic shock and resuscitation rat model.","Kao R","","$21,453,933.00"
"Martin, Claudio","Medicine","2015/07","2018/06","Grants","Funded","True","False","Principal Investigator","Crystalloid FLUID Choices for Resuscitation of Hospitalized Patients: A Pragmatic Cluster Cross Over Pilot Trial","Dr. Lauralyn McIntyre","Ferguson D, Taljaard M, Marshall, J, Fox-Robichaud A, Muscedere J, Martin C, Seely A, Cook D, Graham I, Bee A, Forster A, Hawken S, Kednapa T, Saginur R, McCartney C.","$32,284,358.00"
"Jain, Arsh","Medicine","2014/10","2017/10","Grants","Funded","True","True","Principal Investigator","Connecting Patients and Health Care Staff: A novel approach to remote monitoring PD patients (The CONNECT Trial)","Dr. Arsh Jain","","$31,350,636.00"
"Kao, Raymond","Medicine","2015/09","2016/08","Grants","Applied","False","False","Co-Principal Investigator","The evaluation of Indomethacin and ventolin treatment for trauma-induced lung injury in rats","Kao R, Rui T","","$43,259,078.00"
"Pope, Janet","Medicine","2012/06","2013/12","Grants","Funded","True","False","Principal Investigator","Clinical utility of recently described anti-citrullinated protein antibodies (ACPA) in the optimal management of adults with early inflammatory arthritis (EIA) (CATCH).","Janet Pope","","$16,087,245.00"
"Pickering, J. Geoffrey","Medicine","2015/07","2022/06","Grants","Funded","True","False","Principal Investigator","Vascular aging, repair, and regeneration.","Program Leader: JG Pickering","","$49,498,798.00"
"Khanna, Reena","Medicine","2015/07","2015/07","Grants","Funded","True","False","Principal Investigator","Future Leaders in IBD International Preceptorship","Khanna, R.","","$46,063,443.00"
"Edmonds, Marcia","Medicine","2002/07","2002/07","Grants","Funded","False","False","Principal Investigator","Migraine headache in the emergency department: the effect of corticosteroids on the recurrence of migraine after discharge from the emergency department","Edmonds ML","Rowe BH, Colman IC","$61,317,016.00"
"Edmonds, Marcia","Medicine","2011/07","2015/07","Grants","Funded","True","False","Co-Investigator","ACUTE Study: Acute Congestive Heart Failure Urgant and Transitional Care Evaluation","Lee DS-Y","Alter D, Austin P, Borgundvaag B, Brehaut J, Edmonds M, Friedman S, Grimshaw L, Lee J, Schull M, Stukel T, Tu J, and Wijeysundera H","$10,618,366.00"
"Silverman, Michael","Medicine","2014/07","2015/07","Clinical Trials","Funded","True","False","Co-Investigator","CANFAR (Canadian Foundation for AIDS Research) PROSPAR study of progesterone supplementation in pregnant HIV infected mothers","Michael S Silverman","","$26,760,843.00"
"Silverman, Michael","Medicine","2013/07","2015/07","Clinical Trials","Funded","True","False","Co-Principal Investigator","CIHR Grant –Study of Sex hormone drug levels induced by Antiretroviral Drugs and the Impact on Low Birth weight Birth. Zambia Cohort","Michael S Silverman","","$14,039,785.00"
"Silverman, Michael","Medicine","2012/07","2015/07","Clinical Trials","Funded","True","False","Principal Investigator","CIHR Team Grant HIV co-morbidities $2,500,000. Cognitive Outcomes in HIV Exposed but Un-infected Children in Zambia.","Michael S Silverman","","$24,837,409.00"
"Hramiak, Irene","Medicine","2015/07","2016/05","Clinical Trials","Funded","False","True","Principal Investigator","A long term, randomized, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with type 2 diabetes mellitus.","IM Hramiak","TL Paul, N Suskin, ME Weingert","$7,127,378.00"
"Hramiak, Irene","Medicine","2015/07","2017/07","Clinical Trials","Funded","False","True","Principal Investigator","A phase 3, randomized, double-blind, placebo controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of LX4211 as adjunct therapy in adult patients with type 1 diabetes mellitus who have inadequate glycemic control with insulin therapy.","IM Hramiak","TL Paul, T Spaic","$38,566,686.00"
"McCormack, David","Medicine","2013/10","2014/09","Grants","Funded","True","True","Co-Applicant","Trudell Medical International Grant-in-Aid: Oscillatory positive expiratory pressure in bronchiectasis and chronic bronchitis phenotype of COPD","Parraga G","McCormack DG","$46,763,396.00"
"McCormack, David","Medicine","2012/10","2013/09","Grants","Funded","True","True","Co-Applicant","Trudell Medical International Grant-in-Aid: Imaging oscillating positive expiratory pressure in COPD: A longitudinal study","Parraga G","McCormack DG","$67,166,196.00"
"McCormack, David","Medicine","2010/07","2015/06","Grants","Funded","True","False","Co-Applicant","Hyperpolarized Helium-3 Magnetic Resonance Imaging of Healthy Aging Lung","Parraga G","McCormack DG","$74,346,150.00"
"McCormack, David","Medicine","2010/07","2015/06","Grants","Funded","True","False","Co-Applicant","Hyperpolarized Helium-3 Magnetic Resonance Imaging of Healthy Aging Lung","Parraga G","McCormack DG","$18,459,417.00"
"McCormack, David","Medicine","2008/10","2013/09","Grants","Funded","True","True","Co-Applicant","Broncus Technologies - Safety and efficacy of airway bypass in severely hyperinflated COPD","Parraga G","McCormack DG","$43,658,108.00"
"Al-Judaibi, Bandar","Medicine","2015/01","present","Grants","Applied","False","True","Co-Investigator","Hepatic Drug Metabolism and Transport in Patients with Non-alcoholic Fatty Liver Disease","Dr. Bandar Al-Judaibi","","$14,825,486.00"
"Al-Judaibi, Bandar","Medicine","2015/01","present","Grants","Applied","False","True","Co-Investigator","A registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials","Bandar Al-Judaibi","","$13,385,112.00"
"Al-Judaibi, Bandar","Medicine","2015/01","present","Grants","Applied","False","True","Co-Investigator","A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection","Bandar Al-Judaibi","","$2,302,400.00"
"Al-Judaibi, Bandar","Medicine","2015/01","present","Grants","Applied","False","True","Principal Investigator","Collection of Plasma Samples From Individuals Initiating Therapy with Entecavir or Tenofovir for Chronic Hepatitis B Virus Infection for the Clinical Evaluation of the Aptima HBV Quant Assay","Bandar Al-Judaibi","","$58,839,871.00"
"Al-Judaibi, Bandar","Medicine","2014/01","2014/12","Grants","Applied","False","True","Co-Investigator","A multicenter, Open-Label, Partially Randomized, Parallel-Group, Adaptive Design, Phase II Study on Efficacy and Safety of DEB025/alisporivir in Combination with RG7128/mericitabine Plus Ribavirin in Chronic Hepatitis C genotype 1 Treatment-naïve, Genotype 3 Previous Treatment-Failure, and Genotype 3 Cirrhotic Patients","Bandar Al-Judaibi","","$36,650,923.00"
"Al-Judaibi, Bandar","Medicine","2011/07","2016/06","Grants","Applied","False","True","Co-Investigator","A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve and -Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection Without Cirrhosis","Bandar Al-Judaibi","","$34,587,277.00"
"Al-Judaibi, Bandar","Medicine","2014/01","2014/12","Grants","Applied","False","True","Co-Investigator","A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve or -Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis","Bandar Al-Judaibi","","$3,662,027.00"
"Al-Judaibi, Bandar","Medicine","2014/01","2014/12","Grants","Applied","False","True","Co-Investigator","A Phase 3, Multicenter, Randomized, Open Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve and -Experienced Subjects with Chronic Genotype 1 Hepatitis CVirus Infection Without Cirrhosis","Bandar Al-Judaibi","","$66,872,936.00"
"Al-Judaibi, Bandar","Medicine","2014/01","2014/12","Grants","Applied","False","True","Co-Investigator","A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease","Bandar Al-Judaibi","","$46,703,234.00"
"Al-Judaibi, Bandar","Medicine","2014/01","2014/12","Grants","Applied","False","True","Co-Investigator","A Randomized, Global, Double-blind, Placebo Controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults withThrombocytopenia Associated with Liver Disease Prior to an Elective Procedure","Bandar Al-Judaibi","","$57,134,101.00"
"Al-Judaibi, Bandar","Medicine","2014/01","2014/12","Grants","Applied","False","True","Co-Investigator","A Phase 3B Randomized, Open-Label, Multi- Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection","Bandar Al-Judaibi","","$60,418,681.00"
"Al-Judaibi, Bandar","Medicine","2014/01","2014/12","Grants","Applied","False","True","Co-Investigator","A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant","Bandar Al-Judaibi","","$31,525,189.00"
"Al-Judaibi, Bandar","Medicine","2013/01","2013/12","Grants","Applied","False","True","Co-Investigator","A phase 2b, Dose-Ranignig, Randomized, Doulbe-Blind, Placebo-Controlloed Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis","Bandar Al-Judaibi","","$63,208,233.00"
"Al-Judaibi, Bandar","Medicine","2013/01","2013/12","Grants","Applied","False","True","Co-Investigator","Dose-Ranignig, Randomized, Double-Blind, Placebo-Contolled Trial Evaluating the Safety and Efficacy of GS- 6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis","Bandar Al-Judaibi","","$30,492,972.00"
"Kovacs, Michael","Medicine","2015/07","2016/06","Grants","Funded","False","True","Principal Site Investigator","Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism – The Einstein Choice study.","Dr. M.J. Kovacs","","$41,221,300.00"
"Hames, Heather","Medicine","2010/07","2011/06","Grants","Funded","True","False","Co-Investigator","lidocaine study...","Dr. Wanda Millard","Shelly MacLeod","$49,776,694.00"
"van Uum, Stanislaus","Medicine","2013/01","2014/12","Grants","Funded","True","True","Co-Applicant","Neural Plasticity Associated with the Loss and Recovery of Vision in Patients with Pituitary Tumors Before and After Medical or Surgical Intervention","Neil Duggal","Stan van Uum","$40,898,571.00"
"Kovacs, Michael","Medicine","2015/09","2022/06","Grants","Funded","True","False","Program Expert","Improving long term outcomes after venous thromboembolism (VTE)","Dr. Susan R. Kahn","","$31,701,683.00"
"Ng, Victor","Medicine","2011/07","2011/07","Grants","Funded","False","False","Co-Applicant","Research Travel Grant","Holding CA","Ng VK","$5,234,236.00"
"Ng, Victor","Medicine","2011/07","2011/07","Grants","Funded","False","False","Principal Investigator","Medical Doctorate Management Grant","Ng VK","Irwin ID","$24,827,271.00"
"Ng, Victor","Medicine","2010/07","2010/07","Grants","Funded","False","False","Co-Investigator","Leadership Innovation Fund","Holding CA","Ng VK","$10,562,066.00"
"Ng, Victor","Medicine","2007/07","2007/07","Grants","Funded","False","False","Co-Investigator","New Investigator Grant","Millard W","Hames H, Ng VK","$73,777,827.00"
"Teefy, Patrick","Medicine","2015/09","2015/09","Grants","Applied","True","False","Co-Investigator","Selective Brain Hypothermia via Intranasal Cooling to Limit Brain Injury Post Cardiac Arrest","Ting-Yim Lee","Robert Bartha, Peter Leong-Sit, Jaimie Manlucu, Varinder Randhawa, Patrick Teefy, Gerald Wisenberg","$62,729,683.00"
"Minuk, Leonard","Medicine","2013/02","2014/02","Clinical Trials","Funded","False","True","Principal Site Investigator","A Multicentre, single arm, open label treatment use program for pomalidomide in combination with low dose dexamethasone in subjects with relapsed or refractory multiple myeloma","Dr. Leonard Minuk","","$39,256,128.00"
"Minuk, Leonard","Medicine","2013/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A phase 3 randomized double blind multicentre study comparing oral MLN9708 plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with newly diagnosed multiple myeloma","Dr. Leonard Minuk","","$42,217,799.00"
"Minuk, Leonard","Medicine","2015/09","present","Clinical Trials","Funded","False","True","Principal Site Investigator","A randomized phase 3 study of bendamustine plus rituximab versus ibrutinib plus rituximab versus ibrutinib alone in untreated older patients with chronic lymphocytic leukemia","Dr. Leonard Minuk","","$68,631,750.00"
"Minuk, Leonard","Medicine","2014/01","present","Clinical Trials","Funded","False","True","Principal Site Investigator","Phase 3 study comparing daratumamab, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma","Dr. Leonard Minuk","","$21,271,227.00"
"Skanes, Allan","Medicine","2014/10","2016/09","Grants","Funded","True","False","Co-Principal Investigator","Atrial Imaging-based Clinical Decision Tool to Optimize Outcomes following Atrial Fibrillation Ablation - AID AF Ablation Study","Allan Skanes","Maria Drangova","$297,130.00"
"Borrie, Michael","Medicine","2015/03","2016/06","Clinical Trials","Funded","True","False","Co-Investigator","Understanding Neurodegeneration, Venules, Amyloid Imaging and Leukoaraiosis (UNVAIL)","Sandra Black","Borrie MJ et al(?)","$30,262,620.00"
"Gunaratnam, Lakshman","Medicine","2015/06","2017/05","Grants","Funded","True","False","Co-Principal Investigator","Role of KIM-1 and MFG-E8 in Generation and Clearance of Cell Death-Associated Nanovesicles","Dr. Lakshman Gunaratnam and Dr. Jean-Francois Cail","","$28,250,877.00"
"Mrkobrada, Marko","Medicine","2015/03","2017/03","Grants","Funded","True","False","Principal Investigator","NutriSup RCT","Marko Mrkobrada","","$10,772,318.00"
"Mrkobrada, Marko","Medicine","2015/07","2017/07","Grants","Funded","True","False","Co-Investigator","National Centres of Excellence - Techology Evaluation in the Elderly","Adam Rahman","Marko Mrkobrada","$31,654,268.00"
"Liu, Selina","Medicine","2016/01","2018/12","Clinical Trials","Funded","True","False","Principal Investigator","CLEAR SIGHT: A randomized trial of non-mydriatic ultra-widefield retinal imaging to screen for diabetic eye disease","Selina Liu","Irene Hramiak John Gonder Jeffrey Mahon Neil Klar","$15,248,671.00"
"Pope, Janet","Medicine","2015/01","2017/01","Grants","Funded","True","False","Principal Investigator","Development of systemic sclerosis subset classification criteria","Dr.Janet Pope","Dr. Sindhu Johnson, Dr.D.Khanna","$3,895,960.00"
"Pope, Janet","Medicine","2015/01","2016/01","Grants","Funded","True","False","Co-Investigator","Systemic Sclerosis subset criteria research planning meeting","Dr. Sindhu Johnson","Dr.Janet Pope, Dr. D. Khanna","$63,403,647.00"
"Jevnikar, Anthony","Medicine","2010/07","present","Clinical Trials","Funded","False","True","Principal Investigator","A Comparison of Effects of Standard Dose vs. Low Dose Advagraf with IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without an ACEi/ARB - based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response","Dr. Anthony M. Jevnikar","","$27,041,783.00"
"Khanna, Reena","Medicine","2015/01","2015/12","Grants","Applied","True","False","Principal Investigator","IOIBD","Khanna, R.","","$69,808,632.00"
"Borrie, Michael","Medicine","2015/02","2017/01","Grants","Funded","True","False","Co-Investigator","Metabolic and Functional Brain State: New Indicators of Alzheimer’s Disease","Bartha R.","Menon R, Borrie M.","$19,042,487.00"
"Goldszmidt, Mark","Medicine","2013/12","2015/12","Grants","Funded","True","False","Principal Investigator","Time to move beyond a 'trial-and-error' approach to clinical documentation","Goldszmidt, M.","Cadieux, D.","$69,358,641.00"
"Goldszmidt, Mark","Medicine","2011/07","2012/06","Grants","Funded","True","False","Principal Investigator","Taking a Detour: The Impact of Supervisor Interruptions during Admission Case Review","Goldszmidt, M.","Aziz, N.","$49,469,375.00"
"Leasa, David","Medicine","2014/07","2015/06","Grants","Funded","True","False","Collaborator","Health Service Utilization for Assessment, Monitoring and Management of Respiratory Complications for Individuals with Neuromuscular Disease.","Rose, L.","Rose, L. McKim, D., Leasa, D., Nonoyama, M., Tandon, A., Amin, R., Katz, S., Goldstein, R., Gershon, A.","$23,834,871.00"
"Garg, Pallav","Medicine","2015/09","2018/09","Grants","Applied","True","False","Principal Applicant","Cardiovascular Outcomes Research: An Initiative between ICES Western and Department of Medicine","Pallav Garg","","$41,904,391.00"
"Dreyer, Jonathan","Medicine","2005/02","2009/06","Grants","Funded","True","False","Site Investigator","Resuscitation Outcomes Consortium Epistry Study","Dr. Ian Stiell","","$42,576,598.00"
"Dreyer, Jonathan","Medicine","2004/07","2009/06","Grants","Funded","True","False","Site Investigator","Proposal to Create a Canadian Collaborative Regional Clinical Center within the Resuscitation Consortium","Dr. Ian Stiell","","$51,713,317.00"
"Dreyer, Jonathan","Medicine","2003/07","2007/06","Grants","Funded","True","False","Principal Site Investigator","Implementation of the Canadian C-Spine Rule (Phase III)","Dr. Ian Stiell","","$4,543,290.00"
"Dreyer, Jonathan","Medicine","2003/07","2007/06","Grants","Funded","True","False","Principal Site Investigator","Evaluation of an active strategy to implement the Canadian CT Head Rule: Phase III","Dr. Ian Stiell","","$56,532,404.00"
"Dreyer, Jonathan","Medicine","2002/07","2004/06","Grants","Funded","True","False","Co-Investigator","Causes and Relationships Between Overcrowding and Waiting at Different Emergency Departments","Dr. Michael Schull","","$74,592,597.00"
"Dreyer, Jonathan","Medicine","2001/07","2003/06","Grants","Funded","True","False","Co-Investigator","Pulmonary Embolism Diagnosis Study","Dr. David R. Anderson","","$23,235,702.00"
"Dreyer, Jonathan","Medicine","2000/07","2002/06","Grants","Funded","True","False","Co-Investigator","Controlled Trial of Glucocorticoids in Outpatients with COPD Exacerbation.","Dr. Shawn Aaron","","$9,229,915.00"
"Dreyer, Jonathan","Medicine","2000/07","2003/06","Grants","Funded","True","False","Co-Investigator","Post Motor Vehicle Collision Fibromyalgia Incidence Study","Dr. Kevin White","","$24,694,158.00"
"Dreyer, Jonathan","Medicine","1999/07","2002/06","Grants","Funded","True","False","Site Co-Investigator","A study to prospectively validate a clinical decision rule for the use of cervical spine radiography in alert stable trauma patients.","Dr. Ian Stiell","","$35,742,914.00"
"Dreyer, Jonathan","Medicine","1999/07","2002/06","Grants","Funded","True","False","Site Co-Investigator","A prospective study to derive and validate a clinical decision rule for the use of cervical spine radiography in alert stable trauma patients.","Dr. Ian Stiell","","$7,148,927.00"
"Dreyer, Jonathan","Medicine","1998/07","2001/06","Grants","Funded","True","False","Site Investigator","The Ontario Prehospital Advanced Life Support (OPALS) Study for Cardiac Arrest and Critical Care Patients - Phase III","Dr. Ian Stiell","","$19,680,454.00"
"Dreyer, Jonathan","Medicine","1994/07","2002/06","Grants","Funded","True","False","Site Investigator","A Multicentred Trial of the Introduction of Advanced Paramedics.","Dr. Ian Stiell","","$37,960,219.00"
"Dreyer, Jonathan","Medicine","1997/07","1999/06","Grants","Funded","True","False","Site Investigator","A preliminary randomized controlled study to compare the clinical effects of vasopressin and epinephrine in the treatment of in-hospital cardiac arrest.","Dr. Ian Stiell","","$74,474,703.00"
"Dreyer, Jonathan","Medicine","1996/07","1999/06","Grants","Funded","True","False","Site Co-Investigator","A study to derive and validate a clinical decision rule for the use of cervical spine radiography in alert stable trauma patients.","Dr. Ian Stiell","","$45,986,291.00"
"Dreyer, Jonathan","Medicine","1996/07","1999/06","Grants","Funded","True","False","Site Co-Investigator","A study to derive and validate a clinical decision rule for the use of cervical spine radiography in alert stable trauma patients.","Dr. Ian Stiell","","$33,282,727.00"
"Dreyer, Jonathan","Medicine","1996/07","1999/06","Grants","Funded","True","False","Site Co-Investigator","A study to derive and validate a clinical decision rule for the use of computed tomography in patients with minor head injury.","Dr. Ian Stiell","","$6,697,918.00"
"Dreyer, Jonathan","Medicine","1996/07","2000/06","Grants","Funded","True","False","Site Co-Investigator","A study to derive and validate a clinical decision rule for the use of computed tomography in patients with minor head injury.","Dr. Ian Stiell","","$14,014,696.00"
"Dreyer, Jonathan","Medicine","1993/07","1996/06","Grants","Funded","True","False","Site Co-Investigator","A randomized controlled trial of active compression-decompression versus standard cardiopulmonary resuscitation for cardiac arrest.","Dr. Ian Stiell","","$73,035,052.00"
"Dreyer, Jonathan","Medicine","1993/07","1996/06","Grants","Funded","True","False","Site Co-Investigator","A randomized controlled trial of active compression-decompression versus standard cardiopulmonary resuscitation for cardiac arrest.","Dr. Ian Stiell","","$38,920,265.00"
"Dreyer, Jonathan","Medicine","2005/07","2007/07","Grants","Funded","False","False","Principal Investigator","Predictors of Workload in the Emergency Department.","Dr. Jonathan Dreyer","","$52,750,454.00"
"Dreyer, Jonathan","Medicine","2003/07","2005/07","Grants","Funded","False","False","Principal Investigator","Predictors of Workload in the Emergency Department.","Dr. Jonathan Dreyer","","$4,240,433.00"
"Dreyer, Jonathan","Medicine","1989/07","1990/07","Clinical Trials","Funded","False","True","Site Investigator","Cefcanel Daloxate Clinical Trials","Industry Scientist","","$65,518,815.00"
"Dreyer, Jonathan","Medicine","1990/07","1990/07","Grants","Funded","False","True","Site Investigator","Acute Treatment of Migraine with a Serotonin Agonist","Industry Scientist","","$45,768,250.00"
"Dreyer, Jonathan","Medicine","1987/07","1989/07","Grants","Funded","False","False","Site Investigator","Ontario Study of the Introduction of Automated Defibrillators in the Treatment of Out of Hopital Cardiac Arrest.","Rob Brison","","$59,883,780.00"
"Dreyer, Jonathan","Medicine","1940/07","1940/07","Grants","Funded","False","True","Site Investigator","Norfloxacin in Urinary Tract Infection","Industry Scientist","","$57,219,449.00"
"Dreyer, Jonathan","Medicine","1986/07","1986/07","Grants","Funded","False","False","Principal Investigator","Meperidine VS Chlorpromazine in Migraine","Dr. Jonathan Dreyer","","$7,548,680.00"
"Dreyer, Jonathan","Medicine","1986/07","1986/07","Grants","Funded","False","True","Principal Investigator","Review of Out-Of-Hospital Cardiac Arrest.","Dr. Jonathan Dreyer","","$52,069,125.00"
"Richardson, Christine","Medicine","2012/07","2013/06","Grants","Funded","False","False","Co-Applicant","Improving the Clinical Clerkship Experience in Emergency Medicine","Dr. Lisa Shepherd","Dr. Christine Richardson Dr. Marilyn Innes","$46,281,197.00"
"Khanna, Reena","Medicine","2013/09","2013/09","Grants","Funded","True","False","Principal Investigator","Young Clinicians Program for Gastro 2013","Khanna, R.","","$70,143,446.00"
"Feagan, Brian","Medicine","2013/07","2018/06","Grants","Funded","False","True","Principal Applicant","A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn’s Disease”","Brian Feagan","","$68,417,694.00"
"Feagan, Brian","Medicine","2012/07","2017/06","Grants","Funded","False","True","Principal Applicant","A Study to Evaluate the Pharmacokinetics of Adalimumab in Combination with Methotrexate for the Treatment of Patients with Ulcerative Colitis","Brian Feagan","","$71,012,951.00"
"Feagan, Brian","Medicine","2010/09","2015/08","Grants","Funded","False","False","Co-Applicant","Knowledge Synthesis and Translation by the Cochrane Collaboration in Canada","Dr. Brian Feagan","","$4,464,188.00"
"Feagan, Brian","Medicine","2015/07","2017/06","Grants","Applied","False","False","Principal Applicant","Cochrane IBD Group","Dr. Brian Feagan","","$70,641,941.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2015/06","2016/06","Grants","Funded","True","False","Co-Investigator","CIHR Foundation Scheme – Live Pilot “Know4Go: Combining Evidence, Economics, Ethics & ‘Everything Else’ at the Pace Required for Decision Making in the Hospital Setting” Principal Investigator: Dr. Janet Martin In Progress","Dr. Janet Martin","","$15,476,973.00"
"Cheng, Davy","Anesthesia & Perioperative Medicine","2014/06","2015/06","Grants","Funded","True","False","Co-Principal Investigator","Internal Research Grant Competition, Department of Anesthesia & Perioperative Medicine, Schulich School of Medicine & Dentistry Grant: “Clinical impact of disinvestment in hydroxyethyl starches for patients undergoing cardiac surgery” Co-Principal Investigator (Dr. Ava John-Baptiste) $10,000, Funded",".","","$73,163,818.00"
"Skanes, Allan","Medicine","2015/08","2017/07","Grants","Funded","True","False","Co-Principal Investigator","Structural, functional and autonomic imaging of the atrium in AF-START IMAGING AF","Frank Prato","","$3,281,148.00"
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
"","","","","","","","","","","","",""
